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 Executive summary 
1.1. Background 
Anaemia is defined as a deficiency in red blood cells. It is the most frequent haematological 
manifestation in patients with cancer; more than 50% of all cancer patients will be anaemic 
regardless of the treatment received, and approximately 20% of all patients undergoing 
chemotherapy will require red blood cell transfusion (RBCT). The cause is multifactorial: 
patient-, disease-, or treatment-related. 
Anaemia is associated with many symptoms. These include dizziness, shortness of breath 
on exertion, palpitations, headache and depression. All affect health-related quality of life 
(HRQoL). Severe fatigue is probably the most commonly reported symptom and can lead to 
an inability to perform everyday tasks. However, fatigue in people with cancer can also have 
other causes; e.g. the disease itself, chemotherapy, radiotherapy, anxiety or depression. 
Many people are anaemic when cancer is diagnosed, before any cancer treatment starts. 
The degree of anaemia caused by treatments such as chemotherapy often fluctuates 
depending on the nature of the treatment and the number of courses administered, but is 
typically at its worst two to four weeks after chemotherapy is given. Once cancer treatments 
are stopped, a period of 'normalisation' is likely, during which the haemoglobin (Hb) may 
return to pretreatment levels.  
Options available for the management of cancer treatment-induced anaemia include 
adjustments to the cancer treatment regimen, iron supplementation and RBCT. The majority 
of people who become anaemic do not receive any treatment for their anaemia, but those 
who become moderately or severely anaemic are usually given RBCTs. Complications 
related to RBCT include procedural problems, iron overload, viral and bacterial infections, 
and immune complications. However, there is a small proportion of people unable to receive 
RBCT (Jehovah’s Witnesses and people with multiple antibodies to RBCs as they have 
required regular RBCT in the past). 
1.1.1. Treatment landscape, 10 years on  
Erythropoietin is a glycoprotein hormone, which is produced mainly in the kidney and is 
responsible for regulating red blood cell production. Erythropoietin for clinical use is 
produced by recombinant DNA technology. Erythropoiesis stimulating agents (ESAs) are 
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used as an addition to, rather than a replacement for, existing approaches to the 
management of anaemia induced by cancer treatment. RBCT, in particular, may still be 
needed in people treated with ESAs. 
Previous National Institute for Health and Care Excellence (NICE) guidance (TA142) in 2007 
recommended ESAs: ‘in combination with intravenous iron as an option for the management 
of cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for 
ovarian cancer who have symptomatic anaemia with a haemoglobin level of 8 g/100 ml or 
lower. The use of ESAs does not preclude the use of existing approaches to the 
management of anaemia, including blood transfusion where necessary. ESAs in 
combination with intravenous iron may be considered for people who cannot be given blood 
transfusions and who have profound cancer treatment-related anaemia that is likely to have 
an impact on survival.’ 
While evidence at the time documented a clear improvement in haematological response 
and a reduction in the need for red blood cell transfusions associated with the use of ESAs, 
there was considerable uncertainty surrounding safety (in particular the frequency of 
thromboembolic events), and the impact on survival; giving rise to ongoing debate as to the 
effectiveness and safety of ESAs in this area. Ten years on from the previous appraisal 
(2004) licences have been amended to reflect these concerns. 
Initially all ESAs were recommended for use at Hb level ≤11 g/dl, with target Hb levels not 
exceeding 13 g/dl. A safety review by the Pharmacovigilance Working Party at the request of 
the Committee for Medicinal Products for Human Use in 2008 resulted in changes to the 
Summary of Product Characteristics for all ESAs at the European Medicines Agency’s 
request. These changes came into effect in 2008 – after the previous guidance was issued – 
and included: a decrease in the haemoglobin value for treatment initiation to Hb ≤10 g/dl (to 
either increase haemoglobin by <2 g/dl or to prevent further decline); to amend haemoglobin 
target values to 10–12 g/dl and haemoglobin levels for stopping treatment to >13 g/dl. In 
addition, the EMA added the following criteria to the label: in patients not treated with 
chemotherapy, there is no indication for the use of ESAs and there might be increased risk 
of deaths when ESAs are administered to a target of 12–14 g/dl; and, in people treated with 
curative intent, ESAs should be used with caution. 
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1.1.2. Current evidence 
Previous guidance (TA142) was based on evidence presented as part of the HTA process 
by Wilson and colleagues (2007). This review had a wider focus than the present HTA in 
that it considered the use of ESAs with regard to their effectiveness in treating cancer-
related anaemia irrespective of whether caused by cancer treatment. 
Scoping searches identified two relevant recent Cochrane reviews (Tonia and colleagues, 
2012; and Bohlius and colleagues, 2009). As in Wilson and Colleagues (2007), the focus 
of these reviews was the use of ESAs with regard to their effectiveness in treating cancer-
related anaemia irrespective of whether caused by cancer treatment. 
Current evidence suggests that ESAs reduce the need for RBCT but increase the risk for 
thromboembolic events and deaths. There is suggestive evidence that ESAs may improve 
quality of life. Whether and how ESAs affect tumour control remains uncertain. 
1.2. Objective 
The following question was addressed by this report: ‘What is the effectiveness and cost-
effectiveness of erythropoietin stimulating agents in anaemia associated with cancer 
treatment (specifically chemotherapy)?’ 
The review was based on a pre-defined scope issued by NICE, and conducted in 
accordance with a pre-defined protocol. Given the publication of the 2012 Cochrane review 
(Tonia and colleagues, 2012), and the fact that no studies were completely aligned with the 
current UK authorisation, studies were considered eligible for inclusion in accordance with 
UK marketing authorisations if they used a licensed starting dose irrespective of how they 
dealt with other criteria stipulated by the licence. 
The ESAs considered are: epoetin alfa (Eprex®, [Janssen-Cilag] and Binocrit® [Sandoz]); 
epoetin beta (NeoRecormon®, Roche Products); epoetin theta (Eporatio® [Teva UK]); 
epoetin zeta (Retacrit® [Hospira UK]) Darbepoietin alfa (Aranesp® [Amgen]). All 
interventions will only be considered according to their UK marketing authorisation. The key 
assumption maintained throughout this report is that all ESAs are equally effective. 
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1.3. Methods 
1.3.1. Clinical effectiveness and health-related quality of life:  
The search strategy is based on the strategy used in the previous HTA review on this topic 
(Wilson and colleagues, 2007). The databases searched included: The Cochrane Library, 
MEDLINE, MEDLINE In Process, Embase, Web of Science; CINAHL; British Nursing Index; 
HMIC; Current Controlled Trials; Clinical trials.gov; FDA website; and, EMA website. As this 
is an update of a previous review databases were searched from 2004 to 2013. Search 
filters were applied to retrieve randomised controlled trials (RCTs) and quality of life studies. 
Bibliographies of included papers were scrutinized for further potentially includable studies. 
The reference lists of the industry submissions were also scrutinised for additional studies. 
Due to resource limitations the search was restricted to English language papers only. All 
references were managed using Endnote (X5; Thomson ISI ResearchSoft) and Microsoft 
Excel 2010 software.  
Titles and abstracts returned by the search strategy were examined independently by four 
researchers (LC and MH [clinical] and TJH and LL [health-related quality of life]) and 
screened for possible inclusion.  Disagreements were resolved by discussion. Full texts of 
the identified studies were obtained. Four researchers (LC and MH [clinical], and TJH and LL 
[health-related quality of life]) examined these independently for inclusion or exclusion, and 
disagreements were again resolved by discussion. Included studies from the previous HTA 
review (Wilson and colleagues, 2007) were also screened for inclusion by two researchers 
(LC and MH).  
Dosing strategies vary considerably in the literature in terms of: start dose (fixed or weight-
based); trigger haemoglobin level, target haemoglobin level; dose escalation; stopping rules 
for non-responders; and, duration of use. These aspects will have an impact on effect 
estimates. Given the publication of the 2012 Cochrane review (Tonia and colleagues, 
2012), this HTA review focused on the administration of ESAs in accordance with UK 
marketing authorisations. However, as none of the trials completely met the current licence 
recommendations, they were considered eligible for inclusion if they used a licensed starting 
dose irrespective of how they dealt with other criteria stipulated by the licence; e.g. inclusion 
or target Hb levels. Thus, ESAs administered weekly, for epoetin alfa and epoetin zeta, 
three-times weekly, for epoetin beta; and, every three weeks for darbepoetin alfa were 
considered eligible for inclusion. Fixed (epoetin theta) and weight-based (epoetin alfa, 
epoetin beta, epoetin zeta, and darbepoetin alfa) dosages were allowed. In addition, we also 
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conducted post hoc analyses considering inclusion Hb level closer to licence ≤11 g/dl and 
>11 g/dl; and target Hb closer to licence ≤13g/dl and >13 g/dl. 
Data were extracted by one reviewer and checked by another.  Disagreements were 
resolved by discussion.  
The results of individual trials were pooled using meta-analysis where possible and justified. 
A random-effects model was assumed for all meta-analyses. Where data were not reported 
in the published papers data were extracted from the 2012 Cochrane review (Tonia and 
colleagues, 2012). This was justified on the basis that the Cochrane authors had had 
access to additional unpublished materials when conducting their review. Where meta-
analysis was not possible narrative synthesis, supported by information collected the data 
extraction tables, was used to summarise the evidence base. 
Subgroup analyses were conducted: mean Hb at baseline (<10 g /dl versus <11 g/dl versus 
<12 g/dl versus <14.5 g/dl versus not reported); Hb inclusion criteria (≤11 g/dl and >11 g/dl); 
malignancy type (solid, haematological, mixed, not reported); ovarian cancer; chemotherapy 
type (platinum, non-platinum, chemotherapy plus radiotherapy; mixed chemotherapy; not 
reported); ESA type (short-lasting, long-lasting); iron supplementation (given, not given, 
given differently in treatment arm; not reported); duration of ESA medication (6–9 wks, 12–
16 wks, 17–20 wks, >20 wks); and, study design (blinded [RCT], unblinded [randomized 
open label [ROL]]). 
1.3.2. Cost effectiveness 
1.3.2.1.  Review of past economic evaluations 
The previous NICE appraisal (TA142), published in Wilson and colleagues (2007), 
included a systematic review of published evidence of the cost-effectiveness of ESAs for 
cancer treatment-induced anaemia.  Several databases (including MEDLINE and EMBASE) 
were searched, resulting in 491 records being identified.  After screening by title and 
abstract, 44 full-text articles were retrieved for assessment.  Five studies were eligible for 
inclusion and were critically appraised and summarised.  Of these five studies, three were 
cost-utility analyses (i.e., studies reporting costs and QALYs of interventions). 
We undertook to update the systematic review to identify any evidence regarding the cost-
utility of ESAs, particularly as relevant to the NHS.  ESA administration was considered 
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within licence for inclusion in this review based on dose frequency but not dose quantity (i.e., 
QW for any ESA, TIW for epoetin alfa and epoetin zeta, Q3W for darbepoetin alfa and 3–7 
times weekly for epoetin beta).  Fixed and weight-based dosages were allowed. 
Searches were conducted in several databases (including MEDLINE and EMBASE), with 
results limited to studies published since 2004 where possible, resulting in 1,163 records 
being identified.  Following removal of duplicate records 843 titles and abstracts were 
screened independently by two reviewers.  Fifty four full-text articles were assessed for 
eligibility and 29 were judged to be eligible.  Five studies were excluded as they were 
multiple publications meaning 24 studies were included. 
1.3.2.2.  PenTAG cost-uti l i ty model 
1.3.2.2.1.  Model structure 
In the PenTAG assessment, the model takes the form of a simple, empirical model, informed 
directly by the systematic review of clinical effectiveness. The model compares patients 
receiving  ESA therapy to patients not receiving ESA therapy and is split into two temporal 
sections, one to evaluate the short-term costs and QALYs (while patients are anaemic) and 
one to evaluate long-term QALYs. 
Short-term costs are accrued in the form of ESA drug acquisition and administration, red 
blood cell transfusion costs and costs of adverse events. Cancer costs are assumed equal 
for all patients. No difference in survival time in the short term is modelled between arms.  
Long term costs are not modelled due to the uncertainty of such costs, given the varied 
patient population and to avoid an arbitrary value disadvantaging a strategy with a survival 
benefit. 
Short-term QALYs are accrued as the utility associated with empirical observation of Hb over 
time.  Here, Hb levels over time are taken directly from clinical trials and this approach 
attempts to bolt-on an economic evaluation to the RCTs of ESAs.  The short term QALY gain 
includes time receiving ESA therapy and a time post-ESA therapy called normalisation 
where patients return to their ‘normal’ Hb level (in the base case this is set to 12 g/dL). 
Long-term QALYs are accrued due to potential differences in overall survival between the 
two arms. These are calculated by estimating overall survival in each arm and applying a 
long-term utility common to both arms, i.e., it is assumed long-term QALY differences only 
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come about through a difference in survival due to ESA therapy, not through any enduring 
impact on health-related quality of life.  
An exponential distribution is assumed for overall survival of patients not receiving ESA 
therapy in the base case as this is consistent with results from a number of trials.  A hazard 
ratio is applied to overall survival for lifetime for patients receiving ESA therapy.  Alternative 
modelling assumptions are explored through scenario analyses. 
1.3.2.2.2.  Model parameters 
On recommendation from NICE and in keeping with the clinical effectiveness review, equal 
effectiveness was assumed for ESAs. However, some parameters specific to each ESA, 
such as drug doses and costs, are varied between ESAs. 
In order to ensure consistency between costs and benefits, all parameters are estimated on 
the basis of intention-to-treat.  For example, we use the mean weekly dosage of ESAs 
averaged over all patients at baseline for the full intended treatment duration.  This average 
includes some patients who withdraw from ESA treatment during the trial. 
1.3.2.2.3.  Clinical effectiveness 
Most parameters were estimated from outcomes reported by randomised trials included in 
the systematic review of clinical effectiveness.  No evidence from RCTs was found for 
normalization of Hb levels following chemotherapy cessation, so this part of the model had to 
be parameterised on the basis of clinical expert opinion. 
1.3.2.2.4.  Uti l i t ies 
For the analysis, the model requires two sources of utility values: (1) utility as a function of 
Hb levels during ESA treatment and during normalisation to reflect impact of ESAs on 
HRQoL, and (2) constant utility value after normalisation, equal in all treatment arms. 
A review was conducted of studies for (1) and a single study chosen from which the PenTAG 
base case was calculated (Harrow and colleagues, 2011) and scaled to the EQ-5D, giving 
a 0.028 increase in utility per unit increase in Hb. The long term utility of (2) is calculated 
using an estimate for cancer utility from Tengs and Wallace (2000) and applying the age 
related utility calculated from Ara and Brazier (2010). This gives a utility of 0.76. 
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The model does not explicitly model disutility from adverse events, due to lack of data. 
1.3.2.2.5.  Costs 
In this analysis we model the following costs: blood tests, ESA prices, red blood cell 
transfusion (RBCT) cost (unit cost of blood and cost of transfusion appointment) and costs of 
adverse events. We do not model long term costs in the base case, given the uncertainty 
attached to these values as a result of the wide patient population. We assume that the cost 
of intravenous iron supplementation can be ignored as it will be very similar for all arms. 
Costs are adjusted to 2014/15 prices where appropriate. 
Base case ESA costs are taken from the British National Formulary 2013. Wholesale 
acquisition costs for ESAs have also been obtained and are used in a scenario analysis. 
ESAs are assumed to be administered once weekly in the base case, by a mixture of GP, 
district, hospital staff nurse and self- administration. ESAs are also assumed to incur costs 
for four additional blood tests compared to the no ESA arm, in line with the possibility that 
additional blood tests would continue post-chemotherapy for those patients on ESAs. 
The adverse events we account for in this cost-effectiveness analysis are identified through 
the clinical effectiveness review. In particular we account for the cost of thromboembolic 
events, hypertension, and thrombocytopenia. The unit costs of managing thromboembolic 
events (particularly pulmonary embolism and deep vein thrombosis), hypertension and 
thrombocytopenia are identified through NHS Reference Costs 2012-13. 
Unit costs for the supply of red blood cells (RBCs) are taken directly from NHSBT 2012/13 
costs (£122 per unit) and unit costs of a transfusion appointment are calculated using figures 
reported in Varney and Guest 2003. 
1.3.2.2.6.  Other model characterist ics 
A lifetime time horizon is used in the model.  The perspective adopted was NHS and 
Personal Social Services.  Costs and benefits were discounted at 3.5% per annum. 
The age and weight of patients in the model are estimated from the age and weight reported 
in clinical studies included in the systematic review of clinical effectiveness evidence. 
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1.4. Results 
1.4.1. Clinical effectiveness 
1.4.1.1.  Number and quality of effectiveness studies 
From 1,458 titles and abstracts screened 11 systematic reviews (reported in 14 
publications), and 23 RCTs (reported in 35 publications), were found that matched the 
inclusion criteria for this review. Update searches yielded 70 unique titles and abstracts; 
however, none were considered to meet the criteria for review. All of the included studies 
had been included in the recent Cochrane review (Tonia and colleagues, 2012). The 
PenTAG review included one full paper (Moebus and colleagues, 2013) reporting a study 
for which only an earlier abstract (Moebus and colleagues, 2007) was included in the 
Cochrane review (Tonia and colleagues, 2012).  Thirteen studies compared ESAs plus 
supportive care for anaemia (including transfusions) with placebo plus supportive care for 
anaemia (including transfusions) alone; and, ten studies compared ESAs plus supportive 
care for anaemia (including transfusions) with supportive care for anaemia (including 
transfusions) alone. Of note, none of the included studies evaluated ESAs entirely within the 
remit of their marketing authorisations; in particular, start and target haemoglobin levels, and 
stopping rules were all generally higher than specified in the license.  
Taken as a whole, the quality of the trials was moderate to poor. For most of the trials it was 
difficult to make a general assessment about study quality due to reporting omissions. Most 
notably, all trials lacked clarity in the reporting of allocation methods (the procedure for 
randomisation and/or allocation concealment). 
1.4.1.2.  Assessment of effectiveness 
Overall the analysis of haematological response (defined as an improvement of 2 g/dl or a 
6% increase in haematocrit level) included 10 studies with 2,228 participants. Meta-analysis 
showed a statistically significant difference in Hb response in favour of treatment (RR 3.29, 
95% CI 2.84–3.81). Sixty-three per cent (n/N=759/1,213) of participants who received ESAs 
achieved a haematological response compared with 18% (n/N=182/1,015). Subgroup 
analyses were inconclusive. Treatment with ESAs reduces the number of patients receiving 
RBCTs by an estimated 37%. These estimates are consistent with previously reported 
estimates. 
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Results of previous reviews with respect to survival have varied, and there is much debate 
surrounding the impact of ESAs on survival. Survival data were available from 23 studies 
including 5,064 participants. The HR for survival was 0.97 (95% CI 0.83, 1.13); the forest 
plot suggested that there was a tendency for smaller studies to favour ESA treatment. 
Although this estimate differed from those reported by Wilson and colleagues,2007) and 
Tonia and colleagues,2012) – 1.05 (95% CI 1.00, 1.11), and 1.03 (95% CI 0.83, 1.13) 
respectively, there was considerable uncertainty around this estimate  and statistically 
significant heterogeneity was identified( I2 42.4%; Χ2=29.5, df=17, p=0.03). In addition 
subgroup analyses did not identify groups at lower or higher risk.   
On-study mortality was defined as deaths occurring up to 30 days after the active study 
period. Data, extracted from the Cochrane review (Tonia and colleagues, 2012), were 
available from 21 studies including 5,085 participants. Analyses suggest that treatment with 
ESA in patients with CIA did not have a statistically significant effect on mortality (HR 0.86, 
95% CI 0.67 to 1.11). Eleven per cent (174/1,586) participants who received ESA had died 
within 30 days of the active study period, compared to 12% (164/1,381) of patients in control 
groups. 
All AEs were relatively rare compared to the other outcomes considered in this report. The 
AE with the highest rate was thrombocytopenia/haemorrhage; 6% (55/877) in ESA treatment 
groups, and 6% (54/838) in control groups. The summary estimate for 
thrombocytopenia/haemorrhage in the PenTAG review was RR 0.93 (95% CI 0.65, 1.34) 
compared with RR 1.21 (95% CI 1.04, 1.42) in the Cochrane review (Tonia and colleagues, 
2012). However, although the point estimate is lower compared with previous results the 
data are insufficient to rule out detrimental effects. Overall, data suggest increased risk for 
thromboembolic events, hypertension, seizures and pruritus (skin rash, irritation and pruritus 
were combined in the analyses) consistent with previous estimates.  Analyses suggest that 
treatment with ESA in patients with CIA increases the risk for thromboembolic events (RR 
1.46; 95% CI 1.08 to 1.99), increases the number of hypertension events (RR 1.80 95% CI 
1.14 to 2.85)., increases the number of cases of pruritus (RR 2.04; 95% CI 1.11 to 3.75) and 
suggests a non-significant increase in the number of seizures (RR of 1.19; 95% CI 0.33 to 
4.38). 
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1.4.1.2.1.  Subgroup analyses 
Two of the subgroups evaluated corresponded with the current NICE recommendations: 
women with ovarian cancer receiving platinum-based chemotherapy, and people unable to 
receive blood transfusion. 
One trial (Ten Bokkel and colleagues, 1998) evaluated the use of ESAs in women with 
ovarian cancer. Data confirm results from prior analyses with respect to anaemia-related 
outcomes; i.e. improvements in haematological response and reduction in RBCT 
requirement, but increased risk for thromboembolic events. Overall survival was not 
measured. No trials were identified that evaluated people unable to receive blood 
transfusions. However, it is reasonable to assume that ESAs are likely to be effective in 
improving Hb level in this subpopulation. 
In addition, subgroup analyses considering any type of cancer and platinum-based 
chemotherapy, platinum-based chemotherapy in head and neck malignancies, and iron 
supplementation were conducted.  
1.4.1.2.2.  Other factors for consideration 
As previously stated, studies were eligible for inclusion in the systematic review if they used 
a licensed starting dose irrespective of how they dealt with other criteria stipulated by the 
licence. In addition to this we also considered this in combination with other licence criteria; 
i.e. inclusion Hb criteria (closer to the licence ≤11 g/dl and >11 g/dl), and target Hb (closer to 
the licence ≤13 g/dl and >13 g/dl) in post hoc analyses.  
A trend associated with the administration of ESAs according to licence recommendations 
was noticed. It appeared that effectiveness in terms of some outcomes was improved when 
ESAs were evaluated closer to their licenced indications; e.g. dose and inclusion Hb level 
(≤11 g/dl), and dose, inclusion Hb level (≤11 g/dl) and target Hb level (≤13 g/dl). Findings for 
anaemia-related outcomes showed improvements consistent with prior analyses. The 
effectiveness on malignancy-related outcomes did appear to be affected by the licence 
application and estimated effects of ESAs administered in accordance with licence 
recommendations were notably lower than those reported in prior analyses. Importantly, 
although the results for thromboembolic events from the PenTAG review agree with the 
Cochrane review (Tonia and colleagues, 2012), suggesting an increase in thromboembolic 
events in patients with ESA compared to controls, the closer the studies were to the licence 
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recommendations, the smaller the point estimates (suggesting less detrimental effects of 
ESA). 
However, all subgroup analyses must be interpreted with caution. The number of studies per 
subgroup is small, and the confidence intervals remain wide. The analyses may not have 
statistical power to detect the effects of license application on the effectiveness of outcomes, 
if such effects exist. Furthermore, we have not sought to address multiple testing issues 
which arise when considering subgroups and so the statistical significance of results may 
appear overstated. 
1.4.2. Health-related quality of life 
Thirteen trials measuring HRQoL were reported in 23 publications. Of these publications, 11 
primary studies were included in the review by Wilson and colleagues (2007). Three new 
primary studies were identified in the update searches. 
Taken as a whole, the quality of the trials was moderate to poor. For most of the trials it was 
difficult to make a general assessment about study quality due to reporting omissions. 
Baseline characteristics were unbalanced in two trials. Patients and physicians were blinded 
for the majority of trials, which is considered to have a significant impact of HRQoL assessed 
by self-reporting. Significant patient numbers were lost to follow-up for HRQoL outcomes in 
at least six trials. 
Given the variability of reporting in the published papers FACT-F 13 item (score 0–52), data 
were extracted from the Cochrane review by Tonia and Colleagues (2012) for use in the 
PenTAG analyses. FACT-F scores were available from seven studies with one new primary 
study identified. Overall, conclusions from the PenTAG review are in agreement with the 
Cochrane review (Tonia and colleagues, 2012) in that there is a statistically significant 
difference between patients treated with ESAs and controls when combining HRQoL 
parameters. However, the pooled mean difference between the treatment and control arms 
is <3 units, which is not considered clinically significant for FACT-F. Univariate subgroup 
analyses conducted for FACT-F outcomes according to chemotherapy type, malignancy 
type, intervention (epoetin or darbepoetin), and study duration, also showed similarly 
statistically significant results between intervention and control. 
Meta-analysis was performed on FACT-G and FACT-An (7 items), however, only three 
studies were suitable for inclusion for each scale, and their results displayed high levels of 
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heterogeneity. The results of no statistical difference between intervention and control must 
therefore be treated with caution. 
Overall, conclusions from the PenTAG review are in agreement with the Cochrane review 
(Tonia and colleagues, 2012) and the previous HTA review (Wilson and colleagues, 
2007). We have attempted to include populations closer to the licence for ESAs to 
understand the effects on HRQoL at these doses. Furthermore, as the previous HTA 
(Wilson and colleagues, 2007) was only able to use a vote counting method to estimate 
the positive direction of effect, results from the PenTAG review have been quantified and 
pooled to enable a more direct comparison between treatments. 
1.4.3. Cost-effectiveness 
1.4.3.1.  Published economic evaluations 
Of the 24 included studies, 12 were abstracts only.  Two related to the previous NICE 
appraisal.  Three were new cost-utility studies (Fagnoni and colleagues, 2006; Borg and 
colleagues, 2008; Tonelli and colleagues, 2009).  Two were or included new systematic 
reviews (Duh and colleagues, 2008; Tonelli and colleagues, 2009). 
Data extraction was conducted for all 24 included studies, but attention was focused on the 
new cost-utility studies and new systematic reviews.  New cost-utility studies were critically 
appraised using quality assessment tools (Evers and Philips checklists as appropriate).  
Narrative synthesis was conducted. 
All of the studies (pooling those included from the previous review and the new studies) 
finding favourable cost-effectiveness for ESAs were funded or conducted by industry.  Many 
of these assumed ESA therapy would lead to survival benefit for patients, although this is not 
supported by recent systematic reviews and meta-analyses. 
A key assumption in almost all analyses was that raising Hb levels would improve health-
related quality of life, though in no case was this assumption based on published RCT 
evidence using a preference-based quality of life measure. 
A number of studies assumed a period following the end of chemotherapy treatment during 
which Hb levels would gradually return to normal (termed normalisation),  whilst participants 
in the ESA arm would continue to accrue incremental benefits in quality of life over 
PenTAG          
29 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
participants in the no ESA arm; to our knowledge, no evidence for or against normalisation 
has been presented in the published literature. 
In the absence of survival benefit the expected health gain from ESA therapy is small (up to 
0.035 QALYs) and is subject to uncertainty. 
Studies did not incorporate current list prices or wholesale acquisition costs, which could 
significantly reduce the drug acquisition component of ESA therapy cost and improve cost-
effectiveness. 
There is a need for an up-to-date analysis of the cost-effectiveness of ESAs in the NHS to 
reflect reduced drug acquisition costs, changes to licences and market entry of additional 
comparators.  This analysis will need to explore the significant amount of uncertainty which 
still remains. 
1.4.3.2.  Appraisal of industry submissions 
Six manufacturer submissions were potentially available for this MTA. However, no 
manufacturers’ submitted an economic evaluation.  
1.4.3.3.  PenTAG model 
1.4.3.3.1.  Base case 
We find that the deterministic base case has incremental cost-effectiveness ratios (ICERs) 
for ESA treatment versus no ESA treatment range from £19,429–£35,018 per QALY gained. 
Given that this covers a wide range of values and the entirety of the £20,000–£30,000 per 
QALY range that is often used as a cost-effectiveness threshold by NICE, it was considered 
appropriate to emphasise the results of the probabilistic sensitivity analyses (PSA). 
1.4.3.3.2.  Sensit ivity analyses 
The expected mean results from the PSA gave ICERs that were lower than the deterministic 
base case (£14,724–£27,226 per QALY gained). The QALYs gained for ESA treatment 
compared to no ESA treatment had an average of 0.092 with a confidence interval of (-0.264 
– 0.447). The incremental costs for the most-cost-effective ESA (Binocrit® [epoetin alfa]) 
were £1,349 (£710-£1,987, 95% CI). The ICER for Binocrit had a 95% credible interval (CrI) 
that was dominated by no ESA use (had fewer QALYs and higher costs) at its upper end, 
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with a lower value of £2,350 per QALY gained (rounded to the nearest £50). In 36% of 
simulations there was an overall survival loss, with 31.4% of simulations having an overall 
QALY loss. Given this was the most cost-effective ESA treatment, it is unsurprising that the 
rest of the ESAs were also dominated at their upper credible interval limit. These results 
suggest that ESAs may be cost-effective at a threshold of £20,000 per QALY, but also 
suggest that there is also a potential QALY loss from ESA use. These results suggest that 
ESAs could be cost-effective at a threshold of £20,000 per QALY, but this could also be a 
result of chance variation, and there is a significant chance of QALY loss in patients 
receiving ESA therapy. 
1.4.3.3.3.  Scenario analyses 
Scenario analyses were conducted to investigate what was driving the wide range of values 
in the ICERs credible intervals. The three considered most important are: 
(1) Setting the overall survival hazard ratio to exactly 1, such that survival is the same for 
both patients on ESA therapy and those not on ESA therapy.  
(2) Setting ESA costs to wholesale acquisition costs, in an attempt to establish the real 
costs to the NHS  
(3) Setting the overall survival hazard ratio to exactly 1 and the ESA costs to wholesale 
acquisition costs. 
In the first of these scenarios, where survival is assumed equal for both treatment arms, we 
find that the QALY gain has greatly reduced (as well as the confidence interval: 0.014 
(0.001–0.027), suggesting that much of the variability in the base case QALYs came from 
the QALYs accrued in long term survival.  The reduction in QALYs also increases the 
ICERs, with the most cost-effective ESA achieving an ICER of £96,754 per QALY gained 
(95% CrI: £36,500 to over £300,000 per QALY gained) in the PSA. None of the credible 
intervals for the ICERs fall below £30,000 per QALY gained, suggesting in this scenario that 
ESAs are unlikely to be cost-effective. 
In the second scenario, where wholesale acquisition costs were implemented, 
********************************************************************** (for the least costly ESA- 
Retacrit®) per QALY gained. However, in this scenario the 95% CrI went from ESA 
dominating, (with more QALYs and lower costs than no ESA use) at one end, to being 
dominated by the no ESA arm at the other end. 
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In the third scenario, where survival is assumed equal for both treatment arms and 
wholesale acquisition costs are used 
*********************************************************************************************************
*********************************************************************************************************
********************************************************* 
We also conducted scenario analyses on a subgroup of studies where initial Hb level for 
participants was ≤11 g/dl, and to investigate the assumptions around overall survival. 
Univariate sensitivity analyses were also conducted. All these analyses resulted in less 
significant areas of uncertainty than those identified by the results presented in this section. 
1.5. Discussion 
1.5.1. Strengths and limitations: clinical-effectiveness and quality 
of life reviews 
The overview of clinical effectiveness systematic reviews were conducted by an 
independent, experienced research team using the latest evidence and working to a pre-
specified protocol (PROSPERO CRD42013005812). This technology assessment builds on 
existing secondary research and economic evaluations. However, there are some important 
sources of uncertainty that impact on the conclusions.  
 Relative effectiveness: We did not address the relative effectiveness of different 
ESAs. Lack of head-to-head RCT evidence would have been an important limitation 
if we had tried to do this. 
 Dose: The protocol stated that ESAs should be evaluated in accordance with their 
UK marketing authorisations. However, given the fact that no studies were 
completely aligned with the current UK authorization, we identified studies which 
were closest to the current marketing UK authorization, focusing initially on the 
starting dose. It is important to note that beyond the start dose there was still a 
significant differences from the current licence recommendations of the included 
studies. Also we did not pre-specify the criteria used to define closest to the current 
UK authorization, but we did explore alternative, stricter ways of making this 
definition.  
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 Generalisability: There may be other challenges to the applicability of the included 
trials which were done up to 20 years ago. Chemotherapy has changed during this 
period as has the quality of supportive treatment. 
 Study quality: The included trials were of variable quality but all were flawed to 
some degree. Most notably, all trials lacked clarity about randomisation and 
allocation concealment. The general problem of poor reporting of trials on this 
topicwas greatly assisted by the recent Cochrane review (Tonia and colleagues, 
2012). The authors had gathered further information from Investigators and 
manufacturers, which were used in the meta-analysis for the current review.  
 Heterogeneity: There is considerable considerable unexplained statistical 
heterogeneity for a number of outcomes, particularly survival .  
 Publication bias: There was some evidence in both the previous review and the 
Cochrane review that the results from small negative trials may not be available for 
inclusion in the systematic reviews, suggesting the possibility of publication bias. For 
some outcomes in this review ie HRQoL this could not be further investigated 
because of the small number of included studies, in others such as survival there 
was continuing support for the possibility of publication bias. Industry-sponsored trials 
predominate. 
 Precision: Although there is an apparent wealth of RCTs, only a minority of these 
were included because of the desire to address effectiveness as close as possible to 
current UK authorization. 95% confidence intervals were in consequence often wide 
and include values indicating  no difference in effect. The problem was compounded 
by the fact that total number of patients in the trials included were insufficient to 
establish the true presence of or absence of an effect, either because events are 
uncommon ie adverse events, or because the effect size which would be deemed to 
be clinically important is small, as would be the case with survival.  
 Multiple testing: Although we were aware of the possibility of spuriously positive 
tests for statistical significance arising because of the multiple sub-groups analyses 
done, we did not formally make adjustments for this 
The limitations identified above impact on the key outcomes as follows:  
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 Haematological response and numbers transfused seem robust estimates, with no 
marked heterogeneity or subgroup effects 
 Hb change does have important heterogeneity, which may possibly indicate 
subgroup effects; however, analyses in this respect were inconclusive 
 HRQoL is affected by the variability of instruments used and study quality 
 Adverse events are mainly affected by the quality of information available, the 
variability in the definition of individual adverse events used and the width of the 
confidence intervals.   
 Survival is also subject to all the limitations outlined above. Marked heterogeneity 
was identified for which no explanation could be provided. In addition, OS was 
calculated from the longest follow-up availableans as result there was a mix of short- 
and long-term studies. 
1.5.2. Strengths and limitations: cost-effectiveness 
1.5.2.1.  Systematic review of cost-effectiveness studies 
 The systematic review of cost-effectiveness evidence was conducted by an 
independent research team using the latest evidence and to a pre-specified protocol.  
Two new systematic reviews were identified, neither of which identified studies which 
would have been eligible for this review but were not included. 
 Limitations were identified as follows: 
 The searches were limited to English language due to resource limitations; 
 Only systematic reviews and cost-utility studies were fully critically appraised and 
considered in the narrative synthesis; 
 Records from database searches published pre-2004 were excluded although it was 
not possible to assess whether these had been screened for eligibility in the 
systematic review presented in Wilson and colleagues (2007);Studies using 
darbepoetin alfa once every two weeks were excluded as out of licence although 
these could have usefully contributed to the review.  
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1.5.2.2.  PenTAG model 
The main limitations for viewing the updated model and its outputs with such caution are: 
 Despite being highly influential on the model results, the marginally beneficial overall 
survival hazard ratio identified in the clinical effectiveness section has no strong 
biological rationale.  Although many post hoc suggestions have been advanced to try 
to explain both the increases and decreases survival observed in individual ESA 
RCTs, most of these results can be explained by chance alone. 
 The overall survival hazard ratio is applied assuming proportional hazards applying 
for lifetime after ESA therapy, although to our knowledge the proportional hazards 
assumption has not been tested.  Most included studies had limited follow-up so the 
long-term impact on survival is not well known.  Limiting the effect of ESA therapy on 
survival to three years results in a significant worsening of cost-effectiveness for 
ESAs. 
 The mapping of Hb to utility is a surrogate outcome with the problems this entails. 
Furthermore the utility identified for the base case was not ideal: it had to be 
additionally mapped to the EQ-5D, and the patient population was cancer patients 
without ESA use only. The main weakness of the study design was that it was 
observational.  This means that the estimated relation between utility and Hb level 
may be biased due to unmeasured confounding variables, and it is likely that this 
would bias the results in favour of ESAs versus controls. 
 Furthermore, evidence is lacking for the process of normalisation and this was 
entirely informed by clinical expert opinion. 
 We also assumed constant cancer costs between ESA and no ESA arms, where this 
may not be the case.  
 The model also assumes that there is no long term cost difference between arms, but 
does assume a long term survival benefit.  As previous models indicated, this long 
term aspect of the model is an area which has not been assessed in great detail 
before, as such this is an area where there need to be better understanding. 
 As the model is primarily driven by data from the clinical effectiveness review, the 
input parameters may not be in line with current practice. This also means that 
limitations of the clinical effectiveness review carry over in to the cost-effectiveness 
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results. Furthermore the inherent uncertainty in the estimates from the clinical-
effectiveness meta-analysis and its associated limitations are a main source of 
uncertainty that occurs within the model. This also means that the effectiveness of 
ESAs are assumed equal, as this follows from the clinical effectiveness review. 
1.6. Conclusions 
The previous HTA review (Wilson and colleagues, 2007) concluded: “Epo is effective in 
improving haematological response and reducing RBCT requirements. It also appears to 
improve HRQoL. Its impact on side-effects and survival remains highly uncertain. If there is 
no impact on survival, it seems highly unlikely that ESAs would be considered a cost-
effective use of healthcare resources.” 
Additional clinical effectiveness evidence identified in this update systematic review 
continues to suggest that there is clinical benefit from ESAs with respect to anaemia-related 
outcomes; i.e. improvements in haematological response and reduction in RBCT 
requirement. Data also suggest an improvement in HRQoL and this is better quantified 
compared with the previous HTA review. The impact on side-effects and survival, however, 
remains highly uncertain. Although the point estimates for both survival and thromboembolic 
events are lower than previously reported estimates the 95% confidence intervals are wide. 
Conclusions concerning cost-effectiveness are also no clearer.  Base case ICERs for ESA 
treatment versus no ESA treatment ranged from £19,429–£35,018 per QALY gained, but 
sensitivity and scenario analyses demonstrate that there is considerable uncertainty in these 
ICERs. In line with the previous HTA, survival was an influential parameter. If the survival 
benefit reported in the clinical effectiveness review (0.97 [95% CI 0.83–1.13]) is used, ESAs 
appear to be cost-effective on average but this is highly uncertain and QALY loss cannot be 
ruled out (31.4% of simulations in the base case estimated QALY loss from ESA therapy). 
However, if exactly equal survival is assumed regardless of ESA therapy, ESAs are 
predicted not to be cost-effective, unless wholesale acquisition costs are used, in which case 
ESAs are predicted to be cost-effective on average although approximately 1 in 5 
simulations give an ICER over £30,000 per QALY and approximately 1 in 3 simulations give 
an ICER over £20,000 per QALY.  
In summary, ESAs could be cost-effective but there is considerable uncertainty mainly due 
to unknown impacts on overall survival. 
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1.6.1. Implications for service provision 
 Ongoing safety concerns: When seeking clinical experts to advise us in this 
assessment we found that most relevant clinicians (i.e., oncologists, haematologists 
and gynaecologists) did not use ESA therapy in their clinical practice.  This was 
generally due to concerns about safety and effectiveness (overall survival) as well as 
restriction from previous NICE guidance (TA142). 
 Current usage:  It is difficult to assess how frequently ESA therapy is used within the 
indication of cancer treatment-induced anaemia because prescription records do not 
routinely link medication with indication and ESA therapy is widely used in individuals 
with chronic kidney disease (CKD). Some indirect evidence of the use of ESA 
therapy for cancer treatment-induced anaemia is available from the use of cost 
centres against which ESAs are recorded. Data analysed are suggestive of 
significant variability in current usage, consistent with the experience that many 
clinicians do not use ESAs due to safety concerns and current NICE guidance 
(TA142), although data quality is low and interpretation challenging. 
 Acquisition costs: The cost at which hospitals acquire ESAs may be significantly 
lower than the list price for the drugs.  These prices are the subject of confidential 
negotiations and are commercially sensitive. At present acquisition prices will largely 
be driven by demand for ESAs for individuals with CKD.  Current prices could be 
disturbed if there were developments in the management of CKD or if demand for 
ESAs increased for patients with cancer treatment-induced anaemia (as might be 
expected following positive NICE guidance). 
1.6.2. Suggested research priorities 
 If ESAs are thought to have major potential in improving cancer care, large RCTs 
meeting current methods and reporting standards with adequate follow-up are 
needed to evaluate ESAs as administered in line with current marketing 
authorisations (including licence criteria for haemoglobin levels)  
 There should be improved estimates of the impact on tumour response and mortality; 
if these estimates are neutral or slightly beneficial it is plausible that ESAs could be 
cost-effective 
 There should be assessment of the frequency of the key potential adverse events 
related to ESA administration 
PenTAG          
37 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
 More data are needed to assess the impact on HRQoL. These should include the 
effect on EQ-5D.  
 More evidence is needed to assess the impact of Hb normalisation on utility 
 In addition to new trials, it may be valuable to re-visit Cochrane IPD meta-analysis 
and select studies that better fit ‘licensed recommendations’ with respect to Hb 
criteria and dose administered 
 It may also be helpful to explore reasons why improved anaemia may lead to better 
outcomes i.e. do ESAs allow better compliance with chemotherapy 
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 Background 
2.1. Aim of the review 
The aim of this assessment is to review and update research evidence as necessary, to 
inform National Institute for Health and Care Excellence (NICE) guidance to the National 
Health Service (NHS) in England and Wales on the clinical and cost-effectiveness of 
erythropoiesis-stimulating agents (ESAs) for the treatment of cancer treatment-induced 
anaemia (see Section 2.4.2.2, page 44).  
This previous guidance (TA142) was primarily based on evidence presented to NICE in the 
assessment report by Wilson and colleagues, 2007.1 We will incorporate relevant evidence 
presented in this previous report and report new evidence since 2004. 
2.2. Description of the health problem 
Anaemia is defined as: “a reduction of the haemoglobin (Hb) concentration, red blood cell 
(RBC) count, or packed cell volume below normal levels”.2 A commonly used classification 
of anaemia according to Hb levels is shown in Table 1.2 
Table 1. Classification of anaemia (from Wilson and collegues, 2007)1 
Severity WHO NCI 
Grade 0 (WNL) ≥11 g/dl WNL 
Grade 1 (mild) 9.5–10.9 g/dl >10 g/dl WNL 
Grade 2 (moderate) 8.0–9.4 g/dl 8–10 g/dl 
Grade 3 (serious/adverse) 6.5–7.9 g/dl 6.5–7.9 g/dl 
Grade 4 (life threatening) <6.5 g/dl <6.5 g/dl 
Key: NCI, National Cancer Institute; WHO, World Health Organisation; WNL, within normal limits 
 
It is the most frequent haematological manifestation in patients with cancer; more than 50% 
of all cancer patients will be anaemic regardless of the treatment received, and 
approximately 20% of all patients undergoing chemotherapy will require red blood cell 
transfusion (RBCT).3 
The cause of anaemia is usually multifactorial and may be patient-, disease-, or treatment-
related.3 The haematological features in anaemic patients depend on the different types of 
malignant disease, stage and duration of the disease, the regimen and intensity of tumour 
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therapy and possible intercurrent infections or surgical interventions. Tumour associated 
factors such as tumour bleeding, haemolysis, deficiency in folic acid and vitamin B12, can be 
acute or chronic. In the advanced stages of haematological malignancies, bone marrow 
involvement often leads to progressive anaemia. In addition, interaction between tumour-cell 
populations and the immune system can lead to the release of cytokines, especially 
interferon-gamma, interleukin-1, and tumour necrosis factor. This disrupts endogenous 
erythropoietin synthesis in the kidney and suppresses differentiation of erythroid precursor 
cells in the bone marrow. As a result, patients with tumour anaemia may have relatively low 
levels of erythropoietin for the grade of anaemia observed. Moreover, activation of 
macrophages can lead to a shorter erythrocyte half life and a decrease in iron utilization. 
Chemotherapy may cause both transient and sustained anaemia.3 Mechanisms of drug-
induced anaemia in patients with cancer include stem cell death, blockage or delay of 
haematopoietic factors, oxidant damage to mature haematopoietic cells, long-term 
myelodysplasia, immune-mediated haematopoietic cell destruction etc.3  Patients treated 
with platinum-based regimens develop anaemia most often and frequently need 
transfusions.3  As a consequence, dose-intensified regimens or shortened treatment 
intervals, as well as multimodal therapies, are associated with a higher degree of anaemia.3  
Anaemia can also compromise the effect of treatment, because low tissue oxygenation is 
associated with a reduced sensitivity of tumours to radiation and some forms of 
chemotherapy, contributing to the progression of cancer and reduction in survival.3 
Among patients with solid tumours the incidence of anaemia is highest in patients with lung 
cancer (71%) or gynaecological cancer (65%); these patients have the highest frequency of 
anaemia and the highest rate of transfusion requirements.3,4 The frequency of RBCT 
requirements in these patients varies from 47 to 100% depending on the cumulative dose of 
platinum chemotherapy received and other risk factors; e.g. age, disease stage and pre-
treatment Hb level. In haematological cancers, anaemia is an almost invariable feature of the 
disease.3 In addition, some of the newer chemotherapeutic agents such as taxanes or 
vinorelbine are strongly myelosuppressive and frequently cause anaemia.5 
The clinical manifestation and severity of anaemia can vary considerably among individual 
patients.3  Mild-to-moderate anaemia can typically cause signs and symptoms such as 
headache, palpitations, tachycardia and shortness of breath.3  Chronic anaemia can result in 
severe organ damage affecting the cardiovascular system, immune system, lungs, kidneys, 
and the central nervous system.3  In addition to physical symptoms, the subjective impact of 
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cancer-related anaemia on quality of life (QoL), mental health and social activities may be 
substantial.3  A common anaemia-related problem is fatigue, which impairs the patient’s 
ability to perform normal daily activities.3 
2.3. Relationship between cancer treatment induced 
anaemia and survival 
Although the evidence is uncertain, some researchers hypothesise that anaemia in cancer 
patients is associated with a worse prognosis. According to Bohlius and colleagues, 2009,6 
one explanation may be that, as a result of a low Hb, the tumour cells become hypoxic and 
are subsequently less sensitive to cytotoxic drugs, in particular oxygen-dependent 
chemotherapies.7-9 Evidence for this, as reported in Tonia and colleagues (2012),10 exists 
in studies where tumour control and overall survival are improved in solid tumour patients 
with better tumour oxygenation.9,11  There is also the practical implication that severe 
anaemia may require a dose reduction or delay of chemotherapy, subsequently leading to a 
poorer outcome.  It is therefore plausible that efforts taken to reduce anaemia may improve 
tumour response and overall survival.6 That said, it should be noted that Hb levels elevated 
to >14 g/dl in women and >15 g/dl in men are undesirable and may lead to increased 
viscosity, impaired tumour oxygenation and thromboembolic events.12  
As an intervention used to increase Hb, and by association improve prognosis, some studies 
actually report a detrimental effect of ESAs on survival and tumour progression.13-19 This 
effect is postulated to be due to the presence of erythropoietin receptors on various 
cancers,20-24 whereby the endogenously produced or exogenously administered 
erythropoietin promotes the proliferation and survival of erythropoietin receptor expressing 
cancer cells.6. However, controversy about the functionality of these receptors remains25-29 
and there are several studies which show no effect on tumour progression for patients 
receiving ESAs.16,30-32   
It should be noted that the majority of studies examined in the systematic reviews by 
Bohlius and colleagues (2009)6 and Tonia and colleagues (2012),10 have used a wide 
range of administration frequencies and dosage of ESAs (generally exceeding the license), 
which may cause a rise in adverse events and mortality. This knowledge, along with the 
generally poor reporting and data omission on factors such as tumour stage and method of 
assessment, have lead to the conclusion by Tonia and colleagues (2012),10 that no clear 
evidence was found to either exclude or prove a tumour promoting effect of ESAs.  
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2.4. Current management 
2.4.1. Red blood cell transfusions 
Anaemia in cancer patients can be treated with red blood cell transfusions (RBCTs), and 
15% of people with solid tumours are treated with RBCT.33 
Different cut-off values are used for transfusions, depending on clinical symptoms and 
patient characteristics, with a haemoglobin of <9 g/dl commonly used.33 After administration 
of one unit of RBCs, Hb rises by 1 g /dl and the life span of transfused RBC is 100–110 
days. Complications related to RBCT are procedural problems, iron overload, viral and 
bacterial infections, and immune injury.33 
2.4.2. Erythropoetin stimulating agents 
Erythropoietin is an acidic glycoprotein hormone. Approximately 90% of the hormone is 
synthesised in the kidney and 10% in the liver and is responsible for regulating red blood cell 
production. Erythropoietin for clinical use is produced by recombinant DNA technology.34  
Exogenously administered erythropoietin is used to shorten the period of symptomatic 
anaemia in patients receiving cytotoxic chemotherapy. It is used in addition to, rather than a 
complete replacement of the existing treatments. Blood transfusion, in particular, may still be 
needed.34 
2.4.2.1.  Marketing authorisations: Hb levels 
Initially all ESAs were recommended for use at Hb level ≤11 g/dl, with target Hb levels not 
exceeding 13 g/dl. However, because of data showing a consistent, unexplained, excess 
mortality in cancer patients with anaemia treated with ESAs, a safety review of all available 
data on ESA treatment of patients with cancer treatment-induced anaemia was conducted 
by the Pharmacovigilance Working Party at the request of the Committee for Medicinal 
Products for Human Use (CHMP) in 2008. As a result of this safety review, the European 
Medicines Agency (EMA) requested that the Summary of Product Characteristics (SmPCs) 
for all ESAs were changed to highlight that ESAs should only be used if anaemia is 
associated with symptoms; to establish a uniform target Hb range for all ESAs; to mention 
the observed negative benefit risk balance in patients treated with high target haemoglobin 
concentrations; and, to include the relevant results of the trials triggering the safety review. 
SPCs for all ESAs were therefore revised in 2008 to decrease the Hb value for treatment 
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initiation to Hb ≤10 g/dl and to amend Hb treatment target values to 10–12 g/dl and Hb levels 
for stopping treatment to >13 g/dl. 
The EMA labels the use of ESAs as follows: 
 In patients treated with chemotherapy and an Hb level of ≤10 g/dl, treatment with 
ESAs might be considered to increase Hb to <2 g/dl or to prevent further decline in 
Hb.  
 In patients not treated with chemotherapy, there is no indication for the use of ESAs 
and there might be increased risk of deaths when ESAs are administered to a target 
Hb of 12–14 g/dl. 
 In patients with curative intent, ESAs should be used with caution. 
Table 2. Changes to marketing authorisations  
Pre-2008 2008 onwards 
 An Hb level of ≤11 g/dl, administered to a 
target Hb level <13 g/dl 
 In patients treated with chemotherapy and an 
Hb level of ≤10 g/dl, treatment with ESAs 
might be considered to increase Hb to <2 g/dl 
or to prevent further decline in Hb. 
 In patients not treated with chemotherapy, 
there is no indication for the use of ESAs and 
there might be increased risk of deaths when 
ESAs are administered to a target Hb of 12–
14 g/dl. 
 In patients with curative intent, ESAs should 
be used with caution. 
Key: ESAs, erythropoiesis stimulating agents; Hb, haemoglobin 
 
These changes to the licence (Table 2) were introduced subsequent to the previous NICE 
appraisal. 
Details of current licence recommendations are summarised in Table 3. 
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Table 3.Treatment recommendations according to licence  
 Epoetin alfa 
Epoetin zeta 
Epoetin beta Epoetin theta Darbepoetin alfa 
Manufacturer 
(Product) 
Janssen-Cilag (Eprex®)35 
Sandoz Ltd (Binocrit®)36 
Hospira UK (Retacrit®)37 
Roche Products (Neorecormon®)38 Teva UK (Eporatio®)39 Amgen Ltd (Aranesp®)40 
Marketing 
authorisation 
Treatment of anaemia reduction of RBCT requirements in adults receiving 
chemotherapy for solid tumours, malignant lymphoma, or multiple 
myeloma, who are at risk of transfusion as assessed by their general 
status (e.g. cardiovascular status, pre-existing anaemia at the start of 
chemotherapy 
Treatment of symptomatic anaemia in adults with non-myeloid 
malignancies receiving chemotherapy 
Start Hb level ≤10 g/dl ≤10 g/dl ≤10 g/dl ≤10 g/dl 
Target Hb level 10–12 g/dl 10–12 g/dl 10–12 g/dl 10–12 g/dl 
Initial treatment 150 IU/kg SC TIW  
450 IU/kg SC QW 
150 IU/kg SC TIW  
450 IU/kg SC QW 
20,000 IU/QW 2.25 µg/kg SC QW 
500 µg (6.75 µg/kg) SC Q3W 
Dose increase 4 wks Hb increase <1 g/dl & 
reticulocyte increase ≥ 40 000 
cells/µl dose is doubled 300 IU/kg 
TIW or 900 IU/kg QW 
300 IU/kg SC TIW 4 wks Hb increase <1 g/dl dose is 
doubled 40,000 IU/QW; if Hb 
increase insufficient at 8 wks 
increase to 60,000 IU/QW 
4 wks Hb increase <1 g/dl dose is 
doubled 4.5 µg/kg SC QW 
Dose reduction If Hb increase ≥2 g/dl: 25–50%  
If Hb >12 g/dl: 25–50%  
 If Hb increase ≥2 g/dl: 25–50%  
If Hb ≥12 g/dl: 25–50%  
Dose withholding If Hb >13 g/dl until 12g/dl reinitiate at 25% lower dose Hb >12 g/dl: should be avoided;        
12 wks Hb increase <1 g/dl: 
discontinue 
If Hb >13 g/dl until 12g/dl reinitiate 
at 25% lower dose 
Key: Hb, haemoglobin;  IU, international units; QW, once weekly; Q3W, once every three weeks; RBCT, red blood cell transfusion; SC, subcutaneous; TIW,  thrice weekly; UK, United Kingdom; 
wks, weeks 
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2.4.2.2.  Current service provision 
NICE guidance (Technology Appraisal [TA] 142)34 currently recommends ESAs in 
combination with intravenous iron as an option for: 
 the management of cancer treatment-induced anaemia in women receiving 
platinum-based chemotherapy for ovarian cancer who have symptomatic 
anaemia with a haemoglobin level of 8 g/dl or lower. The use of ESAs does not 
preclude the use of existing approaches to the management of anaemia, 
including blood transfusion where necessary.34  
 people who cannot be given blood transfusions and who have profound cancer 
treatment-related anaemia that is likely to have an impact on survival.34 
 Where indicated the ESA used should be the one with the lowest acquisition 
cost.34 
2.5. Description of technology under assessment 
Several short- and long-acting erythropoiesis stimulating agents (ESAs) are available 
including epoetin alfa, epoetin beta and darbepoetin beta. Since the last appraisal (2004), an 
additional two ESAs have become available: epoetin theta and epoetin zeta; the latter is 
referenced to epoetin alfa. All are administered by subcutaneous injection. This technology 
assessment report (TAR) will consider six pharmaceutical interventions: epoetin alfa 
(Eprex® [Janssen-Cilag], Binocrit® [Sandoz]), epoetin beta (NeoRecormon® [Roche 
Products]), epoetin theta (Eporatio® [Teva UK]), epoetin zeta (Retacrit® [Hospira UK]), and 
darbepoetin alfa (Aranesp® [Amgen]).34 Treatment recommendations according to licence 
are summarised for each in Table 3.  
This NICE appraisal focuses on the treatment of cancer treatment-induced anaemia. As 
such the appraisal does not cover all aspects of the licensed indications such as the 
prevention of anaemia, or the treatment of symptomatic anaemia due to chronic renal failure. 
PenTAG         CONFIDENTIAL 
45 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
2.6. Clinical guidelines 
2.6.1. EORTC 
In Europe, treatment guidelines for cancer treatment induced anaemia have been formulated 
by the European Organisation for Research and Treatment of Cancer (EORTC), which most 
recently updated their recommendations on the use of ESAs in September 2007.41 In 2010, 
joint treatment guidelines were issued by American Society of Clinical Oncology/American 
Society of Hematology (ASCO/ASH).42 
The EORTC guidelines recommend that patients whose Hb level is <9 g/dl should be 
assessed for the need for RBCT, in addition to ESAs.41 The joint ASCO/ASH guidelines 
suggest that RBCT is also an option for patients with CIA and Hb <10 g/dl, depending on the 
severity of the anaemia or clinical circumstances, and may also be warranted by clinical 
conditions in patients with Hb ≥10 g/dl but <12 g/dl.42 
Recommendations for ESA therapy for CIA are broadly similar between the EORTC 
guidelines and those of the 2010 joint American Society of Clinical Oncology/American 
Society of Hematology (ASCO/ASH) guidelines, with small differences in the threshold for 
initiation of ESA therapy and variation in the wording related to Hb levels.41-43 
The EORTC guidelines41 emphasize that reducing the need for RBC transfusions is a major 
goal of therapy in anaemic cancer patients, and highlight that ESAs can achieve a sustained 
increase in Hb level, unlike intermittent transfusions.41 The guidelines also state there is no 
evidence that oral iron supplements increase response to erythropoietic proteins, although 
there is evidence of a better response to erythropoietic proteins with IV iron. 
2.6.2. British Columbia Cancer Agency 
The British Columbia Cancer Agency (BCCA) guidelines recommend treatment with ESAs 
for the treatment of CIA when Hb level is 10 g/dl and there is a minimum of two months 
planned chemotherapy.41 
The guidelines also state that the benefits of treatment must be weighed against the possible 
risks for individual patients: ESAs may increase the risk of death, serious cardiovascular 
events, thromboembolic events, and stroke; and, ESAs may shorten survival and/or increase 
the risk of tumour progression or recurrence, as shown in clinical trials in patients with 
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breast, head and neck, lymphoid, cervical non-small cell lung cancers and patients with 
active malignancies who are not treated with either chemotherapy or radiotherapy.41 
2.7. Existing evidence 
2.7.1. Existing systematic reviews of effectiveness 
There have been a number of well-conducted systematic reviews evaluating the effects of 
ESAs for treating CIA in cancer patients. We identified 11 systematic reviews (reported in 14 
publications) that fulfilled the definition of a systematic review pre-specified in the protocol; a 
summary of eligible systematic reviews and a quality assessment (versus PRISMA 
statement) are in Appendix  I. 
2.7.1.1.  Cochrane review (Tonia and colleagus, 2012) 
The Cochrane review by Tonia and colleagues (2012) was the most recent and 
authoritative. The Cochrane review’s conclusions were: “ESAs reduce the need for RBCTs 
but increase the risk for thromboembolic events and deaths. There is suggestive evidence 
that ESAs may improve QoL. Whether and how ESAs affect tumour control remains 
uncertain. The increased risk of death and thromboembolic events should be balanced 
against the potential benefits of ESA treatment taking into account each patient’s clinical 
circumstances and preferences. More data are needed for the effect of these drugs on 
quality of life and tumour progression. Further research is needed to clarify cellular and 
molecular mechanisms and pathways of the effects of ESAs on thrombogenesis and their 
potential effects on tumour growth.” (Tonia and colleagues, 2012; page 2). 
This was an update of a Cochrane review first published in 2004 (Bohlius and colleagues, 
2004). Searches were conducted in CENTRAL, EMBASE, MEDLINE and other databases. 
Searches were done for the periods January 1985 to December 2001 for the first review, 
January 2002 to April 2005 for the first update, and to November 2011 for the most recent 
update. The authors of the review also contacted experts in the field and pharmaceutical 
companies (access to individual patient data [IPD]).  Inclusion, quality assessment and data 
abstraction were undertaken in duplicate by several reviewers. Eligibility criteria are detailed 
and compared with the PenTAG review in Table 4. The Cochrane review differed from the 
PenTAG review in respect of population (cancer related anaemia vs chemotherapy induced 
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anaemia), and intervention (all ESAs irrespective of licence vs ESAs within licence (defined 
based on start dose). 
Table 4. Differences between Tonia and colleagues (2012) and PenTAG systematic 
reviews 
 Tonia and colleagues, 2012 Current systematic review, 2013 
Population Patients diagnosed with malignant 
disease (using clinical and 
histological/cytological criteria), and at 
risk of transfusion as assessed by the 
patient’s general status (e.g. 
cardiovascular status, pre-existing 
anaemia at the start of chemotherapy). 
Excluded trials where >80% of 
participants were diagnosed with an 
acute leukaemia 
Patients had to be receiving 
chemotherapy for solid tumours, 
malignant lymphoma, multiple myeloma, 
or non-myeloid malignancies, and at risk 
of transfusion as assessed by the 
patient’s general status (e.g. 
cardiovascular status, pre-existing 
anaemia at the start of chemotherapy) 
Intervention ESAs to prevent or reduce anaemia, 
given singly or concomitantly with 
chemotherapy, radiotherapy, or 
combination therapy 
 
ESAsa to prevent or reduce anaemia, 
given concomitantly with chemotherapy  
Dose: included studies or study arms 
with low doses  
Dose: licensed indication, defined by 
start dose even if they did not align with 
other criteria specified by the licence 
Comparator Placebo or ‘no treatment’ was not 
required for inclusion but was considered 
in evaluating study quality 
Placebo; standard care, no 
treatment/usual care  
Outcomes HaemRb; Hb change; RBCT; RBC units; 
OS; mortality; tumour response (CR); 
AEs; HRQoL 
HaemRb; Hb change; RBCT; RBC units; 
OS; tumour response (CR); AEs; HRQoL
Study design RCTs RCTs; SRs of RCTsc 
Key: AEs, adverse events; CR, complete response; ESAs, erythropoiesis stimulating agents; Hb, haemoglobin; 
OS, overall survival; RBC, red blood cell; RBCT red blood cell transfusion; RCTs, randomized controlled trials; 
SRs, systematic review 
Notes: (a) Specifically epoetin alfa, beta, theta, zeta; darbepoetin alfa; (b) Defined as an increase in Hb level of 
≥2 g/dL, or an increase in haematocrit of ≥6% points; (c) Used for scrutinisation of bibliographies and comparison 
of results 
 
A total of 91 studies with 20,102 participants were included in this review. Results from the 
Cochrane review are summarised in Table 5 and compared with the results of the PenTAG 
HTA review throughout Section 0 (page 56). 
Table 5. Results: Cochrane review (Tonia and colleagues, 2012) 
Anaemia-related outcomes 
Hb changea  HaemRb RBCT Units transfused 
WMD 1.57 RR 3.39 RR 0.65 WMD -0.98 
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95% CI 1.51−1.62 
Χ2(het); 564.37; df 74  
(p<0.001) 
75 trials, n=11,609 
95% CI 3.10−3.71 
Χ2(het); 95.56; df 45 
(p<0.001) 
46 trials, n=6,413 
95% CI 0.62−0.68 
Χ2(het) 217.08; df 87 
(p<0.001) 
88 trials, n=16,093 
95% CI -1.17−-0.78 
Χ2(het) 34.52; df 24 
(p=0.080) 
25 trials, n=4,715 
Malignancy-related outcomes 
Tumour response Overall survival Mortality  
RR 1.02 
95% CI 0.98−1.06 
Χ2(het) 16.10; df 18 
(p=0.59) 
19 trials, n=5,012 
HR 1.05 
95% CI 1.00−1.11 
Χ2(het) 95.40; df 75 
(p=0.060) 
80 trials, n=19,003 
  
Safety-related outcomes 
Thromboembolic 
events 
Hypertension Thrombocytopen
ia/haemoorhage 
Seizures Pruritus 
RR 1.52 
95% CI 1.34−1.74 
Χ2(het) 34.99; df 55 
(p=0.980) 
60 trials, n=15,498 
RR 1.30 
95% CI 1.08−1.56 
Χ2(het) 26.87; df 34 
(p=0.800) 
35 trials, n=7,006 
RR 1.21 
95% CI 1.04−1.42 
Χ2(het) 14.50; df 20 
(p=0.800) 
21 trials, n=4,220 
RR 0.77 
95% CI 0.42−1.41 
Χ2(het) 6.19; df 6 
(p=0.400) 
7 trials, n=2,790 
RR 1.49 
95% CI 0.99−2.24 
Χ2(het) 13.18; df 15 
(p=0.590) 
16 trials, n=4,346 
FACT-F 13 item 
(score 0-52) 
Any subgroup effect   
Health related quality of life related outcomes 
MD 2.08 
95% CI 1.43, 2.72 
Χ2(het)36.48; df 17 
(p=0.004) 
18 trials, n=4,965 
Yes: imputed vs. non-
imputed data, baseline 
Hb level, type of anti-
cancer therapy, 
duration of ESA 
treatment and ITT 
analysis. 
  
Key: CI, confidence interval; df, degrees of freedom; haemR, haematological response; het, heterogeneity; 
RBCT, red blood cell transfusion; RR, relative risk; WMD, weighted mean difference 
Notes: fixed effects (Mantel-Haenzel) a change from baseline to end of study; b haematological response  
was defined as the proportion of participants with an increase in Hb level of two g/dl or more, or as an increase 
in haematocrit of six percentage points or more.
2.7.1.2.  Cochrane review: meta-analysis based on IPD data (Bohlius 
and colleagues, 2009) 
Another Cochrane review (Bohlius and colleagues, 2009) examined the effect of ESAs and 
identified factors that modify the effects of ESAs on overall survival, progression free 
survival, thromboembolic and cardiovascular events as well as the need for transfusions and 
other important safety and efficacy outcomes in cancer patients. It concluded: ‘ESA 
treatment in cancer patients increased on study mortality and worsened overall survival. For 
patients undergoing chemotherapy the increase was less pronounced, but an adverse effect 
could not be excluded.’ (Bohlius and colleagues, 2009).  
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The review was conducted in 2009. Searches were conducted in the Cochrane Library, 
MEDLINE, EMBASE, and conference proceedings for eligible trials, and manufacturers of 
ESAs were contacted to identify additional trials. The review included randomised controlled 
trials comparing ESAs plus RBCT (as necessary) versus RBCT (as necessary) alone, to 
prevent or treat anaemia in adult or pediatric cancer patients with or without concurrent 
antineoplastic therapy.Inclusion, quality assessment and data abstraction were undertaken 
in duplicate by several reviewers. A meta-analysis of RCTs was conducted and patient level 
data were obtained and analysed by independent statisticians.  
A total of 13,933 cancer patients from 53 trials were analysed, 1,530 patients died on-study 
and 4,993 overall. ESAs increased on-study mortality (combined hazard ratio [cHR] 1.17; 
95% CI 1.06-1.30) and worsened overall survival (cHR 1.06; 95% CI 1.00-1.12), with little 
heterogeneity between trials (I2 0%, p=0.87 and I2 7.1%, p=0.33, respectively). Thirty-eight 
trials enrolled 10,441 patients receiving chemotherapy. The cHR for on-study mortality was 
1.10 (95% CI 0.98-1.24) and 1.04; 95% CI 0.97-1.11) for overall survival. There was little 
evidence for a difference between trials of patients receiving different cancer treatments (p 
for interaction=0.42). 
Table 6. Results: Cochrane review (Bohlius and colleagues, 2009) 
Malignancy-related outcomes 
Overall survival On-study mortality   
cHR 1.04 
95% CI 0.97–1.11 
38 trials; n=10,441 
cHR 1.10 
95% CI 0.98–1.24 
38 trials; n=10,441 
  
Key: cHR, combined hazard ratio; CI, confidence interval 
2.7.1.3.  Previous HTA review (Wilson and colleagues, 2007) 
The previous HTA (Wilson and colleagues, 2007) informed National Institute for Health and 
Care Excellence (NICE) guidance TA142.1 It assessed the effectiveness and cost-
effectiveness of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with 
cancer, especially that attributable to cancer treatment. The review concluded: “Epo is 
effective in improving haematological response and RBCT requirements, and appears to 
have a positive effect on health-related quality of life (HRQoL). The incidence of side-effects 
and effects on survival remains highly uncertain. If there is no impact on survival, it seems 
highly unlikely that epo would be considered a cost-effective use of healthcare resources.” 
(Wilson and colleagues, 2007; page x). 
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Using the Cochrane review published in 2004 as the start point Wilson and colleagues 
(2007) conducted a systematic review of randomised controlled trials (RCTs) comparing 
ESAs with standard care was conducted. MEDLINE, EMBASE, the Cochrane Library and 
other databases were searched from 2000 (1996 in the case of darbepoetin alfa) to 
September 2004. Inclusion, quality assessment and data abstraction were undertaken in 
duplicate. Eligibility criteria are detailed and compared with the PenTAG review in Table 7. 
Where possible, meta-analysis was employed. The economic assessment consisted of a 
systematic review of past economic evaluations, an assessment of economic models 
submitted by the manufacturers of the three ESAs and development of a new individual 
sampling model (see Section 6.1.1., page 203). 
Table 7. Differences between Wilson and colleagues (2007) and PenTAG systematic 
reviews 
 Wilson and colleagues, 2007 Current systematic review, 2013 
Population Patients diagnosed with malignant 
disease (using clinical and 
histological/cytological criteria), and at 
risk of transfusion as assessed by the 
patient’s general status (e.g. 
cardiovascular status, pre-existing 
anaemia at the start of chemotherapy) 
Patients had to be receiving 
chemotherapy for solid tumours, 
malignant lymphoma, multiple myeloma, 
or non-myeloid malignancies, and at risk 
of transfusion as assessed by the 
patient’s general status (e.g. 
cardiovascular status, pre-existing 
anaemia at the start of chemotherapy) 
Intervention ESAs to prevent or reduce anaemia, 
given singly or concomitantly with 
chemotherapy, radiotherapy, or 
combination therapy 
ESAsa to prevent or reduce anaemia, 
given concomitantly with chemotherapy  
Dose: included studies or study arms 
with low doses  
Dose: licensed indication, defined by 
start dose even if they did not align with 
other criteria specified by the licence 
Comparator Placebo or ‘no treatment’ was not 
required for inclusion but was considered 
in evaluating study quality 
Placebo; standard care, no 
treatment/usual care  
Outcomes HaemRb; Hb change; RBCT; RBC units; 
OS; mortality; tumour response (CR); 
AEs; HRQoL 
HaemRb; Hb change; RBCT; RBC units; 
OS; tumour response (CR); AEs; HRQoL
Study design RCTs RCTs; SRs of RCTsc 
Key: AEs, adverse events; CR, complete response; ESAs, erythropoiesis stimulating agents; Hb, haemoglobin; 
OS, overall survival; RBC, red blood cell; RBCT red blood cell transfusion; RCTs, randomized controlled trials; 
SRs, systematic review 
Notes: (a) Specifically epoetin alfa, beta; darbepoetin alfa; (b) Defined as an increase in Hb level of ≥2 g/dL, or 
an increase in haematocrit of ≥6% points; (c) Used for scrutinisation of bibliographies and comparison of results 
 
A total of 46 RCTs were included in the previous HTA review (Wilson and colleagues, 
2007), 27 of which had been included in the Cochrane review (Bohlius and colleagues, 
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2004). All 46 studies compared ESA plus supportive care for anaemia (including 
transfusions) with supportive care for anaemia (including transfusions alone). Outcomes 
assessed with anaemia-related outcomes (haematological response [haemR], haemoglobin 
(Hb) change, RBCT requirements, malignancy –related outcomes (tumour response and 
overall survival [OS]), health-related quality of life (HRQoL), and adverse events (AEs).  
Results from the previous HTA review (Wilson and colleagues, 2007) are compared with 
the results of the PenTAG HTA throughout Section 0 (page 56). 
Table 8. Results: Wilson and colleagues, 20071 
Hb changea  HaemRb RBCT Units transfused 
Anaemia-related outcomes 
WMD 1.63 
95% CI 1.46−1.80 
Χ2(het) 23.74; df 19 
(p=0.21) 
10 trials, n=1,620 
RR 3.40 
95% CI 3.01−3.83  
Χ2(het) 23.60; df 32 
(p=0.86) 
21 trials, n=3,740 
RR 0.63 
95% CI 0.58−0.67  
Χ2(het) 94.75; df 48 
(p=0.001) 
35 trials, n=5,564 
WMD -1.05 
95% CI -1.32−-0.78 
Χ2(het) 8.96; df 16 
(p=0.91) 
14 trials, n=2,353 
Tumour response Overall survival Mortality  
Malignancy-related outcomes 
RR 1.31 
95% CI 1.08−1.60 
Χ2(het) NR; df NR (p=NR) 
9 trials, n=1,260 
HR 1.03 
95% CI 0.92−1.16 
Χ2(het) 37.74; df 27 
(p=0.08) 
28 trials, n=5,308 
NR  
Safety-related outcomes 
No safety related meta-analysis 
FACT-F 13 item 
(score 0-52) 
Any subgroup effect   
Health related quality of life related outcomes 
No HRQoL meta-analyses 
Key: CI, confidence interval; df, degrees of freedom; haemR, haematological response; het, heterogeneity; 
RBCT, red blood cell transfusion; RR, relative risk; WMD, weighted mean difference 
Notes: fixed effects (Mantel-Haenzel) a change from baseline to end of study; b haematological response  
was defined as the proportion of participants with an increase in Hb level of two g/dl or more, or as an increase 
in haematocrit of six percentage points or more.
 
KEY POINTS  
 Anaemia is defined as a deficiency in red blood cells. It is the most frequent 
haematological manifestation in patients with cancer; more than 50% of all cancer 
patients will be anaemic regardless of the treatment received, and approximately 
20% of all patients undergoing chemotherapy will require red blood cell transfusion. 
The cause is multifactorial; patient-, disease-, or treatment-related. 
 Anaemia is associated with many symptoms, all of which affect quality of life. These 
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symptoms include dizziness, shortness of breath on exertion, palpitations, headache 
and depression. Severe fatigue is probably the most commonly reported symptom 
and can lead to an inability to perform everyday tasks. However, fatigue in people 
with cancer can also have other causes; e.g. the disease itself, chemotherapy, 
radiotherapy, anxiety or depression. 
 Many people are anaemic when cancer is diagnosed, before any cancer treatment 
starts. The degree of anaemia caused by treatments such as chemotherapy often 
fluctuates depending on the nature of the treatment and the number of courses 
administered, but is typically at its worst 2–4 weeks after chemotherapy is given. 
Once cancer treatments are stopped, a period of 'normalisation' is likely, during 
which the haemoglobin may return to pretreatment levels.  
 Options available for the management of cancer treatment-induced anaemia include 
adjustments to the cancer treatment regimen, iron supplementation and blood 
transfusion. The majority of people who become anaemic do not receive any 
treatment for their anaemia, but those who become moderately or severely anaemic 
are usually given blood transfusions. Complications related to red blood cell 
transfusion include procedural problems, iron overload, viral and bacterial infectios, 
and immune injury. 
 Current evidence suggests that ESAs reduce the need for RBCT but increase the 
risk for thromboembolic events and deaths. There is suggestive evidence that ESAs 
may improve quality of life. Whether and how ESAs affect tumour control remains 
uncertain.  
 Current NICE guidance (TA142) recommends: the management of cancer treatment-
induced anaemia in women receiving platinum-based chemotherapy for ovarian 
cancer who have symptomatic anaemia with a haemoglobin level of 8 g/dl or lower. 
The use of ESAs does not preclude the use of existing approaches to the 
management of anaemia, including blood transfusion where necessary; and, in 
people who cannot be given blood transfusions and who have profound cancer 
treatment-related anaemia that is likely to have an impact on survival.  
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 Definition of the decision problem 
3.1. Decision problem 
The purpose of this assessment is to review and update as necessary guidance to the NHS 
in England and Wales on the clinical and cost-effectiveness of erythropoiesis-stimulating 
agents: epoetin alfa (Eprex® [Janssen-Cilag], Binocrit® [Sandoz]), epoetin beta 
(NeoRecormon® [Roche Products]), epoetin theta (Eporatio® [Teva UK]), epoetin zeta 
(Retacrit® [Hospira UK]), and darbepoetin alfa (Aranesp® [Amgen]), within their licensed 
indications for the treatment of cancer-treatment induced anaemia.  
The project was undertaken based on a published scope,42 and in accordance with a 
predefined protocol (see Appendix A). There were no major departures from this protocol. 
The protocol stated that interventions would be evaluated in line with their UK marketing 
authorisations. However, as none of the included studies were completely aligned with 
current licences we applied a definition of ‘within licence’ which was not pre-defined. Given 
the recent publication of the 2012 Cochrane review (Tonia and colleagues, 2012) which 
considered all ESAs irrespective of licence, ‘within licence’ was therefore defined as a 
licensed starting dose irrespective of how other licence criteria were dealt with. 
3.2. Population 
The population will be people receiving chemotherapy for solid tumours, malignant 
lymphoma or multiple myeloma, and people with non-myeloid malignancies at risk of 
transfusion as assessed by general status (e.g. cardiovascular status, pre-existing anaemia 
at the start of chemotherapy). 
Haematological malignancy specifically refers to non-myeloid malignancy (chronic 
lymphocytic leukaemia; non Hodgkin’s lymphoma; Hodgkin’s disease and multiple 
myeloma). 
3.3. Interventions 
The interventions considered are erythropoiesis-stimulating agents: epoetin alfa (Eprex®, 
[Janssen-Cilag] and Binocrit® [Sandoz]); epoetin beta (NeoRecormon®, Roche Products); 
epoetin theta (Eporatio® [Teva UK]); epoetin zeta (Retacrit® [Hospira UK]) Darbepoietin alfa 
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(Aranesp® [Amgen]). All interventions will only be considered according to their UK 
marketing authorisation (Section 4.1.2.3, page 59). 
3.4. Comparators 
The following comparators will be considered:  
 Best supportive care (including adjustment to the cancer treatment regimen, blood 
transfusion and iron supplementation) 
 One of the other interventions under consideration; provided in line with their marketing 
authorisations 
3.5. Outcomes 
Evidence in relation to the following kinds of outcomes will be considered: 
 haematological response to treatment: defined as a transfusion free increase of Hb of 
≥2 g dl-1 or a haematocrit increase of 6% 
 need for blood transfusion after treatment: number of patients transfused, number of 
units transfused per patient, and number of patients transfused per patient per four 
weeks 
 tumour response: time to cancer progression 
 overall survival 
 adverse effects of treatment: hypertension, rash/irritation, pruritus, mortality, 
thromboembolic events, seizure, haemorrhage / thrombocytopenia, fatigue, pure red cell 
aplasia. A note will be made of other adverse events described within the trial reports 
 health-related quality of life: validated quality of life measures; e.g. FACT (FACT-
General, FACT-Fatigue, FACT-Anaemia), EQ-5D, SF-36 
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3.6. Research question 
This assessment will address the question: “What is the effectiveness and cost-effectiveness 
of ESAs (epoetin alfa, beta, theta and zeta; and, darbepoetin alfa) for treating cancer-
treatment induced anaemia (including review of TA142)?” 
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 Assessment of clinical effectiveness 
The review commissioned by the National Institute for Health and Care Excellence (NICE) 
was to update the previous guidance (TA142)34 based on the health technology assessment 
(HTA) review conducted by Wilson and colleagues (2007).1 The differences between the 
remit of the previous review and the current one are discussed in Section 2.7.1.2 (page 48). 
The project was undertaken in accordance with a predefined protocol (see Appendix A). 
There were no major departures from this protocol. The protocol stated that interventions 
would be evaluated in line with their UK marketing authorisations. However, as none of the 
included studies were completely aligned with current licences we applied a definition of 
‘within licence’ which was not pre-defined. Given the recent publication of the 2012 
Cochrane review (Tonia and colleagues, 2012) which considered all ESAs irrespective of 
licence, ‘within licence’ was therefore defined as a licensed starting dose irrespective of how 
other licence criteria were dealt with. 
A scoping search was undertaken to identify existing reviews and other background material. 
Among this literature two recent Cochrane reviews were identified (Bohlius and 
colleagues, 2009 and Tonia and colleagues, 2012),10,43 which assessed the effectiveness 
of erythropoiesis stimulating agents up to 2010 and 2012 respectively.  
The aim was to systematically review the effectiveness of ESAs, with regard to treating 
cancer treatment-related anaemia, its effects on the patient regarding underlying malignancy 
and survival, its effectiveness in improving quality of life and the impact of adverse events. 
Given the recent publication of the Cochrane review (Tonia and colleagues, 2012), the 
focus for this review was to identify and consider trials where ESAs have been used in a 
manner consistent with or closest to their respective marketing authorisations (see Section 
4.1.2.3.1, page 60).  
4.1. Methods 
4.1.1. Identification of studies 
The search strategy is based on the strategy used in the previous MTA on this topic by 
Wilson and colleagues (2007).1 It combines free-text and MeSH terms for epoetin (generic 
and brand names), cancer and anaemia using the AND Boolean operator. Search filters are 
applied to retrieve RCTs, cost effectiveness studies and quality of life studies. The search 
terms and structure of the search is mainly the same as in Wilson and colleagues (2007),1 
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with additional search terms for epoetin theta, epoetin zeta and corresponding drug brand 
names. The search filters for RCTs, cost effectiveness studies and quality of life (QoL) 
studies are different to those used in Wilson and colleagues (2007).1 The filters were 
developed by an information specialist to ensure an appropriate balance of sensitivity and 
specificity.  Changes to the previous MTA search strategy, including the filters, were made in 
MEDLINE and translated as appropriate for other databases. The MEDLINE RCT search 
strategy was checked by a clinical expert for inaccuracies and omissions relating to drug and 
cancer terms. 
The databases were searched from the search end-date of the previous MTA on this topic 
(Wilson and colleagues [2007],1 search end-date: 2004). Although epoetin alfa (Binocrit® 
[Sandoz]), epoetin theta and epoetin zeta were not covered in the previous report, we 
believe that relevant interventional research is highly unlikely to have been published on 
these drugs prior to this date, given that the drugs were launched in 2007 (epoetin alfa 
[Binocrit®, Sandoz]) and 2009 (epoetin theta). All searches were also limited to English 
language papers; although some foreign language papers would have been identified by 
virtue of being included in other systematic reviews. 
The following databases were searched: MEDLINE (Ovid); MEDLINE-in-Process (Ovid); 
EMBASE (Ovid); the Cochrane Library including CENTRAL, the Cochrane Database of 
Systematic Reviews, DARE, HTA, NHS EED and HEED; Web of Science (Thomson 
Reuters); CINAHL (EBSCO); British Nursing Index (ProQuest); HMIC (Ovid); Current 
Controlled Trials; Clinical Trials.gov; FDA website; EMA website. 
In addition, the following websites were searched for background information:  
Medical societies  
British Society for Haematology  http://www.b-s-h.org.uk/ 
The Association of Cancer Physicians http://www.cancerphysicians.org.uk/ 
American Society of Hematology http://www.hematology.org/  
American Society of Clinical Oncology http://www.asco.org/ 
The Canadian Oncology Societies http://www.cos.ca/ 
Haematology Society of Australia and New Zealand http://www.hsanz.org.au/ 
Clinical Oncology Society of Australia http://www.cosa.org.au/ 
New Zealand Society for Oncology http://www.nzsoncology.org.nz/ 
UK charities  
Cancer Research UK http://www.cancerresearchuk.org/home/ 
Macmillan http://www.macmillan.org.uk/ 
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Marie Curie http://www.mariecurie.org.uk/ 
Non-UK charities  
American Cancer Society http://www.cancer.org/ 
Canadian Cancer Society http://www.cancer.ca/ 
Cancer Council Australia http://www.cancer.org.au/ 
Cancer Society of New Zealand http://www.cancernz.org.nz/ 
World Cancer Research Fund http://www.wcrf-uk.org/ 
 
The database search results were exported to, and de-duplicated using Endnote (X5).De-
duplication was also performed using manual checking. The search strategies and the 
numbers retrieved for each database are detailed in Appendix B.  After the reviewers 
completed the screening process, the bibliographies of included papers were scrutinised for 
further potentially includable studies.  
A supplementary search was carried out in MEDLINE (Ovid) to search for utilities as a 
function of Hb levels and for information on Hb levels after chemotherapy ends. A systematic 
search was not required for this part of the review so the search strategy was limited to 
MEDLINE. These searches are detailed in Appendix B. 
4.1.1.1.  Wilson and colleagues, 2007 
Studies included in the previous HTA review (Wilson and colleagues, 2007)1 were 
screened versus the inclusion criteria for the PenTAG review for includable studies. 
4.1.1.2.  Reference l ists  
Reference lists of included guidelines, systematic reviews, and clinical trials were scrutinised 
for additional information. 
4.1.1.3.  Ongoing tr ials 
A search for ongoing trials was also undertaken. Terms for the intervention (“epoetin” OR 
“darbepoetin”) and condition of interest (cancer* OR carcinoma* OR leukemia OR malignan* 
OR neoplasm* OR tumo?r OR myelo* OR lymphoma* OR oncolog* OR chemotherapy*) 
were used to search the following trial registers: ClinicalTrials.gov and Controlled Trials 
(ISRCTN) for ongoing trials. Trials that did not relate to cancer-induced or chemotherapy-
related anaemia were removed by hand-sorting. Finally, duplicates, identified via their study 
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identification numbers where possible, were removed. Searches were carried out on 28 
August 2013.  
4.1.2. Eligibility criteria 
4.1.2.1.  Study design 
Only randomised controlled trials (RCTs) were included. Non-randomised trials and quasi-
randomised trials (such as where allocation is based on date of birth or day of month) were 
excluded. 
4.1.2.2.  Population 
People had to be receiving chemotherapy for solid tumours, malignant lymphoma, or 
multiple myeloma (and people with non-myeloid malignancies), at risk of transfusion as 
assessed by general status (e.g. cardiovascular status, pre-existing anaemia at the start of 
chemotherapy), and non-myeloid malignancies. There were no age restrictions; however, it 
is recognised that the licenses for all the interventions of interest do not cover erythropoietin 
use in children for this indication. Studies where erythropoietin was given in the context of 
myeloablative chemotherapy ahead of bone marrow or peripheral blood stem cell 
transplantation, or for short-term preoperative treatment to correct anaemia or to support 
collection of autologous blood before cancer surgery, were excluded. 
4.1.2.3.  Interventions 
Studies evaluating the use of erythropoiesis stimulating agents (ESAs) were included if given 
to treat cancer treatment-induced anaemia. The ESAs of interest for this appraisal were: 
epoetin alfa (Eprex®, Janssen-Cilag; Binocrit®, Sandoz ), epoetin beta (NeoRecormen®, 
Roche Products), Epoetin theta (Eporatio®, Teva UK), epoetin zeta (Retacrit®, Hospira UK), 
or darbepoetin alfa (Aranesp®, Amgen). 
Concomitant anaemia therapy such as iron or granulocyte colony-stimulating factor (G-CSF) 
supplementation was permitted, as was red blood cell transfusion (RBCT). However, G-CSF 
had to be administered to patients in both the treatment and control arms. 
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4.1.2.3.1.  Dose 
ESA administration varied considerably among the published literature. Variation with 
respect to: Hb levels (trigger [the point below which ESAs should be administered, ≤10.0 
g/dl]; and, targeted [the point above which ESAs should be stopped or titrated, 10–12 g/dl]); 
dose escalation (used if people do not achieve a haematological response within a specified 
time period); abandonment for persistent non-responders; and, duration of use following 
each chemotherapy session. The majority (82%) of studies were initiated before the 2008 
update of the Summary of Products Characteristics (SPCs) and no studies were completely 
aligned with the UK marketing authorisation for these drugs in respect of these criteria (see 
Appendix C). 
For the main analysis for this systematic review, studies were considered eligible for 
inclusion if they used a licensed start dose regardless of how they dealt with other criteria 
stipulated by the license. Thus, ESAs administered weekly, for epoetin alfa and epoetin zeta 
to be administered three-times weekly, for epoetin beta to be administered three to seven 
times per week; and, for darbepoetin alfa to be administered every three weeks. Fixed 
(epoetin theta) and weight-based (epoetin alfa, epoetin beta, epoetin zeta, and darbepoetin 
alfa) dosages were allowed.  
In addition we also considered inclusion Hb criteria as closer to licence ≤11 g/dl and >11 
g/dl; and target Hb as closer to licence ≤13 g/dl and >13 g/dl. 
4.1.2.4.  Comparator 
The main comparators of interest were: placebo, best supportive care (including adjustment 
to the cancer treatment regimen, blood transfusion, and iron supplementation). In addition, 
the comparator could be one of the other ESAs under consideration, provided it was 
administered in line with the relevant marketing authorisations. 
4.1.2.5.  Outcomes 
Outcomes sought from the studies fell into four categories: anaemia-related outcomes, 
malignancy-related outcomes, adverse events data and patient-specific outcomes such as 
quality of life outcomes and patient’s preferences. 
 Anaemia-related outcomes: haematological response to treatment (defined as a 
transfusion free increase of haemoglobin (Hb) of ≥2 g/dL or a haematocrit increase 
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(Hct) increase of 6%), mean Hb change, and RBCT requirements (including number 
of patients transfused, number of units transfused per patient, and number of units 
transfused per average patient (i.e. including participants not requiring transfusion). 
 Malignancy-related outcomes:  tumour response, and overall survival (OS) 
 Adverse events (AEs): hypertension, rash/irritation, pruritus, mortality, 
thromboembolic events, seizure, haemorrhage/thrombocytopenia, fatigue, and pure 
red cell aplasia. A note was made of other adverse events described within the trial. 
 Health-related quality of life (HRQoL): data on validated quality of life (QoL) 
measures was sought, anticipated quality of life measures would include FACT 
(including FACT-General (G), FACT-Fatigue (F), and FACT-Anaemia (A)). A note 
was made of any other HRQL measure reported. 
4.1.3. Selection of studies 
Studies retrieved from the update searches were selected for inclusion according to the 
inclusion/exclusion criteria specified in Section 4.1.2. First, titles and abstracts returned by 
the search strategy were screened for inclusion independently by two researchers (LC and 
MH). Disagreements were resolved by discussion, with involvement of a third reviewer (TJ-H 
or HC). Full texts of identified studies were obtained and screened in the same way. Abstract 
only studies were included provided sufficient methodological details were reported to allow 
critical appraisal of study quality.  
In addition, studies included in the review conducted by Wilson and colleagues (2007)1 
were screened for inclusion against the eligibility criteria for this review. 
Eligible studies were then re-screened to apply the inclusion criteria ‘intervention 
administered in accordance with their licensed indications’. For this systematic review, this 
was defined as a licensed start dose irrespective of how the study dealt with other criteria 
stipulated by the license. Thus, ESAs administered weekly, for epoetin alfa and epoetin zeta 
to be administered three-times weekly, for epoetin beta to be administered three to seven 
times per week; and, for darbepoetin alfa to be administered every three weeks. Fixed 
(epoetin theta) and weight-based (epoetin alfa, epoetin beta, epoetin zeta, and darbepoetin 
alfa) dosages were allowed.  
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4.1.4. Data extraction and management 
Included full papers were split between four reviewers (LC, MH, TJ-H, HC) for the purposes 
of data extraction using a standardised data extraction form, and checked independently by 
another reviewer. Discrepancies were resolved by discussion with the involvement of an 
additional review team member (CH) if necessary. Information extracted and tabulated 
included details of the study’s design and methodology, baseline characteristics of 
participants, and results including HRQL and any AEs if reported (see Appendix D).  
If we identified several publications for one study, we evaluated the data from the most 
recent publication and amended this with information from other publications. 
For studies comparing more than one experimental arm to one control arm, we assigned a 
separate reference for each study arm with the author and publication year of the main 
publication and added the suffixes a; b. For example, the study by Tjulandin and 
colleagues 2010 compared two different experimental study arms with one control group. 
The two different study arms are listed separately in the included studies (Table 10) and 
Section 0, page 649). Due to this referencing system a study may appear more than twice in 
the list of included studies. 
Where there was incomplete information on key data, we referred to the 2012 Cochrane 
Review. For the update of the Cochrane Review the authors evaluated documents 
presented at the Oncology Drug Advisory Committee (ODAC) hearing at the USA Food and 
Drug Administration (FDA) held in May 2004, May 2007, and May 2008. These documents 
were reported to include briefing documents plus additional Powerpoint presentations 
prepared by medical review authors of the FDA, as well as documents and additional 
Powerpoint presentations prepared by the companies Roche, Johnson & Johnson, and 
Amgen. 
4.1.5. Critical appraisal  
Four reviewers (LC, MH, TJ-H, HC) independently assessed quality for the newly identified 
studies (2004 onwards) based on the criteria in Error! Reference source not found. (used 
for the assessment in the previous HTA [Wilson and colleagues, 2007] and Cochrane 
[Tonia and colleagues, 2012] reports).1,10 
Table 9. Quality assessment 
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Table 9. Quality assessment 
Treatment allocation 
1. Was allocation truly random?  
Yes: random numbers, coin toss, shuffle, etc 
No: for patients number, date of birth, alternate 
Unclear: if the method not stated 
2. Was treatment allocation concealed? 
Yes: central allocation at trial office/pharmacy, sequentially 
numbered coded vials, other methods where the trialist allocating 
treatment could not be aware 
Inadequate: allocation was alternate, or based on information 
known to the trialist  
Unclear: Insufficient information given 
Similarity of groups 3. Were the patients' characteristics at baseline similar in all groups? 
Implementation of masking 
4. Was the treatment allocation masked from the participants? (either 
stated explicitly or an identical placebo used) 
5. Was the treatment allocation masked from clinicians? 
Completeness of trial 
6. Were the numbers of withdrawals, dropouts, and lost to follow-up in 
each group stated? 
7. Did the analysis include an ITT or were less than 10% of study arm 
excluded? 
Key: ITT, intention-to-treat 
4.1.6. Methods of data analysis/synthesis 
Where data permitted the results of individual studies were pooled using the methods 
described below. 
A random-effects model was assumed for all meta-analyses. For binary data, risk ratio (RR) 
was used as a measure of treatment effect and the DerSimonian–Laird method was used for 
pooling. For continuous data, mean differences were calculated if the outcome was 
measured on the same scale in all trials. For QoL only identical scales and sub-scales were 
combined in a given meta-analysis.  For time-to-event data; i.e. OS, data were extracted 
from the Cochrane review (Tonia and colleagues, 2012).10 In the Cochrane review hazard 
ratios (HRs) were based on individual patient data (IPD) data; where IPD were not available, 
the HR was calculated from published reports including secondary analyses, using methods 
reported in Parmar and colleagues (1998),44 or binary mortality data.10 Similarly, data from 
the Cochrane review (Tonia and colleagues, 2012)10 were used for mean Hb change, 
transfusion requirement, mean units of blood transfused, complete tumour response, QoL, 
and AEs, if this information was not available in the published trials’ reports. 
One study (Tjulandin and colleagues, 2010)45 had two intervention arms that were 
separately compared with the control arm. To take account of the fact that some study-
specific estimates would use the same control arm, the information was divided across the 
number of comparisons from the study. When pooling RRs, the number of events and the 
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total sample size in the control arm were divided equally across the comparisons, and when 
pooling mean differences the total sample size in the control arm was adjusted and divided 
equally across the comparisons. However, if only one experimental arm was eligible for the 
analysis (Ten Bokkel and colleagues, 1998; Thatcher and colleagues,1999; Hedenus 
and colleagues, 2002; Kotasek and colleagues, 2003),46-49 all participants assigned to the 
control arm were included. 
The following pre-specified subgroup analyses were conducted, if appropriate: 
 Hb level at study entry (<10 g /dl versus <11 g/dl versus <12 g/dl versus <14.5 g/dl 
versus not reported) 
 Hb inclusion criteria (≤11 g/dl versus <11 g/dl versus) 
 Target Hb (≤12 g/dl and >12 g/dl)  
 Solid tumours versus haematological malignancies (solid versus haematological 
versus mixed versus not reported) 
 Ovarian cancer (ovarian cancer versus other cancers) 
 Type of chemotherapy treatment (platinum chemotherapy versus non-platinum 
chemotherapy versus chemotherapy+radiotherapy versus mixed chemotherapy 
versus not reported) 
 Short-lasting ESA versus long-lasting ESA (epoetins versus darbepoetin) 
 Iron supplementation (iron supplementation given versus no iron supplementation 
versus iron handled differently in study arm versus not reported) 
 Duration of ESA medication (six to nine weeks versus 12–16 weeks versus 17–20 
weeks versus >20 weeks) 
 Study design (placebo versus standard care) 
In addition based on subgroup analyses, meta-regression models were conducted including 
random effect and a subgroup as a covariate to assess the effects of subgroups on the 
outcomes. These analyses were conducted if there was sufficient number of studies in each 
subgroup. The Der Simonian-Laird method was used to estimate between-study variance in 
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meta-regression. All covariates showing a significant effect (p<0.05) in a univariate analysis 
were further considered in a model selection. However, these analyses have to be 
interpreted with caution as they can only be exploratory, and should be considered as 
hypothesis generating rather than hypothesis testing analyses.50,51 
In addition, we stated in the protocol that we would consider: the use of iron supplementation 
+ ESAs; people with any type of cancer receiving platinum-based chemotherapy; people 
with head and neck malignancies; women with ovarian cancer; women with ovarian cancer 
receiving platinum-based chemotherapy; and, people unable to receive blood transfusions.  
All analyses were performed using STATA v.12. 
4.1.6.1.  Sensit ivity analysis 
To allow comparison with the Cochrane review (Tonia and colleagues, 2012)10 and with the 
previous HTA review (Wilson and colleagues, 2007),1 fixed-effects meta-analyses for the 
main analysis were also conducted. 
4.1.6.2.  Assessment of bias 
Identified research evidence was interpreted according to the assessment of methodological 
strengths and weaknesses and the possibility of potential biases. Publication bias for the 
main outcomes was assessed using funnel plots. The Egger test was used for continuous 
outcomes (mean difference; SE), and the Harbord test was used for binary outcomes (OR, 
logSE). However, it should be noted that these tests typically have low power to detect 
funnel plot asymmetry, and so the possibility of publication bias existing in the meta-analysis 
cannot be excluded even if there is no statistically significant evidence of publication bias.  In 
addition, meta-regression models including random effect and using publication year as a 
covariate to assess the effect of publication year on the considered outcome were 
conducted. 
4.1.7. Graphical representation of summary trial information  
We present a summary of information relating to each trial at the end of each comparison 
section using Graphical Overview for Evidence Reviews (Gofer) software (developed by Dr 
Will Stahl-Timmins at the University of Exeter Medical School, in association with the 
PenTAG Health Technology Assessment group and the European Centre for Environment 
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and Human Health). These figures graphically represent the study design, study quality and 
results in a format that allows quick comparison between trials.   
4.2. Results 
4.2.1. Studies identified 
We screened the titles and abstracts of 1,458 unique references identified by the PenTAG 
searches and additional sources, and retrieved 293 papers for detailed consideration. Of 
these, 232 were excluded, five because they were unobtainable and 227 for other reasons 
(a list of these items with reasons for their exclusion can be found in Appendix E). Sixty one 
studies met the pre-specified criteria set out in the protocol and were considered eligible for 
inclusion. In assessing titles and abstracts, agreement between the two reviewers was good 
(κ=0.693 [95% CI 0.648–0.738]). At the full-text stage, agreement was substantial (κ=0.792 
[95% CI 0.705–0.879]). At both stages, initial disagreements were easily resolved by 
consensus. 
We then re-assessed included studies (n=46) from the review conducted by Wilson and 
colleagues (2007).1 Of these, 29 studies were considered eligible for inclusion in the update 
review. The scope for Wilson and colleagues (2007)1 differed from the current scope; the 
population of interest was not defined by treatment type compared with the current scope 
which specifies patients on chemotherapy (see Section 2.7.1.2, page 48). Reasons for 
exclusion included: data only available in abstract format, population (either participants not 
receiving chemotherapy or receiving radiotherapy only), or duplicate (studies also retrieved 
in the PenTAG update searches). 
We identified and included one full paper (Boogaerts and colleagues, 2003)52 of an 
abstract (Coiffier and colleagues, 2001)53 included in the review by Wilson and 
colleagues (2007).1 In addition, one study (Abels and colleagues, 1993)54 included in the 
previous HTA review Wilson and colleagues, 2007) was published in five papers; three were 
included in the Wilson and colleagues review (Abels and colleagues, 1993;54 Case and 
colleagues, 1993;55 and, Henry and colleagues, 199456), and an additional two were 
identified when scrutinising the bibliographies of included studies (Henry and colleagues, 
1995;57 and, Abels and colleagues, 199658).  
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Citations of the includable studies (including the 2012 Cochrane Review [Tonia and 
colleagues, 201210]) were also searched by two reviewers (LC, MH). This process revealed 
an additional six papers: 
 Systematic reviews (n=1): Grant and colleagues, 201359 
 Primary studies (n=5): Henry and colleagues (1995);57 Abels and colleagues 
(1996);58 Patrick and colleagues (2003);60 Wagner and colleagues (2004);61 Moebus 
and colleagues (2013)62 
For this review we further specified that eligible interventions should be assessed as 
administered in accordance with their licensed indications. This criterion was applied after 
the first-round of full-paper screening in order to make sure that we captured all relevant 
evidence. As the majority of trials were initiated before the 2008 update of the SmPCs the 
inclusion criteria for these studies did not reflect the revised ESA license with regards to the 
treatment initiation threshold of Hb ≤10 g/dl or Hb treatment target levels of 10–12 g/dl. As a 
result none of the included studies were completely in line with the current UK marketing 
authorisation. We therefore considered studies eligible for inclusion if they used a licensed, 
weight-based starting dose, regardless of other criteria stipulated by the license; e.g. Hb 
levels.  
In applying this eligibility criterion, 47 were considered to have evaluated the interventions 
outside of the licensed indication (a list of these studies together with study characteristics 
can be found in Appendix F). In total, 23 primary studies reported in 35 publications were 
judged to meet the inclusion criteria for the review (Table 10); study characteristics are 
summarised in Appendix G. Primary studies are linked to multiple publications in Appendix 
H. Eleven systematic reviews reported in 14 publications (see Appendix I) were also 
identified; these were used to identify other studies and to compare results. 
Update searches were conducted on 2nd December using the same methodology as 
described earlier.  Seventy records were screened by two reviewers (LC and MH) and eight 
records were selected for full-text retrieval.  No studies were judged eligible on full-text 
appraisal by LC and MH.  A list of these items with reasons for their exclusion can be found 
in Appendix E. 
The process is illustrated in detail in Figure 1. 
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Figure 1. PRISMA flowchart: clinical effectiveness review  
 
Key: DX, data extraction; SRs, systematic reviews; RCTs, randomised controlled trials
Notes:  (a) Studies excluded (reasons for exclusion): abstract: Quirt (1996), Carabantes (1999), Huddart (2002), 
Thomas (2002), Janinis (2003); population (receiving radiotherapy only or not receiving chemotherapy): 
Rose (1994), Wurnig (1996), Sweeney (1998), Italian Coop Study Group (1998),  Henke (1999), Thompson 
(2000), Henze (2002), Blohmer (2003), Henke (2003), Smith (2003); duplicates (studies also returned in the 
update searches): Casadevall 92004), Rosenzweig (2004); (b) Systematic reviews: Grant et al; primary 
studies: Abels (1996), Henry (1994), Patrick (2003), Wagner (2004), Moebus (2013); (c) Four studies (Ten 
Bokkel [1998], Thatcher [1999], Hedenus [2002], Kotasek [2003]) evaluated different ESA doses only the within 
license doses were included in the PenTAG review; details of the excluded treatment arms documented in 
Section 0, page 637; (d) ‘within licence’, based on the administration of ESAs at the licensed weight-based start 
dose; (e) Systematic reviews not formally included; used as a reference with which to compare results and 
identify other citations; (f) A list of primary publications and multiple publications is available in Appendix I 
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Table 10. Study characteristics 
Study, year n Agent Control Malignancy Treatment Outcomes  Multiple publications identified 
Wilson and colleagues (2004 [HTA]) included studies meeting inclusion criteria for the PenTAG review 
Abels,  
199354 
413a Epoetin alfa Placebo Haeme Chemo: mixed HaemR, Hct, RBCT, HRQoLb, AEb Abels, 1996; Case, 1993; Henry 
1994, Henry, 1995 
Aravantinos,  
200363 
47 Epoetin alfa Standard Solid Chemo: plat Hb, HCT, patients' RBCT NA 
Boogaerts,  
200352 
262 Epoetin beta Standard Solid & haeme Chemo: NR HaemR, Hb, RBCT, HRQoL Coiffier, 1999 (abstract) 
Dammacco,  
200164 
145 Epoetin alfa Placebo Haeme Chemo: mixedd HaemR, Hb, RBCT, HRQoL, AE NA 
Del Mastro,  
199965 
62 rHuEPOb Standard Solid (breast) Chemo: non-plat Hb, RBCT, HRQoL, AE NA 
Dunphy,  
199966 
30 rHuEPOb Standard Solid (head & 
neck, lung) 
Chemo: mixed Hb, RBCT NA 
Hedenus,  
200249 
33e Darb alfa Placebo Haeme Chemo: NR HaemR, Hb, RBCT, AE NA 
Hedenus,  
200316 
349 Darb alfa Placebo Haeme Chemo: NR HaemR, RBCT, AE, HRQoL Littlewood, 2006 
Kotasek,  
200346 
249 Darb alfa Placebo Solid Chemo: NR HaemR, Hb, RBCT, HRQoL NA 
Kurz,  
199767 
35 Epoetin alfa Placebo Solid (cervix, 
ovary, uterus) 
Chemo: mixed HaemR, RBCT, HRQoL, AE NA 
Littlewood,  
200168 
375 Epoetin alfa Placebo Mixed Chemo: non-plat HaemR, Hb, RBCT, HRQoL, AE Aapro, 2004; Bajetta, 2004; Patrick 
2003 
Osterborg,  
2002, 200569,70 
349 Epoetin beta Placebo Haeme Chemo: non-plat HaemR, Hb, RBCT, HRQoL, AE Osterborg, 2005 (long-term follow-
up) 
Silvestris,  
199571 
54 Epoetin alfa Standard Haeme Chemo: NR HaemR, Hb, AE NA 
Ten Bokkel,  
199847 122 
Epoetin beta Standard Solid (ovary) Chemo: plat Patients' RBCT, AE NA 
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Study, year n Agent Control Malignancy Treatment Outcomes  Multiple publications identified 
Thatcher,  
199948 130 
Epoetin alfa Standard Solid (SCLC) Chemo: mixed Hb, Patients' RBCT, HRQoL, AE NA 
Vansteenkiste,  
200272 
314 Darb alfa Placebo Solid (lung) Chemo: plat HaemR, Hb, RBCT, HRQoL, AE, 
disease progression, survival 
Vansteenkiste, 2004 
Study characteristics: PenTAG review update 2004 to July 2007 
Grote, 
200573 
224 Epoetin alfa Placebo Solid (SCLC) Chemo: mixed Hb, RBCT, TR; survival; AE NA 
Moebus,  
201362 
643 Epoetin alfa  Standard Solid (breast) Chemo: non-plat Hb, RBCT, HRQoL, survival, AE NA 
Ray-Coquard,  
200974 
218 Epoetin alfa Standard Mixed Chemo: NR RBCT, OS, HRQoL, AE NA 
Strauss,  
200875 
74 Epoetin beta Standard Solid  
(cervix) 
Chemo + Radio Hb RBCT, TR, survival, AE NA 
Tjulandin, 
201045 
223 Epetin theta 
Epoetin beta 
Placebo Solid Chemo: plat HaemR, Patients' RBCT, HRQoL, 
AE 
NA 
Tjulandin,  
201176 
186 Epoetin theta Placebo Mixed Chemo: non-plat HaemR, Patients' RBCT, HRQoL, 
AE 
NA 
Untch,  
2011a, b77,78 
733 Darb alfa Standard Solid (breast) Chemo: non-plat Hb, pathological response, disease 
progression, survival, AE 
NA 
Key: AE, adverse event; Darb, darbepoetin; HaemR, haematopoietic response; Hb, haemoglobin; HRQoL, health-related quality of life; NR, not reported; OS, overall survival; plat, platinum-
based chemotherapy; RBCT, red blood cell transfusion; refs, references; rHuEPO, recombinant human erythropoietin; SCLC, small-cell lung cancer; TR, tumour response 
Notes: (a) Study population included patients not receiving chemotherapy (n=124); beyond the scope for the current review; (b) Outcomes reported for all participants (i.e. includes patients not 
receiving chemotherapy); (c) Assumed to epoetin alfa or epoetin beta based on date of study and dose administered; (d) majority of participants reported to be on non-platinum chemotherapy; e 
Dose-response study other doses of darbepoetin alfa included; (e) specifically haematological non-myeloid malignancies (chronic lymphocytic leukaemia; non Hodgkin’s lymphoma; Hodgkin’s 
disease and multiple myeloma within these studies) 
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4.2.2. Study characteristics 
4.2.2.1.  Study design 
ESAs plus standard care vs placebo plus standard care 
The 2004 review identified nine RCTs investigating the effectiveness of ESAs plus standard 
care compared with placebo plus standard care, those reported by Abels and colleagues 
(1993),54 Dammacco and colleagues (2001),64 Hedenus and colleagues (2002 and 
2003),16,49 Kotasek and colleagues (2003),46 Kurz and colleagues (1997),67 Littlewood 
and colleagues (2001),68 Osterborg and colleagues (2002 and 2005),69,70 and 
Vanseteenkiste and colleagues (2002)72. Three of these evaluated epoetin alfa, one 
epoetin beta, and four darbepoetin alfa. In one study it was uncertain which brand of 
erythropoietin was used (although it was assumed to be either epoetin alfa or epoetin beta 
[based on the study date and dose administered]). 
PenTAG searches identified an additional four RCTs. These are: Grote and colleagues 
(2005),73 Strauss and colleagues (2008),75 Tjulandin and colleagues (2010 and 
2011).45,76 One of these evaluated epoetin alfa, two epoetin beta, and two epoetin theta (one 
was a three-arm study comparing epoetin beta vs epoetin theta vs placebo (Tjulandin and 
colleagues, 2010)). We also identified one paper (Osterborg and colleagues [2005]70) 
evaluating long-term survival for epoetin beta compared with placebo from the earlier 2002 
RCT (Osterborg and colleague [2002]69) identified in the 2004 review. We also identified 
five retrospective analyses based on three primary studies identified in the 2004 review 
(Patrick and colleagues, 2003;60 Bajetta and colleagues, 2004;79 Aapro and colleagues, 
2004;80 Vansteenkiste and colleagues, 2004;81 Littlewood and colleagues, 2006).82  
ESAs plus standard care vs standard care alone 
The 2004 review identified seven RCTs investigating the effectiveness of ESAs plus 
standard care compared with standard care alone, those reported by: Aravantinos and 
colleagues (2003),63 Boogaerts and colleagues (2003),52 Del Mastro and colleagues 
(1999),65 Dunphy and colleagues (1999),66 Silvestris and colleagues (1995),71 Ten 
Bokkel and colleagues (1998),47 and Thatcher and colleagues (1999).48 Three of these 
evaluated epoetin alfa, two epoetin beta, and in two studies it was uncertain which brand of 
erythropoietin was used (although it was assumed to be either epoetin alfa or epoetin 
beta,based on the study date and dose administered). 
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PenTAG searches identified an additional three RCTs (reported in four publications). These 
are: Moebus and colleagues (2013),62 Ray Coquard and colleagues (2009),74 Untch and 
colleagues (2011a,b).77,78 Two studies reported evaluations of epoetin alfa and one study 
(two publications) darbepoetin alfa.  
Head-to-head 
No head-to-head studies were identified in the 2004 review. 
PenTAG searches identified one three-arm study comparing epoetin beta and epoetin theta 
vs placebo (Tjulandin and colleagues, 2010).45 No head-to-head comparison was made.  
4.2.2.2.  Dose 
Dosing strategies varied considerably in the literature in terms of: start dose (fixed or weight-
based); trigger haemoglobin level, target haemoglobin level; dose escalation; stopping rules 
for non-responders; and, duration of use. These aspects will have an impact on the clinical 
effectiveness. Given the publication of the 2012 Cochrane review (Tonia and colleagues, 
2012) this review focused on the administration of ESA in accordance with their UK 
marketing authorisation. Studies were considered eligible for inclusion if they used a 
licensed starting dose irrespective of how they dealt with other criteria stipulated by the 
licence. Thus, ESAs administered weekly, for epoetin alfa and epoetin zeta to be 
administered three-times weekly, for epoetin beta to be administered three to seven times 
per week; and, for darbepoetin alfa to be administered every three weeks. Fixed (epoetin 
theta) and weight-based (epoetin alfa, epoetin beta, epoetin zeta, and darbepoetin alfa) 
dosages were allowed. 
The current licensed weight-based, starting dose for epoetin alfa is 450 IU/kg per week 
(given as either three divided doses or as a once-weekly dose); for epoetin beta the licensed 
dose is 450 IU/kg per week (given in three to seven divided doses). The maximum licensed 
dose for both epoetin alfa and beta is 900 IU/kg per week. For epoetin theta the licensed 
dose is 20,000 IU per week independent of body weight. The maximum licensed dose per 
week is 60,000 IU per week independent of body weight. For darbepoetin alfa the licensed 
weight-based, starting dose is 2.25 µg/kg in a once-weekly dose or 6.75 g/kg once every 
three weeks. The maximum dose is 4.5 g/kg per week. 
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This review focuses only on those studies evaluating the interventions at their licensed 
starting dose (as detailed in the previous paragraph), irrespective of other aspects of the 
license (e.g. Hb levels).  For darbepoetin alfa, two studies were dose-response studies and 
therefore evaluated doses under and over the current licence recommendation (Hedenus 
and colleagues, 2002;49 and Kotasek and colleagues, 200346); and, two included studies 
included a second intervention group evaluating epoetin alfa at a start dose of 300 IU/kg 
(Ten Bokkel and colleagues, 1998;47 and, Thatcher and colleagues, 199948). Only the 
licensed start doses from these studies were included in the PenTAG review). In addition, 
one study (Untch and colleagues, 2011a,b77,78) evaluated darbepoetin alfa at a dose of 4.5 
g/kg once every two weeks this was considered within licence as the equivalent dose per 
week (2.25 g/kg) is a licensed dose. 
Of note, none of the included studies evaluated ESAs entirely within the remit of their 
marketing authorisations; in particular, with respect to start and target haemoglobin levels, 
and stopping rules all of which were generally higher than specified in the license. A table 
summarising the administration of ESAs in relation to their respective licenses within the 
included studies is given in Appendix C. Two additional definitions of ‘within licence’ were 
considered in retrospective sensitivity analyses: (1) licensed start dose plus inclusion Hb ≤11 
g/dl plus target Hb ≤13 g/dl; and, (2) licensed start dose plus inclusion Hb ≤11 g/dl. 
4.2.2.3.  Duration of ESA treatment and duration of study 
The majority of the trials gave erythropoietin therapy over the course of the chemotherapy, 
with many continuing with erythropoietin therapy for four weeks after chemotherapy, which is 
permissible within the licensed indications. The average time on erythropoietin treatment 
was 12 weeks, with trial duration clustering around 12–28 weeks. One study reported follow-
up data (Osterborg and colleagues, 200570). 
4.2.2.4.  Concomitant treatments 
There were several possible concomitant treatments: granulocyte colony-stimulating factor 
(G-CSF), iron supplementation and RBCT, with some protocols giving recommendations for 
when transfusions should be given (referred to in this review as transfusion triggers) (see 
Appendix G.  
Two studies were identified that gave G-CSF. In one study (Del Mastro and colleagues, 
199765) G-CSF was given at a dose of 5 µg/kg from Day 4 until Day 11, during the first five 
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chemotherapy cycles, to allow accelerated chemotherapy. The second study (Ray-Coquard 
and colleagues, 200974) stated that G-CSF could be used in primary or secondary 
prophylaxis as recommended by the American Society of Clinical Oncology (ASCO) and 
French Federation of Cancer Center guidelines. However, it was unclear whether G-CSF 
was administered to any of the study participants during the study period. 
In the majority of studies (n=16) iron supplementation was given. Reporting of details in this 
respect varied. A fixed daily dose of oral iron (either 200 mg or 325 mg)  for all patients was 
most common, although in a few studies administration of oral iron supplementation was 
dependent on transferrin saturation levels (i.e. ≤<20%, or <10%); in one study allowing daily 
oral iron supplementation if transferrin saturation fell to ≤20% i.v. iron was recommended. In 
two studies (Osterborg and colleagues 2002, 2005;69,70 and, Strauss and colleagues, 
200875) enrolled patients with a baseline of <25% and <20% (respectively) participants were 
given i.v. iron supplementation at a dose of 100 mg per week before the start of study 
treatment. In cases where patients were contraindicated or the drug was not available oral 
iron supplementation was administered. In one study (Kurz and colleagues, 199767) i.v. iron 
supplementation was administered following each dose of chemotherapy beginning with the 
next cycle. One trial was identified in which concomitant iron supplementation was given 
only to patients receiving an erythropoietin (Untch and colleagues, 2011a,b77,78). Several 
studies reported that iron supplementation was allowed during the study without specifying 
details, or that supplementation was given at the investigators’ discretion. Nine studies do 
not report concomitant treatment, and in two studies (Thatcher and colleagues, 1999;48 
and Vansteenkiste and colleagues, 200272) iron supplementation during the study period 
was not permitted. 
4.2.2.5.  Population characterist ics 
Population characteristics of the included trials are summarised in Table 11 and Table 12; 
characteristics are described in more detail in Appendix G.  
Trials had an age range of 18–92. In the majority of included studies there was an equal 
distribution of men and women, with the obvious exception of trials whose populations had 
gynaecological and breast malignancies (within the breast malignancies one patient was 
male [Littlewood and colleagues, 2001]68). However, in one study (Dunphy and 
colleagues, 1999;66 head, neck and lung tumours) gender was not distributed equally 
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between the two treatment groups; in the treatment arm 92% of participants were men 
compared with an equal distribution of men and women in the control arm (50% each).  
There was a variety of malignancies (see Table 11): five trials had patients with a mix of 
solid tumours; one of the retrospective analyses identified (Bajetta and colleagues, 2004)79 
was a subgroup analysis of a breast cancer cohort enrolled in the study conducted by 
Littlewood and colleagues, 2001;68 however, the overall study was not powered to 
discriminate treatment differences within subgroups.  Eight of the included studies 
concentrated on specific solid tumour types (breast n=3; ovary n=1; cervix n=1; lung n=3). 
There were four studies with a mix of haematological malignancies (specifically 
haematological non-myeloid malignancies [chronic lymphocytic leukaemia; non Hodgkin’s 
lymphoma; Hodgkin’s disease and multiple myeloma within these studies]); of these, one 
study was reported in two papers; Osterborg and colleagues (2005) reported long-term 
survival data from an earlier study (Osterborg and colleagues, 2002).69,70 One study 
concentrated on multiple myeloma (MM) (Silvestris and colleagues, 1995). Five studies 
included participants with a mix of solid and haematological malignancies. 
Table 11. Malignancies included in the trials 
Malignancy Mixed types Specific malignancies 
Solid tumours Tjulandin, 2010; Aravantinos, 2003; 
Kotasek 2003; Dunphy, 1999; Kurz 
1997 
Moebus, 2013 (breast); Untch, 2011 a,b 
(breast); Strauss, 2008 (cervix); Grote, 
2005 (SCLC); Vansteenkiste, 2002 
(lung); Thatcher, 1999 (SCLC); Ten 
Bokkel, 1998 (ovary); Del Mastro, 1997 
(breast) 
Haematologicalc Hedenus, 2003; Osterborg, 2002 & 
2005a; Hedenus 2002; Dammacco, 
2001 
Silvestris, 1995 (MM) 
Mixed solid & 
haematologicalc 
malignancies 
Tjulandin, 2011; Ray-Coquard, 2009; 
Boogaerts, 2003; Littlewood, 2001; 
Abels, 1993b 
 
Key: ALL, acute lymphoblastic leukaemia; met, metastatic; MM, multiple myeloma; NSCLC, non-small-cell lung 
cancer; SCLC, small-cell lung cancer 
Notes: (a) Follow-up of Osterborg 2002 study; (b) Population includes patients receiving plat and non-plat 
chemotherapy; and, patients receiving no treatment; (c) specifically haematological non-myeloid malignancies 
(chronic lymphocytic leukaemia; non Hodgkin’s lymphoma; Hodgkin’s disease and multiple myeloma within these 
studies) 
 
Malignancy treatments consisted of chemotherapy (platinum-based and non-platinum 
based), and chemotherapy plus radiotherapy. In four studies participants received platinum-
based chemotherapy, in six studies participants were on non-platinum chemotherapy, in six 
studies participants were receiving chemotherapy but the type was unknown, five studies 
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included participants on mixed chemotherapy treatment. Of the latter group, in two of the 
studies the majority of patients received platinum-based chemotherapy (proportion not 
reported); and, in one of the studies the majority of participants received non-platinum based 
chemotherapy (proportion not reported). One trial involved participants on chemotherapy 
plus radiotherapy. 
Table 12. Malignancy treatments 
Malignancy Trials 
Chemo: plat 
based 
Tjulandin, 2010; Vansteenkiste, 2002; Aravantinos, 2003;  Ten Bokkel, 1998; 
Abels, 1993b 
Chemo: non-
plat based 
Moebus, 2013; Tjulandin, 2011; Untch, 2011a, b; Osterborg, 2002, 2005;a 
Littlewood, 2001; Del Mastro, 1997; Abels, 1993b 
Chemo: type 
unknown 
Ray-Coquard, 2009; Boogaerts, 2003; Hedenus, 2003; Kotasek, 2003; Hedenus 
2002; Silvestris, 1995 
Mixed chemo Grote, 2005; Dammacco, 2001; Dunphy, 1999; Thatcher, 1999; Kurz, 1997 
Chemo + Radio Strauss, 2008 
Key: chemo, chemotherapy; plat, platinum; radio, radiotherapy
Notes: (a) Follow-up of Osterborg 2002 study; (c) Population includes participants receiving plat and non-plat 
chemotherapy; and, patients receiving no treatment but data are reported separately for each group 
 
The majority of included studies specified the required baseline degree of anaemia in the 
eligibility criteria; in three studies this baseline degree of anaemia was not specified in the 
eligibility criteria reported. The highest was ≤14.5 g/dl (Grote and colleagues, 2005),73 and 
the lowest was ≤8 g/dl (Silvestris and colleagues, 1995).71 Despite this, mean/median Hb 
level at baseline ranged from 9.2 to 14.1 g/dl in the intervention group and from 9.1 to 14.1 
g/dl in the control group. 
4.2.3. Quality of included studies 
Quality assessment criteria are presented in Error! Reference source not found. (page 
63), and study appraisal is presented in Table 13. All trials were assessed using the same 
quality assessment tool as the previous HTA (Wilson and colleagues, 2007).1 However, 
there is some variation in the method of quality assessment between the previous and the 
current review: In the current appraisal, only information published in the primary studies 
was considered when conducting the quality appraisal, whereas the previous HTA review 
also used quality assessment information published in the 2004 Cochrane review (Issue 3). 
Cochrane review authors contacted the trials investigators to request missing data, including 
information on study conduct. In addition, we have access to new information from papers 
published after the inclusion date for the previous review. Only primary studies were 
PenTAG    
77 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
appraised. Secondary analyses of previously published data were not assessed. Similarly, if 
a trial was reported in multiple publications, only one quality assessment of the trial was 
conducted. In total, 24 trials were assessed, including eight trials not included in the previous 
HTA review. 
4.2.3.1.  Overall  assessment 
The 23 included RCTs were of variable quality, but all are flawed, some due to reporting 
issues, but others more substantially. For most of the trials it was difficult to make a general 
assessment about study quality due to reporting omissions. In fact, 10 of the 23 trials either 
did not report, or lacked clarity on, at least three of the seven items constituting the 
Cochrane risk of bias tool.  Most notably, all trials lacked clarity in the reporting of allocation 
methods (the procedure for randomisation and/or allocation concealment). Three of the 
studies were of generally high quality (Kurz and colleagues, 1997,67 Tjulandin and 
colleagues, 2011,76 Tjulandin and colleagues 2010),45 with each of these satisfactorily 
addressing five of the seven items of the Cochrane risk of bias tool. However, even the 
reports of these three studies omitted important information relating to study quality. The 
study by Dunphy and colleagues (1999)66 has the poorest quality profile, followed by 
Boogaerts and colleagues (2003),52 Ray-Coquard and colleagues (2009),74 and 
Silvestris and colleagues (1995).71 Further details of the quality of included studies, 
according to individual items on the Cochrane risk of bias tool are described as follows.  
4.2.3.2.  Treatment al location  
Random allocation: The method of random allocation was clearly stated and sufficient in 
nine trials while 14 trials did not specify the method used. 
Concealment of allocation: The method of concealment of allocation was not clearly reported 
in any of the included trials. Fifteen trials did not report any information on allocation 
concealment, while eight trials provided some information. A centralised system for 
randomisation was reported in seven trials, and, authors of one trial stated that only the 
person administering study medication was unblinded.  So it is possible that the allocation 
sequence was concealed in these eight trials. However, as no specific details on allocation 
concealment were reported, this remains unclear. 
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4.2.3.3.  Similarity of groups 
Baseline characteristics: Only three trials fully reported baseline characteristics including p-
values for baseline group comparisons. Authors of 14 trials stated “similarity between 
groups”; however no statistical information was reported to support this. Another four studies 
reported some baseline difference for one or more outcomes. Whereas no baseline 
characteristics were reported for two trials; one of these two studies used a Latin square 
design, and baseline characteristics are reported for groups randomised by chemotherapy, 
but not for the erythropoietin randomisation. 
4.2.3.4.  Implementation of masking  
Treatment allocation masked from participants: Participants were blinded to treatment 
allocation in 12 trials. Ten trials did not blind participants from treatment allocation and one 
trial did not report any information about blinding participants to treatment allocation.  
Treatment allocation masked from clinicians: The 12 trials which blinded participants to 
treatment allocation also masked treatment allocation from clinicians. Eight trials did not 
blind clinicians to treatment allocation. Whereas three trials did not report any information 
about clinicians’ blinding to treatment allocation; these three trials compared erythropoietin 
groups with standard care. 
4.2.3.5.  Completeness of tr ial  
Reporting of loss to follow-up, withdrawals and dropouts: loss to follow-up, withdrawals and 
dropouts were fully reported in nine trials and partially reported in 12 trials. In the 12 trials 
where this information was partially reported, five trials reported withdrawals and dropouts 
until the end of trials, but did not provide any data on the follow up period. Two trials did not 
report any information on loss to follow-up, withdrawals and dropouts. 
ITT analysis or less than 10% lost: ITT analyses or less than 10% participants lost were 
reported in 14 studies for all measured outcomes. ITT analyses or less than 10% 
participants lost were reported in seven studies for the primary outcome and most of the 
secondary outcomes. Only two trials did not use ITT or reported 10% and more participants’ 
loss. 
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Table 13. Study quality (Cochrane Risk of Bias tool) 
Study, year Random Concealment 
allocation 
Baseline 
similarity 
Patients 
blinded 
Physicians 
blinded 
Losses ITTor <10%dropout 
Abels, 199354 Uncleara NR Unclearb Yes Yes Partially Yes 
Aravantinos, 200363 Uncleara NR Unclearb No No NR Yes 
Boogaerts, 200352 Uncleara NR No: prior 
chemotherapy, 
FACT-F 
No No Partially Yes 
Dammacco, 200164 Uncleara Uncleard Unclearb Yes Yes Yes Yes, primary endpoint and HRQoL 
only 
Del Mastro, 199965 Yes NR Unclearb No NR Partially Yes, apart from HRQoL (87% and 
84% participants were analysed in 
treatment and control groups 
respectively). 
Dunphy, 199966 Uncleara NR No: gender No No Yes No 
Grote, 200573 Yes NR Unclearb Yes Yes Partiallyc Yes 
Hedenus, 200249 Yes Uncleard No: gender, 
platelet and 
neutrophil counts 
Yes Yes Partially Yesg 
Hedenus, 200316 Yes NR Unclear Yes Yes Partiallyc Yesg 
Kotasek, 200346 Uncleara NR Yese Yes Yes Partiallyc Yesg 
Kurz, 199767 Yes Uncleard Yes Yes Yes NR Yes, results report response for all 
participants; assumed ITT. 
Littlewood, 200168 Uncleara NR Unclearb Yes Yes Yes Yes, apart from HRQoL (80% and 
73% participants were analysed in 
treatment and control groups 
respectively). 
Moebus, 201362 Yes Uncleard Unclearb NR NR Yes Yes 
Osterborg, 200269 Uncleara NR Unclearb Yes Yes Partiallyc Yes 
Ray-Coquard, 200974 Uncleara Uncleard No: HRQoLb No No Partially Yes, apart from HRQoL (54% and 
57% participants were analysed in 
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Study, year Random Concealment 
allocation 
Baseline 
similarity 
Patients 
blinded 
Physicians 
blinded 
Losses ITTor <10%dropout 
treatment and control groups 
respectively. 
Silvestris, 199571 Yes NR NR No No Yes No 
Strauss, 200875 Uncleara Uncleard Yes No No Yes Yes 
Ten Bokkel, 199847 Uncleara NR Unclearb No No Partially Yes, but two participants were 
excluded from ITT analyses. 
Thatcher, 199948 Uncleara NR Unclearb No NR Yes Yes, apart from HRQoL (75% and 
61% participants were analysed in 
treatment and control groups 
respectively). 
Tjulandin, 201176 Yes NR Unclearb Yes Yes Yes Yes, apart from HRQoL (89.5-97.9% 
and 85.7-96.7% participants were 
analysed in treatment and control 
groups respectively). 
Tjulandin, 201045 Yes Unclearh Unclearb Yes Yes Yes Yes 
Untch, 2011a, b77,78 Uncleara NR NRf No No Partiallyc Yes 
Vansteenkiste, 200272 Uncleara Uncleard Unclearb Yes Yes Partially Yesg, apart from   HRQoL (81% 
participants were analysed in both, 
treatment and control groups). 
Key: HRQoL, health-related quality of life; ITT, intention-to-treat; NR not reported.  
Notes:  (a) Randomisation details are not reported;  (b) P-values for baseline comparisons are not reported, although authors report “similarity between groups”; (c) Losses reported for the 
treatment period only, data for the follow up period are not reported. (d) Randomisation was performed using a centralised system, but no details on allocation concealment were not reported; 
(e) Baseline values were similar in the placebo and the 6.75 µg/kg darbepoetin alfa subgroup (subject of this review). In the 12.0-mg/kg group higher proportion of patients had breast cancer the 
mean baseline Hb concentration was higher; (f) Authors stated that “baseline characteristics were similar in the treatment arms”. It is assumed that this refers to the chemo arms, thus a baseline 
comparison is not reported for the epo vs no epo arms. (g) Less than 10% dropout, but ITT was defined as all randomised participants who received at least 1 dose of study drug; (h)  Authors 
stated that ”only the person administering study medication was unblinded”. This may imply that the person allocating treatment was unaware of the next allocation, but there is nothing explicitly 
stated so concealment of allocation remains unclear. 
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4.2.4. Manufacturers’ reviews of clinical effectiveness 
Two submissions were presented summarising evidence on the effectiveness of darbepoetin 
alfa (Aranesp®) and epoetin alfa (Binocrit®, Sandoz UK Ltd).  
One systematic review was presented summarising evidence of the effectiveness of 
darbepoetin alfa (Aranesp®). One manufacturer (Sandoz Ltd) submitted an evidence 
summary; summarising trials from their clinical development programme and post-approval 
trials (biosimilar epoetin alfa [Binocrit®]). Although neither are part of the PenTAG 
systematic review it is presented here for convenience and because the results are 
compared. Each submission is briefly discussed in the sections below. 
4.2.4.1.  Epoetin alfa (Binocrit®, Sandoz UK Ltd) 
Sandoz UK Ltd submitted an evidence summary which contained a number of publications 
that were excluded from the PenTAG review because they did not meet the inclusion criteria. 
A list of these items with reasons for their exclusion can be found in Appendix J. 
 The evidence summary comprised:  
 details of the clinical development programme for Binocrit®  
– three Phase I studies: multiple intravenous (i.v.) doses Binocrit® vs epoetin 
alfa 100 IU.kg thrice weekly (TIW) (Sorgel and colleagues, 2009a);83 multiple 
subcutaneous (s.c.) doses Binocrit® vs epoetin alfa 100 IU.kg TIW (Sorgel and 
colleagues, 2009b);84 multiple sc. doses Binocrit® vs epoetin beta 100 IU.kg 
TIW (Sorgel and colleagues, 2009c).85 All studies were four weeks in 
duration. 
– pivotal data: two Phase III studies (Weigang-Kohler and colleagues, 2009 
and Haag-Weber and colleagues, 2009).86,87 Both of the Phase III studies 
were identified in the PenTAG review; one was excluded on population (chronic 
renal failure [Haag-Weber and colleagues, 2009]), and the other excluded on 
comparator (epoetin alfa assessed by class [Weigang-Kohler and 
colleagues, 2009]).  
 post-approval data: four retrospective studies were identified:  three were abstracts 
(Desrame and colleagues, 2013 [observational study];88 Rodriguez-Garzotto and 
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colleagues, 2013 [single-centre audit];89 Lorenz and colleagues, 2013 
[retrospective, matched-cohort analysis]);90 And one, Kerkhofs and colleagues, 
2012 [retrospective study]), was fully published. These were not included in the 
PenTAG review as they were non-randomised studies.  
Results from the identified studies were reported narratively. One Phase 3 trial evaluated the 
efficacy and safety of Binocrit® in the treatment of CIA in cancer patients (n=114 [n=94 ITT 
population]). The comparator was epoetin alfa (Erypo®/Eprex®, Janssen–Cilag). The 
primary endpoint was haemR (absolute increase in Hb of ≥2 g/dl between the 
screening/baseline period and the evaluation period in the absence of RBCT during the 
preceding four weeks). HaemR (as defined) was reported in 62% (n=37/60) (95% CI, 48.2%, 
78.9%) of participants treated with Binocrit®, and RBCT requirement was 32% (n=19/60) 
compared with 38% (n=13/34) in the epoetin alfa (Erypo®/Eprex®) group. The study 
reported comparable efficacy and a similar safety profile as expected for the therapeutic 
area. 
Results from non-RCT and observational data were presented to support the application with 
regards to the effectiveness of ESAs with regards to HaemR; Hb change; RBCT 
requirement. Reported results are consistent with existing evidence in respect of these 
outcomes. 
Evidence was also presented to support the following additional aspects:  
 pharmacoeconomic rationale for the use of biosimilars 
 adjusting the current recommendation regarding the trigger Hb level (≤8 g/dl) to align 
with UK marketing authorisation, product SPCs, and clinical guidelines (≤10 g/dl)  
 advantages of using Binocrit® over alternative ESAs; e.g. syringes have an 
innovative safety needle protector; extended shelf-life of 24 months. 
4.2.4.2.  Darbepoetin alfa (Aranesp®, Amgen Ltd) 
Amgen Ltd presented a meta-analysis of pivotal trials as part of their submission. Searches 
for the systematic review were based on the previous HTA appraisal (Wilson and 
colleagues, 20071), and included RCT evidence published since 2004 evaluating the 
efficacy and safety of ESAs for the treatment of CIA in cancer patients, specifically 
darbepoetin alfa. Studies which used a licensed starting dose (500 g, 6.75 g/kg Q3W or 
2.25 g/kg QW were considered eligible for inclusion.  
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A total of nine studies were identified evaluating darbepoetin alfa compared with BSC 
(placebo, no treatment, usual care) for the treatment of CIA in cancer patients. Four were 
included in the PenTAG review (Hedenus and colleagues, 2002; Hedenus and 
colleagues, 2003; Kotasek and colleagues, 2003; and Vansteenkiste and colleagues, 
2002).16,46,49,72 Five studies were abstracts (Suzuki and colleagues, 2008; Katsumata and 
colleagues, 2009; Nitz and colleagues, 2009; Delarue and colleagues, 2012; Hartmann 
and colleagues, 2012),91-95 and as such were not appraised in the PenTAG systematic 
review; they are described in Appendix J. 
The pooled summary estimates presented for the effect of darbepoetin alfa on 
chemotherapy induced anaemia in cancer patients are given in Table 14. 
Table 14. Summary of results from meta-analyses: Amgen Ltd 
 Amgen Ltdb 
Anaemia-related outcomes 
Hb change WMD 1.06 
95% CI 0.86, 1.26, p<0.00001 
Χ2(het) 10.79; df 2 (p=0.005); I2 81% 
3 trials, n=1,645 
HaemRa RR 3.67 
95% CI 2.73, 4.94, p<0.00001  
Χ2(het) 1.77; df 3 (p=0.62); I2=0% 
4 trials, n=528 
RBCT RR 0.56 
95% CI 0.49, 0.64; p<0.00001 
Χ2(het) 4.43; df 6 (p=0.62); I2=0% 
7 trials, n=1,744 
Units transfused WMD -1.25 
95% CI -1.84−-0.66; p<0.00001 
Heterogeneity, NA 
1 trial, n=298 
Malignancy-related outcomes 
Tumour response RR 0.99 
95% CI 0.89, 1.09, p=0.84 
Heterogeneity NA 
1 trial, n=599 
OS HR 0.88 
95% CI 0.72, 1.06, p=0.18 
Χ2(het) 4.74; df 3 (p=0.19); I2=37% 
4 trials 
HRQoL 
FACT-F 3 trials: Results indicated darbe alfa and PBO have a similar effect on 
HRQoL; 1 study reported a difference in favour of darbe alfa vs PBO but 
NSD 
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FACT-An 1 trial: Results indicated darbe alfa and PBO have a similar effect on 
HRQoL (NSD between studies) 
1 trial: 1 study reported a difference in favour of darbe alfa vs PBO but 
NSD 
FACT-G 1 trial: Results indicated darbe alfa and PBO have a similar effect on 
HRQoL (NSD between studies) 
Safety-related outcomes 
No. of AEsd RR 1.03 
95% CI 0.94, 1.12, p=0.51 
Χ2(het) 0.02; df 1 (p=0.90); I2=0% 
1 trial, n=665 
No. of SAEse RR 1.13 
95% CI 0.99, 1.29, p=0.08 
Χ2(het) 0.03; df 1 (p=0.86); I2=0% 
2 trials, n=1,798 
Thromboembolic 
eventsf 
RR 2.15 
95% CI 1.41, 3.28, p=0.0004 
Χ2(het) 0.88; df 2 (p=0.64); I2=0% 
3 trials, n=2,112 
Key: AEs, adverse events; CI, confidence interval; darbe alfa, darbepoetin alfa; df, degrees of freedom; FACT, 
Fucntional Assessment of Cancer Therapy (F, Fatigue; G, General; An, Anaemia subscales); haemR, 
haematological response; Hb, haemoglobin; het, heterogeneity; HRQoL, health-related quality of life; NA, not 
applicable; NSD, no significant difference; PBO, placebo; RBCT, red blood cell transfusion; RR, relative risk; 
SAEs, serious adverse events; WMD, weighted mean difference 
Notes: (a) change from baseline to end of study; (b) fixed effects (Mantel-Haenszel); (c) haematological 
response  was defined as the proportion of participants with an increase in Hb level of two g/dl or more, or as 
an increase in haematocrit of six percentage points or more with a mean/median baseline of ≤12 g/dl at study 
entry; (d) Incidence of any AE; (e) Defined as fatal, life-threatening, requires in-patient hospitalisation or 
prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, a congenital 
anomaly/birth defect or is an ‘other significant medical hazard’ that does not meet any of the other criteria; (f)  
Includes DVT, pulmonary embolism, myocardial infarction and stroke 
 
The pooled summary estimates presented for the effect of ESAs (specifically darbepoetin 
alfa for this analysis) were largely consistent with the summary estimates in the PenTAG 
systematic review particularly with respect to improvements for haemR and reduction in 
RBCT requirement. No significant difference was observed for the outcome Hb change. 
Estimates for the malignancy-related outcomes – tumour response and survival - suggested 
a benefit with treatment compared with control; however, the data were not statistically 
significant, and there was evidence of heterogeneity in the case of OS. In addition, data 
were insufficient in this respect to rule out detrimental effects; however, this uncertainty is 
consistent with previously reported estimates. Estimates for thromboembolic events (RR 
2.15; 95% CI 1.41, 3.28) were worse than estimated in the PenTAG review. 
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4.2.5. Ongoing studies 
Searches of ClinicalTrials.gov and Controlled Trials yielded a total of 218 trials (see Section 
4.1.1.3, page 58). Of these, 94 trials were considered as relevant to this review; however, in 
all cases it was not possible to ascertain whether ESAs were evaluated in accordance with 
their licensed indications. Seven studies were identified as ongoing (n=2) or recruiting (n=5) 
In five trials the current status was recorded as ‘unknown’. Ten trials had terminated; of 
these, three had results available. And, 72 studies were completed. An overview of these 
trials is provided in Appendix K. 
4.2.6. Effectiveness 
4.2.6.1.  Anaemia-related outcomes 
Anaemia-related outcomes: mean Hb change (measured as a change in Hb levels (g/dl) 
from baseline until the end of the treatment period), haematological response (defined as the 
proportion of participants with an increase in Hb level of two g/dl or more, or as an increase 
in haematocrit of six percentage points or more, unrelated to transfusion); and, RBCT 
requirements: number of participants transfused, and number of units transfused per 
average patient (i.e. including participants not requiring transfusion). 
4.2.6.1.1.  Haemoglobin change 
The mean Hb change was measured as a change in Hb levels (g/dl) from baseline until the 
end of the treatment period. Two studies, Moebus and colleagues (2013)62 (included as an 
abstract Moebus and colleagues, 2007, in the Cochrane review  by Tonia and colleagues, 
(2012),10 and Strauss and colleagues (2008),75 only reported median change in Hb (g/dl) 
without any measure of variance so they were excluded from the analyses. 
Overall, the analysis included 16 trials with 3,170 participants. Four trials were newly 
identified in the update searches (Grote and colleagues, 2005; Tjulandin and colleagues, 
2010; Tjulandin and colleagues, 2011; Untch and colleagues, 2011a,b;).45,73,76-78 As 
some trials with multiple experimental arms were split into subsets (Tjulandin and 
colleagues, 2010; Abels and colleagues, 1993)45,54 the number of trials displayed is 18.  
The random effects meta-analysis demostrated statistically significant difference in Hb 
change in favour of treatment (WMD 1.59, 95% CI 1.33 to 1.84; Figure 2). Although all 
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individual studies indicated a beneficial effect of ESA with regard to Hb change and varied 
only in magnitude, there was statistically significant heterogeneity between the trials 
(I2=75.9%, p<0.001; Χ2=70.52, df=17, p<0.01). To assess whether publication bias was 
likely, a funnel plot was constructed (Appendix L). The funnel plot analysis did not show 
statistically significant asymmetry (p=0.133). In addition, a meta regression using publication 
year as a covariate (to assess the effect of publication year on Hb change) showed that the 
effects of ESA on Hb change were independent from any effect of publication year 
(p=0.206); the meta-regression plot is presented in Appendix L. The fixed effects meta-
analysis undertaken as a sensitivity analysis also showed statistically significant difference in 
Hb change in favour of treatment (WMD 1.49, 95% CI 1.37 to 1.60; I2=75.9%, p<0.001); the 
forest plot of this analysis is included in Appendix L. 
Figure 2. Forest plot: Hb change overall (random effects) 
 
Key: CI: confidence Intervals; ID: identification; N: number of participants; SD; standard deviation; WMD: weighted mean 
difference 
Notes: Random effects meta‐analysis (Der‐Simonian–Laird) 
 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 75.9%, p = 0.000)
Del Mastro (1999)
Kotasek (2003)
Tjulandin (2011)
Boogaerts (2003)
Tjulandin_Theta (2010b)
Ten Bokkel (1998)
ID
Abels_NonCisplatin (1993)
Littlewood (2001)
Study
Kurz (1997)
Hedenus (2003)
Tjulandin_Beta (2010a)
Untch (2011a,b)
Dammacco (2001)
Abels_Cisplatin (1993)
Osterborg (2002, 2005)
Hedenus (2002)
Aravantinos (2003)
Grote   (2005)
1.59 (1.33, 1.84)
2.25 (1.60, 2.90)
0.88 (0.04, 1.72)
1.45 (0.97, 1.93)
1.20 (0.80, 1.60)
1.40 (0.75, 2.05)
1.23 (0.48, 1.98)
WMD (95% CI)
1.98 (1.42, 2.54)
1.70 (1.27, 2.13)
3.01 (1.77, 4.25)
1.61 (1.22, 2.00)
1.70 (1.01, 2.39)
0.91 (0.65, 1.17)
2.00 (1.42, 2.58)
1.60 (0.87, 2.33)
1.66 (1.29, 2.03)
0.64 (-0.10, 1.38)
1.08 (0.27, 1.89)
2.70 (2.18, 3.22)
1681
28, -.8 (1.4)
17, .86 (1.57)
95, 2.1 (1.3)
133, 2.1 (1.83)
76, 1.6 (1.42)
34, .66 (1.76)
(SD); Treatment
79, 2.35 (2.04)
244, 2.2 (2.18)
N, mean
23, 3.26 (1.98)
174, 1.8 (2.24)
73, 1.9 (1.74)
330, -.07 (2)
69, 1.8 (2.11)
63, 2.04 (2.38)
138, 2.48 (1.74)
17, 1.64 (1.25)
24, 2.31 (1.22)
64, -.2 (1.38)
1489
24, -3.05 (1)
51, -.02 (1.43)
91, .65 (1.94)
129, .9 (1.5)
37, .2 (1.74)
24, -.57 (1.16)
(SD); Control
74, .37 (1.46)
115, .5 (1.79)
N, mean
12, .25 (1.66)
170, .19 (1.3)
37, .2 (1.74)
359, -.98 (1.33)
76, -.2 (1.31)
61, .44 (1.7)
142, .82 (1.4)
6, 1 (.56)
23, 1.23 (1.59)
58, -2.9 (1.53)
100.00
5.28
4.32
6.29
6.69
5.34
4.77
Weight
5.82
6.57
%
2.81
6.79
5.10
7.42
5.71
4.90
6.87
4.81
4.46
6.05
Favours control Favours treatment 
0-4.25 4.25
PenTAG    
87 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
To identify sources of heterogeneity, subgroup analyses were conducted (Table 15). In 
addition, meta-regression models that included random effect and subgroup as covariates 
(to assess the effects of subgroups on Hb change) were performed; the F statistics from 
these analyses are reported in Table 15. All covariates showing a significant effect (p<0.05) 
in a univariate analysis were further considered in a model selection.  
Table 15. Subgroup analysis: Hb change 
 Trials WMD CI I2 Tau2 
Overall 18 1.59 1.33 − 1.84 75.9%; p<0.01 0.22 
Inclusion Hb 
≤11.0 g/dl 13 1.52 1.30 − 1.75 48.1%; p=0.03 0.08 
>11.0 g/dl 5 1.75 1.03 − 2.47 91.4%; p<0.01 0.60 
F (between:within)  F(1,16) =0.47; p=0.50 
Baseline Hb 
≤10.0 g/dl 13 1.51 1.29 − 1.72 43.6%; p=0.05 0.06 
≤11.0 g/dl 1 1.98 1.42 − 2.54 NA 0 
≤12.0 g/dl 1 1.23 0.48 − 1.98  NA 0 
≤14.5 g/dl 3 1.94 0.68 − 3.19 95.5%; p<0.01 1.17 
F (between:within) F(3,14) =0.60; p=0.63 
Target Hb 
≤13.0 g/dl 4 1.29 0.90 − 1.67 61.9%; p=0.05 0.10 
>13.0 g/dl 11 1.59 1.27 – 1.91 74.0%; p<0.01 0.21 
NR 3 2.03 1.42 − 2.65 46.0%; p=0.16 0.14 
F (between:within)  F(2,15) =1.33; p=0.29 
Malignancy type 
Solid tumours 9 1.65 1.11 − 2.18 85.2%; p<0.01 0.53 
Haematological tumours 6 1.63 1.33 − 1.93 49.2%; p=0.08 0.07 
Mixed 3 1.44 1.15 − 1.74 28.1%; p=0.25 0.02 
F (between:within) F(2,15) =0.12; p=0.89 
Ovarian cancer      
Ovarian cancer 1 1.23 0.48 − 1.98 NA 0 
Other cancers 17 1.60 1.34 − 1.87 77.2%; p<0.01 0.23 
F (between:within) F(1,16) =0.34; p=0.57 
Chemotherapy treatment 
Platinum-containing 5 1.42 1.10 − 1.75 0%; p=0.77 0 
Non-platinum-containing 6 1.62 1.20 − 2.03 82.4%; p<0.01 0.21 
NR 4 1.18 0.78 − 1.59 55.0%; p=0.08 0.09 
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Mixed 3 2.47 1.90−3.04 50.0%; p=0.14 0.12 
F (between:within) F(3,14) =4.61; p=0.02 
Iron supplementation 
Iron in both arms 10 1.60 1.38 − 1.82 40.7%; p=0.09 0.0476 
Iron in an intervention arm  1 0.91 0.65 − 1.17 NA 0 
NR  7 1.62 1.07 − 2.16 79.2%; p<0.01 0.42 
F (between:within) F(2,15) =1.07; p=0.37 
Study design 
RCT 13 1.70 1.43 − 1.97 64.9%; p<0.01 0.15 
ROL 5 1.30 0.86 − 1.73 72.0%; p<0.01 0.16 
F (between:within) F(1,16) =1.97; p=0.18 
Study duration 
12–16 wks 12 1.65 1.40 − 1.89 50.4%; p=0.02 0.09 
17–20 wks 2 1.92 0.34 − 3.51 90.8%; p<0.01 1.19 
>20 wks 4 1.24 0.86 − 1.62 69.6%; p=0.02 0.10 
F (between:within) F(2,15) =1.67; p=0.22 
ESA 
Erythropoetin 14 1.74 1.49 − 2.00 62.7%; p<0.01 0.14 
Darbepoetin 4 1.07 0.61 − 1.52 71.4%; p=0.02 0.14 
F (between:within) F(1,16) =6.32; p=0.02 
Key: ESA, erythropoiesis stimulating agents; Hb, haemoglobin; NA, not applicable; NR, not reported; RCT, 
randomised controlled trial; ROL, randomised open label (standard care); wks, weeks. 
 
Univariate analyses identified significant differences between short versus long lasting ESA 
therapy (p=0.023; Figure 3) and between chemotherapy treatments (p=0.019). Trials with 
mixed chemotherapy treatments were significantly different from those using platinum based 
chemotherapy, from those using non-platinum based chemotherapy, and from those not 
reporting what type of chemotherapy was used (Figure 4). The erythropoietin treatment 
(WMD 1.74, 95% CI 1.49 to 2.00; I2=62.7%, p=0.001) seemed to offer greater benefit 
compared to the longer lasting darbepoetin treatment (WMD 1.06, 95% CI 0.61 to 1.52; 
I2=71.4%, p=0.015). Similarly, the mixed chemotherapy treatment (WMD 2.47, 95% CI 1.90 
to 3.04; I2=50.0%, p=0.135) appeared to offer greater benefits compared to the platinum 
based therapy (WMD 1.42, 95% CI 1.10 to 1.74; I2=0.0%, p=0.774), the non-platinum based 
therapy (WMD 1.62, 95% CI 1.20 to 2.03; I2=82.4%, p<0.001), and compared to studies that 
did not report what type of chemotherapy treatment was used (WMD 1.18, 95% CI 0.78 to 
1.59; I2=55.0%, p=0.084).  
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Because of the small number of studies included in the analyses, studies using platinum 
based chemotherapy, non-platinum based chemotherapy and studies not reporting what 
chemotherapy was used, were combined into an “other treatments” group to allow further 
analyses. ESA subgroup (erythropoietin versus darbepoetin) and the new chemotherapy 
subgroup (mixed therapy versus other treatments) were included in the same model to 
explore the effects of the individually significant subgroups on Hb change in one analysis. 
The model including the ESA subgroup and the new chemotherapy subgroup remained 
significant (p=0.002) and is presented in Appendix J (Table 109). However, as stated in 
Section 4.1.6 (page 63) these analyses have to be interpreted with caution. The number of 
studies per subgroup is small (3-6;Table 15). In addition, the heterogeneity between studies 
within the chemotherapy subgroups does not appear to reduce compared to the overall 
analysis (Figure 4). 
The results were also investigated visually. One small study (Kurz and colleagues, 1997;67 
n=35) appeared to differ from most of the other included trials; this study reported the 
highest mean difference between the ESA and control groups. Excluding this study from the 
meta-analysis did not change the overall conclusions (data not reported); we therefore 
included all 18 trials in the analyses of Hb change. 
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Figure 3. Forest plot: Hb change by treatment drug (random effects) 
 
Key: CI: confidence Intervals; ID: identification; N: number of participants; SD; standard deviation; WMD: 
weighted mean difference. 
Notes: Random effects meta-analysis (Der-Simonian–Laird) 
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Figure 4. Forest plot: Hb change by chemotherapy treatment (random effects) 
 
Key: CI: confidence Intervals; ID: identification; N: number of participants; SD; standard deviation; WMD: 
weighted mean difference. 
Notes: Random effects meta-analysis (Der-Simonian–Laird) 
 
Summary: Overall, there is a statistically significant effect of ESA on Hb change. Compared 
to controls, patients receiving ESA achieve a weighted mean Hb level increase of 1.59 g/dl 
from baseline to the end of treatment (CI 1.33−1.84). We identified statistically significant 
heterogeneity between the trials (I2=75.9%, p<0.001), however all individual studies 
indicated a beneficial effect of ESA with regard to Hb change. Subgroup analyses suggested 
that Erythropoietin may offer greater benefits compared to Darbepoetin, and that mixed 
chemotherapy treatment may offer greater benefits compared to other chemotherapy 
treatments, and to studies that did not report what chemotherapy treatment was used. 
However, as the number of studies in the subgroups was very small, these analyses may not 
have a statistical power to detect the effects of chemotherapy treatment and ESA on Hb 
NOTE: Weights are from random effects analysis
.
.
.
.
Overall  (I-squared = 75.9%, p = 0.000)
Boogaerts (2003)
Not reported
Subtotal  (I-squared = 0.0%, p = 0.774)
Kurz (1997)
ID
Grote   (2005)
Abels_NonCisplatin (1993)
Non-platinum based
Platinum based
Tjulandin (2011)
Hedenus (2002)
Tjulandin_Beta (2010a)
Dammacco (2001)
Littlewood (2001)
Osterborg (2002, 2005)
Hedenus (2003)
Ten Bokkel (1998)
Study
Untch (2011a,b)
Mixed therapy
Subtotal  (I-squared = 50.0%, p = 0.135)
Kotasek (2003)
Subtotal  (I-squared = 55.0%, p = 0.083)
Aravantinos (2003)
Subtotal  (I-squared = 82.4%, p = 0.000)
Abels_Cisplatin (1993)
Tjulandin_Theta (2010b)
Del Mastro (1999)
1.59 (1.33, 1.84)
1.20 (0.80, 1.60)
1.42 (1.10, 1.74)
3.01 (1.77, 4.25)
WMD (95% CI)
2.70 (2.18, 3.22)
1.98 (1.42, 2.54)
1.45 (0.97, 1.93)
0.64 (-0.10, 1.38)
1.70 (1.01, 2.39)
2.00 (1.42, 2.58)
1.70 (1.27, 2.13)
1.66 (1.29, 2.03)
1.61 (1.22, 2.00)
1.23 (0.48, 1.98)
0.91 (0.65, 1.17)
2.47 (1.90, 3.04)
0.88 (0.04, 1.72)
1.18 (0.78, 1.59)
1.08 (0.27, 1.89)
1.62 (1.20, 2.03)
1.60 (0.87, 2.33)
1.40 (0.75, 2.05)
2.25 (1.60, 2.90)
1681
133, 2.1 (1.83)
270
23, 3.26 (1.98)
(SD); Treatment
64, -.2 (1.38)
79, 2.35 (2.04)
95, 2.1 (1.3)
17, 1.64 (1.25)
73, 1.9 (1.74)
69, 1.8 (2.11)
244, 2.2 (2.18)
138, 2.48 (1.74)
174, 1.8 (2.24)
34, .66 (1.76)
N, mean
330, -.07 (2)
156
17, .86 (1.57)
341
24, 2.31 (1.22)
914
63, 2.04 (2.38)
76, 1.6 (1.42)
28, -.8 (1.4)
1489
129, .9 (1.5)
182
12, .25 (1.66)
(SD); Control
58, -2.9 (1.53)
74, .37 (1.46)
91, .65 (1.94)
6, 1 (.56)
37, .2 (1.74)
76, -.2 (1.31)
115, .5 (1.79)
142, .82 (1.4)
170, .19 (1.3)
24, -.57 (1.16)
N, mean
359, -.98 (1.33)
146
51, -.02 (1.43)
356
23, 1.23 (1.59)
805
61, .44 (1.7)
37, .2 (1.74)
24, -3.05 (1)
100.00
6.69
24.57
2.81
Weight
6.05
5.82
6.29
4.81
5.10
5.71
6.57
6.87
6.79
4.77
%
7.42
14.57
4.32
22.60
4.46
38.25
4.90
5.34
5.28
Favours control Favours treatment 
0-4.25 4.25
PenTAG    
92 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
change, if such effects exist. Overall, the data confirm results from prior analyses; compared 
to controls, patients receiving ESA improved their Hb levels. 
4.2.6.1.2.  Haematological response  
This binary outcome was defined as the proportion of participants with an increase in Hb 
level of two g/dl or more, or as an increase in haematocrit of six percentage points or more, 
unrelated to transfusion. Eight trials defined haemR as the proportion of participants with an 
increase in Hb level of two g/dl or more (Boogaerts and colleagues, 2003; Dammaco and 
colleagues, 2001; Hedenus and colleagues, 2003; Kotasek and colleagues, 2003; 
Littlewood and colleagues, 2001; Osterborg and colleagues, 2002, 2005; Tjulandin and 
colleagues, 2010; Tjulandin and colleagues, 2011).16,45,46,52,64,68-70,76 One study defined 
haemR as an increase in haematocrit of six percentage points or more (Abels and 
colleagues, 1993).54 One trial reported haemR using both definitions (Hedenus and 
colleagues, 2002);49 for consistency, haemR as defined by an increase in Hb level was 
used in the analyses. Two studies (Kurz and colleagues, 1997 and Vansteenkiste and 
colleagues, 2002),67,72 described haemR as an increase in Hb level of two g/dl or more, or 
as a Hb level greater than 12 g/dl, and were therefore excluded from the analyses. 
Although both the previous HTA review (Wilson and colleagues, 2007)1 and Tonia and 
colleagues, 2012,10 used the same definition of haematological response, only Tonia and 
colleagues, 201210 excluded both Kurz and colleagues,199767 and Vansteenkiste and 
colleagues, 200272 trials from the analyses. The previous HTA review (Wilson and 
colleagues, 2007)1 argued that most of the data in the Vansteenkiste and colleagues, 
200272 trial would have been derived from an increase in Hb of 2 g/dl (considering baseline 
Hb values) and included it in the analyses. Vansteenkiste and colleagues, 200272 reported 
a mean baseline Hb of 10.28 g/dl (SD=1.08) and a mean baseline Hb of 9.93 g/dl (SD=1.01) 
in the treatment and control groups respectively. Kurz and colleagues, 199767 reported a 
mean baseline Hb of 9.88 g/dl (SD=0.89) and a mean baseline Hb of 9.85 g/dl (SD=0.60) in 
the treatment and control groups respectively. For consistency with the previous HTA, 
sensitivity analyses including the Vansteenkinste and colleagues, 2002 and Kurz and 
colleagues, 1997 trials were performed.67,72 
Overall, the analysis of haemR included 10 trials with 2,228 participants. Two trials were 
newly identified in the update searches (Tjulandin and colleagues, 2010; Tjulandin and 
colleagues, 2011).45,76 As some trials with multiple experimental arms were split into 
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subsets (Tjulandin and colleagues, 2010; Abels and colleagues, 1993)45,54 the number of 
trials displayed is 12. 
HaemR was observed in 759 out of 1,213 participants in the ESA-treated groups, compared 
to 182 out of 1,015 in the control groups. The random effects meta-analysis showed 
statistically significant difference in HaemR in favour of treatment (RR 3.29, 95% CI 2.84 to 
3.81; Figure 5). Heterogeneity between the trials was not significant (I2=6.4%, p=0.383; 
Χ2=11.75, df=11, p=0.383), with all individual studies indicating a beneficial effect of ESAs 
with regard to HaemR. To test whether publication bias was present in the meta-analysis, 
funnel plot asymmetry was investigated (Appendix L). The funnel plot analysis did not 
suggest statistically significant asymmetry (p=0.275). A meta-regression using publication 
year as a covariate to assess the effect of publication year on haematological response 
suggested that earlier published studies tended to report higher effects than later published 
studies (p=0.044). The earlier studies also tended to be smaller trials (see the meta-
regression plot in Appendix L).  
The fixed effects meta-analysis undertaken as a sensitivity analysis, also showed statistically 
significant difference in HaemR in favour of treatment (RR 3.41, 95% CI 2.96 to 3.92; 
I2=6.4%, p=0.383); the forest plot of the analysis is included in Appendix L. Similarly 
including the Kurz and colleagues,199767 and Vansteenkiste, 200272 trials in the meta-
analyses did not affect the overall conclusions (RR 3.21, 95% CI 2.81 to 3.68; I2=8.2%, 
p=0.363; the forest plot of the analysis is included in Appendix L). Similar to the Hb change 
outcome, Kurz and colleagues, 1997 (N=35), appeared to differ from most of the other 
included trials. This study reported the highest RR for HaemR with wide CI (RR 14.63, 95% 
CI 0.94−226.68).67 
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Figure 5. Forest plot: HaemR overall (random effects) 
 
Key: CI: confidence intervals; Events, Treatment: number of events/ number of participants in treatment group; 
Events, Control: number of events/ number of participants in control group; ID: identification; RR, risk ratio 
Notes: Random effects meta-analysis (Der-Simonian–Laird) 
 
Pre-specified subgroup analyses were performed (Table 16). None of the studies with 
available HaemR data included ovarian cancer patients. Therefore, the planned ovarian 
cancer subgroup analysis was not completed. In addition, meta-regression models including 
random effect and subgroups as covariates to assess the effects of a subgroup on 
haematological response were performed; the F statistics from these analyses are reported 
in Table 16. All covariates showing a significant effect (p<0.05) in a univariate analysis were 
further considered in a model selection.  
One study (Littlewood and colleagues, 2001)68 provided separate results for solid and 
haematological malignancy, and for participants with less or equal to 10.5 g/dl, and more 
than 10.5 g/dl inclusion Hb levels (but ≤ 12 g/dl). Meta-analyses including the subgroup 
results were conducted for the haemoglobin subgroups (RR 3.29, 95% CI 2.81 to 3.85; 
I2=13.4%, p=0.310; Appendix L), and for the malignancy subgroups (RR 3.28, 95% CI 2.84 
to 3.78; I2=13.4%, p=0.403; Appendix L). The results of these analyses were similar to the 
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main analysis and were used in the subgroup analyses if appropriate (Table 16). In addition, 
the Vansteenkiste and colleagues, 200272 trial provided separate results for participants 
with baseline Hb levels less than 10.0 g/dl, and for participants with baseline Hb levels equal 
to or more than 10.0 g/dl (but ≤11 g/dl). Including Kurz and colleagues, 1997 and 
Vansteenkiste and colleagues, 2002 in the meta-analyses with subgroup results had no 
impact on the overall conclusions.67 
Table 16.Subgroup analysis: HaemR 
 Trials RR CI I2 Tau2 
Analyses using all main trials: 
Overall 12 3.29 2.84 − 3.81 6.4%; p=0.383 <0.01a
Chemotherapy treatment 
Platinum-containing 3 3.93 2.50 − 6.17 11.9%; p=0.32 0.02 
Non-platinum-containing 4 3.05 2.43 − 3.82 29.9%; p=0.23 0.02 
NR 4 3.42 2.64 − 4.44 0%; p=0.93 0 
Mixed 1 6.33 2.87 − 13.96 NA 0 
F (between:within) F(3,8) =1.38; p=0.32 
Iron supplementation 
Iron in both arms 7 3.05 2.63 − 3.54 0%; p=0.67 0 
NR  5 4.94 3.38 − 7.20 0%; p=0.72 0 
F (between:within) F(1,10) =11.94; p<0.01 
Study design 
RCT 11 3.31 2.81 − 3.90 13.8%; p=0.32 0.01 
ROL 1 3.59 2.23 − 5.80 NA 0 
F (between:within) F(1,10) =0.12; p=0.73 
Study duration 
12–16 wks 10 3.29 2.73 − 3.97 18.6%; p=0.27 0.02 
>20 wks 2 3.65 2.71 − 4.92 0%; p=0.94 0 
F (between:within) F(1,10) =0.23; p=0.64 
ESA 
Erythropoetin 9 3.41 2.80 − 4.16 29.7%; p=0.18 0.03 
Darbepoetin 3 3.35 2.45 − 4.58 0%; p=0.83 0 
F (between:within) F(1,10) =0; p=0.96 
 Trials RR CI I2 Tau2 
Analyses using results for Hb inclusion subgroups (Littlewood 2001): 
Overall 13 3.29 2.81 − 3.85 13.4%; p=0.31 0.01 
Inclusion Hb 
≤11.0 g/dl 12 3.20 2.78 − 3.68 2.0%; p=0.43 <0.01 
>11.0 g/dl 1 25.52 1.66 − 392.30 NA 0 
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F (between:within) F(1,11) =104.53; p<0.01 
Baseline Hb 
≤10.0 g/dl 11 3.15 2.72 − 3.63 1.9%; p=0.42 <0.01 
≤11.0 g/dl 1 4.31 2.35 − 7.90 NA 0 
≤12.0 g/dl 1 25.52 1.66 − 392.30 NA 0 
F (between:within) F(2,10) =49.43; p<0.01 
Target Hb 
≤13.0 g/dl 3 3.06 2.28 – 4.09 0%; p=0.79 0 
>13.0 g/dl 8 3.25 2.63 – 4.01 24.5%; p=0.23 0.02 
NR 2 5.00 2.99 – 8.37 0%; p=0.35 0 
F (between:within) F(2,10) =0.31; p=0.74 
 Trials RR CI I2 Tau2 
Analyses using results for malignancy subgroups (Littlewood 2001): 
Overall 13 3.28 2.84−3.79 4.3%; p=0.40 <0.01b
Malignancy type 
Solid tumours 4 3.70 2.63 − 5.18 0%; p=0.844 0 
Haematological tumours 7 3.55 2.70 − 4.67 43%; p=0.10 0.05 
Mixed 2 3.13 2.33 − 4.20 0%; p=0.47 0 
F (between:within) F(2,10) =0.89; p=0.44 
Key: ESA, erythropoiesis stimulating agents; Hb, haemoglobin; NA, not applicable; NR, not reported; RCT, 
randomised controlled trial; ROL, randomised open label (standard care); wks, weeks. 
Notes: (a)Tau2 =0.0044 (b) Tau2 =0.0031 
 
Univariate analyses identified significant differences between trials using iron 
supplementation compared to trials not reporting iron supplementation use (p=0.006; Figure 
6). Trials, that did not report whether they used iron, appeared to offer greater benefits (RR 
4.94, 95% CI 3.38 to 7.20; I2=0%, p=0.752), compared to trials using iron supplementation 
(RR 3.05, 95% CI 2.63 to 3.54; I2=0%, p=0.669). The meta-regression model with iron 
subgroups is presented in Appendix L. However, including Kurz and colleagues (1997)67 
and Vansteenkiste and colleagues (2002)72 in the meta-regression model with iron 
supplementation as a covariate provided different  results; the difference between trials 
using iron supplementation compared to trials not reporting iron supplementation was no 
longer significant (p=0.735). As noted above, the Kurz and colleagues (1997)67 trial 
appeared to differ from the included studies. A sensitivity analysis including Vansteenkiste 
and colleagues (2002),72 but excluding Kurz and colleagues (1997)67 trials, again 
suggested that trials not reporting iron supplementation offer greater benefits (p=0.037). The 
studies not reporting whether they used iron tended to be smaller (Figure 6).67  Univariate 
analyses using the Hb subgroups results identified significant differences based on baseline 
and inclusion Hb levels (Table 16). However, these results seemed to be driven mainly by 
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Littlewood and colleagues (2001)68 study (Hb subgroup <12; R 25.52, 95% CI 1.66 to 
392.3; I2=NA; Figure 7) for both, the baseline and inclusion Hb levels. Because of collinearity 
we did not combine the baseline and inclusion Hb levels subgroups in the same model. A 
model using  the Hb baseline subgroup as a covariate suggests that participants with higher 
baseline Hb level (<12 g/dl; only one study was included in this subgroup) favoured 
treatment  significantly more  (RR 25.52, 95% CI 1.66 to 392.3; I2=NA), compared to trials 
with Hb baseline  values <11 g/dl (RR 3.76, 95% CI 2.62 to 5.39; I2=0%, p=0.583), and 
compared to trials with Hb baseline  values <10 g/dl (RR 3.10, 95% CI 2.64 to 3.64; 
I2=19.7%, p=0.244; Figure 7). The meta-regression with baseline Hb subgroup as a 
covariate is presented in Appendix L. Including the Kurz and colleagues (1997)67 and 
Vansteenkiste and colleagues (2002)72 trials in the meta-analyses with Hb subgroup 
results had no impact on the conclusions. However, it should be highlighted that only one 
trial (N=56) contributed to the subgroup with Hb baseline levels <12 g/dl. 
Due to the small number of studies in the meta-analysis, these meta-regressions and 
subgroups analyses have to be interpreted with caution (Section 4.1.6, page 63), the 
Cohrane handbook recommends at least 10 studies per subgroup.50 In addition, sensitivity 
analyses (e.g. including data from Kurz and colleagues (1997)67 and Vansteenkiste and 
colleagues (2002)72) suggest differences on the impact of covariates.  
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Figure 6. Forest plot: HaemR by iron supplementation (random effects) 
 
Key: CI: confidence intervals; Events, Treatment: number of events/ number of participants in treatment group; 
Events, Control: number of events/ number of participants in control group; ID: identification; RR, risk ratio 
Notes: Random effects meta-analysis (Der-Simonian–Laird) 
 
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 6.4%, p = 0.383)
Subtotal  (I-squared = 0.0%, p = 0.669)
Hedenus (2002)
Tjulandin_Theta (2010a)
Subtotal  (I-squared = 0.0%, p = 0.723)
Study
ID
Abels_Cisplatin (1993)
Littlewood (2001)
Osterborg (2002, 2005)
Iron
Not reported
Kotasek (2003)
Tjulandin_Beta (2010b)
Dammacco (2001)
Abels_NonCisplatin (1993)
Hedenus (2003)
Boogaerts (2003)
Tjulandin (2011)
3.29 (2.84, 3.81)
3.05 (2.63, 3.54)
6.00 (0.89, 40.41)
3.04 (1.61, 5.74)
4.94 (3.38, 7.20)
RR (95% CI)
7.39 (2.77, 19.69)
3.68 (2.51, 5.41)
2.52 (1.93, 3.30)
3.43 (1.46, 8.05)
3.77 (1.90, 7.45)
6.33 (2.87, 13.96)
4.31 (2.35, 7.90)
3.28 (2.33, 4.61)
3.59 (2.23, 5.80)
2.87 (1.98, 4.18)
759/1213
624/965
12/22
50/76
135/248
Events,
Treatment
31/64
172/244
114/170
8/17
52/73
38/66
46/79
104/174
63/133
69/95
182/1015
154/752
1/11
8/37
28/263
Events,
Control
4/61
22/115
46/173
7/51
7/37
6/66
10/74
31/170
17/129
23/91
100.00
85.38
0.59
5.12
14.62
%
Weight
2.20
13.06
24.10
2.89
4.45
3.35
5.60
16.17
8.77
13.71
Favours control Favours treatment 
1.0247 40.4
PenTAG    
99 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Figure 7. Forest plot: HaemR using Hb subgroups by Hb baseline (random effects) 
 
Key: CI: confidence intervals; Events, Treatment: number of events/ number of participants in treatment group; Events, 
Control: number of events/ number of participants in control group; ID: identification; RR, risk ratio 
Notes: Random effects meta‐analysis (Der‐Simonian–Laird) 
 
Summary: Analyses suggests that ESA treatment in CIA is effective in producing a haemR 
as defined as an increase in Hb level of 2 g/dL or more, or increase in haematocrit of six 
percentage points or more. Sixty-three per cent (759/1,213) of participants who received 
ESA treatment had a haemR, in contrast to 18% (182/1,015) of control patients. The 
heterogeneity between the trials was non-significant (I2=6.4%, p=0.383) with all individual 
studies indicating a beneficial effect of ESAs with regard to Hb response. The results of 
subgroups analyses were non-conclusive suggesting that analyses may not have a 
statistical power to detect effects of subgroups on haemR, if such an effect did exist. Overall 
the results support previous analyses. 
4.2.6.1.3.  RBCT requirement 
This binary outcome was defined as the proportion of participants requiring blood 
transfusion. Overall, the analysis of RBCT requirement included 22 studies with 4,779 
NOTE: Weights are from random effects analysis
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participants. Seven studies were newly identified in the update searches (Grote and 
colleagues, 2005; Strauss and colleagues, 2008; Ray-Coquard and colleagues, 2009; 
Tjulandin and colleagues, 2010; Tjulandin and colleagues, 2011; Untch and 
colleagues, 2011a,b; Moebus and colleagues, 2013).45,62,73-78 As some trials with multiple 
experimental arms were split into subsets (Abels and colleagues, 1993; Tjulandin and 
colleagues, 2010)45,54 the number of studies displayed is 24. 
RBCT was required by 554 of 2,480 participants treated with ESAs compared to 835 of 
2,299 participants receiving placebo /no treatment. The random effects meta-analysis 
showed a statistically significant difference in RBCT requirement in favour of the treatment 
group (RR 0.63, 95% CI 0.57, 0.69; Figure 8). The heterogeneity between the trials was not 
significant (I2=10.5%, p=0.315; Χ2=25.71, df =23, p=0.315). All but one individual study 
(Untch and colleagues, 2011a,b)77,78 indicated a beneficial effect of ESAs with regard to 
RBCT requirement. To test whether publication bias was present in the sample included in 
the meta-analysis, funnel plot asymmetry was investigated (Appendix L). The funnel plot 
analysis did not show statistically significant asymmetry (p=0.234). A meta-regression using 
publication year as a covariate to assess the effect of publication year on RBCT requirement 
was not statistically significant (p=0.207; see meta-regression plots Appendix L).  
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Figure 8. Forest plot: RBCT (random effects) 
 
Key: CI, confidence interval; events treatment, control, number of events/participants in treatment/control arms 
ID, identification; RR, risk ratio 
Notes:  (a) Der-Simonian Laird pooled RR; (b) Trial with multiple experimental arm split into subsets in the 
analysis: Tjulandin and colleagues, 2010a, b reports data for epoetin theta (2010a) and epoetin beta (2010b) 
and Abels and colleagues 1993 reported data for participants on platinum-based chemotherapy and non-
platinum based chemotherapy 
 
The fixed effects meta-analysis undertaken as a sensitivity analysis, showed a statistically 
significant difference for RBCT requirement in favour of treatment (RR 0.62, 95% CI 0.51, 
0.67); the forest plot of this analysis is included in (Appendix L). 
Pre-specified subgroup analyses were performed (Table 17). In addition, meta-regression 
models including random effect and subgroups as a covariate to assess the effects of a 
subgroup on RBCT requirement were performed. The F statistics from these analyses are 
reported in Table 17. All covariates showing a significant effect (p<0.05) in a univariate 
analysis were further considered in model selection. 
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One study (Littlewood and colleagues, 2001)68 provided separate results for solid and 
haematological malignancy, and for participants with inclusion Hb levels  ≤10.5 g/dl and 
>10.5 g/dl (but ≤12 g/dl). In addition, Vansteenkiste and colleagues (2002)72 provided 
separate results for participants with baseline Hb levels <10.0 g/dl, and ≥10.0 g/dl (but ≤11 
g/dl). Meta-analyses including these subgroup results were conducted for Hb subgroups (RR 
0.61, 95% CI 0.55, 0.68; I2= 22.4%, p=0.015), and for the malignancy subgroups (RR 0.62, 
95% CI 0.56, 0.68; I2=15.8%, p=0.239; see Appendix L). The results of these analyses were 
similar to the main analysis and were used in the subgroup analyses if appropriate (Table 
17).  
Table 17. RBCT: Subgroup analyses 
 Trials RR CI I2 Tau2 
Analyses using all main trials: 
Overall 24 0.63 0.57 − 0.69 10.5%; p=0.32 0.01 
Chemotherapy treatment 
Platinum-containing 6 0.52 0.37 − 0.72 60.0%; p=0.03 0.08 
Non-platinum-containing 7 0.65 0.53 − 0.79 31.1%; p=0.19 0.02 
NR 5 0.63 0.54 − 0.74 0%; p=1 0 
Mixed 5 0.63 0.50 − 0.79 0%; p=0.48 0 
Chemo+radio 1 0.88 0.42 − 1.84 NA 0 
F (between:within) F(4,19) 0.16; p=0.96 
Iron supplementation 
Iron in both arms 14 0.61 0.54 − 0.68 0%; p=0.460 0 
Iron in an intervention arm  1 3.18 0.13 − 77.7 NA 0 
Iron not used 1 0.77 0.50 − 1.16 NA 0 
NR  8 0.66 0.55 −0.80 29.4%; p=0.193 0.02 
F (between:within) F(3, 20) 1.08; p=0.38 
Study design 
RCT 14 0.66 0.60 − 0.73 0%; p=0.78 0 
ROL 10 0.56 0.45 − 0.71 37.7%; p=0.11 0.04 
F (between:within) F(1,22) 0.61; p=0.44 
Study duration 
6–9 wks 2 0.76 0.40 − 1.47 0%; p=0.39 0 
12–16 wks 14 0.66 0.60 − 0.74 0%; p=0.73 0 
17–20 wks 3 0.50 0.38 − 0.66 26.5%; p=0.26 0.02 
>20 wks 5 0.62 0.45 − 0.85 48.0%; p= 0.10 0.05 
F (between:within) F(3, 20) 0.57; p=0.64 
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 Trials RR CI I2 Tau2 
Analyses using all main trials: 
ESA 
Erythropoetin 19 0.62 0.55 −0.70 27.1%; p=0.13 0.02 
Darbepoetin 5 0.63 0.52 −0.75 0%; p=0.89 0 
F (between:within) F(1,22) 0.03; p=0.86 
Analysed using results for baseline Hb subgroups Littlewood and colleagues, 2001 and 
Vansteenkiste and colleagues, 2002 
Overall 26 0.61 0.55−0.68 22.4%; p=0.15 0.02 
Inclusion HB 
≤11.0 g/dl 16 0.64 0.57 − 0.71 7.3%; p=0.37 <0.01 
>11.0 g/dl 10 0.56 0.44 − 0.72 39.1%; p=0.10 0.05 
F (between:within) F(1.24) 0.72; p=0.40 
Baseline Hb  
≤10.0 g/dl 15 0.64 0.58 − 0.71 0%; p=0.69 0 
≤11.0 g/dl 2 0.60 0.31 − 1.18 81.4%; p=0.02 0.19 
≤12.0 g/dl 3 0.38 0.14 − 1.00 74.1%; p=0.02 0.52 
≤14.5 g/dl 5 0.69 0.52 − 0.92 0%; p=0.69 0 
NR 1 0.47 0.34 − 0.66 NA NA 
F (between:within)  F(1.24) 0.28; p=0.60 
Target HB 
≤13.0 g/dl 4 0.52 0.34 − 0.80 48.4%; p=0.14 0.04 
>13.0 g/dl 19 0.60 0.53 − 0.67 0%; p=0.70 0 
NR 3 0.71 0.51 – 1.00 22.4%; p=0.15 0.02 
F (between:within)  F(2,23) 0.82; p=0.45 
Analysed using results for malignancy subgroups Littlewood and colleagues, 2001 
Overall 25 0.62 0.56−0.68 15.8%; p=0.24 0.01 
Malignancy type 
Solid tumours 15 0.56 0.48 − 0.66 17.2%; p=0.26 0.01 
Haematological tumours 7 0.68 0.59 − 0.79 15.3%; p=0.31 0.02 
Mixed 3 0.61 0.50 − 0.75 0%; p=0.92 0 
F (between:within) F(2, 22) 0.70; p=0.51 
Key: CI, confidence interval; ESA, erythropoiesis stimulating agents; Hb, haemoglobin; NA, not applicable; NR, 
not reported; RCT, randomised controlled trial; ROL, randomised open label (standard care); wks, weeks. 
 
Univariate analyses did not identify any significant differences based on the pre-defined 
subgroups (Table 17). 
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Summary: The RR to receive RBCT was statistically significantly reduced in the study 
groups receiving ESAs by 37% (RR 0.63, 95% CI 0.57, 0.69). The heterogeneity between 
the studies was non significant (I2=10.5%, P=0.315). Overall, the data confirm results from 
prior analyses that ESAs reduce the RR to receive RBCT in patients with cancer-treatment 
induced anaemia. 
4.2.6.1.4.  RBC units transfused  
Overall, 10 studies evaluating a total of 1,920 participants are included. As one study (Abels 
and colleagues, 1993)54 was split into subsets the number of studies displayed is 11. Two 
studies were newly identified (Grote and colleagues, 2005 and Tjulandin and colleagues, 
2011);73,76 neither were included in the Cochrane review (Tonia and colleagues, 201210)for 
the analysis of this outcome. All except one study (Tjulandin and colleagues, 201176) 
reported mean units transfused per average participant (i.e. regardless of whether 
participants had received RBCT). For Tjulandin and colleagues (2011) this was calculated 
from the data presented in the published paper.76 
The overall mean difference showed a statistically significant benefit for participants 
receiving ESAs (WMD -0.87, 95% CI -1.28, -0.46; Figure 9); the ESA group received fewer 
units of blood per participant than the control group. The heterogeneity between the studies 
was significant (I2=59.3%, p=0.006). All but one study indicated a reduced need for RBCs in 
participants receiving ESAs compared to controls. A funnel plot analysis did not suggest 
statistically significant asymmetry (p=0.137; see Appendix L). 
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Figure 9. Forest plot: RBCT mean RBC units transfused (random effects) 
 
Key: CI, confidence interval; ID, identification; N, number of events/participants in treatment/control arms; WMD, 
weighted mean difference 
Notes:  (a) Random effects (Der-Simonian Laird pooled RR); (b) Trial with multiple experimental arm split into 
subsets in the analysis: Abels and colleagues 1993 reported data for participants on platinum-based 
chemotherapy and non-platinum based chemotherapy; (c) Mean units transfused per average participant (i.e. 
regardless of whether participants had received RBCT) 
 
One study (Vansteenkiste and colleagues, 2002)72 provided separate results for 
participants with baseline Hb levels <10.0 g/dl, and ≥10.0 g/dl (but≤ 11 g/dl). Meta-analysis 
including these subgroup results were conducted (WMD -0.87, 95% CI -1.24, -0.50; see 
Appendix L). The fixed effects meta-analysis undertaken as a sensitivity analysis, showed a 
statistically significant difference for number of RBC units transfused in favour of treatment 
(WMD -0.64, 95% CI -0.79, -0.48); the forest plot of this analysis is included in (Appendix L). 
To identify sources of heterogeneity, subgroup analyses were conducted (Table 18). In 
addition, meta-regression models including random effect and a subgroup as a covariate to 
assess the effects of subgroups on Hb change were performed; the F statistics from these 
analyses are reported in Table 18. All covariates showing a significant effect (p<0.05) in a 
univariate analysis were further considered in a model selection.  
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Table 18. RBC units: Subgroup analyses 
 Trials WMD CI I2 Tau2 
Overall 11 -0.87 -1.28 − -0.46 59.3%; p=0.02 0.21 
Chemotherapy treatment 
Platinum-containing 3 -1.11 -1.58 − -0.64 0%; p=0.69 0 
Non-platinum-containing 3 -0.56 -0.73 − -0.40 0%; p=0.97 0 
NR 1 -2.86 -4.16 − -1.56 NA 0 
Mixed 4 -0.76 -1.77 − 0.25 55.7%; p=0.08 0.52 
F (between:within) F(3,7) 5.22; p=0.03 
Iron supplementation 
Iron in both arms 4 -1.30 -2.31 − -0.29 78.3%; p=<0.01 0.73 
Iron not used  1 -2.30 -5.03 − -0.37 NA 0 
NR  6 -0.70 -1.19 − -0.20 43.7%; p=0.11 0.16 
F (between:within) F(2,8) 0.09; p=0.44 
Study design 
RCT 8 -0.63 -0.97 − -0.30 35.4%; p=0.15 0.07 
ROL 3 -1.91 -3.37 − -0.44 68.6%; p=0.04 1.10 
F (between:within) F(1,9) 4.25; p=0.07 
Study duration 
12–16 wks 7 -0.70 -0.96 − -0.44 11.7%; p=0.34 0.02 
17–20 wks 1 0.10 -0.59 − 0.79 NA 0 
>20 wks 3 -1.91 -3.37 − -0.44 68.6%; p= 0.04 1.08 
F (between:within) F(2,8) 3.72; p=0.07 
ESA 
Erythropoetin 10 -0.89 -1.43 − -0.35 53.8%; p=0.02 0.36 
Darbepoetin 1 -1.25 -1.84 − -0.66 NA 0 
F (between:within) F(1,9) 0.27; p=0.61 
Malignancy type 
Solid tumours 5 -0.95 -1.73− -0.17 65.7%; p=0.02 0.44 
Haematological tumours 4 -0.63 -1.19 − -0.06 0%; p=0.99 0 
Mixed 2 -1.62 -3.86 − -0.63 91.6%; p<0.01 2.42 
F (between:within)  F(2,88) 0.50; p=0.62 
Ovarian cancer 
Ovarian cancer 1 -0.94 -1.76− -0.12 NA 0 
Other cancers 10 -0.88 -1.34 − -0.42 62.5%; p<0.01 0.25 
F (between:within) F(1,9) 0.00; p=0.98 
Analysed using results for baseline Hb subgroups Vansteenkiste and colleagues, 2002 
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 Trials WMD CI I2 Tau2 
Overall 12 -0.87 -1.24 − -0.50 55.6%; p=0.01 0.17 
Inclusion Hb 
≤11.0 g/dl 9 -0.99 -1.41 − -0.56 56.2%; p=0.02 0.18 
>11.0 g/dl 3 -0.63 -1.67 – 0.41 64.7%; p=0.06 0.49 
F (between:within) F(1,10) 0.76; p=0.41 
Baseline Hb  
≤10.0 g/dl 7 -1.13 -1.76 − -0.49 65.3%; p=0.01 0.39 
≤11.0 g/dl 2 -0.88 -1.35 − -0.40 0%; p=0.80 0 
≤12.0 g/dl 1 -0.94 -1.76 − -0.12 NA 0 
≤14.5 g/dl 2 -0.75 -3.02 − -1.52 65.8%; p=0.09 1.94 
F (between:within) F(3,8) 0.36; p=0.79 
Target Hb 
≤13.0 g/dl 1 -0.56 -0.74 − -0.39 NA 0 
>13.0 g/dl 8 -1.01 -1.57 − -0.45 65.7%; p<0.01 0.39 
NR 3 -0.94 -1.93 − -0.05 0%; p=0.46 0 
F (between:within) F(2,9) 0.20; p=0.82 
Key: CI, confidence interval; ESA, erythropoiesis stimulating agents; Hb, haemoglobin; NA, not applicable; NR, 
not reported; RCT, randomised controlled trial; ROL, randomised open label (standard care); wks, weeks. 
 
Univariate analyses identified significant differences in the chemotherapy treatments 
subgroup (p=0.033). A study not reporting what chemotherapy was used was significantly 
different from trials with mixed chemotherapy treatments, studies using platinum and studies 
with non-platinum based chemotherapy (Figure 10). The study that did not report what type 
of chemotherapy treatment was used (WMD -2.86, 95% CI -4.16 to -1.56; I2=NA) appeared 
to offer greater benefits compared to the platinum based therapy (WMD -1.11, 95% CI -1.58 
to 0.64; I2=0%, p=0.685), the non-platinum based therapy (WMD -0.56, 95% CI -0.73 to -
0.40; I2=0%, p=0.971) and mixed chemotherapy treatment (WMD -0.76, 95% CI -1.77 to 
0.25; I2=55.7%, p=0.080). 
As stated in Section 4.1.6 (page 63) these analyses have to be interpreted with caution. 
There is only one study in the subgroup not reporting what chemotherapy was used; in 
addition the number of studies per subgroup is small (1-4; Figure 10). Thus the analyses 
may not have statistical power to detect the effects of chemotherapy treatment and ESA on 
RBC units transfused, if such effects exist. 
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Figure 10. Forest plot: RBC units transfused by chemotherapy treatment (random 
effects) 
 
Key: CI, confidence interval; ID, identification; N, number of events/participants in treatment/control arms; WMD, 
weighted mean difference 
 
Summary: Overall, there is a statistically significant effect of ESA on RBC units transfused. 
The weighted mean difference in RBC units was -0.87 (95% CI -1.28− -0.46), suggesting 
that fewer units per participant were used in the treatment arm compared to controls. We 
identified statistically significant heterogeneity between the trials (I2=59.3%, p=0.006); 
however all but one of the individual studies indicated a beneficial effect of ESA with regard 
to RBC units transfused. Overall, the data confirm results from prior analyses, there is only a 
slight difference between the number of RBC units that intervention and control participants 
receive. 
NOTE: Weights are from random effects analysis
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4.2.6.1.5.  Anaemia-related outcomes: overall  summary 
Table 19. Anaemia-related outcomes results comparison: Wilson, 2007 vs Tonia, 2012 
vs PenTAG 20131,10 
 Wilson, 2007b  Tonia, 2012b PenTAG, 2013b PenTAG, 2013c 
Anaemia-related outcomes 
Hb changea WMD 1.63 
95% CI 1.46−1.80 
Χ2(het) 23.74; df 19 
(p=0.21) 
10 trials, n=1,620 
WMD 1.57 
95% CI 1.51−1.62 
Χ2(het); 564.37; df 74  
(p<0.001) 
75 trials, n=11,609 
WMD 1.49 
95% CI 1.37−1.60 
Χ2(het)70.52; df  17 
(p<0.001) 
18 trials, n=3,170 
WMD 1.59 
95% CI 1.33−1.84 
Χ2(het)70.52; df  17 
(p<0.001) 
18 trials, n=3,170 
HaemR RR 3.40 
95% CI 3.01−3.83  
Χ2(het) 23.60; df 32 
(p=0.86) 
21 trials, n=3,740 
RR 3.39 
95% CI 3.10−3.71 
Χ2(het); 95.56; df 45 
(p<0.001) 
46 trials, n=6,413 
RR 3.41 
95% CI 2.96−3.92  
Χ2(het) 11.75; df 11 
(p=0.383) 
12 trials, n=2,228 
RR 3.29 
95% CI 2.84−3.81  
Χ2(het) 11.75; df 11 
(p=0.383) 
12 trials, n=2,228 
RBCT RR 0.63 
95% CI 0.58−0.67  
Χ2(het) 94.75; df 48 
(p=0.001) 
35 trials, n=5,564 
RR 0.65 
95% CI 0.62−0.68 
Χ2(het) 217.08; df 87 
(p<0.001) 
88 trials, n=16,093 
RR 0.62 
95% CI 0.58−0.67 
Χ2(het) 25.71; df 23 
(p=0.315) 
24 trials, n=4,799 
RR 0.63 
95% CI 0.57−0.69 
Χ2(het) 25.71; df 23 
(p=0.315) 
22 trials, n=4,799 
Units 
transfused 
WMD -1.05 
95% CI -1.32−-0.78 
Χ2(het) 8.96; df 16 
(p=0.91) 
14 trials, n=2,353 
WMD -0.98 
95% CI -1.17−-0.78 
Χ2(het) 34.52; df 24 
(p=0.080) 
25 trials, n=4,715 
WMD -0.64 
95% CI -0.79−-0.48 
Χ2(het) 24.55; df 10 
(p=0.006) 
11 trials, n=1,920 
WMD -0.87 
95% CI -1.28−-0.46 
Χ2(het) 24.55; df 10 
(p=0.006) 
11 trials, n=1,920 
Key: CI, confidence interval; df, degrees of freedom; haemR, haematological response; het, heterogeneity; 
RBCT, red blood cell transfusion; RR, relative risk; WMD, weighted mean difference 
Notes: (a) change from baseline to end of study; (b) fixed effects (Mantel-Haenzel); (c) random effects (Der-
Simonian Laird); ), haematological response  was defined as the proportion of participants with an increase in Hb 
level of two g/dl or more, or as an increase in haematocrit of six percentage points or more; (d) the number of 
trials includes multiple experimental arms for some studies. 
 
Hb change was reported in 16 studies; all the studies indicated a beneficial effect of ESA 
with regard to Hb change and varied only in magnitude. The overall EMD Hb increase was 
1.59 g/dl. Hb change was not restricted to patients who were transfusion-free, therefore the 
results may have been confounded by transfusion in some of the patients. HaemR was 
defined as the proportion of participants with an increase in Hb level of two g/dl or more, or 
as an increase in haematocrit of six percentage points or more, unrelated to transfusion. Ten 
studies reported this outcome. This analysis showed that participants treated with ESAs 
were three times more likely to experience a 2 g/dl increase in Hb than participants in the 
control group. Sixty-three per cent (759/1,213) of participants who received ESAs had a 
haemR, compared to 18% (182/1,015) of control patients. 
The number of patients receiving RBCTs was the third outcome assessed to investigate the 
effects of ESAs on cancer-treatment induced anaemia (including data from 22 trials). Data 
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were reported for the trial period; the RR of receiving a RBCT was 0.63 in favour of ESAs, 
equating to 22% of participants in the ESA treatment groups receiving RBCT in comparison 
to 33% in the control groups. The number of transfusions per patient was also investigated. 
Only 10 studies reported this outcome, and many of these data were received by the 
Cochrane review through further questions to the trial authors. There was little difference 
between ESA and control groups regarding the amount of blood transfused. 
Effectiveness estimates were consistent with previously reported estimates for the anaemia-
related outcomes; Table 19. A graphical summary of study characteristics and results for 
these outcomes is presented in Figure 11. 
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Figure 11. Anaemia-related outcomes: Graphical summary  
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Hb chg., Haemoglobin change; HaemR, haematological response ; RBCT, red blood cell transfusion ; units, 
units transfused; Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-platinum; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: Darbe 
Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: Latin sq. des.; 11: 
Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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Figure 11. Anaemia-related outcomes: Graphical summary (continued) 
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Hb chg., Haemoglobin change; HaemR, haematological response ; RBCT, red blood cell transfusion ; units, 
units transfused; Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-platinum; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: Darbe 
Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: Latin sq. des.; 11: 
Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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Figure 11. Anaemia-related outcomes: Graphical summary (continued) 
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Hb chg., Haemoglobin change; HaemR, haematological response ; RBCT, red blood cell transfusion ; units, 
units transfused; Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-platinum; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: Darbe 
Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: Latin sq. des.; 11: 
Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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Figure 11. Anaemia-related outcomes: Graphical summary (continued) 
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Hb chg., Haemoglobin change; HaemR, haematological response ; RBCT, red blood cell transfusion ; units, 
units transfused; Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-platinum; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: Darbe 
Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: Latin sq. des.; 11: 
Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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4.2.6.2.  Malignancy-related outcomes 
Malignancy-related outcomes: complete tumour response and overall survival. In addition 
on study mortality was considered in this section. 
4.2.6.2.1.  Tumour response 
We identified seven studies that measured a complete tumour response. Overall, the 
analysis included seven trials with 1,909 participants. Two trials were newly identified in the 
update searches (Strauss and colleagues, 2008; Untch and colleagues, 2011a,b).75,77,78  
A complete tumour response was reported in 177 out of 1,003 participants in the ESA-
treated groups compared to 142 out of 906 in the control groups. The random effects meta-
analysis showed a RR of 1.10 (RR 1.10; 95% CI 0.86 to 1.41; see Figure 12) that was not 
statistically significant. There was non significant heterogeneity between the trials (I2=37.5%, 
p=0.143; Χ2=9.59, df =6, p=0.143); however the direction of effects of the individual studies 
varied (Figure 12). Because there were only seven primary studies included in the meta-
analysis, the funnel plot analysis to assess whether publication bias was likely was not 
conducted.50 The fixed effects meta-analysis undertaken as a sensitivity analysis showed 
similar non-significant results (RR 1.20, 95% CI 0.85 to 1, 71; I2=37.5%, p=0.143); the forest 
plot of the analysis is included in Appendix L. 
The previous HTA review (Wilson and colleagues, 2007;1 using a fixed effects model) 
suggested that ESAs have detrimental effects with regards to tumour response (RR 1.31; 
95% CI 1.08, 1.60). However, the Cochrane review (Tonia and colleagues, 201210) did not 
find any differences between controls and treatments with regards to tumour response (RR 
1.02; 95% CI 0.98, 1.06). It must be emphasised that the current analysis included only 
studies complying with the licenced ESA dose, while the HTA review and the Cochrane 
review did not apply any restrictions regarding the ESA posology. The HTA meta-analyses 
included nine trials with 1,200 participants, and the Cochrane review included 19 trials with 
5,002 participants. 
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Figure 12. Forest plot: Tumour response (random effects) 
 
Key: CI: confidence intervals; Events, Treatment: number of events/ number of participants in treatment group; 
Events, Control: number of events/ number of participants in control group; ID: identification; RR, risk ratio 
Notes: Random effects meta-analysis (Der-Simonian–Laird) 
 
Pre-specified subgroup analyses, and meta-regression models with subgroups as covariates 
were not conducted because only seven trials were included in the meta-analysis. 
In addition, Tonia and colleagues (2012)10 used additional quality criteria to assess the 
quality of trials reporting data on tumour control. The study’s population had to be 
homogenous (i.e. all participants had to have the same tumour type/stage), all participants  
had to receive a predefined, identical anti-cancer therapy, and the study had to be designed 
to assess tumour outcomes prospectively and/or tumour outcomes were defined as the 
primary or secondary study outcome. Trials were also considered if the study was stratified 
by treatment and /or by tumour type (tumour stage). Only two studies included in the current 
review met the Tonia and colleagues (2012)10 additional criteria, Strauss and colleagues 
(2008)75 and Untch and colleagues (2011a,b).77,78 
Summary: Analyses suggest that treatment with ESA in patients with cancer-induced 
anaemia did not have a significant effect on complete tumour response (RR of 1.10; 95% CI 
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0.86 to 1.41). Fourteen per cent (177/1003) of participants who received ESA had a 
complete tumour response, compared to 16% (142/906) of patients in control groups. There 
was non significant heterogeneity between the trials (I2=37.5%, p=0.143), however the 
direction of the effects of ESA with regard to tumour response varied across the individual 
trials. The data from seven trials suggest no difference between patients treated with ESA 
and patients in control groups with regard to tumour response. Overall, the data confirm 
results from prior analyses. 
4.2.6.2.2.  Overall  survival 
For OS, data were extracted from the Cochrane review (Tonia and colleagues, 2012).10 In 
the Cochrane review reported hazard ratios (HRs) were based on individual patient data 
(IPD). Where IPD were not available, the authors extracted HRs from the published study, or 
calculated them from published reports including secondary analyses, using methods 
reported in Parmar and colleagues (1998),44 or from binary mortality data. OS was 
calculated from the longest follow-up available and varied between studies.  
OS data were available from 23 studies including 5,064 participants. Seven studies (Grote 
and colleagues, 2005; Strauss and colleagues, 2008; Ray-Coquard and colleagues, 
2009; Tjulandin and colleagues, 2010; Tjulandin and colleagues, 2011; Untch and 
colleagues, 2011a,b; Moebus and colleagues, 2013)45,62,73-78  were newly identified. Two 
studies (Abels and colleagues, 1993 and Tjulandin and colleagues, 2010)45,54 were split 
into subsets, two studies (Kurz and colleagues, 1997 and Hedenus and colleagues, 
2002)49,67 reported zero events, and three studies (Ten Bokkel and colleagues, 1998; 
Thatcher and colleagues, 1999; and Kotasek and colleagues, 2003)46-48 reported 
events/effect size for combined treatment arm (studies evaluated different ESA doses) and 
as such included unlicensed doses; as a result the number of included in the meta-analysis 
is 18. 
The overall survival estimate is provided in Figure 13 (HR 0.97, 95% CI 0.83, 1.13). The 
heterogeneity between trials was significant with an I2 of 42.4%; p=0.030 (Χ2=29.5, df=17, 
p=0.030); the forest plot suggested that there was a tendency for smaller studies to favour 
treatment (Figure 13). Funnel plot analysis Appendix L) identified one outlier (Dunphy and 
colleagues, 1999)66 and also suggested that smaller studies had a tendency to favour 
treatment; a funnel plot without the outlier is presented in Appendix L. The Harbord test was 
not performed, because raw data were not available. 
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A meta-regression using publication year as a covariate (to assess the effect of publication 
year on OS) showed that the effects of ESA on OS were independent from any effect of 
publication year (p=0.60; the meta-regression plot is presented in Appendix L). 
Figure 13. Forest plot: Overall survival (random effects) 
 
Key: CI, confidence interval; ES effect size; ID, identification
Notes:  (a) Der-Simonian Laird pooled RR; (b) Trial with multiple experimental arm split into subsets in the 
analysis: Tjulandin and colleagues, 2010a,b reports data for epoetin theta (2010a) and epoetin beta (2010b) 
and Abels and colleagues 1993 reported data for participants on platinum-based chemotherapy and non-
platinum based chemotherapy; (c) Effect sizes reported are hazard ratios; (d)  IPD data as reported in Tonia and 
colleagues, 2012 (Cochrane review): Abels and colleagues, 1993; Boogaerts and colleagues, 2003; Dammacco 
and colleagues, 2001; Grote and colleagues, 2005; Hedenus and colleagues, 2003; Littlewood and colleagues, 
2001; Osterborg and colleagues, 2002; Ray-Coquard and colleagues, 2009; Strauss and colleagues, 2008; 
Vansteenkiste and colleagues, 2002. HRs reported for other trials calculated using other accepted methods. 
 
To identify sources of heterogeneity, we performed subgroup analyses (Table 20). In 
addition, meta-regression models that included random effect and subgroups as covariates 
(to assess the effects of a subgroup on OS) were performed. The F statistics from these 
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analyses are reported in Table 20. All covariates showing a significant effect (p<0.05) in a 
univariate analysis were further considered in model selection. 
Table 20. Overall survival: Subgroup analyses 
 Trials HR CI I2 Tau2 
Overall 18 0.97 0.83 − 1.13 42.4%; p=0.03 0.04 
Inclusion Hb 
≤11.0 g/dl 10 0.91 0.70 − 1.20 51.7%; p=0.03 0.07 
>11.0 g/dl 8 0.99 0.81 − 1.20 35.5%; p=0.15 0.02 
F (between:within) F(1,16) 0.09; p=0.77 
Baseline Hb  
≤10.0 g/dl 11 0.88 0.71 − 1.08 53.0%; p=0.02 0.05 
≤11.0 g/dl 1 1.11 0.45 − 2.73 NA NA 
≤12.0 g/dl 1 2.00 0.65 − 1.13 NA NA 
≤14.5 g/dl 4 1.20 0.96− 1.50 0%; p=0.56 0 
NR 1 0.97 0.67 − 1.41 NA NA 
F (between:within)  F(4,13) 0.78; p=0.56 
Target Hb 
≤13.0 g/dl 4 0.73 0.32 − 1.64 61.8%; p=0.05 0.41 
>13.0 g/dl 12 0.97 0.82 − 1.14 46.6%; p=0.04 0.03 
NR 2 0.88 0.46 − 1.70 0%; p=0.47 0 
F (between:within)  F(2,15) 0.03; p=0.97 
Malignancy type 
Solid tumours 9 0.96 0.74 − 1.25 46.3%; p=0.06 0.06 
Haematological tumours 5 1.01 0.73 − 1.40 48.5%; p=0.10 0.05 
Mixed 4 0.84 0.69 − 1.02 0%; p=0.40 0 
F (between:within) F(2,15) 0.40; p=0.68 
Chemotherapy treatment 
Platinum-containing 4 0.67 0.46 − 0.98 14.5%; p=0.32 0.03 
Non-platinum-containing 7 0.99 0.86 − 1.14 0%; p= 0.42 0 
NR 3 1.11 0.73 − 1.68 69%; p=0.04 0.09 
Mixed 3 0.59 0.14 − 2.40 64.2%; 0.06 0.87 
Chemo + Radio 1 2.00 0.65 − 6.14 NA 0 
F (between:within) F(4,13) 1.33; p=0.31 
Iron supplementation 
No iron 12 0.96 0.79 − 1.17 38.9%; p= 0.08 0.03 
Iron in an intervention arm  1 1.33 0.91 − 1.95 NA 0 
NR  5 0.87 0.61 − 1.23 54.0%; p= 0.07 0.07 
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 Trials HR CI I2 Tau2 
F (between:within) F(2,15) 0.72; p=0.50 
Study design 
RCT 11 0.92 0.75 − 1.13 52.4%; p=0.02 0.05 
ROL 7 1.05 0.81 − 1.36 28.1%; p=0.21 0.03 
F (between:within) F(1,16) 0.50; p=0.49 
Study duration 
6–9 wks 2 1.90 0.63 − 5.76 0%; p=0.51 0 
12–16 wks 11 0.86 0.68 − 1.08 48.8%; p=0.03 0.05 
17–20 wks 2 1.10 0.88 − 1.37 0%; p=0.43 0 
>20 wks 3 1.10 0.72 − 1.67 66.4%; p=0.05 0.09 
F (between:within) F(3,14) 0.87; p=0.48 
ESA 
Erythropoetin 15 0.92 0.77 − 1.10 31.2%; p=0.12 0.03 
Darbepoetin 3 1.10 0.77 − 1.58 74.6%; p=0.03 0.08 
F (between:within) F(1,16) 0.92; p=0.35 
Key: CI, confidence interval; ESA, erythropoiesis stimulating agents; Hb, haemoglobin; NA, not applicable; NR, 
not reported; RCT, randomised controlled trial; ROL, randomised open label (standard care); wks, weeks. 
 
Univariate analyses did not identify any significant differences based on the pre-defined 
subgroups (Table 20). The fixed effects meta-analysis undertaken as a sensitivity analysis, 
showed similar results (HR 0.98, 95% CI 0.89, 1.08); the forest plot of this analysis is 
included in Appendix L. Both fixed and random effects estimates suggested no difference in 
OS between the control and treatment arms. Interestingly, the fixed effects estimate reported 
in the recent Cochrane review (Tonia and colleagues, 2012)10 favoured controls, 
suggesting that higher mortality occurred in patients treated with ESA; HR 1.05 (95% CI 
1.00, 1.11). The previous HTA review (Wilson and colleagues, 2007) did not find a 
significant difference between controls and treatments with regards to survival (HR 1.03; 
95% CI 0.92, 1.16).1 It must be emphasised that the current analysis only included studies 
complying with the licenced ESA dose, while the Cochrane review did not apply any 
restrictions regarding the ESA posology. The Cochrane review included 76 studies in the on 
overall survival meta-analysis; however subgroup analyses comparing studies using 
licenced and unlicensed dose ESA dose were not conducted. 
Summary: Analyses suggest that treatment with ESAs in patients with CIA did not have a 
significant effect on overall survival. Thirty five per cent (818/2,317) participants who 
received ESA had died, and 35% (744/2,137) of patients died in control groups. The risk of 
death was 0.97 (HR 0.97, 95% CI 0.83, 1.13). However, there was significant heterogeneity 
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between the trials (I2=42.4%, p=0.030). In addition, OS was calculated from the longest 
follow-up available (no mnimum was required),as such, there was variation between the 
studies (short- and long-term) and this should be considered when interpreting the results. 
Overall, the data appear different to previous analyses. It appears that if the licenced ESA 
dosage is followed, there are no detrimental effects of ESA on overall survival. However, 
these results should be interpreted with caution, see Section 4.2.7 (page 149) for more 
details.  
4.2.6.2.3.  On-study mortal ity 
For on-study mortality, data were extracted from the Cochrane review (Tonia and 
colleagues, 2012).10 In the Cochrane review reported HRs were based on IPD. Where IPD 
were not available, the authors extracted HR’s from the published study, or calculated them 
from data published in reports, including secondary analyses, using the methods reported in 
Parmar and colleagues (1998)44. On-study mortality was defined as deaths occurring up to 
30 days after the active study period.  
Mortality data were available from 21 studies including 5,085 participants. Seven studies 
(Grote and colleagues, 2005; Strauss and colleagues, 2008; Ray-Coquard and 
colleagues, 2009; Tjulandin and colleagues, 2010; Tjulandin and colleagues, 2011; 
Untch and colleagues, 2011; Moebus and colleagues, 2013)45,62,73-78  were newly 
identified. Two studies (Abels and colleagues, 1993 and Tjulandin and colleagues, 
2010)45,54 were split into subsets, six studies (Del Mastro and colleagues, 1999; Hedenus 
and colleagues, 2002; Kurz and colleagues, 1997; Moebus and colleagues, 2013; 
Strauss and colleagues, 2008 and Untch and colleagues, 2011a,b75,77,78)49,62,65,67 reported 
zero events, and four studies (Hedenus and colleagues, 2002; Kotasek and colleagues, 
2003; Ten Bokkel and colleagues, 1998; Thatcher and colleagues, 1999)46-49 reported 
events/effect size for combined treatment arms (studies evaluated different ESA doses) and 
as such included unlicensed doses. As a result the number of trials included in the meta-
analysis is 14 (including 2,967 participants). One study (Dunphy and colleagues, 1999) 
reported mortality events in the control arm, while there were no deaths recorded in the 
treatment arm; HR 0.14 (95% CI 0.00, 6.82).66 
The results from the on-study mortality meta-anlysis are provided below (Figure 14; HR 0.86, 
95% CI 0.67, 1.11). Heterogeneity between trials was not significant (I2=16.4%, p=0.274; 
Χ2=15.55, df=13, p=0.274); however the forest plot may suggest a tendency for smaller 
studies to favour treatment (Figure 14). Similarly to overall survival data, funnel plot analysis 
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(Appendix L) identified one outlier (Dunphy and colleagues, 1999)66 and was also 
suggestive of a tendency for smaller studies to favour treatment; a funnel plot without the 
outlier is presented in Appendix L. The Harbord test was not performed, because raw data 
were not available. 
A meta-regression using publication year as a covariate (to assess the effect of publication 
year on-study mortality) suggested that the effects of ESA on mortality were independent 
from when the trial results were published (p=0.465; the meta-regression plot is presented in 
Appendix L).  
Figure 14. Forest plot: Mortality (random effects) 
 
Key: CI, confidence interval; ID, identification; HR, Hazard ratio
Notes:  (a) Der-Simonian Laird pooled HR; (b) Trial with multiple experimental arm split into subsets in the 
analysis: Tjulandin and colleagues, 2010a,b reports data for epoetin theta (2010a) and epoetin beta (2010b) 
and Abels and colleagues 1993 reported data for participants on platinum-based chemotherapy and non-
platinum based chemotherapy; (c) IPD data as reported in Tonia and colleagues, 2012 (Cochrane review): Abels 
and colleagues, 1993; Boogaerts and colleagues, 2003; Dammacco and colleagues, 2001; Grote and 
colleagues, 2005; Hedenus and colleagues, 2003; Littlewood and colleagues, 2001; Osterborg and colleagues, 
2002; Ray-Coquard and colleagues, 2009; Vansteenkiste and colleagues, 2002. HRs reported for other trials 
calculated using other accepted methods. 
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The fixed effects meta-analysis undertaken as a sensitivity analysis showed similar results 
(HR 0.87, 95% CI 0.70, 1.09); the forest plot of this analysis is included in (Appendix L). Both 
fixed and random effects estimates suggested no difference in on-study mortality between 
the control and treatment arms. Interestingly, the fixed effects estimate reported in the recent 
Cochrane review (Tonia and colleagues, 2012)10 favoured controls, suggesting that higher 
mortality occurred in patients treated with ESA (HR=1.17; 95% CI 1.03, 1.29). Again it must 
be emphasised that the current analysis included only studies complying with the licenced 
ESA dose, while the Cochrane review did not apply any restrictions regarding the ESA 
posology. The Cochrane review included 64 studies in the on-study mortality meta-analysis 
but subgroup analyses comparing studies using licenced and unlicensed ESA dose were not 
conducted. 
Pre-defined subgroup analyses were performed (Table 21). None of the studies with 
available Hb response data included ovarian cancer patients. Therefore, the planned ovarian 
cancer subgroup analysis was not completed. In addition, to assess the effects of subgroups 
on mortality, meta-regression models were peformed which includedrandom effect and 
subgroups as covariates; the F statistics from these analyses are reported in Table 21. All 
covariates showing a significant effect (p<0.05) in a univariate analysis were further 
considered in model selection. 
Table 21. Mortality: Subgroup analyses 
 Trials HR CI I2 Tau2 
Overall 14 0.86 0.67 − 1.11 16.4%; p=0.27 0.04 
Inclusion Hb 
≤11.0 g/dl 10 0.89 0.61 − 1.30 37.7%; p=0.11 0.13 
>11.0 g/dl 4 0.77 0.55 − 1.08 0%; p=0.98 0 
F (between:within) F(1,12) 0.74; p=0.41 
Baseline Hb  
≤10.0 g/dl 11 0.84 0.62 − 1.15 33.2%; p=0.13 0.09 
≤11.0 g/dl 1 1.11 0.45 − 2.73 NA 0 
≤14.5 g/dl 2 0.78 0.41 − 1.50 0%; p=0.67 0 
F (between:within)  F(2,11) 0.14; p=0.87 
Target Hb 
≤13.0 g/dl 3 0.50 0.20 − 1.22 29.7%; p=0.24 0.19 
>13.0 g/dl 9 0.92 0.70 − 1.22 20.0%; p=0.27 0.04 
NR 2 0.88 0.46 − 1.70 0%; p=0.47 0 
F (between:within)  F(2,11) 0.89; p=0.44 
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 Trials HR CI I2 Tau2 
Malignancy type 
Solid tumours 5 0.71 0.44 − 1.15 17.6%; p=0.30 0.06 
Haematological tumours 5 0.98 0.54 − 1.79 52.7%; p=0.08 0.24 
Mixed 4 0.83 0.58 − 1.17 0%; p=0.88 0 
F (between:within) F(2,11) 0.61; p=0.56 
Chemotherapy treatment 
Platinum-containing 4 0.64 0.34 − 1.18 36.0%; p=0.20 0.14 
Non-platinum-containing 4 1.01 0.71 − 1.43 0%; p= 0.65 0 
NR 3 1.09 0.58 − 2.08 44.4%; p=0.17 0.14 
Mixed 3 0.53 0.21 − 1.30 26.6%; p=0.26 0.21 
F (between:within) F(3,10) 1.06; p=0.41 
Iron supplementation 
Iron in both arms 9 0.89 0.63 − 1.26 25.6%; p= 0.22 0.07 
NR  5 0.82 0.55 − 1.21 14.5%; p= 0.32 0.03 
F (between:within) F(1,12) 0.09; p=0.77 
Study design 
Blinded (RCT) 11 0.86 0.63 − 1.17 33.0%; p=0.14 0.09 
Unblinded (ROL) 3 0.82 0.49 − 1.35 0.0%; p=0.77 0 
F (between:within) F(1,12) 0.07; p=0.80 
Study duration 
6–9 wks 1 0.14 0 − 365.61 NA 0 
12–16 wks 10 0.85 0.59 − 1.23 39.6%; p=0.09 0.13 
17–20 wks 1 0.79 0.41 − 1.52 NA 0 
>20 wks 2 0.84 0.53 − 1.32 0.0%; p=0.61 0 
F (between:within) F(3.10) 0.070; p=0.97 
ESA 
Erythropoetin 12 0.80 0.63 − 1.02 1.0%; p=0.43 <0.01 
Darbepoetin 2 1.42 0.66 − 3.05 43.0%; p=0.19 0.14 
F (between:within) F(1.12) 2.51; p=0.14 
Key: CI, confidence interval; ESA, erythropoiesis stimulating agents; Hb, haemoglobin; NA, not applicable; NR, 
not reported; RCT, randomised controlled trial; ROL, randomised open label (standard care); wks, weeks. 
 
Univariate analyses did not identify any significant differences based on the pre-defined 
subgroups (Table 21). 
Summary: Analyses suggest that treatment with ESA in patients with CIA did not have a 
significant effect on mortality. Eleven per cent (174/1586) of participants who received ESA 
had died within 30 days of the active study period, compared to 12% (164/1381) of patients 
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in control groups. The risk of death was 0.86 (HR 0.86, 95% CI 0.67, 1.1). There was no 
significant heterogeneity between the trials (I2=16.4%, p=0.274). Overall, the data appear 
different to previous analyses. It appears that if the licenced ESA dosage is followed, there 
are no detrimental effects of ESA on overall survival. However, these results should be 
interpreted with caution, see Section 4.2.7 (page 149) for more details. 
4.2.6.2.4.  Malignancy-related outcomes: overall  summary 
Table 22. Malignancy-related outcomes results comparison: Wilson and colleagues, 
2007 vs Tonia and colleagues, 2012 vs PenTAG 20131,10 
 Wilson, 2007a  Tonia, 2012a PenTAG, 2013a PenTAG, 2013b 
Malignancy-related outcomes 
Tumour 
response 
RR 1.31 
95% CI 1.08−1.60 
Χ2(het) NR; df NR 
(p=NR) 
9 trials, n=1,260 
RR 1.02 
95% CI 0.98−1.06 
Χ2(het) 16.10; df 18 
(p=0.59) 
19 trials, n=5,012 
RR 1.20 
95% CI 0.85−1.71  
Χ2(het) 9.59; df 6 
(p=0.14) 
7 trials, n=1,909 
RR 1.10 
95% CI 0.86−1.41  
Χ2(het) 9.59; df 6 
(p=0.14) 
7 trials, n=1,909 
Overall 
survival 
HR 1.03 
95% CI 0.92−1.16 
Χ2(het) 37.74; df 27 
(p=0.08) 
28 trials, n=5,308 
HR 1.05 
95% CI 1.00−1.11 
Χ2(het) 95.40; df 75 
(p=0.060) 
76 trials, n=18.754 
HR 0.98 
95% CI 0.89−1.08 
Χ2(het) 29.50; df 17 
(p=0.03) 
18c trials, n=4,399 
HR 0.97 
95% CI 0.83−1.13 
Χ2(het) 29.50; df 17 
(p=0.03) 
18c trials, n=4,399 
Mortality NR HR 1.17 
95% CI 1.03−1.29 
X2(het) 59.49; df=63 
(p=0.600) 
64 trials, n=14,179 
HR 0.87 
95% CI 0.70−1.09 
X2(het) 15.55; df=13 
(p=0.274) 
14 trials. n=2,967 
HR 0.86 
95% CI 0.67−1.11 
X2(het) 15.55; df=13 
(p=0.274) 
14 trials. n=2,967 
Key: CI, confidence interval; df, degrees of freedom; het, heterogeneity; RR, relative risk 
Notes: The number of trials includes multiple experimental arms for some studies (a) fixed effects (Mantel-
Haenzel); (b) random effects (Der-Simonian Laird); ), haematological response  was defined as the proportion of 
participants with an increase in Hb level of two g/dl or more, or as an increase in haematocrit of six percentage 
points or more; (c) 16 studies; however, two studies split into subsets thus 18 trials included in meta-analysis 
 
Effectiveness estimates are compared with previously reported estimates for the 
malignancy-related outcomes; see Table 22. A graphical summary of study characteristics 
and results for these outcomes is presented in Figure 15.  
Seven studies reported tumour response (complete response). Data available suggest that 
ESAs do not have a beneficial effect on tumour control; however, the data are insufficient to 
exclude detrimental effects. It should also be noted that this is a difficult area of assessment, 
especially in a heterogenous mix of tumour types, and results should be treated with caution. 
Survival estimates (HR) were available for 16 of the included studies; the HR (HR 0.98, 95% 
CI 0.89, 1.08) differed from those previously reported (Table 22). In addition, statistically 
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significant heterogeneity was identified (I2 42.4%; p=0.03), which adds uncertainty to this 
estimate. It was not possible to identify subgroups that were at higher or lower risk. In 
addition, OS was calculated from the longest follow-up available (no mnimum was 
required),as such, there was variation between the studies (short- and long-term) and this 
should be considered when interpreting the results. On-study mortality was assessed in 12 
studies. The risk of death was 0.86 (HR 0.86, 95% CI 0.67, 1.1); with no significant 
heterogeneity between the trials (I2=16.4%, p=0.274).  
Overall the results for malignancy-related outcomes seem to be different to previous 
analyses. It appears that if the licenced ESA dosage is followed, there are no detrimental 
effects of ESA on-study mortality or on overall mortality. However, these results should be 
interpreted with caution. However, these results should be interpreted with caution, see 
Section 4.2.7 (page 149) for more details.
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Figure 15. Malignancy-related outcomes: Graphical summary  
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, 
non-platinum; OS, overall survival; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: 
Darbe Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: 
Latin sq. des.; 11: Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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Figure 15. Malignancy-related outcomes: Graphical summary  
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-
platinum; OS, overall survival; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: 
Darbe Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: Latin 
sq. des.; 11: Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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Figure 15. Malignancy-related outcomes: Graphical summary  
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-
platinum; OS, overall survival; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 23: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: 
Darbe Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: 
Latin sq. des.; 11: Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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Figure 15. Malignancy-related outcomes: Graphical summary  
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-
platinum; OS, overall survival; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: 
Darbe Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: 
Latin sq. des.; 11: Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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4.2.6.3.  Safety  
Adverse events, as included in the Cochrane review (Tonia and colleagues, 201210) 
thromboembolic events, hypertension, thrombocytopenia/haemorrhage, seizures and 
pruritus (pruritus, rash and irritation were considered as defined in Tonia and colleagues, 
201210), and red cell aplasia  
There was considerable variability in the reporting of AEs among the included studies; e.g. 
some reported adverse events (AEs) in >5% of patients; some in >10% of patients; and 
some the overall number of events. In addition, there was some variability in the definitions 
of AEs used in the studies. Given the greater access to data than that reported in the 
primary papers, data from the Cochrane review (Tonia and colleagues, 2012),10 were used 
to conduct meta-analyses for the following adverse events: thromboembolic events, 
thrombocytopenia and haemorrhage, hypertension, seizures and pruritus (defined as 
pruritus, rash and irritation).  
No studies were identified that reported red cell aplasia. In addition, this was safety outcome 
was not analysed in the Cochrane review. 
4.2.6.3.1.  Thromboembolic events 
We identified 14 studies that measured thromboembolic events, including 4,013 participants. 
Of these, 2,029 participants were treated with ESAs. As one multi-arm study (Abels and 
colleagues, 1993)54 was split into subsets the number of studies displayed is 15. Five 
included studies were newly identified in the update searches (Strauss and colleagues, 
2008; Ray-Coquard and colleagues, 2009; Tjulandin and colleagues, 2011; Untch and 
colleagues, 2011a,b; and Moebus and colleagues, 2013).62,74-78 If thromboembolic events 
were not reported, we used data from the Cochrane review by Tonia and Colleagues 
(2012)10 in the PenTAG analyses. One study (Thatcher and colleagues 1999),48 did not 
report any thromboembolic events in the treatment or placebo arms, therefore the number of 
trials included in the meta-analysis is 14. 
Moebus and colleagues (2013)62 replaced Moebus and colleagues (2007)32 (used in 
Tonia and colleagues, 201210), different number of thromboembolic events were used in 
the PenTAG meta-analyses compared to the analysis in Tonia 2012. The Moebus and 
colleagues (2013)62 trial showed an increased risk for patients treated with ESA compared 
to controls (RR 2.26 CI 1.09−4.70), while no difference between treatment and controls was 
reported in Moebus and colleagues (2007).32 
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Thromboembolic events were reported in 103 out of 2,029 participants treated with ESAs 
compared to 66 out of 1,984 participants in the control group. The random effects meta-
analysis showed a RR of 1.46 favouring controls (RR 1.46 95% CI 1.07 to 1.99; see Figure 
16). There was no heterogeneity between the trials (I2=0%, p=0.733; Χ2=9.52, df=13, 
p=0.733); with 11 studies indicating detrimental effects of ESA treatment, and three studies 
indicating beneficial effects of ESA treatment with regard to thromboembolic events. To test 
whether publication bias was present in the sample included in the meta-analysis, a funnel 
plot was constructed (Appendix L). The funnel plot analysis did not show statistically 
significant asymmetry (p=0.627). In addition, a meta-regression using publication year as a 
covariate to assess the effect of publication year on thromboembolic events suggests that 
the effects of ESA on thromboembolic events were independent from when the trial results 
were published (p=0.871); the meta-regression plot is presented in Appendix L. 
Figure 16. Thromboembolic events: overall (random effects) 
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: (a) Random effects (Der-Simonian Laird pooled RR); (b) Trial with multiple experimental arm split into 
subsets in the analysis: Abels and colleagues 1993 reported data for participants on platinum-based 
chemotherapy and non-platinum based chemotherapy
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3.44 (0.14, 81.71)
2.26 (1.09, 4.70)
1.38 (0.51, 3.75)
1.47 (0.78, 2.75)
0.32 (0.01, 7.74)
(Excluded)
3.70 (0.18, 74.51)
1.15 (0.53, 2.50)
1.22 (0.34, 4.41)
3.05 (0.13, 74.41)
0.73 (0.27, 1.98)
103/2029
2/81
6/175
5/69
Treatment
7/155
1/33
22/309
14/251
20/318
0/95
0/42
2/45
12/109
5/110
1/170
6/67
Events,
66/1984
3/76
1/169
1/76
Control
5/159
0/38
10/318
5/124
17/396
1/91
0/44
0/33
11/115
4/107
0/173
8/65
Events,
100.00
3.03
2.12
2.09
Weight
7.42
0.94
17.61
9.44
23.74
0.93
0.00
1.04
15.66
5.68
0.92
9.37
%
Favours treatment Favours control 
1.0122 81.7
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The fixed effects meta-analysis undertaken as a sensitivity analysis showed similar results 
favouring controls compared to ESA (RR 1.52, 95% CI 1.13 to 2.05; I2=0%, p=0.733); the 
forest plot of the analysis is included in Appendix L. 
Pre-specified subgroup analyses were conducted (Table 23). In addition, meta-regression 
models including random effect and a subgroup as a covariate to assess the effects of 
subgroups on thomboembolic events were performed; the F statistics from these analyses 
are reported inTable 23. All covariates showing a significant effect (p<0.05) in a univariate 
analysis were further considered in a model selection.  
Table 23.Thromboembolic events: Subgroup analyses 
 Trials RR CI I2 Tau2 
Overall 14 1.46 1.08 − 1.99 0%; p=0.73 0 
Inclusion Hb 
≤11.0 g/dl 7 1.29 0.66 – 2.54 12.2%; p=0.34 0.10 
>11.0 g/dl 7 1.55 1.08 − 2.21 0%; p=0.88 0 
F (between:within)  F(1,12) =0.35; p=0.57 
Baseline Hb 
≤10.0 g/dl 8 1.34 0.82 − 2.21 0%; p=0.52 0 
≤11.0 g/dl 1 0.63 0.11 −  3.64 NA 0 
≤12.0 g/dl 2 3.58 0.40 − 31.59 0%; p=0.97 0 
≤14.5 g/dl 2 1.33 0.82 − 2.17 0%; p=0.64 0 
NR 1 2.26 1.09 − 4.70 NA 0 
F (between:within) F(4,9) =0.53; p=0.72 
Target Hb 
≤13.0 g/dl 2 1.38 0.75 – 2.57 0%; p=0.36 0 
>13.0 g/dl 10 1.73 1.72 − 2.54 0%; p=0.82 0 
NR 2 0.70 0.29 – 1.68 0%; p=0.88 0 
F (between:within) F(2,11) =1.75; p=0.22 
Malignancy type 
Solid tumours 6 1.59 1.09 − 2.32 0%; p=0.82 0 
Haematological tumours 5 1.57 0.57 − 4.34 35.1%; p=0.19 0.46 
Mixed 3 1.21 0.57 − 2.61 0%; p=0.69 0 
F (between:within) F(2,11) =1.09; p=0.37 
Ovarian cancer 
Ovarian cancer 1 3.97 0.18 − 74.51 NA 0 
Other cancers 13 1.45 1.06 − 1.97 0%; p=0.69 0 
F (between:within) F(1,12) =0.61; p=0.45 
Chemotherapy treatment 
Platinum-containing 3 1.06 0.51 − 2.20 0%; p=0.47 0 
Non-platinum-containing 6 1.57 1.04 − 2.37 0%; p=0.66 0 
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Mixed 2 1.84 0.44 − 7.63 47.3%; p=0.17 0.60 
+Radiotherapy 1 3.44 0.15 − 81.71 NA 0 
NR 2 2.12 0.48 − 9.47 37.4%; p=0.21 0.47 
F (between:within) F(4,9) =0.63; p=0.65 
Iron supplementation 
Iron in both arms 7 1.86 1.13 − 3.07 0%; p=0.73 0 
Iron in an intervention arm  1 1.47 0.78 − 2.75 NA 0 
NR  6 1.15 0.70 − 1.89 0%; p=0.53 0 
F (between:within) F(2,11) =0.21; p=0.82 
Study design 
RCT 9 1.24 0.81 − 1.90 0%; p=0.55 0 
ROL 5 1.74 1.12 − 2.69 0%; p=0.83 0 
F (between:within) F(1,12) =0.01; p=0.94 
Study duration 
6–9 wks 1 3.44 0.15 − 81.71 NA 0 
12–16 wks 8 1.24 0.72 − 2.13 0%; p=0.45 0 
17–20 wks 2 1.64 0.84 − 3.18 35.7%; p=0.21 0.08 
>20 wks 3 1.48 0.88 − 2.51 0%; p=0.83 0 
F (between:within) F(3,10) =0.17; p=0.91 
ESA 
Erythropoetin 11 1.40 0.96 − 2.04 0%; p=0.65 0 
Darbepoetin 3 1.60 0.94 − 2.71 0%; p=0.46 0 
F (between:within) F(1,12) =037; p=0.56 
Key: ESA, erythropoiesis stimulating agents; Hb, haemoglobin; NA, not applicable; NR, not reported; RCT, 
randomised controlled trial; ROL, randomised open label (standard care); wks, weeks. 
 
Univariate analyses did not identify any significant differences based on the pre-defined 
subgroups (Table 23). 
Summary:  Analyses suggest that treatment with ESA in patients with CIA increases the risk 
for thromboembolic events (RR 1.46; 95% CI 1.08 to 1.99).  Five per cent (103/2,029) 
participants who received ESA reported thromboembolic events, compared to 3% (66/1,984) 
of patients in control groups. There was no heterogeneity between the trials (I2=0%, 
p=0.733).  Overall, the data confirm results from prior analyses; an increased risk of 
thromboembolic events in patients with ESA compared to controls. 
4.2.6.3.2.  Hypertension 
We identified ten studies that measured hypertension. Overall, the analysis included nine 
studies with 2,032 participants; of these, 1,122 participants were treated with ESAs. As two 
multi-arm studies (Abels and colleagues, 1993 and Tjulandin and colleagues, 2010)45,54 
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were split into subsets the number of studies displayed is 12. Two included studies were 
newly identified in the update searches (Tjulandin and colleagues, 2010 and Tjulandin 
and colleagues, 2011).45,76 If hypertension was not reported, we used data from the 
Cochrane review by Tonia and Colleagues (2012)10 in the PenTAG analyses. 
Hypertension was reported in 62 out of 1,152 participants (5%) treated with ESAs compared 
to 27 out of 934 participants (3%) in the control groups. The random effects meta-analysis 
showed a risk ratio of 1.80 (95% CI 1.14 to 2.85; see Figure 17) favouring controls. There 
was no statistical heterogeneity between the trials (I2=0%; Χ2=7.10, df=11, p=0.791); 
however the direction of the effects of ESA with regard to hypertension varied across the 
individual trials (Figure 17). To test whether publication bias was present in the sample 
included in the meta-analysis, a funnel plot was constructed (Appendix L). The funnel plot 
analysis did not show statistically significant asymmetry (p=0.689). In addition, a meta-
regression using publication year as a covariate to assess the effect of publication year on 
hypertension suggests that the effects of ESA on hypertension were independent from when 
the trial results were published (p=0.735); the meta-regression plot is presented in Appendix 
L.  
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Figure 17. Hypertension: overall (random effects) 
 
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: (a) Random effects (Der-Simonian Laird pooled RR); (b) Trial with multiple experimental arm split into 
subsets in the analysis: Tjulandin and colleagues, 2010a, b reports data for epoetin theta (2010a) and epoetin 
beta (2010b) and Abels and colleagues 1993 reported data for participants on platinum-based chemotherapy and 
non-platinum based chemotherapy 
 
The fixed effects meta-analysis undertaken as a sensitivity analysis showed similar results 
(RR 1.97, 95% CI 1.27 to 3.07; I2=0%, p=0.791); the forest plot of the analysis is included in 
Appendix L. 
Pre-specified subgroup analyses were conducted (Table 24). In addition, meta-regression 
models including random effect and a subgroup as a covariate to assess the effects of 
subgroups on hypertension were performed; the F statistics from these analyses are 
reported in Table 24. All covariates showing a significant effect (p<0.05) in a univariate 
analysis were further considered in a model selection.  
Table 24. Hypertension: subgroup analyses 
 Trials RR CI I2 Tau2 
Overall 12 1.80 1.14 − 2.85 0%; p=0.79 0 
Inclusion Hb 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.791)
Tjulandin_Beta (2010b)
ID
Thatcher (1999)
Tjulandin (2011)
Study
Vansteenkiste (2002)
Dammacco (2001)
Littlewood (2001)
Silvestris (1995)
Ten Bokkel (1998)
Abels_Cisplatin (1993)
Osterborg (2005)
Abels_NonCisplatin (1993)
Tjulandin_Theta (2010a)
1.80 (1.14, 2.85)
0.97 (0.09, 10.40)
RR (95% CI)
3.14 (0.13, 74.98)
7.66 (0.98, 60.06)
1.54 (0.56, 4.22)
3.30 (0.35, 31.03)
4.45 (0.57, 34.70)
7.26 (0.41, 128.50)
1.95 (0.21, 17.85)
0.49 (0.09, 2.56)
1.70 (0.76, 3.77)
1.88 (0.35, 9.95)
1.01 (0.09, 10.82)
62/1152
2/76
Treatment
1/42
8/95
Events,
9/155
3/69
9/251
4/30
3/43
2/67
15/170
4/81
2/73
27/934
1/37
Control
0/44
1/91
Events,
6/159
1/76
1/124
0/24
1/28
4/65
9/173
2/76
1/37
100.00
3.77
Weight
2.10
4.99
%
20.79
4.22
5.01
2.56
4.32
7.66
33.17
7.61
3.78
Favours treatment Favours control 
1.00778 129
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≤11.0 g/dl 9 1.68 1.03 – 2.74 0%; p=0.64 0 
>11.0 g/dl 3 3.06 0.78− 11.91 0%; p=0.86 0 
F (between:within)  F(1,10) =0.07; p=0.79 
Baseline Hb 
≤10.0 g/dl 9 1.76 1.07 − 2.89 0%; p=0.54 0 
≤11.0 g/dl 1 1.88 0.35 − 9.95 NA 0 
≤12.0 g/dl 1 1.95 0.21 − 17.85   NA 0 
≤14.5 g/dl 1 3.14 0.13 − 74.98 NA 0 
F (between:within) F(3,8) =0.10; p=0.96 
Target Hb 
≤13.0 g/dl 3 2.19 0.53 – 9.12 16.8%; p=0.30 0.27 
>13.0 g/dl 6 1.89 1.09 − 3.28 0%; p=0.94 0 
NR 3 1.39 0.35 – 5.53 32.9%; p=0.23 0.49 
F (between:within) F(2,9) =0.07; p=0.93 
Malignancy type 
Solid tumours 5 1.51 0.69 − 3.28 0%; p=0.97 0 
Haematological tumours 5 1.63 0.88 − 3.02 0%; p=0.48 0 
Mixed 2 5.83 1.36 − 24.98 0%; p=0.71 0 
F (between:within) F(2,9) =4.07; p=0.06 
Ovarian cancer 
Ovarian cancer 1 1.95 0.21 − 17.85 NA 0 
Other cancers 11 1.79 1.12 − 2.87 0%; p=0.72 0 
F (between:within) F(1,10) =0.14; p=0.71 
Chemotherapy treatment 
Platinum-containing 5 1.17 0.57 − 2.41 0%; p=0.81 0 
Non-platinum-containing 4 2.20 1.15 − 4.19 0%; p=0.49 0 
NR 1 7.26 0.41 − 128.50 NA 0 
Mixed 2 3.25 0.52 − 20.25 0%; p=0.99 0 
F (between:within) F(3,8) =3.07; p=0.09 
Iron supplementation 
Iron in both arms 6 2.13 1.13 − 3.99 0%; p=0.55 0 
No iron supplementation 1 3.14 0.13 − 74.98 NA 0 
NR 5 1.44 0.72 − 2.86 0%; p=0.552 0 
F (between:within) F(2,9) =0.96; p=0.42 
Study design 
RCT 9 1.70 1.05 − 2.76 0%; p=0.65 0 
ROL 3 3.17 0.68 − 14.72 0%; p=0.77 0 
F (between:within) F(1,10) =0.84; p=0.38 
Study duration 
12–16 wks 8 1.61 0.98 − 2.64 0%; p=0.66 0 
>20 wks 4 3.58 1.05 − 12.24 0%; p=0.90 0 
F (between:within) F(1,10) =1.69; p=0.22 
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ESA 
Erythropoetin 11 1.88 1.12 − 3.15 0%; p=0.73 0 
Darbepoetin 1 1.54 0.56 − 4.22 NA 0 
F (between:within) F(1,10) =0.38; p=0.55 
Key: ESA, erythropoiesis stimulating agents; Hb, haemoglobin; NA, not applicable; NR, not reported; RCT, 
randomised controlled trial; ROL, randomised open label (standard care); wks, weeks. 
 
Univariate analyses did not identify any significant differences based on the pre-defined 
subgroups (Table 24). 
Summary:  Analyses suggest that treatment with ESAs in patients with CIA increases the 
number of hypertension events (RR 1.80 95% CI 1.14 to 2.85).  Five per cent (62/1,152) of 
participants who received ESA reported hypertension, compared to 3% (27/934) of 
participants in control groups. There was no heterogeneity between the trials (I2=0%, 
p=0.791). Overall, the data confirm results from prior analyses; an increased risk of 
hypertension in patiens with ESA compared to controls. 
4.2.6.3.3.  Thrombocytopenia/haemorrhage 
Data for thrombocytopenia (decrease of platelets in the blood)/haemorrhage were available 
from seven studies. Overall, the analysis included seven studies with 1,715 participants. If 
thrombocytopenia/haemorrhage was not reported, data were obtained from the Cochrane 
review by Tonia and Colleagues (2012).10 
Thrombocytopenia/haemorrhage was reported in 55 out of 877 participants treated with 
ESAs compared to 54 out of 838 participants in the control groups. The random effects 
meta-analysis showed a RR of 0.93 (95% CI 0.65 to 1.34; see Figure 18) that was not 
statistically significant. There was no statistical heterogeneity between the trials (I2=0%; 
Χ2=3.02, df=6, p=0.807); however the direction of the effects of ESA with regard to 
hypertension varied across the individual trials. Because there were only seven primary 
studies included in the meta-analysis, the funnel plot analysis to test whether publication 
bias was present was not conducted.50 
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Figure 18. Thrombocytopenia/haemorrhage: overall (random effects) 
 
Key: CI, confidence interval; events treatment control, number of events/participants in the treatment and control 
groups; ID, identification; RR, risk ratio 
Notes: (a) Random effects (Der-Simonian Laird pooled RR) 
 
The fixed effects meta-analysis undertaken as a sensitivity analysis showed similar non-
significant results (RR 0.91, 95% CI 0.63, 1.30; see Appendix L). 
Pre-specified subgroup analyses and meta-regressions models with subgroups as 
covariates were not conducted because only seven trials were included in the meta-analysis. 
Summary:  Analyses suggest that treatment with ESAs in patients with cancer indused 
anaemia did not have an effect on thrombocytopenia/haemorrhage (RR 0.93 95% CI 0.65 to 
1.34).  Six per cent (55/877) of participants who received ESA reported 
thrombocytopenia/haemorrhage, and 6% (54/838) of participants in control groups reported 
thrombocytopenia/haemorrhage. There was no heterogeneity between the trials (I2=0%, 
p=0.807). Overall, the data seem to be different to previous analyses. Data suggest that 
ESAs do not have a detrimental effect on thrombocytopenia/haemorrhage. However, these 
results should be interpreted with caution, see Section 4.2.7 (page 149) for more details. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.807)
Untch (2011a,b )
Littlewood (2001)
Del Mastro (1999)
Thatcher (1999)
Strauss (2008)
Study
Dammacco (2001)
Boogaerts (2003)
ID
0.93 (0.65, 1.34)
1.00 (0.40, 2.49)
0.99 (0.46, 2.14)
1.00 (0.27, 3.65)
1.28 (0.59, 2.77)
0.29 (0.03, 2.45)
1.10 (0.33, 3.64)
0.60 (0.26, 1.39)
RR (95% CI)
55/877
8/318
18/251
4/31
11/42
1/33
Events,
5/69
8/133
Treatment
54/838
10/396
9/124
4/31
9/44
4/38
Events,
5/76
13/129
Control
100.00
15.92
22.59
8.02
22.46
2.93
%
9.38
18.71
Weight
Favours treatment Favours control 
1.0338 29.6
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4.2.6.3.4.  Seizures 
Data on seizures were available from one study (Abels and colleagues, 1993)54 including 
289 participants. As this trial was split into subsets the number of studies in the Forest plot is 
two. If seizure was not reported, we used data from the Cochrane review by Tonia and 
Colleagues (2012)10 in the PenTAG analyses. 
Overall, five events of seizure were reported in the ESA-treated group (n=148) and four 
events in the control group (n=141), resulting in a RR of 1.19 (RR 1.19; 95% CI 0.33 to 4.38; 
see Figure 19). There was no heterogeneity between the trials (I2=0%, p=0.742; Χ2=0.11, 
df=5, p=0.742); although the two included trials indicated effects in opposite directions. 
Because there were only two primary studies included in the meta-analysis, the funnel plot 
analysis to test whether publication bias was present was not conducted.50 The fixed effects 
meta-analysis undertaken as a sensitivity analysis showed similar non-significant results (RR 
1.19, 95% CI 0.33, 4.35; I2=0%, p=0.742; Appendix L). 
Pre-specified subgroup analyses and meta-regression models with subgroups as covariates 
were not conducted because only two trials were included in the meta-analysis. 
Figure 19. Seizures: overall (random effects) 
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: (a) Der-Simonian Laird pooled RR; (b) Trial with multiple experimental arm split into subsets in the 
analysis: Abels and colleagues 1993 reported data for participants on plat-based and non-plat based chemo 
 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.742)
Abels_NonCisplatin  (1993)
ID
Study
Abels_Cisplatin (1993)
1.19 (0.33, 4.38)
0.94 (0.14, 6.50)
RR (95% CI)
1.46 (0.25, 8.43)
5/148
2/81
Treatment
Events,
3/67
4/141
2/76
Control
Events,
2/65
100.00
45.18
Weight
%
54.82
Favours treatment Favours control 
1.119 8.43
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Summary: Analyses suggest that treatment with ESAs in patients with CIA did not have a 
significant effect on seizures (RR of 1.19; 95% CI 0.33 to 4.38). Less than 1% (5/148) of 
participants who received ESAs had a seizure, similarly less than 1% (4/141) of participants 
in control groups had a seizure. There was no heterogeneity between the trials (I2=0%, 
p=0.742). While data from one study suggests that ESAs do not have a detrimental effect on 
seizures, there was no significant difference between groups. The possibility of detrimental 
effects of ESAs on the number of seizures, however, can not be excluded. Overall, the data 
confirm results from prior analyses.  
4.2.6.3.5.  Pruritus (pruritus, rash and irr i tation) 
We identified seven studies that measured pruritus (pruritus, rash and irritation were 
considered; Tonia and colleagues, 201210) including 904 participants. Of these, 450 
participants were treated with ESA. Two included studies were newly identified in the update 
searches (Strauss and colleagues, 2008; Tjulandin and colleagues, 2011).75,76 If pruritus 
events were not reported, we used data from the Cochrane review by Tonia and 
Colleagues (2012)10 in the PenTAG analyses.  One study (Kurz and colleagues 1997),67 
did not report any events of pruritus in the treatment and placebo arms, therefore the 
number of trials included in the meta-analysis is six. 
The random effects meta-analysis showed a risk ratio of 2.04 (RR 2.04; 95% CI 1.11 to 3.75; 
see Figure 20) favouring controls. There was no heterogeneity between the trials (I2=0%, 
p=0.872; Χ2=1.83, df=5, p=0.872); with all of the individual studies indicating a detrimental 
effect of treatment with ESA with regard to the number of pruritus. Because there were only 
six primary studies included in the meta-analysis, the funnel plot analysis to test whether 
publication bias was present was not conducted.50 The fixed effects meta-analysis 
undertaken as a sensitivity analysis showed similar results (RR 2.16; 95% CI 1.18 to 3.92; 
I2=0%, p=0.872); the forest plot of the analysis is included in Appendix L. 
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Figure 20. Pruritus: overall (random effects) 
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: (a) Random effects (Der-Simonian Laird pooled RR) 
 
The pre-specified subgroup analyses and meta-regressions models with subgroups as 
covariates were not conducted because only six trials were included in the meta-analysis. 
Summary: Analyses suggest that treatment with ESA in patients with cancer treatment 
induced anaemia increases the number of cases of pruritus (RR 2.04; 95% CI 1.11 to 3.75).  
Seven per cent (30/450) participants who received ESA reported pruritus, compared to 3% 
(13/454) of patients in control groups. There was no heterogeneity between the trials (I2=0%, 
p=0.872), with all of the individual studies indicating a detrimental effect of treatment with 
ESAs with regard to pruritus. Overall, the data seem to be different to previous analyses. 
Data suggest that ESAs increase the number of cases of pruritus in patients with 
chemotherapy induced anaemia. The definition of pruritus considered pruritus, rash and 
irritation (as defined in the Cochrane review [Tonia and colleagues, 201210]). The marked 
variation in event rates may be due to the definition of pruritus. However, these results 
should be interpreted with caution, see Section 4.2.7 (page 149) for more details. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.872)
Abels_Cisplatin (1993)
Strauss (2008)
ID
Study
Tjulandin (2011)
Thatcher (1999)
Del Mastro (1999)
Kurz (1997)
Osterborg (2005)
2.04 (1.11, 3.75)
3.40 (0.73, 15.74)
3.44 (0.14, 81.71)
RR (95% CI)
1.78 (0.74, 4.26)
1.31 (0.38, 4.55)
5.00 (0.25, 100.08)
(Excluded)
5.09 (0.25, 105.20)
30/450
7/67
1/33
Treatment
Events,
13/95
5/42
2/31
0/12
2/170
13/454
2/65
0/38
Control
Events,
7/91
4/44
0/31
0/12
0/173
100.00
15.72
3.69
Weight
%
48.57
23.87
4.12
0.00
4.03
Favours treatment Favours control 
1.00951 105
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4.2.6.3.6.  Safety-related outcomes: summary 
Table 25. Safety-related outcomes results comparison: Wilson, 2007 vs Tonia, 2012 vs 
PenTAG 20131,10 
 Wilson, 2007b Tonia, 2012b PenTAG, 2013b PenTAG, 2013c 
Safety-related outcome  
Thromboembolic 
events 
NR RR 1.52 
95% CI 1.34−1.74 
Χ2(het) 34.99; df 55 
(p=0.980) 
60 trials, n=15,498 
RR 1.52 
95% CI 1.13−2.05 
Χ2(het) 9.52; df 14 
(p=0.872) 
15d trials, n=1,984 
RR 1.46 
95% CI 1.07−1.99 
Χ2(het) 9.52; df 14 
(p=0.872) 
15d trials, n=1,984 
Hypertension NR RR 1.30 
95% CI 1.08−1.56 
Χ2(het) 26.87; df 34 
(p=0.800) 
35 trials, n=7,006 
RR 1.97 
95% CI 1.27−3.07 
Χ2(het) 7.10; df 11 
(p=0.791) 
10 trials, n=2,032 
RR 1.80 
95% CI 1.14−2.85 
Χ2(het) 7.10; df 11 
(p=0.791) 
10 trials, n=2,032 
Thromobocytopenia/ 
haemorrhage 
NR RR 1.21 
95% CI 1.04−1.42 
Χ2(het) 14.50; df 20 
(p=0.800) 
21 trials, n=4,220 
RR 0.91 
95% CI 0.63−1.30 
Χ2(het) 3.02; df 11 
(p=0.807) 
7 trials, n=1,715 
RR 0.93 
95% CI 0.65−1.34 
Χ2(het) 3.02; df 11 
(p=0.807) 
7 trials, n=1,715 
Seizure NR RR 0.77 
95% CI 0.42−1.41 
Χ2(het) 6.19; df 6 
(p=0.400) 
7 trials, n=2,790 
RR 1.19 
95% CI 0.33−4.35 
Χ2(het) 0.11; df 1 
(p=0.742) 
2 trials, n=289 
RR 1.19 
95% CI 0.33−4.38 
Χ2(het) 0.11; df 1 
(p=0.742) 
2 trials, n=289 
Pruritus NR RR 1.49 
95% CI 0.99−2.24 
Χ2(het) 13.18; df 15 
(p=0.590) 
16 trials, n=4,346 
RR 2.16 
95% CI 1.18−3.92 
Χ2(het) 1.83; df 5 
(p=0.872) 
7d trials, n=904 
RR 2.04 
95% CI 1.11−3.75 
Χ2(het) 1.83; df 5 
(p=0.872) 
7d trials, n=904 
Key: CI, confidence interval; df, degrees of freedom; het, heterogeneity; HR, hazard ratio; RR, relative risk 
Notes: (a) change from baseline to end of study; (b) fixed effects (Mantel-Haenzel); (c) random effects (Der-
Simonian Laird); (d) one study was excluded as no events were reported in treatment and placebo arms; (e) the 
number of trials includes multiple experimental arms for some studies
 
Overall, data suggest increased risk for thromboembolic events and hypertension consistent 
with previous estimates (Table 25). Data for seizures are also consistent with previous meta-
analyses, showing no effects of ESA on seizures (Table 25). Of note is that all adverse 
effects are relatively rare compared to other outcomes considered in this report (eg. RBCT, 
Hb change and mortality). 
The PenTAG analyses suggest an increased risk of pruritus; a significant diffrence between 
patients treated with ESA compared to participants in control arms was found (RR 2.04; 95% 
CI 1.11 to 3.75). In comparision, the Cochrane review (Tonia and colleagues, 2012)10 did 
not find significant diffrences between patients treated with ESA and in control arms (RR 
1.49; 95% CI 0.99 to 2.24). It must be highlighted, that both the current review and the 
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Cochrane review (Tonia and colleagues, 2012)10 combined events of skin rash, irritation 
and pruritus, in the meta-analyses. However, the rates of skin rash, irritation and pruritus 
may differ and the way this outcome has been defined may be the cause of the marked 
variation in event rates.. 
Also the summary estimate for risk of thrombocytopenia/haemorrhage associated with ESA 
treatment found in the PenTAG review was RR of 0.93 (RR 0.93; 95% CI 0.65 to 1.34) 
suggesting that treatment with ESAs in patients with cancer indused anaemia did not have 
an effect on thrombocytopenia/haemorrhage.  However the Cochrane review (Tonia and 
colleagues, 2012)10 found RR of 1.21 (RR 1.21; 95% CI 1.04 to 1.42) suggesting 
detrimental effects of ESA on thrombocytopenia/haemorrhage. 
It must be emphasised that the current analyses included only studies complying with the 
licenced ESA dose, while the Cochrane review did not apply any restrictions regarding the 
ESA posology. However, these results should be interpreted with caution, see Section 4.2.7) 
for more details. 
A graphical summary of study characteristics and results for the safety outcomes is 
presented in Figure 21. 
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Figure 21. Safety-related outcomes: Graphical summary  
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-
platinum; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: 
Darbe Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: 
Latin sq. des.; 11: Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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Figure 21. Safety-related outcomes: Graphical summary (continued) 
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-
platinum; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: 
Darbe Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: Latin 
sq. des.; 11: Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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Figure 21. Safety-related outcomes: Graphical summary (continued) 
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-
plat, non-platinum; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : 
Hb chg.: Darbe Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & 
PBO N=124; 10: Latin sq. des.; 11: Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO 
N=359. 
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Figure 21. Safety-related outcomes: Graphical summary (continued) 
 
Key: Chemo, chemotherapy: ?: unknown. Duration, recorded in weeks; Outcomes: Darbe, darbepoetin; Epo, epoetin; Haem, haematological; N: Number of participants; Non-plat, non-
platinum; Plat, platinum. 
Notes: 1: Hb chg.: Epo Alfa N=63; 3: HaemR & units: Epo Alfa N=66 & PBO N=66; 4: Hb chg.: rHuEPO N=28 & Control N=24; 5: Hb chg.: Epo Alfa N=64 & Control N=58; 6 : Hb chg.: 
Darbe Alfa N=17 & PBO N=6; 7: RBCT: Darbe Alfa N=167 & PBO N=165; 8: HaemR = participants with inc. ≥2 g/dl and/or Hb>12 g/dl; 9: RBCT: Epo Alfa N=251 & PBO N=124; 10: 
Latin sq. des.; 11: Hb chg.: Epo Beta N=138 & PBO N=142; 12: Hb chg.: licenced Epo Alfa N=34 & Control N=24; 13: Hb chg.: Darbe Alfa N=330 & PBO N=359. 
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4.2.7. Specific subgroup analyses 
Iron supplementation + 
erythropoiesis-stimulating 
agents 
In 16 of the included trials participants received iron 
supplementation. Usage varied among the studies; e.g. oral 
iron supplementation given as needed (dosage and trigger 
level differed between studies) or as standard, and/or i.v. 
iron supplementation (see Section 4.2.2.4, page 73). In 
addition, limited detail from the publications hinders the 
interpretation of this outcome. Subgroup analyses did not 
identify any significant differences between groups. 
  
People with any type of 
cancer receiving platinum-
based chemotherapy 
Five studies (Abels, 1993;54 Aravantinos, 2003;63 Ten 
Bokkel, 1998;47 Tjulandin, 2010;45 Vansteenkiste, 200272) 
evaluated the use of ESAs in people with any type of cancer 
receiving platinum-based chemotherapy. The point estimates 
for this subgroup are reported in Table 26. 
Table 26. People with any type of cancer receiving platinum-based chemotherapy; 
outcomes summary 
 
Anaemia-related outcomesa 
Hb change HaemR 
 
RBCT 
 
RBC units 
WMD 1.42 
95% CI 1.10 –1.75 
I2=0%; p=0.774 
Trials: 5 
RR 3.93 
95% CI 2.50–6.17 
I2=11.9%; p=0.321 
Trials: 3 
RR 0.52 
95% CI 0.37–0.72 
I2=60.0%; p=0.029 
Trials: 6 
WMD -1.11 
95% CI -1.58 – -0.64 
I2=0%; p=0.685 
Trials: 3 
Malignancy-related outcomes 
Tumour response Overall survival On-study mortality 
RR 0.91 
95% CI 0.62–1.33 
I2=NA 
Trials: 1 
HR 0.67 
95% CI 0.46 − 0.98 
I2=14.5%; p=0.319 
Trials: 4 
HR 0.63 
95% CI 0.34 – 1.18 
I2=36.0%; p=0.196 
Trials: 4 
Safety-related outcomes 
Thromboembolic 
events 
Hypertension Seizures Pruritus 
RR 1.06 
95% CI 0.51 – 2.20 
I2=0%; p=0.473 
Trials: 3 
RR 1.17 
95% CI 0.57–2.41 
I2=0%; p=0.808 
Trials: 5 
RR 1.19 
95% CI 0.33–4.38 
I2=0%; p=0.742 
Trials: 2 
RR 3.40 
95% CI 0.73–15.74 
I2=NA 
Trials: 1 
Key: CI, confidence intervals; Hb, haemoglobin; HR, hazard ratio; RBC, red blood cell; RBCT, red blood cell 
transfusion; RR, risk ratio; WMD, weighted mean difference. 
(a) the number of trials includes multiple experimental arms for some studies. 
 
 
Results from this subgroup analysis are consistent with 
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findings from the overall analysis for the anaemia-related 
outcomes; i.e. improved haemR and reduction in RBCT 
requirements and are different compared to the results 
erported in the Cochrane review (Tonia and colleagues, 
2012)10. Similar to the overall analysis, results for the 
malignancy-related outcomes (overall survival and on-study 
mortality) suggest less detrimental effects for people with 
chemotherapy induced anaemia treated with ESAs. These 
effects are also reflected in the decrease in the number of 
people experiencing thromboembolic events. However, 
these results should be interpreted with caution. The number 
of studies per subgroup is small, some of the changes are 
not statistically significant and the confidence intervals 
remain wide. It is also important to remember that multiple 
testing issues arise when subgroups are tested and that 
confidence intervals presented here have not been adjusted 
for multiple testing. 
  
People with head and neck 
malignancies receiving 
platinum-based 
chemotherapy 
No studies were identified that evaluated people with head 
and neck malignancies receiving platinum-based 
chemotherapy.  
  
Women with ovarian 
cancer and women with 
ovarian cancer receiving 
platinum-based 
chemotherapy 
Only one included study evaluated participants with ovarian 
cancer (Ten Bokkel, 199847); all participants (n=122) 
received platinum-chemotherapy. The outcomes measured 
were: Hb change, RBCT, RBC units transfused, and safety. 
The point estimates for these outcomes are reported in 
Table 27. Other included studies may have included a 
proportion of ovarian cancer patients; however, results are 
reported for the whole study population and not by 
malignancy type. 
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Table 27. Women with ovarian cancer and women with ovarian cancer receiving 
platinum-based chemotherapy; outcomes summary 
Anaemia-related outcomes 
HaemR Hb change 
 
RBCT RBC units 
NR WMD 1.23 
95% CI 0.48–1.98 
Trials: 1 
RR 0.11 
95% CI 0.03–0.47 
Trials: 1 
WMD -0.94 
95% CI -1.76 – -0.12 
Trials: 1 
Malignancy-related outcomes 
Tumour response Overall survival On-study mortality 
RR 0.91 
95% CI 0.62–1.33 
Trials: 1 
NR NR 
Safety-related outcomes 
Thromboembolic events Hypertension 
RR 3.70 
95% CI 0.18–74.51 
Trials: 1 
RR 0.11 
95% CI 0.03–0.47 
Trials: 1 
Key: Hb, haemoglobin; NR, not reported; RBC, red blood cell; RBCT, red blood cell transfusion; RR, risk ratio; 
WMD, weighted mean difference 
 
 
Data confirm results from prior analyses that ESAs reduce 
the risk of RBCT (RR 0.11 [95% CI 0.03–0.47), improve 
physiologic parameters such as Hb level (Hb change WMD 
1.23 (95% CI 0.48–1.98), but increase the risk for 
thromboembolic events (RR 3.70 (95% CI 0.18–74.51). 
Overall survival was not measured in this study.   
People unable to receive 
blood transfusions 
No trials were identified that evaluated people unable to 
receive blood transfusions. However, it is reasonable to 
assume that ESAs are likely to work in improving Hb in this 
sub-population. It is also reasonable to believe that if people 
can be supported through the period of life-threatening 
anaemia, their Hb level will recover; if ESAs are not allowed 
they run the risk of death. Fortunately this is a small group 
(Jehovah’s Witnesses and people who have multiple 
antibodies to red cells because they have required regular 
transfusions in the past).  
4.2.8. Other factors for consideration 
As previously stated, studies were eligible for inclusion in the systematic review if they used 
a licensed starting dose irrespective of how they dealt with other criteria stipulated by the 
licence. In addition to this we also retrospectively considered this criteria in combination with 
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inclusion Hb criteria (closer to the licence ≤11 g/dl and >11 g/dl), and target Hb (closer to the 
licence ≤13 g/dl and >13 g/dl). 
Compared to the Cochrane review (Tonia and colleagues, 2012)2 and the previous HTA 
review (Wilson and colleagues, 2007)1 a trend associated with the administration of ESAs 
according to licence recommendations was noticed. It appeared that the effectiveness of 
some outcomes was improved when ESAs were evaluated closer to their licenced 
indications; e.g. dose, inclusion Hb level (≤11 g/dl), and/or target Hb leve l (≤13 g/dl). The 
results for all outcomes as defined by these aspects are summarised in Table 28, and the 
effectiveness estimates were consistent with previously reported estimates for the anaemia-
related outcomes (Table 19). 
The effectiveness of malignancy-related outcomes did appear to be affected by the licence 
application and point estimates were notably different to those reported in previous analyses 
(Table 22 and Table 28). Compared to the Cochrane review (Tonia and colleagues, 
2012)10 which reported a detrimental effect of ESAs on survival and on-study mortality, the 
PenTAG review did not identify any significant differences between the ESA and control 
groups. In addition, in studies evaluating ESAs closest to their licenced indications the point 
estimate decreased (suggesting lower mortality in patients taking ESA) (Table 28). However, 
these results should be interpreted with caution, as the point estimates are not statistically 
significant and the confidence intervals around the estimate remain wide.  
Similarly, although results for tumour response from the PenTAG review agree with the 
Cochrane review (Tonia and colleagues, 2012),10 the closer the studies complied with the 
licenced administration of ESAs, the larger the point estimate (suggesting better tumour 
response in patients taking ESA) (Table 28). Again, this estimate should be interpreted with 
caution as they are not statistically significant and the confidence intervals around the 
estimate are very wide. 
Safety outcomes were also affected by the application of the licence (Table 25 and Table 
28). The point estimates of pruritus and hypertension did not appear to be affected by the 
licence application and are consistent across the subgroup analyses (Table 28), suggesting 
increase in pruritus and hypertension events in participants taking ESA compared to 
controls. Of note though is that the increase in pruritus was not found significant by the 
Cochrane review (Tonia and colleagues, 2012).10 
In addition, the Cochrane review (Tonia and colleagues, 2012)10 found a significant 
increase in thromobocytopenia/haemorrhage events, while the PenTAG review did not 
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identify any significant differences between the ESA and control groups (Table 28). Overall, 
the effectiveness of thromobocytopenia/haemorrhage and seizures does not appear to be 
affected by the application of licence (Table 28).  
Importantly, although results from the PenTAG review for thromboembolic events agree with 
the Cochrane review (Tonia and colleagues, 2012),10 suggesting an increase in 
thromboembolic events in patients with ESA compared to controls, the closer the studies 
were to the licence recommendations, the smaller the point estimates (suggesting fewer 
detrimental effects of ESA) (Table 28). Interestingly, the increase in thromboembolic events 
in patients taking ESA compared to controls is no longer significant (Table 28). The 
confidence intervals around the estimate are wide.  
In summary, there appears to be some limited evidence to suggest that if the licenced 
recommendations for ESA administration are followed, there are no detrimental effects of 
ESA on-study mortality or on overall mortality in patients with chemotherapy induced 
anaemia. These effects are consistent with an improved tumour response and a decrease in 
the number of thromboembolic events. However, these analyses must be interpreted with 
caution. The number of studies per subgroup is small, some of the changes are not 
statistically significant and the confidence intervals remain wide. The analyses may not have 
statistical power to detect the effects of license application on the effectiveness of outcomes, 
if such effects exist. It should also be noted that this is a difficult area of assessment, 
especially in a heterogenous mix of tumour types. Furthermore, we have not sought to 
address multiple testing issues which arise when considering subgroups and so inference is 
not straightforward.
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Table 28. Effectiveness as per licence recommendations; subgroup analyses using Hb subgroups results from Littlewood and colleagues, 2001 
and Vansteenkiste and colleagues, 2002 
 Starting dose criteria met Starting dose criteria met  and 
double blind RCT 
Starting dose criteria met  and 
inclusion Hb ≤11 g/dl 
Starting dose criteria met, 
inclusion Hb ≤11 g/dl and 
double blind RCT 
Starting dose criteria met, 
inclusion Hb ≤11 g/dl and 
target Hb ≤13 g/dl 
Outcome   N ES 
(95% CI) 
I2; p N ES 
(95% CI) 
I2; p N ES (95% CI) I2; p N ES (95% CI) I2; p N ES (95% CI) I2; p 
Hb 
changed,e 
18 WMD 1.59  
(1.33−1.84) 
75.9%;  
p<0.01 
13 WMD 1.70  
(1.43–1.97) 
64.9%;  
p<0.01 
13 WMD 1.52 
(1.30–1.75) 
48.1%;  
p=0.03 
11 WMD 1.59 
(1.35–1.84) 
46.4%;  
p=0.05 
3 WMD 1.50  
(1.16–1.83) 
0%;  
p=0.80 
HaemR 
a,d,e 
13 RR 3.29 
(2.81–3.85) 
13.4%;  
p=0.31 
12 RR 3.30 
(2.77–3.93) 
19.5%;  
p=0.25 
12 RR 3.20 
(2.78–3.68) 
2.0%;  
p=0.43 
11 RR 3.20 
(2.74–3.75) 
8.9%;  
p=0.36 
3 RR 3.06 
(2.28–4.09) 
0%;  
p=0.79 
RBCTb,d,e 26 RR 0.61 
(0.55−0.68) 
22.4%;  
p=0.15 
16 RR 0.64 
(0.58−0.72) 
6.4%;  
p=0.38 
16 RR 0.64 
(0.57–0.71) 
7.3%;  
p=0.37 
14 RR 0.66
(0.59–0.74) 
0%;  
p=0.52 
3 RR 0.50 
(0.33–0.77) 
0%;  
p=0.92 
Unitsc,d 12 WMD -0.87 
(-1.24–-0.50) 
55.6%;  
p=0.01 
9 WMD -0.9
(-0.93–-0.36) 
28.0%;  
p=0.20 
9 WMD -0.99 
(-1.41–-0.56) 
56.2%;  
p=0.01 
8 WMD -0.63
(-0.79–-0.47) 
0.6%;  
p=0.43 
1 WMD -0.56  
(-0.74–-0.39) 
NA 
Tumour 
response 
7 RR 1.10  
(0.86–1.41) 
37.5%;  
p=0.14 
4 RR 1.50 
(1.01–2.23) 
21.5%;  
p=0.28 
2 RR 1.60  
(0.88–2.90) 
0%;  
p=0.70 
2 RR 1.60  
(0.88–2.90) 
0%;  
p=0.70 
0 NA NA 
Overall 
survivald,e 
18 HR 0.97  
(0.83–1.13) 
42.4%;  
p=0.03 
11 HR 0.92 
(0.75–1.13) 
52.4%; 
p=0.02 
10 HR 0.91  
(0.70–1.20) 
51.7%;  
p=0.03 
9 HR 0.87 
(0.65–1.15) 
53.7%;  
p=0.03 
3 HR 0.50  
(0.20–1.23) 
29.7%;  
p=0.24 
On study 
mortalityd,e 
14 HR 0.86  
(0.67–1.11) 
16.4%; 
p=0.27 
11 HR 0.86  
(0.63–1.17) 
33.0%; 
p=0.14 
10 HR 0.89  
(0.61–1.30) 
37.7%;  
p=0.11 
9 HR 0.86 
(0.56–1.32) 
44.5%;  
p=0.07 
3 HR 0.50  
(0.20–1.23) 
29.7%;  
p=0.24 
T’embolic 
eventsd 
14 RR 1.46 
(1.07–1.99) 
0%;  
p=0.73 
9 RR 1.24 
(0.81–1.90) 
0%;  
p=0.55 
7 RR 1.29  
(0.66–2.54) 
12.2%;  
p=0.34 
7 RR 1.29  
(0.66–2.54) 
12.2%; 
p=0.34 
1 RR 0.32  
(0.01–7.74) 
NA 
HTNd,e 12 RR 1.80 
(1.14–2.85) 
0%;  
p=0.79 
9 RR 1.70
(1.05–2.76) 
0%;  
p=0.65 
9 RR 1.68 
(1.03–2.74) 
0%;  
p=0.64 
8 RR 1.61  
(0.98–2.64) 
0%;  
p=0.66 
3 RR 2.19  
(0.53–9.12) 
16.8%;  
p=0.30 
T’cytopeni
a/haemor 
7 RR 0.93  
(0.65–1.34) 
0%;  
p=0.81 
5 RR 0.89 
(0.57–1.39) 
0%;  
p=0.58 
2 RR 0.73  
(0.37–1.46) 
0%;  
p=0.41 
1 RR 1.10  
(0.33–3.64) 
NA 0 NA NA 
Seizuresd 2 RR 1.19  
(0.33–4.38) 
0%;  
p=0.74 
2 RR 1.19  
(0.33–4.38) 
0%;  
p=0.74 
2 RR 1.19  
(0.33–4.38) 
0%;  
p=0.74 
2 RR 1.19  
(0.33–4.38) 
0%;  
p=0.74 
0 NA NA 
Pruritus 6 RR 2.04 
(1.11–3.75) 
0%;  
p=0.87 
3 RR 2.20 
(1.05–4.58) 
0%;  
p=0.66 
3 RR 2.20 
(1.05–4.58) 
0%;  
p=0.66 
3 RR 2.20 
(1.05–4.58) 
0%;  
p=0.66 
1 RR 1.78  
(0.74–4.26) 
NA 
Key: HaemR, haematological response; Haemor, haemorrhage; Hb, haemoglobin; HTn, hypertension; NA, not applicable; RBCT, red blood cell transfusion; Units, units transfused per participant; RR, risk ratio; 
HR, hazard ratio; T’cytopenia, thrombocytopenia; T’embolic, thromboembolic; WMD, weighted mean difference. 
Notes: (a) Using Littlewood and colleagues, 2001 Hb subgroups; (b) Using Littlewood and colleagues, 2001 and Vansteenkinste and colleagues, 2002 Hb subgroups; (c) Using Vansteenkinste and 
colleagues, 2002 Hb subgroups; (d) Abels and colleagues, 1993 reported data for participants on plat-based and non-plat based chemotherapy which were combined; (e) Tjulandin and colleagues, 2010 
reported data for erythropoietin beta and theta which were combined. 
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4.3. Summary 
KEY POINTS 
 From a total of 1,458 titles and abstracts screened 11 systematic reviews (reported in 
14 publications), and 23 RCTs (reported in 35 publications), were found that matched 
the inclusion criteria and were considered ‘within licence’ based on the start dose 
administered 
 Of note none of the included studies evaluated ESAs entirely within the remit of their 
marketing authorisations; in particular start and target haemoglobin levels, and 
stopping rules were all generally higher than specified in the licence. This could be 
due to the fact that the majority of studies (82%) were initiated before the changes to 
the licence in 2008 
 Overall the included trials were of moderate-to-poor quality. All are flawed due to 
reporting issues but others more substantially. For most of the studies it was difficult 
to make a general assessment about quality due to reporting omissions. Most 
notably, all trials lacked clarity in the reporting of allocation methods (the procedure 
for randomisation and/or allocation concealment).  
 Pooled estimates for anaemia-related outcomes were consistent with previous 
estimates in terms of both haematological response and requirement for RBCT in 
favour of ESA treatment  
 The HR for survival was 0.97 (95% CI 0.83, 1.13) although the Forest plot suggested 
that there was a tendency for smaller studies to favour treatment. However, this 
estimate is subject to uncertainty and no definitive conclusions can be drawn from 
this 
 The HR for on-study mortality (deaths occurring up to 30 days after the active study 
period) was 0.86 (95% CI 0.67, 1.11).  
 Overall, pooled data suggest increased risk for thromboembolic events, hypertension, 
seizure and rash consistent with previous estimates. The risk for 
thrombocytopenia/haemorrhage associated with ESA treatment remains unclear, and 
the data were insufficient to rule out detrimental effects 
 Only one study evaluated the use of ESAs in women with ovarian cancer. All 
participants in this study received platinum-based chemotherapy. Subgroup analyses 
of platinum-based chemotherapy in people with any type of cancer showed a trend 
for a slight benefit associated with ESA treatment and on-study mortality or overall 
survival in patients with chemotherapy-induced anaemia. However, these results 
should be treated with caution due to the small number of studies included in the 
analysis. 
 No studies were identified that considered the use of ESAs among people unable to 
receive RBCT. However, it is reasonable to assume that ESAs are likely to work in 
improving Hb in this sub-population. It is also reasonable to believe that if the patients 
can be supported through the period of life-threatening anaemia, their Hb level will 
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recover; if ESAs are not allowed they run the risk of death. 
 A trend based on adhering to the conditions of licence was noticed; i.e. start dose + 
include Hb level and start dose + include Hb level + target Hb level. There appears to 
be some limited evidence to suggest that if the licenced recommendations for ESA 
administration are followed, there are no detrimental effects of ESA on-study mortality 
or on overall mortality in patients with chemotherapy induced anaemia. These effects 
are consistent with improved tumour response and a decrease in the number of 
thromboembolic events. However, these results should be interpreted with caution, as 
the point estimates are not statistically significant and the confidence intervals around 
the estimate remain wide. Furthermore, we have not sought to address multiple 
testing issues which arise when considering subgroups and so inference is not 
straightforward. 
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 Assessment of quality of life 
Anaemia is often associated with cancer, either due to the disease itself or the subsequent 
treatment. Therefore, the patient may experience exhaustion, fatigue, weakness, impaired 
concentration, respiratory distress, and chest pain which will in turn, significantly impact 
HRQoL.68 Since ESAs may relieve CIA by increasing Hb levels, HRQoL is a particular 
outcome of interest for the interventions under review. 
5.1. Tools to Measure HRQoL 
A range of questionnaires are used to measure HRQoL and subsequent changes according 
to treatment. The scales are summarised in Table 29 (page 158), however, this review 
focuses on the Functional Assessment of Cancer Therapy (FACT) tool, since it is the most 
widely used, validated scale employed to measure cancer related fatigue (CRF) and 
anaemia. This tool, which asks patients to focus on HRQoL issues over the previous seven 
days, is part of a collection of HRQOL questionnaires beginning with a generic questionnaire 
called the Functional Assessment of Cancer Therapy-General (FACT-G).  There are now 
over 50 different scales and symptom indexes, some of which have been modified over time. 
The FACT scales used in this review are highlighted in Figure 22 and included in Appendix 
M. It should be noted that since 1997, the scale has been known as FACIT (Functional 
Assessment of Chronic Illness Therapy). 
Figure 22. Overview FACT scales used in this review 
 
Key: FACT, Functional Assessment Cancer Therapy (-An, Anaemia; -F, Fatigue; -G, General) 
 
Using both anchor-based and distribution-based methods to analyse FACT-F, FACT-G, and 
FACT-An data on three samples of patients (n=50, n=131 and n=2,402),96 determined the 
clinically important difference to be FACT-F = 3.0, FACT-G =4.0 and FACT-An = 7.0.   
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Table 29. Summary of scales included in this review 
Scale Type of HRQoL 
instrument 
Domains Items Implication of value 
FACT-General  
(FACT-G)97 
Specific for use with 
patients of any tumour 
type 
Physical wellbeing 
Social/family wellbeing 
Emotional wellbeing 
Functional wellbeing 
27 Items 
Response between 0 and 4 for each 
question  
Maximum score 108 
Increased score indicates improved 
HRQoL 
FACT-Fatigue 
(FACT-F)97 
Symptom specific (fatigue) Fatigue related questions often used 
in isolation or as a component of 
other FACT questionnaires 
13 Items  
Response between 0 and 4 for each 
question 
Maximum score 52 
Increased score indicates improved 
HRQoL 
FACT-Anaemia 
(FACT-An)97 
Symptom specific (fatigue 
or anaemia) 
Composed of FACT-G, FACT-F and 
FACT-An-An 
47 Items 
Response between 0 and 4 for each 
question 
Maximum score 188 
Increased score indicates improved 
HRQoL 
FACT-An-An97 Symptom specific 
(additional concerns for 
anaemia) 
Anaemia related questions which do 
not include fatigue 
7 Items 
Response between 0 and 4 for each 
question 
Maximum score 0 to 28 
Increased score indicates improved 
HRQoL 
SF-3698 Generic Physical functioning 
Role-physical 
Bodily pain 
General health 
Vitality 
Social functioning 
Role-emotional 
Mental health 
Questions compare experiences to a 
time in the past e.g.; four weeks ago. 
36 Items 
Each scale is directly transformed 
into a 0–100 scale 
The lower the score, the greater the 
disability 
Nottingham Health 
Profile (NHP)99 
Generic Sleep 
Energy level  
38 Items 
Scores on first component are 
The higher the score, the lower the 
HRQoL, however, it should be noted 
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Physical mobility 
Pain 
Emotional reactions 
Social isolation 
weighted to give a score between 0 
and 100. 
the NHP was not originally intended 
to measure HRQoL and is not 
considered highly sensitive.1,100 
Cancer Linear 
Analogue Scale or 
Linear Analogue Self 
Assessment 
(CLAS/LASA)101,102 
Specific for cancer patients 
to indicate feelings  
Symptoms and effects of disease and 
treatment 
Psychological consequences 
Physical indices 
Personal relationships 
25 Items 
100 mm lines 
Increased score indicates improved 
HRQoL 
Brief Symptom 
Inventory (BSI)103 
Generic 
psychiatry/psychology 
Somatisation 
Obsessive-compulsive 
Interpersonal sensitivity 
Depression 
Anxiety 
Hostility 
Phobic anxiety 
Paranoid ideation 
Psychoticism 
Global severity index 
Positive symptom distress index 
Positive symptom total 
53 Items 
Scores between 0 and 4 
Maximum score 212 
The higher the score the greater the 
distress 
Psychological Distress 
Inventory (PDI)104 
Specific for cancer patients Reactive anxiety to cancer and its 
therapies 
Reactive depression 
Emotional reactions 
13 Items 
Score between 0 and 5 
A higher score indicates a higher 
level of distress 
The European 
Organisation for 
Research and 
Treatment of Cancer 
Quality of Life 
Questionnaire 
(EORTC-QLQ-C30)105 
Specific for cancer patients A range of questions including daily 
activities, sleep, pain, mobility, 
emotions and health. 
30 Item 
28 items score between 0 and 4 ans 
2 items between 0 and 7 
Maximum score of 126 
The higher the score, the higher the 
level of functioning 
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5.2. Methods 
The search strategy was based on the strategy used in the previous MTA on this topic by 
Wilson and colleagues (2007)1 with additional search terms for epoetin theta, epoetin zeta 
and corresponding drug brand names. It combined free-text and MeSH terms for epoetin 
(generic and brand names), cancer and anaemia using the AND Boolean operator. A search 
filter was developed by an information scientist to retrieve HRQoL studies, ensuring an 
appropriate balance of sensitivity and specificity (see Section 4.2.1, page 66; and, Appendix 
B for further details).   
The database search results were exported to Endnote (X5) and de-duplicated using the 
software and manual checking. The search strategies and the numbers retrieved for each 
database are detailed in Appendix B.  After the reviewers (TJH and LL) completed the 
screening process, the bibliographies of included papers were scrutinised for further 
potentially includable studies.   
Inclusion criteria were the same as the main review (see Section 4.1.2, page 59). Data were 
tabulated and analysed by meta-analysis to provide an overview with an estimate of overall 
effect.  
5.3. Results 
5.3.1. Studies identified 
We screened the titles and abstracts of 1,268 unique references identified by the PenTAG 
searches and additional sources, and retrieved 221 papers for detailed consideration. Of 
these, 183 were excluded (a list of these items with reasons for their exclusion can be found 
in Appendix E). Update searches conducted on 2nd December 2013 yielded 61 titles and 
abstracts, none were considered eligible for inclusion. Forty one studies met the pre-
specified criteria set out in the protocol and were considered eligible for inclusion in the 
HRQoL review. At both stages, initial disagreements were easily resolved by consensus.  
We then re-assessed included studies (n=42) from the review conducted by Wilson and 
colleagues (2007).1 Of these, 11 primary studies reported in 15 publications were 
considered eligible for inclusion in the update of the HRQoL review (see Section 5.3.3.3, 
page 175). We identified one full paper (Boogaerts and colleagues, 2003) 52of an abstract 
(Coiffier and colleagues, 2001)53 included in the review by Wilson and colleagues 
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(2007).1 In addition, one study (Abels and colleagues, 1993)54 included in the previous HTA 
review was published in five papers; three were included in the previous review (Abels and 
colleagues, 1993;54 Case and colleagues, 1993;55 and, Henry and colleagues, 199456), 
and an additional two were identified when scrutinising the bibliographies of included studies 
(Henry and colleagues 199557; and, Abels and colleagues, 199658). 
Citations of the includable studies (including the 2012 Cochrane Review [Tonia and 
colleagues, 2012]10) were also searched and this process revealed one additional study: 
Patrick and colleagues (2003)60 relevant to the HRQoL review (see Section 5.3.3.5, page 
190). 
In total, 13 studies reported in 23 publications, and eight systematic reviews were included in 
the review. Of these studies six retrospective analyses and eight systematic reviews were 
identified in the updated searches. 
This process is illustrated in detail in Figure 23. 
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Figure 23. PRISMA flowchart: quality of life review 
 
Key: RCTs, randomised controlled trials; SRs, systematic reviews 
Notes: (a) ‘within licence’, based on the administration of ESAs at the licensed weight-based start dose 
5.3.2. Systematic reviews 
The update searches identified eight systematic reviews relevant to the review of HRQoL 
(Lawrence and colleagues, 2004106; Bokemeyer and colleagues, 2007107; Ross and 
colleagues, 2007108; Shehata and colleagues, 2008109; Wilson and colleagues, 20071; 
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Kvam and colleagues, 2009110; Minton and colleagues, 2010111; Tonia and colleagues, 
201210). Characteristics of the identified systematic reviews and quality appraisal are detailed 
in Appendix I. 
5.3.2.1.  Previous HTA review (Wilson and colleagues, 2007)1 
The HRQoL search undertaken by Wilson and colleagues (2007), identified 20 trials and 
used a vote counting method to summarise the data.1 It should be noted that a slightly 
broader population was investigated with any type of malignant disease included, 
irrespective of stage or previous therapy, whereas this review only included people receiving 
chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of 
transfusion as assessed by the patient’s general status (see Section 2.7.1, page 46; and 
Section 3.2, page 53).  
All of the trials published before 2000 (n=9) had a sample size of less than 100 and used 
unvalidated HRQoL instruments.  Of the remaining trials, ten used FACT, five used LASA 
and two used SF-36. A total of 3,185 patients were evaluated. 
Over half of the studies did not blind patients or physicians to treatment and over half did not 
include an ITT analysis or lost more than 10% of patient final evaluations. Wilson and 
colleagues (2007) consider blinding the most likely quality parameter to affect HRQoL 
scores, as patients may be prone to placebo effect.1 
Although overall, the vote-counting analysis showed a positive direction of effect in favour of 
ESAs on HRQoL, there was considered to be potential for a variety of within-study 
methodological problems due to missing data and shifts in patient responses over time due 
to repeat questionnaires.  
5.3.2.2.  Cochrane Review (Tonia and colleagues, 2012)1 0 
The Cochrane review undertaken by Tonia and colleagues (2012), also investigated the 
effect of ESAs on HRQoL in patients with cancer (see also Section 2.7.1.1, page 46).10 
Again, this was a slightly different population to the current review since it included 
participants diagnosed with malignant disease, using clinical and histological/cytological 
criteria, regardless of type or stage of the disease or previous therapy. Radiotherapy was 
also included in the current review only as an adjacent treatment to chemotherapy.  
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Tonia and colleagues (2012) focused on the FACT scales for measurement of HRQoL, 
since they considered this instrument and its subscales to have been widely used in ESA 
trials, have good responsiveness to change and good convergent and discriminant validity.10 
Twenty-three studies including 5,584 patients reported results on HRQoL, as measured with 
FACT-F, FACT-An 20 or FACT-An 47. In order to perform a meta-analysis for the FACT 
measures, means and SDs were extracted. Where no numerical data were given, attempts 
were made to either calculate or obtain the missing values. Table 30 lists the methods for 
those studies included in the current review. 
Table 30. Methods for obtaining unreported data by Tonia and colleagues (2012), in 
studies used for current review10 
Study Method of obtaining unreported data 
Boogaerts, 2003;52 Hedenus, 200316 No numerical data given, therefore means and/or SDs 
determined via graphs or figures. 
Littlewood 200168 No SDs provided, therefore previously published SDs by 
Tonelli and colleagues (2009),112 were used. 
Kotasek, 2003,46 Vansteenkiste, 
200272 
The mean and SDs reported in a meta-analysis by (Minton 
and colleagues, 2008111), were used. These data were not 
available in the publications and were obtained by the 
authors of the meta-analysis from the authors of the original 
studies or the pharmaceutical companies.  
Key: SD, standard deviation 
5.3.2.2.1.  FACT-F 13 subscale 
A total of 18 studies (4,695 patients) reported data for this outcome. The mean difference 
(MD) was 2.08 (95% CI 1.43 to 2.72). Heterogeneity between the included studies was 
moderate (I2=53%). A funnel plot showed significant asymmetry (p=0.02772) with over 
reporting of studies that showed beneficial effects of ESAs (note not performed in current 
review as <10 studies). (Other effects found, but in populations not relevant to current review 
- only studies relevant to current review are included here). The observed effect was larger in 
unblinded trials (MD 3.76, 95% CI 2.60 to 4.92) compared with double blind trials (MD 1.33, 
95% CI 0.56 to 2.10, p=0.0006). 
Overall, it appears that there is an effect on fatigue-related symptoms for patients with 
erythropoietin or darbepoietin compared with controls; this effect, however, did not reach the 
threshold for a clinically important difference defined as 3.0.96  
PenTAG     CONFIDENTIAL 
165 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
5.3.2.2.2.  FACT-An 20 
This scale is the anaemia subscale with 13 questions from FACT-F, plus seven anaemia 
specific questions. Six studies were included to give an estimated MD of 6.14 (95% CI 4.55 
to 7.73, n=1,085). There was no evidence for statistical heterogeneity between the studies (I2 
= 0%). ESAs were found to be beneficial reaching both clinical and statistical significance. 
5.3.2.2.3.  FACT-An 47 
Using 20 questions from the FACT-An subscale with 27 from the FACT-General scale. Nine 
included studies gave an estimated MD of 6.92 (95% CI 4.59 to 9.25, n=1815). 
Heterogeneity was high with I2 of 85%. Since one study reported an exceptionally high 
change for the treatment group, a sensitivity analysis was conducted where this study was 
excluded. The MD became 3.46 (95% CI 0.96 to 5.96, n=1715) with I2 of 0%. The result was 
still statistically significant (p=0.007) in favour of treatment; however, this was not considered 
likely to be clinically significant. 
5.3.2.3.  Cochrane Review (Minton and colleagues) (2010)1 1 3 
The objective of this update review was to assess the efficacy of drugs for the management 
of cancer related fatigue.111 ESAs were one of the interventions under investigation. 
Participants at any point of the cancer treatment spectrum were included. Eleven 
erythropoietin studies and four darbapoetin studies were included (n=2,801). Treatment was 
favoured with a small MD of -0.23 (95% CI 0.32 to -0.14). For studies using the FACT-F tool 
combined in a random effects model, a MD of -4.29 was estimated (95% CI-5.04 to -2.60). 
5.3.2.4.  Other systematic reviews 
A further five systematic reviews appraised HRQoL evidence for ESAs in patients with CRF. 
Additional details can be found in Appendix I.  
5.3.3. Primary and retrospective studies 
Thirteen trials measuring HRQoL were reported in 23 publications (study and baseline 
characteristics for these studies is detailed in Appendix G).  
Of these publications, 11 primary studies were included in the review by Wilson and 
colleagues (2007)1 (Abels and colleagues, 199354; Kurz and colleagues, 199767; Del 
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Mastro and colleagues, 199965; Thatcher and colleagues, 199948; Dammacco and 
colleagues, 200164; Littlewood and colleagues, 200168; Osterborg and colleagues 
200269; Vansteenkiste and colleagues, 200272; Boogaerts and colleagues, 200352; 
Hedenus and colleagues, 200316; Kotasek and colleagues, 200346).  
Abels and colleagues (1993)54 was reported in five publications the primary publication (also 
in Case and colleagues, 199355; Henry and colleagues, 199456; Henry and colleagues, 
199557; and Abels and colleagues, 199658) (see Section 5.3.1, page 160). 
Two new primary studies were identified in the update searches (Ray-Coquard and 
colleagues, 2009; Tjulandin and colleagues, 2011). Six retrospective studies were 
identified (Aapro and colleagues, 2004; Bajetta and colleagues, 2004; Patrick and 
colleagues, 2003; Osterborg and colleagues (2005) Littlewood and colleagues (2006); 
Vansteenkiste and colleagues (2004). (primary and multiple publications also detailed in 
Appendix H) 
5.3.3.1.  General description 
The summary characteristics for included studies in the HRQoL review can be found in 
Figure 25, page 197 and Appendix G. As mentioned in Wilson and colleagues (2007)1, all 
the trials published before 2000 had small sample sizes of less than 100 and used 
unvalidated questionnaires, such as VAS or NHP. The remaining trials, other than 
Dammacco and colleagues (2001)64 use one of the FACT scales. HRQoL instruments used 
in the studies are detailed in Table 32. 
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Table 31. Study characteristics for HRQoL 
Study year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia  
treatment 
Malignancy type  
and treatment 
HRQoL 
measures 
sought 
Incl. in 
Cochrane 
2012, Y/N 
WILSON AND COLLEAGUES, 2007: PRIMARY STUDIES  
Abels 
1993 
RCT 
 
Multiple pubs.: 
Abels 1996, 
Henry, 1995; 
Henry, 1994; 
Case, 1993 
n = 153/213 (analysed 
143/206)a 
Age, yrs: 61.2 ± 13.0 
n (%) Male: 102 (47.8) 
Hb BL g/dl: NR 
Epo mU/ml BL: 146 ± 260 
n = 200 (analysed 135/190) 
Age, yrs: 62.5 ± 12.3 
n (%) Male: 95 (47.5) 
Hb BL g/dl: NR 
Epo mU/ml BL: 149 ± 217 
Brand: rHuEPOb 
Dose: 150 IU/kg/TIW 
Dose adj.: NR 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wksc 
Follow-up: NR 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: ≤10.5 
g/dl) 
Disease: haem & solid  
Treatment: chemo, 
mixed 
VAS Y 
Boogaerts, 
2003 
ROL 
(Abstract – 
Coiffier, 2001 
included in 
Wilson and 
colleagues 
review) 
n = 133 
Age, yrs: 62 (24–85)* 
n (%) Male: 46 (35) 
Hb BL g/dl: 9.0 (5–13)* 
Epo mU/ml BL: 54 (7–
1,650)* 
n = 129 
Age, yrs: 62 (24–85)* 
n (%) Male: 52 (40) 
Hb BL g/dl: 9.2 (5–12)* 
Epo mU/ml BL: 58 (5–4,300)* 
Brand: Epoetin beta 
Dose: 150 IU/kg/TIW 
Dose adj.: Y  
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: NR 
SC Iron: Y, oral (as indicated by 
transferrin sat. level) 
G-CSF: NR 
RBCT trigger: Hb <8.5 g/dl 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: haem & solid 
Treatment: chemo, NR 
VAS, SF-36, 
FACT-F, FACT-
An-An 
Y 
Dammacco  
2001 
RCT 
 
NCT00270101; 
CR005911 
n = 69 
Age, yrs: 67 (43–80)* 
n (%) Male: 34 (49) 
Hb BL g/dl: 9.3 ± 1.27 
Epo mU/ml BL: 116 (18–
5,220)* 
n = 76 
Age, yrs: 65 (38–89)* 
n (%) Male: 31 (41) 
Hb BL g/dl: 9.6 ± 0.95 
Epo mU/ml BL: 93 (10–408)* 
Brand: Epoetin alfa 
Dose: 150 IU/kg/TIW 
Dose adj.: Y 
Dur. of epo tx: 12 
Dur. of trial: 12 wksc 
Follow-up: 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: Hb <8 g/dl 
(Hb incl. criteria level: <11.0 
g/dl) 
Disease: haem 
Treatment: chemo, 
mixedd 
CLAS, NHP Y 
Del Mastro  
1997 
ROL 
n = 31 
Age, yrs: 54 (31–68)* 
n (%) Male: NR 
Hb BL g/dl: 13.0 ± 0.7 
Epo mU/ml BL: 21.0 (0–
512)* 
n = 31 
Age, yrs: 56 (29–68)* 
n (%) Male: NR 
Hb BL g/dl: 13.1 ± 0.6 
Epo mU/ml BL: 25.5 (0–800)* 
Brand:rHuEPOb 
Dose: 150 IU/kg/TIW 
Dose adj.: Y 
Dur. of epo tx: 14 wks 
Dur. of trial: 14 wks 
Follow-up: 6 mths 
SC Iron: Y, oral iron (as indicated 
by serum iron, ferritin, & 
transferrin sat. levels) 
G-CSF: Y, 5 mcg/kg SC D4-
11; C1-5 
RBCT trigger: Hb <8 g/dl 
(Hb incl. criteria level: ≥12.0 
g/dl) 
Disease: solid (breast) 
Treatment: chemo, non-
plat 
PDI Y 
Hedenus  
2003 
RCT 
 
Multiple pubs.: 
Littlewood, 2006 
n = 176 (analysed 174)e 
Age, yrs: 64.8 (13.8) 
n (%) Male: 87 (50) 
Hb BL g/dl: 9.59 (1.22) 
Epo mU/ml BL: 68.99 (2.3–
1,522.7)* 
n = 173 (analysed 170) 
Age, yrs: 64.6 (12.2) 
n (%) Male:78 (46) 
Hb BL g/dl: 9.5 (1.21) 
Epo mU/ml BL: 54.49 (10.9–
3,169.1)* 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg/QWe 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 16 wks 
Follow-up: median ~11 
mths 
PBO Iron: prn 
G-CSF: NR 
RBCT trigger: Hb ≤8 g/dl prn
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: haem 
Treatment: chemo, NR 
FACT-F Y 
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Kotasek  
2003 
RCT 
 
Dose response 
study, 5 
unlicensed 
doses excluded 
n = 17/198a,e 
Age, yrs: 58.3 (11.9)a 
n (%) Male: 56 (28)a 
Hb BL g/dl: 9.93 (1.00)a 
Epo mU/ml BL: NR 
n = 51 
Age, yrs: 56.2 (12.4) 
n (%) Male:16 (31) 
Hb BL g/dl: 9.87 (1.12) 
Epo mU/ml BL: NR 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg/QWe 
Dose adj.: Y, 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wksc 
Follow-up: Unclear 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: solid (breast, 
gynae, GI, lung) 
Treatment: chemo, NR 
FACT-F Y 
Kurz  
1997 
RCT 
n = 23 
Age, yrs: 54.4 ± 9.7 
n (%) Male: NR 
Hb BL g/dl: 9.88 ± 0.8 
Epo mU/ml BL: NR 
n = 12 
Age, yrs: 52.7 ± 7.5 
n (%) Male: NR 
Hb BL g/dl: 9.85 ± 0.60 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 U/kg/TIW 
Dose adj.: Y,  
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: NR 
PBO Iron: Y, i.v. iron 
G-CSF: NR 
RBCT trigger: Hb <8 g/dl 
(Hb incl. criteria level: <11.0 
g/dl) 
Disease: solid (overy, 
cervix, uterus) 
Treatment: chemo, 
mixedh 
VAS Y 
Littlewood  
2001 
RCT 
 
EPO-INT-1 
 
Multiple pubs.: 
Aapro, 2004; 
Bajetta, 2004; 
Patrick, 2003 
n = 251 (analysed 244) 
Age, yrs: 58.3 ± 14.2 
n (%) Male: 85 (34) 
Hb BL g/dl: 9.9 ± 1.1 
Epo mU/ml BL: NR 
n = 124 (analysed 115) 
Age, yrs: 59.5 ± 13.9 
n (%) Male: 39 (31) 
Hb BL g/dl: 9.7 ± 1.1 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 U/kg/TIW
Dose adj.: Y 
Dur. of epo tx: up to 28 
wks 
Dur. of trial: up to 28 
wks 
Follow-up: 12-mthf 
PBO Iron: Y, oral (or i.v. as 
indicated by transferrin sat. 
level) 
G-CSF: No 
RBCT trigger: Hb <8 g/dl prn 
(Hb incl. criteria level: ≤10.5 
g/dL or >10.5 but ≤12.0 g/dl 
after a ≥1.5 g/dl decrease in 
Hb) 
Disease: solid + haem
Treatment: chemo, non-
plat 
FACT-F, FACT-
G, FACT-An-An, 
CLAS 
Y 
Osterborg  
2002 
2005, follow-up 
RCT 
n = 173 (analysed 170) 
Age, yrs: 63 (32–86)* 
n (%) Male: 91 (54) 
Hb BL g/dl: 9.2 ± 1.1 
Epo U/L BL: 38 (20–72)* 
n = 176 (analysed 173) 
Age, yrs: 64 (28–83)* 
n (%) Male: 82 (47) 
Hb BL g/dl: 9.3 ± 1.0 
Epo U/L BL: 41 (21–77)* 
Brand: Epoetin beta 
Dose: 150 U/kg/TIW 
Dose adj.: Y  
Dur. of epo tx: 16 wks 
Dur. of trial: up to 16 
wks 
Follow-up: min 17.5 
mths both tx grps 
PBO Iron: Y, i.v. (or oral if i.v. 
precluded) 
G-CSF: NR 
RBCT trigger: Hb <8.5 g/dl or 
inc.in Hb <0.5 g/dl vs BL 
(Hb incl. criteria level: <10 
g/dlg) 
Disease: haem 
Treatment: chemo, non-
plat 
FACT-F, FACT-
G, FACT-An, 
FACT-An-An 
Y 
Thatcher  
1999 
ROL 
 
Multiple 
treatment arms, 
1 unlicensed 
dose excluded 
n = 42 e 
Age, yrs: 59 (43–72)* 
n (%) Male: 26 (61.9) 
Hb BL g/dl: 13.7 (10.7–16.1) 
Epo mU/ml BL: NR 
n = 44 
Age, yrs: 60 (39–74)* 
n (%) Male: 27 (61.3) 
Hb BL g/dl: 13.4 (10.9–16.4) 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 U/kg/TIW 
Dose adj.: Y 
Dur. of epo tx: 26 wks  
Dur. of trial: 26 wks 
Follow-up: NR 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: prn 
(Hb incl. criteria level: ≥10.5 
g/dl) 
Disease: solid (SCLC) 
Treatment: chemo: 
mixedh 
EORTC-QLQ-
C30 
Y 
Vansteenkiste 
2002 
RCT 
 
Multiple pubs.: 
Vansteenkiste, 
2004 
n = 156 
Age, yrs: 61.6 (9.2) 
n (%) Male: 111 (71) 
Hb BL g/dl: 10.28 (1.08) 
Epo mU/ml BL: 53.17 
(58.87)i 
n = 158 
Age, yrs: 61.3 (8.8) 
n (%) Male: 116 (73) 
Hb BL g/dl: 9.93 (1.01) 
Epo mU/ml BL: 51.10 (71.72) i 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg/QW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: 12 mths 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: Hb ≤8 g/dl  
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: solid (lung) 
Treatment: chemo: plat 
FACT-F Y 
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PENTAG REVIEW: STUDY CHARACTERISTICS: PRIMARY STUDIES 2004 to CURRENT  
Ray-Coquard  
2009 
ROL 
 
ELYPSE study 
n = 110 
Age, yrs: 62.7 (11.6) 
n (%) Male: 52 (47.3) 
Hb BL g/dl: 10 (1.2) 
Epo mU/ml BL: NR 
n = 108 
Age, yrs: 61.7 (11.6) 
n (%) Male: 41 (38) 
Hb BL g/dl: 10 (1.2) 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 U/kg/TIW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: 12 mths 
(95% CI 12–12.4)* 
SC Iron: Y, oral  
G-CSF: Y 
RBCT trigger: NR 
(Hb incl. criteria level: ≤12.0 
g/dl) 
Disease: solid & haem 
Treatment: chemo: NR 
EPRTC-QLQ-
C30 
Y 
Tjulandin  
2011 
RCT 
n = 95 
Age, yrs: 56.9 ± 14.7 
n (%) Male: 30 (31.6) 
Hb BL g/dl: 9.2 ± 1.3 
Epo mU/ml BL: NR 
n = 91 
Age, yrs: 55.8 ± 14.3 
n (%) Male: 34 (37.4) 
Hb BL g/dl: 9.1 ± 1.3 
Epo mU/ml BL: NR 
Brand: Epoetin theta 
Dose: 20,000 U/QW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: NR 
PBO Iron: Y, not specified 
G-CSF: NR 
RBCT trigger: ≤8.5 g/dL 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: solid & haem 
Treatment: chemo: non-
plat 
FACT-G, FACT-
F, FACT-An 
Y 
MULTIPLE PUBLICATIONS: PENTAG REVIEW  
Aapro  
2004 
 
Primary study: 
Littlewood, 2001 
n = 251 (analysed 244) 
Age, yrs: 58.3 ± 14.2 
n (%) Male: 85 (34) 
Hb BL g/dl: 9.9 ± 1.1 
Epo mU/ml BL: NR 
n = 124 (analysed 115) 
Age, yrs: 59.5 ± 13.9 
n (%) Male: 39 (31) 
Hb BL g/dl: 9.7 ± 1.1 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 U/kg/TIW
Dose adj.: Y 
Dur. of epo tx: up to 28 
wks 
Dur. of trial: up to 28 
wks 
Follow-up: 12-mthf 
PBO Iron: Y, oral or i.v.  
G-CSF: No 
RBCT trigger: Hb <8 g/dl prn 
(Hb incl. criteria level: ≤10.5 
g/dL or >10.5 but ≤12.0 g/dl 
after a ≥1.5 g/dl decrease in 
Hb) 
Disease: solid + haem
Treatment: chemo, non-
plat 
FACT-G, FACT-
F, FACT-An-An 
N 
Bajetta 
2004 
 
Primary study: 
Littlewood, 2001 
SUBGROUP: BREAST POP 
n = 78 (analysed 75) 
Age, yrs: 54.6 
n (%) Male: 1 (1) 
Hb BL g/dl: 10.0 ± 1.6 
Epo mU/ml BL: NR 
SUBGROUP: BREAST POP 
n = 36 (analysed 35) 
Age, yrs: 52.9 
n (%) Male: all female 
Hb BL g/dl: 9.9 ± 1.01 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 U/kg/TIW
Dose adj.: Y 
Dur. of epo tx: up to 28 
wks 
Dur. of trial: up to 28 
wks 
Follow-up: 12-mthf 
PBO Iron: Y, oral (or i.v. as 
indicated by transferrin sat. 
level) 
G-CSF: No 
RBCT trigger: Hb <8 g/dl prn 
(Hb incl. criteria level: ≤10.5 
g/dL or >10.5 but ≤12.0 g/dl 
after a ≥1.5 g/dl decrease in 
Hb) 
Disease: solid + haem
Treatment: chemo, non-
plat 
FACT-F, FACT-
G, CLAS 
N 
Littlewood  
2006 
 
Primary study: 
Hedenus, 2003 
SUBGROUP: HRQoL SAMPLE 
n = 303l 
Age, yrs: 64.8 (12.8) 
n (%) Male: 146 (48.2) 
Hb BL g/dl: 9.6 (1.2) 
Epo mU/ml BL: NR 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg/QW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: median ~11 
mths 
PBO Iron: prn 
G-CSF: NR 
RBCT trigger: Hb ≤8 g/dl  
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: haem 
Treatment: chemo, NR 
FACT-F, D&A 
(from BSI) 
N 
Osterborg  
2005, follow-up 
of Osterborg 
2002 
RCT 
 
Primary study: 
n = 173 (analysed 170) 
Age, yrs: 63 (32–86)* 
n (%) Male: 91 (54) 
Hb BL g/dl: 9.2 ± 1.1 
Epo U/L BL: 38 (20–72)* 
n = 176 (analysed 173) 
Age, yrs: 64 (28–83)* 
n (%) Male: 82 (47) 
Hb BL g/dl: 9.3 ± 1.0 
Epo U/L BL: 41 (21–77)* 
Brand: Epoetin beta 
Dose: 150 U/kg/TIW 
Dose adj.: Y  
Dur. of epo tx: 16 wks 
Dur. of trial: up to 16 
wks 
Follow-up: min 17.5 
PBO Iron: Y, oral iron, or i.v. iron if 
transferrin saturation ≤20% 
G-CSF: No 
RBCT trigger: Hb <8.5 g/dl or 
inc.in Hb <0.5 g/dl vs BL 
(Hb incl. criteria level: <10 
g/dlg) 
Disease: haem 
Treatment: chemo, non-
plat 
FACT-F, FACT-
G, FACT-An, 
FACT-An-An 
Y 
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Osterborg, 2002 mths both tx grps 
Patrick 
2003 
 
Primary study: 
Littlewood, 2001 
n = 251 (analysed 244) 
Age, yrs: 58.3 ± 14.2 
n (%) Male: 85 (34) 
Hb BL g/dl: 9.9 ± 1.1 
Epo mU/ml BL: NR 
n = 124 (analysed 115) 
Age, yrs: 59.5 ± 13.9 
n (%) Male: 39 (31) 
Hb BL g/dl: 9.7 ± 1.1 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 U/kg/TIW
Dose adj.: Y 
Dur. of epo tx: up to 28 
wks 
Dur. of trial: up to 28 
wks 
Follow-up: 12-mthf 
PBO Iron: Y, oral (or i.v. as 
indicated by transferrin sat. 
level) 
G-CSF: No 
RBCT trigger: Hb <8 g/dl prn 
(Hb incl. criteria level: ≤10.5 
g/dL or >10.5 but ≤12.0 g/dl 
after a ≥1.5 g/dl decrease in 
Hb) 
Disease: solid + haem
Treatment: chemo, non-
plat 
SF-36, FACT-F, 
FACT-G, CLAS 
N 
Vansteenkiste 
2004 
 
Primary study: 
Vansteenkiste, 
2002 
SUBGROUP <10 g/dl 
n = 51 
Age, yrs: 63 (47–76) 
n (%) Male: 42 (82) 
Hb BL g/dl: 9.2 (7.4–9.9) 
Epo mU/ml BL: 50.3 (13.3–
739.8) 
SUBGROUP ≥10 g/dl 
n = 105 
Age, yrs: 62 (39–80) 
n (%) Male: 69 (66) 
Hb BL g/dl: 10.8 (10.0–13.6) 
Epo mU/ml BL: 28.8 (12.0–
106.1) 
SUBGROUP <10 g/dl 
n = 69 
Age, yrs: 60 (42–78) 
n (%) Male: 52 (75) 
Hb BL g/dl: 9.2 (6.6–9.9) 
Epo mU/ml BL: 52.2 (14.3–
1,998.6) 
SUBGROUP ≥10 g/dl 
n = 89 
Age, yrs: 62 (36–76) 
n (%) Male: 64 (72) 
Hb BL g/dl: 10.6 (10.0–12.3) 
Epo mU/ml BL: 30.2 (12.0–
109.8) 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg/QW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: 12 mths 
PBO Iron: No 
G-CSF: No 
RBCT trigger: Hb ≤8 g/dl & 
prn 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: solid (lung) 
Treatment: chemo: plat 
FACT-F Y 
Key: ~, approximately; , decrease only; AE, adverse event; BSI, Brief Symptom Inventory ; BL, baseline; CLAS,  Cancer Linear Analogue Score; C, cycles; chemo, chemotherapy; D, days; D&A, Depression and Anxiety subscale ; 
EORTC QLQ C-30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; FACT, Functional Assessment of Cancer Therapy (-An, Anaemia; -F, Fatigue; G, General); G-CSF, granulocyte 
colony stimulating factor; GI, gastrointestinal; grps., groups; gynae, gynaecological; HaemR, haematopoietic response; Hb, haemoglobin; HRQoL, health-related quality of life; inc., increase; incl., includ(e/ing); med., median; min., 
minimum; mths., months; NHP, Nottingham Health Profile; NR, not reported; OS, overall survival; PBO, placebo; plat, platinum-based chemotherapy; prn, pro re nata (as needed); PDI, Psychological Distress Inventory; QoL, quality of 
life; QW, once weekly; RBCT, red blood cell transfusion; rHuEPO, recombinant human erythropoietin; SC, standard care; SCLC, small-cell lung cancer; SF-36, Short Form 36; TIW, three times weekly; TR, tumour response; TVEs, 
thrombovascular events; tx, treatment; VAS, Visual Analogue Scale; wks., weeks; yrs., years 
Notes: * indicates median (range) (a) BL characteristics /and some efficacy outcomes reported for all participants randomised (i.e. includes participants not receiving chemotherapy [Abels, 1993]); for all doses of Darbepoetin alfa 
[Kotasek 2003]); for intervention and control combined at randomisation [Untch 2011a,b]); (b) Assumed to be either Epoetin alfa or Epoetin beta based on date of trial and dose administered in the trial; (c) Double-blind phase only; 
participants given the option to enter 12-week open-label treatment period; (d) Majority of participants received non-platinum chemotherapy; (e) Study includes other doses of intervention under review (either dose-response study 
Hedenus,2002, 2003; Kotasek, 2003; or three-arm trial Ten-Bokkel, 1998; Thatcher, 1999); (f) Survival based on data collected during 12-mth after study completed by last participant; Reported based on proportion of patients 
randomised (only available for a proportion of patients randomised; 151 and 145 intervention and control groups respectively); (g) Inclusion criteria for Hb further stratified by serum epo level; (h) Majority of participants received platinum-
based chemotherapy; (i) Serum endogenous epo (mU/mL not available for all participants randomised; n= 145 and n= 151 in intervention and control group respectively; (j) Patients evaluated for HRQoL from trial sample (Hedenus 
2003), not separated by intervention and control for HRQoL sample 
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Table 32. HRQoL intruments included in the studies 
HRQoL measure Study (year) 
FACT-G Osterborg, 200269; Littlewood, 200168; Aapro, 200480; Bajetta, 200479; 
Patrick, 200360; Tjulandin, 201176 
FACT-An Osterborg, 200269; Tjulandin, 201176 
FACT-F Osterborg, 200269; Littlewood, 200168; Boogaerts, 200352; Hedenus, 200316; 
Vansteenkiste, 200272; Aapro, 200480; Bajetta, 200479; Kotasek, 200346; 
Littlewood, 200682; Patrick, 200360; Tjulandin, 201176 
FACT-An-An Aapro, 200480; Boogaerts, 200352; Littlewood, 200168; Osterborg, 200269 
SF-36 Boogaerts 200352; Patrick 200360 
CLAS/LASA Dammacco, 200164; Littlewood, 200168, Aapro, 200480, Bajetta, 200479, 
Patrick, 200360 
PDI Del Mastro, 199965 
EORTC-QLQ-C30 Ray-Coquard, 200974 
BSI Littlewood, 200682 
NHP Dammacco, 200164 
VAS Abels, 199354; Boogaerts, 200352, Kurz, 199767, Thatcher, 199948 
Key: BSI, Brief Symptom Inventory; CLAS< Cancer Linear Analogue Score; EORTC QLQ C-30, European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; FACT, Functional 
Assessment of Cancer Therapy (-An, Anaemia; -F, Fatigue; G, General); HRQoL, health-related quality of life; 
LASA, Linear Analogue Scale Assessment; NHP, Nottingham Health Profile; PDI, Psychological Distress 
Inventory; SF-36, Short Form 36; D&A, Depression and anxiety subscale; VAS, visual analogue scale 
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5.3.3.2.  Quality of included studies 
The quality of the included studies was assessed according to the criteria presented in Table 
9 (page 63). Twenty three primary studies were evaluated in the clinical effectiveness section 
(Section 4.2.3; Error! Reference source not found., page 63). As six secondary analyses 
are discussed in the HRQoL review, and only 13 primary studies were included in the 
HRQoL review; quality appraisal for these 19 studies is presented in Table 33, page 173. 
The method of randomisation was unclear in 12 studies with all reports having unclear 
allocation concealment. Only two trials fully reported baseline similarity. Baseline similarity 
was unclear in 15 publications with two trials unbalanced; in Boogaerts and colleagues 
(2003)52 a higher proportion of participants in the control group had prior chemotherapy (80 
vs. 68%; p=0.025), and patients randomised to epoetin beta had lower FACT scores 
(p=0.02); and, in Ray-Coquard and colleagues (2009)74 participants had EORTC QLQ-C30 
scores which were significantly different. 
Patients were reported as blinded in 15 trials, which has been reported to have a particularly 
significant impact on HRQoL results.1 Physicians were also blinded in all trials which blinded 
participnts; only four trials were unmasked or unclear. Although many trials included an ITT 
analysis or had less than 10% exclusions for primary outcomes, HRQoL suffered significant 
losses for at least six trials.48,65,68,72,74  
A graphical summary of study quality is presented in Figure 25, page 197.  
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Table 33. Study quality (Cochrane Risk of Bias tool): Retrospective analyses 
Study, year Random Concealment 
allocation 
Baseline 
similarity 
Patients 
blinded 
Physicians 
blinded 
Losses ITTor <10%dropout 
Aapro, 200480 
 
Primary study: Littlewood, 
200168 
Yes NR Uncleara Yes Yes Partiallyb Yes 
Abels, 199354 Unclearc NR Uncleara Yes Yes Partially Yes 
Bajetta, 200479 
 
Primary study: Littlewood, 
200168 
Yes NR Uncleara Yes Yes Partially NA 
Boogaerts, 200352 Unclearc NR No: prior 
chemotherapy, 
FACT-F 
No No Partially Yes 
Dammacco, 200164 Unclearc Uncleard Uncleara Yes Yes Yes Yes, primary endpoint and HRQoL only 
Del Mastro, 199965 Yes NR Uncleara No NR Partially Yes, apart from HRQoL (87% and 84% 
participants were analysed in treatment 
and control groups respectively). 
Hedenus, 200316 Yes NR Unclear Yes Yes Partiallye Yesf 
Kotasek, 200346 Unclearc NR Yes8 Yes Yes Partiallye Yesf 
Kurz, 199767 Yes Uncleard Yes Yes Yes NR Yes, results report response for all 
participants; assumed ITT. 
Littlewood, 200168 Unclearc NR Uncleara Yes Yes Yes Yes, apart from HRQoL (80% and 73% 
participants were analysed in treatment 
and control groups respectively). 
Littlewood, 200682 
 
Primary study: Hedenus, 
200316 
Unclear NR Uncleara Yes Yes Yes Unclearg 
Osterborg, 200269 Unclearc NR Uncleara Yes Yes Partiallye Yes 
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Study, year Random Concealment 
allocation 
Baseline 
similarity 
Patients 
blinded 
Physicians 
blinded 
Losses ITTor <10%dropout 
Osterborg, 200570 
 
Primary study: Osterborg, 
200269 
NR NR Uncleara Yes Yes Yes Yes 
Patrick, 200360 
 
Primary study: Littlewood, 
200168 
Yes NR NR Yes Yes NR NR 
Ray-Coquard, 200974 Unclearc Uncleard No: HRQoLb No No Partially Yes, apart from HRQoL (54% and 57% 
participants were analysed in treatment 
and control groups respectively. 
Thatcher, 199948 Unclearc NR Uncleara No NR Yes Yes, apart from HRQoL (75% and 61% 
participants were analysed in treatment 
and control groups respectively). 
Tjulandin, 201176 Yes NR Uncleara Yes Yes Yes Yes, apart from HRQoL (89.5-97.9% 
and 85.7-96.7% participants were 
analysed in treatment and control 
groups respectively). 
Vansteenkiste, 200272 Unclearc Uncleard Uncleara Yes Yes Partially Yese, apart from   HRQoL (81% 
participants were analysed in both, 
treatment and control groups). 
Vansteenkiste, 200481  
 
Primary study: 
Vansteenkiste, 200272 
NR NR Uncleara Yes Yes No Unclearh 
Key: HRQoL, health-related quality of life; ITT, intention-to-treat; NR not reported.  
Notes: (a) p-values for baseline similarities not reported; (b) Loss discussed for treatment period only;  (c) Randomisation details are not reported; (d) Randomisation was performed using a 
centralised system, but details on allocation concealment were not reported; (e) Losses reported for the treatment period only, data for the follow up period are not reported;  (f) Less than 10% 
dropout, but ITT was defined as all randomised participants who received at least 1 dose of study drug;  (g) Data for arms pooled as trial not powered for FACT-F analysis; (h) FACT outcomes 
not imputed 
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5.3.3.3.  Tr ials identi f ied in previous HTA (Wilson and colleagues, 
2007)1 
5.3.3.3.1.  Abels and colleages (1993)5 4 
Trial/population characteristics.  
The safety of epoetin alfa, its impact on haematocrit, transfusion requirements and quality of 
life were investigated in the trial reported by Abels and colleagues (1993), which is the 
primary study. It should be noted that this study is reported in a further five papers, by Case 
and colleagues (1993), Henry and colleagues (1994), Henry and colleagues (1995) and 
Abels and colleagues (1996) as retrospective studies. 
 The intervention arm of this trial included 413 patients from three populations: cyclic non-
cisplatin chemotherapy (n=157), cyclic cisplatin-chemotherapy (n= 132) and no 
chemotherapy (n=124), to be compared against placebo (n=200). All patients recruited had 
anaemic cancers.  
Results 
The rHuEPO-treated population as a whole had a statistically significant (p≤0.05) increase in 
baseline-to-final evaluation for overall quality of life (Table 34). When comparing responders 
to placebo, a significant improvement was seen for all three parameters (p≤0.05).  
Summary 
A statistically significant increase measured by VAS was found in favour of epoetin alfa. 
Table 34.  HRQoL: Results for Abels and colleagues (1993)54 
 Baseline Week 4 
Mean 
change 
Week 8 
Mean 
change 
 
≥ Week 
12 Mean 
change a 
 
Difference between 
ESA and controlc 
Change in VAS (100 mm) from baseline; a higher score indicates a higher HRQoLb   
Energy level 
Intervention (n=59) NR NR NR 7.2  2.9 in favour of ESA 
Control (n=143) NR NR NR 4.3  
ESA responders (n=83) NR NR NR 13c  
Daily activity 
Intervention (n=59) NR NR NR 5.8  4.8 in favour of ESA 
Control (n=143) NR NR NR 1  
ESA responders (n=83) NR NR NR 11.53  
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Overall HRQoL 
Intervention (n=59) 50.0±24.0 NR NR 5c  7.1 in favour of ESA 
Control (n=143) 50.4±26.0 NR NR -2.1  
ESA responders (n=83) NR NR NR 9.5c  
Key: ESA, erythropoiesis stimulating agent; NR, not reported;
Notes: a Assessment performed after study period ; b Data taken from Wilson and colleagues (2007) as results 
only presented by Abels and colleagues (1993) graphically; c Calculated by PenTAG, d Statistically significant 
(p<0.05). 
5.3.3.3.2.  Boogaerts and colleagues (2003)5 2 
Trial/population characteristics 
This trial investigated the impact of epoetin beta on HRQoL in anaemic patients with 
lymphoid or solid tumour malignancies receiving myelosuppressive chemotherapy (n=133 for 
intervention; n=129 for standard care). Change in HRQoL was measured from baseline to 
week 12 in SF-36, FACT-An, FACT-F and VAS. The method of randomisation was not 
reported and neither assessors nor patients were blinded. An ITT analysis was performed. 
Results 
The data are presented in Table 35 with and without LOCF. Compared with transfusion 
therapy, epoetin beta produces a clinically significant improvement in HRQoL in patients with 
anaemia associated with malignancy. Epoetin beta improved physical function and well-
being as measured by the FACT-An and FACT-F questionnaires. The internal consistency 
reliability was also estimated for each scale, using Crohnbach α, with the FACT-An and 
FACT-F subscale showing high consistency (>0.9). SF-36 subscales varied from 0.83 to 0.90 
for the pooled population, apart from the General health subscale (0.75). The FACT-F 
subscale showed a significant improvement in favour of epoetin beta, unlike FACT-An 
(p=0.068). 
Summary 
Epoetin beta improved physical function and well-being as measured by the FACT-An and 
FACT-F questionnaires.  
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Table 35. HRQoL: Results for Boogaerts and colleagues (2003)52  
 Baseline 
Mean score 
(SD) 
 
Week 4 
Mean 
changea 
Mean 
change from 
BL w/o 
LOCF (SD) 
Week 8 
Mean 
changea 
Mean 
change from 
BL w/o 
LOCF (SD) 
Week 12 
Mean 
changea 
Mean 
change from 
BL w/o 
LOCF (SD) 
Difference 
between 
ESA and 
controlc 
SF-36 PCS (0–100%); the higher the score, the lower the disability 
Intervention (n=133) 35 (8.4) 2.0 (1.0) 3.3 (1.0) 3.5 (1.5) 
4.2 Control (n=129) 38 (9.5) 1.0 (0.5) -0.5 (0.5) -0.7 (0.8) 
FACT-F (13 items: score 0–52); the higher the score, the higher the HRQoL 
Intervention (n=133) 27 (12)  3.5 (1.25) 4.5 (1.5) 5.5 (1.5) 
5.0 Control (n=129) 31 (11)b  1.3 (1.0) 0.7 (1.5) 0.5 (1.5) 
FACT-An (7 items: 0–28); the higher the score, the higher the HRQoL 
Intervention (n=133) 20 (3.8)  0.8 (0.3) 1.0 (0.4) 0.9 (0.5 
1.0 Control (n=129) 21 (4.4)  0.4 (0.5) 0.0 (0.3) -0.1 (0.4) 
VAS (100 mm); the higher the score, the higher the HRQoL 
Intervention (n=133) 56 (17)  5.0 (2.0) 7.0 (2.0) 11.0 (2) 
11.3 Control (n=129) 62 (17)  -0.5 (0.75) 0.5 (1.0) -0.5 (-2.0) 
Key: ESA, erythropoiesis stimulating agent FACT, Functional Assessment of Cancer Therapy –F, Fatigue; -An, 
Anaemia); LOCF, last observation carried forward; PCS=Short form 36, physical component summary; VAS, 
visual analogue score 
Notes: a Data taken from Wilson and colleagues (2007) as results only presented by Boogaerts and colleagues 
(2003) graphically  b p=0.02; c Calculated by PenTAG 
 
Table 36. HRQoL: Results for Boogaerts and colleagues (2003)52 according to median 
change score 
 Baseline 
Median 
(range) 
Week 4 
Median 
change 
score  
Week 8
Median 
change 
score 
Week 12 
Median 
change 
score 
(LOCF)a 
Week 12 
Median 
change 
score (w/o 
LOCF)a 
 
Difference 
between 
ESA and 
controlb 
SF-36 PCS (0–100%) [n]; the higher the score, the lower the disability 
Intervention   35 (17-60) NR NR 3.1 [104] 3.3 [77] 
NR Control 38 (15-60) NR NR NR [109] NR 
p value    <0.05 0.01 
FACT-F (13 items: score 0–52) [n]; the higher the score, the higher the HRQoL 
Intervention  28 (1-49) NR NR 3.0 [104] 4.0 [90] 
NR Control   33 (2-51) NR NR NR [109] NR 
p value    <0.05 0.001 
FACT-An (7 items: 0–28) [n]; the higher the score, the higher the HRQoL 
Intervention 21 (6-27) NR NR 1.0 [104] 1.0 [89] NR 
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Control 22 (2-28) NR NR NR [109] NR 
p value    0.08 0.068 
VAS (100 mm); the higher the score, the higher the HRQoL 
Intervention 53 (11-96) NR NR 10 [111] 10 [89] 
9.0 Control  60 (18-96) NR NR 1.0 [112] 3.0 [98] 
p value    0.004 0.001 
Key: ESA, erythropoiesis stimulating agent; FACT, Functional Assessment of Cancer Therapy (–F, Fatigue; -An, 
Anaemia); LOCF, last observation carried forward; NR, not reported; PCS=Short form 36, physical component 
summary; VAS, visual analogue score 
Notes: (a) p value refers to invervention versus control; (b) Calculated by PenTAG 
5.3.3.3.3.  Dammacco and colleagues (2001)6 4 
Trial/population characteristics 
This was a trial involving 145 patients with multiple myeloma who had received 
chemotherapy for at least six months. The intervention arm received epoetin alfa and the 
control arm received a placebo over 12 weeks. The scales used were the Nottingham Health 
Profile (NHP) and the CLAS/LASA. Both patients and assessors were blinded. HRQoL 
analyses were performed for the ITT population minus patients who died during the double-
blind phase of the study for whom HRQoL data were incomplete. 
Results 
HRQoL assessed for 138 patients (66 epoetin alfa and 72 placebo). Data were not reported, 
however, authors state that both treatment groups showed some improvement in HRQoL but 
multivariate analysis did not show a significant difference between the groups for Week 12 
change scores, although nearly all trends favoured patients treated with epoetin alfa. 
Univariate analyses of within-group mean changes from baseline to Week 12 indicated 
significant improvement in four HRQoL scales for the epoetin alfa group (NHP scale 
emotional reaction p<0.001 & social isolation p=0.05; and for the CLAS energy level (p=0.01) 
and ability to do daily activities (p<0.001)) and one HRQoL scale for the placebo group (NHP 
scale sleep p=0.03).  A trend towards improvement was also noted for CLAS, Overall HRQoL 
for the epoetin alfa treated group whereas for the placebo group scores were virtually 
unchanged since baseline. 
HRQoL during the open-label phase was also evaluated for 78 patients, using within group 
analysis. A consistent trend towards improved HRQoL in three out of six NHP scales 
(energy, sleep, physical mobility) and all three CLAS items was observed for patients in the 
placebo to epoetin alfa group at Week 24. 
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Summary 
The scales used to measure HRHRQoL in this trial found epoetin alfa is an effective and well 
tolerated agent for the management of myeloma-associated anaemia, although it should be 
noted that one is not validated. 
5.3.3.3.4.  Del Mastro and colleagues (1999)6 5 
Trial/population characteristics 
The trial reported by Del Mastro and colleagues (1999) evaluated the ability of rHuEPO 
(assumed to be epoetin alfa) in preventing the development of clinically significant anaemia 
in patients with Stage II breast cancer being treated with chemotherapy (n=62). The duration 
of treatment was 12 weeks, with the control arm being best supportive care. HRQoL was 
measured by Psychological Distress Inventory (PDI) with data only available for 85.5% of 
patients. Patients were not blind to treatment. 
Results 
Only 87% and 84% of participants were analysed in the intervention and control groups for 
HRQoL, respectively (Table 37). Psychological distress increased during treatment and 
decreased at first follow-up visit (p=0.03). Treatment groups did not significantly differ in 
terms of psychological distress. 
Summary 
Epoetin alfa was not effective over best supportive care in improving psychological distress. 
Table 37. HRQoL: Results for Del Mastro and colleagues (1999)65 
 Baseline 
(mean ± SD) 
During 
treatment 
(mean ± SD) 
Follow-up 
(mean ± SD) 
 
Mean 
pre/post 
changea 
Mean 
difference 
between 
ESA and 
control a,b 
PDI score (13‐items, score 0 to 65); the higher the score, the higher the level of distress 
Control (n=26) 27.1±7.3 28.3±8.0 26.3±9.8 -0.8 2.3 in favour 
of control Intervention (n=27) 27.5±8.6 30.6±10.4 27.4±11.2 -0.1 
Key: ESA, erythropoiesis stimulating agent; No., number; PDI, psychological distress inventory 
Notes: a Calculated by PenTAG, b During treatment 
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5.3.3.3.5.  Hedenus and colleagues (2003)1 6 
Trial/population characteristics 
The objective of this trial was to evaluate the efficacy and safety of darbepoetin alfa in 
anaemic patients with lymphoproliferative malignancies (n=349). The study included patients 
with myeloma and lymphoma, and was stratified to enable a comparison of darbepoetin alfa 
and placebo within each malignancy type. All patients were scheduled to receive cytotoxic 
chemotherapy, along with the intervention, for 12 weeks. The HRQoL scale used was FACT-
F and the analysis was intention to treat. 
Results 
Only 84% of patients had completed the FACT-Fatigue subscale at Week 13 (Table 38). 
Improvement in their score compared with placebo, regardless of their level of fatigue at 
baseline. However, those patients with the lowest baseline FACT-Fatigue subscale scores 
reported the largest improvement at the end of treatment. After adjusting for the effect of 
baseline score, increases in FACT-Fatigue subscale scores with darbepoetin alfa treatment 
were significantly greater than those observed with placebo (p=0.032). 
Summary 
Statistically significant improvements in HRQoL were observed with darbepoetin alfa relative 
to placebo. 
Table 38. HRQoL: Results for Hedenus and colleagues (2003)16 
 Baseline 
Score 
Week 4 
Mean 
change 
Week 8 
Mean 
change 
Week ≥12a 
Mean 
change 
Pre/post 
change 
Difference 
between 
ESA and 
controlb 
FACT-F (13 items: score 0-52); the higher the score the higher the HRQoL 
For patients with baseline score <24 
Intervention (n=38) <24 NR NR 8 8 2 in favour 
of ESA Control (n=42) <24 NR NR 6 6 
For patients with baseline score 25-36 
Intervention (n=64) 25-36 NR NR NR 5 6 in favour 
of ESA Control (n=63) 25-36 NR NR NR -1 
For patients with baseline score >36 
Intervention (n=50) >36 NR NR NR -3 3 in favour 
of ESA Control (n=46) >36 NR NR NR -6 
Key: ESA, erythropoiesis stimulating agent; NR, not reported
Notes: a Data taken from Wilson and colleagues (2007) as results only presented by Hedenus and colleagues 
(2003) graphically  , b Calculated by PenTAG 
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5.3.3.3.6.  Kotasek and colleagues (2003)4 6 
Trial/population characteristics 
The safety of darbepoetin alfa in patients with solid cancers receiving cyclic chemotherapy 
(n=249) and the feasibility of administering darbepoetin alfa three weekly was assessed in 
the trial reported by Kotasek and colleagues (2003). This was a 12-week, double blinded 
study where the intervention was compared to placebo. The scales used to measure HRQoL 
were FACT-G and FACT-F, with analysis performed on patients randomised to study drug 
who received at least one dose. 
Results 
Although no data were reported for baseline characteristics between the intervention and 
control arms, the authors state that a slightly higher proportion of patients in the 12.0 mg/kg 
group had breast cancer (61%) and a higher mean baseline Hb concentration (104 g/l) 
compared with the other groups. All randomised patients who received ≥1 dose of study drug 
were analysed (100% and 95% participants in the darbepoetin arm and placebo arm, 
respectively). The mean change in FACT-F score appeared to increase with increasing Hb 
concentration, from roughly no change in patients who had no improvement in their Hb to 
approximately 5-point improvements in patients whose Hb increased by >2.0 g/dl. A trend 
test of the relationship between FACT-F score and Hb concentration was significant at a 
level of p=0.0023.  
Summary 
There appears to be no data in this report comparing placebo with darbepoetin alfa for 
HRQoL. However, authors report a statistically significant improvement in FACT-F with 
increase in Hb. 
5.3.3.3.7.  Kurz and colleagues (1997)6 7 
Trial/population characteristics 
This small trial was intended to evaluate the effectiveness of rHuEPO with respect to 
increasing Hb levels and decreasing RBCT requirements and to assess the influence on 
HRQoL parameters. Participants all had solid malignancies and were receiving platinum and 
non-platinum based chemotherapy (n=35). Treatment was either intervention or placebo for 
12 weeks with iron saccharate substitution following each dose of chemotherapy beginning 
with the next cycle. It is unclear whether treatment allocation was concealed, but both 
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patients and assessors were blinded. A self-administered visual analogue scale was 
employed to measure HRQoL, which had not been validated. ITT analysis appears to have 
been performed, but not explicitly expressed.  
Results 
Baseline characteristics were similar for placebo and darbepoetin groups (Table 39). Using 
an unvalidated assessment tool (Health State Utility Scale), there was no significant 
difference between treatment arms within each activity or across the ten different scores.  
Summary 
No statistically significant difference in HRQoL was seen between darbepoetin alfa and 
placebo. 
Table 39. HRQoL: Results for Kurz and colleagues (1997)67 
 Baseline 
Score 
Interim time 
pointsa 
Pre/post 
change 
Mean change 
difference 
between ESA 
and controlb, c, 
d 
Health State Utility scale (VAS of 1 to 5) 
unclear whether higher or lower scores indicate higher HRQoL  
Feeling of well being 
Intervention (n=23) NR NR 0.004 -0.16  
p=0.77 Control (n=12) NR NR -0.16 
Pts achieving response under 
intervention (SD) (n=13) 
NR NR -0.25 (0.76) p=0.26 
Mood 
Intervention (n=23) NR NR -0.21 -0.03  
p=0.94 Control (n=12) NR NR -0.18 
Level of activity 
Intervention (n=23) NR NR 0.26 0.32 
p=0.71 Control (n=12) NR NR 0.58 
Pts achieving response under 
intervention (SD) (n=13) 
NR NR -0.36 (1.14) p=0.27 
Pain 
Intervention (n=23) NR NR  0.37 0.11  
p=0.32 Control (n=12) NR NR  -0.26 
Nausea 
Intervention (n=23) NR NR -0.11 -0.32  
p=0.17 Control (n=12) NR NR -0.43 
Appetite 
Intervention (n=23) NR NR -0.32 -0.25  
p=0.61 Control (n=12) NR NR -0.07 
Physical ability 
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Intervention (n=23) NR NR -0.33 -0.01  
p=0.53 Control (n=12) NR NR -0.32 
Pts achieving response under 
intervention (SD) (n=13) 
NR NR -0.62 (0.87) p= 0.02 
Social activities 
Intervention (n=23) NR NR -0.04 -0.47  
p=0.89 Control (n=12) NR NR -0.51 
Pts achieving response under 
intervention (SD) (n=13) 
NR NR -0.20 (0.99) p=0.48 
Anxiety 
Intervention (n=23) NR NR 1.92 0.53  
p=0.38 Control (n=12) NR NR 2.45 
Treatment is helping 
Intervention (n=23) NR NR 1.76 0.58  
p=0.11 Control (n=12) NR NR 2.34 
Key:; ESA, erythropoiesis stimulating agent; NR, not reported
Notes: a Questionnaires administered at beginning of treatment and then every 4 weeks before receiving 
chemotherapy. It is unclear which timepoint the results refer to, b Calculated by PenTAG, c Multivariate 
Hotelling’s T2 for responders: p=0.21, d Multivariate Hotelling’s T2: p=0.34 
5.3.3.3.8.  Litt lewood and colleagues (2001)6 8 
Trial/population characteristics 
Littlewood and colleagues (2001) report on a trial evaluating the effects of epoetin alfa on 
RBCT requirements, haematopoetic parameters, HRQoL, and safety in patients receiving 
non-platinum based chemotherapy. Participants had solid or non-myeloid haematologic 
malignancies and were scheduled to receive non-platinum chemotherapy (n=375). HRQoL 
was measured via change from baseline to last value on 5 cancer specific scales (FACT-An, 
FACT-G, FACT-An Fatigue, CLAS/LASA) with both patients and assessors blinded. 
Treatment duration was 28 weeks. 
Results 
Only 80% and 73% participants were analysed in the epoetin alfa and placebo groups, 
respectively. The mean change score for FACT-An:fatigue, FACT-An:anaemia, FACT-G, 
CLAS-Energy, CLAS-Daily Active and CLAS-Overall displayed a statistically significant 
difference in favour of epoetin alfa over placebo (Table 40). 
Summary 
Epoetin alfa significantly improves HRQoL in cancer patients receiving non-platinum 
chemotherapy. 
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Table 40. HRQoL: Results for Littlewood and colleagues (2001)68 
 Baseline 
Score 
Interim time 
points 
Pre/post mean 
change 
Difference 
between ESA 
and controla 
FACT-G (27 items: score 0-108); the higher the score, the higher the HRQoL  
Intervention (n=194) NR NR 2.5 
6.1 in favour of 
ESA Control (n=88) NR NR -3.6 
p value   0.004 
FACT-An-Fatigue (13 items: score 0-52); the higher the score, the higher the HRQoL  
Intervention (n=200) NR NR 3.0 
5.2 in favour of 
ESA Control (n=90) NR NR -2.2 
p value   0.004 
FACT-An-Anaemia (7 items: score 0-28) the higher the score, the higher the HRQoL 
Intervention (n=200) NR NR 4.0 
6.6 in favour of 
ESA Control (n=90) NR NR -2.6 
p value   0.001b 
CLAS Energy level (100 mm); the higher the score, the higher the HRQoL 
Intervention (n=228) NR NR 8.1 
13.9 in favour of 
ESA Control (n=108) NR NR -5.8 
   0.001 
CLAS Daily activities (100 mm); the higher the score, the higher the HRQoL  
Intervention (n=228) NR NR 7.5 
13.5 in favour of 
ESA Control (n=108) NR NR -6.0 
p value   0.002 
CLAS Overall HRQoL(100mm) the higher the score, the higher the HRQoL;  
Intervention (n=228) NR NR 4.8 
10.8 in favour of 
ESA Control (n=107) NR NR -6.0 
p value   0.005 
Key: CLAS, Cancer Linear Analogue Scale; ESA, erythropoiesis stimulating agent; FACT, Functional 
Assessment of Cancer Therapy; NR, not reported; (-An, Anaemia; -G, General) 
Notes: a Calculated by PenTAG, b p value for the Anaemia subscale (secondary measure) is unadjusted. All 
other p values, which correspond to primary measures, are adjusted for multiple comparisons (sequentially 
rejective Bonferroni procedure).  
5.3.3.3.9.  Osterborg and colleagues (2002)6 9 
Trial/participant characteristics 
The effect of epoetin beta on HRQOL, as compared to placebo, was assessed in this trial 
using the FACT scale in patients with lymphoproliferative malignancies (advanced MM, low 
grade NHL and CLL). All patients (n=349) were scheduled to receive anti-tumour therapy for 
the following 4 months. Treatment duration was 16 week and both patients and assessors 
were blinded. The results were ITT.  
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Results 
After 12 and 16 weeks, the improvement in FACT-An and FACT-G score was greater in the 
epoetin beta arm (p<0.5) (Table 41 and Table 42). Analysis of the dimensions of the FACT-G 
scale revealed statistically significant differences after 12 weeks: p<0.01 and p<0.05 
favouring epoetin beta for social and family wellbeing and emotional wellbeing, respectively. 
Overall, the improvement in HRQoL was particularly apparent in patients with Hb increases 
of ≥2 g/dl.  
Summary 
Two of the scales used to measure HRQoL found a statistically significant increase in favour 
of epoetin beta. 
Table 41. HRQoL: Results according to treatment, Osterborg and colleagues (2002)69 
 Baseline 
Mean 
score±SD 
(n) 
Week 4 
Mean 
change±SD
(n) 
Week 8 
Mean 
change±SD
(n) 
Week 12 
Mean 
change±SD 
(n) 
Week 16 
Mean 
change±SD 
(n) 
Mean 
change 
difference 
between 
ESA and 
controla 
FACT-An (49 items, score 0-196) the higher the score, the higher the HRQoL;  
Intervention 115.2±28.0 (128) 
4.9±21.4 
(127) 
7.9±25.7 
(118) 
13.1±27.6* 
(114) 
14.8±28.0* 
(105) 6.1 in favour 
of ESA 
Control 114.0±28.3  (121) 
5.3±19.5  
(119) 
7.4±22.7  
(110) 
7.1±26.3  
(102) 
8.7±28.9  
(101) 
FACT-G (29 items, score 0-116); the higher the score, the higher the HRQoL  
Intervention 69.1±14.4 (129) 
1.7±11.8 
(128) 
3.7±13.0 
(118) 
5.9±14.5* 
(114) 
6.5±13.8* 
(106) 3.4 in favour 
of ESA 
Control 68.5±15.0 (122) 
2.2±10.1 
(120) 
2.9±11.5 
(112) 
2.6±12.9 
(104) 
3.1±14.4 
(103) 
FACT-F subscale (13 items, score 0-52); the higher the score, the higher the HRQoL 
Intervention 28.8±10.7 (160) 
2.2±8.7 
(157) 
2.8±10.8 
(148) 
4.2±11.7 
(145) 
5.2±12.2 
(133) 2.2 in favour 
of ESA 
Control 29.2±11.0 (157) 
1.8±8.4 
(157) 
1.9±9.8 
(145) 
2.5±10.9 
(135) 
3.0±12.1 
(130) 
FACT-An subscale (7 items, score 0-28) the higher the score, the higher the HRQoL;  
Intervention 17.3±4.6 (160) 
0.9±3.3 
(157) 
1.2±4.2 
(148) 
1.7±4.4 
(145) 
2.0±4.3 
(133) 0.3 in favour 
of ESA 
Control 17.0±5.0 (157) 
0.8±3.5 
(157) 
1.2±4.1 
(145) 
1.2±4.5 
(135) 
1.7±5.2 
(130) 
Key: Epo beta, epoetin beta; ESA, erythropoiesis stimulating agent; FACT, Functional Assessment of Cancer 
Therapy (-An, Anaemia; -F, Fatigue; -G, General); PBO, placebo; SD, standard deviation;  
Notes: a Calculated by PenTAG, bStatistically significant difference with placebo (p<0.05) 
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Table 42. HRQoL: Results according to response, Osterborg and colleagues (2002)69 
 Baseline Week 4 Week 8 Week 12 Week 16 
Mean score ± 
SD 
(n) 
Mean score ± 
SD 
(n) 
Mean score ± 
SD 
(n) 
Mean score ± 
SD 
(n) 
Mean score ± 
SD 
(n) 
FACT-An (49 items, score 0-196); the higher the score, the higher the HRQoL 
R 118.9±25.1 (92) 
5.1±21.6 
(91) 
9.7±25.2*  
(87) 
15.2±26.3*  
(88) 
17.4±25.9*  
(82) 
NR 105.7±32.9 (36) 
4.3±21.0 
(36) 
3.0±27.0  
(31) 
5.8±31.0  
(26) 
5.8±33.7  
(23) 
FACT-G (29 items, score 0-116); the higher the score, the higher the HRQoL 
R 70.6±12.9 (92) 
1.5±12.2 
(91) 
4.9±12.4*  
(87) 
6.9±14.3*  
(88) 
7.8±13.4*  
(83) 
NR 65.6±17.2 (37) 
2.0±10.8 
(37) 
0.5±14.2  
(31) 
2.6±14.7  
(26) 
1.9±14.5  
(23) 
FACT-F (13 items, score 0-52); the higher the score, the higher the HRQoL 
R 30.4±10.1 (114) 
2.5±8.3* 
(112) 
3.8±10.5*  
(108) 
5.3±10.5*  
(110) 
6.3±10.5*  
(102) 
NR 24.8±11.2 (46) 
1.3±9.5 
(45) 
0.2±11.4  
(40) 
0.5±14.3  
(35) 
1.7±15.0  
(31) 
FACT-An-An (7 items, score 0-28); the higher the score, the higher the HRQoL  
R 17.8±4.4 (114) 
1.0±3.2 
(112) 
1.3±4.3  
(108) 
2.1±3.9* 
(110) 
2.2±4.0  
(102) 
NR 16.0±4.7 (46) 
0.7±3.5 
(45) 
1.2±4.2  
(40) 
0.4±5.4  
(35) 
1.3±5.2  
(31) 
Key: ESA, erythropoiesis stimulating agent; NR-, non-responder; R-, responder, SD, standard deviation 
Notes: *Statistically significant difference with placebo (p<0.05) 
5.3.3.3.10.  Thatcher and colleagues (1999)4 8 
Trial/participant characteristics 
This trial involved 130 patients with small cell lung cancer undergoing cyclic chemotherapy, 
although only 86 patients were relevant to this review since the third arm dose was outside of 
licence. The treatment duration was a maximum of 26 weeks. To assess HRQoL, patients 
responses to a questionnaire containing three levels (energy level, daily activity and overall 
HRQoL) were scored on a 100mm VAS and WHO performance score. The analysis was ITT, 
however, there was no placebo, therefore patients were not blinded.  
Results 
Only the overall HRQoL level revealed a statistically significant improvement favouring 
epoetin alfa (p<0.05) (Table 43). There were no significant between group differences which 
may be related to the fact that all groups had similar Hb values at study end. Evaluation of 
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WHO performance scores revealed similar findings, with no significant between- or within-
group differences. 
Summary 
This trial found a statistically significant increase in favour of epoetin alfa for one of three 
levels within an unvalidated scale. 
Table 43. HRQoL: Results for Thatcher and colleagues (1999)48 
 Baseline 
Mean score ± 
SD 
(n) 
Interim time 
points 
Pre/post change Mean change 
difference 
between ESA 
and controla 
CLAS Energy level (100 mm); the higher the score, the higher the HRQoL 
Intervention 53.6±27.7 (n=37) NR -2.3±31.9 (n=33) 3.9 in favour of 
control Control  48.4±23.6 (n=37) NR 1.6±23.9 (n=27) 
CLAS Daily activities (100 mm); the higher the score, the higher the HRQoL  
Intervention  50.8±29.3 (n=37) NR 3.0±31.7 (n=33) 7.8 in favour of 
control Control  41.7±28.1 (n=37) NR 10.8±35.6 (n=27) 
CLAS Overall HRQoL (100 mm); the higher the score, the higher the HRQoL 
Intervention  49.0±28.1 (n=37) NR 11.7±30.6b (n=33) 4.2 in 
 favour of ESA Control  47.9±26.7 (n=37) NR 7.5±29.1 (n-27) 
Key: CLAS, Cancer Linear Analogue Scale; ESA, erythropoiesis stimulating agent; NR, not reported; SD, 
standard deviation 
Notes: a Calculated by PenTAG, b p<0.05 vs baseline  
5.3.3.3.11.  Vansteenkiste and colleagues (2002)7 2 
Trial/patient characteristics 
The trial compared the effect of darbepoetin alfa with placebo for 314 patients with lung cancer 
receiving platinum chemotherapy. Treatment duration was 12 weeks with HRQoL assessed by FACT‐
Fatigue. Both patients and assessors were blinded. 
Results 
The patient compliance rates for patients completing the FACT–Fatigue scale at least once 
during the treatment phase was 91.2% (95% CI; 87.4% to 94.2%). Fatigue was evaluated for 
255 (127 darbepoetin alfa, 128 placebo) patients who received a study drug, who completed 
the FACT–Fatigue scale through study week 4, and who completed the scale at baseline and 
at least one time from week 5 until the end-of-treatment phase. Fifty-six percent (95% CI; 
47% to 65%) of the patients in the darbepoetin alfa group and 44% (95% CI; 35% to 52%) of 
patients in the placebo group had an improvement in the FACT– Fatigue scale score (P =0 
.052). Thirty-two percent (95% CI; 23% to 40%) of patients in the darbepoetin alfa group 
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showed at least a 25% improvement, whereas only 19% (95% CI; 12% to 26%) of patients in 
the placebo group showed at least a 25% improvement (mean difference = 13%; 95% CI ; 
2% to 23%; P =0 .019). 
Summary 
There is a trend towards improved HRQoL for darbepoetin alfa as compared to placebo. 
5.3.3.4.  Tr ials identif ied 2004 to current  
5.3.3.4.1.  Ray-Coquard and colleagues (2009)7 4 
Trial/patient characteristics 
The effect of epoetin alfa on HRQoL, as compared to no treatment, was assessed in this 
trial, using the EORTC QLQ-C30 scale. Patients with solid and haematological tumours 
receiving their first or second course of chemotherapy were recruited (n=218). The trial was 
open label with treatment was administered for 12 weeks. Only 54% and 57% participants for 
the intervention and control groups, respectively, were analysed. 
Results 
Authors state that no statistically detectable differences were noted during the study period, 
whatever the date of evaluation (at one, two, three or four months or at the end of the study, 
all p>0.2), although none of this data was reported. Furthermore, there was a significant 
difference between groups at baseline for the EORTC QLQ-C30 measurement (p=0.048) 
Summary 
No statistically significant difference in HRQoL was detected between epoetin alfa and no 
treatment. 
5.3.3.4.2.  Tjulandin and colleagues (2011)7 6 
Trial/patient characteristics 
This trial compared the effectiveness of epoetin theta to placebo for patients with a solid or 
non-myeloid haematological malignancies and receiving non-platinum based chemotherapy. 
The duration of treatment was 12 weeks and both patients and assessors were blinded. The 
scale used to measure HRQoL was FACT-An, FACT-G and FACT-F.  
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Results 
ITT analysis was not undertaken for HRQoL with 89.5–97.9% and 85.7–96.7% of participants 
analysed in the epoetin theta and placebo groups, respectively (Table 44). No significant 
difference was evident between trial arms.  
Summary 
No statistically significant difference was detected between epoetin theta and placebo. 
Table 44. Results for Tjulandin and colleagues (2011)76 
 Baseline 
Mean 
score±SD 
(n) 
Interim time 
points 
Mean 
change±SD 
(n) 
Pre/post Mean 
change±SD 
(n) 
Mean change 
difference between 
ESA and controla 
FACT-An (49 items, score 0-196); the higher the score, the higher the HRQoL  
Intervention (n=88) NR NR 6.3 ± 21.7 
5.7 in favour of ESA Control (n=84) NR NR 0.6 ± 22.0 
p value NR NR 0.243 
FACT-G (29 items, score 0-116); the higher the score, the higher the HRQoL 
Intervention (n=88) NR NR 3.0 ± 12.7 
3.2 in favour of ESA Control (n=84) NR NR -0.2 ± 12.4 
p value NR NR 0.224 
FACT-F subscale (13 items, score 0-52); the higher the score, the higher the HRQoL 
Intervention (n=88) NR NR 2.9 ± 7.9 
2.3 in favour of ESA Control (n=84) NR NR 0.6 ± 8.8 
p value NR NR 0.142 
FACT-An trial outcome indexb; the higher the score, the higher the HRQoL 
Intervention (n=88) NR NR 1.2 ± 18.8 
4.4 in favour of control Control (n=84) NR NR 5.6 ± 17.1 
p value NR NR 0.222 
Key: ESA, erythropoiesis stimulating agent; FACT, Functional Assessment of Cancer Therapy (-An, Anaemia; -F, 
Fatigue; -G, General); SD, standard deviation 
Notes: a Calculated by PenTAG, b unclear number of items or score 
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5.3.3.5.  Post hoc studies identif ied, 2004 to current 
5.3.3.5.1.  Aapro and colleagues (2004)8 0 
Trial/patient characteristics 
Secondary analysis of the trial reported by Littlewood and colleagues (2001)68 which includes 
further HRQoL data. The scales employed were Cancer Linear Analog Scale (CLAS) and 
FACT-G; FACT-An-Fatigue and FACT-An-anaemia. 
Results 
Of the 375 participants, 349 were evaluated for changes in HRQoL (n=200–228 for 
intervention; n=90–108 for control). All scales showed a statistically significant improvement 
in favour of epoetin alfa (results are presented graphically, however, they appear to comply 
with the data for Littlewood and colleages (2001).68 
Summary 
This trial found a statistically significant increase in favour of epoetin alfa. 
5.3.3.5.2.  Bajetta and colleagues (2004)7 9 
Trial/patient characteristics 
Further secondary analysis of the trial reported by Littlewood and colleagues (2001)68, 
looking at 114 participants with breast cancers from a total of 375 participants. The scales 
employed were as for Aapro and colleagues (2004)80 above. 
Results 
Statistical significance was not assessed, however, change in mean HRQoL score appears 
to favour epoetin alfa. 
Summary 
There is a trend towards improved HRQoL for epoetin alfa as compared to placebo. 
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5.3.3.5.3.  Litt lewood and colleagues (2006)8 2 
Trial/patient characteristics 
Secondary analysis of the trial reported by Hedenus and colleagues (2003),16 aiming to 
investigate the effects of Hb on patients’ fatigue, subsequent to treatment with darbepoetin 
alfa, and to examine the relationship between improvements in fatigue and HRQoL. The 
tools used were FACT, Brief Symptom Inventory (BSI) Depression and Anxiety Subscales, 
numeric rating scales (NRS) of Energy Activity and Overall Health.  Of the 344 patients, 303 
patients completed the FACT-F subscale at baseline and at least once after receiving four 
weeks of treatment.  
Results 
Mean change in FACT-F subscale in score from baseline to end of treatment indicates an 
improvement for darbepoetin alfa, but this is not analysed statistically, since the trial is 
underpowered. Data for the other scales are not presented. 
Summary 
There is a trend towards improved HRQoL for epoetin alfa as compared to placebo. 
5.3.3.5.4.  Osterborg and colleagues (2005)7 0 
Trial/patient characteristics 
Analysis of follow-up data from the original trial reported by Osterborg and colleagues 
(2002).69 The minimum length of follow up was approximately 17.5 months in both treatment 
groups, with only four patients in each group receiving less (n=349). FACT-An questionnaires 
were completed at baseline and every four weeks during the study. 
Results 
For HRQoL, reported results are given up to Week 16 as for Osterborg and colleagues 
(2002).69  
Summary 
Two of the scales used to measure HRQoL found a statistically significant increase in favour 
of epoetin beta, however, the variability between patients was considerable. 
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5.3.3.5.5.  Patr ick and colleagues (2003)6 0 
Trial/participant characteristics 
Additional secondary analysis of the trial reported by Littlewood and colleagues (2001),68 
investigating the observed effects of increased Hb on HRQOL. The scales used were FACT-
G, FACT-An Fatigue, CLAS (energy level, daily activities and overall HRQoL), SF-36 
Physical and SF-36 Mental. 
Results 
Patients were pooled across treatment groups and then most patients were assigned to 
‘Improved’ patients (defined as those who experienced an increase in Hb of at least 1 g/dL) 
and ‘stable, or unchanged’, patients (change in Hb of less than 1 g/dL to a lower limit of -
1g/dL) (Table 45).The difference in the mean HRQoL change score between the improved 
and stable groups is minimally important difference (MID). If the observed difference between 
treatment groups is greater than or equal to the MID, then that difference was considered 
clinically important. The actual difference in mean Hb change between the improved and 
stable groups in the clinical trial was approximately 2.8 g/dL.  
Summary 
This trial found a statistically significant increase in favour of epoetin alfa. 
Table 45. HRQoL: Results for Patrick and colleagues (2003)60 
 Baseline 
Score 
Interim time 
points 
Pre/post 
change 
 
Difference 
between 
ESA and 
controla 
Minimally 
important 
difference 
FACT-G (27 items: score 0-108); the higher the score, the higher the HRQoL 
Intervention (n=200) NR NR 2.49 6.06 in 
favour of 
ESA 
2.54 Control (n=90) NR NR -3.57 
p value   0.004 
FACT-An-Fatigue (13 items: score 0-52); the higher the score, the higher the HRQoL  
Intervention (n=200) NR NR 2.97 5.15 in 
favour of 
ESA 
4.24 Control (n=90) NR NR -2.18 
p value   0.004 
CLAS Energy level (100 mm); the higher the score, the higher the HRQoL 
Intervention (n=228) NR NR 8.06 13.87 in 
favour of 
ESA 
9.61 Control (n=108) NR NR -5.8 
p value   0.001 
CLAS Daily activities (100 mm); the higher the score, the higher the HRQoL 
Intervention (n=228) NR NR 7.51 13.5 in 
favour of 8.74 Control (n=108) NR NR -5.99 
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p value   0.002 ESA 
CLAS Overall HRQoL (100 mm); the higher the score, the higher the HRQoL 
Intervention (n=228) NR NR 4.79 10.76 in 
favour of 
ESA 
9.81 Control (n=107) NR NR -5.97 
p value   0.005 
SF-36 Physical (0–100%); the higher the score, the lower the disability 
Intervention (n=NR) NR NR 1.77 2.3 in favour 
of ESA NR Control (n=NR) NR NR -0.53 
p value   NR 
SF-36 Mental (0–100%) [n]; the higher the score, the lower the disability 
Intervention (n=NR) NR NR 2.14 2.39 in 
favour of 
ESA 
NR Control (n=NR) NR NR -0.25 
p value   NR 
Key: CLAS, Cancer Linear Analogue Scale; ESA, erythropoiesis stimulating agent; FACT, Functional 
Assessment of Cancer Therapy (-An, Anaemia; -G, General); NR, not reported; 
Notes: a Calculated by PenTAG, b p value for the Anaemia subscale (secondary measure) is unadjusted. All 
other p values, which correspond to primary measures, are adjusted for multiple comparisons (sequentially 
rejective Bonferroni procedure).  
5.3.3.5.6.  Vansteenkiste and colleagues (2004)8 1 
Trial/participant characteristics 
Secondary analysis of the trial reported by Vansteenkiste and colleagues (2004) to 
determine if the degree of benefit obtained from treatment with darbepoetin alfa is affected 
by patient’s Hb level at the start of treatment. The FACT-F scale was used for assessment of 
HRQoL.  
Results 
As per the primary study, results were reported as percentages. Additional results in this 
report indicate a significant difference (p=0.0147) between darbepoetin alfa and placebo with 
a baseline Hb of <10 g/dl. In contrast, no difference was apparent between groups with a 
baseline Hb ≥10 g/dl. 
Summary 
The trial found a statistically significant improvement in HRQoL for participants with a 
baseline Hb <10 g/dl at baseline. 
5.3.4. Meta-analysis: FACT-F score (random effects) 
Given the variability of reporting in the published papers FACT-F 13 item (score 0–52), data 
were extracted from the Cochrane review by Tonia and Colleagues (2012)10 for use in the 
PenTAG analyses. 
PenTAG     CONFIDENTIAL 
194 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
FACT-F scores were available from seven studies (Littlewood and colleagues, 200168; 
Osterborg and colleagues, 2002, 200569,70; Vansteenkiste and colleagues, 200272; 
Boogaerts and colleagues, 200352;Hedenus and colleagues, 200316; Kotasek and 
colleagues, 200346; Tjulandin and colleagues, 201176)  including 1,794 participants. One 
new primary study was identified (Tjuandin and colleagues, 2011). 
The WMD was 2.54 (95% CI 1.42, 3.65; Figure 24).  There was low heterogeneity between 
the trials (I2=14.9%, p=0.32) (Table 46, page 194). Because there were only seven primary 
studies included in the meta-analysis, the funnel plot analysis to test whether publication bias 
was present was not conducted.50 The fixed effects meta-analysis undertaken as a sensitivity 
analysis showed similar significant results (Appendix M). In terms of quality, all the studies 
were at a similar level, however, the trial reported by Boogaerts and colleagues (2003) did 
not employ blinding for participants (Figure 26). Removing this study from the meta-analysis 
had a minimal impact on results with a WMD of 2.21 (95% CI 1.131, 3.280; Appendix M) but 
did improve heterogeneity (I2=0%, p=0.51). Meta-analysis was performed on FACT-G and 
FACT-An (7 items), however, only three studies were suitable for inclusion for each scale 
with high levels of heterogeneity (Table 46, page 194; Appendix M). The results of no 
statistical difference between intervention and control must therefore be treated with caution. 
Univariate subgroup analyses were conducted for FACT-F outcomes according to 
chemotherapy type, malignancy type, intervention (epoetin or darbepoetin), and study 
duration, showed significant results, however, the number of studies included was small 
(Table 46, page 194, Appendix M). 
5.3.5. HRQoL outcomes: overall summary 
Effectiveness estimates are compared with previously reported estimates for HRQoL; see 
Table 46. A graphical summary of study characteristics and results for these outcomes is 
presented in Figure 25, page 197. 
Table 46. HRQoL: results comparison for FACT: Wilson and colleagues, 2007 vs Tonia 
and colleagues, 2012 vs PenTAG 20131,10 
 Wilson, 2007b Tonia, 2012b PenTAG, 2013b PenTAG, 2013c 
HRQoL 
FACT-F 13 
item (score 
0-52) 
NR MD 2.08 
95% CI 1.43, 2.72 
Χ2(het)36.48; df 17 
(p=0.004) 
18 trials, n=4,965 
MD 2.49 
95% CI 1.48,3.51 
Χ2(het)7.05; df 6 
(p=0.000) 
7 trials, n=1,794
MD 2.54 
95% CI 1.42, 3.65 
Χ2(het)7.05; df 6 
(p=0.000) 
7 trials, n= 1,794 
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Any 
subgroup 
effect 
NR Yes: imputed vs. non-
imputed data, baseline 
Hb level, type of anti-
cancer therapy, 
duration of ESA 
treatment and ITT 
analysis. 
– Possible: malignancy, 
intervention and 
duration 
FACT-F 13 
item (score 
0-52) 
without 
Boogaerts, 
2003 
– – – MD 2.21 
95% CI 1.13, 3.28 
Χ2(het)4.31; df 5 
(p=0.000) 
6 trials, n= 1,581 
FACT-G 27 
item (score 
0-108) 
NR NR MD 3.16e 
95% CI 1.11, 5.21 
Χ2(het)6.82; df 2 
(p=0.003) 
3 trials, n=686 
MD 2.98e 
95% CI -0.83, 6.78 
Χ2(het)6.82; df 2 
(p=0.13) 
3 trials, n=686 
FACT-An 7 
item (score 
0-28) 
NR NRd MD 1.05f 
95% CI 0.93, 1.12 
Χ2(het)80.66; df 2 
(p=0.00) 
3 trials, n=686 
MD 2.60f 
95% CI -0.52, 5.72 
Χ2(het)80.66; df 2 
(p=0.00) 
3 trials, n=686 
Key: CI, confidence interval; df, degrees of freedom; het, heterogeneity; ITT, intention-to-treat; MD, minimal 
difference; WMD, weighted mean difference 
Notes: (a) change from baseline to end of study; (b) fixed effects (Mantel-Haenszel); (c) random effects (Der-
Simonian Laird); (d) FACT-An ( 47 item) only used gy Tjulandin (2011) and Osterborg (2005), so no meta-
analysis performed on this scale. Three studies analysed the FACT-An subscale (7 items ). Tonia (2012)  refer to 
a FACT-An (20 items) which is likely to be FACT-F subscale + FACT-An 7which they may have been able to use 
dueto additional information received by them. The reports of included studies here confirm 7-item FACT-An; (e) 
Standard deviation for Littlewood (2001)  imputed from Tjulandin (2011) and Osterborg (2005); (f)  Standard 
deviation for Littlewood (2001)  imputed from Osterborg (2005); 
 
Overall, conclusions from the PenTAG review are in agreement with the Cochrane review 
(Tonia and colleagues, 2012)10 in that there is a statistically significant difference between 
patients treated with ESAs and controls when combining HRQoL parameters, which is, 
however, most likely not clinically important (the threshold MD of 3.0 [Cella and colleagues, 
2002])96. As with previous reviews, however, it should be noted that there are several 
methodological concerns which may result in bias; e.g. the substantial quantity of missing 
data, expecting patients to complete repeated questionnaires leading to a shift in patient 
response and various modes of administration of questionnaire.  
PenTAG     CONFIDENTIAL 
196 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Figure 24. HRQoL: overall (random effects) 
 
Key: CI, confidence interval; N number of events/participants in the treatment and control groups; ID, identification; WMD, weighted mean difference 
Notes: (a) Random effects (Der-Simonian Laird pooled RR) 
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Figure 25. HRQoL: Graphical summary  
 
Key: ?, unknown; BSI, Brief Symptom Inventory; CLAS, Cancer Linear Analogue Score; EORTC QLQ C-30, European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire C30; FACT, Functional Assessment of Cancer Therapy (-An, Anaemia; -F, Fatigue; G, General); HRQoL, health-related quality of life; LASA, Linear Analogue Scale 
Assessment; NHP, Nottingham Health Profile; PDI, Psychological Distress Inventory; SF-36, Short Form 36; VAS, Visual Analogue Scale; D&A, Depression and Anxiety subscale of BSI 
Notes: 1 Study population included pts not receiving chemotherapy; 2 87% and 84% participants were analysed in treatment and control groups, respectively, 3 80% and 73% participants 
were analysed in treatment and control groups, respectively, 4 54% and 57% participants were analysed in treatment and control groups, respectively, 5 75% and 61% participants were 
analysed in treatment and control groups, respectively, 6 90-98% and 86-97% participants were analysed in treatment and control groups, respectively, 7 81% participants were analysed 
in treatment and control groups 
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Figure 26. HRQoL: Graphical summary (continued) 
 
 
Key: ?, unknown; BSI, Brief Symptom Inventory; CLAS, Cancer Linear Analogue Score; EORTC QLQ C-30, European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire C30; FACT, Functional Assessment of Cancer Therapy (-An, Anaemia; -F, Fatigue; G, General); HRQoL, health-related quality of life; LASA, Linear Analogue Scale Assessment; 
NHP, Nottingham Health Profile; PDI, Psychological Distress Inventory; SF-36, Short Form 36; VAS, Visual Analogue Scale; D&A, Depression and Anxiety subscale of BSI 
Notes: 1 Paediatric population evaluated; 2 Study population included pts not receiving chemotherapy; 3 87% and 84% participants were analysed in treatment and control groups, respectively, 4 
80% and 73% participants were analysed in treatment and control groups, respectively, 5 54% and 57% participants were analysed in treatment and control groups, respectively, 6 75% and 61% 
participants were analysed in treatment and control groups, respectively, 7 90-98% and 86-97% participants were analysed in treatment and control groups, respectively, 8 81% participants were 
analysed in treatment and control groups 
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Figure 26. HRQoL: Graphical summary (continued) 
Key: ?, unknown; BSI, Brief Symptom Inventory; CLAS, Cancer Linear Analogue Score; EORTC QLQ C-30, European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire C30; FACT, Functional Assessment of Cancer Therapy (-An, Anaemia; -F, Fatigue; G, General); HRQoL, health-related quality of life; LASA, Linear Analogue Scale Assessment; 
NHP, Nottingham Health Profile; PDI, Psychological Distress Inventory; SF-36, Short Form 36; VAS, Visual Analogue Scale; D&A, Depression and Anxiety subscale of BSI 
Notes: 1 Paediatric population evaluated; 2 Study population included pts not receiving chemotherapy; 3 87% and 84% participants were analysed in treatment and control groups, respectively, 4 
80% and 73% participants were analysed in treatment and control groups, respectively, 5 54% and 57% participants were analysed in treatment and control groups, respectively, 6 75% and 61% 
participants were analysed in treatment and control groups, respectively, 7 90-98% and 86-97% participants were analysed in treatment and control groups, respectively, 8 81% participants were 
analysed in treatment and control groups 
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Figure 26. HRQoL: Graphical summary (continued) 
Key: ?, unknown; BSI, Brief Symptom Inventory; CLAS, Cancer Linear Analogue Score; EORTC QLQ C-30, European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire C30; FACT, Functional Assessment of Cancer Therapy (-An, Anaemia; -F, Fatigue; G, General); HRQoL, health-related quality of life; LASA, Linear Analogue Scale Assessment; 
NHP, Nottingham Health Profile; PDI, Psychological Distress Inventory; SF-36, Short Form 36; VAS, Visual Analogue Scale; D&A, Depression and Anxiety subscale of BSI 
Notes: 1 Paediatric population evaluated; 2 Study population included pts not receiving chemotherapy; 3 87% and 84% participants were analysed in treatment and control groups, respectively, 4 
80% and 73% participants were analysed in treatment and control groups, respectively, 5 54% and 57% participants were analysed in treatment and control groups, respectively, 6 75% and 61% 
participants were analysed in treatment and control groups, respectively, 7 90-98% and 86-97% participants were analysed in treatment and control groups, respectively, 8 81% participants were 
analysed in treatment and control groups 
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Figure 26. FACT-F analysis 
Key: ?, unknown; BSI, Brief Symptom Inventory; CLAS, Cancer Linear Analogue Score; EORTC QLQ C-30, European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire C30; FACT, Functional Assessment of Cancer Therapy (-An, Anaemia; -F, Fatigue; G, General); HRQoL, health-related quality of life; LASA, Linear Analogue Scale 
Assessment; NHP, Nottingham Health Profile; PDI, Psychological Distress Inventory; SF-36, Short Form 36; VAS, Visual Analogue Scale; D&A, Depression and Anxiety subscale of 
BSI 
Notes: 1 80% and 73% participants were analysed in treatment and control groups, respectively, 2 90-98% and 86-97% participants were analysed in treatment and control groups, 
respectively, 3 81% participants were analysed in treatment and control groups 
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5.4. Summary 
KEY POINTS 
 Fourteen trials measuring HRQoL were reported in 24 publications. Of these 
publications, 11 primary studies were included in the review by Wilson and 
colleagues (2007).1 Three new primary studies were identified in the update 
searches  
 The method of randomisation was unclear in seven of the primary studies with all 
reports having unclear allocation concealment. Baseline characteristics were 
unbalanced in two trials. Patients and physicians were blinded for the majority of 
trials, which is considered to have a significant impact of HRQoL assessed by self-
reporting. HRQoL suffered significant losses for at least six trials. 
 FACT-F 13 item data were extracted from review by Tonia and colleagues (2012),10 
given their greater access to data than that provided in the primary papers. FACT-F 
scores were available from seven studies with one new primary study identified.  
 Overall, conclusions from the PenTAG review are in agreement with the Cochrane 
review (Tonia and colleagues, 2012)10 in that there is a statistically significant 
difference between patients treated with ESAs and controls when combining HRQoL 
parameters, which is, however, most likely not clinically important (the threshold MD 
of 3.0 [Cella and colleagues, 2002])96.  
 Univariate subgroup analyses conducted for FACT-F outcomes according to 
chemotherapy type, malignancy type, intervention (epoetin or darbepoetin), and study 
duration, also showed similarly statistically significant results between intervention 
and control. 
 Meta-analysis was performed on FACT-G and FACT-An (7 items), however, only 
three studies were suitable for inclusion for each scale with high levels of 
heterogeneity.The results of no statistical difference between intervention and control 
must therefore be treated with caution. 
 Publication bias was noted in the Cochrane review (Tonia and colleagues, 2012)10, 
suggesting over reporting of studies that showed beneficial effects of ESAs. It was 
not possible to examine publication bias using funnel plots because <10 included 
studies. Therefore, it was not possible to confirm or refute the claims made in the 
Cochrane review. 
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 Assessment of cost-effectiveness 
6.1. Systematic review of existing cost-effectiveness 
evidence 
The cost-effectiveness of erythropoiesis-stimulating agents (ESAs) within their licensed 
indications for the treatment of chemotherapy-induced anaemia (CIA) against each other and 
against best supportive care (BSC) was assessed in a systematic review of the literature. 
This systematic review of cost effectiveness evidence was an update of a systematic review 
reported by Wilson and colleagues (2007)1 which informed previous NICE guidance 
TA142.34 The methods and results of the previous systematic review are summarised in 
Section 6.1.1, the methods for this update review are described in Section 6.1.2 and the 
results of the update review are shown in Section 6.1.2.3. 
Economic evaluations submitted by manufacturers in this appraisal would have been 
included in the systematic review but no such evaluations were submitted. 
6.1.1. Wilson and colleagues (2007): Summary 
A systematic review of cost-effectiveness evidence was reported by Wilson and colleagues 
(2007) which informed previous NICE guidance TA142.1,34 
6.1.1.1.  Objective 
The objective of this systematic review was: ‘to identify and appraise past economic 
evaluations of erythropoietin in the treatment of anaemia associated with cancer treatment.’ 
6.1.1.2.  Methods 
Searches were conducted in databases as detailed in Table 47. Industry submissions were 
also evaluated and searched for additional references. 
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Table 47. Databases searched in systematic review by Wilson and colleagues, 20071 
Database Interface Date range 
MEDLINE Ovid 1966 to July week 4 2004
EMBASE Ovid 1980 to 2004 week 30 
DARE   2004 Issue 3 
NHS EED   2004 Issue 3 
OHE HEED   July 2004 issue 
Key: DARE, Database of Reviews and Effects; EED, Economic Evaluation Database; OHE EED, Office of 
Health Economics Health Economic Evaluations Database 
 
Separate search strategies were developed for costs, economic models and quality of life 
studies and are detailed in Appendix 3 of Wilson and colleagues (2007).1 
The inclusion criteria were such that included studies were: ‘all economic evaluations (cost-
benefit, cost-utility, cost-effectiveness and cost-consequence analyses) of erythropoietin for 
anaemia associated with cancer treatment from 1995 to July 2004.’  Screening was 
performed by one reviewer. 
Included studies were critically appraised using the checklist suggested by Drummond and 
colleagues.114  Single points were also assigned to all but one criteria on the Drummond 
checklist when met and summed to give an overall quality score for a study. 
Data were abstracted from the studies using a framework used by the West Midlands group 
in previous technology appraisals.  Data abstraction was performed by one reviewer and 
checked by another. 
Qualitative analysis was performed by one reviewer based on manually identified patterns in 
tabulated data.  Conclusions were scrutinised by two other reviewers. 
6.1.1.3.  Results 
Electronic database searches resulted in 491 citations.  No additional citations were 
identified from industry submissions.  Full texts were retrieved for 44 citations (the remainder 
being excluded as irrelevant on the basis of title and/or abstract).  Five studies (Barosi and 
colleagues, 1998; Cremieux and colleagues, 1999; Martin and colleagues, 2003; Ortega 
and colleagues, 1998; Sheffield and colleagues, 1997) were included following full text 
screening (the remainder generally being excluded for not considering both costs and 
benefits).115-119  Figure 27 shows the study flow diagram for the systematic review. 
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Figure 27. Study flow diagram for systematic review of cost-effectiveness evidence 
reported by Wilson and colleagues (2007)1 
 
Notes: Adapted from PRISMA flow diagram120 
 
The results of three cost-utility studies included in the systematic review reported by Wilson 
and colleagues (2007)1 are also included in the update review results in Section 6.1.2.3 
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Two other studies were included, one by Ortega and colleagues (1998)118 and one by 
Sheffield and colleagues (1997).119 Ortega and colleagues (1998)118 used a willingness-
to-pay experiment to determine the societal benefit of epoetin alfa in monetary terms and 
compare this to the predicted incremental costs of epoetin alfa.  The benefit described was 
avoidance of transfusion and was separately valued by cancer patients and by the general 
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outweighed the benefits in monetary terms and the conclusion was therefore that epoetin alfa 
was less cost-effective than standard care with RBCT.  Sheffield and colleagues (1997)119 
used a decision tree to model the costs and consequences of epoetin alfa use and 
concluded that epoetin alfa would be dominated by standard care with RBCT; i.e., it would be 
more expensive and produce worse outcomes.  Wilson and colleagues (2007) highlighted 
several assumptions made which seemed implausible.1 
6.1.2. Update review 
6.1.2.1.  Objective 
The objective of the update review was specified in the appraisal protocol: 
This systematic review aims to update the systematic review of cost-effectiveness studies 
which was conducted in 2004 as part of the review of evidence to inform NICE’s earlier 
guidance on these drugs (TA142).34 
The review will aim to summarise the main results of past studies, and identify any key 
economic costs and trade-offs relevant to the decision problem.  It may also indicate the 
strengths and weaknesses of different modelling approaches in this treatment area. 
Therefore, it will fully extract study data and assess study quality only for those economic 
evaluations or costing studies published since 2004 which are of relevance to the current 
decision problem. 
6.1.2.2.  Methods 
6.1.2.2.1.  Searches 
Search strategies were designed by an information specialist (SB) and were based on the 
searches for clinical effectiveness evidence, with additional terms to limit to economic 
evaluations (see Appendix B).  Table 48 gives a summary of the databases searched.  
Where possible, searches were limited to publications since 2004. 
Table 48. Databases searched in the update review 
Database Host Date range 
MEDLINE Ovid 1946 to May week 3 2013
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MEDLINE In-Process & Other 
Non-Indexed Citations 
Ovid To 28 May 2013 
EMBASE Ovid 1980 to 2013 week 21 
NHS EED Cochrane library Issue 2 of 4, April 2013 
Web of Science Thomson Reuters Searched 29/05/2013 
CINAHL EBSCO Searched 29/05/2013 
OHE HEED Cochrane library Searched 29/05/2013 
Key: DARE, Database of Reviews and Effects; NHS EED, NHS Economic Evaluation Database; OHE EED, 
Office of Health Economics Health Economic Evaluations Database 
Notes: A date filter term was used to specify publication date from 2004 (except for OHE HEED) 
 
In addition, supplementary searches not limited to cost-effectiveness were conducted in the 
following databases on 24–30 May 2013 (see Appendix B): 
 Cochrane Database of Systematic Reviews (via the Cochrane Library): Issue 4 of 12, 
April 2013 
 Database of Abstracts of Reviews of Effects (DARE) and Health Technology 
Assessment (HTA) database (via the Cochrane Library): Issue 2 of 4, April 2013 
 Health Management Information Consortium (HMIC) database (via Ovid): 1979 to 
March 2013. 
6.1.2.2.2.  Screening 
Inclusion and exclusion criteria were the same as for the clinical effectiveness systematic 
review (Section 4.1.2, page 59), with the following exceptions (as specified in the appraisal 
protocol): 
 Non-randomised studies were included (e.g., decision model based analyses or 
analyses of patient-level cost and effectiveness data alongside observational 
studies). 
 Full cost-effectiveness analyses, cost-utility analyses, cost-benefit analyses and cost 
consequence analyses were included. (Economic evaluations which only report 
average cost-effectiveness ratios were only included if the incremental ratios could be 
easily calculated from the published data). 
 Standalone cost analyses based in the UK NHS were also sought and appraised. 
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For the purpose of this review ‘administered in accordance with licensed indications’ was 
taken to mean the frequency of administration but not the dose quantity.  Licences allowed 
for all ESAs to be administered weekly, for darbepoetin alfa to be administered every three 
weeks, for epoetin alfa and epoetin zeta to be administered three times a week and for 
epoetin beta to be administered three to seven times a week.  Fixed dosage and weight-
based dosages were allowed; this is a different application of the licence to the systematic 
review of clinical effectiveness evidence (Section 6.1.2.2.7, page 209). 
Titles and abstracts were screened for relevance by two reviewers (NH and TS), with 
disagreements resolved by discussion.  Full texts were retrieved for references judged to be 
relevant and were screened for eligibility by the same reviewers, with disagreements 
resolved by discussion. 
The bibliographies of review articles not judged eligible for inclusion were examined by one 
reviewer (TS) to identify other potentially relevant references.  These references were 
retrieved and checked for eligibility in the same way as full texts from database searches. 
6.1.2.2.3.  Data extraction 
Study characteristics and results were abstracted by one reviewer (TS) using a template 
adapted from the systematic review by Wilson and colleagues (2007).1  In addition, 
parameters which could be used in the construction of an independent economic model were 
identified and noted. 
6.1.2.2.4.  Selection of studies for detailed appraisal and reporting 
Data extraction was conducted for all included studies, but for reasons of expediency, not all 
studies which were eligible according to the inclusion and exclusion criteria were selected for 
detailed appraisal and reporting.  Instead, only systematic reviews (n=2) and cost-utility 
studies (n=3) were selected for detailed appraisal and reporting. Data extraction for these 
studies was checked by a second reviewer (HC). 
6.1.2.2.5.  Quality appraisal 
Selected studies  (all new systematic reviews and cost-utility studies) were quality assessed 
using the checklist developed by Evers and colleagues (2005)121 by one reviewer (TS).  In 
line with the instructions accompanying the final checklist, where there was insufficient 
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information available in the article to assess quality the item was marked ‘No’.  In contrast to 
the previous review there was no attempt to assign scores to studies on the basis of the 
quality appraisal checklist. 
Where these studies were based on decision models, they were further quality assessed 
using the checklist developed by Philips and colleagues (2006).122 
6.1.2.2.6.  Analysis 
The results of included studies were qualitatively analysed on the basis of visual inspection 
of the tabulated extracted data.  Draft conclusions were drawn by one reviewer (TS) and 
scrutinised by all authors from PenTAG. 
6.1.2.2.7.  Changes from protocol 
For the purpose of the cost-effectiveness review ‘administered in accordance with licensed 
indications’ was taken to mean the frequency of administration but not the dose quantity or 
calculation (i.e., fixed and weight-based doses were accepted).  Had the same criteria been 
used as for the systematic review of clinical effectiveness evidence then several cost-utility 
analyses would have been excluded: 
 Cremieux and colleagues (1999),116 Fagnoni and colleagues (2006)123 and Tonelli 
and colleagues (2009)112 would have been excluded for using fixed doses; 
 The Roche and Ortho Biotec submissions would have been excluded as the doses 
were not reported in Wilson and colleagues (2007)1; 
 The de novo analysis in Wilson and colleagues (2007)1 would have been excluded 
as doses were not reported. 
Given the importance of the above studies to the conclusions of this review it appears 
reasonable to have not included dose quantity or calculation method in the assessment of 
study eligibility for the cost-effectiveness review. 
At the full-text screening stage only one study was excluded due to unlicensed dose 
schedule, Glaspy and colleagues (2002),124 which was only published as an abstract and 
used darbepoetin alfa once every two weeks.   
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Data extraction was conducted for all included studies but only a subset of studies 
(systematic reviews and cost-utility studies) was selected for detailed appraisal and 
reporting.  This change was to ensure that efforts were focused on the most relevant studies 
to the appraisal given the significant number of non-QALY outcomes of limited utility to 
decision makers attempting to maximise the total health benefit across healthcare spending.  
This resulted in the exclusion of 12 studies in abstract form only (characteristics and results 
given in Appendix P) and six studies in full paper form (characteristics and results in Section 
6.1.2.3, page 210). 
6.1.2.3.  Results 
Figure 28 (page 212) shows the study flow diagram of this update review.  The electronic 
database search for cost-effectiveness evidence identified 1,131 records, and the 
supplementary search identified 32 records.  After de-duplication 843 records remained, all 
of which were screened by title and abstract.  Of these 47 were identified for full-text 
screening and 43 full texts were retrieved and assessed for eligibility.  The bibliographies of 
six reviews (Cornes and colleagues, 2007; Herrmann and colleagues, 2008; Marchetti 
and colleagues, 2004; Reeder and colleagues, 2007; Repetto and colleagues, 2006; 
Stasi and colleagues, 2005)125-130 (which were excluded as they were not deemed to be 
systematic) were examined by one reviewer (TS) and a further seven records were identified 
for full-text screening, of which six were retrieved.  A total of five records could not be 
retrieved. 
One study which could not be obtained was by Roungrong and colleagues (2008)131 which 
is a cost-utility analysis of epoetin alfa for cancer patients with anaemia in Thailand.  The 
Centre for Reviews and Dissemination produced a critical appraisal of the study for the NHS 
Economic Evidence Database (NHS EED),132 which reveals that the study was generally well 
conducted except for the limited reporting of clinical data sources and that it concluded 
epoetin alfa would not be a cost-effective alternative to standard care with RBCT. 
Three studies which could not be obtained were published in 1997/1998, one of which was 
by Sheffield and colleagues (1997)119 and included in the previous systematic review by 
Wilson and colleagues (2007).1  Two studies by Griggs and colleagues (1997 and 
1998)133,134 also could not be obtained.  One appears to be a conference abstract of a cost-
utility study (Griggs and colleagues, 1997).133 The other (Griggs and colleagues, 1998) 
appears to be a full paper but likely to be a review rather than a primary study.134 
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Finally one conference abstract by Malonne and colleagues (2005) could not be obtained, 
although the title suggests it may have only evaluated costs.135 
Of the 47 full texts assessed for eligibility, 29 were deemed to meet the eligibility criteria.  
Reasons for exclusion after full text screening are detailed in Appendix N.  Five texts (Borget 
and colleagues, 2006; Borget and colleagues, 2007; Chouaid and colleagues, 2005; 
Finek and colleagues, 2010; Klarenbach and colleagues, 2010)136-140 were deemed to be 
multiple publications, including four abstracts and a peer-reviewed journal paper by 
Klarenbach and colleagues (2010)140 deemed to be a multiple publication of the CADTH 
technology assessment report by Tonelli and colleagues (2009)112 (see Appendix O), 
leaving 24 primary studies from which data was abstracted.  Twelve primary publications 
were conference abstracts (Szucs and colleagues, 2001; Cremieux and colleagues, 2003; 
Mark and colleagues, 2003; Hout and colleagues, 2004; Ben-Hamadi and colleagues, 
2005; Van Bellinghen and colleagues, 2006; Esposito and colleagues, 2007; Van 
Bellinghen and colleagues, 2007; Finek and colleagues, 2010; Liwing and colleagues, 
2010; Walter and colleagues, 2010; Fragoulakis and colleagues, 2011);141-152 three were 
or included systematic reviews (Wilson and colleagues, 2007; Duh and colleagues, 2008; 
Tonelli and colleagues, 2009),1,112,153 and two were related to the previous NICE appraisal 
(Wilson and colleagues, 2007; NICE TA142, 2007);1,34 these are described elsewhere in 
this report (Section 2.7.1, page 46) and are not appraised as a part of this update review, 
although the results of Wilson and colleagues (2007)1 are considered as conclusions are 
drawn. 
Summary tables of characteristics, key parameters and findings for abstracts are given in 
Appendix P.  Summary tables of characteristics, key parameters and findings for full papers 
are shown in Table 56, Table 57 and Table 58 respectively. 
Of the eligible studies, four (Fagnoni and colleagues, 2006; Borg and colleagues, 2008; 
Duh and colleagues, 2008; Tonelli and colleagues, 2009)112,123,153,154 were selected for 
detailed appraisal. These comprised one standalone systematic review by Duh and 
colleagues (2008)153 and three new cost-utility studies(Fagnoni and colleagues, 2006; 
Borg and colleagues, 2008; Tonelli and colleagues, 2009)112,123,154 of which one also 
contained a systematic review (Tonelli and colleagues, 2009).112 
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Figure 28. PRISMA flow diagram of update review 
 
PenTAG   CONFIDENTIAL 
213 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
6.1.2.3.1.  Summaries of identif ied systematic reviews 
Duh and col leagues, 20081 53 
Duh and colleagues (2008) conducted a systematic review of the medical literature to 
identify cost and cost-effectiveness studies of epoetin alfa, epoetin beta and darbepoetin 
alfa.  MEDLINE® and ‘all other PubMed databases’ were searched from January 2000 to 
April 2007 for English-language journals with human subjects and combinations of the 
following sets of terms: 
 Intervention terms: epoetin, darbepoetin, Procrit®, Aranesp®, Epogen®, 
erythropoietin, erythropoietic agent 
 Outcome terms: cost, effectiveness, pharmacoeconomic 
It is notable that the authors did not include studies comparing ESAs with standard care not 
comprising ESA therapy. 
The authors identified 67 studies in the field of oncology in addition to 39 in chronic kidney 
disease and 46 in other areas.  We report only the aspects of the report relating to oncology.  
Ten of the 67 studies were selected for review and a further nine were identified through 
conferences (meetings of ASCO, ASH, ESMO and EHA in the period 2003–2006) or 
bibliographies to give a total of 19 studies reviewed. 
The authors appear to have conducted some limited critical appraisal although no specific 
critical appraisal tool appears to have been used.  A narrative synthesis was conducted 
utilising textual descriptions and tabulation. 
All nineteen studies identified compared epoetin alfa with darbepoetin alfa, and three studies 
additionally included epoetin beta as a comparator.  No evaluations included standard care 
without ESA therapy as a comparator. 
Various outcome measures were found, and in five studies no effectiveness measures were 
reported.  No cost-utility studies (i.e., studies with QALYs as the outcome measure) were 
identified. 
Cost ratios are presented for all but one study and suggest that epoetin alfa is cheaper than 
darbepoetin alfa in most cases, although the authors acknowledge that many studies do not 
include costs other than drug acquisition costs. 
PenTAG   CONFIDENTIAL 
214 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Cost-effectiveness results were not always presented when effectiveness outcomes were 
listed as being included; only measures of drug costs were given for nine of the fourteen 
studies with listed effectiveness outcomes, and in all five studies where cost-effectiveness 
results are presented epoetin alfa has a lower average cost-effectiveness ratio than 
darbepoetin alfa. 
The authors made a number of arguments which seemed to be designed to undermine 
results from existing cost-utility studies which produced ICERs above cost-utility thresholds, 
notably: 
 The studies are outdated and corresponding changes in pricing and practice patterns 
as well as emerging clinical effectiveness evidence should be considered. 
 ESAs only approach acceptable cost-utility thresholds when a survival benefit is 
assumed.  As survival benefit is not a ‘main outcome’ of ESA therapy and such 
benefits are uncertain, cost-utility results ‘may be best used to augment evidence 
from studies that measure costs and effectiveness separately.’ 
The authors also suggested that cumulative changes in haemoglobin levels are more 
relevant for payers than overall responses at a particular point in time, suggesting that failing 
to use cumulative measures will underestimate the value of epoetin alfa which is claimed to 
achieve a response more rapidly than darbepoetin alfa (the authors cited an earlier 
publication sharing two authors with the systematic review, including the primary author). 
The authors acknowledged that financial support was provided by Ortho Biotec 
(manufacturers of epoetin alfa) who provided editorial review and approval of the manuscript.  
There was inconsistent reporting of study results which may have biased the apparent 
results in favour of epoetin alfa. 
Tonel l i  and col leagues, 20091 12 
Tonelli and colleagues conducted a systematic review of the medical literature and health 
economic literature to identify economic evaluations of ESAs in adult patients with 
malignancy and anaemia.  MEDLINE, EMBASE, EconLit and NHS EED were searched on 
11–21 October 2007 using search strategies listed in an appendix. 
Studies were included if they met the following criteria (reproduced verbatim as permitted): 
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 Evaluated the incremental impact of an ESA against a comparator group on relevant 
costs and health outcomes 
 included one of the following in the comparator group: placebo, no therapy with 
ESAs, different ESA or same ESA but varying hemoglobin target, dose or schedule 
 included (in a cost-minimization analysis) comparisons of different ESAs or 
comparisons of alternative route or schedule of administration of ESAs to achieve a 
similar hemoglobin target, only if based on RCT data for effectiveness 
 Examined a cohort of adult patients with malignancy and anemia 
Included studies were quality appraised using a checklist adapted from the literature and 
relevant data (including industry funding) was extracted. 
A qualitative synthesis of included studies was planned as a small number of studies were 
expected. 
The combined searches produced 1,134 citations, of which 58 were identified for scrutiny by 
full text.  Forty-seven studies were excluded to leave 11 primary studies included in the 
systematic review. 
Five of the 11 studies were cost-utility analyses: 
 Wilson and colleagues (2007),1 produced for the previous NICE appraisal 
 Fagnoni and colleagues (2006),123 also identified in this update review 
 Martin and colleagues (2003),117 Cremieux and colleagues (1999)116 and Barosi 
and colleagues (1998);115 all included in the systematic review reported in Wilson 
and colleagues (2007)1 
Quality appraisal of these studies demonstrated that none met all quality criteria but all met 
most quality criteria. 
Narrative review identified that only one study, by Martin and colleagues (2003),117 reported 
an attractive incremental cost-utility ratio (ICUR).  Tonelli and colleagues (2009)112 note that 
this was an industry-sponsored study and that a subgroup of RCT patients with Stage IV 
breast cancer were identified to inform the model who demonstrated a survival advantage 
with epoetin use (although this survival advantage did not reach statistical significance), and 
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the favourable cost-effectiveness results did not remain when the whole population of the 
RCT was used instead. 
The six non-cost-utility studies were: 
 Ossa and colleagues (2007),155 a discrete choice experiment to ascertain the utility 
of anaemia-related health states and the willingness-to-pay for epoetin alfa 
 Borget and colleagues (2006),156 a model-based cost-effectiveness analysis of 
darbepoetin alfa versus standard care without ESA use in patients with lung cancer 
with an effectiveness measure related to the final haemoglobin level achieved 
 Reed and colleagues (2006),157 a cost-consequences analysis based on an open-
label RCT of epoetin alfa once weekly and darbepoetin alfa every two weeks in 
patients with solid malignancies 
 Casadevall and colleagues (2004),158 a study of epoetin and rHuG-CSF and 
supportive care in patients with myelodysplastic syndrome (this was excluded from 
this review due to concomitant treatment with G-CSF) 
 Ortega and colleagues (1998)118 and Sheffield and colleagues (1997);119 both 
identified in the systematic review reported by Wilson and colleagues (2007)1 
Tonelli and colleagues (2009)112 noted in their discussion that ESA use leads to large 
incremental costs which do not tend to be significantly altered across a range of costs for 
RBCT.  They noted that where health outcomes were converted to a common metric (QALYs 
for cost-utility analyses, costs for cost-benefit analyses), most of the base case analyses 
indicated that ESAs were not a cost-effective use of health resources. 
Tonelli and colleagues (2009)112 identified that the lack of preference-based utility scores 
from RCTs was a weakness, and that even with many opportunities for confounding and bias 
which could favour ESA use, nevertheless most studies produced unfavourable estimates of 
cost-effectiveness. 
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6.1.2.3.2.  Characterist ics of new cost-uti l i ty studies 
Fagnoni and col leagues, 20061 23 
In this study the authors retrospectively identified 192 consecutive breast cancer patients 
receiving either of two standard adjuvant chemotherapy regimens between 1999 and 2004, 
of which 91 were treated before the use of EPO was allowed (1999–2001), and 101 could 
have received EPO (2002–2004).  Patients were excluded if their disease progressed during 
the 22-week study period or if they failed to complete the chemotherapy course within the 
study period.  A cost-utility analysis was conducted from a healthcare perspective by 
modelling costs and quality of life for patients in the study according to individual patient 
records. 
Per patient costs were calculated by extracting resource use from individual patient 
computerised records and applying unit costs (see Table 54, page 226).  All costs were in 
euros at 2004 prices.  Exact doses administered were recorded and priced.  An official tariff 
was used for the cost of blood transfusion per red blood cell transfusion unit.  Double 
counting owing to the tariff for blood transfusion was avoided by removing costs already 
collected for blood transfusions from hospitalisation costs. 
Quality of life was modelled as a function of haemoglobin level, according to the Linear 
Analog Scale Assessment (LASA) methodology described by Crawford and colleagues 
(2002)159 after being placed in discrete sections.  Haemoglobin levels were measured at least 
every three weeks (i.e., at least once per chemotherapy cycle).  The lowest haemoglobin 
level measured was taken as the haemoglobin level for each chemotherapy cycle. 
Four sensitivity analyses were conducted.  In the first, different methodologies were explored 
for modelling quality of life as a function of haemoglobin level.  In the second, unit costs were 
all scaled up or down by 30%.  In the third, subgroups were identified by age or 
chemotherapy regimen.  In the fourth, indirect costs relating to sick leave were included, 
reducing the population to those initially active and for whom French Public Health Insurance 
data were available. 
Borg and col leagues, 20081 54 
In this study the authors constructed an economic model based on the model presented by 
Wilson and colleagues (2007)1 to evaluate the cost-utility (measured in euros or Swedish 
kronor per QALY) of epoetin alfa compared to red blood cell transfusion. 
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Two epoetin alfa strategies were included, in both of which red blood cell transfusion was 
given and epoetin alfa treatment was initiated if the Hb level fell below 10 g/dL.  In the first 
epoetin alfa strategy, called EPOLOW, patients received EPO until they reached a target Hb 
level of 12 g/dL (reflecting Swedish treatment guidelines at the time of writing).  In the second 
epoetin alfa strategy, called EPOHIGH, the target Hb level was 13 g/dL (reflecting earlier 
Swedish treatment guidelines).  Patients responding to epoetin alfa were classed as 
responders and did not discontinue epoetin alfa until the target Hb was reached.  Patients 
not responding were treated with epoetin alfa for two chemotherapy cycles (each four weeks) 
before being discontinued.  No dose doubling was included in the base case analysis. 
Three red blood cell transfusion strategies were included, with trigger Hb levels of 9, 10 and 
11 g/dL for transfusion of two units red blood cells. 
After chemotherapy cessation (six treatment cycles of four weeks each) Hb levels normalise 
to 13 g/dL at a rate of 1 g/dL per four weeks. 
The effectiveness of epoetin alfa in achieving a haemoglobin response was estimated by 
calibrating to a study in which doses were doubled if a response was not achieved within four 
weeks, with some adjustment (perhaps arbitrary) to remove the impact of dose doubling. 
A healthcare perspective was adopted and the following costs were included: drug 
acquisition, nurse-led hospital oncology clinic (one-off drug administration for epoetin alfa), 
filtered red blood cells acquisition, red blood cell transfusion administration.  Unit costs for 
drug acquisition were derived from Pharmaceutical Specialities in Sweden, FASS (it is not 
clear whether these are list prices or acquisition prices); other unit costs were derived from 
the price list of the Swedish Southern Health Care Region for 2007. 
Utilities were mapped from Hb levels using data from Wilson and colleagues (2007).1 
Tonel l i  and col leagues, 20091 12 
In this study the authors constructed an economic model to examine the cost-utility of ESA 
use in adults matching those enrolled in trials of ESAs for the treatment of anaemia related to 
cancer. 
The economic model consists of two submodels, one which represents the fifteen weeks 
during which ESA is administered in RCTs and another which represents the following year, 
during which the impact of ESAs on long-term survival are assessed. 
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Inputs for the model were drawn from a systematic review of clinical effectiveness evidence 
conducted by the authors and included: 
 Quality of life improvement (calculated using a relationship between haemoglobin 
levels and health-related quality of life) 
 Haemoglobin level improvement from baseline to end of trial period 
 Reduction in RBC units transfused 
 Short-term mortality (within 15 weeks) 
 Long-term mortality (within one year) 
Although an increase in all adverse events was found in the systematic review of clinical 
effectiveness this was not included in the base-case analysis due to the heterogeneous 
nature of those adverse events and the lack of data regarding resource utilisation and costs 
of these adverse events. 
A healthcare perspective was adopted and costs were included for: 
 ESA acquisition (epoetin alfa in the base-case, darbepoetin alfa in a scenario 
analysis) 
 RBC transfusion (acquisition and administration) 
In the base-case analysis, gains in haemoglobin level for patients receiving ESA therapy 
over patients not receiving ESA therapy were assumed to be instantaneous (acting in favour 
of ESA cost-effectiveness) but the gains were not assumed to persist beyond the 15 weeks 
from RCTs (i.e., instantaneous normalisation, acting against the cost-effectiveness of ESA 
therapy).  In a scenario analysis the gains were assumed to persist for an additional 11 
weeks. 
6.1.2.3.3.  Quality of new cost-uti l i ty studies 
The quality appraisal checklist developed by Evers and colleagues121 was applied to the 
three new cost-utility studies (see Table 49).  None of the studies reported the use of 
discounting, although given the short time horizons used discounting would have been 
unlikely to materially affect the results.  All three studies performed an incremental analysis 
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and included some sensitivity or scenario analyses, but only Tonelli and colleagues 
(2009)112 were judged to have included sensitivity analyses of all important variables.  No 
study produced a probabilistic sensitivity analysis. 
The reviewer (TS) believes the only item where quality was not indicated which would 
materially affect conclusions is that Borg and colleagues (2008)154 did not subject many of 
the key parameters, the values of which were uncertain, to sensitivity analyses. 
Table 49. Quality appraisal of new cost-utility studies using the checklist developed by 
Evers and colleagues121 
 Fagnoni, 
2006123 
Borg, 
2008154 
Tonelli, 
2009112 
1. Is the study population clearly described? Yes Yes Yes 
2. Are competing alternatives clearly described? Yes Yes Yes 
3. Is a well-defined research question posed in an 
answerable form? 
Yes Yes Yes 
4. Is the economic study design appropriate to the stated 
objective? 
Yes Yes Yes 
5. Is the chosen time horizon appropriate to include 
relevant costs and consequences? 
No Yes No 
6. Is the actual perspective chosen appropriate?a Yes Yes Yes 
7. Are all important and relevant costs for each alternative 
identified? 
No Yes No 
8. Are all costs measured appropriately in physical units? Yes Yes Yes 
9. Are costs valued appropriately? No Yes Yes 
10. Are all important and relevant outcomes for each 
alternative identified? 
No Yes Yes 
11. Are all outcomes measured appropriately? Yes Yes Yes 
12. Are outcomes valued appropriately? Yes Yes Yes 
13. Is an incremental analysis of costs and outcomes of 
alternatives performed? 
Yes Yes Yes 
14. Are all future costs and outcomes discounted 
appropriately? 
No No No 
15. Are all important variables, whose values are uncertain, 
appropriately subjected to sensitivity analysis? 
No No Yes 
16. Do the conclusions follow from the data reported? Yes Yes Yes 
17. Does the study discuss the generalisability of the 
results to other settings and patient/client groups? 
No No Yes 
18. Does the article indicate that there is no potential 
conflict of interest of study researcher(s) and funder(s)? 
Yes No No 
19. Are ethical and distributional issues discussed 
appropriately? 
No No Yes 
Notes: (a) For this decision problem, a healthcare perspective was deemed to be appropriate 
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Table 50. Quality appraisal of new model-based cost-utility studies using the checklist 
developed by Philips and colleagues122 
 Borg, 2008154 Tonelli, 2009112 
Structure (S) 
S1: Statement of decision problem/objective No Yes 
S2: Statement of scope/perspective Yes Yes 
S3: Rationale for structure No No 
S4: Structural assumptions No Yes 
S5: Strategies/comparators No No 
S6: Model type Yes Yes 
S7: Time horizon Yesa No 
S8: Disease states/pathways Yes Yes 
S9: Cycle length No N/A 
Data (D) 
D1: Data identification No Yes 
D2: Pre-model data analysis (No) (Yes) 
D2a: baseline data Yes Yes 
D2b: treatment effects No Yes 
D2c: quality-of-life weights (utilities) Yes Yes 
D3: Data incorporation Yes No 
D4: Assessment of uncertainty (No) (No) 
D4a: methodological No Yes 
D4b: structural No Yes 
D4c: heterogeneity No Yes 
D4d: parameter No No 
Consistency (C) 
C1: Internal consistency No Yes 
C2: External consistency Yes Yes 
Notes: (a) Assuming no survival benefit from ESAs
 
6.1.2.3.4.  Key parameters of al l  cost-uti l i ty studies 
ESA dosage 
ESA dosing strategies vary significantly in the literature in terms of: 
 Start dose (fixed or weight-based) 
 Trigger Hb level (i.e., the point below which ESAs should be administered) 
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 Target Hb level (i.e., the point above which ESAs should be stopped or titrated) 
 Dose escalation (sometimes used if patients do not achieve a haematological 
response within a specified time period) 
 ESA abandonment for persistent non-responders 
 Duration of continued ESA use following chemotherapy cessation 
These aspects of dosing will potentially affect clinical effectiveness (Section 4.1.2.3.1, page 
60 and Appendix C) and almost certainly affect cost-effectiveness. 
Start doses were generally well reported and were broadly consistent with licensed doses.  
Trigger Hb levels were not always reported and varied from 10 g/dL in Borg and colleagues 
(2008)154 to 13 g/dL in Wilson and colleagues (2007).1 Target Hb level was only reported in 
two studies, 13 g/dL in Wilson and colleagues1 and 12 g/dL in Borg and colleagues.154 
Dose escalation was included in the analyses by Martin and colleagues (2003)117 and by 
Fagnoni and colleagues (2006),123 in both case doubling the dose, after four and six weeks 
of inadequate response respectively.  Dose escalation may improve clinical effectiveness but 
adds costs, which may lead to an overall worsening of cost-effectiveness (indeed Borg and 
colleagues (2008)154 found that dose doubling was not cost-effective relative to non-
escalated dosing). 
ESA abandonment was included in the analyses by Wilson and colleagues (2007)1 at 12 
weeks, Fagnoni and colleagues (2006)123 at 12 weeks and Borg and colleagues (2008)154 
at eight weeks.  Abandoning ESA therapy for non-responders is likely to improve cost-
effectiveness as such patients are unlikely to benefit from further therapy which would incur 
significant costs.  Earlier abandonment may improve the cost-effectiveness of ESA therapy. 
Continuation of ESA therapy following chemotherapy cessation was only explicitly reported in 
the study by Martin and colleagues (2003),117 where patients were expected to receive ESA 
therapy for four weeks following chemotherapy cessation, although delays in chemotherapy 
treatment would reduce the duration of continued use.  Continuation of ESA therapy is 
allowed for in the ESA licenses up to four weeks, which could hasten the return to normal Hb 
levels for patients receiving ESA and increase the QALY benefit estimated to arise in the 
normalisation period. 
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Table 51. Dosage in primary cost-utility analyses 
 Start dose Trigger Hb Target Hb Dose 
escalation 
ESA 
abandon-
ment 
Duration of 
continued 
use 
Barosi, 
1998115 
Epo-a 
Q3W: 150 
IU/kg 
10.7 g/dL None None None NR 
Cremieux, 
1999116 
Epo-a 
Q3W: 
10,000 IU 
NR None None None None 
Martin, 
2003117 
Epo-a 
Q3W: 150 
IU/kg 
10.5 g/dL None After 4 
weeks (no 
further 
details) 
NR 4 weeks 
(expected) 
Amgen 
model1 
Darb-a: 
2.25 µg/kg 
per week 
NRc NRc NRc NRc NRc
Ortho Biotec 
model1 
NRc NRc NRc NRc NRc NRc
Roche 
model1 
NRc NRc NRc NRc NRc NRc
Wilson, 
20071 
Not clear 13 g/dL 13 g/dLa None 12 weeks NR 
Fagnoni, 
2006123 
Epo-a QW: 
40,000 IU 
11.5 g/dL NR Dose ×2 if 
no response 
after 6 
weeks 
12 weeks NR 
Borg, 2008154 Epo-a 
Q3W: 150 
IU/kg 
10 g/dL 12 g/dL None 8 weeks NRb 
Tonelli, 
2009112 
Epo-a QW: 
42,148 IU 
Nonec None None None NR 
Key: Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; ESA, erythropoiesis stimulating agent; Hb, 
haemoglobin  
Notes: (a) Half dose was assumed if Hb 12–13 g/dL; (b) A possible interpretation is that use was continued until 
target Hb reached; (c) In the base case patients were assumed to start with Hb 10.3 g/dL; (c) Not reported in 
Wilson and colleagues, 20071 
 
Impact of ESA use on ut i l ity/health-related qual ity of l i fe 
The impact of ESA use on utility or health-related quality of life (HRQoL) in all cost-utility 
studies is shown in Table 52. 
All cost-utility studies except Martin and colleagues (2003)117 include an improvement in 
utility or HRQoL due to ESA use.  Several studies (those published most recently) estimate 
utility or HRQoL as a function of Hb level and therefore indirectly estimate the impact of ESA 
use on utility or HRQoL by estimating the impact of ESA use on Hb levels.  Fagnoni and 
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colleagues (2006)123 estimate the impact of Hb level on QoL as measured by the linear 
analog scale assessment (LASA).  Barosi and colleagues (1998)115 and Cremieux and 
colleagues (1999)116 both estimate the impact of ESA use on HRQoL directly. 
It was not always clear whether the impact of ESA use on utility/HRQoL was instantaneous.  
Wilson and colleagues (2007)1 and Borg and colleagues (2008)154 explicitly model the 
proportion of patients in different haemoglobin levels over time which results in a gradual 
improvement in utility for patients responding to ESA treatment.  A gradual improvement in 
utility is also seen in the Amgen model in the previous NICE appraisal.1  Tonelli and 
colleagues (2009) explicitly state that the improvement in Hb levels and hence utility is 
assumed to be instantaneous (which acts in favour of ESA use in their analysis).  Fagnoni 
and colleagues (2006)123 map the Hb levels of patients in a retrospective observational 
study to HRQoL, and hence the improvement in Hb levels is translated exactly into HRQoL 
improvement. 
Table 52. Methods for short-term QALY estimation in primary cost-utility analyses 
 Utility/HRQoL estimation method Utility profile over time 
Barosi, 
1998115 
Baseline HRQoL from Glaspy, 1997160 adjusted 
according to Abels, 1992161 (visual analog scale) 
Instantaneous 
improvement (not 
explicitly stated) 
Cremieux, 
1999116 
HRQoL reported by randomised placebo-controlled trial 
patients (LASA method)54 
Not clear 
Martin,  
2003117 
N/Aa N/A 
Amgen 
model1 
Hb level (6 levels) mapped to utility using unpublished 
data from Amgen study (EQ-5D from Phase III active 
controlled darbepoetin alfa trial, data collected weekly 
from around 100 patients over 16 weeks)1 
Gradual improvement1 
Ortho Biotec 
model1 
Hb level (4 levels) mapped to utility using unpublished 
data from Ortho Biotec study (TTO from community 
values of different levels of fatigue)1 
NRb 
Roche 
model1 
Hb level (4 levels) mapped to utility using unpublished 
data from Roche study (TTO study of general 
population)1 
– 
Wilson, 20071 Hb level (7 levels) mapped to utility using unpublished 
data provided by Ortho Biotec 
Gradual improvement for 
responders 
Fagnoni, 
2006123 
Hb level (11 levels ever experienced by patients) 
mapped to HRQoL (LASA) following Crawford, 2002159 
Clincal study 
Borg, 2008154 Hb level (7 levels) mapped to utility following Wilson, 
20071 
Gradual improvement for 
responders 
Tonelli, 
2009112 
Hb increment linearly mapped to utility following Ossa, 
2007155 
Instantaneous 
improvement 
Key: ESA, erythropoiesis stimulating agent; Hb, haemoglobin; HRQoL, health-related quality of life; LASA, linear 
analog scale assessment; N/A, not applicable 
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Notes: (a) ESA use is assumed to have no impact on quality of life; QALY benefits are obtained through 
improved survival for patients receiving ESA; (b) Not reported in Wilson and colleagues, 20071 
Normalisat ion 
Normalisation is the process of Hb recovering to normal levels following chemotherapy 
cessation.  This was explicitly modelled in all three submissions in the previous NICE 
appraisal as reported by Wilson and colleagues (2007).1  Wilson and colleagues (2007) 
also assumed normalisation in their base case analysis, although they assumed a slightly 
faster reversion to normal Hb levels.1  Borg and colleagues (2008)154 followed the model 
design of Wilson and colleagues (2007)1 and as a result used the same rate of recovery.  
Earlier studies did not include normalisation. 
Fagnoni and colleagues (2006)123 produced a cost-utility analysis based on a retrospective 
observational study, in which patients were followed-up for up to seven weeks following 
chemotherapy cessation.  If normalisation did occur this would have been measured and 
included in the analysis, but there is no mention of normalisation in the text. 
Tonelli and colleagues (2009)112 did not assume normalisation in their base case analysis 
but in a sensitivity analysis they extended the utility benefit of ESA use for 11 weeks after 
chemotherapy cessation.  No explicit rate of normalisation or normal Hb level was defined. 
In general, assuming a slower rate of normalisation or a higher ‘normal’ Hb level favours ESA 
use. 
None of the studies explicitly stated whether or for how long ESA treatment was continued 
beyond chemotherapy cessation, which could impact on the rate of normalisation as well as 
increasing costs. 
Table 53. Normalisation in primary cost-utility analyses 
 Timeframe for 
normalisation 
Rate of 
normalisation 
(slower rate 
favours ESA use) 
Normal Hb level 
(higher level favours 
ESA use) 
Duration of 
continued 
ESA use 
Amgen model1 12 weeks 0.1 g/dL per week NRa NRa 
Ortho Biotec 
model1 
Overall timeframe 
36 months 
0.2 g/dL per week 13 g/dL NRa 
Roche model1 NR in Wilson, 
20071 
0.2 g/dL per week Solid tumours: 13 g/dL 
Haem tumours: 11.9 
g/dL 
NRa 
Wilson, 20071 NR 0.25 g/dL per 
week 
13 g/dL NR 
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Borg, 2008154 32 weeks 0.25 g/dL per 
week 
13 g/dL NR 
Key: ESA, erythropoiesis stimulating agent; haem, haematological; Hb, haemoglobin; NR, not reported 
Notes: (a) Not reported in Wilson and colleagues, 20071 
Drug acquis it ion costs 
The drug acquisition costs for ESAs would be expected to have a significant impact on the 
cost-effectiveness of ESAs given that these costs tend to account for the majority of total 
incremental costs.  Quality of reporting was variable, notably with Wilson and colleagues1 
reporting cost per dose rather than unit costs for epoetin alfa and epoetin beta.  None of the 
studies appear to be outliers in respect of drug acquisition costs, but it is notable that the 
current NHS list prices appear to be lower than the prices used in the UK studies and that 
pharmacies may reasonably be expected to obtain some discount on list prices. 
Table 54. Drug acquisition unit costs in primary cost-utility studies 
 Price year; 
currency 
Epo-a 
(per 1,000 IU) 
Epo-b (per 1,000 
IU) 
Darb-a (per µg) 
Barosi, 1998115 NR; USD ≈ 10.00 – – 
Cremieux, 
1999116 
1997; USD 9.50 – – 
Martin, 2003117 2000; GBP 8.38 – – 
Amgen model1 NRc  – 1.68 
Ortho Biotec 
model1 
NRc 83.30 per dose 
(Q3W) 
– – 
Roche model1 NRc  83.80 per dose 
(Q3W) 
– 
Wilson, 20071 NR; GBP 83.30 per dose 
(Q3W) 
83.80 per dose 
(Q3W) 
1.68 
Fagnoni, 
2006123 
2004; EUR 8.90 – – 
Borg, 2008154 2007; EUR 10.55 – – 
Tonelli, 2009112 2008; CAD 14.40 – 2.88 
NHS list 
price162 
2013; GBP Eprex: 5.53 
Binocrit: 5.09 
7.01 1.47 
Key: Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; IU, international unit 
Notes: (a) Note that in several places in the paper euro signs (€) are used without any apparent conversion and 
that in an abstract publication156 euros were used throughout again without any apparent conversion.  The 
reviewer (TS) concluded it was more likely US dollars were the actual currency; (b) Calculated from cost in 
Swedish kronor per IU epoetin alfa; (c) Not reported in Wilson and colleagues, 20071 
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6.1.2.3.5.  Results of al l  cost-uti l i ty studies 
Table 55 compares the base case results across the cost-utility studies identified in this 
review.  More detailed reporting of results for the studies is given below. 
Table 55. Base case results for all cost-utility studies 
 Costs QALYs Inc. costs Inc. QALYs ICER (cost 
per QALY) 
Barosi, 1998115 Epo-a: $4,568 
No ESA: $206 
 +$4,362 +0.023 $190,000 
Cremieux, 
1999116 
Epo-a: $7,551 
No ESA: 
$1,416 
No base case +$6,135 No base case $111,000–
$214,000 
Martin, 2003117 Epo-a: 
£10,768 
No ESA: 
£6,515 
Epo-a: 1.0375 
No ESA: 
0.5570 
+£4,253 +0.4805 £8,851 
Amgen model1 
(short-term 
analysis) 
Darb-a: 
£3,570 
No ESA: 
£1,156 
Darb-a: 
0.0309 
No ESA: 
0.0146 
+£2,594 +0.0163 £159,000 
Amgen model1 
(long-term 
analysis) 
– –  – – £23,600 
Ortho Biotec 
model1 
–  –  +£4,021 – £13,000 
Roche model1 
(solid 
tumours) 
–  –  +£3,727 +0.132 £28,200 
Roche model1 
(haematologic
al tumours) 
–  –  +£3,510 +0.042 £83,700 
Wilson, 20071 –  –  +£4,450 +0.030 £150,000 
Fagnoni, 
2006123 
Epo-a: €1,649 
No ESA: €34 
– +€1,615 +0.0052 €311,000 
Borg, 2008154 Epo-a: €3,750 
No ESA: 
€2,881 
Epo-a: 0.5687 
No ESA: 
0.5334 
+€870 +0.035 €24,700 
Tonelli, 2009112 
(short-term 
analysis) 
–  –  +$8,643 +0.03 $267,000 
Tonelli, 2009112 
(long-term 
analysis) 
–  –  +$8,643 −0.086 ESA use 
dominated by 
no ESA use 
Key: Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; ESA, erythropoiesis stimulating agent; 
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year 
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Barosi and col leagues (1998)1 1 5 
The combination of improved quality of life and reduced risk from blood-borne diseases 
transmitted through RBC transfusions resulted in a gain of 0.023 QALYs (8.4 quality-adjusted 
life days) at an additional cost of $4,362, resulting in an ICER of $190,000 per QALY. 
Various sensitivity analyses were considered, of which most did not result in ICERs below 
$100,000 per QALY, including varying the risk of blood-borne infections, extending survival 
for cancer patients to match general population life expectancy, adjusting patient age and 
varying the quality of life improvement from ESA use.  If the ESA acquisition cost was 
reduced by 50% the ICER fell below $100,000 per QALY.  A scenario analysis was 
considered in which all patients receiving ESA had no RBC transfusions and anaemia was 
improved in all patients and for this the ICER remained high at $146,000 per QALY.  Using 
the base case drug acquisition cost ESA use was only cost-effective (ICER below $100,000 
per QALY) if used in patients who would be heavily transfused and could avoid at least 4.5 
RBC units. 
Cremieux and col leagues (1999)1 1 6 
Patients in the epoetin alfa arm accrued total costs of $7,551 compared to total costs of 
$1,416 for patients in the standard care arm.  These costs included indirect costs for patients 
who needed to attend hospital three times weekly for epoetin alfa administration and for 
patients requiring transfusion.  Opportunity costs accounted for $723 in the epoetin alfa arm 
and $176 in the standard care arm.  Reduced transfusion usage in the epoetin alfa arm 
resulted in cost savings of $428 but these were more than offset by epoetin alfa costs of 
$6,563.  Drug acquisition was the most expensive resource, accounting for $4,560 in the 
epoetin alfa arm. 
Cumulative haemoglobin was measured as an objective effectiveness measure, measured 
as 21.0 for the epoetin arm and 3.2 for the standard care arm, giving an incremental 
effectiveness of 17.8 (units g/dL week). 
Effectiveness in terms of quality of life was measured at baseline and at the end of the study 
using the Linear Analog Scale Assessment (LASA).  Epoetin alfa patients gained 8.3 mm 
(the scale is 100 mm in length) versus standard care patients losing 1.0 mm, therefore the 
incremental effectiveness was 9.3 mm.  Two methods were suggested for converting LASA 
measurements to “utilities”: the first assuming that a 9.3 mm gain would correspond to a 
0.093 gain in utility; the second assuming that a 9.3 mm gain would correspond to a 0.184 
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gain in utility (based on the mean measurement of 50.6 mm).  Neither of these methods 
actually produces a preference-based utility estimate.  Using transfusion rates and 
cumulative doses from the RCT which provided the LASA measurements results in ICERs of 
$214,000 per QALY when the utility gain of 0.093 is assumed and $111,000 per QALY when 
the utility gain is assumed to be 0.184. 
Various sensitivity analyses were performed but in all the ICER was over $100,000 per 
QALY for epoetin alfa use. 
Mart in and col leagues (2003)1 1 7 
In their base case analysis epoetin alfa use results in greater discounted mean costs 
(£10,768 vs £6,515; difference +£4,253) and greater discounted QALYs (1.0375 versus 
0.5570; difference +0.4805).  The base case ICER was £8,851 per QALY. 
The increased costs for epoetin alfa patients were due to epoetin alfa costs (£3,995) and 
increased costs in the follow-up phase (due to greater time spent in the follow-up phase).  
Increased costs were partially compensated by decreased costs in the active, supportive and 
terminal phases and a very small reduction in blood unit costs. 
The difference in QALYs comes about solely through improved survival, i.e., there is no 
QALY gain due to relieving symptoms of anaemia.  Patients receiving epoetin alfa accrued 
0.5079 more QALYs in the follow-up phase, with very small reductions in QALYs in the 
active, supportive and terminal phases. 
A joint sensitivity analysis was conducted by bootstrapping effectiveness and cost estimates 
from the RCT.  This analysis demonstrated a 94% probability of cost-effectiveness at the 
£30,000 per QALY threshold. 
A number of scenario analyses were conducted, in which the resulting ICER was below 
£30,000 per QALY except in one case where an ICER of £39,300 per QALY was obtained in 
which all patients from the RCT (rather than only Stage IV breast cancer patients) were 
included to estimate effectiveness of epoetin alfa. 
Fagnoni and col leagues (2006)1 2 3 
The authors state that “The population studied in both groups had no difference in terms of 
clinical and therapeutic characteristics when one takes into account the evolution of the 
diagnostic diagrams and recommended treatment strategies between the two studied 
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periods (1999–2001 and 2002–2004).”  The initial haemoglobin and haematocrit levels were 
very similar for both patient groups.  The median number of haemoglobin level 
measurements per patient was the same (six) for both groups. 
In the group with possible use of EPO, 46/101 (45.5%) actually received EPO.  The mean 
haemoglobin level at initiation of EPO treatment was 11.3 g/dL (range 9.4–12.5).  No red 
blood cell transfusions occurred in either group, and a similar proportion of patients were 
hospitalised related to anaemia in both groups (2.0% possible EPO versus 2.2% no EPO).  
On average patients with possible EPO spent almost 6 weeks with haemoglobin level over 
13.49 g/dL compared to just over 3 weeks for patients with no EPO.  Mapping haemoglobin 
levels to quality of life resulted in an increase of 0.0052 QALYs after the introduction of EPO 
over the 22-week study period. 
The average cost of EPO treatment was €1,593 per patient for the group with possible use of 
EPO.  The average cost of hospitalisation was €56 per patient for the group with possible 
use of EPO versus €34 for the group with no EPO, although this was not statistically 
significant. 
The base case ICER was €311,000 per QALY. 
None of the sensitivity analyses reduced the ICER for possible EPO versus no EPO below 
€160,000 per QALY.  The different methodologies for estimating quality of life according to 
haemoglobin level produced some differences in the QALY difference between the groups: 
using the relationship between haemoglobin level and FACT-General resulted in the greatest 
QALY difference (0.0099 QALYs), while an alternative LASA methodology resulted in the 
smallest (0.0046 QALYs).  It should be noted that none of these HRQL measures are 
preference-based. 
Borg and col leagues (2008)1 5 4 
The base case comparison was between the EPO arm with a target Hb of 12 g/dL and the 
RBCT arm with a trigger level of 10 g/dL (the same trigger level as in the EPO arm).  Patients 
in the EPO arm were estimated to incur total costs of €3,750 versus expected total costs of 
€2,881 in the RBCT arm (difference +€870).  The additional cost of epoetin alfa (€2,054) was 
partially compensated for by savings in RBCT costs (€1,185).  Patients were expected to 
accrue 0.5687 QALYs in the EPO arm and 0.5334 QALYs in the RBCT arm (difference 
+0.0353 QALYs).  The base case ICER was €24,700 per QALY. 
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A scenario analysis was conducted in which the rate of normalisation was doubled from 1 
g/dL per four-week model cycle to 2 g/dL per cycle; the resulting ICER (EPO versus RBCT) 
was €29,500 per QALY. 
Another scenario analysis was conducted in which patients not responding to EPO after 4 
weeks had their dose doubled; the resulting ICER (EPO double-dose versus standard EPO) 
was €136,900 per QALY. 
An EPO strategy with a higher target Hb level of 13 g/dL was more expensive than the base 
case EPO strategy (+€609) but generated very little benefit (+0.0018 QALYs), resulting in an 
ICER of €336,500 per QALY. 
RBCT strategies with trigger levels of 9 and 11 g/dL were also considered.  Increased trigger 
levels led to increased costs and QALYs.  With a trigger level of 9 g/dL, RBCT cost €2,360 
and resulted in 0.4948 QALYs.  With a trigger level of 11 g/dL, RBCT cost €3,340 and 
resulted in 0.5605 QALYs.  All strategies were on the cost-effectiveness frontier (i.e. no 
strategies were dominated or extended dominated), and therefore if RBCT with a trigger level 
of 11 g/dL were to be considered a valid comparator the ICER of EPO would be €50,000 per 
QALY. 
Tonel l i  and col leagues (2009)1 1 2 
In the base case analysis epoetin alfa use resulted in increased costs ($8,643) and 
increased benefits (0.03 QALYs) over 15 weeks, resulting in an ICER of $267,000 per QALY.  
Over a one-year time frame costs were unchanged but increased long-term mortality resulted 
in decreased benefits (−0.086 QALYs); epoetin alfa use was dominated by standard care as 
a result.  Similar results were obtained with darbepoetin alfa. 
Several univariate sensitivity analyses and scenario analyses were conducted.  When the 
mortality parameters were varied within their 95% confidence intervals ESA use remained 
not cost-effective even at a threshold of $100,000 per QALY.  When alternative methods of 
estimating the relationship between haemoglobin levels and utility were used, ESA use 
became less cost-effective.  A number of other scenario analyses were conducted, the most 
favourable of which involved limiting the studies informing the model to those with a target 
Hb level ≤ 12 g/dL and/or an initial Hb level ≤ 10 g/dL, but even in these the ICERs remained 
above $70,000 per QALY. 
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6.1.2.3.6.  Summary tables for other studies 
Summary tables for other studies are summarised in Table 56. 
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Table 56: Study characteristics of full non-selected studies 
  Ben-Hamadi, 2005163 Persson, 2005164 Borget, 2006137 
Evaluation type Cost-effectiveness analysis Cost-consequences analysis Cost-effectiveness analysis 
Modelling used Limited Yes Yes 
Nature of modelling Integration of drug acquisition costs 
based on dose escalation rate 
Calculation of drug costs Markov model 
Perspective Payer Healthcarea Healthcare perspective 
Country (setting) USA (not explicitly stated) Sweden France (not explicitly stated) 
Intervention/comparator Epo-a QW: 40,000 IU, escalated to 
60,000 IU after 4 weeks if Hb increase < 
1 g/dL 
Darb-a QW: 2.25 µg per kg, escalated to 
4.5 µg per kg if Hb increase < 1 g/dL 
and/or given RBCT 
Epo-a TIW: 150 IU/kgb 
Darb-a QW: 2.25 µg/kgb 
Darb-a QW 
Standard care: RBCT if Hb < 8 g/dL or 8–10 g/dL 
and signs of poor tolerance of anaemia 
Population Patients with chemotherapy-induced 
anaemia 
Patients with cancer therapy-related 
anaemia receiving Epo-a or Darb-a 
Lung cancer patients 
Outcomes considered Treatment success (proportion of 
patients not requiring RBCT) 
Haematologic response 
AUCHB 
Proportion of patients receiving RBC 
transfusion 
Number of RBC units transfused 
Proportion of patients receiving RBCT 
Number of RBC units transfused 
Mean Hb level 
Time-frame 16 weeks 16 weeks 36 weeks 
Discounting Not stated Not stated Not stated 
Funding Ortho-Biotec (manufacturers of Epo-a) Johnson & Johnson (manufacturers of 
Epo-a) 
Not stated 
Key: AUCHB, area under Hb change curve; Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Hb, haemoglobin; IU, international unit; QW, once weekly; RBC(T), red blood cell (transfusion); 
TIW, three times weekly 
Notes: (a) Included costs: drug acquisition, hospitalisation, RBCT; (b) Swedish treatment guidelines; dose doubled if inadequate response after four weeks; treatment discontinued if Hb > 
14 g/dL 
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Table 52: Study characteristics of full non-selected studies (continued) 
  Spaepen, 2008165 Aapro, 2012166 Pashos, 2012167 
Evaluation type Cost-consequences analysis Cost-minimisation study Cost-consequences analysis 
Modelling used Limited Minimal No 
Nature of modelling Statistical matching of patients receiving 
different ESAs to estimate costs 
Multiplication of dosing level by unit price  
Perspective Healthcare Healthcare Drug costs only 
Country (setting) Belgium (hospital) Germany, France, UK, Italy, Spain USA 
Intervention/comparator Darb-a 
Epo-a 
Epo-ba 
Originator Epo-a QW: 40,000 IU; 450 
IU/kg 
Biosimilar Epo-a QW: 30,000 or 40,000 
IU; 450 IU/kg 
Epo-b QW: 30,000 IU; 450 IU/kg 
Darb-a QW: 150 µg; 2.25 µg/kg 
Darb-a Q3W: 500 µg; 6.75 µg/kg 
Epo-a QW: 40,000 IU 
Darb-a Q3W: 500 µg 
Population Adult cancer patients receiving ESA 
support at some point 
Patients with chemotherapy-induced 
anaemia 
Adult cancer patients receiving ESA therapy 
Outcomes considered TA-free survival (composite of 
transfusion-free survival and anaemia-
related readmission-free survival) 
None (costs only) Proportion of patients requiring  packed RBC 
transfusion 
Units of packed RBC transfused per patient 
Increase in Hb from baseline 
Time-frame For duration of records until loss of 
follow-up at end of calendar year 
18 weeks Duration of ESA treatment up to maximum 16 weeks 
Discounting Not stated  Not discounted Not stated 
Funding Amgen (manufacturers of Darb-a) Sandoz Biophamaceuticals 
(manufacturers of biosimilar Epo-a, 
Binocrit) 
Ortho Biotec (manufacturers of Epo-a) 
Key: Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IU, international units; QW, once weekly; Q3W, once 
every three weeks; RBC(T), red blood cell (transfusion) 
Notes: (a) Reimbursed only if administered to patients with Hb < 11 g/dL and/or receiving platinum-based chemotherapy 
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Table 57: Key parameters of full non-selected studies 
  Ben-Hamadi, 2005163 Persson, 2005164 Borget, 2006156 
Effectiveness (source): 
transfusion, response rate, 
survival, QALYs 
Epo-a: Witzig et al. (J Clin Oncol 
2005;23[12]:2606-2617) 
Darb-a: Kotasek et al. (Poster 
presentation, American Society of 
Hematology, December 4-7, 2004, 
San Diego, CA) 
Retrospective chart review 
performed at three Swedish hospitals
Two-year retrospective study 
Effectiveness (data): transfusion, 
response rate 
Treatment success (proportion of 
patients not requiring RBCT) 
Weeks 0-16: Epo-a, 75%; Darb-a, 
63% 
Weeks 5-16: Epo-a, 85%; Darb-a, 
73% 
[Results by day 112a] 
Haem. response (Hb increase ≥ 1 
g/dL): Epo-a, 100%; Darb-a, 80% 
Haem. response (Hb increase ≥ 2 
g/dL): Epo-a, 86%; Darb-a, 63% 
AUCHB (Hb g / day / dL; mean ± 
SD): Epo-a, 203.0 ± 122.9; Darb-a, 
157.0 ± 162.3 
Patients receiving 1+ RBCT: Epo-
a, 14/29; Darb-a, 14/30 
Mean units RBC transfused: Epo-
a, 1.71; Darb-a, 1.95 
Proportion of patients receiving RBCT: Darb-
a, 19.1%; standard care, 33.6% 
Mean number of RBC units transfused: Darb-
a, 2.11 ± 0.47; standard care, 2.97 ± 1.47 
Effectiveness (data): survival, 
QALYs 
N/A N/A N/A 
HRQoL/utility (source) N/A N/A N/A 
HRQoL/utility (data) N/A N/A N/A 
Costs (source) Medi-Span Master Drug Data Base 
(MDDB) May 2005 
Drug acquisition: List price in 2003 
Swedish Pharmacopeia 
Hospitalisation and RBCT: Official 
list of regional administrative prices 
Transfusion costs from national unit costs.  Darb-
a drug costs from drug purchase prices paid by 
hospital. 
Cost year 2005 2003 Not stated 
Key: AUCHB, area under the Hb change curve; Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Hb, haemoglobin; HRQoL, health-related quality of life; RBC(T), red blood cell (transfusion) 
Notes: (a) Results also presented at 28, 56 and 84 days 
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Table 53: Key parameters of full non-selected studies 
  Spaepen, 2008165 Aapro, 2012166 Pashos, 2012167 
Effectiveness (source): 
transfusion, response rate, 
survival, QALYs 
Retrospective analysis of Belgian 
national patient database 
Assumed equivalent Dosing and Outcomes Study of Erythropoiesis-
Stimulating Therapies (DOSE) 
Effectiveness (data): transfusion, 
response rate 
TA-free survival: 
Darb-a, 84.37% (79.22%-88.35%); 
Epo-a, 84.60% (80.72%-87.75%); 
Epo-b, 84.94% (80.03%-88.72%) 
Transfusion-free survival: 
Darb-a, 84.46% (79.29%-88.43%); 
Epo-a, 84.86% (81.00%-87.99%); 
Epo-a, 85.51% (80.70%-89.19%) 
Anaemia-readmission-free 
survival: 
Darb-a, 89.16% (84.71%-92.38%); 
Epo-a, 88.66% (85.18%-91.36%); 
Epo-b, 87.91% (83.31%-91.29%) 
N/A Proportion of patients requiring RBCT: Epo-a, 
13.9%; Darb-a, 22.5% (p=0.026) 
RBC units: Epo-a, 0.4; Darb-a, 0.7 (p=0.020) 
Increase in Hb from baseline (g/dL) at week 
12: Epo-a, 0.6; Darb-a, 0.1 (p=0.032) 
Effectiveness (data): survival, 
QALYs 
N/A N/A N/A 
HRQoL/utility (source) N/A N/A N/A 
HRQoL/utility (data) N/A N/A N/A 
Costs (source) Belgian national databases This study; list price (Germany, 
France, Italy, Spain); negotiated 
price (UK) 
Wholesale acquisition costs 
Cost year 2003-2005 (patient-specific); 2006 
across all patients in sensitivity 
analysis 
2010 2009 (May) 
Key:  Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; Hb, haemoglobin; HRQoL, health-related quality of life; RBC(T), red blood cell (transfusion)
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Table 58: Results of full non-selected studies 
  Ben-Hamadi, 2005163 Persson, 2005164 Borget, 2006156 
Measure Cost per 1% successful treatment Cost Cost per g/dL Hb 
Cost year; currency 2005; US dollars (USD; $) 2003; Swedish kronor (SEK) Not stated; US dollars (USD; $) 
Base case Epo-a dominates 
 
Average cost-effectiveness ratios 
Weeks 0-16: Epo-a, $121; Darb-a, $215 
Weeks 5-16: Epo-a, $106; Darb-a, $186 
Total treatment cost at day 112: 
Epo-a, SEK 74,701 
Darb-a, SEK 85,285 
Darb-a: mean Hb, 13.0 ± 0.5; mean cost, $1,732 ± 
897 
Standard care: mean Hb, 11.9 ± 1.0; mean cost, 
$996 ± $643 
ICER: $669 per g/dL Hb 
Probabilistic 
results 
NR NR N/A 
Sensitivity analyses [Using average sale price + 6% (as used 
for reimbursement for Medicare Part B 
covered drugs)] 
 
Epo-a dominates 
 
Average cost-effectiveness ratios 
Weeks 0-16: Epo-a, $97; Darb-a, $159 
Weeks 5-16: Epo-a, $86; Darb-a, $137 
Costs modelled for observed/fixed patient 
body weights and response rates 
Reducing cost of transfusion or baseline prevalence of 
anaemia led to standard care having a lower average 
cost-effectiveness ratio 
Key: Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Hb, haemoglobin
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Table 54.  Results of full non-selected studies 
  Spaepen, 2008165,166 Aapro, 2012166 Pashos, 2012167 
Measure Cost per patient Relative savings with use of biosimilar 
Epo-aa 
Cumulative drug cost per patient 
Cost year; currency 2003-2005; euros (EUR; €) 2010; euros (EUR; €) 2009; US dollars (USD; $) 
Base case Overall costs 
Darb-a, €16,949 ± €1,025 
Epo-a, €19,472 ± €901 
Epo-b, €19,295 ± €1,048 
Fixed dosing using biosimilar Epo-a 
40,000 / 30,000 IU per week 
Originator Epo-a: 13.8% / 35.4% 
Epo-b: 16.4% / 37.3% 
Darb-a QW: 25.5% / 44.2% 
Darb-a Q3W: 33.0% / 49.7% 
 
Weight-based dosing using biosimilar 
Epo-a 
Originator Epo-a: 13.8% 
Epo-b: 16.4% 
Darb-a QW: 44.2% 
Darb-a Q3W: 44.2% 
Epo-a: $4,261 
Darb-a: $8,643 
Probabilistic 
results 
N/A N/A N/A 
Sensitivity analyses Applying 2006 prices does not alter 
conclusion that Darb-a significantly 
cheaper than Epo-a and Epo-b 
Results presented individually for five 
treatment scenarios; relative savings are 
unchanged 
N/A 
Key: Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; QW, once weekly; Q3W, once every three weeks 
Notes: (a) Results presented are calculated from costs for each treatment averaged (unweighted) across five treatment scenarios.  Costs represent European G5 cost as 
calculated by calculating weighted average of price, weighted by population of European G5 countries. 
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6.1.2.4.  Discussion 
All cost-utility studies presenting favourable results were funded or produced by industry. 
Martin and colleagues (2003)117 produced an analysis demonstrating good cost-
effectiveness in a subgroup of cancer patients on the basis of a substantial survival 
advantage in an RCT, but there are numerous problems with this analysis: 
 The stage IV breast cancer subgroup was not identified a priori (nor indeed were any 
subgroups identified a priori) and was likely selected as the subgroup in which the 
observed survival benefit was greatest 
 Survival was not a primary outcome of the RCT, indeed the RCT was not powered to 
detect survival differences and survival was added as a supplementary outcome after 
the trial started;79 this leaves open the possibility of reporting bias of survival results 
 The RCT was neither powered nor stratified for subgroup analyses and there were 
baseline differences between the epoetin alfa and placebo arms 
The three industry submissions in the previous NICE appraisal achieved ICERs below 
£30,000 per QALY only by the inclusion of survival benefits which have not generally been 
reproduced in more recent meta-analyses. 
Analyses not including survival benefit seem to predict small incremental benefits of ESA 
therapy in the range of 0.0052 to 0.035 QALYs. 
The only analysis not including a survival benefit and producing a favourable estimate of 
cost-effectiveness was by Borg and colleagues (2008),154 which demonstrated a 
significantly lower incremental cost of ESAs than other analyses, including others funded or 
produced by industry.  The average cumulative dose predicted by the model may be 
calculated by dividing the total cost of epoetin alfa (€2,054) by the cost of epoetin alfa per 
four week cycle (€1,329) to estimate an average 1.546 cycles, approximately 195,000 IU 
(based on 70 kg patient weight as chosen by the authors) whereas data from the clinical 
study informing the model by Persson and colleagues (2005)164 suggests a cumulative 
dose of 460,000 IU.  Dose doubling was included in the clinical study, but this would not 
account for the discrepancy – indeed maximum mean dosage for those receiving epoetin 
alfa was 37,143 IU versus the start mean dosage of 31,786 IU.  This suggests that the 
analysis by Borg and colleagues (2008) assumes patients discontinue epoetin alfa sooner 
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than expected from the study from which clinical effectiveness estimates were drawn, 
leading to questions about the internal validity of the study.  
None of the studies incorporated any impact of ESA therapy on chemotherapy management. 
6.1.2.5.  Conclusions 
For ESA therapy to be cost-effective some or all of the following seem to be necessary: 
 A significant survival advantage for patients receiving ESA therapy 
 Utility improvements as a result of Hb level improvement 
 Low cumulative dose of ESA 
 Normalisation period in which benefits of ESA persist beyond chemotherapy 
cessation (and beyond ESA cessation) 
A significant survival advantage has not been shown in general either by the recent 
Cochrane review (Tonia and colleagues, 2012)10 or by the systematic review in Section 0, 
page 56. 
The primary claimed benefit of ESA therapy is improved health-related quality following 
correction of anaemia, but this has not been demonstrated on general health-related quality 
of life measures (such as EQ-5D) in published and peer-reviewed RCT.  Significant 
predicted improvements in utility have resulted from the application of results of Ossa and 
colleagues (2007)155 but this study has several methodological weaknesses (see Section 
7.1.2.1, page 258).  Tonelli and colleagues (2009)112 have noted that as a result of using 
utility estimates derived from Ossa and colleagues (2007)155 a 0.15 difference in utility 
between the ESA and non-ESA arm were predicted, on a par with the utility associated with 
kidney transplant for a patient with end-stage kidney disease on dialysis, which they 
regarded as a potential overestimation. 
Achieving a low cumulative dose of ESA (without sacrificing significant clinical effectiveness) 
will likely result from: identifying non-responders as early as possible and discontinuing ESA 
therapy in them; focussing ESA therapy on patients with moderate to severe anaemia likely 
to impact on quality of life and survival rather than continuing ESA therapy to achieve Hb 
levels over 12 g/dL; and employing dose escalation only if it is shown to be clinically 
effective.  These strategies have largely been included in current licences and guidance 
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notes, but there is not yet RCT evidence of clinical effectiveness when ESAs are used fully 
within licence. 
Some amount of normalisation would logically be expected, but no clinical evidence for this 
has been presented in the economic analyses, even from observational studies.  If 
normalisation is a significant contributor to the benefit of ESAs in analyses it should be 
subjected to extensive sensitivity analysis to reflect the significant amount of uncertainty. 
Wilson and colleagues (2007)1 concluded that adverse events relating to ESA therapy or 
RBCT would be unlikely to impact on cost-effectiveness.  The two new model-based cost-
utility analyses do not include adverse events and provide no further insight on this.  
Fagnoni and colleagues (2006)123 include anaemia-related hospitalisation costs but it 
appears these costs are valued according to average costs of hospitalisation rather than 
adverse event-specific hospitalisation costs.  They do not demonstrate a significant 
difference in costs in this area. 
The new cost-utility studies did not demonstrate a significant impact on cost-effectiveness of 
the cost of RBCT. 
All studies appear to include greater drug acquisition costs than would be expected now in 
the NHS as the list price has come down.  As drug acquisition costs are the largest 
component of incremental costs in all analyses any discounts would be expected to impact 
total incremental costs but disaggregated total costs as well as incremental costs would be 
needed to make an appropriate adjustment and these have not been reported by Wilson 
and colleagues (2007).1  Furthermore NHS hospitals could be expected to achieve 
discounts from the list price, further improving cost-effectiveness. 
Following this update review there remains some uncertainty about the cost-effectiveness of 
ESAs given the recent reduction in drug acquisition costs and changes to licences designed 
to address safety concerns.  If no survival benefit is assumed then a maximum QALY gain of 
0.030–0.035 seems reasonable based on results from Wilson and colleagues (2007),1 
Borg and colleagues (2008)154 and Tonelli and colleagues (2009).112 This could be an 
overestimate as there is a lack of high quality evidence that ESA therapy improves health-
related quality of life on generic measures such as EQ-5D. 
There is a need for an up-to-date analysis of the cost-effectiveness of ESAs in the NHS to 
reflect reduced drug acquisition costs, changes to licences and market entry of additional 
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comparators.  This analysis will need to explore the significant amount of uncertainty which 
still remains. 
6.1.2.6.  Strengths and l imitations 
This review included a comprehensive search of the literature and inclusion and exclusion 
criteria were not unnecessarily restrictive unlike those of the systematic review by Duh and 
colleagues (2008)153 which excluded standard care without ESAs as a comparator.  The two 
systematic reviews by Duh and colleagues (2008)153 and Tonelli and colleagues (2009)112 
did not identify cost-utility studies which were not identified in this review.  The full text of one 
cost-utility study by Roungrong and colleagues (2008)131 could not be obtained but the 
Centre for Reviews and Dissemination critical appraisal of this study suggests that it would 
not change the conclusions of the review.132 
The methods and results of included cost-utility studies were described and critically 
appraised and conclusions were drawn by comparing the methods and results of all cost-
utility studies. 
Records from database searches published pre-2004 were excluded although it was not 
possible to assess whether these had been screened for eligibility in the systematic review 
presented in Wilson and colleagues (2007). 
The reviewers (TS and NH) excluded darbepoetin alfa given once every two weeks as an 
allowed intervention as biweekly administration is not allowed within the licence of 
darbepoetin alfa.  This could be viewed as a limitation of the review, but at the full paper 
screening stage this only resulted in the exclusion of a single abstract not describing a cost-
utility analysis. 
No critical appraisal or narrative synthesis of non-cost-utility studies was performed, which 
could also be viewed as a limitation of this review.  Cost-utility analyses are preferred for 
NICE appraisals and therefore this is not a significant limitation within the NICE appraisal 
context but the value of this review to other audiences may have been limited, although cost-
utility analyses are also preferred by many other decision makers. 
The analyses identified in this review are outdated in some ways due to changes in ESA 
costs and licences and the market entry of new ESAs, but this is a drawback of the 
published literature rather than the review methods. 
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6.1.2.7.  Areas of uncertainty 
It is not clear what incremental costs could be expected by the introduction of ESAs at 
current list prices or wholesale acquisition prices.  The cost of drug administration is also 
uncertain and dependent on whether patients are assumed to self-administer.  The cost of 
RBCT in the NHS has not been recently evaluated by studies identified but there is evidence 
that cost-effectiveness may not be particularly sensitive to the cost of RBCT (although this is 
from studies where drug acquisition costs dominate to a greater extent than would now be 
expected).  Studies did not include costs of blood tests or outpatient clinics so it is not clear 
how these might impact on cost-effectiveness.  Cumulative doses of ESAs when given in 
line with licence are also uncertain. 
The benefits from ESAs are highly uncertain.  If ESAs impact on survival then this will have a 
significant effect on cost-effectiveness, even though ESAs are not given to enhance survival.  
A systematic review and meta-analysis was conducted as a part of this appraisal and 
several others exist which do not rule out an impact on survival.  If ESA therapy does not 
result in a meaningful improvement in quality of life then this will also have a significant 
impact on cost-effectiveness.  There is an absence of high-quality evidence in this area.  
Benefits from normalisation are also highly uncertain and have a significant impact on cost-
effectiveness. 
Overall the clinical effectiveness of ESAs measured in QALYs is highly uncertain as are the 
costs of ESAs. 
6.1.2.8.  Update searches 
Update searches were conducted on 2nd December using the same methodology as 
described earlier.  Fifty-three records were screened by two reviewers (TS and LC) and one 
record was selected for full-text retrieval.  The study was judged eligible on full-text appraisal 
by TS and NH.  The study was neither a cost-utility study nor a systematic review and its 
results do not alter the conclusions of this review.  See Appendix Q for further details. 
6.2. Economic evaluations submitted by manufacturers 
No economic evaluations were submitted by any of the manufacturers. 
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6.3. Summary 
KEY POINTS 
 Ten cost-utility analyses and two systematic reviews were identified by updating an 
existing review by Wilson and colleagues (2007)1 
 Five cost-utility analyses suggested that ESA therapy is cost-effective, these were all 
funded by industry (Martin and colleagues, 2003; Borg and colleagues, 2006) or 
conducted by industry (submissions by Amgen, Roche and Ortho Biotec as reported 
by Wilson and colleagues, 2007) 
 The inclusion of survival benefits was common to four favourable analyses (Martin 
and colleagues, 2003 and the industry submissions as reported by Wilson and 
colleagues, 2007) although no statistically significant survival benefit has been 
shown 
 The fifth favourable analysis (Borg and colleagues, 2006) may suffer from problems 
of internal validity as it appears the cumulative dose of epoetin alfa in the analysis 
was less than half that in the clinical study informing the effectiveness estimates; this 
would account for the lower than usual incremental drug acquisition costs 
 A key assumption in almost all analyses was that raising Hb levels would improve 
health-related quality of life, though in no case was this assumption based on 
published RCT evidence using a preference-based quality of life measure 
 A number of studies assumed a period following treatment during which Hb levels 
would gradually return to normal (termed normalisation), during which patients in the 
ESA arm would continue to accrue incremental benefits in quality of life over patients 
in the no ESA arm; no evidence for or against normalisation has been presented 
 In the absence of survival benefit the expected health gain from ESA therapy is small 
(up to 0.035 QALYs) and is subject to uncertainty 
 Studies did not incorporate current list prices or wholesale acquisition costs, which 
could significantly reduce the drug acquisition component of ESA therapy cost and 
improve cost-effectiveness 
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 Independent economic assessment 
7.1. Methods 
7.1.1. Model structure 
In the PenTAG assessment, the economic evaluation takes the form of a simple, empirical 
model, informed directly by the systematic review of clinical effectiveness. This differs from 
standard mechanistic modeling approaches (such as Markov or discrete event simulation 
models), which require specific states and processes to be modelled. 
The model compares patients receiving ESA therapy to patients not receiving ESA therapy 
(referred to as the ESA arm and control arm from here) and is split into two temporal 
sections, one to evaluate the short-term costs and QALYs (while patients are anaemic) and 
one to evaluate long-term QALYs. 
Short-term costs are accrued in the form of ESA drug acquisition and administration, red 
blood cell transfusion costs and costs of adverse events.  Although patients may incur 
significant costs through cancer treatment (e.g., chemotherapeutic agents) these costs are 
not modelled as they are assumed to be equal for the ESA and control arms (the potential 
ramifications of this assumption are discussed in Section 8.3.4.6, page 388).  Short-term 
QALYs are accrued as health-related quality of life (HRQoL) is improved by ESA therapy 
correcting anaemia and associated symptoms (e.g., fatigue); no difference in time spent in 
the short-term phase is modelled between the arms. 
Long-term QALYs are accrued due to potential differences in overall survival between the 
two arms; it is assumed that health-related quality of life is equal for both arms in this phase 
as patients no longer have cancer treatment-induced anaemia and health-related quality of 
life is driven by symptoms of cancer.  Although patients may incur significant ongoing costs 
related to cancer treatment (e.g., costs of maintenance chemotherapy, subsequent 
chemotherapy cycles or relapse), as these are highly uncertain (due to the wide range of 
cancers patients may have and the treatments for them) and because the inclusion of such 
costs could perversely worsen cost-effectiveness for the arm with greater overall survival, 
these costs are not modelled in the base case.  The potential ramifications of this 
assumption are explored through a univariate sensitivity analysis in Section 7.2.7.1 (page 
367) and discussed in Section 8.3.4.6 (page 388). 
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7.1.1.1.  Short-term costs and QALYs 
Short-term costs in the model include ESA drug acquisition and administration, red blood cell 
transfusion related costs and costs relating to adverse events.  In all cases resource use and 
unit costs are estimated separately.  Resource uses of ESA drug acquisition and 
administration are estimated in Sections 7.1.2.1.2 (page 266) and 7.1.2.1.3 (page 268).  
Resource uses of red blood cell transfusion related costs are estimated in Section 7.1.2.1.1 
(page 266).  Resource uses of adverse events are estimated in Section 7.1.2.3.6 (page 
304).  Unit costs are estimated in Section 7.1.2.3 (page 298). 
We have considered three possible model structures for the estimation of short-term QALYs 
(Table 59, page 248): 
1. Using reported HRQoL outcomes directly from RCTs of ESAs.  Hb levels are not 
modelled. 
Ideally, this would be the preferred model structure.  However, this option is not available 
because: 
 Whilst many RCTs report outcomes measured by disease-specific health 
questionnaires, such as FACT-An, FACT-Fatigue, EORTC QLQ C-30, no RCTs 
report generic preference-based health-related quality-of-life measures, such as EQ-
5D or SF-6D, which are required to estimate health utilities.  Indeed, this limitation 
has been noted by Grant and colleagues (2013).59 
 Very little information can be gained from mapping from the disease-specific health 
questionnaires to the EQ-5D, see Section 7.1.2.2.4 (page 295).   
Despite this, some previous cost-effectiveness analyses (e.g., Cremieux and colleagues 
(1999)116) have taken this approach, using quality of life based on visual analogue scales or 
linear analogue self-assessment (LASA) scales, which is not recommended as health state 
values elicited using these scales are not based on stated trade-offs between quantity and 
quality of life by surveyed individuals.168 
A variant of this method is seen in Fagnoni and colleagues (2006)123 in which Hb levels 
over time were taken directly from a clinical trial and then mapped to utility, although this was 
not according to generic health-related quality of life measures such as EQ-5D. 
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2. Mechanistic modelling of exact Hb level over time during ESA treatment.  It is 
necessary to model many processes, including: 
 Doses of ESAs at all times, which are driven by Hb levels.  Hb responses to ESAs. 
 Times when RBCTs given, and Hb responses to these. 
 Starting Hb levels. 
One of the motivations for modelling Hb levels over time is that these are widely reported in 
the ESA RCTs and it is possible to estimate health utilities as a function of Hb level. 
This option has the attraction of flexibility to depart from the characteristics of the RCTs.  
However, we have not chosen this option because (a) data for many required parameters is 
simply not available; and, (b) it is not possible to incorporate many of the outcomes from the 
systematic review of clinical effectiveness (Table 61). 
3. Empirical observation of Hb over time.   
Here, Hb levels over time are taken directly from clinical trials.  This approach attempts to 
bolt-on an economic evaluation to the RCTs of ESAs.  This option has been chosen because 
(a) good estimates of all necessary parameters are available and (b) the method can use 
many of the outcomes from the systematic review of clinical effectiveness (see Section 0, 
page 56). 
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Table 59: Possible model structures for short-term economic evaluation of ESAs 
 Model structures 
QoL from trial Mechanistic 
modelling of Hb over 
time 
Empirical 
observation of Hb 
over time 
Complexity Simplest Complex, more parameters required. 
Intermediate. 
Flexibility to depart 
from characteristics of 
the RCTs, e.g. patient 
age, initial Hb level, 
subsequent Hb level, 
ESA doses. 
Less flexibility. More flexibility, e.g. to 
mirror difference in 
clinical practice 
compared to RCTs, 
changes in licence. 
Less flexibility. 
Data availability 
Preference-based 
HRQoL not available 
from RCTs. 
Quality data for many 
parameters not 
available. e.g. impact 
of Hb of increase in 
ESA dose. 
Yes, taken from 
PenTAG systematic 
review of RCTs 
Ability to use outcomes 
from multiple RCTs 
(PenTAG systematic 
review of RCTs) 
Yes. Not for some 
parameters, e.g. 
incremental change in 
Hb level. 
Also, some 
parameters are a 
function of 
characteristics of 
RCTs, e.g. OS HR of 
ESAs.  
Yes, with exception of 
HRQoL outcomes. 
Accuracy of utilities 
during ESA treatment 
and normalisation 
Accurate, but 
excluding Hb 
outcomes 
Assumes HRQoL impact of ESAs captured via 
Hb level.  QoL due to AEs captured 
independently. 
Examples of previous 
economic evaluations 
Barosi (1998),115 
Cremieux (1999)116 
Wilson (2007)1, Borg 
(2008)154 
Tonelli (2009),112 
Fagnoni (2006)123 
Key: AEs, adverse events; ESAs, erythropoiesis stimulating agents; Hb, haemoglobin; HR, hazard 
ratio; HRQoL, health-related quality of life; OS, overall survival;  QoL, quality of life; RCTs, 
randomised controlled trials 
 
A summary model diagram is presented in Figure 29 (page 249). This diagram demonstrates 
how Hb levels are modelled according to the baseline Hb level (Section 7.1.2.1.4, page 269), 
the expected change in Hb level for patients not receiving ESA therapy (Section 7.1.2.1.5, 
page 271) the expected final difference in Hb level between arms (Table 61, page 262), and 
the average difference in Hb levels between arms as a proportion of the final difference 
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(Section 7.1.2.1.6, page 273).  The concept of normalization, which takes place after cancer 
treatment has ended, is described fully in Section 7.1.2.1.7 (page 275). 
It is important to note that we model the average haemoglobin profiles across the patient 
population, rather than modelling individual patients’ haemoglobin profiles.  As such the 
haemoglobin profile is considerably smoother than that expected for an individual patient. 
Figure 29. Diagram indicating model assumptions about Hb levels by model stage 
 
Key: ESA, erythropoiesis stimulating agent; Hb, haemoglobin 
Note: Hb levels mapped to utility to calculate short-term QALYs 
7.1.1.2.  Long-term QALYs 
Long-term QALYs are calculated by estimating overall survival in each arm and applying a 
long-term utility common to both arms, i.e., it is assumed long-term QALY differences only 
come about through a difference in survival due to ESA therapy, not through any enduring 
impact on health-related quality of life.  Long-term utility is estimated in Section 7.1.2.2.6 
(page 297). 
The systematic review of clinical effectiveness provided estimates for the hazard ratio (HR) 
for survival between the ESA and control arms, but to implement this in the model required 
baseline survival for patients without ESA treatment.  As ESAs can be administered to 
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individuals with a range of cancers a wide range of overall survival estimates appear in 
clinical studies. 
7.1.1.2.1.  Review of best practice 
Here we briefly outline key points from Latimer (2011)169 which suggests some points for 
best practice, as they apply in to this setting (note that this paper principally advises on best 
practice in the case of patient-level data from a single study rather than summary data from 
multiple studies): 
1. Mean time-to-event should be estimated rather than medians. 
2. Parametric models should be used, rather than restricted means approaches, unless data 
is almost entirely complete. 
3. The analyst should demonstrate that a range of parametric models have been considered 
and compared, in order to make evident that the model choice has not been arbitrary. […] 
4. The fit of alternative models should be assessed systematically. […] 
5. [Proportional hazards] modelling should only be used if the proportional hazards 
assumption can be clearly justified […] 
6. Where parametric models are fitted separately to individual treatment arms it is sensible to 
use the same ‘type’ of model […] 
7. The duration of treatment effect assumption is important when a PH approach is taken, 
and in the extrapolated portion of survival curves when individual parametric models are 
fitted to treatment arms. […] 
8. The process of excluding data points should only be undertaken when it can be clearly 
demonstrated that certain points are erroneous outliers. […] 
7.1.1.2.2.  Modelling approach 
We examined overall survival curves from all studies included in the systematic review of 
clinical effectiveness where such survival curves were shown for patients receiving and not 
receiving ESA therapy. 
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For each survival curve we constructed the corresponding cumulative hazard curve to 
assess how the hazard function behaved over time.  Plots of cumulative hazard over time 
can be useful in identifying candidate parametric survival functions, e.g., if the cumulative 
hazard curve is a straight line then an exponential distribution may be appropriate; if the 
cumulative hazard function has a sigmoid shape this suggests the need for a survival 
function with non-monotonic hazard. 
Where overall survival figures were provided as vector graphics (as was the case for Ray-
Coquard and colleagues, 200974 and Moebus and colleagues, 201362) the exact survival 
curve was extracted using Inkscape [freely available from http://www.inkscape.org/] and 
transformed appropriately using Excel® (Microsoft, Redmond, Washington, USA).  Where 
overall survival figures were provided as raster graphics the underlying image was extracted 
using Inkscape and then transformed using GNU Image Manipulation Program [freely 
available from http://www.gimp.org/] and MathMap [freely available from 
http://www.complang.tuwien.ac.at/schani/mathmap/] as outlined in Appendix T.  This 
approach means that no data points were excluded. 
We additionally constructed the corresponding Weibull plot (a plot of log cumulative hazard 
versus log time) using the same methodology.  A straight line on a Weibull plot suggests a 
Weibull distribution may be appropriate and parallel straight lines for different arms suggests 
the use of proportional hazards Weibull model. 
The extracted survival curves and calculated cumulative hazard and Weibull plots are shown 
in Table 60 (page 253). 
Visual inspection of the cumulative hazard plots suggests that an exponential survival 
function would fit both arms in Vansteenkiste and colleagues (2002)72 and Osterborg and 
colleagues (2005).70 
The plots for Littlewood and colleagues (2001)68 suggest that neither a Weibull nor 
exponential survival function would fit the arms well.  It is also not clear whether a 
proportional hazards assumption would be valid as the survival curves converge after 
significant censoring. 
The plots for Grote and colleagues (2005)73 suggest an exponential survival function could 
be valid as the cumulative hazard plot only diverges from being linear after significant 
censoring, although if the Kaplan–Meier curve beyond divergence is considered informative 
it could suggest a delayed treatment effect on overall survival. 
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The survival plot Ray-Coquard and colleagues (2009)74 suggests that overall survival data 
is mature in this study (as 0% Kaplan–Meier survival is reached) but in fact the vast majority 
of patients are censored after around 12 months follow-up; up to this time exponential 
survival does not seem unreasonable. 
The plots for Untch and colleagues (2011)78 suggest that exponential survival may not be 
appropriate.  Examination of the Weibull plot suggests a Weibull survival function may be 
appropriate. It might also be appropriate to use piecewise exponential survival with very low 
hazard rate for the first year and then a higher hazard rate thereafter given the rightmost 
upturn in the cumulative hazard plot only occurs after significant censoring.  A proportional 
hazards assumption would not be unreasonable given the Weibull plot. 
The plots for Moebus and colleagues (2013)62 are noteworthy as they seem to suggest a 
non-monotonic hazard function, ruling out exponential, Weibull and Gompertz distributions 
for fitting.  This study evaluated performance in breast cancer (stages II to IIIa) patients, who 
might be expected to have a reasonable prognosis and hence a long tail (as would be 
associated with a log-logistic or log-normal distribution) might not be inappropriate as it could 
be for other cancers. 
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Table 60. Overall survival curves extracted from RCTs 
Study Survival curve Cumulative hazard curve Weibull plot 
Littlewood, 200168 
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Study Survival curve Cumulative hazard curve Weibull plot 
Vansteenkiste, 
200272 
 
  
Grote, 200573 
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Study Survival curve Cumulative hazard curve Weibull plot 
Osterborg, 200570 
 
  
Ray-Coquard, 
200974 
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Study Survival curve Cumulative hazard curve Weibull plot 
Untch, 
2011a,b77,78 
   
Moebus, 201362 
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Given that some included studies support the use of an exponential survival function and that 
the exponential survival function is frequently used in the modelling of cancer we use an 
exponential survival function in the base case with proportional hazards. 
To explore the significant structural uncertainty we also perform three scenario analyses: 
1. The survival in the control arm is unchanged from the base case and survival for 
patients receiving ESA therapy is estimated by using proportional hazards for the first 
three years followed by equal hazard rate to that of the control arm (as though the 
effect of ESA therapy on mortality lasts only three years).  The length of follow-up is 
not reported for a number of studies contributing to the hazard ratio for overall 
survival although it is likely for a number of studies that follow-up was extremely 
limited.  Of the studies giving Kaplan–Meier curves follow-up was only over three 
years for Untch and colleagues (2011)78 (median follow-up 43.5 months) and 
Moebus and colleagues (2013)62 (median follow-up 62 months) 
2. A Weibull survival function is fitted to the control arm survival curve from Untch and 
colleagues (2011)78 and a proportional hazards assumption is applied, using the 
same hazard ratio as applied in the base case. 
3. Two log-normal survival functions are fitted to the two arms in Littlewood and 
colleagues (2001)68 and are extrapolated to mean life expectancy for 59 year old 
members of the general population (weighted average of male and female life 
expectancy according to the gender balance in the study).  Limiting the extrapolation 
to life expectancy is to approximate the inclusion of background mortality, which is not 
otherwise modelled and would not have been adequately represented in the Kaplan–
Meier curve (which only covers approximately three years of follow-up). 
We are able to perform a probabilistic sensitivity analysis for the first two scenarios (although 
the OS in the control arm is not varied probabilistically in the second scenario) but a 
probabilistic sensitivity analysis is not performed for the third scenario as we had no 
adequate information to incorporate uncertainty about overall survival in this instance. 
Closed-form expressions for the expected discounted life years in each arm are available for 
the exponential distribution and for the first scenario (assuming a rate of continuous 
discounting of rc): 
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Mean discounted life years in control arm (base case and first scenario; λ = mortality rate) = 
1/(λ + rc); 
Mean discounted life years in ESA arm (base case; λ = mortality rate, β = hazard ratio) = 1/(λ 
× β + rc); 
Mean discounted life years (first scenario; λ = mortality rate, β = hazard ratio) = (1 − exp(−(λ 
× β + rc) × 3.0))/(λ × β + rc) + exp(−(λ + rc) × 3.0)/(λ + rc). 
Closed-form expressions for the expected discounted life years are not available for the 
Weibull or log-normal distributions so these are calculated numerically using trapezoidal 
integration with a step size of 0.1 years. 
Section 7.1.2.1.8 (page 277) describes how the overall survival models are parameterised. 
7.1.2. Model parameters 
On guidance from NICE, and so that a larger set of clinical study results can be used, clinical 
effectiveness parameters are not given for individual ESAs, but for ESAs as whole. In other 
words, in the PenTAG cost-effectiveness modelling there are assumed to be no differences 
in clinical effectiveness between the alternative ESAs.  The only exceptions are for 
parameters unique to each of the ESAs, such as drug doses and costs. 
Appendix R provides a summary table including all model parameters. 
7.1.2.1.  Clinical effectiveness parameters 
As explained in Section 7.1.1 (page 245), the PenTAG economic evaluation is intended to 
link directly to the clinical evidence from the RCTs of ESAs.  In this section, we outline the 
relevant parameters and their estimates taken from the RCTs.  
In order to ensure consistency between costs and benefits, all parameters are estimated on 
the basis of intention-to-treat.  For example, we use the mean weekly dosage of ESAs 
averaged over all patients at baseline for the full intended treatment duration.  This average 
includes some patients who withdraw from ESA treatment during the trial.  This ensures 
consistency with clinical outcomes such as the mean difference between treatment arms in 
the change in Hb level from baseline, and the mean difference in the number of units of 
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RBCs transfused between the ESA and control arms, as these quantities are also estimated 
from all randomised patients. 
The ESA withdrawal rate and mean weekly dose are two parameters that are used in the 
economic model, but which are often reported only indirectly.  The derivations of these 
parameters, shown in Table 62 (page 263), are given in Section 7.1.2.1.1 (pages 266–269).  
Similarly, the mean difference in Hb levels between treatment arms over the entire ESA 
treatment period (as a proportion of the difference at the end of the trial) is another key 
parameter for the economic model, but which is often reported only indirectly. The derivation 
of this parameter is given in Section 7.1.2.1.6 (pages 273–275). 
The mean weekly dose and frequency of administering can differ between ESAs, due to 
differences in their licensing. These differences are discussed in Section 7.1.2.1.1 (pages 
266–269) and Section 7.1.2.3.4 (page 302), respectively.  
Some parameters are taken directly from random effects meta-analyses in the PenTAG 
systematic review of clinical evidence (see Table 61, page 262): 
 Overall survival hazard ratio; 
 Difference in Hb change from baseline; 
 Difference in RBC units transfused; 
 Relative risk of adverse events (thromboembolic events, hypertension and 
thrombocytopenia). 
Other parameters are calculated from the inputs in those meta-analyses (Table 61, page 
262): 
 Hb change from baseline in control arm; 
 RBC units transfused in control arm; 
 Absolute risk of adverse events in control arm. 
Further parameters were not extracted as a part of the systematic review of clinical 
effectiveness evidence and needed to be additionally extracted for the economic analysis: 
 Overall survival in control arm; 
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 Baseline Hb level; 
 Mean weekly ESA dose (adjusted for dose escalation, interruption and withdrawal); 
 Mean difference between Hb change curves as a proportion of final difference in Hb 
change from baseline; 
 Duration of ESA treatment; 
 Age; 
 Weight. 
Table 62 (page 263) gives the estimates of these outcomes from clinical studies which are 
then pooled as described in later sections. 
We found no evidence from RCTs for normalization of Hb levels following chemotherapy 
cessation, so this part of the model had to be parameterised on the basis of clinical expert 
opinion (Section 7.1.2.1.7, page 275). 
In the base case we use all 24 studies included in the systematic review of clinical 
effectiveness evidence (Section 0). 
There is some heterogeneity in this collection of studies which may be due to treatment 
intention differences, e.g., in some studies the intention may be to correct anaemia while in 
others the intention may be to prevent anaemia. 
To attempt to produce an analysis more consistent with the licensed use of ESAs (for anemia 
correction) we perform a scenario analysis where the subgroup of studies with inclusion Hb 
level ≤ 11.0 g/dL (or lower) is used. While this subgroup still includes 13 studies the precision 
of some effectiveness estimates is reduced (particularly as not all studies include all 
outcomes) and the subgroup may still include studies in which a higher target Hb level than 
recommended in the licence is chosen.  
If target Hb level is used to identify subgroups, the number of included studies falls 
significantly; only two studies have inclusion Hb level ≤ 11.0 g/dL and target Hb level ≤ 13.0 
g/dL: Tjulandin and colleauges (2010)45 and Tjulandin and colleagues (2011).76 Only one 
additional study, Untch and colleagues (2011)78 had target Hb level ≤ 13.0 g/dL (but did not 
have inclusion Hb level ≤ 11.0 g/dL). We did not believe these subgroups to be adequate to 
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inform the model due to lack of precision and possible bias as Untch and colleagues 
(2011)77,78 did not meet a number of study quality standards. 
Two notable clinical outcomes from the RCTs were not used in the economic model: the 
haematological response rate and the tumour response rate.  The haematological response 
rate is defined as the proportion of patients achieving either an increase in Hb of at least 
2 g/dl or a haematocrit increase of at least 6%.  We do not use this outcome in the model for 
two reasons.  First, we use more detailed information on the change in Hb from the RCTs.  
Second, as far as we are aware, the impact of haematocrit on quality of life is unknown.  
Tumour response rate RCT data are not used in the PenTAG model, because the tumour 
response rate is modelled indirectly by its impact on survival and we do not model the cancer 
disease pathway. 
There is significant uncertainty surrounding a number of clinical effectiveness parameters 
and it is important that the impact of this uncertainty on the decision problem is 
demonstrated.  We perform a probabilistic sensitivity analysis (PSA) in which model 
parameters are varied according to probability distributions with expected values equal to the 
deterministic parameter values.  While it would be best practice for certain parameters to be 
correlated in the PSA there is not enough data for such an approach and as such all 
parameters are drawn independently. 
It would also be best practice to have the distributions of parameters in the PSA reflect the 
between-study variance after accounting for the within-study variance, however the within-
study variance was not reported or not extracted for outcomes not included in the systematic 
review of clinical effectiveness.  As a result for some parameters we use the sample 
standard deviation of the extracted outcomes from studies as the standard error in the 
model.  This is preferable to using the sample standard error as this would underestimate 
uncertainty (as it would not incorporate the within-study variance).  The sample standard 
deviation is also weighted using the same weights as the central estimate. 
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Table 61. Clinical parameters used in economic model taken directly from the PenTAG 
systematic review 
Parameter Pooled mean used in 
PenTAG model base case 
(SE) 
Pooled mean 
used in scenario 
analysis (SE) 
Section in report 
Overall survival 
(HR) 
0.967 (0.079) 0.914 (0.137) Section 4.2.6.2.2 (page 
117) 
Change in Hb from 
baseline to end of 
ESA treatment: 
difference 
between ESA and 
control arms 
1.59 (0.130) 1.52 (0.115) Section 4.2.6.1.1 (page 
85) 
Mean number of 
units transfused in 
control arm 
2.09 2.30 Calculated from 
reported outcomes of 
the RBC units meta-
analysis, Section 
4.2.6.1.4 (page 104) 
Mean difference # 
units RBCs 
transfused ESA 
vs. control arm 
−0.87 (0.21) −0.99 (0.22) Section 4.2.6.1.4 (page 
104)  
Relative risk of adverse event rates in ESA vs. control arm (reported on natural log scale) 
Thromboembolic 
events 
ln(1.46) = 0.378 (0.158) ln(1.29) = 0.255 
(0.344) 
Section 4.2.6.3.1 (page 
131) 
Hypertension  ln(1.8) = 0.588 (0.234) ln(1.68) = 0.519 
(0.250) 
Section 4.2.6.3.2 (page 
134) 
Thrombocytopenia ln(0.93) = −0.073 (0.185) ln(0.73) = −0.315 
(0.350) 
Section 4.2.6.3.3 (page 
138) 
Probability of adverse event in control arm 
Thromboembolic 
events 
3.3% (0.4%) 3.7% (0.8%) Calculated from 
reported numbers of 
adverse events in 
Section 4.2.6.3 (page 
131) 
Hypertension  2.9% (0.5%) 1.8% (1.0%) 
Thrombocytopenia 6.4% (0.8%) 2.5% (0.8%) 
Key: ESA, erythropoiesis stimulating agents; HR, hazard ratio; RBCs, red blood cells; RBCT, red blood cell 
transfusion; SE, standard error 
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Table 62. Additional clinical effectiveness outcomes from RCTs 
Study, year 
Mean weekly 
ESA dosea 
Hb 
Mean overall survival 
Mean baseline Hb 
level (g/dl) 
Mean increase Hb 
(g/dl) control 
Mean difference in Hb levels 
between treatment arms as a 
proportion of difference at end of 
trialb 
Wilson and colleagues (2004 [HTA]) included studies meeting inclusion criteria for the PenTAG review 
Abels, 199354 307 IU/kgc NR NR NR NR 
Aravantinos, 
200363 
NR EA, 9.80 
No tx, 9.32 
+1.23 23% NR 
Boogaerts, 200352 463 IU/kg EB, 9.0 
No tx, 9.2 
+0.9d 68%d NR 
Dammacco,  
200164 
496 IU/kg EA, 9.3 
PBO, 9.6 
0.0 56% NR 
Del Mastro, 
199765 
429 IU/kg EA, 13.0 
No tx, 13.1 
−3.05 73% NR 
Dunphy, 199966 467 IU/kg 14.1 −2.8 77% NR 
Hedenus,  
200249 
2.20 µg/kg DA (2.25 µg/kg 
QW), 9.4 (1.3) 
PBO, 9.5 (1.0) 
+1.00 59% NR 
Hedenus, 200316 NR 9.54 +0.19 NR NR 
Kotasek, 200346 2.025 µg/kg DA, 9.93e
PBO, 9.87 
−0.02 NR NR 
Kurz, 199767 NR EA, 9.88 
No tx, 9.85 
+0.25 50% NR 
Littlewood, 200168 NR 9.8 +0.5 110% 12-month survival: 
EA, 60% 
PBO, 49% 
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Study, year 
Mean weekly 
ESA dosea 
Hb 
Mean overall survival 
Mean baseline Hb 
level (g/dl) 
Mean increase Hb 
(g/dl) control 
Mean difference in Hb levels 
between treatment arms as a 
proportion of difference at end of 
trialb 
Median survival: 
EA, 17 mths 
PBO, 11 mths 
Osterborg, 2002, 
200569,70 
NR EB, 9.2 
PBO, 9.3 
NR NR EB, 17.4 mthsd
PBO, 18.0 mthsd 
Silvestris, 199571 733 IU/kg [From figure] Non-
transfusion-
dependent: EA, 
7.6d No tx, 7.8d 
Transfusion-
dependent: EA, 
7.4d No tx, 7.8d 
[From figure; 
combining 
transfusion-
dependent and non-
transfusion-
dependent] +0.22d 
[Combining transfusion-dependent 
and non-transfusion-dependent] 
 
84%d 
NR 
Ten Bokkel, 
199847 
302 IU/kg EA (150 IU/kg TIW), 
12.0d 
No tx, 11.8d 
NR NR NR 
Thatcher, 199948 335 IU/kg EA, 13.7d 
PBO, 13.4d 
NR 92% NR 
Vansteenkiste, 
200272 
161 µgf 10.11 NR NR DA, 46 wksd
PBO, 36 wksd 
PenTAG review update 2004 onwards 
Grote, 
200573 
(Cannot be 
calculated as 
intended 
treatment duration 
not fixed) 
EA, 12.8;  
PBO, 13.0 
−2.7 232%g EA, 10.5 mthsd
PBO, 10.4 mthsd 
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Study, year 
Mean weekly 
ESA dosea 
Hb 
Mean overall survival 
Mean baseline Hb 
level (g/dl) 
Mean increase Hb 
(g/dl) control 
Mean difference in Hb levels 
between treatment arms as a 
proportion of difference at end of 
trialb 
Moebus,  
201362 
414 IU/kg EA, 12.40d 
No tx, 12.80d 
−2.20 77% 5-year OS: 
EA, 81% 
No tx, 83% 
Ray-Coquard,  
200974 
NR EA, 10.0 
No tx, 10.0 
NR NR EA, 7.6 mthsd 
No tx, 6.0 mthsd 
Strauss,  
200875 
26,338 IU EB, 11.4,  
No tx, 11.6 
−0.7 76% NR 
Tjulandin, 
201045 
ET: 23,594 IU 
EB: 31,251 IU 
ESA, 9.5 
PBO, 9.4 
+0.2 ET: 62% 
EB: 60% 
NR 
Tjulandin,  
201176 
ET: 22,235 IU 
 
ET, 9.2 
PBO, 9.1 
+0.65 50% NR 
Untch,  
2011a,b77,78 
NR DA, 13.64 
No tx, 13.61 
−0.98 NR At median follow-up (43.5 months): 
DA, 88.0% 
No tx, 91.8% 
Key: DA, darbepoetin alfa; diff, difference; EA, epoetin alfa; EB, epoetin beta; ESA, erythropoiesis stimulating agents; est., estimated; ET, epoetin theta; Hb, haemoglobin; IQR, 
interquartile range; IU, International Units; No tx, No treatment; NR, not reported; OS, overall survival; PBO, placebo 
Notes: Study and baseline characteristics are reported in Appendix G; and, dose administered (application of licence) within the studies is reported in Appendic C; (a) See Section 
7.1.2.1.2 (page 242) for description of estimation methods; (b) See Appendix S for calculation details; (c) Reported in Henry and colleagues (1994)56; (d) Median; (e) Includes patients 
randomized to unlicensed doses; (f) Calculated from data reported in Vansteenkiste and colleagues (2004)81; (g) The final Hb levels shown in Figure 2 of Grote and colleagues 
(2005)73 do not coincide with those described in the text – data has been extracted from the graph for the mean diff Hb over time and from the text for the mean increase in Hb level in 
the control arm. 
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7.1.2.1.1.  Number of red blood cell  transfusions 
The systematic review of clinical effectiveness evidence provides a summary estimate for the 
difference in RBC units transfused per patient between patients receiving and not receiving 
ESAs of −0.87 (95% CI, −1.28 to −0.46).  The confidence interval corresponds to a standard 
error of 0.21 units.  This summary estimate is from a random effects meta-analysis and we 
use the same weights to estimate the absolute mean RBC units transfused for patients not 
receiving ESA therapy (2.09 units).  Since the absolute mean RBC units transfused does not 
affect cost-effectiveness this is not varied in the PSA. 
In the scenario analysis with the subgroup of studies in which inclusion Hb level was ≤ 11.0 
g/dL the difference in RBC units transfused was −0.99 (95% CI, −1.41 to −0.56) and the 
absolute mean RBC units transfused in the no ESA arm was 2.30 units. 
Assuming the average number of red blood cell (RBC) units per transfusion is equal 
regardless of ESA use, we can calculate the average number of transfusions that occur for 
each transfused patient. In the base case we take an average number of units per 
transfusion to be 2.7 units.170 A Normal distribution is used for this parameter in the PSA, 
with SE equal to 20% of the mean. 
7.1.2.1.2.  ESA withdrawal rate and mean weekly dose 
ESA dosages are adaptive, in many cases being increased when an inadequate initial 
response is obtained and being decreased or interrupted if Hb levels rise too fast or too high.  
Furthermore patients may withdraw from ESA therapy for a number of reasons.  As most of 
the clinical effectiveness data informing the model is calculated on an intention-to-treat basis 
(the general exception being adverse event data), it is important that the amount of ESA drug 
use is commensurate. 
The modelling approach adopted is to combine the withdrawal rate, dose escalation, dose 
reduction, etc. into a single parameter, the ITT mean weekly dose. 
This was estimated where possible from data published in the studies included in the 
systematic review of clinical effectiveness.  No single method of estimation would work for all 
studies, so we briefly outline the most common methods employed: 
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 If the mean dose actually administered (denoted D) is reported and so are the mean 
treatment duration (T) and intended treatment duration (T*), the ITT mean weekly 
dose is calculated as D × T ÷ T* 
 The mean treatment duration can also be estimated if it is not reported: if the number 
or proportion of patients remaining on ESA therapy is reported at various time points, 
these can be interpolated, then the area under the Proportion–Time curve is 
approximately equal to the mean treatment duration 
 If the mean cumulative dose per patient is given this can be divided by the intended 
treatment duration to calculate the ITT mean weekly dose. 
Table 63 lists the clinical effectiveness studies with estimates of ITT mean weekly dose and 
the corresponding weights of those studies in the random effects meta-analyses of Hb 
change.  In the base case the weights are taken from the full set of RCTs.  As a scenario 
analysis the weights are used from the subgroup when initial Hb level must be ≤ 11 g/dL.  An 
average weight of 66.6 kg was assumed to convert from weight-based to fixed doses and 
produce the estimates in Table 64.  As no studies were found with epoetin zeta ITT mean 
weekly doses we assumed the same mean weekly dose as epoetin alfa due to the similarity 
of their licences. 
As there is significant uncertainty in the ITT mean weekly dose we assumed a Gamma 
distribution with means as shown in Table 64 and standard errors equal to 20% of means. 
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Table 63. Mean weekly doses from clinical effectiveness studies 
Study ESA ITT mean weekly 
dose 
Weighta 
Base caseb Scenario 
analysisc 
Abels, 199354 Epoetin alfa 307 IU/kgd 10.72f 14.61f 
Boogaerts, 200352 Epoetin beta 463 IU/kg 6.69 11.14 
Dammacco, 
200164 
Epoetin alfa 496 IU/kg 5.71 8.11 
Del Mastro, 
199765 
Epoetin alfa 429 IU/kg 5.28 n/a 
Dunphy, 199966 Epoetin alfa 467 IU/kg n/a n/a 
Hedenus, 200249 Darbepoetin alfa 2.20 µg/kg 4.81 6.01 
Kotasek, 200346 Darbepoetin alfa 2.025 µg/kg 4.32 5.07 
Silvestris, 199571 Epoetin alfa 733 IU/kg n/a n/a 
ten Bokkel, 199847 Epoetin alfa 302 IU/kg 4.77 n/a 
Thatcher, 199948 Epoetin alfa 335 IU/kg n/a n/a 
Vansteenkiste, 
200272 
Darbepoetin alfa 161 µge n/a n/a 
Moebus, 201362 Epoetin alfa 414 IU/kg n/a n/a 
Strauss, 200875 Epoetin beta 26,338 IU n/a n/a 
Tjulandin, 201045 Epoetin theta 23,594 IU 5.34 7.18 
Epoetin beta 31,251 IU 5.10 6.64 
Tjulandin, 201176 Epoetin theta 22,235 IU 6.29 9.78 
Key: ESA, erythropoiesis stimulating agent; Hb, haemoglobin; IU, international units 
Notes: (a) Weighting taken from random effects meta-analysis of mean Hb change in systematic review; (b) 
Studies with licensed start dose; (c) Studies with licensed start dose and initial Hb < 11 g/dL; (d) Reported in 
Henry and colleagues (1994); (e) Reported in Vansteenkiste and colleagues (2004); (f) Sum of weights for 
cisplatin and non-cisplatin chemotherapy 
 
Table 64. ESA doses in model 
ESA Base case Scenario analysis 
Epoetin alfa (IU per week) 24,729 24,745 
Epoetin beta (IU per week) 31,021 30,840 
Epoetin theta (IU per week) 22,859 22,810 
Epoetin zeta (IU per week) 24,729 24,745 
Darbepoetin alfa (µg per week) 141.1 140.1 
7.1.2.1.3.  Duration of ESA treatment 
As stated in Section 7.1.2.1 (page 258), clinical effectiveness parameters are estimated on 
an intention-to-treat basis. As such the duration of ESA treatment is taken to be 12 weeks in 
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this analysis as this is the estimate acquired from the majority (13 of 23) of the RCTs 
included in the PenTAG meta-analysis. Some RCTs included longer treatment durations, but 
17 of 23 reported durations of 18 weeks or less and all but one study with unambiguous 
reporting reported durations of 24 weeks or less. In a univariate sensitivity analysis we 
explore the impact of varying treatment duration up to 24 weeks, which is also the maximum 
duration included in Wilson and colleagues (2007).1 It is noted that the duration of ESA 
treatment affects the short term QALY gain, as a longer duration of treatment allows time for 
more QALYs to accrue. 
ESA drug administration is modelled per protocol rather than on intention-to-treat basis (i.e., 
withdrawals are not incorporated. This does, in the base case, give a higher cost of 
administration for ESAs than we would otherwise expect, however, this increase in cost of 
drug administration is small enough that it does not greatly influence the overall costs. This 
cost is further discussed in Section 7.1.2.3.4 (page 302).   
7.1.2.1.4.  Init ial (baseline) Hb level 
The initial Hb level of patients has an impact on the Hb level after chemotherapy has 
finished, and therefore has an impact on how long it takes for Hb levels to return to normal.  
Initial Hb level is well reported in the included RCTs.  Figure 30 (page 270) shows the range 
of baseline Hb levels.  There is heterogeneity in the initial Hb levels which is likely due to 
different inclusion criteria.   
PenTAG   CONFIDENTIAL 
270 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Figure 30. Initial Hb level, by study 
 
Key: Hb, haemoglobin; ○, Study included in base case and scenario analysis; ●, Study not included in scenario 
analysis; ×, Study excluded (not included in meta-analysis of Hb level change) 
 
 
In the base case we calculate a weighted average baseline Hb level with weights taken from 
the random effects meta-analysis of mean Hb change.  As a scenario analysis the weights 
from the subgroup with inclusion criteria of Hb ≤ 11.0 g/dL is used. 
The resulting baseline Hb levels are 10.38 g/dL (base case) and 9.40 g/dL (scenario 
analysis), as shown in Table 65.  The standard error in the base case is estimated from the 
weighted standard deviation of baseline Hb levels and calculated as 1.59 g/dL such that 95% 
of simulated values fall in the range [7.28, 13.49].  The standard error in the scenario 
analysis is calculated as 0.22 g/dL such that 95% of simulated values fall in the range [8.97, 
9.84].   
Table 65. Calculation of baseline Hb level parameter 
Study 
Baseline Hb level 
Weight 
Base caseb Scenario analysisc
Aravantinos, 200363 9.56 4.46 5.34 
Boogaerts, 200352 9.1 6.69 11.14 
Dammacco, 200164 9.45 5.71 8.11 
Del Mastro, 199765 13.05 5.28 n/a 
Dunphy, 199966 14.1 n/a n/a 
Hedenus, 200249 9.45 4.81 6.01 
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Hedenus, 200316 9.54 6.79 11.51 
Kotasek, 200346 9.90 4.32 5.07 
Kurz, 199767 9.865 2.81 2.78 
Littlewood, 200168 9.8 6.57 n/a 
Osterborg, 2002, 200569,70 9.25 6.87 11.82 
Silvestris, 199571 7.65 n/a n/a 
ten Bokkel, 199847 11.9 4.77 n/a 
Thatcher, 199948 13.55 n/a n/a 
Vansteenkiste, 200272 10.11 n/a n/a 
Grote, 200573 12.9 6.05 n/a 
Moebus, 201362 12.60 n/a n/a 
Ray-Coquard, 200974 10.0 n/a n/a 
Strauss, 200875 11.5 n/a n/a 
Tjulandin, 201045 9.45 10.44d 13.82d 
Tjulandin, 201176 9.15 6.29 9.78 
Untch, 2011a,b77,78 13.625 7.42 n/a 
Summary estimate (base 
case) 
10.38 89.28 (100%)  
Summary estimate 
(scenario) 
9.40  85.38 (100%) 
Key: Hb, haemoglobin 
Notes: (a) Weighting taken from random effects meta-analysis of mean Hb change in systematic review; (b) 
Studies with licensed start dose; (c) Studies with licensed start dose and initial Hb <11 g/dL; (d) Weights 
summed over epoetin beta and epoetin theta arms 
7.1.2.1.5.  Change in Hb for patients not receiving ESA therapy 
Haemoglobin levels are expected to vary over time for patients even if they do not receive 
ESA therapy.  This has an important impact on how long Hb levels take to return to normal.  
It is to be expected that the Hb trajectories for patients in different studies would vary due to 
the differing effects of chemotherapy regimens and cancers on haemoglobin levels. 
Figure 31 (page 272) shows the data from RCTs and  
Table 66 (page 272) shows how these are combined to form the parameter values in the 
model base case and scenario analysis with inclusion Hb level ≤ 11.0 g/dL. 
The resulting change in Hb for patients not receiving ESA therapy is −0.155 g/dL in the base 
case and 0.469 g/dL in the scenario analysis.  The weighted sample standard deviation was 
used to estimate the standard error in the base case and was calculated as 1.25 g/dL 
meaning 95% of simulated values fall in the range [−2.60, 2.29].  In the scenario analysis the 
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standard error was estimated as 0.41 g/dL meaning 95% of simulated values fall in the range 
[−0.33, 1.27]. 
Figure 31. Change in Hb level for patients not receiving ESAs at end of study period 
 
Key: ESAs, erythropoiesis stimulating agents; Hb, haemoglobin; ○, Study included in base case and scenario 
analysis; ●, Study not included in scenario analysis; ×, Study excluded (not included in meta-analysis of Hb level 
change) 
 
Table 66. Change in Hb level for patients not receiving ESAs 
Study 
 
 Weighta 
Change in Hb level 
for patients not 
receiving ESAs 
Base caseb Scenario analysisc 
Aravantinos, 200363 1.23 4.46 5.34 
Boogaerts, 200352 0.9 6.69 11.14 
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Dammacco, 200164 0.0 5.71 8.11 
Del Mastro, 199765 -3.05 5.28 n/a 
Dunphy, 199966 -2.8 n/a n/a 
Hedenus, 200249 1.00 4.81 6.01 
Hedenus, 200316 0.19 6.79 11.51 
Kotasek, 200346 -0.02 4.32 5.07 
Kurz, 199767 0.25 2.81 2.78 
Littlewood, 200168 0.5 6.57 n/a 
Osterborg, 2002, 200569,70 NR 6.87 11.82 
Silvestris, 199571 0.22 n/a n/a 
ten Bokkel, 199847 NR 4.77 n/a 
Thatcher, 199948 NR n/a n/a 
Vansteenkiste, 200272 NR n/a n/a 
Grote, 200573 -2.7 6.05 n/a 
Moebus, 201362 -2.20 n/a n/a 
Ray-Coquard, 200974 NR n/a n/a 
Strauss, 200875 -0.7 n/a n/a 
Tjulandin, 201045 0.2 10.44d 13.82d 
Tjulandin, 201176 0.65 6.29 9.78 
Untch, 2011a,b77,78 -0.98 7.42 n/a 
Summary estimate (base 
case) 
−0.155 77.64 (100%)  
Summary estimate (scenario 
analysis) 
0.469  73.56 (100%) 
Key: Hb, haemoglobin 
Notes: (a) Weighting taken from random effects meta-analysis of mean Hb change in systematic review; (b) 
Studies with licensed start dose; (c) Studies with licensed start dose and initial Hb < 11 g/dL; (d) Weights 
summed over epoetin beta and epoetin theta arms 
7.1.2.1.6.  Mean difference in Hb levels between treatment arms as a 
proportion of dif ference at end of tr ial 
The mean difference in Hb levels between treatment arms over the entire ESA treatment 
period, as a proportion of difference at the end of the trial is another key parameter for the 
economic model, but which is often reported only indirectly.  
We therefore calculated, for each week, the improvement in Hb level from baseline in each 
treatment arm and this quantity as a proportion of the improvement from baseline to end of 
treatment. We then took an average to give mean difference over the treatment period. See 
Appendix S for details. 
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Figure 32 (page 274) shows the values from included studies. While for most studies the 
parameter value is under 100%, for two studies the parameter value is over 100% because 
the final difference in Hb level is less than at earlier times in the trial (i.e., the Hb trajectories 
of the two arms converge over time).  Table 67 (page 274) shows the derivation of the 
parameter values used in the model (on the basis of a weighted-average using weights from 
the random effects meta-analysis of Hb level change). 
The parameter value in the base case is 80.6% and the value in the scenario analysis is 
55.5%.  The weighted sample standard deviation was used to estimate the standard error, 
calculated as 55.0% in the base case and 12.0% in the scenario analysis.  A Gamma 
distribution was assumed such that in the base case 95% of simulated values fall in the 
range [10.9%, 218.6%] and in the scenario analysis 95% of simulated values fall in the range 
[34.4%, 81.4%]. 
Figure 32. Mean difference in Hb levels between treatment arms as a proportion of 
difference at end of trial 
 
Key: ESAs, erythropoiesis stimulating agents; Hb, haemoglobin; ○, Study included in base case and scenario 
analysis; ●, Study not included in scenario analysis; ×, Study excluded (not included in meta-analysis of Hb level 
change) 
 
Table 67. Mean difference in Hb level over time from RCTs 
Study Mean diff Hb over 
time / mean final 
diff Hb 
Weighta 
Base caseb Scenario analysisc 
Aravantinos, 200363 23% 4.46 5.34 
0%
50%
100%
150%
200%
250%
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Boogaerts, 200352 68% 6.69 11.14 
Dammacco, 200164 56% 5.71 8.11 
Del Mastro, 199765 73% 5.28 n/a 
Dunphy, 199966 77% n/a n/a 
Hedenus, 200249 59% 4.81 6.01 
Hedenus, 200316 NR 6.79 11.51 
Kotasek, 200346 NR 4.32 5.07 
Kurz, 199767 50% 2.81 2.78 
Littlewood, 200168 110% 6.57 n/a 
Osterborg, 2002, 200569,70 NR 6.87 11.82 
Silvestris, 199571 84% n/a n/a 
ten Bokkel, 199847 NR 4.77 n/a 
Thatcher, 199948 92% n/a n/a 
Vansteenkiste, 200272 NR n/a n/a 
Grote, 200573 232% 6.05 n/a 
Moebus, 201362 77% n/a n/a 
Ray-Coquard, 200974 NR n/a n/a 
Strauss, 200875 76% n/a n/a 
Tjulandin, 201045 ET: 62% 
EB: 60% 
Midpoint: 61% 
10.44d 13.82d 
Tjulandin, 201176 50% 6.29 9.78 
Untch, 2011a,b77,78 NR 7.42 n/a 
Summary estimate (base 
case) 
80.6% 59.11 (100%)  
Summary estimate (scenario 
analysis) 
55.5%  56.98 (100%) 
Key: EB, epoetin beta; ET, epoetin theta; Hb, haemoglobin; NR, not reported 
Notes: (a) Weighting taken from random effects meta-analysis of mean Hb change in systematic 
review; (b) Studies with licensed start dose; (c) Studies with licensed start dose and initial Hb < 11 
g/dL; (d) Weights summed over epoetin beta and epoetin theta arms 
7.1.2.1.7.  Normalisation of haemoglobin levels fol lowing chemotherapy 
cessation 
It has been assumed in some previous economic evaluations of ESAs1,154 that after 
chemotherapy cessation haemoglobin levels would return to ‘normal’ (see Section 0 , page 
203). While this is an intuitive assumption that is generally supported by clinical expert 
opinion, we have not found direct evidence of the process (termed normalisation) in the 
published literature.  Given that approximately half the QALY gain from ESA therapy could 
be accrued during normalisation,1 the modelling of normalisation is likely to be very important 
in determining overall cost-effectiveness. 
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The PenTAG modelling approach matches that adopted in previous economic evaluations, 
namely that in the normalisation period Hb levels rise at a constant rate (the same rate for all 
patients regardless of treatment) until they reach a ‘normal level’. 
Assuming a slower rate of normalisation results in improved incremental effectiveness of 
ESA therapy over standard care, as does assuming a higher normal Hb level. 
Table 68 gives normalisation parameters in previous economic evaluations and those 
suggested by clinical experts.  A normal Hb level of 12 g/dL appears to be a good 
compromise of the values suggested (the figure may be lower for haematological cancers but 
this is not modelled).  This is varied in the PSA with distribution ࣨሺߤ, ߪଶሻ, with μ = 12.0, σ = 
0.51 such that 95% of simulated values lie in the range (11.0, 13.0).  It is possible for patients 
receiving ESA in the model to finish ESA therapy with Hb level higher than the ‘normal level’, 
in which case their actual Hb level is assumed to be the normal level on the basis that 
clinicians would not seek to raise Hb levels above normal levels for a patient. We also 
assume that the same utility gradient with respect to Hb level is observed (contrary to some 
studies which show levelling off), on the basis that clinicians would only raise Hb levels in 
such patients to improve HRQoL and therefore utility.  If it is actually the case that utility 
levels off this method will overestimate the short-term QALY gain when Hb levels above 12 
g/dL are modelled. 
Given the base case initial Hb is 10.38 g/dL and the base case change in Hb for patients not 
receiving ESA is −0.15 g/dL, normalisation is expected to take Hb from 10.23 g/dL to 12.00 
g/dL: a rise of 1.77 g/dL.  One clinical expert suggested that normalisation could be complete 
within 6–8 weeks, this would suggest a rate of normalisation of 0.22–0.30 g/dL per week, 
which is consistent with other estimates.  
A normalisation rate of 0.2 g/dL per week is broadly consistent with previous evaluations and 
clinical expert opinion and this is the PenTAG base case value.  In PSA this is varied 
according to ࣨሺߤ, ߪଶሻ with μ = 0.2 and σ = 0.051 such that 95% of simulated values lie in the 
range (0.1, 0.3). 
It is assumed on the basis of clinical opinion that normalisation will be complete within three 
months and this is incorporated in the model as a cap on the maximum time to normalisation, 
with the rate of normalisation effectively being increased where necessary to meet this cap. 
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Table 68. Normalisation parameters 
Source Rate of normalisation  
(g/dL per week) 
Normal Hb level  
(g/dL) 
Previous economic evaluations 
Amgen model1 0.1 ≥ 12 
Roche model1 0.2 13 (Solid); 11.9 (Haem) 
Ortho Biotec model1 0.2 13 
Birmingham model1 0.25 13 
Borg et al. (2008)154 0.25 13 
Clinical expert opinion 
Expert 1 (KS) (Normalised within 3 mths) 
Expert 2 (CR) 0.125 11 
Expert 3 (MN) 0.25 11 
Expert 4 (NR) (Normalised within 6–8 wks) 12 
Key: Haem, haematological; Hb, haemoglobin; Solid, solid 
7.1.2.1.8.  Overall  survival 
To parameterise the base case (exponential survival function with proportional hazards) we 
calculated what rate parameter (λ) would be necessary to achieve either the reported median 
survival or reported Kaplan–Meier survival at a specified point in time in the control arm for 
each included study.  We then calculated a weighted geometric mean of the rates (using the 
weights from the random effects meta-analysis of overall survival hazard ratio) using the 
formula: 
ߣҧீெ ൌ ൭ෑߣ௜௪೔
௡
௜ୀଵ
൱
ଵ ∑ ௪೔೙೔సభ⁄
ൌ exp ቆ∑ ݓ௜ ln ߣ௜
௡௜ୀଵ
∑ ݓ௜௡௜ୀଵ ቇ 
Where λi is the estimate of λ from a study and wi is the weight given to that study.  The 
weighted geometric mean was chosen as the same mean OS is obtained whether the 
average of λ values or the average of OS is taken. 
Table 69 gives the calculation of the summary estimates in the base case (all studies 
included) and in the scenario analysis (only including studies with Hb level ≤ 11.0 g/dL 
inclusion criteria). 
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Table 69. Calculation of OS parameter 
Study Reported OS Calculated λ Weighta 
Base caseb Scenario 
analysisc 
Littlewood, 200168 KM at 1y: 49% 0.713 11.32 n/a 
Vansteenkiste, 
200272 
Median: 34w 1.060 11.22 21.13 
Grote, 200573 Median: 10.4m 0.800 6.05 n/a 
Osterborg, 200570 Median: 18.0m 0.462 12.40 22.46 
Ray-Coquard, 
200974 
Median: 6.0m 1.386 10.22 n/a 
Untch, 
2011a,b77,78 
KM at 43.5w: 91.8% 0.024 8.48 n/a 
Moebus, 201362 KM at 5y: 83% 0.037 8.69 n/a 
Summary estimate (base case) 0.374 100%  
Summary estimate (scenario analysis) 0.691  100% 
Key: KM, Kaplan–Meier survival estimate; m, months; n/a, not applicable; OS, overall survival; w, weeks; y, years 
Notes: (a) Weights taken from random-effects meta-analysis of OS hazard ratio; (b) Including only studies with 
licensed start dose; (c) Studies with licensed start dose and inclusion Hb level ≤ 11.0 g/dL 
 
The resulting values for λ correspond to mean OS in the control arm of 2.670 years in the 
base case and 1.447 years in the scenario analysis. In the PSA the baseline OS is set to 
follow a Gamma distribution with SE 50% of the mean to capture the high level of uncertainty 
and the range of cancers from which patients receiving ESA therapy may suffer. 
The overall survival for patients in the ESA arm is calculated by applying the hazard ratio 
provided in the clinical effectiveness review to the overall survival for patients not on ESAs. 
In the base case the hazard rate is 0.967, giving a mean undiscounted survival for patients 
on ESAs of 2.762 years. In the scenario analysis the hazard rate is 0.914, resulting in a 
mean undiscounted survival for patients on ESAs of 1.583 years.  In the PSA the hazard 
ratio is distributed as log-normal to match the result of the random effects meta-analysis (as 
the hazard ratio was meta-analysed following log transformation).Using a hazard ratio 
possibly derived from Cox proportional hazards and other non-parametric analyses to adjust 
a parametric survival function could result in a different result to derivation of the hazard ratio 
by parametric fitting, but given the limited data we believe this is the most appropriate 
approach.  We allow for the alternative survival distributions to examine whether our results 
are robust to the adopted base case assumptions.  
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Analyses of structural uncertainty in modelling overall survival 
In the first scenario analysis exploring structural uncertainty in the modelling of overall 
survival the hazard ratio for the first three years is equal to the hazard ratio used in the base 
case and thereafter a hazard ratio of exactly 1 is used. 
In the second scenario analysis exploring structural uncertainty in the modelling of overall 
survival (where a Weibull curve is fitted to the control arm of Untch and colleagues, 
(2011a,b)78 and a proportional hazards assumption is applied) the hazard ratio derived from 
the systematic review of clinical effectiveness evidence is used as in the base case.  The 
Weibull curve was fitted to the control arm of the survival plot by extracting several data 
points and then finding the fit which minimized the sum of squared errors using Solver in 
Microsoft Excel.  The resulting parameters (using the proportional hazards parameterisation: 
S(t) = exp(-λ × tγ); t in years) were λ = 0.010987; γ = 1.950282.  Figure 33 shows the Weibull 
function overlaid on the original Kaplan–Meier curve and demonstrates very good fit. 
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Figure 33. Weibull distribution fitted to Kaplan–Meier survival from Untch and 
colleagues (2011a,b)77,78 
Key: Black dashed line = Weibull fitted to control arm 
 
In the third scenario analysis exploring structural uncertainty all parameters are estimated by 
fitting to the survival curves in Littlewood and colleagues (2001).68  The hazard ratio from 
the systematic review of clinical effectiveness evidence cannot be applied in this case as a 
log-normal curve is used, which cannot be used in conjunction with a proportional hazards 
assumption.  The resulting parameters (time measured in months) are μ = 2.501676 in the 
control arm and 2.826619 in the ESA arm; σ = 1.483129 in the control arm and 1.348525 in 
the ESA arm.  According to interim life tables for England and Wales (2010–12) the 
additional life expectancy for an individual aged 59 (the approximate mean age of patient in 
Littlewood and colleagues [2001]68) is 23.2 years for males and 26.0 years for females.171  
As 251 of 375 participants were female we estimate additional life expectancy of 25.1 years.  
Figure 34 shows the log-normal functions overlaid on the original Kaplan–Meier plot and 
PenTAG   CONFIDENTIAL 
281 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
appears to demonstrate a reasonable fit.  Under 2% of the population in both arms is 
modelled as still alive at 25.1 years after which it is assumed survival is zero. 
Figure 34. Log-normal survival functions fitted to Kaplan–Meier survival curves from 
Littlewood and colleagues (2001)68 
 
Figure 35 and Figure 36 show the various overall survival distributions employed for the 
control and ESA arms respectively. 
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Figure 35. Overall survival distributions used for the control arm 
 
Figure 36. Overall survival distributions used for the ESA arm 
 
Figure 37 to Figure 41 show the overall survival distributions for both arms under each 
overall survival modelling assumption. 
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Figure 37. Overall survival distributions in the deterministic base case 
 
Figure 38. Overall survival distributions in the subgroup analysis where inclusion 
haemoglobin level ≤11.0 g/dL 
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Figure 39. Overall survival distributions in the first scenario analysis (as the base case 
except hazard ratio only applies for first 3 years) 
 
Figure 40. Overall survival distributions used in the second scenario analysis (Weibull 
distribution fitted to Untch and colleagues [2011a,b]77,78) 
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Figure 41. Overall survival distributions used in the third scenario analysis (log-
normal distributions fitted to Littlewood and colleagues [2001]68 and truncated at 25.1 
years) 
 
7.1.2.2.  Uti l i t ies 
As explained in Section 7.1.1 (page 245), the PenTAG model requires two sources of utility 
values: (1) utility as a function of Hb levels during ESA treatment and during normalisation to 
reflect impact of ESAs on HRQoL, and (2) constant utility value after normalisation, equal in 
all treatment arms. 
The cost-effectiveness of ESAs is likely to be very sensitive to the both of these, depending 
on how survival is accounted for in the model.  In particular, cost-effectiveness is sensitive to 
the rate at which utilities change with respect to changes in Hb (i.e. the gradient of the utility / 
Hb graph) and this appears to be an area which has not been researched in depth for 
previous cost-effectiveness reviews.  Therefore, it is necessary to research this carefully and 
in detail. 
As explained in Section 7.1.1, p245, given that we model utilities during ESA treatment and 
during normalisation purely as a function of Hb level and due to disutilities due to ESAs, we 
implicitly assume that ESAs do not impact HRQoL in any other way.  For example, it is 
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possible that ESAs affect some other aspect of health which is not captured by changes in 
Hb levels. 
We used only randomised controlled trials (RCTs) to populate these parameters since only 
RCTs can support valid causal inferences about the effects of a particular treatment on 
quality of life.59   With randomised studies potentially confounding factors, such as disease 
severity, that may affect both direct treatment outcome and quality of life should be 
distributed equally among trial arms and therefore do not bias estimates of the effect of 
treatment on quality of life.59  
7.1.2.2.1.  Uti l i t ies in cost-effectiveness models of ESAs 
In Section 7.1.1 (page 245), we outlined approaches to estimating utilities in published 
economic evaluations of ESAs for cancer anaemia.  Here, we elaborate on this (Table 70), in 
order to assess the usefulness of approaches to incorporation of utilities in published 
economic evaluations. 
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Table 70.  Summary of use of utilities in previous models of the cost-effectiveness of ESAs for cancer anaemia 
Cost-
effectiveness 
analysis 
During ESA treatment After ESA treatment 
Method of 
utility 
estimation 
Source data and method of utility 
estimation 
Critique Source data and method of utility 
estimation 
Critique 
Barosi 1998115 ESAs affect 
HRQoL directly 
VAS from Abels (1992)161 VAS method not 
recommended by NICEa 
Not modelled, as short time horizon.  
Cremieux 1999116 ESAs affect 
HRQoL directly 
LASA from Abels (1993)54 LASA scale not 
recommended. 
Not modelled, as short time horizon.  
Martin 2003117  ESAs do not 
affect quality of 
life. 
NA Justification not given. Utilities: 0.13 – 0.73 depending on 
stage of breast cancer.  Estimated from 
30 nurses using Standard Gamble. 
Poor methodology and 
restricted to breast cancer. 
Amgen TA142 
model1 
Utility 
distribution per 
Hb level 
Unpublished study of EQ-5D by Hb 
during Amgen RCT of darbepoetin.  
Data collected weekly from approx. 
100 patients over 16 weeks. 1 
Details unpublished, 
therefore unable to 
critique. 
0.66 (assumed same as baseline) 1 Justification not given. 
Ortho Biotec 
TA142 model1 
Function of Hb 
level 
Data from Ossa et al. 2004172 from 
Ortho Biotec study (TTO from 
community values) by anaemia 
states.. 
Abstract only.Translation 
of anaemia states to Hb 
levels unreported 
Not reported.  
Roche TA142 
model1 
Function of Hb 
level 
Utilities from Ossa 2004, TTO, 
regression analysis 
Abstract only. Authors 
include employee of 
Roche  
0.81 (assumed same as baseline) Justification not given, mix of 
utility measurements  used to 
choose baseline (SG, TTO and 
EQ-5D) 
Wilson 2007 
TA1421 
Function of Hb 
level 
Unpublished data from Ortho Biotec Unpublished, therefore 
unable to critique. 
Not reported. 
 
 
Fagnoni 2006123 Function of Hb 
level 
LASA from Crawford (2002)159 LASA not recommended 
as no value set. 
Not modelled, as short time horizon.  
Borg 2008154 Function of Hb 
level 
Following Wilson (2007) model1 Based on unpublished 
utilities study, therefore 
unable to critique. 
Not modelled.  
Tonelli 2009112 Function of Hb 
level 
Ossa, 2007155 See critique,  Section 
7.1.2.2.3, page 289 
Not reported.  
Key: ESAs, erythropoiesis stimulating agents; Hb, haemoglobin; LASA, linear analogue scale assessment; HRQoL, health-related quality of life; VAS, visual analogue scale 
aNot recommended as it does not reflect patient or public relative valuations or preferences for health states 
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All studies except Martin and colleagues (2003)117 assume that ESAs affect HRQoL during 
ESA treatment.  Most studies, including the previous technology assessment group’s model 
(Wilson and colleagues, 20071), estimate the impact of ESAs on HRQoL via the impact of 
ESAs on Hb levels. 
Only two analyses modelled the impact of ESAs on health-related quality-of-life directly, 
rather than via the impact on Hb levels.  One of these, Barosi and colleagues (1998)115, used 
the Visual Analogue Scale, and the other, Cremieux 1999116, the Linear Analog Scale 
Assessment (LASA) to estimate HRQoL.  We believe both instruments are seriously flawed 
in assessing utilities as they do not allow trading off life expectancy with quality of life, as 
required by NICE.168 
Of the seven studies that modelled the impact of ESAs on HRQoL via the impact of ESAs on 
Hb levels: 
We consider the approach of Fagnoni and colleagues (2006)123 to be inappropriate, because 
it also used the Linear Analog Scale Assessment (LASA). 
Both the Ortho Biotec TA142 and Roche TA142 models use utility data from Ossa and 
colleagues (2004).172 This is only reported in abstract form, but is reported fully in Ossa and 
colleagues (2007),155 which we have identified and critiqued in Section 7.1.2.2.3, p289. The 
industry submissions differ in their partitioning of Hb levels into anaemia states.  
The Amgen TA142 submission relied on unpublished data and used utility values elicited 
from patients on both experimental and licensed doses of Darbepoetin (patients who 
discontinued Darbepeotin were not followed up). 
The data underlying the estimates of utilities as function of Hb levels from Borg and 
colleagues (2008)154 also relied on unpublished data.   
Utilities after ESA treatment are reported in only two cost-effectiveness studies: Martin 
2003117 and the Amgen TA142 model.1  We do not consider the corresponding utilities further 
because the values from Martin and colleagues (2003)117 relate to breast cancer only, and 
minimal detail is given for the value used in the Amgen TA142 model.1  Some studies (e.g., 
Cremieux and colleagues, 1999116 and Fagnoni and colleauges, 2006123) do not report 
utilities after ESA treatment because they consider only a short time horizon. 
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7.1.2.2.2.  Principles for identi f ication of studies to inform choice of 
uti l i t ies 
In this section, we follow the principles for the identification, review and synthesis of health 
state utility values from the literature, as recommended recently by the NICE Decision 
Support Unit in the UK.173  There are no agreed reporting standards for studies of utilities, but 
the following information is key to understand the nature and quantity and quality of 
evidence:173 
 the population describing the health state (e.g. age, sex, disease severity), 
 the approach used to describe the health state, 
 utility value elicitation technique e.g. time trade-off, standard gamble, visual analogue 
score, 
 sample size, 
 respondent selection and recruitment, inclusion and exclusion criteria, 
 survey response rates,  numbers lost to follow-up (and reasons), methods of handling 
missing data. 
Clearly, the relevance of the data to the decision model and to the agency to which the 
model will be submitted is important.  In the current project, the NICE reference case is 
used.168  Modification of utility values from the literature for use in economic models, and 
sensitivity analyses using less relevant utility values should be considered.173 
A systematic search for studies reporting utilities should be undertaken.173  For the current 
project, the search method is given in Appendix B.  In addition, sources of utility values were 
obtained from published models on the cost-effectiveness of ESAs (Section 7.1.2.2.1, p286). 
7.1.2.2.3.  Studies reporting uti l i t ies as a function of Hb level 
Our search for studies to inform utility values as a function of Hb levels yielded 235 
publications.  On inspection of titles and abstract, four papers were deemed sufficiently 
relevant to read in full: Harrow and colleagues (2011),174 Lloyd and colleagues (2008),175 
Tajima and colleagues (2010),176 and Wisloff and colleagues (2005).177  
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The first three papers reported studies that measured HRQoL as a function of Hb level.  
Wisloff and colleagues (2005)177 did not provide estimates of utilities as a function of Hb.  
Instead, in a study of multiple myeloma patients, the authors concluded that Hb level has 
limited impact on HRQoL, as measured by the cancer-specific questionnaire EORTC QLQ-
C30.  They stressed that Hb level may be correlated with tumour type, disease severity and 
response to treatment, which themselves may affect quality of life.  The authors therefore 
concluded that it is essential to adjust for these variables in order to assess the impact of Hb 
on health-related quality of life. 
In addition, we critiqued two further studies. Firstly, Ossa and colleagues (2007),155 whose 
preliminary results (Ossa and colleagues, 2004172) were used in the cost-effectiveness 
analysis of two of the TA142 industry submissions and therefore formed the basis of the 
utility values reported in the Wilson and colleagues 2007 model. It was also used in the cost-
effectiveness analysis of Tonelli and colleagues (2009).112 We also critiqued Crawford and 
colleagues (2002),159 used in the cost-effectiveness analysis of Fagnoni and colleagues 
(2006).123  The key characteristics and results of all five fully critiqued studies are given in 
Table 71 below. We do not critique the industry submissions from TA142 as the data 
underpinning the Roche and Ortho Biotec submissions are presented in Ossa and 
colleagues (2007) and the methods of the Amgen TA142 submission did not explicitly report 
utility as a function of Hb. 
In the study by Harrow and colleagues (2011),174 13,433 women with cancer completed the 
SF-6D questionnaire at baseline.  This represents a useful dataset as the sample size was 
very large, health was appropriately elicited by patients, and an appropriate preference 
elicitation instrument SF-6D was used (Table 71).  However, the main weakness is that this 
was an observational study, which means that there could have been unmeasured 
covariates which contributed to the observed relationship between utility values and Hb 
levels.  For example, patients with low Hb may have been more likely to have had more 
advanced cancer.  This would tend to bias the apparent impact of Hb level on utilities, most 
likely in the direction of a steeper gradient.  However, the authors tried to minimise the risk of 
confounding by controlling for many covariates in their analysis.  Utilities were found to 
increase only slightly from Hb 9 to 14 g/dl, and thereafter decrease (Figure 42, Figure 43, 
Table 71). 
Tajima and colleagues (2010)176 is also an observational study, which, amongst other 
factors, investigated the impact of Hb on utilities for patients with chronic kidney disease in 
Japan. This is also a useful dataset because, as preferred by NICE,168 health was self-
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reported by patients using the EQ-5D classification system, and the resulting health states 
were valued using utilities elicited from the general public using the Time Trade-Off 
technique.  However, the two main weaknesses are that (1) this was also an observational 
study, which means that there could have been unmeasured covariates which contributed to 
the observed relationship between utility values and Hb levels, and (2) patients had chronic 
kidney disease, not cancer.  Any bias due to (1) was minimised as several potentially 
confounding variables were included in the regression analysis.  As for (2), it would only be a 
minor weakness if one could plausibly assume that the co-morbidity of anaemia impacts 
health-related quality of life additively and in the same way in different patient groups.  In this 
study utilities were found to increase only slightly, at a rate of 0.016 per unit change in Hb 
(Table 71). It should also be noted that as this study was conducted in Japan the results may 
not entirely translate to a British population. 
We believe that there are substantial weaknesses in the remaining three studies.   
There are many weaknesses in the study by Ossa and colleagues (2007),155 including the 
use of health state vignettes (Table 71).  Hence, we attach little importance to the finding that 
utility increases steeply from Hb 7 to 11 g/dl (Figure 42).  
The study by Lloyd and colleagues (2008)175 also has many important weaknesses, including 
use of health state vignettes and very small sample size.   Hence, we attach little importance 
to the finding that utility increases steeply from Hb 7.5 to 11.5 g/dl (Figure 42). 
In the study by Crawford and colleagues (2002),159 health was appropriately elicited from 
patients.  However, the one important weakness of the study was that the health preference 
elicitation instrument was the Linear Analogue Scale Assessment (LASA), whose self-
assessment consists of five questions on the physical, emotional, spiritual, intellectual and 
overall well-being, rated on a scale from 0-10. As suchutilities are not obtained by a choice-
based method, such as the time trade-off or standard gamble, which is required by NICE.168  
Hence, we attach little importance to the finding that utility increases moderately from Hb 7 to 
14 g/dl (Figure 42). 
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Table 71: Summary of characteristics of studies measuring utility as a function of Hb levels 
Study Harrow (2011)174a Tajima (2010)176 Ossa (2007)155 Lloyd (2008)175 Crawford (2002)159 Amgen TA142 
submission 
Health elicitation 
by patients 
(pts)? 
Yes Yes No 1st study: Yes,  
2nd study: No. 
Yes Yes 
Preference 
elicitation 
instrument 
SF-6D EQ-5D Health state vignettes 
reflecting chemo-induced 
anaemia based on FACT-
An and EQ-5D.  Validated 
by 3 oncology specialists 
and 6 cancer anaemia 
pts. 
Health state vignettes 
reflecting cancer 
anaemia.  Reviewed by 
clinicians and QoL 
experts. 
LASA EQ-5D 
Preference 
valuation 
General public used SG Japanese general 
publication used TTO 
General public used TTO 1st study: General public 
used SG 
2nd study: Cancer pts 
used TTO 
None. Not reported, presumably 
TTO 
Study 
population size 
13,433 537 110 1st study: 85 members of 
general public 
2nd study: 26 cancer pts 
Approx. 4,000 Not reported 
Study 
population 
Women with cancer aged 
50-79, mean age 63 
Chronic kidney disease 
pts.52% males, mean age 
55, mean Hb 12.7 
100 members of general 
population 
1st study: General 
population. 
2nd-study: Cancer pts 
received chemo;some 
anaemia, mean age 60 
Cancer pts undergoing 
chemotherapy.  Mean age 
63 
Pts on Darbepoetin, some 
on experimental dosing. 
Country US Japan UK UK US Not reported 
Year 1993-8 2008 2004 Not stated, but assume 
2000s. 
1990s Not reported, pre 2004 
Loss to follow 
up? 
NA as measurement at 
baseline. 
NA as measurement at 
baseline. 
NA NA Appears not to be large Numbers not reported, 
but there was loss to 
follow up 
Study funding Study funded by US 
government.  Analysis 
funded by industry 
(Pfizer). 
Funded by Japanese 
government.   
Industry (Roche) Industry (Ortho Biotec) Industry (Ortho Biotec) Industry (Amgen) 
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Study Harrow (2011)174a Tajima (2010)176 Ossa (2007)155 Lloyd (2008)175 Crawford (2002)159 Amgen TA142 
submission 
Results: ΔUtility 
for Δ1 Hb 
 
0.009 over Hb 9-12 g.dl 0.016 0.109 over Hb 8.7-11.0 1st-study: 0.032, 
2nd-study: 0.062. 
Over Hb 8.5-11.5. 
0.029 over Hb 9-11. 0.030 over Hb 8.5-11.5 
Major strengths Sample size very large. 
Health elicited by pts, as 
required by NICE.168 
Generic preference 
elicitation instrument SF-
6D. 
 
EQ-5D is preferred by 
NICE.168 
Public valued using TTO, 
as preferred by NICE.168 
Sample size large. 
Health elicited by pts, as 
required by NICE168 
None 
 
In 2nd-study, health 
elicited by pts with 
experience of CIA 
Sample size very large 
Health elicited by pts, as 
required by NICE168 
Pts with CIA 
 
Health elicited by pts, as 
required by NICE168 
Pts with CIA 
EQ-5D is preferred by 
NICE.168 
 
Minor strengths Preference valuation SG 
appropriate (although 
TTO preferred by 
NICE168). 
Government funded. 
 
Government funded UK-based. 
TTO preferred by 
NICE168. 
 
UK-based 
 
  
Major 
weaknesses 
Observational study, 
hence possibly 
unmeasured confounding 
variablesb.  However, 
many covariates were 
controlled for in analysis 
Pts with chronic kidney 
disease, not cancer 
Observational study, 
hence possibly 
unmeasured confounding 
variables.  However, 
many covariates were 
controlled for in analysis; 
e.g. albumin, creatinine, 
GFR, age, gender 
Health status not elicited 
from pts. A requirement 
for NICE reference 
case168 
Health state vignettes 
assessed by experts, 
whereas NICE prefers pts 
self-reports using 
classifications systems of 
generic 
questionnairesSmall 
sample size of 110 
Health state vignettes, 
whereas NICE prefer 
patient self-reports using 
generic questionnaires.168 
Very small sample size of 
26 cancer pts 
LASA instrument utilities 
are not obtained by a 
choice-based method, 
which is required by 
NICE168 
Observational study, 
hence possibly 
unmeasured confounding 
variablesb.   
All utilities taken from pts 
on some dose of ESA 
(utilities not taken when 
ESA use discontinued). 
Poorly reported  
Minor 
weaknesses 
Women only 
US, not UK 
NICE prefer EQ-5D to 
SF-6D 
Pts not necessarily taking 
chemotherapy. 
 
Utility values of health 
states derived elicited 
from Japanese, not UK 
general public 
Although health vignettes 
reported to reflect CIA, 
descriptions could equally 
apply to cancer-anaemia. 
Population under-
represents ethnic 
minorities and over-
represents wealthy 
people b. 
Industry funded. 
Industry funded. US, not UK. 
Industry funded. 
Industry funded 
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As stated above, the cost-effectiveness of ESAs may be very sensitive to the rate at which 
utilities change with respect to changes in Hb (i.e. the gradient of the utility / Hb graph).  
Cost-effectiveness is likely to be insensitive to the absolute utilities during the period of 
treatment with ESAs because mortality is assumed to be zero during this period for both the 
ESA and best supportive care treatment arms. 
Figure 42. Utilities as a function of Hb level by study 
Key: Hb, haemoglobin 
Notes: For Tajima and colleagues (2010)176, slope of line taken from regression and utility at Hb 7 arbitrarily 
assumed to equal 0.6. Utilities cannot be directly compared as they are reported on different scales and elicited 
through different tools. 
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Figure 43. Utilities as a function of Hb level from Harrow and colleagues (2011)174 
 
Key: Hb, haemoglobin  
Source: Harrow and colleagues (2011)174 
7.1.2.2.4.  Estimation of impact of ESAs on health uti l i t ies from mapping 
disease-specif ic questionnaires to EQ-5D 
As mentioned in Section 7.1.2.1 (page 258), very little information can be gained from 
mapping from the disease-specific health questionnaires to the EQ-5D.  Of the RCTs 
included in the PenTAG systematic review of clinical effectiveness, one study (Ray-Coquard 
and colleagues, 2009)74 used the EORTC QLQ C-30 questionnaire, and one Tjulandin and 
colleagues (2011)76 used the FACT-G questionnaire.  These have been mapped to EQ-5D 
by Dakin 2013.178  
However, in the first case, it is not possible to perform such a mapping, because the required 
EORTC QLQ C-30 information is not provided.   
In the second case, it is possible to make an approximate estimation of the impact of an 
epoetin alfa on utilities. At the end of treatment, we can estimate the difference in utilities 
between arms, in the case of Ray-Coquard and colleagues (2009)74 this is 0.007 × 6.1 = 
0.04, where 6.1 is the difference in FACT-G total score in Littlewood and colleagues (2001)68 
(2.5 + 3.6) and 0.007 is the coefficient from the utility mapping paper.178  The authors of this 
paper found a better mapping function using the dimensions of the FACT-G questionnaire, 
rather than using total score. 
All the other RCTs in the PenTAG systematic review that reported HRQoL use 
questionnaires for which we understand there is no mapping to EQ-5D nor to the SF-6D.178 
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7.1.2.2.5.  PenTAG base case uti l i t ies by Hb level 
As mentioned in the previous section, we consider the studies by Harrow and colleagues 
(2011)174 and Tajima and colleagues (2010)176 to be the most methodologically robust.  The 
key differences between the two studies are: 
 Harrow and colleagues (2011)174 has the advantage of relating to people with cancer, 
whereas Tajima and colleagues (2010)176 concerns people with chronic kidney 
disease. 
 Tajima and colleagues (2010)176 has the advantage of using the EQ-5D valued using 
Time Trade Off, both preferred by NICE,173 whereas Harrow and colleagues (2011)174 
used the SF-6D valued using the Standard Gamble. 
Both studies find that the impact of Hb level on utilities is rather slight.  In Harrow and 
colleagues (2011),174 over the range Hb 9–12 g/dl, utilities increase by 0.009 per unit 
increase in Hb. This scales to 0.028 per unit increase in Hb on the EQ-5D, using the results 
of Brazier and colleagues (2004)179 regression analysis.  In Tajima and colleagues (2010),176 
over a similar Hb range, utilities increase by 0.016 per unit increase in Hb. 
These results are consistent with the findings of Wisloff and colleagues (2005),177 and with 
our review of HRQoL that there is only weak evidence that ESAs improve HRQoL (Section 
0, page 157). 
The results are also consistent with the estimated impact of epoetin alfa on utilities (Section 
7.1.2.2.4, page 295).   At end of treatment, the estimated difference in utilities between arms 
is 0.04.  Given that we estimate a coefficient for Hb of 0.016, and that difference between 
arms in Hb in Littlewood and colleagues (2001) was 1.7,68 we would estimate difference in 
utility of 0.022 for Littlewood, which is plausibly close. 
For our base case utilities we take the scaled utility value from Harrow and colleagues 
(2011). This is chosen over the EQ-5D results from Tajima and colleagues (2010) mainly on 
the basis that Harrow and colleague’s population of people with cancer more closely 
matches our own. We therefore assume that utilities increase by 0.028 per unit increase in 
Hb. This utility is then applied until the end of normalization and adjusted for mean difference 
in Hb levels between ESA and no ESA arms, at the relevant time points, to calculate the 
short term QALY gain. 
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For the probabilistic sensitivity analysis, we assumed a gamma distribution with mean 0.028, 
standard error 20% of the mean, reflecting Harrow and colleagues (2011)174. We also 
perform univariate sensitivity analyses using the estimate from Tajima and colleagues 
(2010), 0.016, as well as using the unscaled value from Harrow and collegues, 0.009, and 
the estimate used in the previous HTA, 0.06.  
As stated above, the main weakness of both studies is that they are observational.  This 
means that the estimated relation between utility and Hb level may be biased due to 
unmeasured confounding variables.  However, as suggested by Tonelli and colleagues 
(2009),112 any such bias is likely to lead to an over-estimate of the rate of change of utility as 
a function of Hb.   This is because: (1) people with low Hb may be more likely to have more 
advanced cancer, and hence lower reported utilities; and, (2) people who are told that their 
Hb level is low may underestimate their reported quality of life.  This bias has the effect of 
biasing cost-effectiveness in favour of ESAs versus control. 
7.1.2.2.6.  PenTAG base case uti l i t ies after ESA discontinuation 
The value of utilities after ESA discontinuation is difficult to generalise as the patient 
populations in source studies cover a wide range of cancers. The average age (59.1 years) 
taken from the RCTs is equivalent to a utility of 0.830, using the formula published by Ara 
and Brazier (2010)180 (see below) and assuming the probability of being male to be 46% 
based on ONS Cancer Registration statistics for 2011 for people aged 50–60 years. 
 
Source: Ara and Brazier (2010) 180 
 
We can therefore surmise that the utility must be lower than this. In TA142, once people had 
returned to an Hb level of 13g/dL or higher, their utility was 0.810.1 In this assessment 
people normalise to a lower Hb value than the previous HTA; and given the similarity of this 
value to people in the general population, we use a lower utility value for people in the long 
term. Tengs and Wallace (2000)181 report a utility for cancer of 0.83-0.92 (irrespective of 
age) using a time trade off method. Applying these to the age-related utility gives a range of 
values of 0.68 to 0.76. Comparing this range to the values to those reported in the ESA 
specific utilities reported in Section 7.1.2.2.1 as well as to previous PenTAG cancer HTA 
Equation 1. Formula for age related utility 
U= 0.9508566 + 0.0212126 × male – 0.0002587 × age – 0.0000332 × age² 
PenTAG   CONFIDENTIAL 
298 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
assessments,182,183 we conclude that using the higher estimate of 0.76 is the most 
appropriate utility. 
Again this is a parameter that is highly uncertain (due to lack of data) which could have a 
potentially large impact on the overall QALYs accrued in the analysis. As such, in the PSA 
we vary the utility multiplier 0.92 as a Beta distribution with standard error 20% of the mean 
(0.184). The resulting standard error of the long-term utility is 0.830 × 0.184 = 0.153. 
7.1.2.2.7.  Uti l t ies not included in the PenTAG model 
In the previous sections, we have described two sources of utility values within the model. 
An additional source of disutility can come from the adverse events associated with ESA 
use. These utilities are not modelled explicitly and instead the disbenefit associated with 
adverse events is only accounted for by cost. 
This decision was made for several reasons, the main reason being that adverse events 
data in the RCTs are extremely poorly defined. Firstly, the adverse events themselves are 
poorly defined and for example a thromboembolic event can refer to several events, 
including pulmonary embolism and deep vein thrombosis. These specific adverse events are 
often not specified within the RCTs or different RCTs will include different adverse events 
within their definition. Secondly, severity and length of impact of the adverse events are not 
consistent across the RCTs and are undefined for the pooled results. These poor definitions 
make it difficult to assign either costs or QALYs to adverse events, but make it especially 
difficult to define the disutility of an adverse event and translate this into a QALY and indeed 
there was no data to define these results.  
One area where the long term disbenefit of adverse events is implicitly included is in the 
survival. As with short term mortality, any mortality associated with adverse events should be 
implicitly identified by the survival estimates encountered in the RCTs, as these are 
extracted from the same pool of studies. 
We acknowledge the lack of utility associated with adverse events as a limitation of the 
model and discuss this in Section 8.3.4.7 (page 388). 
7.1.2.3.  Costs 
In this analysis we model the following costs: blood tests, ESA prices, red blood cell 
transfusion (RBCT) cost (unit cost of blood and cost of transfusion appointment) and costs of 
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adverse events. We do not model long term costs in the base case, given the uncertainty 
attached to these values as a result of the wide patient population. Additionally, any arbitrary 
cost added to long term survival would disadvantage any arm with a survival benefit, which 
will be demonstrated in a sensitivity analysis. 
7.1.2.3.1.  Adjustments to 2014/15 prices 
All costs and prices in the model are inflated to 2011/12 prices using the Hospital and 
Community Health Services (HCHS) Pay and Prices index184 and then further inflated by 
3.65% per annum for two years to 2014/15 prices, where 3.65% is the average (geometric 
mean) inflation of the index between 2006/07 and 2011/12. 
7.1.2.3.2.  ESA prices 
Table 72 presents the current drug prices for ESAs, which have been taken from the British 
National Formulary.162 Separately we report the expected wholesale acquisition costs 
(Section 7.1.2.3.3, page 300), which we will use to conduct a sensitivity analysis on plausible 
actual costs to the NHS.  
The majority of ESA dosages are calculated based on weight, with the exception of Epoetin 
theta. As such, there is no standard dose for each patient and Table 72 demonstrates the 
various vial sizes for the ESAs which can make up a dose. Given the wide variety of vial 
sizes, we believe that drug wastage will be minimal and therefore do not account for it in our 
analysis. 
Table 72. Available vial sizes and costs of ESAs 
ESA BNF prices 
Units 
Epo alfa Epo beta Epo theta Epo zeta 
mcg 
Darbe alfa 
Eprex Binocrit NeoRecormon Eporatio Retacrit Aranesp 
500 £3.51 10 £14.68 
1,000  £5.53 £5.09 £5.99 £5.66 15 £22.02 
2,000  £11.06 £10.18 £14.03 £11.98 £11.31 20 £29.36 
3,000  £16.59 £15.27 £21.04 £17.98 £16.97 30 £44.04 
4,000  £22.12 £20.36 £28.06 £23.97 £22.63 40 £58.73 
5,000  £27.65 £25.46 £35.07 £29.96 £28.28 50 £73.41 
6,000  £33.19 £30.55 £42.08 £33.94 60 £88.09 
8,000  £44.25 £40.73 £45.25 80 £117.45 
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10,000  £55.31 £50.91 £70.14 £59.92 £56.57 100 £146.81 
20,000 £110.62 £140.29 £119.84 £113.13 130 £190.86 
30,000  £199.11 £210.43 £179.75 £169.70 150 £220.22 
40,000  £265.48 £226.26 300 £440.43 
50,000  £374.48 500 £734.05 
Notes: Sourced from British National Formulary 2013162 
 
Using the various vial sizes, we calculate the costs per 1,000 IU for the epoetin alfa, beta, 
theta and zeta; and per mcg for darbepoetin. These alter depending upon the vial size of the 
ESA for some of the ESAs; e.g.  the cost of a vial size no greater than 20,000 IU for Eprex 
works out at £5.53 per 1,000 IU, but the larger vial sizes work out to be £6.64 per 1000IU. In 
the base case we used the lowest cost per 1,000 IU for each of the ESAs, as this covered 
the largest range of vial sizes.  These base case costs are given in Table 73. 
Table 73. PenTAG base case ESA costs 
ESA base case unit cost (based on BNF prices) 
per 1,000 IU per mcg 
Epoetin alfa 
Eprex £5.53 
Binocrit £5.09 
Epoetin beta NeoRecormon £7.01 
Epoetin theta Eporatio £5.99 
Epoetin zeta Retacrit £5.66 
Darbepoetin alfa Aranesp £1.47 
Key: ESA, erythropoiesis stimulating agent 
 
The overall cost per dose for each ESA was then calculated using the number of units/ mcg 
per week. 
ESA unit costs are not varied in the PSA. 
7.1.2.3.3.  Wholesale acquisit ion costs 
Drug manufacturers are free to sell to hospitals below the list price and acquisition costs 
under these sales would usually be commercially confidential.  Manufacturers will typically 
employ a price–volume methodology in which more substantial savings are available to 
purchasers if commitments are made regarding the minimum quantity to be purchased.  Due 
to different purchasing decisions by hospitals (due in part to different patient population 
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sizes) the same drug will be acquired at a range of prices.  Ideally in an economic evaluation 
one would wish to use the average acquisition cost for each drug in the base case, but such 
information is generally kept confidential. 
In this appraisal the manufacturers consented at the NICE Consultee Information Meeting (7 
August 2013) to pharmacists revealing the confidential prices to PenTAG.  We received the 
latest tenderings to London hospitals (South East England Specialist Pharmacy Services, 
Commercial Medicines Unit; personal communication, 27 September 2013).  These are 
understood to be from the most recent tendering process and therefore the most 
representative prices going forwards. 
As can be seen in Table 74 all manufacturers were prepared to offer some level of discount 
from list prices and some (not all) were prepared to offer a discount with minimal 
commitment to volume.  It can also be seen that the London hospitals did not secure the 
cheapest prices for all ESAs. 
Table 74. ESA wholesale prices offered to London hospitals 
ESA ******************* *********** ************ ********** 
Epoetin alfa (Eprex) ***** ***** ***** ***** 
Epoetin alfa (Binocrit) ***** ***** ***** ***** 
Epoetin beta 
(NeoRecormon) ***** ***** ***** ***** 
Epoetin zeta (Retacrit) ***** ***** ***** ***** 
Darbepoetin alfa 
(Aranesp) ***** ***** ***** ***** 
********************************************************************************************************************************
*************************************************************************************************************** 
 
If PenTAG were to adopt the strike prices agreed by London hospitals this would represent a 
significant bias in favour of the ESAs for which significant discounts were obtained.  London 
entered contracts committing to a volume of at least 8,000 people, which would have been 
sufficient to command the best offer from any manufacturer had all volume been promised to 
a single manufacturer. 
If all ESAs are deemed to be equally effective then all purchasers should exclusively 
purchase the ESA which minimises total costs (i.e., with the lowest combined drug 
acquisition and administration costs).  By concentrating full purchasing power it should be 
possible for all purchasers to get the best offer price from each manufacturer. 
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We therefore believe that the best offer to London hospitals is the best unbiased estimate of 
the wholesale acquisition cost of ESAs.  PenTAG note that epoetin theta is not included in 
the list of ESAs offered to the London hospitals and therefore no wholesale acquisition cost 
can be estimated for this ESA. 
The best offer prices cannot be guaranteed to last beyond the contract agreed between 
manufacturer and purchaser – in the case of London hospitals the contract was for twelve 
months with the option to extend by a further 24 months.  
7.1.2.3.4.  Cost of administering ESAs 
There are multiple dosing options for most of the ESAs and we have chosen the base case 
dosing schedule for each on both the evidence available in the RCTs and on the advice of 
our clinical experts. This allows us to be consistent with our other evidence as well as clinical 
practice, including incorporating information on missed doses. In the base case we assume 
that dosing is given once a week, for all ESAs. Sensitivity analysis will investigate the 
different dosing schedules for each ESA as given in Table 75 (page 302). 
Table 75. Dosing schedule for ESAs, based on licensed indications 
 Base case dose Sensitivity analyses 
Epoetin alfa Once weekly 3 times a week 
Epoetin beta Once weekly 3–7 times a week 
Epoetin theta Once weekly 3 times a week 
Epoetin zeta Once weekly 3 times a week 
Darbepoetin alfa Once weekly Once every 3 weeks 
 
In the context of chronic kidney disease (CKD), ESAs are typically self-administered by the 
patient when possible (MN), and in the case of the industry submissions presented in this 
review, the majority of patients are expected to self-administer. However, consultations with 
our clinical experts (KS, MN, CR, NR) suggested a more varied view on ESA administration, 
with some indicating that in this disease area, with a comparatively short period of treatment, 
it may be more likely for patients to not self-administer.  As our experts covered a range of 
cancers and backgrounds, we decided the most appropriate decision in the base case was 
to take an average of the opinions on how ESAs should be administered in practice. 
Therefore, of the ESAs administered each week, 16.25% are administered during patients’ 
chemotherapy appointments, 43.13% during a GP appointment or by a district nurse, and 
40.63% self-administer in the base case (see Table 76). We do not allocate these values to 
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specific patients, as patients are likely to encounter a combination of these practices during 
their time on ESAs (advice from CR). This also means we do not explicitly account for 
instances such as the weeks where patients do not have a chemotherapy appointment, as 
this is factored into the average values. Given the uncertainty around these values, as part 
of our sensitivity analysis we examine the situation where ESAs are administered to cancer 
patients in a similar manner to CKD patients. The costs of each type of administration and 
overall average cost for ESA administration are presented in Table 76. In the PSA the 
probabilities are drawn from a Dirichlet distribution. 
As stated in Section 7.1.2.1.3 (page 268), duration of ESA treatment is calculated on an 
intention to treat basis and as such, the cost of administration may be slightly exaggerated. 
However, as the average cost per ESA administration is £8.16 the cost does not have a 
significant impact upon the results, compared to the cost of ESA drug price in the base case. 
Table 76. ESA administration costs 
ESA administration Cost Source % of ESA Source 
Appointment with district nurse £18.80 PSSRU 21.56% 
Clinical experts 
NR, KS, MN, 
CR 
Appointment with GP nurse £10.74 PSSRU 21.56% 
Appointment with hospital staff nurse £11.01 PSSRU 16.25% 
ESA self-administered £0 Assumed 40.63% 
Average cost per ESA administration £8.16 
Key: ESA, erythropoiesis stimulating agent; GP, general practitioner; PSSRU, Personal Social Services 
Research Unit 
Notes: % of ESA may not add to 100% due to rounding 
7.1.2.3.5.  Addit ional blood tests for ESAs 
Another additional cost for ESAs is incurred by an increase in blood tests, advised by our 
clinical experts (KS, NR). Opinion appears divided on how much of an increase this would 
be. In our base case we assume that blood tests would occur regularly for both patients who 
are on ESAs and those who are not whilst patients are undergoing chemotherapy treatment, 
but that additional blood tests would continue post-chemotherapy for those patients on 
ESAs. In our base case we cost for four additional blood tests. We assume this is 
administered by a GP nurse at a cost of £42.98 per hour (£40 in 2012/2013185 inflated to 
2014) and that the appointment takes 15.5 minutes of the GP nurse time, based on the 
average surgery consultation time,186 resulting in a cost of £11.10. We also add the NHS 
Reference Cost for Phlebotomy (HRG DAPS08) of £3.91 (inflated from £3.64 in 
2012/2013).187 The total cost of a blood test is then £15.01. As the cost of blood tests is 
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relatively small compared to the other costs associated with cancer treatment induced 
anaemia, we do not expect any increase or reduction in the number of blood tests to have a 
significant impact upon the results. To represent uncertainty in these parameters all 
parameters are drawn from Gamma distributions in the PSA with SE equal to 20% of the 
mean. 
7.1.2.3.6.  Adverse event costs 
The adverse events we account for in this cost-effectiveness analysis are identified through 
the clinical effectiveness review. In particular we account for the cost of: 
 thromboembolic events  
 hypertension, and  
 thrombocytopenia.  
Resource use for patients not receiving ESA therapy is estimated from the systematic review 
of clinical effectiveness evidence by simple pooling of all studies to calculate how many 
patients did and did not experience at least one adverse event. A beta distribution was 
constructed on the basis of these figures for the PSA. Patients are assumed to experience at 
most one adverse event of each type. Resource use for patients receiving ESA therapy is 
calculated similarly but also applying the relative risk obtained from the systematic review of 
clinical effectiveness evidence (Section 0, page 56). 
The unit costs of managing thromboembolic events (particularly pulmonary embolism and 
deep vein thrombosis), hypertension and thrombocytopenia are identified through NHS 
Reference Costs 2012-13187 and updated to 2014/15 prices. These figures are presented in 
Table 77, p305 and are the weighted averages dependent on HRG code. No decision is 
made to specify HRG codes beyond the particular adverse event, to reflect that the relative 
risks identified in the PenTAG clinical effectiveness systematic review refer to any adverse 
event, regardless of severity. These costs are significantly larger than those reported in 
TA142, where the cost of an adverse event was only £101, but attempts to identify how this 
figure arose were unsuccessful, beyond identifying it in the Ortho-Biotec submission. The 
previous Roche submission in TA142 had previously attached a cost of monitoring for 
hypertension at £4 a week and the Amgen submission a cost of £185 for a DVT, though 
sources of these costs were unclear. The NHS Reference costs themselves report a wide 
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range of costs for managing each of the adverse events and as such these costs will be 
altered in the PSA following a Gamma distribution with SEs equal to 20% of the means. 
Table 77. Cost of adverse events 
 PenTAG 
base case 
HRG Codes 
Thromboembolic 
events 
£1,243 DZ09D, DZ09E, DZ09F, DZ09G, DZ09H (pulmonary embolus), 
QZ20A, QZ20B, QZ20C, QZ20D, QZ20E (DVT) 
Hypertension £826 EB04Z (hypertension) 
Thrombocytopenia £744 SA12G, SA12H, SA12J, SA12K (thrombocytopenia) 
Key: DVT, deep vein thrombosis; HRG healthcare resource group 
7.1.2.3.7.  Red blood cell  acquisit ion costs 
Unit costs for the supply of red blood cells (RBCs) are taken directly from NHSBT 2012/13 
costs (£122 per unit)188 and uprated to 2014/15 prices. This cost is significantly different to 
the cost of blood products in outpatient care that are reported in the NHS Reference costs 
2013, where the average cost is around £1,300.187 However this cost is for all blood 
products, not just red blood cells and as such has a skewed distribution: for HRG code 
XD05Z (Blood Products, Band 1) the average unit cost is £1,269, but the upper quartile cost 
is £482. We do not use the NHS Reference costs due to the imprecision around the term 
‘Blood Products’. Furthermore, the cost of RBCs from the NHSBT is similar to the unit cost 
reported in a publicly accessible letter detailing the outcomes of National Commissioning 
Group for Blood meeting on 9th October 2007,189 which detailed the cost of RBCs for 2008/9 
as £139.72. A Gamma distribution is used for the cost of an RBC unit with SE equal to 20% 
of the mean. 
7.1.2.3.8.  Cost of transfusion appointment 
The closest cost reported in NHS Reference costs for an outpatient blood transfusion 
appointment is the outpatient cost for blood and bone marrow transplant. As with the cost of 
blood products, this covers more than the specific figure needed for our analysis.  Returning 
to the TA142 analysis we find that the cost value reported originally came from the Varney 
and Guest (2003) paper.170 Attempts were made to find updated versions of the figures 
reported in this paper, with marginal success. Audits from the NHSBT indicate that the 
numbers of transfusions as well as percentages of associated complications have decreased 
since the Varney and Guest study was conducted, but the associated costs were not 
available for this analysis. As such, we use the same figures as reported in Varney and 
PenTAG   CONFIDENTIAL 
306 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Guest 2003 and uprate this cost to 2014/15 costs. A Gamma distribution is used for the unit 
cost of a RBC transfusion appointment with SE equal to 20% of the mean. 
Table 78. Unit costs of red blood cell transfusion 
 PenTAG base case Source 
Unit cost of RBCs £127 NHSBT 
Cost of transfusion appointment £688 Varney and Guest 2003 
Key: NHSBT, NHD Blood & Transplant; RBCs, red blood cells 
 
7.1.2.3.9.  Intravenous iron supplementation 
NICE guidance from TA142 is that in circumstances where ESA therapy is recommended it 
should be used in combination with intravenous iron as this was associated with greater 
probability of haematological response.34 
Intravenous iron supplementation was not included in any cost-utility studies identified in the 
update systematic review of cost-effectiveness (Section 6.1.2). 
Iron supplementation is likely to be given to anaemic patients independently of whether they 
receive ESA therapy, so differences in resource use between patients receiving and not 
receiving ESA therapy are likely to be very small (e.g., if anaemia is corrected sooner then 
iron supplementation would be used for less time) and we have not sought studies from 
which to estimate such resource use differences. 
The cost of intravenous iron has been assumed to be neglible in previous economic studies.  
To check that this is a reasonable assumption we briefly estimated the cost of acquisition 
and administration of intravenous iron. 
Assuming that intravenous iron would be given in the form of iron dextran 100 mg once 
weekly (alongside ESA administration), the acquisition cost of CosmoFer® (Pharmacosmos) 
would be £7.97 per week (2 mL ampule of 50 mg/mL iron dextran).190 
Resource use for drug administration is difficult to estimate as patients may already be 
attending an outpatient clinic for chemotherapy and ESA therapy.  We assume that the 
incremental resource use of intravenous iron supplementation is minimal and of the same 
order of magnitude as the drug acquisition cost. 
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Given resource use is likely to be very similar between patients receiving and not receiving 
ESA therapy (and that no clinical data would directly inform an estimate of the difference), 
and given unit costs are also small in comparison to the cost of ESA acquisition and RBCT, 
we assume that the cost of intravenous iron supplementation can be ignored as it will be 
very similar for all arms. 
7.1.2.4.  Other model characterist ics 
7.1.2.4.1.  Time horizon, perspective and discounting 
A lifetime time horizon is used in the model.  The perspective adopted was NHS and 
Personal Social Services.  Costs and benefits were discounted at 3.5% per annum. 
7.1.2.4.2.  Patient characterist ics 
The age and weight of patients in the model are estimated from the age and weight reported 
in clinical studies included in the systematic review of clinical effectiveness evidence.  A 
simple average was taken to estimate the mean and standard deviation across studies was 
used to estimate the standard error for the PSA. 
The mean age in the base case is estimated as 59.1 years (SE 5.3 years) and in the 
scenario analysis with inclusion Hb ≤ 11.0 g/dL it is estimated as 60.8 years (SE 4.2 years). 
The mean weight in the base case is estimated as 66.6 kg (SE 3.3 kg) and in the scenario 
analysis as 66.1 kg (SE 3.6 kg). 
The proportion of patients who are male is estimated as 46% based on cancer registration 
statistics in England, 2011 (individuals aged 50–59).191 
KEY POINTS 
 Our economic model consists of two components: short term and long term. 
 In the short-term component: 
– Mean Hb levels across the population are estimated as a function of time for 
those receiving and not receiving ESA therapy.  Hb levels are mapped to utility to 
derive QALYs. 
– The difference in Hb levels between the ESA and non-ESA arms at the end of 
treatment is taken from the systematic review of clinical effectiveness (Section 0, 
page 56). 
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– Anaemia correction is not assumed to be instantaneous in the ESA arm, instead 
the average difference in Hb levels between the ESA and non-ESA arms across 
the duration of treatment is set to a proportion of the final difference in Hb levels 
based on results from randomised trials. 
– The short-term component includes a period during which Hb levels return to 
normal, a process called ‘normalisation’.  We found no published data on 
normalisation and so clinical expert advice and previous economic models were 
used to inform our modelling. 
– Dose adjustment, dose interruption and treatment withdrawal from ESA therapy 
were incorporated into an intention-to-treat mean weekly dose estimated from 
randomised trials to attempt to achieve consistency between drug acquisition 
costs and effectiveness outcomes. 
– The relationship between Hb levels and utility was estimated from the published 
literature and assumed to be linear in the range of interest. 
– The drug acquisition costs for ESAs were taken from NHS list prices. 
– Some patients (41%) were assumed to self-administer ESAs while the rest 
required an appointment with a nurse. 
– Thromboembolic events, hypertension and thrombocytopenia were included as 
adverse events which incurred costs, but which did not incur disutility. 
– Red blood cell transfusions 
 In the long-term component: 
– A constant rate of mortality is assumed with an expected survival duration of 
2.67 years for those not receiving ESA therapy, calculated from studies identified 
in the systematic review of clinical effectiveness.  The rate of mortality is 
adjusted for those receiving ESA therapy using the hazard ratio derived in the 
systematic review of clinical effectiveness (Section 0, page 56). 
– A constant utility of 0.76 was assumed for the whole population to derive QALYs. 
 
7.2. Results 
We first present the base case cost-effectiveness results, comparing six different ESA 
anaemia treatments with usual treatment not involving ESAs, for adult patients with cancer 
treatment induced anaemia. The options for anaemia treatment are either red blood cell 
transfusions (RBCTs) only, or ESAs with red blood cell transfusions. Given the differing cost 
of ESAs, results for patients on ESAs are examined across the different manufacturers.  
Next we present the cost-effectiveness results under a number of scenarios and their PSA 
results. These scenarios include: 
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 Analysis where the survival is assumed equal in both ESA and no ESA arms 
 Impact of wholesale acquisition costs for ESAs, both when applied to base case 
results and to the scenario analysis where survival is assumed equal in both arms  
 Subgroup analysis based on studies where the initial Hb level of patients was <= 
11g/dL 
 Analyses investigating the overall survival assumptions. 
We also present a comparison of our base case to those presented in TA142.34 
We do not present results for either of the subgroups originally recommended for ESA 
therapy from TA142: ovarian cancer patients on platinum based chemotherapy and patients 
unable to have blood transfusion (on medical or religious grounds). These analyses are not 
presented given the absence of suitable data on these two subgroups (see Section 0, page 
56). 
7.2.1. Base case 
For our base case, we present the summary results, but emphasise the uncertainty in the 
model through scenario analyses and the PSA, since the deterministic results do not 
account for such uncertainty. 
7.2.1.1.  Cost-effectiveness results 
The summary cost-effectiveness results are presented in Table 79 (page 312) and in Figure 
44. Costs, which all occur within the first year, and short term QALY gain remain 
undiscounted, but QALYs gained in the long term are discounted. 
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Figure 44. Incremental costs and QALYs per patient, by anaemia treatment strategy 
 
Key: ESA, erythropoiesis stimulating agent; QALYs, quality adjusted life years  
 
As Table 79 shows, the incremental cost-effectiveness ratios for the ESA strategies versus 
no ESA use in the deterministic base case range from £19,429 to £35,018 per QALY gained. 
Five of these ICERs are all above the NICE designated willingness to pay threshold of 
£20,000 per QALY, and two (NeoRecormen and Aranesp) lie above the upper limit of the 
£30,000 per QALY willingness to pay threshold. One ESA lies below the £20,000 per QALY 
threshold, but is very close to this threshold with an ICER of £19,429 per QALY gained.  
These results are represented pictorially in Figure 44. As our ICERs cover a range from 
below £20,000 to above £30,000 per QALY and are highly sensitive to the parameter 
estimates, it is important that we demonstrate the impact of the uncertainty in these ICERs 
and quantify the probability that these ICERs represent the true results. 
When the ICERs are translated into incremental net health benefit (INHB) compared to no 
ESA use, the INHB ranges from -0.053 to 0.002 QALYs at a willingness to pay of £20,000 
per QALY, and from  -0.012 to 0.025 QALYs at a willingness to pay of £30,000 per QALY, 
depending on the ESA. This represents a slight net health benefit from the use of ESAs  for 
most ESAs at the £30,000 per QALY willingness to pay thresholds, but only a net health 
benefit for one at the £20,000 per QALY threshold Again it is important to assess the 
likelihood of this very modest potential net benefit.Inevitably, given the assumed identical 
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effectiveness, we also find that when the ESA strategies are compared to each other, they 
are dominated by the ESA with the lowest total ESA cost (in this case Binocrit® [Sandoz 
Ltd]). This is because the only model parameters that differ between each type of ESA is the 
cost of the drug itself. Therefore ESAs with a higher cost are dominated by the ESA with the 
lowest cost, when they are directly compared.
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Table 79. Summary base case results 
Treatment arm 
No ESA Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
– Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per strategy £912 £2,414 £2,283 £3,384 £2,416 £2,451 £3,258 
Total incremental costs 
vs. no ESA 
– £1,502 £1,371 £2,472 £1,504 £1,539 £2,346 
Total discounted QALYs 
gained vs. no ESA 
– 0.0706 0.0706 0.0706 0.0706 0.0706 0.0706 
ICER vs. no ESA 
(£/QALY) 
– £21,279 £19,429 £35,018 £21,309 £21,804 £33,233 
ICER (£/QALY) 
– Dominated by 
Binocrit® 
(Sandoz Ltd) 
£19,429 Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
INHB vs. no ESA at 
WTP £20,000/QALY 
– -0.005 0.002 -0.053 -0.005 -0.006 -0.047 
INHB vs. no ESA at 
WTP £30,000/QALY 
– 0.021 0.025 -0.012 0.020 0.019 -0.008 
Key: Darbe alfa, darbepoetin alfa; ESA, erythropoiesis stimulating agents; ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life 
years; vs, versus; WTP, willingness to pay 
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We now briefly describe the breakdown of costs and QALY results that give our overall 
results. 
7.2.1.2.  Costs  
In the base case, costs are only accrued in the short term (within the first year), so that long 
term costs unrelated to anaemis do not disadvantage a treatment with survival benefit. The 
costs reported in the base case are therefore not discounted. 
Table 80 (page 314) shows the total cost per patient in all arms is not particularly large, 
implying that small changes to these costs may have large impacts to the overall results. 
The largest cost for all ESA arms is the cost of the ESA itself (£1,510–£2,485). The largest 
cost for a patient not on ESA is the cost of red blood cell transfusions (£799).  
Adverse events (AEs) have the one of the smallest total costs, in both the ESA and no ESA 
arms. However, it is important to note that the data from the RCTs used to populate the 
values of the adverse event model parameters were only available as probabilities of having 
at least one AE (hypertension, thrombocytopenia, thromboembolic events), and the model 
costs this as only one AE. Given the uncertainty around the adverse events data, we explore 
its impact on the results in sensitivity analyses (see Section 7.2.7.6, page 369). 
As we have assumed the same dosing schedule for all ESAs in the base case (once weekly) 
and that all ESAs are likely to be administered in the same manner, the administration cost 
for each ESA is equal. Similarly, due to assumptions of equal effectiveness, the cost of 
adverse events, RBCTs and additional blood tests are the same for all ESAs.
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Table 80. Summary of costs in the base case 
 
Treatment arm 
No ESA Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
– Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per strategy £912 £2,414 £2,283 £3,384 £2,416 £2,451 £3,258 
ESA cost £0 £1,641 £1,510 £2,611 £1,643 £1,678 £2,485 
ESA administration cost £0 £98 £98 £98 £98 £98 £98 
Adverse event cost £113 £148 £148 £148 £148 £148 £148 
RBCT cost £799 £467 £467 £467 £467 £467 £467 
Cost of additional blood tests £0 £60 £60 £60 £60 £60 £60 
Incremental results        
Incremental cost vs. no ESA - £1,502 £1,371 £2,472 £1,504 £1,539 £2,346 
ESA cost - £1,641 £1,510 £2,611 £1,643 £1,678 £2,485 
ESA administration cost - £98 £98 £98 £98 £98 £98 
Adverse event cost - £35 £35 £35 £35 £35 £35 
RBCT cost - -£332 -£332 -£332 -£332 -£332 -£332 
Cost of additional blood tests - £60 £60 £60 £60 £60 £60 
Key: Darbe alfa, darbepoetin alfa; ESA, erythropoiesis stimulating agent; RBCT, red blood cell transfusion 
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Incremental results (Table 80 and Figure 45) demonstrate that though there is an estimated 
cost saving of £332 for RBCTs avoided, this is outweighed by the additional costs accrued in 
each ESA arm. 
Figure 45. Incremental costs versus no ESA use in the base case 
 
Key: AE, adverse event; ESA, erythropoiesis stimulating agents; RBCT, red blood cell transfusion 
7.2.1.3. QALY and survival gain 
As Table 81 (page 316) demonstrates, there is a life year (LY) and QALY gain for patients 
on ESA compared to no ESAs, both in the short term (QALY gain as a consequence of Hb 
level increase) and the long term (a survival gain resulting in a QALY increase). We do not 
report QALYs for the no ESA arm, instead reporting all QALYs as incremental compared to 
no ESA treatment. This is because in the short term we do not allocate a specific utility value 
to each Hb level, instead assigning an increase in utility per Hb increase of 1g/dL. We 
therefore do not calculate the short term utility for the patients who do not have ESAs, 
instead calculating the difference in utility between arms using the Hb levels. QALYs gained 
(or lost) by the ESA arm compared to the no ESA arm are then calculated by applying this 
difference in utility across the appropriate time frame. For consistency, the long term utility is 
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applied to the difference in survival between the arms, giving the QALYs gained (or lost) by 
the ESA arm, rather than specific QALYs for each arm.  
As the results are based new meta-analyses of PenTAG’s clinical effectiveness review, 
these results are not conducted separately for each ESA product.   
Table 81. Incremental life years (LYS) and quality-adjusted life years (QALYs), ESA vs. 
no ESA 
Treatment arm Incremental LY and QALY gain  
(ESA vs. no ESA) 
Undiscounted LY gained vs. no ESA (undiscounted)  0.0911 
Discounted life years gained vs. no ESA 0.0762 
Total discounted QALYs gained vs. no ESA 0.0706 
Total short term 0.0124 
Short term- during cancer treatment 0.0083 
Short term- during normalisation 0.0042 
Long term 0.0582 
Key: ESA, erythropoiesis stimulating agents; LY, life year(s); QALY, quality-adjusted life year 
 
Figure 46 (page 317), demonstrates where these QALYs are accrued. Over three-quarters 
of the QALY gain is due to the modelled increased survival. 
Short term QALYs are accrued during chemotherapy, and in the post-chemotherapy period 
designated as normalisation. Again, all ESA types are treated as equal in this regard and, as 
with the costs, these values are not discounted due to the short time frame they occur within. 
In our analysis, we do not explicitly model any additional ESA use during the normalisation 
period (it is possible for patients to still be on ESA for up to four weeks after chemotherapy) 
and therefore this QALY gain could be greater. Our estimated short term QALY gain, 0.0124, 
is lower than in other comparable studies (e.g. Wilson and colleagues [2007],1 where short 
term gain in the base case is 0.030), due to PenTAG’s smaller utility gain associated with 
increase in Hb level. 
The long term QALY gain for patients on ESA compared to those not on ESA is a direct 
result of the life years gained, as the utility is assumed the same in both arms once patients’ 
Hb levels have normalised. Given the timeframe of this section of the model, the life years 
gained and associated QALYs are discounted in the final results. The discounted life years 
gained for patients on ESA are therefore 0.0762 years. This translates to a discounted QALY 
gain of 0.0582, which is significantly larger than the QALY gain from short term Hb level 
improvement. This demonstrates the importance of the estimated survival effect of ESA 
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usage. Though our base case includes a survival benefit associated with ESA use, this 
survival benefit is not demonstrated with statistical significance, as discussed in PenTAG 
clinical effectiveness review, and is one parameter that is investigated thoroughly in 
sensitivity analysis, in an attempt to quantify its effects on results. It is this parameter in 
particular that drives the cost-effectiveness results and emphasizes the importance of our 
PSA. 
Figure 46. Incremental QALY gain versus no ESA 
 
Key: ESA, erythropoiesis stimulating agent; QALYs, quality-adjusted life years 
7.2.2. Probabilistic sensitivity analysis of PenTAG base case 
Here we present the results of the probabilisitic sensitivity analysis (PSA) for our base case. 
Table 82 presents the average PSA results, with a comparison to the ICERs in the 
deterministic base case. On average the ICERs are slightly reduced in the probabilistic 
analysis compared to the deterministic base case. However, as we see from the 95% 
confidence intervals for the costs and QALYs, the true ICERs are likely to cover a wide 
range.  Indeed the credible intervals cover a range of £2,500 per QALY to the point where 
they are dominated (with ESAs having higher costs and lower QALYs than the no ESA arm). 
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The average incremental net health benefit (INHB) for each ESA in the PSA are slightly 
higher than in the deterministic base case, especially in the case where ESAs were close to 
the boundary of the £20,000 per QALY willingness to pay threshold in the deterministic base 
case. However, when the 95% CI for each INHB are examined, they demonstrate that there 
is quite a range that each INHB can lie upon. The breakdown of costs and QALYs indicates 
where the majority of the uncertainty in the overall costs and QALYs is coming from. 
Unsurprisingly, as they appeared to be the main drivers in the deterministic scenario, the 
ESA costs and the long term QALY gain appear to have the largest impact on the 
uncertainty around the overall costs and QALYs.
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Table 82. Summary base case probabilistic results 
Treatment arm 
Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Deterministic ICER vs no 
ESA £21,279 £19,429 £35,018 £21,309 £21,804 £33,233 
Mean probabilistic ICER vs 
no ESA (95% CrI) 
£16,135 
(£2,529 – Dtda)  
£14,724 
(£2,322 – Dtda) 
£27,226 
(£4,067 – Dtda) 
£16,312 
(£2,581 – Dtda) 
£16,484 
(£2,439 – Dtda) 
£25,684 
(£3,841 – Dtda) 
Incremental QALYs vs. no 
ESA (95% CI) 
0.092 
(-0.264 – 0.447) 
0.092 
(-0.264 – 0.447) 
0.092 
(-0.264 – 0.447) 
0.092 
(-0.264 – 0.447) 
0.092 
(-0.264 – 0.447) 
0.092 
(-0.264 – 0.447) 
Incremental short term 
QALYs vs. no ESA (95% CI) 
0.014 
(0.001 – 0.028) 
0.014 
(0.001 – 0.028) 
0.014 
(0.001 – 0.028) 
0.014 
(0.001 – 0.028) 
0.014 
(0.001 – 0.028) 
0.014 
(0.001 – 0.028) 
Incremental long term 
QALYs vs. no ESA (95% CI) 
0.077 
(-0.278– 0.433) 
0.077 
(-0.278– 0.433) 
0.077 
(-0.278– 0.433) 
0.077 
(-0.278– 0.433) 
0.077 
(-0.278– 0.433) 
0.077 
(-0.278– 0.433) 
Incremental costs vs. no 
ESA (95% CI) 
£1,478 
(£792 – £2,164) 
£1,349 
(£710 - £1,987) 
£2,494 
(£1,401 - £3,586) 
£1,494 
(£826 - £2,163) 
£1,510 
(£720 - £2,249) 
£2,353 
(£1,327- £3,379) 
Incremental ESA cost vs. no 
ESA (95% CI) 
£1,624 
(£986-£2,262) 
£1,495 
(£908 - £2,082) 
£2,640 
(£1,588 - £3,693) 
£1,641 
(£1,005 - £2,277) 
£1,656 
(£953 - £2,360) 
£2,499 
(£1,492 - £3,507) 
Incremental ESA admin cost 
vs. no ESA (95% CI) 
£97 
(£4 - £191) 
£97 
(£4 - £191) 
£97 
(£4 - £191) 
£97 
(£4 - £191) 
£97 
(£4 - £191) 
£97 
(£4 - £191) 
Incremental AE cost £37 (£1- £74) £37 (£1- £74) £37 (£1- £74) £37 (£1- £74) £37 (£1- £74) £37 (£1- £74) 
Incremental RBCT cost vs. 
no ESA (95% CI) 
-£341 
(-£556 - -£125) 
-£341 
(-£556 - -£125) 
-£341 
(-£556 - -£125) 
-£341 
(-£556 - -£125) 
-£341 
(-£556 - -£125) 
-£341 
(-£556 - -£125) 
Cost of additional blood tests 
vs. no ESA (95% CI) £60 (£41 - £79) £60 (£41 - £79) £60 (£41 - £79) £60 (£41 - £79) £60 (£41 - £79) £60 (£41 - £79) 
INHB vs no ESA at WTP 
£20,000 per QALY (95% CI) 
0.018 
(-0.339 – 0.375) 
0.024 
(-0.332– 0.381) 
-0.033 
(-0.392 – -0.326) 
0.017 
(-0.338 – 0.372) 
0.016 
(-0.342 – 0.374) 
-0.026 
(-0.386 – -0.334) 
Key: AE, adverse event; CI, confidence interval; CrI, credible interval; darbe alfa, darbepoetin alfa; Dtd, dominated (more expensive and less QALYs than relevant comparator); ESA, 
erythropoiesis stmulating agent; ICER, incremental cost effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life years; RBCT, red blood cell 
transplantation; WTP, willingness to pay 
Notes: a Not applicable as ESA is dominated by no ESA in more than 2.5% of simulations regardless of cost-effectiveness threshold 
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Figure 47. Probabilistic sensitiyic analysis base case incremental cost and QALYs, 
scatterplot 
 
Key: PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life years 
 
To represent the uncertainty further, we plot the simulation results for Binocrit (currently the 
cheapest of the different ESAs) in Figure 47.  
The scatterplot demonstrates that all datapoints fall within the north-west and north-east 
quadrants, so that none of the simulations resulted in a cost-saving from ESA use. We have 
summarised the four quadrants and their proportion of data points in 83.  From examining 
the costs results of the model, in 100% of simulations the ESA arm had higher costs for ESA 
use, reduced costs for RBCTs and in 0.8% of simulations, there was a reduction in costs for 
adverse events compared to the no ESA arm. This 0.8% occurs when the RR of 
thrombocytopenia is favourable for ESA use and the additional costs of thrombocytopenia in 
the control arm outweigh the costs in the ESA arm. However, as the simulations 
demonstrate, this reduction in cost for the adverse events does not produce an overall cost 
saving (the cost saving for ESA in these occurrences is less than £10). 
A significant proportion (31.4%) of the datapoints also reflect an estimated loss in QALYs. 
This suggests the possibility that ESAs may actually reduce QALYs whilst still having an 
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increased cost. There is always a QALY gain from ESA use in the short term, as the 
confidence interval for difference in Hb level at end of trial between ESA and no ESA arms 
never favours no ESA use, and therefore this loss of QALYs is a direct result of the wide 
confidence interval for the overall survival hazard ratio. The model shows that 36% of 
simulations have a QALY loss in the long term (as a result of the overall survival HR 
favouring no ESA over ESA use), and in the majority of these simulations (~87.2%) this is 
larger than the QALY gain from the short term, resulting in an overall QALY loss. This 
suggests that the overall survival HR is the primary driver of the QALY results for the 
simulations. 
Table 83. Percentage of probabilistic sensitivity analysis simulations, by cost 
increase/saving and health loss/gain 
 Health loss Health gain 
Cost increase 31.4% 68.6% 
Cost saving 0% 0% 
Key: PSA, probabilistic sensitivity analysis 
 
Table 84 shows that at a willingness to pay threshold of £20,000 per QALY, 50.9% of 
simulations fall above this threshold (of which 31.4% are dominated by the no ESA arm). 
The percentage of simulations that therefore put ESAs within the region of being cost-
effective at £20,000 per QALY is 48.1%. Comparing this value to the 31.4% of simulations 
where ESA use is dominated, we can conclude that the likelihood of ESAs being cost-
effective is highly uncertain. 
Table 84. Percentage of probabilistic sensitivity analysis simulations where ESA is 
not cost-effective. 
 ESA dominated vs. 
No ESA 
ICERs >£20,000 per 
QALY vs. no ESA 
Total where ESA is 
not cost-effective 
(at £20,000 threshold) 
Probability  31.4% 19.5% 50.9% 
Key: ESA, erythropoiesis stimulating agent; PSA, probabilistic sensitivity analysis; QALY, quality adjusted life 
year 
 
When we compare the CEACs (cost-effectiveness acceptability curves) of all the ESA 
strategies, Figure 48, we see that below a willingness to pay threshold of £150,000 per 
QALY, no single ESA strategy is as probable to be cost-effective as the current practice arm, 
with majority converging to a probability far below that of the no ESA arm. The probability of 
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the no ESA arm being cost-effective reduces swiftly as the willingness to pay threshold 
increases, such that by a willingness to pay of £20,000 per QALY this falls to below 50%. 
However at this £20,000 per QALY threshold we also see that the ESA arm most likely to be 
cost-effective still has a less than 25% probability of being cost-effective. All other ESA arms 
have a probability of being cost-effective of less than 20% for any willingness to pay 
threshold less than £150,000 per QALY. 
Figure 48. Cost effectiveness acceptability curves from base case probabilistic 
sensitivity analysis 
 
Key: ESA, erythropoiesis stimulating agent; PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life 
years 
 
The cost-effectiveness acceptability frontier (CEAF), Figure 49, compares the expected net 
health benefit of strategies at various willingness to pay thresholds. Given the higher 
average costs and equal QALY gains of the other ESAs, Binocrit consisitently has the 
highest net health benefit of the ESAs and therefore is the only ESA to appear on the CEAF. 
We see that at a willingness to pay of £15,000 per QALY Binocrit appears to be the most 
favourable option (i.e. it has the highest probability of producing the most net health benefit).  
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Figure 49. Cost-effectiveness acceptability frontier for probabilistic sensitivity 
analysis of base case 
 
Key: ESA, erythropoiesis stimulating agent; PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life 
years 
 
Overall, the PSA results demonstrate that the uncertainty inherent in the parameter 
estimates, particularly those relating to long term QALY gains is highly influential on the 
results. There appears to be potential for ESAs to be cost-effective at a £20,000 per QALY 
threshold, depending upon their cost, but this is to be viewed with caution, given that there is 
also the possibility of ESAs producing a survival loss and there is also uncertainty which 
ESA would be cost-effective. 
7.2.3. Scenario analysis 1: Setting overall survival equal across 
arms 
As the long term QALYs from any potential survival benefit are highly influential on the cost-
effectiveness results and both the clinical and statistical significance of any survival benefit 
may be disputed, we present the scenario where the overall survival hazard ratio is set to 
exactly 1 (and not varied in the PSA). For the purposes of this scenario we present first the 
deterministic results; then a threshold analysis of mean weekly cost to establish the cost at 
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which ESAs become cost-effective; and a probabilistic sensitivity analysis to investigate how 
removing the long term survival benefit of the model affects the model results.  
7.2.3.1.  Determinist ic analysis (scenario 1) 
As this scenario is identical to the base case, but with the long term aspect effectively 
removed, the costs and short term QALYs of the deterministic analysis are the same as 
those from the base case, but long term incremental QALYs become equal to 0. This can be 
demonstrated by comparing Table 85, p325 to Table 79, p312 .  
The overall QALY gain is now greatly reduced from 0.0706 in the base case to 0.0124, a 
reduction of 82%. As the costs have remained the same we see that the ICERs are greatly 
increased, such that all ESAs have an ICER greater than £110,000 per QALY compared to 
the non ESA arm. These ICERs lie well above the £30,000 per QALY threshold depicted in 
Figure 50 (page 326). This therefore suggests that if no survival benefit is assumed, ESAs 
do not appear to be cost-effective compared to current practice.
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Table 85. Summary cost-effectiveness results for scenario analysis 1 
Treatment arm No ESA Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per strategy £912 £2,414 £2,283 £3,384 £2,416 £2,451 £3,258 
Total incremental costs vs. no 
ESA 
– £1,502 £1,371 £2,472 £1,504 £1,539 £2,346 
Total discounted QALYs 
gained vs. no ESA 
– 0.0124 0.0124 0.0124 0.0124 0.0124 0.0124 
ICER vs. no ESA (£/QALY) – £120,995 £110,477 £199,118 £121,166 £123,983 £188,968 
ICER (£/QALY) 
– Dominated by 
Binocrit® 
(Sandoz Ltd) 
£110,477 Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
INHB vs. no ESA at WTP 
£20,000/QALY 
– -0.063 -0.056 -0.111 -0.063 -0.065 -0.105 
INHB vs. no ESA at WTP 
£30,000/QALY 
– -0.038 -0.033 -0.070 -0.038 -0.039 -0.066 
Key: Darbe alfa, darbepoetin alfa; ESA, erythropoiesis stimulating agents; ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life 
years; vs, versus; WTP, willingness to pay 
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Figure 50. Incremental costs and QALYs for scenario analysis 1 
 
Key: ESA, erythropoiesis stimulating agent; QALYs, quality-adjusted life years 
7.2.3.2.  Threshold analysis of ESA costs 
As part of this scenario analysis that assumes no impact on overall survival, we considered 
what ESA cost would bring down the ICERs to below the £20,000 per QALY threshold. As 
ESA dose cost relies on both unit cost and size of dose we performed a threshold analysis 
on the weekly ESA cost. In the base case we see that the dose cost per week ranges from 
£137 to £218.  By testing a range of dose costs per week and fixing all other values, we see 
that for an ICER to fall below £20,000 per QALY gained in this scenario, the weekly cost of 
ESAs must fall below £32. Since any alteration in dose would likely affect the effectiveness 
of ESAs, the only variation to the base case analysis implied by this scenario is a reduction 
in unit cost of roughly between 75-85%. 
*********************************************************************************************************
******************. An analysis of the wholesale acquisition costs is provided separately in 
Section 7.2.4 (page 332), but this analysis does indicate that for a certain cost, ESAs may be 
cost-effective, even without a modelled survival gain. 
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Table 86. Threshold analysis results for ESA cost per week 
Dose cost per week Total ESA cost ICER 
£30 £360 £17,799 
£31 £372 £18,765 
£32 £384 £19,732 
£33 £396 £20,699 
£34 £408 £21,666 
£35 £420 £22,632 
Min. base case value: £137 £2,283 £110,477 
Key: ESA, erythropoiesis stimulating agent; ICER, incremental cost-effectiveness ratio; min., minimum 
7.2.3.3.  Probabil ist ic analysis (scenario analysis 1) 
We also perform a PSA on this scenario, to see how uncertain the results remain once the 
uncertainty around the survival is removed. As the results in Table 87 show, the 95% CIs 
around the incremental QALYs and INHB are much reduced compared to the base case, 
suggesting a large component of the uncertainty has been removed by eliminating the 
uncertainty surrounding overall survival. This is also consistent with no ESA being cost-
effective at the highest CE threshold. The lower limit of the 95% credible interval for the 
ICERs does not fall below £30,000 per QALY gained for any of the ICERs, suggesting that in 
this scenario ESAs are unlikely to be cost-effective.
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Table 87. Summary PSA results for scenario analysis 1 
Treatment arm 
Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Deterministic ICER 
vs no ESA 
£120,995 £110,477 £199,118 £121,166 £123,983 £188,968 
Mean probabilistic 
ICER vs no ESA 
(95% CrI) 
£106,007 
(£40,506 - 
>£300,000) 
£96,754 
(£36,897 - 
>£300,000) 
£174,193 (£71,732- 
>£500,000 ) 
£104,706 
(£41,987 - 
>£300,000) 
£106,745 
(£40,827 - 
>£300,000) 
£166,848 
(£69,324 - 
>£500,000) 
Inc. QALY (95% CI) 0.014 (0.001 – 0.027) 
0.014 
(0.001 – 0.027) 
0.014 
(0.001 – 0.027) 
0.014 
(0.001 – 0.027) 
0.014 
(0.001 – 0.027) 
0.014 
(0.001 – 0.027) 
Inc. cost (95% CI) £1,504 (£777 - £2,232) 
£1,373 
(£695- £2,051) 
£2,472 (£1,387 - 
£3,556) 
£1,486 (£816 - 
£2,156) 
£1,515 (£787 - 
£2,242) 
£2,368 
(£1,311 - £3,425) 
INHB vs no ESA at 
WTP £20,000 per 
QALY (95% CI) 
-0.061 
(-0.100 - -0.022) 
-0.054 
(-0.091 - -0.018) 
-0.109 
(-0.165- -0.054) 
-0.060 
(-0.096 - -0.024) 
-0.062 
(-0.100 - -0.023) 
-0.104 
(-0.159 - -0.050) 
Key: CI, confidence interval; ESA, erythropoiesis stimulating agent; ICER, incremental cost effectiveness ratio; Inc., incremental; INHB, incremental net health benefit; QALY, quality-
adjusted life year 
Notes: NB: Results slightly different from base case due to a different simulation being run 
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Indeed, when we examine the scatterplot of simulations (Figure 51) we see that the 
distribution of points along the horizontal axis as greatly reduced, both as there is no longer 
a QALY loss, nor is the QALY benefit spread across such a wide area. In fact if we consider 
the scatterplot on the same axes as the base case result (Figure 52), we see a much 
narrower distribution of QALY estimates. Given the much smaller QALY difference estimates 
in this case and the same size costs differences from the base case, we find that 99.7% of 
the data points lie above the £20,000 per QALY threshold. 
Figure 51. Incremental costs and QALYs, by probabilistic sensitivity analysis 
simulation for scenario 1 
 
Key: PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life years 
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Figure 52. Incremental costs and QALYs, by probabilistic sensitivity analysis 
simulation for scenario analysis 1 and scaled to axes of base case 
 
Key: PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life years 
 
The CEAC for this scenario (Figure 53) demonstrates a much more gradual decline in 
probability of cost-effectiveness for the no ESA arm, as well as increase in the ESA arms, 
compared with that of the base case. The ESA arms also begin to converge to a higher 
probability than in the base case, though this still well below 50%. The CEAF (Figure 54) 
also demonstrates a much higher willingness to pay threshold, £100,000 per QALY, at which 
one of ESAs may produce a higher net health benefit compared to the no ESA arm. 
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Figure 53. Cost effectiveness acceptability curve for scenario analysis 1 
 
Key: CEAC, cost-effectiveness acceptability curve; RBCT, red blood cell transfusion 
 
Figure 54. Cost effectiveness acceptability frontier for scenario analysis 1 
 
Key: CEAF, cost-effectiveness acceptability frontier; RBCT, red blood cell transfusion 
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The results from this PSA suggest that if ESA use is assumed to have exactly no impact 
upon survival, then the current practice of not using ESAs appears to be the most cost-
effective option at a willingness to pay threshold of £30,000 per QALY.  
7.2.4. Scenario analysis 2: Using ESA wholesale acquisition costs 
Though we have partly investigated the impact of reducing the cost of ESAs in Scenario 1, 
we also consider it important to apply the actual costs we have available into the model. To 
give a complete picture, we apply these costs both in the base case and to Scenario 1, 
where there is no survival benefit accounted for.  This allows us to investigate the impact of 
these costs, regardless of the beliefs about survival. 
As we did not receive any cost information for Epoetin theta, we omit this from these results. 
7.2.4.1.  Scenario analysis 2a): application to base case results 
As Table 88 shows, all costs in this scenario are greatly reduced compared to the base case 
and the ICERs range from **************** per QALY gained, depending on the ESA, in the 
deterministic case. As with the base case, when the averages are taken from the PSA 
results, we see that the ICERs are further reduced, but in either case, they are all far below 
the willingness to pay threshold of £20,000 per QALY gained. Though the ICERs indicate 
that the most cost-effective ESA is Retacrit (having the lowest cost), the INHB PSA results 
indicate that the 95% confidence intervals for INHB overlap for all ESAs, suggesting that the 
cost-effectiveness of the ESAs is similar. 
***************************************************************************************** 
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Table 88. Summary results for scenario analysis 2a), wholesale acquisition costs applied in the base case, deterministic and probabilistic 
Treatment arm 
No ESA Epoetin alfa Epoetin beta Epoetin zeta Darbe alfa 
– Eprex® Binocrit® NeoRecormen® Retacrit® Aranesp® 
Deterministic results 
Total costs per strategy **** ****** ****** ****** ****** ****** 
Total incremental costs 
vs. no ESA
* **** **** **** **** **** 
Total discounted QALYs 
gained vs. no ESA
– 0.0706 0.0706 0.0706 0.0706 0.0706 
ICER vs. no ESA 
(£/QALY)
– ****** ****** ****** ****** ****** 
ICER (£/QALY) – *************************************** 
***************************
************ 
***************************
************ 
****** ***************************
************ 
Probabilistic results 
Total costs per strategy **** ****** ****** ****** ****** ****** 
Total incremental costs 
vs. no ESA (95% CI)
 ****************** ****************** ***************** ******************* **************** 
Total discounted QALYs 
gained vs. no ESA (95% 
CI)
 0.083 (-0.251 – 0.418) 0.083 (-0.251 – 0.418) 0.083 (-0.251 – 0.418) 0.083 (-0.251 – 0.418) 0.083 (-0.251 – 0.418) 
ICER vs. no ESA 
(£/QALY)
 ******************** ******************** ******************** ******************** ******************** 
INHB vs. no ESA at 
WTP £20,000/QALY 
(95% CI)
 ********************** ********************** ********************** ******************** ********************** 
Key: CI, confidence interval; Dtd, dominated (more expensive and less QALYs than relevant comparator); Dts, dominates (less expensive and more QALYs than relevant comparator); ESA, erythropoiesis 
stimulating agent; ICER, incremental cost effectiveness ratio; Inc., incremental; INHB, incremental net health benefit; QALY, quality-adjusted life year; WTP willingness to pay 
Notes: a Not applicable as ESA dominates no ESA in more than 2.5% of simulations regardless of cost-effectiveness threshold, b Not applicable as ESA is dominated by no ESA in more than 2.5% of 
simulations regardless of cost-effectiveness threshold 
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If we examine the PSA results for the most cost-effective ESA in this scenario (Figure 55), 
we see that the majority of datapoints lie around the origin. A summary of where the 
datapoints lie is available in Table 89 and shows that 26.4% of simulations the ESA was 
dominated by no ESA (cost increase and QALY gain), but in 5% of cases the ESA 
dominated the no ESA arm (cost saving and QALY gain). In the case where ESA dominates, 
this occurs when the cost saving from RBCT reduction outweighs the additional costs from 
ESA use. For a significant proportion of the simulations (37.1%)  the cost of ESA (dose and 
administration) is smaller than the cost saving from RBCT use, but the additional adverse 
event costs and blood test costs prevent the majority of these simulations from having an 
overall cost-saving. Therefore, when the unit costs of ESA are reduced, the other potential 
costs associated with ESA use become more important. 
Figure 55. Incremental costs and QALYs, probabilistic sensitivity analysis results for 
scenario analysis 2a) 
 
 
 
 
 
 
 
 
 
 
Key: PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life years 
 
Table 89. Percentage of probabilistic sensitivity analysis simulations by cost 
increase/saving and health loss/gain for scenario analysis 2a) applied to base case 
 Health loss Health gain 
Cost increase 26.4% 65.9% 
Cost saving 2.7% 5.0% 
Key: PSA, probabilistic sensitivity analysis 
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The CEAC for this scenario shows that at a willingness to pay of at least £3,500 per QALY, 
Retacrit has the highest probability of being cost-effective.  Furthermore the probability of no 
ESA use being cost-effective is greatly reduced for all thresholds and the CEAF 
demonstrates that the the Retacrit becomes the optimal strategy, at a willingness to pay 
threshold of £2,000 per QALY. 
Figure 56. Cost effectiveness acceptability curve scenario analysis 2a) 
 
Key: CEAC, cost-effectiveness acceptability curve; ESA, erythropoiesis stimulating agent 
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Figure 57. Cost effectiveness acceptability frontier scenario analysis 2a) 
 
Key: CEAF, cost-effectiveness acceptability frontier; ESA, erythropoiesis stimulating agent 
 
The results of this scenario suggest that the ESAs appear are more cost-effective than in the 
base case. However, the long term QALYs are still highly uncertain and the reduction of 
costs has now made the impact of their uncertainty more influential than in the base case. 
As such the probability of ESAs being cost-effective is still uncertain. 
7.2.4.2.  Scenario analysis 2b): application to scenario analysis 1 
results,  no survival benefit 
The summary results of the wholesale acquisition costs applied to scenario analysis 1, such 
that survival is assumed equal for both ESA and no ESA arms, are presented in Table 90.  
As expected, the ICERs in both the deterministic and average probabilistic results are larger 
than those found when the wholesale acquisition costs are applied to the base case. 
However, the majority of ESAs have ICERs less than £20,000 per QALY and there is 
therefore an indication that at the prices ESAs can be paid for, ESAs could be cost-effective, 
regardless of survival benefit. However, the upper limit of the 95% credible intervals is still 
above £30,000 per QALY for all ESAs. It is noted that there is still much crossover in INHB 
95% confidence intervals, suggesting that it is difficult to choose between ESAs.
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Table 90. Summary results for scenario analysis 2b), wholesale acquisition costs applied with no survival benefit, deterministic and 
probabilistic 
Treatment arm No ESA Epoetin alfa Epoetin beta Epoetin zeta Darbe  
alfa 
– Eprex® Binocrit® NeoRecormen® Retacrit® Aranesp® 
Deterministic results 
Total costs per strategy **** ****** ****** ****** ****** ****** 
Total incremental costs vs. 
no ESA 
* **** **** **** **** **** 
Total discounted QALYs 
gained vs. no ESA 
* ***** ***** ***** ***** ***** 
ICER vs. no ESA (£/QALY) * ******* ******* ******* ******* ******* 
Probabilistic results 
Total costs per strategy **** ****** ****** ****** ****** ****** 
Total incremental costs vs. 
no ESA (95% CI) 
 ******************* ******************* ******************* ******************** ***************** 
Total discounted QALYs 
gained vs. no ESA (95% CI) 
 ********************** ********************** ********************** ********************** ********************** 
ICER vs. no ESA (£/QALY)  *************
**********
** 
***********************
** 
***********************
* 
********************** **********************
***** 
INHB vs. no ESA at WTP 
£20,000/QALY (95% CI) 
 **********************
* 
**********************
* 
**********************
* 
********************* **********************
** 
Key: CI, confidence interval; Dts, dominated (less expensive and more QALYs than relevant comparator);  ESA, erythropoiesis stimulating agent; ICER, incremental cost 
effectiveness ratio; Inc., incremental; INHB, incremental net health benefit; QALY, quality-adjusted life year; vs, versus; WTP willingness to pay 
Notes: Some results differ between this and Section 7.2.5.1 due to simulation run, a Not applicable as ESA dominates no ESA in more than 2.5% of simulations regardless of cost-
effectiveness threshold 
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As with scenario analysis 1, when the survival component is removed from the model, the 
distribution of datapoints is greatly reduced. In this scenario, 8.2% are both cost saving and 
QALY increasing, but 34.4% still lie above the £20,000 per QALY threshold. As before, for a 
significant proportion of the simulations (36.7%),  the cost of ESA (dose and administration) 
is smaller than the cost saving from RBCT use, but the additional adverse event costs and 
blood test costs prevent the majority of these simulations from having an overall cost-saving. 
This value is slightly different to the case when wholesale acquisition costs are applied in the 
base case, due to a different run of the simulations. 
Figure 58. Incremental costs and QALYs, probabilistic sensitivity analysis results for 
scenario analysis 2b), equal survival assumed 
 
 
 
 
 
 
 
 
 
 
 
Key: PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life years 
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Figure 59. Cost effectiveness acceptability curve for scenario analysis 2b), equal 
survival assumed  
 
Key: CEAC, cost-effectiveness acceptability curve; ESA, erythropoiesis stimulating agent; QALYs, quality-
adjusted life years 
 
The CEAC for this scenario (Figure 59) appears to be quite different from those in the 
previous scenarios. By a willingness to pay of £75,000 per QALY all ESAs have a higher 
probability of being cost-effective than no ESA. Furthermore, the probability that Retacrit is 
cost-effective at a willingness to pay threshold of £20,000 per QALY is above 50%, higher 
than in other scenarios.  
The CEAF for this scenario indicates the Retacrit is the most optimal choice at a willingness 
to pay threshold of £9,500 per QALY (Figure 60). 
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Figure 60. Cost-effectiveness acceptability frontier for scenario analysis 2b), equal 
survival assumed 
 
Key: ESA, erythropoiesis stimulating agent 
 
The overall results of this scenario demonstrate that when the ESA prices are lowered to 
those that are available currently to the NHS, the cost-effectiveness of ESAs appear much 
improved, regardless of whether survival is accounted for in the model. If the survival is 
assumed equal in both the ESA and no ESA arms then the use of ESA being cost-effective 
seems plausible, but equally plausible that it is not cost-effective. Even if survival is not 
assumed equal, there is still a significant proportion of the simulations where a survival 
disbenefit occurs and as such the possibility of ESAs being dominated by current practice. 
7.2.5. Scenario analysis 3: Subgroup of RCTs based on initial Hb 
level 
7.2.5.1.  Determinist ic analysis (scenario 3) 
We next present a scenario analysis that uses only data from RCTs where only patients with 
Hb level ≤ 11 g/dL are included. This subgroup was used in an attempt to get closer to the 
licensed indication, whilst maintaining a large enough subgroup of studies to gain estimates 
for all parameters. Summary estimates are presented in Table 28 (page 154). The input 
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parameters for this scenario are given in Appendix R and described in Section 7.1 (page 
245). One of the main changes in input parameters in this scenario analysis is a higher 
estimated gain in overall survival due to ESAs (HR reducing from 0.97 [95% CI 0.83–1.13] to 
0.91 [95% CI 0.70–1.20]) 
As Table 91 shows, the incremental cost-effectiveness ratios for the ESA strategies versus 
no ESA use in the deterministic base case range from £12,593 to £23,013 per QALY gained. 
Four of these ICERs are below the NICE designated willingness to pay threshold of £20,000 
per QALY, and two (NeoRecormen® and Aranesp®) lie above this threshold, but below the 
upper limit of the £30,000 per QALY willingness to pay threshold.  These results are 
represented pictorially in Figure 61. As with our base case, the ICERs cover a range around 
the £20,000 per QALY threshold, so we felt it important that we demonstrate the impact of 
the uncertainty in these ICERs and quantify the probability that these ICERs represent the 
true results. 
When these ICERs are translated into incremental net health benefit (INHB) compared to no 
ESA use, the INHB ranges from -0.016 to 0.039 QALYs at a willingness to pay of £20,000 
per QALY, and from 0.024 to 0.060 QALYs at a willingness to pay of £30,000 per QALY, 
depending on the ESA. This represents a net health benefit from the use of ESAs for all 
ESAs at the £30,000 per QALY willingness to pay thresholds, and a net health benefit for 
most ESAs at the £20,000 per QALY threshold.   
When the ESA strategies are compared to each other, we find that as in the base case they 
are dominated by the ESA with the lowest total ESA cost (in this case Binocrit® [Sandoz 
Ltd]). This is mostly expected as the parameters altered from the base case are those 
relevant to effectiveness, but there are also differences in the mean weekly dose of each 
ESA compared with the base case.
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Table 91. Summary cost-effectiveness results for scenario analysis 3 
Treatment arm No ESA Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per 
strategy 
£956 £2,396 £2,266 £3,350 £2,394 £2,434 £3,222 
Total incremental 
costs vs. no ESA 
– £1,441 £1,310 £2,394 £1,438 £1,478 £2,267 
Total discounted 
QALYs gained vs. 
no ESA 
– 0.1040 0.1040 0.1040 0.1040 0.1040 0.1040 
ICER vs. no ESA 
(£/QALY) 
– £13,849 £12,593 £23,013 £13,826 £14,206 £21,785 
ICER (£/QALY) 
– Dominated by 
Binocrit® (Sandoz 
Ltd) 
£12,593 Dominated by 
Binocrit® (Sandoz 
Ltd) 
Dominated by 
Binocrit® (Sandoz 
Ltd) 
Dominated by 
Binocrit® (Sandoz 
Ltd) 
Dominated by 
Binocrit® (Sandoz 
Ltd) 
INHB vs. no ESA at 
WTP 
£20,000/QALY 
– 0.032 0.039 -0.016 0.032 0.030 -0.009 
INHB vs. no ESA at 
WTP 
£30,000/QALY 
– 0.056 0.060 0.024 0.056 0.055 0.028 
Key: Darbe alfa, darbepoetin alfa; ESA, erythropoiesis stimulating agents; ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life 
years; vs, versus; WTP, willingness to pay 
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Figure 61. Incremental costs and QALYs for scenario analysis 3 
 
Key: ESA, erythropoiesis stimulating agent; QALYs, quality-adjusted life years 
 
Figure 62 shows that the incremental costs in this scenario are similar to those in the PenTAG base case (Figure 44, page310). The incremental 
QALYs in the short term are more equal (Figure 63), due to a lower start Hb and longer normalisation period, but are a similar value to those in the 
base case (0.011 as opposed to 0.012). The total QALYs gained due to the mortality difference is also higher than in the base case (0.093 as opposed 
to 0.058). This gives a much higher overall QALY gain of 0.104 (compared to 0.071 in the base case) and explains why the ICERs appear much 
reduced. 
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Figure 62. Incremental costs versus no ESA for scenario analysis 3 
 
Key: AEs, adverse events; ESA, erythropoiesis stimulating agent; RBCT, red blood cell transfusion 
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Figure 63. Incremental QALYs gained vs no ESA in scenario analysis 3 
 
Key: ESA, erythropoiesis stimulating agent; QALYs, quality-adjusted life years 
7.2.5.2.  Probabil ist ic analysis (scenario 3) 
We also conducted a PSA for this scenario, to see the effect that limiting the subgroup had on the uncertainty of the results. A summary of 
the average results is presented in Table 92, where, as in the base case, the average PSA ICERs are slightly less than the estimates from the 
deterministic results, bu the upper limit of their credible intervals are still dominated by no ESA use. 
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Figure 64 shows that, compared to the equivalent plot for the base case, there appears to be 
just as much, if not more uncertainty in this subgroup of studies, particularly in terms of 
QALY gains.  
As with the base case, we see that a significant proportion (23.1%) of datapoints incur an 
increase in cost with a loss in QALYs and another 19.4% have a health gain but are above 
the £20,000 per QALY threshold. 3.2% of simulations had an overall QALY gain, but a 
survival disbenefit, with QALYs gained only in the short term. The percentage of simulations 
where ESAs are within the region of being cost-effective at £20,000 per QALY is 57.5%, 
which is slightly larger than the base case.
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Table 92. Summary results from probabilistic sensitivity analysis of scenario analysis 3 
Treatment arm 
Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Deterministic ICER 
vs no ESA 
£13,849  £12,593  £23,013  £13,826  £14,206  £21,785  
Mean probabilistic 
ICER vs no ESA 
(95% CrI) 
£11,403  
(£1,916- Dtda) 
£10,363  
(£1,706 – Dtda) 
£19,157  
(£3,473- Dtda) 
£11,339  
(£1,888 – Dtda)  
£11,573  
(£1,929- Dtda)  
£17,745  
(£3,351 – Dtda)  
Inc QALY (95% CI) 0.126  (-0.276 – 0.528) 
0.126  
(-0.276 – 0.528) 
0.126  
(-0.276 – 0.528) 
0.126  
(-0.276 – 0.528) 
0.126  
(-0.276 – 0.528) 
0.126  
(-0.276 – 0.528) 
Inc cost (95% CI) £1,436  (£701 - - £2,171) 
£1,305  
(£620- £1,991) 
£2,413  
(£1,305 – £3,521) 
£1,428  
(£729 - £2,128) 
£1,458  
(£722 - £2,193) 
£2,235  
(£1,193 – £3,277) 
INHB vs no ESA at 
WTP £20,000 per 
QALY (95% CI) 
0.054  
(-0.350 – 0.458) 
0.061  
(-0.343 – 0.465) 
0.005  
(-0.399 – 0.409) 
0.055  
(-0.350 – 0.459) 
0.053  
(-0.352 – 0.458) 
0.014  
(-0.390 – 0.418) 
Key: Darbe alfa, darbepoetin alfa; Dtd, dominated (more expensive and less QALYs than relevant comparator); ESA, erythropoiesis stimulating agents; ICER, incremental cost-
effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life years; vs, versus; WTP, willingness to pay 
Notes: a Not applicable as ESA is dominated by no ESA in more than 2.5% of simulations regardless of cost-effectiveness threshold
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Figure 64. Incremental cost and QALYs of PSA simulations for scenario analysis 3 
 
Key: PSA, probabilistic sensitivity analysis; QALYS, quality-adjusted life years 
The CEAC for this PSA (Figure 65) suggests that Binocrit® (Sandoz Ltd) may have a higher 
probability of being cost-effective compared to no ESA use, at a willingness to pay of 
£42,000 per QALY, but that this probability if still fairly low (less than 35%). All other ESA 
arms have a probability of being cost-effective of less than 25% for any willingness to pay 
threshold less than £150,000 per QALY. 
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Figure 65. Cost effectiveness acceptability curve for scenario analysis 3 
 
Key: CEAC, cost-effectiveness acceptability curve; ESA, erythropoiesis stimulating agent 
The cost-effectiveness acceptability frontier, Figure 66 suggests that at a willingness to pay 
of at least £10,500 per QALY Binocrit appears to be the most favourable option.  
Figure 66. Cost effectiveness acceptability frontier for Scenario analysis 3 
 
Key: CEAF, cost-effectiveness acceptability frontier; ESA, erythropoiesis stimulating agent; RBCT, red blood cell 
transfusion 
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The implications of this scenario suggest that ESAs may appear more cost-effective when 
patients are limited to this subgroup. This could be interpreted as an indication that when 
ESAs are used within correct licensing, they appear to be more cost-effective. However, the 
PSA clearly shows that there is still a high level of uncertainty within this subgroup, and as 
such this should be kept in mind when considering these results. In particular, in 23.1% of 
the simulations for Binocrit® (Sandoz Ltd), ESA use is dominated, having fewer QALYs and 
higher costs than no ESA use. 
7.2.6.  Overall survival scenario analyses 
As described in Section 7.1.1.2 (page 249) we perform three scenario analyses exploring the 
structural assumptions regarding overall survival. 
7.2.6.1.  Hazard ratio applying only for three years 
Overall survival in the base case is estimated for both arms using an exponential distribution, 
with the overall survival in the control arm estimated by synthesising outcomes from included 
RCTs and the overall survival in the ESA arm estimated by applying a constant hazard ratio 
to the survival in the control arm, with the hazard ratio taken from the systematic review of 
clinical effectiveness evidence.  As follow-up is limited for trials we explore the impact of 
assuming the hazard ratio only applies for the first three years, after which patients in both 
arms experience the same rate of mortality.  Deterministic and probabilistic results are both 
available in this scenario. 
7.2.6.1.1.  Determinist ic analysis 
The short-term costs and QALYs remain unchanged for both arms.  The long-term life years 
and QALYs are unchanged in the control arm but in the ESA arm they are slightly reduced: 
 Mean incremental undiscounted life years are estimated at 0.028 years, reduced 
from 0.091 years in the base case; 
 Mean incremental discounted long-term QALYs are estimated at 0.0198, reduced 
from 0.0582 in the base case; 
 Mean incremental discounted total QALYs are estimated at 0.0322, reduced from 
0.0706 in the base case. 
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These results suggest that 66% of the long-term QALY gain and 54% of the total QALY gain 
in the base case are accrued over three years after ESA treatment. 
The reduction in QALY gain means that cost-effectiveness is worsened and now none of the 
ESAs are cost-effective at thresholds of £20,000 or £30,000 per QALY (Table 93).  Binocrit® 
(Sandoz Ltd) remains the most cost-effective of the ESAs but its ICER is estimated at 
£42,584 per QALY.
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Table 93. Summary deterministic cost-effectiveness results for scenario analysis in which the OS hazard ratio applies for only three years 
Treatment arm No ESA Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
– Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per 
strategy 
£912 £2,414 £2,283 £3,384 £2,416 £2,451 £3,258 
Total incremental 
costs vs. no ESA 
–  £1,502   £1,371   £2,472   £1,504   £1,539   £2,346  
Total discounted 
QALYs gained vs. no 
ESA 
– 0.0322 0.0322 0.0322 0.0322 0.0322 0.0322 
ICER vs. no ESA 
(£/QALY) 
– £46,638 £42,584 £76,751 £46,704 £47,790 £72,839 
ICER (£/QALY) 
– Dominated by 
Binocrit® 
(Sandoz Ltd) 
£42,584 Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
INHB vs. no ESA at 
WTP £20,000/QALY 
– -0.043 -0.036 -0.091 -0.043 -0.045 -0.085 
INHB vs. no ESA at 
WTP £30,000/QALY 
– -0.018 -0.014 -0.050 -0.018 -0.019 -0.046 
Key: Darbe alfa, darbepoetin alfa; ESA, erythropoiesis stimulating agents; ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life 
years; vs, versus; WTP, willingness to pay 
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7.2.6.1.2.  Probabil ist ic analysis 
The PSA scatter plot for the incremental cost-effectiveness of Binocrit® (Sandoz Ltd) versus 
no ESA is given in (with the same axis scales as presented in the base case).  The scatter 
plot shows that a considerable amount of uncertainty about the incremental QALYs has 
been eliminated by assuming a hazard ratio of 1 from three years onwards.  Even so, 
approximately 1 in 4 simulations predicts an overall QALY loss for patients receiving ESA 
therapy due to adverse impact on overall survival in the first three years (Figure 67). 
Figure 67. Incremental costs and QALYs, PSA results for scenario analysis in which 
the OS hazard ratio applies for only three years 
 
Key: OS, overall survival; PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life years 
Table 94. Percentage of PSA simulations, by cost increase/saving and health 
loss/gain 
 Health loss Health gain 
Cost increase 24.9% 75.1% 
Cost saving 0% 0% 
Key: PSA, probabilistic sensitivity analysis 
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The summary probabilistic cost-effectiveness results are shown in Table 95 and show that 
ICERs are not changed significantly from the deterministic results, with the ICER for 
Binocrit® (Sandoz Ltd) remaining lowest versus no ESA therapy at £39,836 per QALY 
Cost-effectiveness acceptability curves and the cost-effectiveness acceptability frontier are 
given in Figure 68 and Figure 69.  The cost-effectiveness acceptability frontier switches from 
no ESA to Binocrit® (Sandoz Ltd) at WTP ≥ £40,000 per QALY. 
Figure 68. CEAC for scenario analysis in which the overall survival hazard ratio 
applies for only three years 
 
Key: CEAC, cost-effectiveness acceptability curve; ESA, erythropoiesis stimulating agent; OS, overall survival 
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Table 95. Summary probabilistic cost-effectiveness results for scenario analysis in which the OS hazard ratio applies for only three years 
Treatment arm No ESA Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
– Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per strategy £941 £2,440 £2,308 £3,398 £2,436 £2,475 £3,293 
Total incremental costs 
vs. no ESA
– £1,499 £1,367 £2,457 £1,495 £1,534 £2,352 
Total discounted QALYs 
gained vs. no ESA
– 0.0343 0.0343 0.0343 0.0343 0.0343 0.0343 
ICER vs. no ESA 
(£/QALY)
– £43,667 
(£9,371–Dtda) 
£39,836 
(£8,523–Dtda) 
£71,589 
(£15,002–Dtda) 
£43,568 
(£9,422–Dtda) 
£44,689 
(£8,795–Dtda) 
£68,532 
(£14,287–Dtda) 
INHB vs. no ESA at WTP 
£20,000/QALY
– -0.041 -0.034 -0.089 -0.040 -0.042 -0.083 
INHB vs. no ESA at WTP 
£30,000/QALY
– -0.016 -0.011 -0.048 -0.016 -0.017 -0.044 
Key: Darbe alfa, darbepoetin alfa; Dtd, dominated (more expensive and less QALYs than relevant comparator); ESA, erythropoiesis stimulating agents; ICER, incremental cost-
effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life years; vs, versus; WTP, willingness to pay 
Notes: a Not applicable as ESA is dominated by no ESA in more than 2.5% of simulations regardless of cost-effectiveness threshold 
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Figure 69. Cost-effectiveness acceptability frontier for scenario analysis in which the 
overall survival hazard ratio applies for only three years 
 
Key: CEAF, cost-effectiveness acceptability frontier; ESA, erythropoiesis stimulating agent; OS, overall survival 
7.2.6.2.  Weibull  curve f i t ted to Untch and colleagues (2011a,b) 
In this scenario the hazard ratio from the systematic review of clinical effectiveness is 
maintained as in the base case, but the overall survival in the control arm is set to a Weibull 
distribution fitted to the overall survival in Untch and colleagues (2011a,b).78  Deterministic 
and probabilistic results are given for this scenario analysis, although the overall survival in 
the control arm is not varied in the PSA. 
7.2.6.2.1.  Determinist ic results 
The short-term costs and QALYs remain unchanged for both arms.  The long-term 
incremental life years and QALYs are increased: 
 Mean incremental undiscounted life years are estimated at 0.156 years, increased 
from 0.091 years in the base case; 
 Mean incremental discounted long-term QALYs are estimated at 0.0807, increased 
from 0.0582 in the base case; 
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 Mean incremental discounted total QALYs are estimated at 0.0931, increased from 
0.0706 in the base case. 
The increase in QALY gain means that cost-effectiveness is improved and now four of the 
ESAs are cost-effective at a threshold of £20,000 per QALY (Table 96).  Binocrit® (Sandoz 
Ltd) remains the most cost-effective of the ESAs with its ICER is estimated at £14,726 per 
QALY.
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Table 96. Summary deterministic cost-effectiveness results for scenario analysis in which control arm overall survival is fitted to Untch and 
colleagues (2011)77,78 
Treatment arm 
No ESA Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
– Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per strategy £912 £2,414 £2,283 £3,384 £2,416 £2,451 £3,258 
Total incremental costs 
vs. no ESA 
–  £1,502   £1,371   £2,472   £1,504   £1,539   £2,346  
Total discounted QALYs 
gained vs. no ESA 
– 0.0931 0.0931 0.0931 0.0931 0.0931 0.0931 
ICER vs. no ESA 
(£/QALY) 
– £16,128 £14,726 £26,541 £16,150 £16,526 £25,188 
ICER (£/QALY) 
– Dominated by 
Binocrit® 
(Sandoz Ltd) 
£14,726 Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
INHB vs. no ESA at 
WTP £20,000/QALY 
– 0.018 0.025 -0.030 0.018 0.016 -0.024 
INHB vs. no ESA at 
WTP £30,000/QALY 
– 0.043 0.047 0.011 0.043 0.042 0.015 
Key: Darbe alfa, darbepoetin alfa; Dtd, dominated (more costly and less QALYs than relevant comparator); ESA, erythropoiesis stimulating agents; ICER, incremental cost-
effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life years; vs, versus; WTP, willingness to pay 
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7.2.6.2.2.  Probabil ist ic analysis 
The PSA scatter plot for the incremental cost-effectiveness of Binocrit® (Sandoz Ltd) versus 
no ESA is given in Figure 70 (with the same axis scales as presented in the base case).  
The scatter plot shows that a considerable amount of uncertainty about the incremental 
QALYs has been eliminated by assuming a hazard ratio of 1 from three years onwards.  
Even so, approximately 1 in 4 simulations predicts an overall QALY loss for patients 
receiving ESA therapy due to adverse impact on overall survival in the first three years 
(Table 97). 
Figure 70. Incremental costs and QALYs, PSA results for scenario analysis in which 
control arm overall survival is fitted to Untch and colleagues (2011a,b)77,78 
 
Key: PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life years 
Table 97. Percentage of PSA simulations, by cost increase/saving and health 
loss/gain 
 Health loss Health gain 
Cost increase 30.7% 69.3% 
Cost saving 0% 0% 
Key: PSA, probabilistic sensitivity analysis 
The summary probabilistic cost-effectiveness results are shown in Table 98 and show that 
ICERs are not changed significantly from the deterministic results, with the ICER for 
Binocrit® (Sandoz Ltd) remaining lowest versus no ESA therapy at £12,649 per QALY.
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Table 98. Summary probabilistic cost-effectiveness results for scenario analysis in which control arm overall survival is fitted to Untch and 
colleagues (2011a,b) 77,78 
Treatment arm 
No ESA Epoetin alfa Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
– Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per 
strategy 
£932 £2,438 £2,307 £3,379 £2,428 £2,471 £3,279 
Total incremental 
costs vs. no ESA 
– £1,506 £1,375 £2,447 £1,496 £1,539 £2,347 
Total discounted 
QALYs gained vs. no 
ESA 
– 0.1087 0.1087 0.1087 0.1087 0.1087 0.1087 
ICER vs. no ESA 
(£/QALY) 
– £13,857  
(£2,297, Dtd) 
£12,649  
(£2,091, Dtd) 
£22,516  
(£4,004, Dtd) 
£13,767  
(£2,243, Dtd) 
£14,160  
(£2,319, Dtd) 
£21,590  
(£3,573, Dtd) 
INHB vs. no ESA at 
WTP £20,000/QALY 
– 0.033  
(−0.400, 0.467) 
0.040  
(−0.393, 0.473) 
−0.014  
(−0.449, 0.422) 
0.034  
(−0.402, 0.470) 
0.032  
(−0.405, 0.468) 
−0.009  
(−0.447, 0.429) 
INHB vs. no ESA at 
WTP £30,000/QALY 
– 0.058  
(−0.374, 0.491) 
0.063  
(−0.370, 0.496) 
0.027  
(−0.407, 0.461) 
0.059  
(−0.376, 0.494) 
0.057  
(−0.378, 0.492) 
0.030 
 (−0.405, 0.466) 
Key: Darbe alfa, darbepoetin alfa; Dtd, dominated; ESA, erythropoiesis stimulating agents; ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; QALYs, 
quality-adjusted life years; vs, versus; WTP, willingness to pay
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Cost-effectiveness acceptability curves and the cost-effectiveness acceptability frontier are 
given in Figure 71 and Figure 72.  The cost-effectiveness acceptability frontier switches from 
no ESA to Binocrit at WTP ≥ £13,000 per QALY.  It is notable that no ESA is cost-effective in 
more simulations than any of the ESAs at cost-effectiveness thresholds up to £150,000 per 
QALY. 
Figure 71. Cost effectiveness acceptability curve for scenario analysis in which 
control arm overall survival is fitted to Untch and colleagues (2011a,b)77,78 
 
Key: CEAC, cost-effectiveness acceptability curve; ESA, erythropoesis stimulating agent 
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Figure 72. Cost-effectiveness acceptability frontier for scenario analysis in which 
control arm overall survival is fitted to Untch and colleagues (2011a,b) 
 
Key: CEAF, cost-effectiveness acceptability frontier; ESA, erythropoiesis stimulating agent 
7.2.6.3.  Log-normal curves f i t ted to Lit t lewood and colleagues (2001) 
Kaplan–Meier curves from Littlewood and colleagues (2001)68 suggest that neither 
exponential nor Weibull curves would fit overall survival in the population accurately.  A log-
normal distribution was shown graphically to give a reasonable fit and so for this scenario 
analysis separate log-normal survival functions were fitted to the Kaplan–Meier curves for 
the two arms and extrapolated.  The hazard ratio from the systematic review of clinical 
effectiveness cannot be applied as the log-normal distribution allows only accelerated failure 
time modelling and not proportional hazards. 
No probabilistic results are presented for this scenario as we did not attempt to quantify the 
uncertainty in the fitting of the log-normal distributions, but given the improved survival in the 
ESA arm was not statistically significant (P = 0.13 by the log-rank test) it is likely that 
uncertainty would remain in the cost-effectiveness results, given how critical overall survival 
is to cost-effectiveness. 
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The short-term costs and QALYs remain unchanged for both arms.  The long-term 
incremental life years and QALYs are significantly increased: 
 Mean incremental undiscounted life years are estimated at 0.471 years, increased 
from 0.091 years in the base case; 
 Mean incremental discounted long-term QALYs are estimated at 0.3087, increased 
from 0.0582 in the base case; 
 Mean incremental discounted total QALYs are estimated at 0.3211, increased from 
0.0706 in the base case. 
The increase in QALY gain means that cost-effectiveness is improved and now all of the 
ESAs are cost-effective at a threshold of £20,000 per QALY (Table 99).  Binocrit remains the 
most cost-effective of the ESAs with its ICER is estimated at £4,271 per QALY. 
It is worth noting that Littlewood and colleagues (2001) is just one study out of a number of 
studies to which we could have fitted overall survival curves, including two (Grote and 
colleagues, 200573; Untch and colleagues, 201178) suggesting a survival disbenefit from 
ESA use (though not statistically significant) and two (Osterborg and colleagues, 200570; 
Moebus and colleagues, 201362) showing no clear effect on survival of ESA therapy.  We 
are not presenting this scenario as an alternative base case, but simply demonstrating the 
very significant impact assumptions about overall survival have on cost-effectiveness.
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Table 99. Summary deterministic cost-effectiveness results for scenario analysis in which overall survival curves are fitted to Littlewood 
and colleagues (2001)68 
Treatment arm 
No ESA Epoetin alfa  Epoetin beta Epoetin theta Epoetin zeta Darbe alfa 
– Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Total costs per strategy £912 £2,414 £2,283 £3,384 £2,416 £2,451 £3,258 
Total incremental costs 
vs. no ESA 
– £1,502 £1,371 £2,472 £1,504 £1,539 £2,346 
Total discounted QALYs 
gained vs. no ESA 
– 0.3211 0.3211 0.3211 0.3211 0.3211 0.3211 
ICER vs. no ESA 
(£/QALY) 
– £4,678 £4,271 £7,698 £4,684 £4,793 £7,306 
ICER (£/QALY) 
– Dominated by 
Binocrit® 
(Sandoz Ltd) 
£4,271 Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
Dominated by 
Binocrit® 
(Sandoz Ltd) 
INHB vs. no ESA at WTP 
£20,000/QALY 
– 0.246 0.253 0.197 0.246 0.244 0.204 
INHB vs. no ESA at WTP 
£30,000/QALY 
– 0.271 0.275 0.239 0.271 0.270 0.243 
Key: Darbe alfa, darbepoetin alfa; ESA, erythropoiesis stimulating agents; ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; QALYs, quality-adjusted life 
years; vs, versus; WTP, willingness to pay 
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7.2.7. Univariate sensitivity analysis 
As the scenario analyses examine in depth the impact of the ESA cost and the overall 
survival, as well as the overall uncertainty in the model parameters, the univariate sensitivity 
analysis is used to investigate particular aspects identified or not covered by the PSA. A 
summary of these univariate sensitivity analyses are given in Table 100.
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Table 100. Summary results for univariate sensitivity analysis 
Parameter Value in base case Sensitivity analysis alternative 
values 
ICERs vs. no ESA
Eprex® Binocrit® NeoRecormen® Eporatio® Retacrit® Aranesp® 
Base case £21,279 £19,429 £35,018 £21,309 £21,804 £33,233 
Long term costs £0 £20,000/yr £42,877 £41,027 £56,616 £42,907 £43,402 £54,831 
Utility associated with Hb 
level increase of 1g/dL 
0.028 0.009 £24,162 £22,062 £39,763 £24,196 £24,759 £37,736 
0.016 £23,013 £21,013 £37,872 £23,046 £23,582 £35,942 
0.060 £17,718 £16,177 £29,157 £17,743 £18,155 £27,671 
ESA dosing schedule 1 per week, all ESAs DA Q3W £21,279 £19,429 £35,018 £21,309 £21,804 £32,308 
EA TIW £24,053 £22,204 £35,018 £21,309 £21,804 £33,233 
EB TIW £21,279 £19,429 £37,792 £21,309 £21,804 £33,233 
EB 7 times/wk £21,279 £19,429 £43,342 £21,309 £21,804 £33,233 
EZ TIW £21,279 £19,429 £35,018 £21,309 £24,579 £33,233 
ESA administration 43.1%a & 16.3%b nurse; 
40.6% self administer 
25% nurse,  
75% self administer 
£20,519 £18,669 £34,258 £20,549 £21,045 £32,473 
RBCT appointment costs £688 £344 appt £22,849 £20,999 £36,588 £22,879 £23,375 £34,803 
£1,376 £18,138 £16,288 £31,877 £18,168 £18,663 £30,092 
Adverse event costs 
Thromboembolic event £1,243 £621 £21,144 £19,294 £34,883 £21,174 £21,670 £33,098 
£2,486 £21,548 £19,698 £35,287 £21,578 £22,074 £33,502 
Hypertension £826 £413 £21,143 £19,294 £34,882 £21,173 £21,669 £33,097 
£1,652 £21,549 £19,700 £35,288 £21,579 £22,075 £33,503 
Thrombocytopenia £744 £372 £21,302 £19,453 £35,041 £21,332 £21,828 £33,257 
£1,488 £21,231 £19,381 £34,970 £21,261 £21,757 £33,185 
Duration of ESA treatment 12 wks 24 wks £41,108 £37,796 £65,710 £41,162 £42,049 £62,514 
24 wks with wholesale acq costs ****** ****** ****** *** ****** ******* 
Key: acq, acquisition; appt, appointment; DA, darbepoetin alfa; EA, epoetin alda; EB, epoetin beta; EZ, epoetin zeta; ESA, erythropoiesis stimulating agent(s); Hb, haemoglobin; ICER, incremental cost effectiveness 
ratio; QW once per week; Q3W, once every three weeks; RBCT, red blood cell transfusion; TIW, thrice weekly; wks, weeks; yr, year 
Notes: (a) GP or District; (b) Nurse at chemotherapy appointment 
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7.2.7.1.  Long term costs 
As discussed in Section 7.1 (page 245), long-term costs are not accounted for in the base 
case of the model, partly as the difference in costs between arms was problematic given the 
range of cancers and to set an equal annual cost to both arms would disadvantage any arm 
with a survival benefit. Therefore this sensitivity analysis is not supposed to be an account of 
true costs, as it is not unexpected that patients with a survival benefit would have different 
cancer treatment costs and that these costs may even be reduced.Instead, the long term 
annual costs are set to an arbitrary £20,000 (regardless of ESA use) to demonstrate how 
this value disadvantages the ESAs in the base case. Indeed in this analysis, the additional 
long term costs increase the ICERs of all ESAs to above £30,000 per QALY gained.  
7.2.7.2.  Uti l i ty associated with Hb level increase of 1g/dL 
There was a range of values available for the utility associated with Hb level that were 
investigated in the methods section. PenTAG’s chosen base case value was based on a 
cancer population and transformed to the EQ-5D, as preferred by NICE. In the sensitivity 
analysis, the original SF-6D value (0.009), the EQ-5D value identified from CKD patients 
(0.016) and the original Wilson value are (0.060) are used as alternatives. 
As the model is quite sensitive to changes in the QALYs, by reducing the utility to 0.009 or 
0.016, the ICERs of the ESAs increase, such that they all lie above the £20,000 per QALY 
threshold, with the most cost-effective ICERs calculated at £22,062 per QALY gained for a 
short term utility of 0.009 (equal to a short term gain of 0.004 QALYs) and £21,013 per 
QALY gained for a short term utility of 0.016 (equal to a short term gain of 0.007 QALYs). 
Increasing the utility to 0.06, as in the case of TA142 model, increase the short term QALY 
gain to 0.027 QALYs and reduces the ICERs such that all ESAs have an ICER below 
£30,000 per QALY compared to no ESA. 
7.2.7.3.  ESA dosing schedule 
The licenced doses for ESAs can be given on different schedules. In the base case this was 
set to once per week as this was in line with both what licensing allows and what occurred 
most frequently in the RCTs. However, previous assessments, including TA142, assumed 
that doses would be given three times a week. As such we explore the alternative dosing 
schedules for each of the ESAs, as applicable. 
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Darbepoetin alfa has the option of being given once every three weeks, reducing its total 
administration cost to £33, from £98. This had a fairly minor impact on the ICER for 
Aranesp®, reducing it from £33,200 per QALY gained to £32,300 per QALY gained. As none 
of the other ESAs were affected, their ICERs remained the same as the base case 
Epoetins alfa and zeta can be given three times a week, increasing their total administration 
cost to £294. In the scenario where epoetin alfa is increased to a three times a week 
schedule and the other ESAs held as in the base case, Binocrit no longer has an ICER 
below £20,000 per QALY gained and Eporatio® becomes the least costly ESA. When 
Epoetin zeta is assumed to have a three times a week schedule, the ICER for Retacrit® 
increases from £21,800 to £24,600 per QALY gained (rounded to the nearest hundred). 
Epoetin beta can be given either once weekly or have the dose divided and administered 3-7 
times per week. This dosing schedule gives ICERs between £37,792 and £43,342 per QALY 
gained, an increase of 8–24% from the base case ICER of £35,018 per QALY gained. 
These results demonstrate that even though ESA administration is a small component of the 
overall costs in the base case, it can have a larger impact on the results if the ESAs are to 
be administered more than once a week. This is particularly true if the ICERs lie close to a 
threshold: in the base case Binocrit is cost-effective at a threshold of £20,000 per QALY, but 
if ESAs are administered three times per week as opposed to once, Binocrit® no longer 
appears cost-effective at this threshold. 
Though this sensitivity analysis demonstrates the impact of changes to the administration 
costs, it is possible that when the dosing schedule is altered in practice, then how the dose is 
administered may also change. For example, it is possible that if a dose was required daily, 
patients could more frequently be expected to self-administer.  
7.2.7.4.  ESA administration 
As was dicussed in Section 7.1 (page 245) who administers ESAs is not entirely agreed by 
clincians. This may be due to many factors, including factors such as patient 
ability/preferences and chemotherapy schedule. As such, our base case reflects an average 
view across the clinicians’ opinions available.  
In this analysis we examine the possibility that ESAs would be given on a schedule closer to 
that of CKD patients, 25% of the time by a nurse and 75% of the time self-administering. If 
this approach was adopted for cancer patients, the overall cost of ESA administration 
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reduces to £44 and the ICERs for all ESAs are reduced such that in particular Eprex and 
Eporatio have ICERs of £20,500 per QALY gained (rounded to the nearest hundred), very 
close to the £20,000 per QALY threshold. 
7.2.7.5.  Red blood cell  transfusion appointment costs 
The cost of the transfusion appointment was taken from a very old source and uprated to 
2014/15 prices. As such the true cost may vary considerably. Therefore this sensitivity 
analysis attempts to investigate the impact that altering the cost of RBCT has, by halving 
and then doubling the cost a transfusion appointment. 
When the cost of an RBCT transfusion appointment is halved to £344, the ICERs for the 
ESAs compared to no ESA increase by around £1,500 each, such that all lie above the 
willingness to pay threshold of £20,000 per QALY. This is a result of the reduced RBCT cost 
making the cost saving from ESA use smaller. Similarly, when the RBCT costs are doubled 
to £1,376, the cost saving between ESA and no ESA arms increases and the ICERs are 
reduced, such that four of the ESAs lie below the £20,000 per QALY ICER.  
It is therefore shown that the cost of an RBCT appointment can have an effect on the ICER, 
particularly if in the base case they are close to a willingness to pay threshold. 
7.2.7.6.  Adverse event costs 
Another cost parameter for which limited data were found in the base case was that of the 
adverse events and as such this sensitivity analysis investigates the impact of changing 
these costs. As with the RBCT costs, they are halved and doubled to demonstrate the 
impact, rather than to demonstrate alternative values. 
The results in Table 100 (page 366) show that altering individual adverse events cost has 
very little impact on the overall cost-effectiveness, with ICERs altering by only a few hundred 
pounds in each case. As in the base case the no ESA arm is more likely to suffer from 
thrombocytopenia, the ICERs alter differently for thrombocytopenia compared to the other 
adverse events, with a reduction in cost of thrombocytopenia causing an increase in the 
ICERs for the ESAs versus no ESA use. 
The reason that the adverse events cost appears to have such a small impact is due to how 
similar the costs are for both patients in the ESA and no ESA arms. This is primarily driven 
by the lack of information on the number of each type of adverse event that occur in each 
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arm and the severity of the adverse events, as both are likely to affect the overall cost of the 
adverse event. In the model the arms are assumed to have the same level of severity and 
the number of adverse events is only set to cost for one instance of any individual adverse 
event, rather than multiple instances. As such further information would be required to 
properly evaluate the effect of a change in adverse event costs on the overall 
results.Duration of ESA treatment 
Another parameter that varied quite substantially in the RCTs was the duration of the ESA 
therapy. As such we assess the impact of increasing the duration to 24 weeks, as described 
in the Section 7.1 (page 245).  
Doubling the duration of treatment increases both the short term QALYs (from 0.0124 in the 
base case to 0.0207 when the duration is doubled) and the costs. This is because doubling 
the duration doubles both the QALYs gained on ESA treatment and the costs directly 
associated with ESA use. However as treatment duration is a small component of the overall 
QALYs gained, but a large component of the overall costs, the ICERs for ESAs versus no 
ESA use are greatly increased when the treatment duration increases.  All ICERs lie above 
the £30,000 per QALY threshold, with the lowest ICER at £7,796 per QALY versus no ESA 
use. 
Of note, when the ESA costs are reduced to that of their wholesale wholesale acquisition 
costs, the ICERs all fall below £13,000 per QALY. 
7.2.8. Comparison with Wilson and colleagues (2007; TA142) 
As we are conducting an update of the Wilson and colleagues (2007) HTA review, we 
attempt to compare our results to those previously reported.  Table 101 demonstrates that 
there is a large difference between the most cost-effective ESA in the PenTAG base case 
and the base case reported in TA142: with ICERs of £19,429 and £150,342 per QALY 
respectively.  
To attempt to account for these differences, we have adjusted the PenTAG model to 
incorporate parameters used in the TA142 report. Parameters we were able to identify and 
enter into the model included: baseline and normalised Hb levels, utility associated with Hb 
level and long term utility, mean survival, overall survival hazard ratio, ESA weekly cost 
(dose and administration), transfusion costs and probabilities, adverse event costs and 
probability, and ESA duration.The values for these parameters are reported in Appendix R. 
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Preferably we would have updated the TA142 model to match our parameters, but no model 
copy was available. We have attempted to discover whether the differences in the results 
are primarily due to model structure or due to the updated parameters. To make the results 
of our adjusted model comparable, costs are kept as reported in the TA142 monograph.   
Unfortunately, as only limited outputs were reported in Wilson and colleagues (2007), the 
comparison of the models is also restricted. Certain parameters in the PenTAG model, 
particularly those crucial to short term utility could not be accounted for using the parameters 
given in the TA142 monograph. One specific example of this is the mean difference in Hb 
levels between treatment arms as a proportion of difference at end of trial, which as a 
parameter in our model identifies when the benefit to Hb level from ESA use occurs. This 
was obviously not parameterised in the Wilson model, as the Hb level changes were 
modelled mechanistically. Also the normalisation rate was only approximated to 0.2 g/dL in 
the TA142 model, but had to be entered as exactly 0.2 g/dL in the PenTAG model. 
Table 101. Comparison of base case results between PenTAG and TA142 
 PenTAG base 
case (Binocrit) 
TA142 base case PenTAG model, 
adapted to use 
TA142 base case 
parameters 
Short term QALY gain vs. no ESA 0.012 0.030 0.059 
Long term QALY gain vs. no ESA 0.058 0.000 0.000 
Incremental QALY, ESA vs no ESA 0.071 0.030 0.059 
Incremental cost, ESA vs no ESA £1,371 £4,450 £6,448 
ICER, ESA vs no ESA £19,429 £150,342 £109,055 
Key: ESA, erythropoiesis stimulating agent; QALY, quality-adjusted life year 
Notes: Costs of TA142 and adjusted PenTAG model are given at TA142 prices, but PenTAG base case is 
reported for 21014/15 prices 
 
Table 101 shows, that when the PenTAG model is adapted to use parameters reported in 
TA142, the ICER rises to £110,680 per QALY gained, a value much closer to the original 
TA142 model results. 
By comparing the adjusted PenTAG model and the TA142 base case, we see that the 
altered PenTAG model has both a larger QALY gain and a larger cost than that reported in 
TA142. We believe this is mostly the result of not being able to substitute all the parameters 
from TA142 into the PenTAG model or having to use parameters from the TA142 model in a 
different manner than they were intended, based on underlying model assumptions. 
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One particular example of this is the use of the maximum duration of  ESA treatment from 
TA142 of 24 weeks, as an average value could not be calculated, which would result in both 
higher costs and QALYs in the PenTAG model, than those reported in TA142.  Furthermore 
the weekly cost is taken as a maximum and does not reflect the dose reduction that could 
occur in the TA142 model. This occurs because the PenTAG model accounts for dose 
changes by setting the input parameter for mean dose to reflect the ITT basis, but the Wilson 
model approaches this mechanistically, adjusting the dose depending on the health state. 
Unfortunately, no information on the size of initial dose was reported in the TA142 model and 
therefore we do not know what size dose the cost is equivalent to. Comparing our weekly 
ESA dose cost (£126–£218) to the weekly ESA cost calculated using the TA142 values 
(£251) we can see that there is a slight increase in cost per week for ESAs in the TA142, 
which is partly due to a change in the unit cost, but would primarily be due to the difference 
in size of the dose.  
As previously discussed, one parameter that greatly affects the QALY gains in the short term 
of the PenTAG model, but was not available from the TA142 monograph is the mean 
difference in Hb levels between treatment arms as a proportion of difference at end of trial. 
The larger this value is, the larger the benefits of ESA and the greater the QALY gain in the 
short term. In the PenTAG base case this value is set to 81%. By varying this parameter, we 
can see how easily this alters the results in Table 102, p372. We do not use this analysis to 
find the appropriate value for this parameter (as there are other factors affecting the QALY 
gain, some of which are also linked to cost results), but merely to show that this is one 
parameter in the PenTAG model that could not be altered based on the information given in 
the TA142 monograph, but is likely to be different and as such has an impact on the ICERs. 
Table 102. Sensitivity analysis of mean difference in Hb levels between treatment 
arms as a proportion of difference at end of trial, when applied to TA142 parameters 
Value Total QALY gain ICER 
Base case: 81% 0.059 £109,055 
10% 0.027 £235,633 
20% 0.032 £202,366 
30% 0.036 £177,331 
40% 0.041 £157,808 
50% 0.045 £142,157 
60% 0.050 £129,330 
70% 0.054 £118,627 
80% 0.059 £109,560 
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90% 0.063 £101,780 
100% 0.068 £95,032 
Key: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year 
 
We also note that the measure for the utility gain in the short term for the TA142 model was 
elicited using the time trade-off method, whereas the values in the PenTAG model have 
been converted to the EQ-5D. The utility value fromt TA142 could not be converted to the 
EQ-5D, so this also accounts for some of the differences in QALYs between the PenTAG 
adapted model and the TA142 model. This is discussed in more detail in Section [Utilities] 
We believe these model differences account for the difference between the adjusted 
PenTAG model and the TA142 base case. 
Notwithstanding the comparison difficulties just described, by comparing the adjusted 
PenTAG results with the PenTAG base case, we can identify which updated parameters 
have had the most impact. The main ones are: 
 The short term QALY gain is reduced in the PenTAG base case, as a result of our 
much reduced utility gain associated with increases in Hb level.  
 The PenTAG base case also includes a long term QALY gain due to a modelled 
favourable impact on survival, which was not assumed in the TA142 modelling.   The 
overall survival hazard ratio, was 1 in the TA142 model, but is 0.97 in the PenTAG 
base case based on a pooled estimate from 18 studies identified as more closely 
reflecting current licensed usage (i.e. patients receiving chemotherapy and receiving 
the licensed start dose).  
 The costs of receiving ESAs are also greatly reduced in the PenTAG base case, due 
to a reduction in the cost of ESAs (both in terms of unit cost and dose reduction), a 
reduction in the number of administrations of ESAs and a reduced time frame where 
ESAs are administered.  
7.3. Summary 
KEY POINTS 
 Cost of ESA is the largest cost component in any ESA arm and cost of red blood cell 
transfusions (RBCTs) is the largest cost for no ESA use.  
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 Costs of adverse events, RBCTs and additional blood tests are the equal across ESA 
arms.  
 When ESA are used there cost savings in RBCTs 
 Incremental cost-effectiveness ratios (ICERs) for ESA treatment versus no ESA 
treatment range from £19,429–£35,018 per QALY gained in the deterministic 
caseThe PSA gave ICERs that were lower than the deterministic base case 
(£14,724–£27,226 per QALY gained). The QALYs gained for ESA treatment 
compared to no ESA treatment had an average of 0.092 with a confidence interval of 
(-0.264 – 0.447). The incremental costs for the most-cost-effective ESA (Binocrit® 
[epoetin alfa]) were £1,349 (£710-£1,987, 95% CI)The ICER for Binocrit had a 95% 
credible interval (CrI) that was dominated by no ESA use (had fewer QALYs and 
higher costs) at its upper interval, with a lower value of £2,332 per QALY gained 36% 
of simulations from the PSA had an overall survival loss, with 31.4% of simulations 
having an overall QALY loss 
 Three important scenario analyses considered are: (1) Setting the overall survival 
hazard ratio to exactly 1, such that survival is the same for both patients on ESA 
therapy and those not on ESA therapy; (2) Setting ESA costs to wholesale 
acquisition costs, in an attempt to establish the real costs to the NHS; (3) Setting the 
overall survival hazard ratio to exactly 1 and the ESA costs to wholesale acquisition  
 In the first of these scenarios, where survival is assumed equal for both treatment 
arms, the QALY gain has greatly reduced (as well as the confidence interval: 0.014 
(0.001–0.027)) compared to the base case. The most cost-effective ESA achieving 
an ICER of £96,754 per QALY gained (95% CrI: £36,897 to over £300,000 per QALY 
gained) in the PSA. 
 In the second scenario, where wholesale acquisition costs were implemented, there 
was a reduction in the expected mean ICER from the PSA to ****** (for the least 
costly ESA- Retacrit®) per QALY gained. However, in this scenario the 95% CrI went 
from ESA dominating, with more QALYs and lower costs than no ESA use, to being 
dominated by the no ESA arm. 
 In the third scenario, where survival is assumed equal for both treatment arms and 
wholesale acquisition costs are used the expected ICER from the PSA for Retacrit® 
is *****************************************. 
 We also conduct scenario analyses on a subgroup of studies where initial Hb level 
for participants was ≤11 g/dl. This meant changes to many of the parameters and in 
particular the overall survival HR reduced to 0.91 in the deterministc results. 
Expected ICERs were reduced compared to base case, but the level of uncertainty 
was maintained. 
 Scenario analyses were conducted on the overall survival modelling assumptions. 
Though all affected the ICERs, the most significant result showed that when the 
impact of survival benefit is only included for 3 years, ESAs appear to become much 
less cost-effective, with all ICERs above £30,000 per QALY. 
 Univariate sensitivity analyses are also conducted, the most significant of these 
appeared to be the duration of ESA treatment. 
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 Discussion 
8.1. Aim 
The remit for this report has been to up-date the evidence used to inform the previous NICE 
guidance on erythropoietin stimulating agents (ESAs) for the treatment of anaemia in cancer 
patients, particularly as laid out in the report by the West Midlands Health Technology 
Assessments Centre (WMTAC).  In general they considered evidence up to 2004, and this is 
the start date we have used for this report.   
Based on the previous assessment current NICE guidance (TA142)34 recommends ESAs: 
“in combination with intravenous iron as an option for: the management of cancer treatment-
induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer who 
have symptomatic anaemia with a haemoglobin level of 8 g/dl or lower. The use of ESAs 
does not preclude the use of existing approaches to the management of anaemia, including 
blood transfusion where necessary”.34 The use of ESAs is also recommended: “in 
combination with intravenous iron in people who cannot be given blood transfusions and 
who have profound cancer treatment-related anaemia that is likely to have an impact on 
survival.”34 
Initially all ESAs were recommended for use at Hb level ≤11 g/dl, with target Hb levels not 
exceeding 13 g/dl. Following a safety review by the Pharmacovigilance Working Party at the 
request of the Committee for Medicinal Products for Human Use in 2008 changes were 
made to the Summary of Product Characteristics for all ESAs at the European Medicines 
Agency’s request. These changes came into effect in 2008 – after the previous guidance 
was issued – and included: decrease in haemoglobin value for treatment initiation to Hb ≤10 
g/dl (to either increase haemoglobin by <2 g/dl or to prevent further decline); to amend 
haemoglobin target values to 10–12 g/dl and haemoglobin levels for stopping treatment to 
>13 g/dl. 
The scope of this update review differed from the previous HTA review (Wilson and 
colleagues, 20071) in respect of the population under consideration. Whereas the review 
conducted by Wilson and colleagues (2007)1 considers cancer-related anaemia, the 
population covered in the PenTAG review is narrower, restricting to cancer patients with 
treatment-induced anaemia (specifically chemotherapy treatment). Similarly, the recent 
Cochrane review (Tonia and colleagues, 201210) considers the broader population. Given 
the publication of the Cochrane review the PenTAG review aimed to include only studies 
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evaluating ESAs as close to the licensed recommendations as possible. This was defined in 
the first instance based on start dose administered irrespective of other criteria specified in 
the license; e.g. Hb levels (start and target Hb). In sensitivity analyses the definition of ‘within 
licence’ was tightened to: (1) start dose administered plus inclusion haemoglobin level ≤11 g 
/dl; and, (2) start dose administered plus inclusion haemoglobin level ≤11 g /dl plus target 
haemoglobin level l≤13 g /dl. 
8.2. Clinical effectiveness 
From 1,458 titles and abstract screened, 11 systematic reviews (reported in 14 papers), and 
23 RCTs (reported in 35 publications), were found that matched our inclusion criteria. These 
combined studies eligible for inclusion from the previous HTA review (Wilson and 
colleagues, 20071) with more recent studies identified by the PenTAG review team. 
Included studies were cross-checked with the recent Cochrane review (Tonia and 
colleagues, 201210) to ensure completeness. Only one study (Moebus and colleagues, 
201362) was identified that was not included in the 2012 Cochrane review; it was included in 
abstract format (Moebus and colleagues, 200732).  
Taken as a whole the quality of the studies ranged from moderate to poor. For most of the 
trials it was difficult to make a general assessment about study quality due to omissions in 
study reporting. Most notably, all trials lacked clarity in the reporting of allocation methods 
(the procedure for randomisation and/or allocation concealment). 
All of the included trials evaluated ESAs as administered in accordance with the start dose 
recommended as per the current licence specifications. However, none of the included 
studies evaluated ESAs entirely within the remit of their marketing authorisations; in 
particular, start and target Hb levels, and stopping levels were all generally higher than 
specificed in the licence. Thirteen studies compared ESAs plus supportive care (including 
transfusions) with placebo plus supportive care (including transfusions). The remaining 
studies compared ESAs plus supportive care (including transfusions) with supportive care 
(including transfusions) alone.  
Analysis of haematological response (haemR) (defined as and improvement of 2 g/dl or a 
6% increase in haematocrit level) showed a statistically significant difference in Hb response 
in favour of treatment (RR 3.29; 95% CI 2.84, 3.81; 12 trials, n=2,228). Sixty three per cent 
(n/N=759/1,213) of participants who received ESAs achieved a haemR compared with 18% 
(n/N=182/1,015) of participants who did not receive ESAs. Subgroup analyses were 
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inconclusive. This and previous analyses provide consistent evidence that ESAs reduced the 
requirement for RBCT by an estimated 37%. The point estimate generated in the current 
update is in line with previous and other systematic reviews and meta-analyses. The 
analysis also provides consistent evidence that ESAs reduce the average number of RBC 
units transfused. 
We identified no evidence for a beneficial effect of ESAs on tumour response (RR 1.10; 95% 
0.86, 1.41; 7 trials, n=1,909). Results of previous reviews with respect to survival have 
varied, and there is much debate surrounding the impact of ESAs on survival. The HR was 
0.97 (95% CI 0.83, 1.13; 18 studies, n=4,399). Although this estimate differed from those 
reported by Wilson and colleagues (2007)1 and Tonia and colleagues (2012)10 – 1.05 
(95% CI 1.00, 1.11; 76 trials, n=18,754) and 1.03 (95% CI 0.83, 1.13; 28 trials, n=5,308) 
respectively – there was considerable uncertainty around this estimate (statistically 
significant heterogeneity identified I2 42.4%; p=0.03). In addition subgroup analyses could 
not identify groups at lower or higher risk. In summary, the data with respect to overall 
survival remains inconclusive. 
On-study mortality was defined as deaths occurring up to 30 days after the active study 
period. Data, extracted from the Cochrane review (Tonia and colleagues, 201210), were 
available from 21 studies including 5,085 participants. Analyses suggest that treatment with 
ESAs in patients with cancer treatment induced anaemia did not have a significant effect on 
mortality (HR 0.86, 95% CI 0.67 to 1.11; 14 trials, n=2,967). Eleven per cent (174/1,586) 
participants who received ESA had died within 30 days of the active study period, compared 
to 12% (164/1,381) of patients in control groups. 
In agreement with the Cochrane review (Tonia and colleagues, 201210), there is a 
statistically significant difference between patients treated with ESAs and controls when 
combining HRQoL parameters, although this is most likely not clinically important. Univariate 
subgroup analyses conducted for FACT-F outcomes according to chemotherapy type, 
malignancy type, intervention (epoetin or darbepoetin), and study duration, also showed 
similarly statistically significant results between intervention and control, however, the 
number of included studies was small, therefore results must be treated with caution. 
All AEs were relatively rare compared to the other outcomes considered in this report. The 
AE with the highest rate was thrombocytopenia/haemorrhage; 6% (55/877) of participants 
who received ESA treatment reported thrombocytopenia/haemorrhage, and 6% (54/838) of 
participants in control groups reported thrombocytopenia/haemorrhage.. The summary 
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estimate from the random effects meta-analysis for thrombocytopenia/haemorrhage  in the 
PenTAG review was RR 0.93 (95% CI 0.65, 1.34) compared with RR 1.21 (95% CI 1.04, 
1.42) in the Cochrane review (Tonia and colleagues, 201210). The data are insufficient to 
rule out detrimental effects. Overall, data suggest increased risk for thromboembolic events, 
hypertension, seizures and pruritus (skin rash, irritation and pruritus were combined in the 
analyses) consistent with previous estimates.  Analyses suggest that treatment with ESA in 
people with chemotherapy induced anaemia increases the risk for thromboembolic events 
(RR 1.46; 95% CI 1.08 to 1.99), increases the number of hypertension events (RR 1.80 95% 
CI 1.14 to 2.85)., increases the number of cases of pruritus (RR 2.04; 95% CI 1.11 to 3.75) 
and suggests a non-significant increase in the number of seizures (RR of 1.19; 95% CI 0.33 
to 4.38). 
Important gaps in the evidence remain with respect to survival, mortality, adverse events, 
and impact on quality of life 
8.2.1.1.  Subgroup analyses 
Two of the subgroups evaluated corresponded with the current NICE recommendations: 
women with ovarian cancer receiving platinum-based chemotherapy and people unable to 
receive blood transfusion.  
Only one included trial (Ten Bokkel and colleagues, 199847) evaluated the use of ESAs in 
women with ovarian cancer; all participants received platinum-based chemotherapy.  Data 
confirm results from prior analyses that ESAs reduce the risk of RBCT (RR 0.11 [95% CI 
0.03–0.47 ), improve physiologic parameters such as Hb level (Hb change WMD 1.23 (95% 
CI 0.48–1.98), but increase the risk for thromboembolic events (RR 3.70 (95% CI 0.18–
74.51). Overall survival was not measured in this study.  No trials were identified that 
evaluated people unable to receive blood transfusions. However, it is reasonable to 
generalize from the wider RCT pool that ESAs are likely to work in improving Hb level in this 
subpopulation. It is also reasonable to believe that if people can be supported through the 
period of life-threatening anaemia, their Hb level will recover; if ESAs are not allowed they 
run the risk of death in the absence of RBCT. Fortunately this is a small group (Jehovah’s 
Witnesses and people who have multiple antibodies to red cells because they have required 
regular transfusions in the past).   
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In addition, subgroups analyses considering any type of cancer and platinum-based 
chemotherapy, platinum-based chemotherapy in head and neck malignancies, and iron 
supplementation were conducted.  
Five trials evaluated the use of ESAs in people with any type of cancer receiving platinum-
based chemotherapy. Results from this subgroup analysis are consistent with findings from 
the overall analysis for the anaemia-related outcomes; i.e. improved haematological 
response and reduction in RBCT requirements and are different compared to the results 
reported in the Cochrane review (Tonia and colleagues, 201210). Similar to the overall 
analysis, results for the malignancy-related outcomes (overall survival and on-study 
mortality) suggest less detrimental effects for people with chemotherapy induced anaemia 
treated with ESAs. These effects are also reflected in the decrease in the number of people 
experiencing thromboembolic events. However, these results should be interpreted with 
caution. The number of studies per subgroup is small, some of the changes are not 
statistically significant and the confidence intervals remain wide. It is also important to 
remember that multiple testing issues arise when subgroups are tested and that confidence 
intervals presented here have not been adjusted for this. 
Subgroup analyses for the use of ESAs plus iron supplementation did not identify any 
significant differences between groups. Usage of iron supplementation varied between the 
studies hindering comparison of results. No trials were identified that considered the use of 
ESAs in people with head and neck malignancies receiving platinum-based chemotherapy 
8.2.1.1.1.  The impact of “within l icence” 
In addition, post hoc sensitivity analysis considered the impact of administering ESAs ‘closer 
to licence’. For the purposes of these analyses this was defined as: licensed start dose plus 
inclusion Hb criteria ≤11 g/dl, and licensed start dose plus inclusion Hb criteria ≤11 g/dl plus 
target Hb ≤13 g/dl. It appeared that the effectiveness of some outcomes was improved when 
ESAs were evaluated closer to their licenced indications. Results for anaemia-related 
outcomes showed improvements consistent with prior analyses. The effectiveness of 
malignancy-related outcomes did appear to be affected by the licence application and point 
estimates were notably lower to those reported in prior analyses when ESAs were 
administered in accordance with licence recommendations (licensed start dose plus 
inclusion Hb level ≤11 g/dl). Importantly, although the results for thromboembolic events 
from the PenTAG review agree with the Cochrane review (Tonia and colleagues, 201210), 
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suggesting an increase in thromboembolic events in patients with ESA compared to controls, 
the closer the studies were to the licence recommendations, the smaller the point estimates 
(suggesting fewer detrimental effects of ESA). 
Although the evidence is uncertain, some researchers hypothesise that anaemia in cancer 
patients is associated with a worse prognosis. According to Bohlius and colleagues, 2009, 
one explanation may be that, as a result of a low Hb, the tumour cells become hypoxic and 
are subsequently less sensitive to cytotoxic drugs, in particular oxygen-dependent 
chemotherapies. 9,192,193 Evidence for this, as reported in Tonia and colleagues (2012),10 
exists in studies where tumour control and overall survival are improved in solid tumour 
patients with better tumour oxygenation (Hockel 1993; Knocke 1999).  There is also the 
practical implication that severe anaemia may require a dose reduction or delay of 
chemotherapy, subsequently leading to a poorer outcome.  It is therefore plausible that 
efforts taken to reduce anaemia may improve tumour response and overall survival.194 That said, 
it should be noted that Hb levels elevated to >14 g/dl in women and >15 g/dl in men are undesirable and may lead to increased viscosity, 
impaired tumour oxygenation,{Vaupel, 2008 #667 and thromboembolic events.  
As an intervention used to increase Hb, and by association improve prognosis, some studies 
actually report a detrimental effect of ESAs on survival and tumour progression.13,14,16-19,195 
This effect is postulated to be due to the presence of erythropoietin receptors on various 
cancers,20,23,24,196,197 whereby the endogenously produced or exogenously administered 
erythropoietin promotes the proliferation and survival of erythropoietin receptor expressing 
cancer cells194. However, controversy about the functionality of these receptors remains,25-29 
and there are several studies which show no effect on tumour progression for patients 
receiving ESAs.16,30,32,198   
It should be noted that the majority of studies examined in the systematic reviews by 
Bohlius and colleagues (2009)194 and Tonia and colleagues (2012),10 have used a wide 
range of administration frequencies and dosage of ESAs (generally exceeding the license), 
which may cause a rise in adverse events and mortality. This knowledge, along with the 
generally poor reporting and data omission on factors such as tumour stage and method of 
assessment, have lead to the conclusion by (Tonia and colleagues, 201210) that no clear 
evidence was found to either exclude or prove a tumour promoting effect of ESAs. 
Importantly, all subgroup analyses must be interpreted with caution. The number of studies 
per subgroup is small, and the confidence intervals remain wide. The analyses may not have 
statistical power to detect the effects of license application on the effectiveness of outcomes, 
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if such effects exist. Furthermore, we have not sought to address multiple testing issues 
which arise when considering subgroups and so inference is not straightforward. 
8.3. Cost effectiveness 
8.3.1. Published economic evaluations 
Ten cost-utility analyses and two systematic reviews were identified by updating an existing 
review by Wilson and colleagues (2007)1 Five cost-utility analyses suggested that ESA 
therapy is cost-effective, these were all funded by industry (Martin and colleagues, 2003; 
Borg and colleagues, 2006) or conducted by industry (submissions by Amgen, Roche and 
Ortho Biotec as reported by Wilson and colleagues, 2007) 
The inclusion of survival benefits was common to four favourable analyses (Martin and 
colleagues [2003] and the industry submissions as reported by Wilson and colleagues 
[2007]) although no statistically significant survival benefit has been shown 
The fifth favourable analysis (Borg and colleagues, 2006) may suffer from problems of 
internal validity as it appears the cumulative dose of epoetin alfa in the analysis was less 
than half that in the clinical study informing the effectiveness estimates; this would account 
for the lower than usual incremental drug acquisition costs 
A key assumption in almost all analyses was that raising Hb levels would improve health-
related quality of life, though in no case was this assumption based on published RCT 
evidence using a preference-based quality of life measure 
A number of studies assumed a period following treatment during which Hb levels would 
gradually return to normal (termed normalisation), during which patients in the ESA arm 
would continue to accrue incremental benefits in quality of life over patients in the no ESA 
arm; no evidence for or against normalisation has been presented 
In the absence of survival benefit the expected health gain from ESA therapy is small (up to 
0.035 QALYs) and is subject to uncertainty 
Studies did not incorporate current list prices or wholesale acquisition costs, which could 
significantly reduce the drug acquisition component of ESA therapy cost and improve cost-
effectiveness 
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8.3.2. Strengths and limitations of the systematic review of 
studies of effectiveness 
The overview of clinical effectiveness systematic reviews were conducted by an 
independent, experienced research team using the latest evidence and working to a pre-
specified protocol (PROSPERO CRD42013005812). This technology assessment builds on 
existing secondary research and economic evaluations. However, there are some important 
sources of uncertainty that impact on the conclusions.  
 Relative effectiveness: We did not address the relative effectiveness of different 
ESAs. Lack of head-to-head RCT evidence would have been an important limitation 
if we had tried to do this. 
 Dose: The protocol stated that ESAs should be evaluated in accordance with their 
UK marketing authorisations. However, given the fact that no studies were 
completely aligned with the current UK authorization, we identified studies which 
were closest to the current marketing UK authorization, focusing initially on the 
starting dose. It is important to note that beyond the start dose there was still a 
significant differences from the current licence recommendations of the included 
studies. Also we did not pre-specify the criteria used to define closest to the current 
UK authorization, but we did explore alternative, stricter ways of making this 
definition.  
 Generalisability: There may be other challenges to the applicability of the included 
trials which were done up to 20 years ago. Chemotherapy has changed during this 
period as has the quality of supportive treatment. 
 Study quality: The included trials were of variable quality but all were flawed to 
some degree. Most notably, all trials lacked clarity about  randomisation and 
allocation concealment. The general problem of poor reporting of trials on this 
topicwas greatly assisted by the recent Cochrane review (Tonia and colleagues, 
2012). The authors had gathered further information from Investigators and 
manufacturers, which were used in the meta-analysis for the current review.  
 Heterogeneity: There is considerable considerable unexplained statistical 
heterogeneity for a number of outcomes, particularly survival .  
 Publication bias: There was some evidence in both the previous review and the 
Cochrane review that the results from small negative trials may not be available for 
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inclusion in the systematic reviews, suggesting the possibility of publication bias. For 
some outcomes in this review ie HRQoL this could not be further investigated 
because of the small number of included studies, in others such as survival there 
was continuing support for the possibility of publication bias. Industry-sponsored trials 
predominate. 
 Precision: Although there is an apparent wealth of RCTs, only a minority of these 
were included because of the desire to address effectiveness as close as possible to 
current UK authorization. 95% confidence intervals were in consequence often wide 
and include values indicating  no difference in effect. The problem was compounded 
by the fact that total number of patients in the trials included were insufficient to 
establish the true presence of or absence of an effect, either because events are 
uncommon ie adverse events, or because the effect size which would be deemed to 
be clinically important is small, as would be the case with survival.  
 Multiple testing: Although we were aware of the possibility of spuriously positive 
tests for statistical significance arising because of the multiple sub-groups analyses 
done, we did not formally make adjustments for this 
The limitations identified above impact on the key outcomes as follows:  
 Haematological response and numbers transfused seem robust estimates, with no 
marked heterogeneity or subgroup effects 
 Hb change does have important heterogeneity, which may possibly indicate 
subgroup effects; however, analyses in this respect were inconclusive 
 HRQoL is affected by the variability of instruments used and study quality 
 Adverse events are mainly affected by the quality of information available, the 
variability in the definition of individual adverse events used and the width of the 
confidence intervals.   
 Survival is also subject to all the limitations outlined above. Marked heterogeneity 
was identified for which no explanation could be provided. In addition, OS was 
calculated from the longest follow-up availableans as result there was a mix of short- 
and long-term studies. 
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8.3.3. Strengths and limitations of the systematic review of 
studies of cost-effectiveness 
 The systematic review of cost-effectiveness evidence was conducted by an 
independent research team using the latest evidence and to a pre-specified protocol.  
Two new systematic reviews were identified, neither of which identified studies which 
would have been eligible for this review but were not included. 
 Limitations were identified as follows: 
 The searches were limited to English language due to resource limitations; 
 Only systematic reviews and cost-utility studies were fully critically appraised and 
considered in the narrative synthesis; 
 Records from database searches published pre-2004 were excluded although it was 
not possible to assess whether these had been screened for eligibility in the 
systematic review presented in Wilson and colleagues (2007);Studies using 
darbepoetin alfa once every two weeks were excluded as out of licence although 
these could have usefully contributed to the review.  
8.3.4. Strengths and limitations of the economic modelling by 
PenTAG 
The PenTAG model is an independent model that is not sponsored by any of the 
manufacturers producing ESAs. We have used up to date clinical effectiveness data, which 
has been acquired through a systemic review of current evidence. As such, though we have 
built on past economic analyses of ESAs, we have also been able to identify key areas 
where information is scarce or uncertain and, where possible, attempted to address some of 
these limitations. These limitations are discussed below: 
8.3.4.1.  Data quality for ESA dose 
According to licence the dose of ESAs can be varied in a number of situations.  Doses may 
be escalated if patients do not achieve an adequate response or may be reduced or 
withdrawn if patients’ Hb level rises at an unacceptable pace or to an unacceptable level. 
We estimated the mean weekly dose for patients on an intention-to-treat basis to ensure 
consistency between modelled costs and benefits.  The mean weekly dose was estimated 
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by pooling estimates from a number of studies, which could improve external validity, but the 
individual estimates from studies typically required assumptions such as uniform withdrawal 
rate.  As a result, estimates from individual studies may not be accurate. 
We estimated a mean weekly dose for epoetin alfa of 24,729 IU, over a course of 12 weeks, 
resulting in a modelled cumulative dose of approximately 297,000 IU.  Tonelli and 
colleagues (2009)112 estimate a weekly dose of 30,150 IU, over a course of 15 weeks, 
resulting in a modelled cumulative dose of approximately 452,000 IU (52% larger than our 
cumulative dose).  Tonelli and colleagues did not attempt to model dose adjustment and this 
combined with the assumption of three weeks extra treatment may explain the difference. 
8.3.4.2.  Uncertainty in overall  survival 
Differing assumptions regarding overall survival (OS) for patients receiving and not receiving 
ESA therapy have a significant impact on the estimated cost-effectiveness of ESAs. 
Systematic reviews of the clinical effectiveness of ESAs (including our own) have conducted 
meta-analyses of hazard ratios for OS, but to our knowledge the assumption of proportional 
hazards (which must be made when calculating hazard ratios) has never been formally 
tested.  Furthermore, it is likely that follow-up for a number of trials for which hazard ratios 
have been estimated has been very short and therefore there is considerable uncertainty in 
the effect of ESA therapy on long-term mortality.  Individual patient data has been shared 
with the Cochrane review group on this subject and this could potentially be scrutinised to 
address these concerns. 
Even when the assumption of proportional hazards is made and the random effects meta-
analysis hazard ratio is used, there remains significant parameter and structural uncertainty. 
Parameter uncertainty exists in that the confidence interval for the OS hazard ratio is very 
wide (0.83–1.13).  There have not been sufficiently many studies powered to detect 
differences in OS for this parameter to be estimated precisely.  Parameter uncertainty also 
exists in that the OS hazard ratio appears to be somewhat sensitive to the choice of 
inclusion criteria for studies.  Further parameter uncertainty exists regarding the overall 
survival estimated for patients not receiving ESA therapy – this also has a significant impact 
on cost-effectiveness but is uncertain and likely to differ according to patient population. 
Structural uncertainty exists in that even when assuming proportional hazards there are a 
number of distributions which permit proportional hazards assumption: exponential, Weibull, 
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and Gompertz distributions.  These distributions allow for quite different mortality rates over 
time, but none appears to be compatible with all reported survival data. 
We have demonstrated that uncertainty surrounding OS is the principal contributor to 
uncertainty regarding cost-effectiveness by exploring cost-effectiveness when exactly no 
difference in OS is assumed.  This should not be seen as advocacy of the view that there is 
exactly no difference in OS, since there are biologically plausible explanations for beneficial 
and detrimental effects of ESA therapy on OS, and there is no reason to suppose these 
would cancel out.   
8.3.4.3.  Normalisation of Hb levels 
Clinical expert opinion seems to be in agreement that following chemotherapy cessation Hb 
levels will gradually increase, potentially up to pre-chemotherapy levels.  Unfortunately we 
have not found any published clinical studies documenting normalisation, so the modelled 
behaviour of Hb levels during normalisation is based entirely on clinical expert opinion. 
Our economic evaluation suggests that the QALY gain from normalisation accounts for 
approximately one third of the short-term QALY gain and 6% of the total QALY gain 
estimated in the base case.  This is a significant portion of the predicted benefits to be 
largely based on clinical expert opinion, even though the expert opinion was at least not 
conflicting. 
8.3.4.4.  Exclusion of transfusion-dependent Hb level measurements 
Some clinical studies (e.g., Tjulandin and colleagues, 201045) excluded Hb level 
measurements from certain statistical analyses if the patient had received a transfusion in 
the previous 28 days.  The rationale for this exclusion is that transfusions are assumed to 
increase Hb levels temporarily and that to include measurements which could be affected by 
transfusion could lead to biased estimates of effectiveness. 
Our economic evaluation assumes that Hb outcomes reported in trials are unbiased 
estimates of Hb outcomes for patients in clinical practice where transfusions may be used.  
Transfusion costs are modelled to “pay” for the transient benefits in terms of Hb level; if the 
impact of transfusions on Hb level has been stripped from effectiveness results then we 
model the costs but not the benefits of transfusion.  Since there is greater utilisation of 
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transfusion in patients not receiving ESA therapy it is possible that the cost-effectiveness of 
ESA therapy is overestimated. 
Ideally we would ensure that all outcomes relating to Hb levels used in the model are based 
on Hb levels from all patients (i.e., not excluding patients with recent transfusion), but there 
is insufficient data reported in clinical studies to achieve this. 
Ultimately the QALY gains from short-term correction of anaemia are dwarfed by the highly 
uncertain impact of ESAs on overall survival, and so small biases such as these in the 
estimation of short-term QALYs are unlikely to materially affect cost-effectiveness. 
8.3.4.5.  Hb to uti l i ty mapping 
The short term QALYs associated with anaemia require mapping of Hb to utility. This is a 
surrogate outcome and requires several assumptions. Firstly, the relationship between Hb 
level and utilities is assumed linear. Whilst our review of previous studies into this are 
suggest that this is appropriate for Hb levels below 12 g/dL, the model does allow for 
normalization above 12g/dL in the PSA, where this assumption of linearity no longer seems 
to hold. Furthermore, review of previous studies showed that the evidence base for mapping 
Hb to utility appears to include many different measurement tools for utility (SF-6D, EQ-5D, 
health state vignettes, LASA), suggesting that if all studies could be mapped to the same 
scale, this linear relationship may not hold. However, as linear scaling was used to scale the 
SF-6D results to the EQ-5D, this was not a problem in our base case. To assess the impact 
of scaling this utility, we also conducted a sensitivity analysis using the unscaled SF-6D 
value and another using an unscaled EQ-5D value from a population of CKD patients. In 
both instances the QALY gains for ESA use were lower and the ICERs compared to no ESA 
use increased. 
There were several additional problems with the base case source of our utility estimate 
associated with a change in Hb level. Aside from having to map the reported outcomes to 
the EQ-5D, the patient population was restricted to female cancer patients and did not 
include patients on ESA. This meant that the study examined the association of anaemia 
and utility rather than association of anaemia correction and utility improvement, which our 
analysis was attempting to model. Furthermore, the study design was observational, though 
this appeared to be the case for most of the studies identified in our review. This does mean 
that the estimated relation between utility and Hb level may be biased due to unmeasured 
confounding variables. As discussed in Section 7.1 (page 245), results from Tonelli and 
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colleagues (2009)112, suggest that it is likely that this would bias the results in favour of 
ESAs versus controls. Bias may also have occurred in the mapping study of SF-6D to EQ-
5D due to measurement error in SF-6D values, which would result in an underestimation of 
the relationship between the two measures (i.e. attenuation bias). 
8.3.4.6.  Chemotherapy costs 
The PenTAG model assumes that chemotherapy costs are equal both in the short term and 
long term, regardless of ESA use. Short term chemotherapy costs may differ, in accordance 
with on study mortality or with compliance to chemotherapy treatments, whose effects are 
not captured in the short term. Although the review of clinical effectiveness studies did not 
identify any statistically significant difference between the ESA and control arms for on-study 
mortality the overall estimate (HR 0.87, 95% CI 0.70, 1.09), suggests a trend to improved 
survival under ESA. There is also the possibility that ESA use may affect adherence to a 
chemotherapy regimen: ESA use appears to reduce the time in hospital for RBCTs and this 
may impact patient attitude to their treatment. It is difficult to speculate what this impact may 
be on costs, as there appears to be no evidence currently to make any claim. Furthermore, 
in the long term results, if an impact on overall survival is assumed then the chemotherapy 
costs are likely to differ between groups. Again is difficult to speculate how these costs might 
differ, as a longer survival might mean a longer follow up and larger chemotherapy costs, or 
it might mean a better prognosis and therefore fewer chemotherapy costs or a different 
approach to treatment. There may also be a follow on cost difference according to the 
effects of the chemotherapy adherence from the short term. Without a clear clinical 
understanding of the impact on ESAs on survival and patient preferences, it is difficult to 
address how chemotherapy costs may alter, which is why they are assumed equal in both 
arms for the base case.  
8.3.4.7.  Adverse events 
Adverse events rates associated with ESAs are also highly uncertain. The level of severity 
and specificity of each event is not well reported. The model specifically does not include 
rash or seizure as adverse events, even though they are reported in the clinical 
effectiveness systematic review, as these cover a wide, non-specific symptom base. The 
model included the adverse events of thromboembolic events, hypertension and 
thrombocytopenia, which cover a more specific symptom base, but are still not well-defined 
within or across the studies in the review of clinical effectiveness. As such the review of 
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clinical effectiveness included all definitions of the adverse events at all levels of severity. 
This makes it problematic to assign either costs or disutilities to these adverse events in the 
model.  Base costs were extracted from the NHS Reference costs 2012-13 for events likely 
to fall into the categories of adverse events, but these costs are averages from a wide 
variety of scenarios and as such highly uncertain. Our sensitivity analysis, doubling and 
halving the costs, did not appear to make a significant difference to the results, but this 
assumes that the underlying event costs for adverse events are the same in both arms. The 
model only identifies the proportion of patients who had at least one adverse event, 
regardless of severity or number. As such, the costs in the model only reflect one adverse 
event and do not account for the possibility that adverse events may be more severe in one 
arm than another. It is therefore probable that the unit cost for an adverse event is less likely 
to have an impact on the overall costs than the number of events or the cost according to 
severity. 
Assigning utilities to the adverse events is even more problematic, both in estimating the 
utility and the time that the disutility should apply for. As such the model does not account for 
utility loss associated with the adverse events and the disbenefit of adverse events is only 
reflected in their costs. Given the sensitivity of the model to changes in the QALYs, this 
could likely have a significant impact on the overall results. The findings from the clinical 
effectiveness review were mostly in favour of the control arm: thromboembolic events and 
hypertension occurred more frequently for patients on ESAs, but thrombocytopenia 
appeared to be common for the control arm. As such the addition of adverse event utilities 
into the model would likely worsen the cost-effectiveness of ESAs. However, this situation 
would also lead to the slightly unusual result that the group with the higher risk of adverse 
events had a better survival outcome. This could be explained by the lack of detail on the 
adverse events (the higher risk may not actually correspond to the more severe adverse 
events) or to the possible spurious nature of the survival benefit. Again, without a clear 
clinical understanding of the possible difference in overall survival, it is difficult to speculate. 
8.3.4.8.  Other considerations 
The base case cost for each of the ESAs may not be representative of the actual cost 
currently paid by individual organisations within the NHS. We therefore use the data 
collected on wholesale acquisition prices in a sensitivity analysis, with the caveat that these 
prices cannot be guaranteed. 
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The cost of administering ESAs is not adjusted for missed doses in the model, which 
therefore gives an increased cost for patients in the ESA arm. The sensitivity analysis where 
alternative dosing schedules are considered does not address this issue directly, but does 
demonstrate that altering these costs does not have a big impact on the model. Similarly, 
though it appears that there could be debate over how or who should administer the ESAs 
amongst clinicians, our results demonstrate that if ESAs were administered similar to the 
case of CKD patients, there is still little impact on the overall results. 
There is also uncertainty over implications for other tests that may occur during ESA use. 
Some clinicians caution additional blood tests and one of the manufacturer submissions from 
the previous HTA, TA142, costed for additional blood pressure checks, but other clinicians 
believe that no additional tests are required, as patients will be under fairly high surveillance 
during their cancer treatment. However, the impact of this cost seems minimal and the base 
case results of the model seem fairly insensitive to changes in this cost. 
The model also does not include the adverse events associated with red blood cell 
transfusions. However, we believe this risk to be minimal and the consequences are not 
easily defined or accounted for. 
The cost of red blood cell transfusions has been updated from a particularly old source, 
making it unlikely to be representative of current costs. Without current information to better 
inform this cost, we alter it sensitivity analyses to show the potential impact that changing 
this costs may have. Again the results demonstrate that the model is not overly sensitive to 
this cost, particularly if the cost is reduced. 
The model also assumes that the number of red blood cell units per transfusion is equal both 
in the ESA and no ESA arm, as we have found no evidence to inform a difference between 
arms. This may not be an accurate representation of the actual number of RBCs per 
transfusion. If it is likely that the number of units transfused per transfusion is less for the 
ESA arm than the no ESA arm, then the number of transfusions for the ESA arm will 
increase and their cost-effectiveness will reduce. 
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 Assessment of factors relevant to the 
NHS and other parties 
9.1. Existing safety concerns 
When seeking clinical experts to advise us in this assessment we found that most relevant 
clinicians (i.e., oncologists, haematologists and gynaecologists) did not use ESA therapy in 
their clinical practice.  This was generally due to concerns about safety and effectiveness 
(overall survival), alongside restrictions set by the previous NICE guidance (TA142). 
As this assessment is unlikely to reduce safety concerns it is relevant to the NHS that many 
clinicians aoppear to have judged that the potential risks of ESAs outweight the potential 
benefits. 
9.2. Current usage 
It is difficult to assess how frequently ESA therapy is used within the indication of cancer 
treatment-induced anaemia because prescription records do not routinely link medication 
with indication and ESA therapy is widely used in individuals with chronic kidney disease.  
Some indirect evidence of the use of ESA therapy for cancer treatment-induced anaemia is 
available from the use of cost centres against which ESAs are recorded. 
We were provided data (Personal communication, South East England Specialist Pharmacy 
Services, 3 October 2013) detailing how much had been spent on erythropoietin and 
darbepoetin alfa by hospital trusts (anonymised) in the East of England.  This data was 
provided for the cost centres haematology and oncology.  The oncology cost centre would 
be unlikely to include CKD patients but would not necessarily include all patients with cancer 
treatment-induced anaemia.  The haematology cost centre could include CKD patients.  By 
including only the haematology and oncology cost centres 87.4% of ESA expenditure was 
excluded, although the proportion varied according to hospital trust (see Figure 73), which 
suggests the trusts may record ESA prescriptions differently.  Total ESA expenditure is 
highly variable but appears to be somewhat correlated with the size of population served 
(see Figure 74).  This correlation disappears when only haematology and oncology are 
considered (see Figure 75).  This is suggestive of significant variability in current usage, 
consistent with the experience that many clinicians do not use ESAs due to safety concerns 
(see Section 0), although data quality is low and interpretation challenging. 
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Figure 73: Total ESA expenditure for hospital trusts in East of England 
 
Key: ESA, erythropoiesis stimulating agent(s) 
 
Figure 74: Comparison of total ESA expenditure with population served 
 
Key: ESA, erythropoiesis stimulating agent(s) 
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Figure 75: Comparison of ESA expenditure in haematology and oncology with 
population served 
 
Key: ESAs, erythropoiesis stimulating agent(s) 
9.3. Acquisition cost of ESAs 
As noted in Section 0 (page 245), the cost at which hospitals acquire ESAs may be 
significantly lower than the list price for the drugs.  These prices are the subject of 
confidential negotiations and are commercially sensitive. 
The NICE Process Methods Guide168 states the following: 
“5.5.1 For the reference case, costs should relate to resources that are under the control of 
the NHS and personal and social services. These resources should be valued using the 
prices relevant to the NHS and personal and social services. Evidence should be presented 
to demonstrate that resource use and cost data have been identified systematically.” 
“5.5.2 The public list prices for technologies (for example, pharmaceuticals or medical 
devices) should be used in the reference-case analysis. When there are nationally available 
price reductions, for example for medicines procured for use in secondary care through 
contracts negotiated by the NHS Commercial Medicines Unit, then the reduced price should 
be used in the reference-case analysis to best reflect the price relevant to the NHS. The 
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Commercial Medicines Unit publishes information on the prices paid for some generic drugs 
by NHS trusts through its Electronic Marketing Information Tool (eMIT); focusing on 
medicines in the National Generics Programme Framework for England. Analyses based on 
price reductions for the NHS will only be considered when the reduced prices are 
transparent and consistently available across the NHS, and if the period for which the 
specified price is available is guaranteed. When a reduced price is available through a 
patient access scheme that has been agreed with the Department of Health, the base-case 
analysis should include the costs associated with the scheme. The review date for the 
appraisal will be informed by the period of time over which the manufacturer or sponsor can 
guarantee any such pricing agreements.” 
At the time of writing no manufacturer has agreed a Patient Access Scheme (PAS) with the 
Department of Health and there are no contracts negotiated by the NHS Commercial 
Medicines Unit.  Current acquisition prices are confidential and therefore not transparent and 
there are no guarantees that current prices will continue into the future. 
At present acquisition prices will largely be driven by demand for ESAs for individuals with 
CKD.  Current prices could be disturbed if there were developments in the management of 
CKD or if demand for ESAs increased for patients with cancer treatment-induced anaemia 
(as might be expected following positive NICE guidance). 
In the event of positive NICE guidance for ESAs for cancer treatment-induced anaemia at list 
prices there would be no need for local decision analysis (pharmacists would simply attempt 
to obtain ESAs at the lowest price).  However, if NICE were to issue negative guidance, local 
decision makers may be required to perform decision analyses with the offered prices from 
manufacturers.  Such decisions would likely not perfectly match the counterfactual decision 
that would have been made by NICE had such offered prices been guaranteed and 
presented as reference case. 
PenTAG   CONFIDENTIAL 
395 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
 Conclusions 
The previous HTA review (Wilson and colleagues, 20071) concluded: “Epo is effective in 
improving haematological response and reducing RBCT requirements. It also appears to 
improve HRQoL. Its impact on side-effects and survival remains highly uncertain. If there is 
no impact on survival, it seems highly unlikely to be considered that epo is a cost-effective 
use of healthcare resources.” 
Additional clinical effectiveness evidence identified in this update systematic review 
continues to suggest that there is clinical benefit from ESAs with respect to anaemia-related 
outcomes; i.e. improvements in haematological response and reduction in RBCT 
requirement. Data also suggest an improvement in HRQoL and this is better quantified 
compared with the previous HTA review. The impact on side-effects and survival, however, 
remains highly uncertain. Although the point estimates for both survival and thromboembolic 
events are lower than previously reported estimates the 95% confidence intervals are wide 
and not statistically significant.  
Conclusions concerning cost-effectiveness are also no clearer.  Base case ICERs for ESA 
treatment versus no ESA treatment ranged from £19,429–£35,018 per QALY gained, but 
sensitivity and scenario analyses demonstrate that there is considerable uncertainty in these 
ICERs. In line with the previous HTA, survival was an influential parameter. If the survival 
benefit reported in the clinical effectiveness review (0.97 [95% CI 0.83–1.13]) is used, ESAs 
appear to be cost-effective on average but this is highly uncertain and QALY loss cannot be 
ruled out (31.4% of simulations in the base case estimated QALY loss from ESA therapy). 
However, if exactly equal survival is assumed regardless of ESA therapy, ESAs are 
predicted not to be cost-effective, unless wholesale acquisition costs are used, in which case 
ESAs are predicted to be cost-effective on average although approximately 1 in 5 
simulations give an ICER over £30,000 per QALY and approximately 1 in 3 simulations give 
an ICER over £20,000 per QALY.. 
In summary, ESAs could be cost-effective but there is considerable uncertainty mainly due 
to unknown impacts on overall survival. 
10.1. Suggested research priorities 
 If ESAs are thought to have major potential in improving cancer care, large RCTs 
meeting current methods and reporting standards with adequate follow-up are 
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needed to evaluate ESAs as administered in line with current marketing 
authorisations (including licence criteria for haemoglobin levels)  
 There should be improved estimates of the impact on tumour response and mortality; 
if these estimates are neutral or slightly beneficial it is plausible that ESAs could be 
cost-effective 
 There should be assessment of the frequency of the key potential adverse events 
related to ESA administration 
 More data are needed to assess the impact on HRQoL. These should include 
the effect on EQ-5D.  
 More evidence is needed to assess the impact of Hb normalisation on utility. If 
clinical studies of normalisation are conducted it would also be valuable for HRQoL 
outcomes to be measured, preferably using EQ-5D or another universal HRQoL 
questionnaire, such that incremental QALYs due to normalising from a higher Hb 
level can be modelled directly rather than by using the surrogate of Hb level. 
 In addition to new trials, it may be valuable to re-visit Cochrane IPD meta-analysis 
and select studies that better fit ‘licensed recommendations’ with respect to Hb 
criteria and dose administered 
 It may also be helpful to explore reasons why improved anaemia may lead to 
better outcomes i.e. do ESAs allow better compliance with chemotherapy 
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 Appendix A: Protocol 
Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and 
zeta; and, darbepoetin alfa) for treating cancer-treatment 
induced anaemia (including review of TA142) 
 
Technology Assessment Report commissioned by the NETSCC HTA 
Programme on behalf of the National Institute for Health and Care Excellence: 
HTA 12/42/01 
19 July 2013 
12.1. Title of the project:  
Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta; and, darbepoetin alfa) 
for treating cancer-treatment induced anaemia (including review of TA142) 
12.2. Name of TAR team and project ‘lead’ 
TAR Team PenTAG, University of Exeter Medical School 
Name Louise Crathorne 
Title Research Fellow in HTA 
Address Veysey Building, Salmon Pool Lane, Exeter, EX2 4SG 
Telephone number 01392 726084 
Email L.Crathorne@exeter.ac.uk 
Address for correspondence: All correspondence should be sent to the project 
lead (Louise Crathorne, L.Crathorne@exeter.ac.uk), the TAR Team Director (Chris 
Hyde, C.J.Hyde@exeter.ac.uk), and Sue Whiffin (S.M.Whiffin@exeter.ac.uk) 
12.3. Plain English Summary 
This project will review and update the evidence presented to the National Institute of Health 
and Care Excellence in 2004 reviewing the effectiveness and cost-effectiveness of 
erythropoietin-stimulating agents (ESAs) epoetin alfa (Eprex [Janssen-Cilag], Binocrit 
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[Sandoz]), epoetin beta (NeoRecormon [Roche Products]), epoetin theta (Eporatio [Teva 
UK]), epoetin zeta (Retacrit [Hospira UK]), and darbepoetin alfa (Aranesp [Amgen]). The 
assessment will also assess whether the reviewed drugs are likely to be considered good 
value for money for the NHS. 
12.4. Background 
Anaemia is defined as a reduction of haemoglobin concentration, red cell count or packed 
cell volume to below normal levels. The World Health Organization has defined anaemia as 
a haemoglobin level of less than 12 g/dl in women and less than 13 g/dl in men. A reduction 
in the red blood cells can result from either the defective production of red blood cells or an 
increased rate of loss of cells, either by premature destruction or bleeding. Production of red 
blood cells (erythropoiesis) is primarily stimulated and regulated by a hormone called 
erythropoietin. Erythropoietin is a glycoprotein hormone that is produced naturally in the 
kidneys, but can also be manufactured for clinical use using recombinant DNA technology. 
Anaemia can lead to a marked reduction in aspects of quality of life, such as increased 
fatigue, reduced exercise capacity and decreased sense of wellbeing. Fatigue is one of the 
commonest symptoms of anaemia. Anaemia is a common side-effect of cancer treatments 
and the anaemia-related fatigue has been shown to have a significant impact on cancer 
patients. Nearly 60% of patients with solid tumours undergoing chemotherapy became 
anaemic with a haemoglobin (Hb) <11 g/dl during their treatment. Anaemia is also common 
in haematological malignancies; up to 75% of patients with multiple myeloma are anaemic at 
diagnosis, and 70% of patients with lymphoma are anaemic by Cycles 3-4 of their 
chemotherapy. 
Cancer treatment-induced anaemia is managed by adjustments to the cancer treatment 
regimen, iron supplementation and blood transfusion in cases of severe anaemia. NICE 
Technology Appraisal Guidance 142: “Epoetin alfa, epoetin beta and darbepoetin alfa for 
cancer treatment-induced anaemia’ recommends erythropoietin analogues [ESAs] only for 
women receiving platinum-based chemotherapy for ovarian cancer who have a blood 
haemoglobin level of 8 g/100 ml or lower, and also for people who have very severe 
anaemia and cannot receive blood transfusions.”34 
12.5. Current evidence 
The conclusions from the previous review were:1 
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 ESAs are effective in improving haematological response and red blood cell 
transfusion requirements, and appears to have a positive effect on health-related 
quality of life. 
 The incidence of side-effects and effects on survival remains highly uncertain. If there 
is no impact on survival, it seems highly unlikely that ESAs would be considered a 
cost-effective use of healthcare resources. 
A recent Cochrane Review (2012) was identified in background searches: 
 Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, 
Engert A, Bohlius J. Erythropoietin or darbepoetin for patients with cancer. Cochrane 
Database of Systematic Reviews 2012, Issue 12.10  
This review assessed the effects of ESAs to either prevent or treat anaemia in cancer 
patients. It included a total of 91 trials with a total of 20,102 participants. The review found 
that ESAs: “… reduce the need for red blood cell transfusions but increase the risk for 
thromboembolic events and deaths. There is suggestive evidence that ESAs may improve 
QoL. Whether and how ESAs affect tumour control remains uncertain. The increased risk of 
death and thromboembolic events should be balanced against the potential benefits of ESA 
treatment taking into account each patient’s clinical circumstances and preferences. 
More data are needed for the effect of these drugs on quality of life and tumour progression. 
Further research is needed to clarify cellular and molecular mechanisms and pathways of 
the effects of ESAs  on thrombogenesis and their potential effects on tumour growth.” (Tonia 
T et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of 
Systematic Reviews 2012, Issue 12).10 
12.6. Decision problem 
12.6.1. Purpose of the decision to be made 
The assessment will address the question: “What is the effectiveness and cost-effectiveness 
of ESAs (epoetin alfa, beta, theta and zeta; and, darbepoetin alfa) for treating cancer-
treatment induced anaemia (including review of TA142)?” 
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12.6.2. Interventions 
Exogenously administered erythropoietin is the intervention under assessment. It is used in 
addition to, rather than a complete replacement of the existing components of management. 
Since the last appraisal (2004), an additional two types of recombinant human erythropoietin 
are available: epoetin theta and epoetin zeta; the latter is referenced to epoetin alfa. Epoetin 
alfa, beta, theta and zeta are recombinant human erythropoietin analogues, Epoetins are 
used to shorten the period of symptomatic anaemia in patients receiving cytotoxic 
chemotherapy. Darbepoetin alfa is a hyperglycosylated derivative of epoetin that stimulates 
erythropoiesis by the same mechanism as the endogenous hormone. For the treatment of 
anaemia associated with cancer treatment, they are administered by injection.  
This technology assessment report (TAR) will consider six pharmaceutical interventions: 
epoetin alfa (Eprex [Janssen-Cilag], Binocrit [Sandoz]), epoetin beta (NeoRecormon [Roche 
Products]), epoetin theta (Eporatio [Teva UK]), epoetin zeta (Retacrit [Hospira UK]), and 
darbepoetin alfa (Aranesp [Amgen]).42 
Epoetin alfa (Eprex®, [Janssen-Cilag] and Binocrit® [Sandoz]), and epoetin zeta (Retacrit® 
[Hospira UK]) have UK marketing authorisations for the treatment of anaemia and for the 
reduction of transfusion requirements in adults receiving chemotherapy for solid tumours, 
malignant lymphoma, or multiple myeloma, who are at risk of transfusion as assessed by 
their general status (e.g. cardiovascular status, pre-existing anaemia at the start of 
chemotherapy).35-37 Binocrit® (Sandoz) and epoetin zeta (Retacrit®, Hospira UK) are 
biosimilar medicines references to Eprex which contains epoetin alfa. Epoetin beta 
(NeoRecormon®, Roche Products), epoetin theta (Eporatio® [Teva UK]), and darbepoetin 
alfa (Aranesp [Amgen]) have UK marketing authorisations for the treatment of symptomatic 
anaemia in adult patients with non-myeloid malignancies receiving chemotherapy.38-40 A 
summary of the UK marketing authorisation for each intervention along with a description of 
administration method is given below. 
12.6.2.1.  UK marketing authorisations 
All interventions of interest in this review are administered by administered by the 
subcutaneous route to patients with anaemia (e.g. haemoglobin concentration ≤10 g/dl (6.2 
mmol/l)) in order to increase haemoglobin to not greater than 12 g/dl (7.5 mmol/l). All 
therapies should be continued up to four weeks after the end of chemotherapy. 
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Epoetin alfa (Eprex [Janssen-Cilag], Binocrit [Sandoz], and epoetin zeta (Retacrit, Hospira 
UK): the initial dose is 150 IU kg-1 given subcutaneously three times per week.35-37 
Alternatively, epoetin alfa can be administered at an initial dose of 450 IU kg-1 
subcutaneously once weekly.35-37 The maximum recommended dose is 900 IU kg-1 body 
weight per week.35-37 Haemoglobin variability should be addressed through dose 
management, with consideration for the haemoglobin target range of 10g/dl (6.2 mmol/l) to 
12g/dl (7.5mmol/l).35-37 A sustained haemoglobin level of greater than 12g/dl (7.5mmol/l) 
should be avoided; guidance for appropriate dose adjustment for when haemoglobin values 
exceed 12g/dl (7.5mmol/l) (see Figure 76).35,36,120 Once the therapeutic objective for an 
individual patient has been achieved, the dose should be reduced by 25 to 50% in order to 
maintain haemoglobin at that level.35-37 
Figure 76. Epoetin alfa and epoetin zeta administration guidance35-37 
 
Epoetin beta (NeoRecormen, Roche Products): the weekly dose can be given as one 
injection per week or in divided doses three to seven times per week.38 The recommended 
initial dose is 450 IU kg-1 body weight per week.38 If, after four weeks of therapy, the 
haemoglobin value has increased by at least 1 g/dl (0.62 mmol/l), the current dose should be 
continued. If the haemoglobin value has not increased by at least 1 g/dl (0.62 mmol/l), a 
doubling of the weekly dose should be considered. If, after eight weeks of therapy, the 
haemoglobin value has not increased by at least 1 g/dl (0.62 mmol/l), response is unlikely 
and treatment should be discontinued.38 The maximum recommended dose is 900 IU kg-1 
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body weight per week.38 Haemoglobin variability should be addressed through dose 
management, with consideration for the haemoglobin target range of 10 g/dl (6.2 mmol/l) to 
12 g/dl (7.5 mmol/l).38 A sustained haemoglobin level of greater than 12 g/dl (7.5 mmol/l) 
should be avoided.38 Once the therapeutic objective for an individual patient has been 
achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that 
level.38 Appropriate dose titration should be considered.38 
Epoetin theta (Eporatio, Teva UK): the recommended initial dose is 20,000 IU, independent 
of bodyweight, given once-weekly.39 Haemoglobin variability should be addressed through 
dose management, with consideration for the haemoglobin target range of 10 g/dl (6.21 
mmol/l) to 12 g/dl (7.45 mmol/l).39 A sustained haemoglobin level of greater than 12 g/dl 
(7.45 mmol/l) should be avoided.39 If, after four weeks of therapy, the haemoglobin value has 
increased by at least 1 g/dl (0.62 mmol/l), the current dose should be continued. If the 
haemoglobin value has not increased by at least 1 g/dl (0.62 mmol/l) a doubling of the 
weekly dose to 40,000 IU should be considered.39 If, after an additional four weeks of 
therapy, the haemoglobin increase is still insufficient an increase of the weekly dose to 
60,000 IU should be considered. The maximum dose should not exceed 60,000 IU per 
week.39 If, after 12 weeks of therapy, the haemoglobin value has not increased by at least 1 
g/dl (0.62 mmol/l), response is unlikely and treatment should be discontinued.39 
Darbepoetin alfa (Aranesp, Amgen): the recommended initial dose is 500 μg (6.75 μg kg-1) 
given once every three weeks, or once weekly dosing can be given at 2.25 μg kg-1 body 
weight.40 The maximum recommended dose is 4.5 μg kg-1 per week.40 If the clinical 
response of the patient (fatigue, haemoglobin response) is inadequate after nine weeks, 
further therapy may not be effective.40 Once the therapeutic objective for an individual 
patient has been achieved, the dose should be reduced by 25% to 50% in order to ensure 
that the lowest approved dose of is used to maintain haemoglobin at a level that controls the 
symptoms of anaemia.40 Appropriate dose titration between 500 μg, 300 μg, and 150 μg 
should be considered.40 Patients should be monitored closely, if the haemoglobin exceeds 
12 g/dl (7.5 mmol/l), the dose should be reduced by approximately 25 to 50%.40 Treatment 
with darbepoetin alfa should be temporarily discontinued if haemoglobin levels exceed 13 
g/dl (8.1 mmol/l).40 Therapy should be reinitiated at approximately 25% lower than the 
previous dose after haemoglobin levels fall to 12 g/dl (7.5 mmol/l) or below.40 If the rise in 
haemoglobin is greater than 2 g/dl (1.25 mmol/l) in four weeks, the dose should be reduced 
by 25 to 50%.40 
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12.6.2.2.  Place of the interventions in the treatment pathway 
NICE guidance (Technology Appraisal Guidance 142)34 currently recommends ESAs in 
combination with intravenous iron as an option for: 
 the management of cancer treatment-induced anaemia in women receiving platinum-
based chemotherapy for ovarian cancer who have symptomatic anaemia with a 
haemoglobin level of 8 g/100 ml or lower. The use of ESAs does not preclude the 
use of existing approaches to the management of anaemia, including blood 
transfusion where necessary.34  
 people who cannot be given blood transfusions and who have profound cancer 
treatment-related anaemia that is likely to have an impact on survival.34 
Where indicated the ESA used should be the one with the lowest acquisition cost.34 
In addition, the NICE guidance recommends ESAs for people who are currently being 
treated with ESAs for the management of cancer treatment-related anaemia but who do not 
fulfil either of the above criteria should have the option to continue their therapy until they 
and their specialists consider it appropriate to stop.34 
12.6.3. Relevant comparators 
The main comparators of interest are:42 
 placebo 
 best supportive care (including adjustment to the cancer treatment regimen, blood 
transfusion, and iron supplementation) 
 one of the other interventions under consideration, compared in line with their 
marketing authorisations. 
12.6.4. Population  
The population will be:42 
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 people receiving chemotherapy for solid tumours, malignant lymphoma or multiple 
myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g. 
cardiovascular status, pre-existing anaemia at the start of chemotherapy) 
 people with non-myeloid malignancies who are receiving chemotherapy 
There are no age restrictions; however, it is recognised that all licences for all drugs do not 
cover erthyropoietin use in children. 
The scope issued by NICE states that if evidence allows subgroups should be considered; 
e.g. by cancer type and status, by chemotherapy, or by best supportive care received (see 
Section 12.7.5, page 428 for more information). 
12.6.5. Outcomes to be addressed   
Evidence in relation to the following kinds of outcomes will be considered:42 
 haematological response to treatment 
 need for blood transfusion after treatment 
 tumour response (time to cancer progression) 
 survival 
 adverse effects of treatment 
 health-related quality of life. 
12.7. Methods for synthesis of evidence of clinical 
effectiveness 
The assessment report will include a systematic review of the evidence for the clinical 
effectiveness of epoetin alfa (Eprex® [Janssen-Cilag], Binocrit® [Sandoz]), epoetin beta 
(NeoRecormon® [Roche Products]), epoetin theta (Eporatio® [Teva UK]), epoetin zeta 
(Retacrit® [Hospira UK]), and darbepoetin alfa (Aranesp® [Amgen]).  
The review will update the previous review of clinical effectiveness undertaken in 2004 to 
inform NICE’s TA142 Guidance.34  The review will be undertaken following the general 
principles published by the NHS Centre for Reviews and Dissemination.132  
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12.7.1. Search strategy  
The search strategy will comprise the following main elements: 
 searching of electronic databases using an appropriately sensitive search strategy 
designed and executed by an information specialist  
 contact with experts in the field 
 scrutiny of bibliographies of retrieved papers. 
The following electronic databases will be searched: MEDLINE (Ovid); MEDLINE-in-Process 
(Ovid); EMBASE (Ovid); The Cochrane Library including the Cochrane Database of 
Systematic Reviews, CENTRAL,  DARE, NHS EED, HEED and HTA databases; CINAHL 
(EBSCO); British Nursing Index (ProQuest); Web of Science (Thomson Reuters); HMIC 
(Ovid); Current Controlled Trials; Clinical Trials.gov; FDA website; EMA website. 
In addition the following websites will be searched for background information: 
 
Medical societies  
British Society for Haematology  http://www.b-s-h.org.uk/ 
The Association of Cancer Physicians http://www.cancerphysicians.org.uk/ 
American Society of Hematology http://www.hematology.org/  
American Society of Clinical Oncology http://www.asco.org/ 
The Canadian Oncology Societies http://www.cos.ca/ 
Haematology Society of Australia and New Zealand http://www.hsanz.org.au/ 
Clinical Oncology Society of Australia http://www.cosa.org.au/ 
New Zealand Society for Oncology http://www.nzsoncology.org.nz/ 
 
UK charities  
Cancer Research UK http://www.cancerresearchuk.org/home/ 
Macmillan http://www.macmillan.org.uk/ 
Marie Curie http://www.mariecurie.org.uk/ 
Non-UK charities  
American Cancer Society http://www.cancer.org/ 
Canadian Cancer Society http://www.cancer.ca/ 
Cancer Council Australia http://www.cancer.org.au/ 
Cancer Society of New Zealand http://www.cancernz.org.nz/ 
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World Cancer Research Fund http://www.wcrf-uk.org/ 
 
The databases will be searched from search end-date of the last MTA on this topic (2004).  
The searches will be developed using the search strategies detailed in the MTA by Wilson et 
al as the starting point (see Appendix A for more information).1 Search filters will be used to 
find clinical effectiveness, cost effectiveness and quality of life studies, and all searches will 
be limited to English language studies.  
All references will be exported into Endnote X5 (Thomson Reuters) where automatic and 
manual de-duplication will be performed. 
12.7.2. Inclusion/exclusion criteria  
12.7.2.1.  Inclusion criteria  
The inclusion criteria are as reported in Table 103. The review of clinical effectiveness will 
include any randomised controlled trial (RCT) reporting at least one of the outcomes of 
interest. However, if there are no RCTs reporting one of the listed outcomes of interest or if 
there are no RCTs with over 12 months' follow up, we will extend our inclusion criteria to 
controlled clinical trials to search for studies with missing outcomes or longer follow up. 
Studies published as abstracts or conference presentations will only be included if sufficient 
details are presented to allow an appraisal of the methodology and the assessment of the 
results to be undertaken. Systematic reviews and clinical guidelines will be included as 
sources of references for finding further RCTs and to compare with our systematic review. 
These criteria may be relaxed for consideration of adverse events, for which non-
randomised and observational studies may be included.    
For the purpose of this review, a systematic review120,132,199 will be defined as one that has: 
a focused research question 
 explicit search criteria that are available to review, either in the document or on 
application 
 explicit inclusion/exclusion criteria, defining the population(s), intervention(s), 
comparator(s), and outcome(s) of interest 
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 a critical appraisal of included studies, including consideration of internal and external 
validity of the research 
 a synthesis of the included evidence, whether narrative or quantitative. 
Table 103. Inclusion criteria (PICOS) as per the final scope and accompanying notes42 
Population People receiving 
chemotherapy for solid 
tumours, malignant 
lymphoma or multiple 
myeloma, and at risk of 
transfusion as assessed by 
the patient’s general status 
(e.g. cardiovascular status, 
pre-existing anaemia at the 
start of chemotherapy).  
People with non-myeloid 
malignancies who are 
receiving chemotherapy 
There are no age restrictions; 
however, it is recognised that 
the licences for all three drugs 
do not cover eruthropoietin use 
in children. 
Exclude studies where 
erythropoietin was given in the 
context of myeloablative 
chemotherapy ahead of bone 
marrow or peripheral blood stem 
cell transplantation, or for short-
term preoperative treatment to 
correct anaemia or to support 
collection of autologous blood 
before cancer surgery. 
Intervention(s) Epoetin alfa (Eprex, 
[Janssen-Cilag] and Binocrit 
[Sandoz]) 
Epoetin beta 
(NeoRecormon, Roche 
Products) 
Epoetin theta (Eporatio 
[Teva UK]) 
Epoetin zeta (Retacrit 
[Hospira UK]) 
Darbepoietin alfa (Aranesp 
[Amgen]). 
These interventions will be 
assessed as administered in 
accordance with licensed 
indications. 
Concomitant anaemia therapy 
such as granulocyte colony-
stimulating factor (G-CSF) 
supplementation was permitted 
should be given equally in the 
control arm. This criterion was 
relaxed for iron supplementation 
which can be used in the 
experimental but not in the 
control arm as well.  
Comparator(s) Placebo 
Best supportive care 
(including adjustment to the 
cancer treatment regimen, 
blood transfusion and iron 
Concomitant anaemia therapy 
such as granulocyte colony-
stimulating factor (G-CSF) 
supplementation was permitted 
should be given equally in the 
intervention arm. This criterion 
was relaxed for iron 
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supplementation) 
One of the other 
interventions under 
consideration; compared in 
line with their marketing 
authorisations 
supplementation which can be 
used in the experimental but not 
in the control arm as well.  
Outcomes Haematological response to 
treatment 
Defined as a transfusion free 
increase of Hb of ≥2 g dl-1 or a 
haematocrit increase of 6% 
Need for blood transfusion 
after treatment 
 
Number of patients transfused, 
number of units transfused per 
patient, and number of patients 
transfused per patient per four 
weeks 
Tumour response  
 
Time to cancer progression 
Survival 
 
Overall survival 
Adverse effects of treatment  Hypertension, rash/irritation, 
pruritus, mortality, 
thromboembolic events, seizure, 
haemorrhage / 
thrombocytopenia, fatigue, pure 
red cell aplasia. 
Particular interest 
thromboembolic events 
A note will be made of other 
adverse events described within 
the trial reports 
Health-related quality of life Health-related quality of life – 
data on validated quality of life 
measures; e.g. FACT (FACT-
General, FACT-Fatigue, FACT-
Anaemia); EQ-5D, SF-36 
Study design RCTs 
SRs of RCTs (to be used to 
cross-check for any 
For the purpose of this review, a 
systematic review will be 
defined as one that has: a 
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additional RCTs and to 
compare the findings of our 
review with) 
focused research question; 
explicit inclusion/exclusion 
criteria, defining the 
population(s), intervention(s), 
comparator(s), and outcome(s) 
of interest; a critical appraisal of 
included studies, including 
consideration of internal and 
external validity of the research 
synthesis of the included 
evidence, whether narrative or 
quantitative. 
If insufficient data are available 
from RCTs, observational 
studies or non-randomised trials 
may be considered. For 
example this criterion will be 
relaxed for the consideration of 
adverse events and long term 
evidence of effectiveness, for 
which observational studies and 
disease registers of sufficiently 
long follow-up and good quality 
may be included 
Exclude: non-randomised 
studies; animal models; 
preclinical and biological 
studies; narrative reviews, 
editorials, opinions; non-English 
language papers; reports 
published as meeting abstracts 
only, where insufficient 
methodological details are 
reported to allow critical 
appraisal of study quality 
 
12.7.2.2.  Exclusion criteria  
Reviews of primary studies will not be included in the analysis, but will be retained for 
discussion and identification of additional trials. Studies which are considered 
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methodologically unsound in terms of either study design or the method used to assess 
outcomes will be excluded from the results. 
The following publication types will also be excluded from the analysis: 
 non-randomised studies  
 animal models 
 preclinical and biological studies 
 narrative reviews, editorials, opinions 
 non-English language papers 
 reports published as meeting abstracts only, where insufficient methodological details 
are reported to allow critical appraisal of study quality. 
12.7.3. Data extraction strategy 
Studies retrieved from the update searches will be selected for inclusion through a two-stage 
process according to the inclusion/exclusion criteria specified in Table 103. First, abstracts 
and titles returned by the search strategy will be screened for inclusion independently by two 
researchers. Disagreements will be resolved by discussion, with involvement of a third 
reviewer when necessary. Full texts of identified studies will be obtained and screened in the 
same way. At each step studies which do not satisfy those criteria; abstract-only studies will 
be included provided sufficient methodological details are reported to allow critical appraisal 
of study quality. Where multiple publications of the same study are identified, data will be 
extracted and reported as a single study. 
In addition, if time and resources permit, studies included in the 2004 review may be re-
abstracted using the data extraction process detailed below. This will facilitate examination 
of sub-groups not examined in detail in the original report. 
Included full papers will be split between two reviewers for the purposes of data extraction 
using a standardised data specification form, and checked independently by another. 
Information extracted and tabulated will include details of the study’s design and 
methodology, baseline characteristics of participants and results including any adverse 
events if reported. Where there is incomplete information on key data, we will attempt to 
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contact the study’s authors to gain further details. Discrepancies will be resolved by 
discussion, with involvement of a third reviewer if necessary. 
Included studies and industry submissions will be analysed to ensure the saturation of 
relevant studies (see Section 12.9 [page 432]). 
12.7.4. Quality assessment strategy 
The methodological quality of each included study will be assessed by one reviewer and 
checked by a second reviewer, using the Cochrane Risk of Bias tool,50or criteria based on 
those proposed by the NHS Centre for Reviews and Dissemination for randomised 
controlled trials (RCTs).132 
12.7.5. Methods of analysis/synthesis 
Data will be tabulated and discussed in a narrative review. If appropriate (i.e. if a number of 
studies which report data relating to a given outcome are comparable in terms of key 
features such as their design, populations, and interventions), meta-analysis will be 
employed to estimate a summary measure of effect on relevant outcomes based on 
intention-to-treat analyses. 
Where appropriate, meta-analysis will be carried out using STATA and/or WinBugs software, 
with the use of fixed- and/or random-effects appropriate to the assembled datasets.  
Heterogeneity will be explored through consideration of the study populations, methods and 
interventions, by visualisation of results and, in statistical terms, by the χ2 test for 
homogeneity and the I2 statistic.   
A network meta-analysis was considered but not thought to be particular relevance to this 
topic.  
We will investigate the likelihood of publication bias using funnel plots if there are sufficient 
included studies. 
If evidence allows, the following subgroups will be considered:  
 iron supplementation given with erythropoiesis-stimulating agents  
 people with any type of cancer receiving platinum-based chemotherapy 
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 people with head and neck malignancies receiving platinum-based chemotherapy 
 women with ovarian cancer  
 women with ovarian cancer receiving platinum-based chemotherapy 
 people unable to receive blood transfusions. 
12.7.6. Publication bias 
If time and resource permit, reporting bias1 in our systematic review and meta-analyses will 
be assessed. We will follow best practice as recommended in the Cochrane Handbook for 
Reviewers, who have dedicated a whole chapter to the avoidance, identification and 
investigation of possible reporting bias.50 This may include researching trials that have only 
ever appeared as conference abstracts in previous reviews. 
12.8. Methods for synthesising evidence of cost-
effectiveness 
12.8.1. Review of economic studies  
This review aims to update the systematic review of cost-effectiveness studies which was 
conducted in 2004 as part of the review of evidence to inform NICE’s earlier guidance on 
these drugs (TA142).34  
A review, using a systematic approach, will be of economic evaluations of erythropoietin 
stimulating agents for the treatment of cancer treatment induced anaemia will be 
undertaken.  Full economic evaluations will be included where they meet the inclusion 
criteria set out for the review of clinical effectiveness (see Section 12.7.2).  Exceptions 
include: (a)non-randomised studies will be included (e.g. decision model based analyses, or 
analyses of patient-level cost and effectiveness data alongside observational studies.); (b) 
full cost-effectiveness analyses, cost-utility analyses, cost-benefit analyses and cost 
consequence analyses will be included. (Economic evaluations which only report average 
cost-effectiveness ratios will only be included if the incremental ratios can be easily 
calculated from the published data); and, (c) standalone cost analyses based in the UK NHS 
will also be sought and appraised.   
                                                            
1 Where the term ‘reporting bias’ covers all types of publication, language, outcome, location etc 
biases defined in the Cochrane Handbook. 
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The sources to be searched will be similar to those in the clinical effectiveness review (see 
Section 12.7.1), and extend to NHS EED and HEED. Searches will be limited to English 
language sources. 
Key included economic evaluations identified in the search will be critically assessed using 
accepted frameworks, such as the consensus-developed list of criteria developed by Evers 
and colleagues121 For included economic evaluations based on decision models, critical 
appraisal of these studies will make use of guidelines for good practice in decision analytic 
modelling in HTA. 
Methods and findings from key included economic evaluations will be summarised in a 
tabular format and synthesised in a narrative review.  Economic evaluations carried out from 
the perspective of the UK NHS and Personal Social Services (PSS) perspective will be 
particularly highlighted. 
12.8.2. Economic modelling  
A new cost-effectiveness analysis will be carried out from the perspective of the UK NHS 
and PSS using a decision analytic model.  The evaluation will be constrained by available 
evidence.  
Model structure will be determined on the basis of available research evidence and clinical 
expert opinion. 
The sources of parameter values that determine the effectiveness of the interventions being 
compared will be obtained from our own systematic review of clinical effectiveness or other 
relevant research literature. Where required parameters are not available from good quality 
published studies in the relevant patient group we may use data from sponsor submissions 
to NICE.  
Resource use will be specified and valued from the perspective of the NHS and PSS. The 
resource use associated with different health states or clinical events will be obtained or 
estimated either from trial data, sponsor submissions, other published sources, or – where 
published sources are unavailable – relevant expert contacts or NHS Trusts.  Unit cost data 
will be identified from national NHS and PSS reference cost databases for the most recent 
year, or, where these are not relevant, will be extracted from published work and/or sponsor 
submissions to NICE. If insufficient data are retrieved from published sources, costs may be 
derived from individual NHS Trusts or groups of Trusts.   
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Analysis of uncertainty will focus on cost utility, assuming cost per QALY can be estimated. 
Uncertainty will be explored through one way sensitivity analysis and, if the data and 
modelling approach permit, probabilistic sensitivity analysis (PSA). The outputs of PSA will 
be presented using plots on the cost-effectiveness plane and cost-effectiveness acceptability 
curves. 
Search strategies for additional information regarding model parameters or topics not 
covered within the clinical effectiveness and cost-effectiveness reviews will be based on the 
methodological discussion paper ‘Methods for establishing parameter values for decision 
analytic models’ commissioned by the UK Dept. of Health and produced by InterTASC 
(January 2005). In addition to systematic reviews and RCTs other UK studies will be 
considered if appropriate. 
ICERs estimated from Consultee models will be compared with the respective ICERs from 
the Assessment Group’s model, and reasons for large discrepancies in estimated ICERs will 
be explored and, where possible, explained. 
12.8.2.1.  Methods for measuring and valuing health effects 
Ideally, the measurement of changes in health-related quality of life (HRQL) should be 
reported directly from patients.  The value of changes in patients’ HRQL (that is, utilities) 
should be based on public preferences using a choice-based method.  The EQ-5D will be 
the preferred measure of HRQL for the purposes of estimating QALYs.  In the absence of 
reliable EQ-5D utility data from relevant trials or patient groups, the use of alternative 
sources for utility weights for health states will be informed by the NICE Guide to the 
methods of technology appraisal (2013).168  
12.8.2.2.  Time horizon, perspective and discounting 
The time horizon of our analysis will be sufficiently long to reflect any differences in costs or 
outcomes between the technologies being compared. 
The perspective will be that of the National Health Services and Personal Social Services.  
Both costs and QALYs will be discounted at 3.5%.168 
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12.9. Handling of information from the companies  
All data submitted by the manufacturers/sponsors will be considered if received by the ERG 
no later than 02/10/2013. Data arriving after this date may not be considered.  
Any economic evaluations included in the company submission will be assessed against 
NICE’s guidance on the Methods of Technology Appraisal and will also be assessed for 
clinical validity, reasonableness of assumptions and appropriateness of the data used.  
Where the TAR team have undertaken further analyses, using models submitted by 
manufacturers/sponsors or via de novo modelling and cost effectiveness analysis, a 
comparison will be made of the alternative models used for the analysis. 
Tabulated summaries and technical commentaries on the economic models used in the 
manufacturer submissions will be provided. This will not be a full critique as for a single 
technology appraisal but will be used to reflect on the results from the PenTAG de novo 
model and to discuss any differences identified in the outcomes provided. 
Any ‘commercial in confidence’ data provided by manufacturers, and specified as such, will 
be ********************************** in the assessment report (followed by company name in 
parentheses). Any ‘academic in confidence’ data provided by manufacturers, and specified 
as such, will be ************************************ in the assessment report. Any confidential 
data used in the cost-effectiveness models will also be highlighted.  
12.10. Expertise in this TAR team 
Name Institution Expertise 
Simon Briscoe PenTAG, University of 
Exeter Medical School 
Information Specialist 
Helen Coelho PenTAG, University of 
Exeter Medical School 
Assessment of publication bias 
Louise 
Crathorne 
PenTAG, University of 
Exeter Medical School 
Systematic reviewing (clinical effectiveness 
review) and project management 
Marcela 
Haasova 
PenTAG, University of 
Exeter Medical School 
Systematic reviewing (clinical effectiveness 
review) 
Martin Hoyle PenTAG, University of 
Exeter Medical School 
Health economics and economic modelling 
(lead) 
Nicola Huxley PenTAG, University of 
Exeter Medical School 
Economic modelling and economic 
evaluation 
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Chris Hyde PenTAG, University of 
Exeter Medical School 
Systematic reviewing and economic 
evaluation. Director of TAR group and 
project guarantor 
Tracey Jones-
Hughes 
PenTAG, University of 
Exeter Medical School 
Lead systematic reviewer (quality of life 
review) 
Linda Long PenTAG, University of 
Exeter Medical School 
Systematic reviewing (quality of life review) 
Ruben Mujica-
Mota 
PenTAG, University of 
Exeter Medical School 
Health Economist 
Mark Napier Royal Devon & Exeter 
Hospital, Devon 
Clinical Medical Oncologist 
Jaime Peters PenTAG, University of 
Exeter Medical School 
Advising re publication bias and mixed 
treatment comparison 
Claudius 
Rudin 
Royal Devon & Exeter 
Hospital, Devon 
Consultant Haematologist 
Kate 
Scatchard 
Royal Devon & Exeter 
Hospital, Devon 
Consultant Oncologist 
Tristan 
Snowsill 
PenTAG, University of 
Exeter Medical School 
Economic modelling and economic 
evaluation 
 
Other external experts:  We are also collaborating with Simon Stanworth of the NHS Blood 
and Transplant Centre (NHSBT), and Julia Bohlius and Thomy Tonia from the Cochrane 
Haematological Malignancies Group. 
Other PenTAG resources: Depending on the agreed scope of work we will draw on other 
PenTAG resources as required. 
12.11. TAR centre 
12.11.1. About PenTAG: 
The Peninsula Technology Assessment Group is part of the University of Exeter Medical 
School.  PenTAG was established in 2000 and carries out independent Health Technology 
Assessments for the UK HTA Programme, systematic reviews and economic analyses for 
the NICE Centre for Public Health Excellence, as well as for other local and national 
decision-makers.  The group is multi-disciplinary and draws on individuals’ backgrounds in 
public health, health services research, computing and decision analysis, systematic 
reviewing, statistics and health economics.  The Institute of Health Research is made up of 
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discrete but methodologically related research groups, among which Health Technology 
Assessment is a strong and recurring theme.   
Health technology assessment projects include: 
 A systematic review and economic evaluation of intraoperative tests (RD-100i OSNA 
system and Metasin test) for detecting sentinel lymph node metastases in breast 
cancer 
 Dasatinib and Nilotinib for the 1st line treatment of chronic phase chronic myeloid 
Leukaemia (CML): a systematic review and economic model 
 Bevacizumab, Cetuximab, and Panitumumab for in colorectal cancer (metastatic) 
after failure of 1st line chemotherapy: a systematic review and economic model 
 The psychological consequences of false positive mammograms: a systematic 
review 
 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet 
stage B or C) in patients for whom fludarabine combination chemotherapy is not 
appropriate: a critique of the submission from Napp 
 The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and 
memantine for the treatment of Alzheimer’s disease (review of TA111): a systematic 
review and economic model 
 Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in 
patients who are refractory to fludarabine and alemtuzumab: a critique of the 
submission from GSK 
 Everolimus for the second-line treatment of advanced and/or metastatic renal cell 
carcinoma: a critique of the submission from Novartis 
 The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal 
stromal tumours: a critique of the submission from Pfizer 
12.12. Competing interests of authors 
None 
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12.13. Timetable/milestones 
Action Expected due date 
Draft protocol due 3 June 2013 
Comments on draft protocol sent to AG 10 June 2013 
Final protocol due 13 June 2013 
Sign-off of final protocol 24 June 2013 
Consultee information meeting 12 August 2013 
Manufacturers submissions due 2 October 2013 
Progress report due 9 October 2013 
Draft assessment report due 10 December 2013 
Comments on draft assessment report 17 December 2013 
Assessment report due 14 January 2014 
1st Appraisal Committee meeting 19 March 2014 
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 Appendix B: Literature search 
strategies 
13.1. Clinical Effectiveness 
Database: MEDLINE(R) 
Host: OVID 
Data Parameters: 1946 to May Week 3 2013 
Date Searched: 24/5/2013 
Searcher: SB 
Hits: 342 
Strategy:   
 
1. (erythropoietin* or EPO).tw. 
2. Erythropoietin/ 
3. Receptors, erythropoietin/ 
4. erythropoiesis.tw. 
5. Erythropoiesis/ 
6. (epoetin adj1 (alfa or beta or theta or zeta)).tw. 
7. darbepoetin.tw. 
8. CERA.tw. 
9. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp).tw. 
10. or/1-9 
11. an?emi?.tw. 
12. exp anemia/ 
13. 11 or 12 
14. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or 
lymphoma* or oncolog* or chemotherap*).tw. 
15. exp neoplasms/ 
16. 14 or 15 
17. (random* or rct* or "controlled trial*" or "clinical trial*").tw. 
18. randomized controlled trial.pt. 
19. 17 or 18 
20. 10 and 13 and 16 and 19 
21. limit 20 to (english language and yr="2004 -Current") 
 
Database: MEDLINE(R) In-Process & Other Non-Indexed Citations 
Host: OVID 
Data Parameters: May 23, 2013 
Date Searched: 24/5/2013 
Searcher: SB 
Hits: 28 
Strategy:   
 
1. (erythropoietin* or EPO).tw. 
2. erythropoiesis.tw. 
3. (epoetin adj1 (alfa or beta or theta or zeta)).tw. 
4. darbepoetin.tw. 
5. CERA.tw. 
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6. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp).tw. 
7. or/1-6 
8. an?emi?.tw. 
9. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or 
lymphoma* or oncolog* or chemotherap*).tw. 
10. (random* or rct* or "controlled trial*" or "clinical trial*").tw. 
11. 7 and 8 and 9 and 10 
12. limit 11 to yr="2004 -Current" 
 
Database: EMBASE  
Host: OVID 
Data Parameters: 1980 to 2013 Week 21 
Date Searched: 29/5/2013 
Searcher: SB 
Hits: 865 
Strategy: 
1. (erythropoietin* or EPO).tw. 
2. Erythropoietin/ 
3. Receptors, erythropoietin/ 
4. recombinant erythropoietin/ 
5. erythropoiesis.tw. 
6. Erythropoiesis/ 
7. (epoetin adj1 (alfa or beta or theta or zeta)).tw. 
8. darbepoetin.tw. 
9. novel erythropoiesis stimulating protein/ 
10. CERA.tw. 
11. continuous erythropoiesis receptor activator/ 
12. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp).tw. 
13. or/1-12 
14. an?emi?.tw. 
15. exp anemia/ 
16. 14 or 15 
17. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or 
lymphoma* or oncolog* or chemotherap*).tw. 
18. exp neoplasms/ 
19. 17 or 18 
20. (random* or rct* or "controlled trial*" or "clinical trial*").tw. 
21. 13 and 16 and 19 and 20 
22. limit 21 to (english language and yr="2004 -Current") 
Database: CENTRAL 
Host: Cochrane Library 
Data Parameters: Issue 4 of 12, April 2013  
Date Searched: 24/5/2013 
Searcher: SB 
Hits: 219 
Strategy:   
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1. (erythropoietin* or EPO):ti or (erythropoietin* or EPO):ab from 2004, in Cochrane 
Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments 
and Economic Evaluations  
2. MeSH descriptor: [Erythropoietin] explode all trees  
3. MeSH descriptor: [Receptors, Erythropoietin] explode all trees  
4. erythropoiesis:ti or erythropoiesis:ab from 2004, in Cochrane Reviews (Reviews and 
Protocols), Other Reviews, Trials, Technology Assessments and Economic 
Evaluations  
5. MeSH descriptor: [Erythropoiesis] explode all trees  
6.  (epoetin near/1 (alfa or beta or theta or zeta)):ti or (epoetin near/1 (alfa or beta or 
theta or zeta)):ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other 
Reviews, Trials, Technology Assessments and Economic Evaluations  
7. darbepoetin:ti or darbepoetin:ab from 2004, in Cochrane Reviews (Reviews and 
Protocols), Other Reviews, Trials, Technology Assessments and Economic 
Evaluations  
8. CERA:ti or CERA:ab from 2004, in Cochrane Reviews (Reviews and Protocols), 
Other Reviews, Trials, Technology Assessments and Economic Evaluations  
9.  (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp):ti or (eprex or erypo or 
HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or 
retacrit or silapo or aranesp):ab from 2004, in Cochrane Reviews (Reviews and 
Protocols), Other Reviews, Trials, Technology Assessments and Economic 
Evaluations  
10. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9   
11. anemi? or anaemi?:ti or anemi? or anaemi?:ab from 2004, in Cochrane Reviews 
(Reviews and Protocols), Other Reviews, Trials, Technology Assessments and 
Economic Evaluations  
12. MeSH descriptor: [Anemia] explode all trees  
13. #11 or #12   
14. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumour* or tumor* or 
myelo* or lymphoma* or oncolog* or chemotherap*):ti or (cancer* or carcinom* or 
leukemia or neoplasm* or malignan* or tumour* or tumor* or myelo* or lymphoma* or 
oncolog* or chemotherap*):ab from 2004, in Cochrane Reviews (Reviews and 
Protocols), Other Reviews, Trials, Technology Assessments and Economic 
Evaluations  
15. MeSH descriptor: [Neoplasms] explode all trees 
16. #14 or #15  
17. #10 and #13 and #16 from 2004, in Cochrane Reviews (Reviews and Protocols), 
Other Reviews, Trials, Technology Assessments and Economic Evaluations 
Database: Web of Science  
Host: Thomson Reuters 
Data Parameters: N/A 
Date Searched: 28/5/2013 
Searcher: SB 
Hits: 745 
Strategy: 
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1. Title=((erythropoietin* or EPO)) OR Topic=((erythropoietin* or EPO)) 
2. Title=(erythropoiesis) OR Topic=(erythropoiesis) 
3. Title=((epoetin near/0 (alfa or beta or theta or zeta))) OR Topic=((epoetin near/0 (alfa 
or beta or theta or zeta))) 
4. Title=(darbepoetin) OR Topic=(darbepoetin) 
5. Title=(CERA) OR Topic=(CERA) 
6. Title=((eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp)) OR Topic=((eprex or erypo 
or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio 
or retacrit or silapo or aranesp)) 
7. #1 OR #2 OR #3 OR #4 OR #5 OR #6 
8. Title=(anemi* OR anaemi*) OR Topic=(anemi* OR anaemi*) 
9. TI=((cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumour* or 
tumor* or myelo* or lymphoma* or oncolog* or chemotherap*)) OR TS=((cancer* or 
carcinom* or leukemia or neoplasm* or malignan* or tumour* or tumor* or myelo* or 
lymphoma* or oncolog* or chemotherap*)) 
10. Title=((random* or rct* or "controlled trial*" or "clinical trial*")) OR Topic=((random* or 
rct* or "controlled trial*" or "clinical trial*")) 
11. #7 AND #8 AND #9 AND #10 Timespan=2004-2013 
Database: CINAHL  
Host: EBSCO 
Data Parameters: N/A 
Date Searched: 29/5/2013 
Searcher: SB 
Hits: 79 
Strategy: 
1. TI(erythropoietin* or EPO) OR AB(erythropoietin* or EPO) 
2. (MH "Erythropoietin")  
3. TI(erythropoiesis) OR AB(erythropoiesis)  
4. (MH "Erythropoiesis")  
5. TI(epoetin n0 (alfa or beta or theta or zeta)) OR AB(epoetin n0 (alfa or beta or theta 
or zeta))  
6. TI(darbepoetin) OR AB(darbepoetin)  
7. TI(CERA) OR AB(CERA)  
8. TI(eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp) OR AB(eprex or erypo or 
HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or 
retacrit or silapo or aranesp)  
9. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8  
10. TI(anemi* or anaemi*) OR AB(anemi* or anaemi*) 
11. (MH "Anemia+")  
12. S10 OR S11  
13. TI(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumor* or tumour* 
or myelo* or lymphoma* or oncolog* or chemotherap*) OR AB(cancer* or carcinom* 
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or leukemia or neoplasm* or malignan* or tumor* or tumour* or myelo* or lymphoma* 
or oncolog* or chemotherap*)  
14. (MH "Neoplasms+")  
15. S13 OR S14  
16. TI(random* or rct* or "controlled trial*" or "clinical trial*") OR AB(random* or rct* or 
"controlled trial*" or "clinical trial*")  
17. PT(randomized controlled trial)  
18. S16 OR S17  
19. S9 AND S12 AND S15 AND S18 
Date limited 2004-current 
Numbers of references retrieved and de-duplicated: clinical effectiveness 
 
Database Hits 
MEDLINE 342 
MEDLINE-in-Process 28 
EMBASE 865 
CENTRAL 219 
Web of Science 745 
CINAHL 79 
Total 2278 
Automatically de-duplicated 845 
Manually de-duplicated 97 
Total records to screen 1,336 
13.2. Cost effectiveness 
Database: MEDLINE(R) 
Host: OVID 
Data Parameters: 1946 to May Week 3 2013 
Date Searched: 29/5/2013 
Searcher: SB 
Hits: 144 
Strategy:  
 
Lines 1-16: see MEDLINE clinical effectiveness strategy 
17.  (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua 
or "health utilit*" or "value for money").tw. 
18. (fiscal or funding or financial or finance* or expenditure* or budget*).tw. 
19. ("resource* alloca*" or "resource* use").tw. 
20. exp Economics/ 
21. exp models, economic/ 
22. exp "Costs and Cost Analysis"/ 
23. Cost of illness/ 
24. ec.fs. 
25. (decision adj2 (model* or tree* or analy*)).tw. 
26. markov.tw. 
27. decision trees/ 
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28. or/17-27 
29. 10 and 13 and 16 and 28 
30. limit 29 to (english language and yr="2004 -Current")  
 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 
Host: OVID 
Data Parameters: May 28, 2013 
Date Searched: 29/5/2013 
Searcher: SB 
Hits: 13 
Strategy:  
 
Lines 1-9: see MEDLINE-in-Process clinical effectiveness strategy 
10. (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua 
or "health utilit*" or "value for money").tw. 
11. (fiscal or funding or financial or finance* or expenditure* or budget*).tw. 
12. ("resource* alloca*" or "resource* use").tw. 
13. (decision adj2 (model* or tree* or analy*)).tw. 
14. markov.tw. 
15. or/10-14 
16. 7 and 8 and 9 and 15  
17. limit 16 to yr="2004 -Current" 
 
Database: EMBASE 
Host: OVID 
Data Parameters: 1980 to 2013 Week 21 
Date Searched: 29/5/2013 
Searcher: SB 
Hits: 677 
Strategy:  
 
Lines 1-19: see EMBASE clinical effectiveness strategy 
20.  (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua 
or "health utilit*" or "value for money").tw. 
21. (fiscal or funding or financial or finance* or expenditure* or budget*).tw. 
22. ("resource* alloca*" or "resource* use").tw. 
23. exp Economics/ 
24. models, economic/ 
25. exp health economics/ 
26. exp "Costs and Cost Analysis"/ 
27. Cost of illness/ 
28. resource allocation/ 
29. pe.fs. 
30. (decision adj2 (model* or tree* or analy*)).tw. 
31. markov.tw. 
32. decision trees/ 
33. or/20-32 
34. 13 and 16 and 19 and 33 
35. limit 34 to (english language and yr="2004 -Current") 
 
Database: NHS EED 
Host: Cochrane Library 
Data Parameters: Issue 2 of 4, April 2013 
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Date Searched: 24/5/2013 
Searcher: SB 
Hits: 10 
Strategy: See CENTRAL clinical effectiveness strategy 
 
Database: Web of Science  
Host: Thomson Reuters 
Data Parameters: N/A 
Date Searched: 29/5/2013 
Searcher: SB 
Hits: 173 
Strategy: 
 
Lines 1-9: see Web of Science clinical effectiveness strategy 
10. TI=((pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or 
cua or "health utilit*" or "value for money")) OR TS=((pharmacoeconomic* or 
economic* or price* or pricing* or cost* or cba or cea or cua or "health utilit*" or 
"value for money")) 
11. Title=((fiscal or funding or financial or finance* or expenditure* or budget*)) OR 
Topic=((fiscal or funding or financial or finance* or expenditure* or budget*)) 
12. Title=(("resource* alloca*" or "resource* use")) OR Topic=(("resource* alloca*" or 
"resource* use")) 
13. Title=((decision near/1 (model* or tree* or analy*))) OR Topic=((decision near/1 
(model* or tree* or analy*))) 
14. Title=(markov) OR Topic=(markov) 
15. #14 OR #13 OR #12 OR #11 OR #10 
16. #15 AND #9 AND #8 AND #7 Timespan=2004-2013 
 
Database: CINAHL  
Host: EBSCO 
Data Parameters: N/A 
Date Searched: 29/5/2013 
Searcher: SB 
Hits: 81 
Strategy:  
Lines 1-15: see CINAHL clinical effectiveness strategy 
16. TI(pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or 
cua or "health utilit*" or "value for money") OR AB(pharmacoeconomic* or economic* 
or price* or pricing* or cost* or cba or cea or cua or "health utilit*" or "value for 
money")  
17. TI(fiscal or funding or financial or finance* or expenditure* or budget*) OR AB(fiscal 
or funding or financial or finance* or expenditure* or budget*)  
18. TI("resource* alloca*" or "resource* use") OR AB("resource* alloca*" or "resource* 
use")  
19. (MH "Economics+")  
20. TI(decision n1 (model* or tree* or analy*)) OR AB(decision n1 (model* or tree* or 
analy*))  
21. TI(markov) OR AB(markov)  
22. (MH "Decision Trees")  
23. S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22  
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24. S9 AND S12 AND S15 AND S23 
Date limited 2004-current 
 
Database: HEED  
Host: Cochrane Library 
Data Parameters: N/A 
Date Searched: 29/5/2013 
Searcher: SB 
Hits: 33 
Strategy: 
1. TI=(erythropoietin* or EPO) 
2. TI=erythropoiesis 
3. TI=(epoetin alfa or epoetin beta or epoetin theta or epoetin zeta) 
4. TI=darbepoetin 
5. TI=CERA 
6. TI=(eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp) 
7. AB=(erythropoietin* or EPO) 
8. AB=erythropoiesis 
9. AB=(epoetin alfa or epoetin beta or epoetin theta or epoetin zeta) 
10. AB=darbepoetin 
11. AB=CERA 
12. AB=(eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp) 
13. CS=(1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12) 
14. TI=(anaemi* or anemi*) 
15. AB=(anaemi* or anemi*) 
16. CS=(14 or 15) 
17. TI=(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumor* or 
tumour* or myelo* or lymphoma* or oncolog* or chemotherap*) 
18. AB=(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumor* or 
tumour* or myelo* or lymphoma* or oncolog* or chemotherap*) 
19. CS=(17 or 18) 
20. CS=(13 and 16 and 19) 
 
Numbers of references retrieved and de-duplicated: cost effectiveness 
 
Database Hits 
MEDLINE 144 
MEDLINE-in-Process 13 
EMBASE 677 
NHS EED 10 
Web of Science 173 
CINAHL 81 
HEED 33 
Total 1131 
Automatically de-duplicated 279 
Manually de-duplicated 38 
Total records to screen 814 
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13.3. Quality of Life 
Database: MEDLINE(R) 
Host: OVID 
Data Parameters: 1946 to May Week 4 2013 
Date Searched: 30/5/2013 
Searcher: SB 
Hits: 369 
Strategy: 
 
Lines 1-16: see MEDLINE clinical effectiveness strategy 
17. ("quality of life" or QoL or HRQL or HRQoL).tw. 
18. quality of life/ 
19. ("quality adjusted life year*" or QALY*).tw. 
20. quality-adjusted life years/ 
21. "activities of daily living".tw. 
22. activities of daily living/ 
23. ("quality of wellbeing" or QWB or "QWB SA").tw. 
24. ("health* year* equivalent*" or HYE*).tw. 
25. "health status".tw. 
26. health status/ 
27. health status indicators/ 
28. Psychometrics/ 
29. psychometric*.tw. 
30. ("short form 36" or "SF-36" or SF36).tw. 
31. ("short form 20" or "SF-20" or SF20).tw. 
32. ("short form 12" or "SF-12" or SF12).tw. 
33. ("short form 8" or "SF-8" or SF8).tw. 
34. (Euroqol or "EQ-5D").tw. 
35. exp Questionnaires/ 
36. or/17-35 
37. 10 and 13 and 16 and 36 
38. limit 37 to (english language and yr="2004 -Current") 
 
Database: MEDLINE(R) In-Process & Other Non-Indexed Citations 
Host: OVID 
Data Parameters: May 29, 2013 
Date Searched: 30/5/2013 
Searcher: SB 
Hits: 19 
Strategy: 
 
Lines 1-9: see MEDLINE-in-Process clinical effectiveness strategy 
10. ("quality of life" or QoL or HRQL or HRQoL).tw. 
11. ("quality adjusted life year*" or QALY*).tw. 
12. "activities of daily living".tw. 
13. ("quality of wellbeing" or QWB or "QWB SA").tw. 
14. ("health* year* equivalent*" or HYE*).tw. 
15. "health status".tw. 
16. psychometric*.tw. 
17. ("short form 36" or "SF-36" or SF36).tw. 
18. ("short form 20" or "SF-20" or SF20).tw. 
19. ("short form 12" or "SF-12" or SF12).tw. 
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20. ("short form 8" or "SF-8" or SF8).tw. 
21. (Euroqol or "EQ-5D").tw. 
22. or/10-21 
23. 7 and 8 and 9 and 22 
24. limit 23 to yr="2004 -Current" 
 
Database: EMBASE 
Host: OVID 
Data Parameters: 1980 to 2013 Week 21 
Date Searched: 30/5/2013 
Searcher: SB 
Hits: 952 
Strategy: 
 
Lines 1-19: see EMBASE clinical effectiveness strategy 
20. ("quality of life" or QoL or HRQL or HRQoL).tw. 
21. exp quality of life/ 
22. ("quality adjusted life year*" or QALY*).tw. 
23. "activities of daily living".tw. 
24. daily life activity/ 
25. ("quality of wellbeing" or QWB or "QWB SA").tw. 
26. ("health* year* equivalent*" or HYE*).tw. 
27. "health status".tw. 
28. health status/ 
29. health status indicators/ 
30. psychometric*.tw. 
31. psychometry/ 
32. ("short form 36" or "SF-36" or SF36).tw. 
33. ("short form 20" or "SF-20" or SF20).tw. 
34. ("short form 12" or "SF-12" or SF12).tw. 
35. ("short form 8" or "SF-8" or SF8).tw. 
36. exp questionnaire/ 
37. or/20-36 
38. 13 and 16 and 19 and 37 
39. limit 38 to (english language and yr="2004 -Current") 
 
Database: Web of Science  
Host: Thomson Reuters 
Data Parameters: N/A 
Date Searched: 30/5/2013 
Searcher: SB 
Hits: 646 
Strategy: 
Lines 1-9: see Web of Science clinical effectiveness strategy 
10. Title=(("quality of life" or QoL or HRQL or HRQoL)) OR Topic=(("quality of life" or 
QoL or HRQL or HRQoL)) 
11. Title=(("quality adjusted life year*" or QALY*)) OR Topic=(("quality adjusted life year*" 
or QALY*)) 
12. Title=("activities of daily living") OR Topic=("activities of daily living") 
13. Title=(("quality of wellbeing" or QWB or "QWB SA")) OR Topic=(("quality of 
wellbeing" or QWB or "QWB SA")) 
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14. Title=(("health* year* equivalent*" or HYE*)) OR Topic=(("health* year* equivalent*" 
or HYE*)) 
15. Title=("health status") OR Topic=("health status") 
16. Title=(psychometric*) OR Topic=(psychometric*) 
17. Title=(("short form 20" or "SF-20" or SF20)) OR Topic=(("short form 20" or "SF-20" or 
SF20)) 
18. Title=(("short form 12" or "SF-12" or SF12)) OR Topic=(("short form 12" or "SF-12" or 
SF12)) 
19. Title=(("short form 8" or "SF-8" or SF8)) OR Topic=(("short form 8" or "SF-8" or SF8)) 
20. Title=((Euroqol or "EQ-5D")) OR Topic=((Euroqol or "EQ-5D")) 
21. #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR 
#10 
22. #21 AND #9 AND #8 AND #7 Timespan=2004-2013 
 
Database: CINAHL  
Host: EBSCO 
Data Parameters: N/A 
Date Searched: 30/5/2013 
Searcher: SB 
Hits: 111 
Strategy: 
Lines 1-15: see CINAHL clinical effectiveness strategy 
16. TI("quality of life" or QoL or HRQL or HRQoL) OR AB("quality of life" or QoL or HRQL 
or HRQoL)  
17. (MH "Quality of Life+")  
18. TI("quality adjusted life year*" or QALY*) OR AB("quality adjusted life year*" or 
QALY*)  
19. (MH "Quality-Adjusted Life Years")  
20. TI("activities of daily living") OR AB("activities of daily living")  
21. (MH "Activities of Daily Living+")  
22. TI("quality of wellbeing" or QWB or "QWB SA") OR AB("quality of wellbeing" or QWB 
or "QWB SA")  
23. TI("health* year* equivalent*" or HYE*) OR AB("health* year* equivalent*" or HYE*)  
24. TI("health status") OR AB("health status")  
25. (MH "Health Status+")  
26. (MH "Health Status Indicators")  
27. TI(psychometric*) OR AB(psychometric*)  
28. (MH "Psychometrics")  
29. TI("short form 36" or "SF-36" or SF36) OR AB("short form 36" or "SF-36" or SF36)  
30. TI("short form 20" or "SF-20" or SF20) OR AB("short form 20" or "SF-20" or SF20)  
31. TI("short form 12" or "SF-12" or SF12) OR AB("short form 12" or "SF-12" or SF12)  
32. TI("short form 8" or "SF-8" or SF8) OR AB("short form 8" or "SF-8" or SF8)  
33. TI(Euroqol or "EQ-5D") OR AB(Euroqol or "EQ-5D")  
34. (MH "Questionnaires+")  
35. S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 
OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34  
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36. S9 AND S12 AND S15 AND S35 
Date limited 2004-current 
 
Database: BNI  
Host: ProQuest 
Data Parameters: N/A 
Date Searched: 31/5/2013 
Searcher: SB 
Hits: 43 
Strategy: 
(TI,AB((erythropoietin* or EPO or erythropoiesis) OR (epoetin near/1 (alfa or beta or theta or 
zeta)) OR (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp))) AND (TI,AB(anaemi* or anemi*)) 
AND (TI,AB(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or 
myelo* or lymphoma* or oncolog* or chemotherap*)) 
 
Date limited 2004-current 
 
Numbers of references retrieved and de-duplicated: quality of life  
 
Database Hits 
MEDLINE 369 
MEDLINE-in-Process 19 
EMBASE 952 
Web of Science 646 
CINAHL 111 
BNI 43 
Total 2140 
Automatically de-duplicated 805 
Manually de-duplicated 67 
Total records to screen 1268 
 
13.4. Update searches 
Numbers of references retrieved and de-duplicated 
All update searches were run on 2nd December 2013 and date limited from 1st January 2013 
– 2nd December 2013. 
Clinical effectiveness 
 
Database Hits 
MEDLINE 11 
MEDLINE-in-Process 8 
EMBASE 44 
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CENTRAL 2 
Web of Science 32 
CINAHL 1 
Total 98 
Automatically de-duplicated 30 
Manually de-duplicated 0 
Total records to screen 68 
 
Cost effectiveness 
 
Database Hits 
MEDLINE 8 
MEDLINE-in-Process 5 
EMBASE 47 
NHS EED 2 
Web of Science 11 
CINAHL 0 
HEED 0 
Total 73 
Automatically de-duplicated 17 
Manually de-duplicated 5 
Total records to screen 51 
 
Quality of Life 
 
Database Hits 
MEDLINE 9 
MEDLINE-in-Process 8 
EMBASE 46 
Web of Science 25 
CINAHL 0 
BNI 0 
Total 88 
Automatically de-duplicated 24 
Manually de-duplicated 3 
Total records to screen 61 
 
13.5. Supplementary searches (1): reviews and reports 
Database: CDSR, DARE and HTA 
Host: Cochrane Library 
Data Parameters: CDSR: Issue 4 of 12, April 2013; DARE and HTA: Issue 2 of 4 Apr 2013  
Date Searched: 24/5/2013 
Searcher: SB 
Hits: CDSR=8; DARE=16; HTA=6 
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Strategy: See CENTRAL clinical effectiveness strategy 
 
Database: HMIC 
Host: OVID 
Data Parameters: 1979 to March 2013 
Date Searched: 30/5/2013 
Searcher: SB 
Hits: 2 
Strategy:  
 
1. (erythropoietin* or EPO).tw. 
2. erythropoiesis.tw. 
3. (epoetin adj1 (alfa or beta or theta or zeta)).tw. 
4. darbepoetin.tw. 
5. CERA.tw. 
6. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or 
neorecormon or eporatio or retacrit or silapo or aranesp).tw. 
7. or/1-6 
8. an?emi?.tw. 
9. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or 
lymphoma* or oncolog* or chemotherap*).tw. 
10. 7 and 8 and 9 
11. limit 10 to yr="2004 -Current" 
 
Numbers of references retrieved and de-duplicated: reviews and reports 
 
Database Hits 
CDSR 8 
DARE 16 
HTA 6 
HMIC 2 
Total 32 
Manually de-duplicated 3 
Total records to screen 29 
 
13.6. Supplementary searches (2): Hb level 
The references for these two searches were not de-duplicated because they were only 
searched in MEDLINE and each search was sent to the review team as a separate Endnote 
file. 
 
Hb level over time after stopping chemotherapy 
 
Database: MEDLINE(R) 
Host: Ovid 
Data Parameters: 1946 to September Week 1 2013  
Date Searched: 17/9/2013 
Searcher: SB 
Hits: 159 
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Strategy:   
 
1. (haemoglobin* or hemoglobin*).tw. 
2. exp Hemoglobins/ 
3. (hgb or hb).tw. 
4. or/1-3 
5. ((post or after* or subsequent* or following) adj5 chemo*).tw. 
6. postchemo*.tw. 
7. or/5-6 
8. an?emi?.tw. 
9. exp anemia/ 
10. or/8-9 
11. 4 and 7 and 10 
 
Utilities as a function of Hb level 
 
Database: MEDLINE(R) 
Host: Ovid 
Data Parameters: 1946 to September Week 1 2013  
Date Searched: 18/9/2013 
Searcher: SB 
Hits: 258 
Strategy:   
 
1. (haemoglobin* or hemoglobin*).tw. 
2. exp hemoglobins/ 
3. (hgb or hb).tw. 
4. or/1-3 
5. an?emi?.tw. 
6. exp anemia/ 
7. or/5-6 
8. (utility or utilities or "EQ-5D" or "SF-6D" or "EORTC-QLQ-C30" or HUI2 or "time 
trade-off" or TTO or "standard gamble" or SG or "quality-adjusted life year*" or 
QALY? or "discrete choice" or "stated preference").tw. 
9. Quality-Adjusted Life Years/ 
10. 8 or 9 
11. 4 and 7 and 10 
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 Appendix C: Application of license in included studies 
Study, year n Arms Malignancy Treatment Initial treatment 
Start Hb 
level 
Target Hb 
level Dose adjustment 
Licence details 
Epoetin Alfa 
Epoetin Betaa 
Initial treatment:     150 IU/kg SC TIW or 450 IU/kg SC QW  
Start Hb level:         Hb ≤10 g/dl 
Target HB level:     10−12 g/dl 
Dose adjustment:  4 wks: Hb increase <1 g/dl and reticulocyte increase ≥ 40 000 cells/µl: 300 IU/kg Q3W or 900 IU/kg QW 
                                Hb increase ≥2 g/dl Hb: reduce dose 25-50% 
                                Hb ≥12 g/dl: reduce dose 25-50% 
                                Hb ≥13 g/dl: stop & re-initiate at Hb 12 g/dl at 25% lower dose 
Abdelrazik, 
2007b 
60 Epoetin 
alfa 
vs 
Standard 
Haem  Chemo: NR 450 IU/kg 
QW 
<10.5 g/dl 11−13 g/dl From Wk 5: dose increased in 50% if Hb ≤11.5 g/dl; if 
transfusion was needed; if ≤ 1 g/dl increase.  
Hb >15 g/dl or rapid increase (>1.3 g/dl in any 2 wks 
period): decrease dose by 50%. 
If Hb >16 g/dl dose withheld until Hb <12 g/dl or in the 
event of complications (deep vein thrombosis, 
hypertension, flushing). 
Abels,  
1993 
413c Epoetin 
alfa 
vs Placebo 
Solid & haem Chemo: 
mixed 
150 IU/kg 
TIW 
≤10.5 g/l or 
haematocrit  
≤32%  
NR No dose escalation used.  
Dosing continued for 12 wks; if haematocrit ≥ 38% 
withheld until haematocrit fell below 38%. 
Aravantinos,  
2003 
47 Epoetin 
alfa 
vs 
Standard 
Solid Chemo: 
mixed 
150 IU/kg 
TIW 
<10.5 g/dl NR No dose escalation used.  
Hb >14 g/dl: stop & re-initiate Hb <12.5 g/dl at 25% lower 
than start dose. 
Boogaerts,  
2003 
262 Epoetin 
beta 
vs 
Standard 
Solid & haem Chemo: NR 150 IU/kg 
TIW 
≤11 g/dl 12-14 g/dl 3-4 wks Hb increase <0.5 g/dl Hb, or Hb increase <1 g/dl 
Hb at 6- wks: dose doubled. 
Hb increase >2 g/dl: dose reduced by 50%. 
Hb > 14 g/dl: stop & re-initiate at Hb <12 g/dl at 50% lower 
than start dose. 
Dammacco,  
2001 
145 Epoetin 
alfa 
Haem Chemo: 
mixed 
150 IU/kg 
TIW 
<11 g/dl 12-14 g/dl 4 wks Hb increase <1 g/dl: dose doubled. 
4 wks Hb increase ≥2 g/dl: dose reduced by 25%. 
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Study, year n Arms Malignancy Treatment Initial treatment 
Start Hb 
level 
Target Hb 
level Dose adjustment 
vs Placebo Hb >14 g/dl stop & re-initiate at Hb ≤12 g/dl at 25% lower 
than start dose. 
Del Mastro,  
1999 
62 rHuEPOd 
vs 
Standard 
Solid (breast) Chemo: non-
plat 
150 IU/kg 
TIW 
≤12 g/dl NR If Hb >15.0 g/dl in 2 consecutive weekly assays, treatment 
stopped until Hb <13.0 g/dl. 
Dunphy,  
1999 
30 rHuEPOd 
vs 
Standard 
Solid (head & 
neck, lung) 
Chemo: 
mixed 
150 IU/kg 
TIW 
NR; note 
rHuEPO 
was 
initiated if 
Hb≤16g/dl  
NR 1st course of chemo: Hb increase <1 g/dl: dose doubled. 
2nd course of chemo: Hb increase <1 g/dl: dose increased 
to 450 IU/kg. 
Hb ≥18 g/dl stop & re-initiate at Hb ≤16 g/dl. 
Grote, 
2005 
224 Epoetin 
alfa 
vs Placebo 
Solid (SCLC) Chemo: 
mixed 
150 IU/kg 
TIW 
≤14.5 g/dl 14-16 g/dl Dose escalation not permitted.
Hb >16 g/dl: stop & re-initiate at Hb <14 g/dl at 50% lower 
dose. 
Kurz,  
1997 
35 Epoetin 
alfa 
vs Placebo 
Solid (cervix, 
ovary, uterus) 
Chemo: 
mixed 
150 IU/kg 
TIW 
<11 g/dl NR 4 wks Hb increase <1 g/dl: dose doubled. 
Littlewood,  
2001 
375 Epoetin 
alfa 
vs Placebo 
Mixed Chemo: non-
plat 
150 IU/kg 
TIW 
≤10.5g/dl, 
or >10 and 
≤ 12g/dl 
with ≥1.5 
g/dl 
decrease 
in Hb 
per/cycle, 
per/month  
12-15 g/dl 4 wks Hb increase <1 g/dl and reticulocyte count increase 
<40 000 cells/µl: dose was doubled to 300 IU/kg 
4 wks Hb increase ≥2 g/dl: reduce dose by 25%.  
If Hb >15 g/dl: stop & re-initiate at Hb <12 g/dl at 25% 
lower dose. 
Moebus,  
2013 
643 Epoetin 
alfa  
vs 
Standard 
Solid (breast) Chemo: non-
plat 
150 IU/kg 
TIW 
NR 12.5−13 g/dl 4 wks Hb increase <2 g/dl: dose doubled. 
If Hb >14 g/dl: stop & re-initiate at Hb <13 g/dl. 
Osterborg,  
2002, 2005 
349 Epoetin 
beta vs 
Haem Chemo: non-
plat 
150 IU/kg 
TIW 
<10g/dl e 13-14 g/dl 4 wks Hb increase <0.5 g/dl : dose doubled. 
4 wks Hb <8.5 g/dl or transfusion: dose doubled. 
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Study, year n Arms Malignancy Treatment Initial treatment 
Start Hb 
level 
Target Hb 
level Dose adjustment 
Placebo 4 wks Hb increase >2 g/dl: reduce dose by 50%.  
If Hb >14 g/dl: stop & re-initiate at Hb ≤13 g/dl at 50%. 
Ray-Coquard,  
2009 
218 Epoetin 
alfa 
vs 
Standard 
Mixed Chemo: NR 150 IU/kg 
TIW 
<12 g/dl 12-14 g/dl 4 wks Hb increase <1 g/dl and Hb <10.5 and reticulocyte 
count <40 000 cells/µl: dose increased to 60 000 UI 
weekly. 
4 wks Hb increase ≥2 g/dl: reduce dose by 25%. 
If Hb >12 g/dl: stop & re-initiate at ≤12 g/dl  
Silvestris,  
1995 
54 Epoetin 
alfa 
vs 
Standard 
Haem Chemo: NR 150 IU/kg 
TIW 
≤8 g/dl NR By 6th week: dose doubled 
Strauss,  
2008  
74 Epoetin 
beta 
vs 
Standard 
Solid  
(cervix) 
Chemo + 
Radio 
150 IU/kg 
TIW 
9−13 g/dl 14-15 g/dl 4 wks Hb increase <0.5 g/dl: dose doubled. 
4 wks Hb increase >2 g/dl: reduce dose by 50%.  
If Hb >15 g/dl: stop & re-initiate at ≤14 g/dl at 50%. 
If Hb <8.5 g/dl: dose doubled. 
Ten Bokkel,  
1998 122 
Epoetin 
beta 
vs 
Standard 
Solid (ovary) Chemo: plat 150 IU/kg 
TIW 
<13 g/dl 14-15 g/dl 4 wks Hb increase ≥2 g/dl: reduce dose by 50%. 
Hb >15 g/dl: stop & re-initiate at Hb ≤14 g/dl at 50% dose.  
Epo withheld while platelet counts were < 20 000µg/l. 
Thatcher,  
1999 130 
Epoetin 
alfa 
vs 
Standard 
Solid (SCLC) Chemo: plat 150 IU/kg 
TIW 
≥10.5 g/dl ≥10 g/dl Hb >15 g/dl: stop & re-initiate at Hb ≤13 g/dl at 50% dose.  
 
Licence details 
Epoetin Theta 
Dose: 20 000 IU QW 
Start Hb level: ≤10 g/dl 
Target HB level: 10−12 g/dl 
Dose adjustment:  4 wks Hb increase <1 g/dl dose is doubled; increase to 60 000 IU if Hb increase insufficient at 8 wks 
                               Hb >12 g/dl: should be avoided 
                               12 wks Hb increase <1 g/dl: discontinue. 
Tjulandin, 
2010  
223 Epetin 
theta, 
Solid Chemo: plat Epoetin 
theta: 
≤11 g/dl NR 4 wks Hb increase <1 g/dl: dose doubled; further 
increase to 60 000 IU if no response at 8 wks. 
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Study, year n Arms Malignancy Treatment Initial treatment 
Start Hb 
level 
Target Hb 
level Dose adjustment 
Epoetin 
beta 
vs Placebo 
20 000 IU 
QW 
 
4 wks Hb increase >2 g/dl: reduce dose by 50%.  
Hb >13 g/dl: stop or reduce dose by 50%. 
Epoetin 
Beta: 
150 IU/kg 
Q3W 
≤11 g/dl NR 4 wks Hb increase <1 g/dl: dose doubled; no further 
increase allowed. 
4 wks Hb increase >2 g/dl: dose reduced by 50%.  
Hb >13 g/dl: stop or reduce dose by 50%. 
Tjulandin,  
2011 
186 Epoetin 
theta 
vs Placebo 
Mixed Chemo: non-
plat 
20 000 IU 
QW 
 
≤11 g/dl NR 4 wks Hb increase <1 g/dl: dose doubled; further 
increase to 60 000 IU if no response at 8 wks. 
4 wks Hb increase >2 g/dl: reduce dose by 50%.  
Hb >13 g/dl: stop or reduce dose by 50%. 
Licence details 
Darbepoetin Alfa 
Dose: 2.25 µg/kg SC QW; 500 µg (6.75 µg/kg) SC Q3W 
Start Hb level: Hb ≤10 g/dl 
Target HB level:10−12 g/dl 
Dose adjustment: 4 wks <1 g/dl Hb inc. dose doubled 
                               4 wks ≥2 g/dl Hb reduce dose 25-50% 
                               Dose adj Hb ≥12 g/dl: reduce dose 25-50% 
                               Dose adj Hb ≥13 g/dl: stop & re-initiate at Hb 12 g/dl at 25% lower dose 
Hedenus,  
2002 
33e Darb alfa 
vs Placebo 
Haem Chemo: NR 2.25 µg/kg 
QW 
≤11 g/dl NR 4 wks Hb increase ≥2 g/dl: 50% dose reduction. 
If Hb >15.0 g/dl (men) or >14.0 g/dl (women): stop & re-
initiate at Hb ≤13.0 g/dl dose reinitiated at 50%. 
Hedenus,  
2003 
349 Darb alfa 
vs Placebo 
Haem Chemo: NR 2.25 µg/kg 
QW 
≤11 g/dl 13-14 g/dl 4 wks Hb increase ≤1 g/dl: dose doubled. 
If Hb >15.0 g/dl (men) or >14.0 g/dl (women): stop & re-
initiate at Hb ≤13.0 g/dl at 50% dose. 
Kotasek,  
2003 
249 Darb alfa 
vs Placebo 
Solid Chemo: NR 6.75  µg/kg 
Q3W 
≤11 g/dl 13-14 g/dl 
(women), 13-
15 g/dl (men) 
Dose increase not allowed. 
If Hb >15.0 g/dl (men) or >14.0 g/dl (women): stop & re-
initiate at Hb ≤13.0 g/dl at 50% dose. 
Untch,  
2011 
733 Darb alfa 
vs 
Standard 
Solid (breast) Chemo: non-
plat 
4.5 µg/kg 
(ev. 2 wks) 
f 
NR 12.5−13 g/dl 4 wks Hb increase <1 g/dl: dose doubled.  
If Hb >14.0 g/d: stop & re-initiate at Hb ≤13.0 g/dl at 50% 
dose. 
Vansteenkiste 314 Darb alfa Solid (lung) Chemo: plat 2.25 µg/kg ≤11 g/dl 13-14 g/dl 6 wks Hb increase <1 g/dl: dose doubled.  
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Study, year n Arms Malignancy Treatment Initial treatment 
Start Hb 
level 
Target Hb 
level Dose adjustment 
,  
2002 
vs Placebo QW (women), 13-
15 g/dl (men) 
If Hb >15.0 g/dl (men) or >14.0 g/dl (women): stop & re-
initiate at Hb ≤13.0 g/dl at 50% dose. 
Key: ; Darb, darbepoetin; Hb, haemoglobin;  NR, not reported ; IU, international units; QW, once weekly; Q3W, once every three weeks; RBCT, plat, platinum-based chemotherapy ; red blood cell 
transfusion; SC, subcutaneous; TIW,  thrice weekly;  
Notes: (a) Dose increase to 300IU/kg SC TIW (b) Intervention evaluated in paediatric population (c) Study population included patients not receiving chemotherapy (n=124); beyond the scope for 
the current review; (d) Assumed to epoetin alfa or epoetin beta based on date of study and dose administered (e) >9 to <10g/dl (if serum epo ≤100IU/L); >8 to ≤9 g/dl (if serum epo ≤180 IU/L; or, ≤8 
g/dl (if serum epo 300 IU/L); (f) dose correct but frequency given not. Highlighted text = following licence. (unclear whether dose reduced).  
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 Appendix D: Data extraction forms 
15.1. Clinical effectiveness and health-related quality of life 
review: Data extraction forms (primary studies) 
Endnote Ref ID 
 
2706 Malignancy type Anaemic cancer (primary myeloid 
malignancies and acute leukaemias 
excluded) 
Treatment r-HuEPO (Amgen; assumed epo alfa) 
STUDY DESIGN PARTICIPANTS 
Author, year Abels 1993 N  413: Three populations: Cyclic  
non-cisplatin chemotherapy 
(n=157) and cyclic cisplatin-
chemotherapy (n= 132) and no 
chemo (n=124) vs Placebo 
(n=200)* 
Objective to examine the safety of r-
HuEPO treatment, and its 
impact on haematocrit, 
transfusion requirements 
and quality of life 
Inclusion criteria: 
 >18 years of age  
 biopsy-proven diagnosis of cancer (with 
primary myeloid malignancies and acute 
leukaemias excluded). 
 Anaemia: haematocrit of ≤32% or a 
haemoglobin ≤10.5 g/l 
 ECOG ≤3 
 Life expectancy ≥3 months 
 cyclic cisplatin an d non-cisplatin  
chemotherapy was to be administered <5 
days every 3-4 weeks 
 
Exclusion  criteria:  
 Known cerebral metastases  
 uncontrolled hypertension 
 acute illness within 7 days of study entry 
 radiation or surgery within 30 days of 
study entry 
 experimental therapy within 30 days of 
study entry 
 androgen therapy within 2 months of 
study entry 
 evidence of renal insufficiency (i.e. serum 
creatinine >_2 mg/dl), 
 evidence of folate 
 B12 and/or iron deficiency 
 Autoimmune haemolysis or presence of 
gastrointestinal bleeding 
# centres NR 
Other references/aliases Abels 1996; Henry 1994; 
Henry 1995; Case 1993; 
see notes for more details.
 
Geographical setting NR 
Duration of treatment 12 weeks 
Length of follow-up (if 
different) 
After completion of 
double-blind therapy, 
patients were 
eligible to receive r-
HuEPO on an open-label 
basis 
Henry 1994 provides 
results for the first 6 
month of EPO therapy 
(combined double-blind 
and open-label data: the 
mean duration of epo 
therapy was 17.1, 18.2 
and 15.8 weeks for no 
chemo, no-cisplatin and 
cisplatin chemotherapy 
respectively. 
Country of corresponding 
author 
USA 
Language of publication English 
Sources of funding NR 
PenTAG   CONFIDENTIAL 
457 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
RANDOMISATION & 
ALLOCATION 
Series of double-blind, placebo-controlled trials: three populations of anemic 
cancer patients were randomized to rHuEPO or placebo. The three 
populations were: A) patients not receiving concomitant chemotherapy, B) 
patients receiving chemotherapeutic regimens which did not contain cisplatin, 
and C) patients receiving chemotherapeutic regimens which contained 
cisplatin. 
TREATMENT ARMS 
ARM Drug name/s Epo Placebo 
N 206 (efficacy population) 190 (efficacy population) 
Dose & freq (od, bd etc) 150 U/kg 3 times a week 150 U/kg 3 times a week 
Dose adjustment Y/N Y  
Route of administration subcutaneously subcutaneously 
Duration of epo tx   
Adj anaemia treatment NR NR 
Transfusion trigger NR NR 
OUTCOMES 
Primary 
outcome  Other outcomes 
RBCT (number of units of blood transfused per 
patient and the proportion of patients transfused 
requirements); haemR (haematocrit: change 
from baseline, mean weekly haematocrit,# 
correctors and responders** neutrophil 
analyses; platelet analyses; HRQL (100 mm 
VAS: energy level, ability to perform daily 
activities and overall quality of life) 
NOTES: 
Other analyses included the determination of whether tumour type (haematological vs. non-haematological) 
or tumour in filtration of the bone marrow influenced the response to therapy 
* Prior to study completion, a decision was made to pool data within each study type (according to type of 
cancer treatment). Thus, data in each category were pooled and reported as a single entity as follows: no 
chemotherapy treatment (Protocols H87 032, 87-014, 87-015), treatment with noncisplatin chemotherapy 
(Protocols I88-037, 87-016, 87-017), and treatment with cisplatin chemotherapy (Protocols I88-036, 87-018, 
87-019) 
** Correctors= patients who attained a haematocrit ≥38% unrelated to transfusion; Responders= patients 
whose haematocrit increased ≥6% unrelated to transfusion. Unrelated to transfusion: means that no 
transfusion was administered in the month prior to documenting attainment of the criterion 
ANALYSIS 
Statistical technique used? 
Fischer's exact test was used for statistical inference for 
dichotomous variables (e.g. sex by treatment group) formulated as 
2x2 tables. The extended Mantel-Haenszel test with integer scores 
was used for other types of discrete data. 
 
Between-group comparisons of means were analysed with two-
sample t-tests, and changes from baseline to final value were 
analysed via paired t-tests.  
 
A linear model approach was used for inference on major efficacy 
variables such as transfusion requirements. These models were 
constructed with treatment group and covariant factors such as 
endogenous serum EPO level, haematocrit, performance score, 
etc.  
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All statistical tests were two-sided, with α = 0.05. 
Intention to treat analysis? 
Patients were considered evaluable for efficacy if they completed 
>15 days on study.  
All patients were evaluable for safety. 
Does statistical technique adjust for 
confounding? NR 
Power calculation (priori sample 
calculation)? NR 
Attrition rate (loss to follow-up)? 
Unclear:  
ITT=413; epo =213 and placebo =200; 
Efficacy population = 396; epo =206, placebo =190 
Was attrition rate adequately dealt 
with? NR 
Number (%) followed up from each 
condition? 
Unclear; 
Henry 1994 provides results for first  6 month of EPO therapy 
(combined double-blind and open-label data): n=363, efficacy 
population =347. 
BASELINE CHARACTERISTICS 
Malignancy type (e.g.solid / solid head neck, lung, ovarian, cervical 
/ haem / MDS / mixed) 
Anaemic cancer (primary myeloid 
malignancies and acute leukaemias 
excluded) 
Treatment (e.g. chemotherapy platinum / non-platinum based; 
chemo + radio; no specific malignancy treatment; not reported) 
Cyclic  non-cisplatin chemotherapy 
(n=157) and cyclic cisplatin-
chemotherapy ( n= 132) 
Adjuvant anaemia treatment 
Iron NR 
G-CSF NR 
Transfusion trigger NA; assessing RBCT req 
Hb inclusion criteria level Anaemia: haematocrit of ≤32% or a haemoglobin ≤10.5 g/l 
 
Arm 1 =  
EPO 
N=213 
Arm 2 =  
Placebo 
N=200 
Arm 3 =  
N =  
Baseline demographics and clinical characteristics reported for the entire enrolled patient 
population, and are not separated out by chemotherapy treatment 
male, n 102 95   
female, n 111 105   
Age years  61.2 (13) 62.5 (14.1)   
patients evaluable for efficacy Arm 1 =  EPO N=206 
Arm 2 = Placebo 
N=190   
Patients transfused, n (%) 44.7% 48.4%   
# RBC units transfused per patient 
per month prior to study 0.67 (1.08) 0.73 (1 .04)   
Mean Haematocrit, n (%) 29.1 (4) 28.5 (3.8)   
Haematocrit,  (%):     
Non-cisplatin Chemo 
N=79 N=74   
28.6 (3.9) 29.4 (3)   
Cisplatin chemo 
N=64 N=61   
29.4 (4) 28.4 (14.5)   
Endogenous EPO level, mU/mL, 
mean (SD) [median] 146 (260) [76] 149 (217) [85]   
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Median Serum EPO (mU/ml)     
Overall quality of life (mm) 50 (24) 50.4 (26)   
Tumour type: 
Haematologic, n (%) 32% 32.1%   
Non-haematologic, n (%): 68% 67.9%   
Prostate, n (%) 11.2% 9%   
Breast, n (%) 10.7% 12.6%   
Gastrointestinal, n (%) 10.2% 5.3%   
Lung, non-small cell, n (%) 10.2% 9%   
Gynaecological, n (%) 9.2% 12.1%   
Lung, small cell, n (%) 3.9% 8%   
Head and neck, n (%) 2.4% 1.6%   
Oesophagus, n (%) 1.0% 1.6%   
Unknown primary, n (%) 3.4% 1.1%   
Other, n (%) 5.8% 7.9%   
Were intervention and control groups comparable? 
No p values reported, authors stated “Pooling 
patients across all trials shows equivalent  
emographic characteristics between the patients 
randomised to r-HuEPO and the patients  
andomised to placebo” 
 
RESULTS  
Reported for plat chemo & non-plat chemo (data available for no chemo but outside of scope for this 
appraisal) 
patients evaluable for efficacy 
Arm 1 =   
EPO 
N=206 
Arm 2 =  
Placebo 
N=190 
Arm 3 =  
N =  p  
Response of haematocrit therapy 
Non-cisplatin Chemo N=79 N=74   
Change in haematocrit  6.9 (6) 1.1 (4.3) Fig 2, pS5 represents Mean 
weekly 
haematocrit 
(+S.E.) comparing
EPO and placebo 
in all three 
populations. 
<0.004 
Final haematocrit 35.5 (6) 30.5 (4)  
Correctors 40.5 4.1 <0.008 
Responders 58.2 13.5 <0.008 
Area under the curve for 
neutrophil count versus time 
(cells x week/µl) 
30 203 34 189 
As reported in Case 1993 
Platelet counts/µL (% change 
from baseline to final value) -39 -48 
Rise in haematocrit to ≥38% 
unrelated to transfusion, n (%) 32 (40.5%) 3 (4.1%) 
6% point or more rise in 
haematocrit from baseline 
unrelated to transfusion 
46 (58.2%) 10 (13.5%) 
Cisplatin chemo N=64 N=61   
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Change in haematocrit  6 (7) 1.3 (5) Fig 2p S5 represents Mean 
weekly 
haematocrit 
(+S.E.) comparing
EPO and placebo 
in all three 
populations. 
<0.004 
Final haematocrit 35.4 (7) 29.7 (4.5)  
Correctors 35.9 1.6 <0.008 
Responders 48.4 6.6 <0.008 
HaemR (≥6% points HcT 
withour a transfusion in the four 
weeks prior to that Hct value); 
chg from BL (mean ± SD) 
6.0 ± 7.0 1.3 ± 5.0 
As reported in Henry 1995; 
also reports BL Hct 29.4 ± 4.0 
(rHuEPO) and 28.4 ± 4.5 
(PBO).   Diff. 4.7; p<0.0001 (favours epo) 
Transfusions 
Non-cisplatin Chemo N=79 N=74   
Proportion of pts transfused 
(%); overall 40.5 48.6 
When the non-
Cisplatin  and 
cisplatin Chemo 
populatins were 
combined there 
was sig 
difference for  
Proportion of pts 
transfused at  
Month 2-3 
(p≤0.005) and 
mean units per 
patients at month 
2-3 (p=0.009; 
Table 7 page 
S5). 
 
Mean units per patients;  
overall 2.03 (3.88) 2.75 (4.15)  
Proportion of pts transfused 
(%) ; Month 1 25.3 27  
Mean units per patients; 
Month 1 0.69 (N=70) 0.71(N=68)  
Proportion of pts transfused 
(%);  Month 2-3 28.6 (N=70) 36.8 (N=68)  
Mean units per patients; 
Month 2-3 0.91 1.65 0.056 
Patients transfused, n (%)  
As reported in 
Case 1993 
 
 
 
 
 
 
Month1 (n=79) 20 (25.3) 20 (27.0) 
Months 2 & 3 (n=70) 20 (28.6) 25 (36.8) 
Transfusion rate (least squares mean from linear analysis), mean ± SE 
Month1 (n=79) 0.69 ± 0.16 0.71 ± 0.16 
Months 2 & 3 (n=70) 0.91 ± 0.27 1.65 ± 0.27 =0.056 
Cisplatin chemo N=64 N=61   
Proportion of pts transfused 
(%); overall 53.1 68.9 
When the non-
cisplatin and 
cisplatin chemo 
populations were 
combined there 
was sig 
difference for  
Proportion of pts 
transfused at  
Month 2-3 
 
Mean units per patients;  
overall 3.56 (7.01) 4.01 (4.87)  
Proportion of pts transfused 
(%) ; Month 1 43.8 44.3  
Mean units per patients; 
Month 1 1.71 1.2  
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Proportion of pts transfused 
(%);  Month 2-3 26.8 (N=56) 56.4 (N=55) 
(p≤0.005) and 
mean units per 
patients at month 
2-3 (p=0.009; 
Table 7, pS5). 
≤0.005 
Mean units per patients; 
Month 2-3 1.2 (N=56) 2.02 (N=55) 0.089 
Neutrophil and platelet analyses , and mean haematocrit were similar across all groups at time of 
transfusion (see Table 7 & 8, p S5 and S6 for more details. 
 
RBCT least squares mean 
Patients transfused, n (%)   
 
 
As 
reported 
in Henry 
1995 
 
 
N 64 61  
All patients 34 (53.1) 42 (68.9) p>0.05 
Month1 (n=64) 28 (43.8) 27 (44.3) p>0.05 
Month 2 (n=56) 12 (21.4) 27 (49.1) p<0.005 
Month 3 (n=47) 8 (17.0) 13 (28.3)  
Months 2 & 3 (n=56) 15 (26.8) 31 (56.4)  
Mean units transfused ± SE  
N 56 53  
Mean units transfused ± SE 4.01 ± 0.85 3.95 ± 0.84 p>0.05 
Month1 (n=79) 1.71  ± 0.28 1.20 ± 0.29 p>0.05 
Month 2 0.71 ± 0.22 1.30 ± 0.22 p=0.0572 
Month 3 0.42  ± 0.16 0.62 ± 0.16 - 
Months 2 & 3 (n=70) 1.20  ± 0.33 2.02  ± 0.33 P=0.0893 
Haematological vs. non-haematological  tumour 
Change in haematocrit from baseline to final value by tumour type (%) 
 CLL 6 (N=7) 0.9 (N=9)  
Since the data for 
any turnout type 
may include 
patients from the 
NC, NCC and CC 
treatment groups, 
duration of 
therapy can range 
from 8 (NC) to 12 
(NCC, CC) 
weeks. 
0.077 
 Myeloma 3.7 (N=19) 0.3 (N=23) 0.058 
 Lymphoma 6 (N=40) 0.5 (N=29) ≤0.05 
 Breast cancer 6.5 (N=22) 1.6 (N=24) ≤0.05 
 Lung cancer 6.4 (N=29) 1.1 (N=32) ≤0.05 
 Prostate cancer 2.3 (N=23) 0.1 (N=17)  
 GI cancer 5.8 (N=21) 1.6 (N=10) ≤0.05 
 Gynaecological cancer 7.7 (N=18) -0.3 (N=23) ≤0.05 
Tumour type and bone marrow infiltration was similar at baseline and among responders (Table 10 p S6). 
Health-related QoL 
 reported for the entire enrolled patient population, and are not separated out by 
chemotherapy treatment. Data presented graphically: Fig 3 and 4, pS6  
As reported in Case 1993:  
Prestudy and post study QoL assessments were available for 124 patients (rHuEPO n=63; placebo n=61); 
rHuEPO-treated population as a whole had a statistically significant (p≤0.05) increase in baseline-to-final 
evaluation for energy level and ability to perform daily activities, as well as a near statistically significant  
(p=0.86) improvement for overall QoL. No similar improvements in QoL assessments were seen in 
placebo-treated patients. The changes in QoL scores were of somewhat greater magnitude in the rHuEPO-
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treated populations with an increase in haematocrit to 38% or more or an increase of 6 % points or more 
(both unrelated to transfusion) than in the rHuEPO-treated population as a whole. DATA NOT SHOWN; 
DATA REPORTED GRAPHICALLY 
As reported in Henry 1995  
Patients in the rHuEPO-treated group experienced a significant p≤0.05 prestudy to poststudy improvement 
in energy level, ability to perform daily activities, and overall QoL. Patients in the PBO group also 
experienced a significant (p≤0.05) prestudy to poststudy improvement in their energy levels, but not in their 
ability to perform daily activities or overall QoL. Comparing the two treatment arms , there was a 
significantly greater prestudy to poststudy change in the overall QoL for the rHuEPO-treated group than for 
the placebo treated group (p=0.013). When only responders in the rHuEPO treated group were compared 
with the placebo treated group, QoL changes were even greater in favour of rHuEPO, but did not achieve 
significance, because of smaller numbers. DATA NOT SHOWN; DATA REPORTED GRAPHICALLY 
Adverse effects of tmt:  
reported for the entire enrolled patient population, and are not separated out by chemotherapy 
treatment 
reported by at least 10% of 
patients: N=213 N=200    
Nausea  23% 29%    
Pyrexia  22% 21%    
Asthenia 17% 16%    
Fatigue  15% 20%    
Vomiting  15% 18%    
Diarrhoea  15% 9%    
Oedema  14% 8%    
Dizziness  10% 9%    
Skin reaction at medication site  10% 10%    
Constipation  10% 9%    
Shortness of breath  8% 15%   <0.03 
Decreased appetite  8% 12%    
Chills  7% 10%    
Trunk pain  8% 12%    
no antibodies against r-HuEPO developed during the course of therapy. 
Hypertension 5% 3.5%   >0.05 
Non-cisplatin Chemo As reported in Case 1993: 
ITT population N=81 N=76   >0.05 
# patients completed the study 63 (78%) 63 (83%)   >0.05 
# pts who discontinued study 
prematurely because of an 
adverse experience, 
death, or disease progression 
13 (16%) 8 (11%) 
  
=0.05 
Diarrhoea, n (%) 18 (22%) 8 (10%)   <0.05 
Diaphoresis, n (%) 9 (11%) 1 (1%)    
Hypertension, n (%)* 4 2    
Seizure, n (%)** 2 2    
Thromboembolic events, n (%) 4 4    
No statistically significant difference in the incidence of any adverse experience in rHuEPO –treated 
patients compared with placebo –treated patients except for Diarrhoea (p=0.05) and Diaphoresis (p<0.05). 
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* Hypertension in the rHuEPO treated patients tended to be more severe than in the placebo-treated 
patients, with the diastolic blood pressure in one of the rHuEPO-treated patients reaching 140 mm Hb. The 
haematocrit in this patient increased from 31% at baseline to 43% at the time the hypertension was 
reported (Day 57)  
** Seizures occurred in the context of a substantial increase in haematocrit and blood pressure. However, 
these patients also had structural abnormalities of the central nervous system (cerebral metastases and/or 
abnormal cells in the cerebrospinal fluid and increased cerebrospinal fluid protein) . 
Cisplatin Chemo As reported in Henry 1995 
 rHuEPO PBO    
N 67 65    
Overall 58 (87) 58 (89)    
≥10% patients 
Fever 16 (24) 17 (26)    
Nausea 15 (22) 25 (28)    
Vomiting 13 (19) 17 (26)    
Fatigue 11 (16) 12 (18)    
Diarrhoea 10 (15) 4 (6)    
Abdominal/ trunk pain 10 (15) 12 (18)    
Asthenia 9 (13) 9 914)    
Edema 9 (13) 6 (9)    
Anorexia 7 (10) 10 (15)    
Bacterial infection 7 (10) 7 (11)    
Paresthesia 7 (10) 5 (8)    
Med site RXN 7 (10) 4 (6)    
Constipation 7 (10) 3 (5)    
Rash 7 (10) 2 (3)    
Shortness of breath 5 (7) 13 (20)    
Arthralgia 5 (7) 7 (11)    
<10% patients selected AEs 
Thrombosis 6 (9) 2 (3)    
Headache 5 (7) 3 (5)    
Seizure 3 (4) 2 (3)    
Hypertension 2 (3) 4 (6)    
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM 
ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients 
number, date of birth, alternate; Unclear = if the method not stated) 
Unclear  
(states randomised but no details 
given) 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY 
CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially 
numbered coded vials; other methods where the triallist allocating 
treatment could not be aware ; Inadequate = allocation was 
alternate, or based on information known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? 
Unclear; 
No p values reported, authors 
stated “Pooling patients across all 
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trials shows equivalent  
demographic characteristics 
between the patients randomised to 
r-HuEPO and the patients  
randomised to placebo” 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Y 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT 
ALLOCATION?  Y (states double-blind) 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? Y (states double-blind) 
7. WERE THE POINT ESTIMATES AND MEASURE OF 
VARIABILITY PRESENTED FOR THE PRIMARY OUTCOME 
MEASURE? 
Partially 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPOTED? N 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT 
ANALYSIS OR WERE LESS THAN 10% OF EACH STUDY ARM 
EXCLUDED? 
Unclear 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-
UP IN EACH GROUP STATED? 
After completion of double-blind 
therapy, patients were eligible to 
receive r-HuEPO on an open-label 
basis,  
NOTES: 
References: 
Abels, 1996: Reports pooled data from the three chemotherapy populations: 
Abels, R. I., Larholt, K. M., Krantz, K. D., & Bryant, E. C. (1996). Recombinant Human Erythropoietin 
(rHuEPO) for the Treatment of the Anemia of Cancer. Oncologist, 1(3), 140-150. 
Henry, 1994: After completion of double-blind therapy, patients were offered to receive r-HuEPO on 
an open-label basis, this paper reports open-label follow up data: 
Henry, D. H. and R. I. Abels (1994). "Recombinant human erythropoietin in the treatment of cancer and 
chemotherapy-induced anemia: results of double-blind and open-label follow-up studies." Semin Oncol 21: 
21-28. 
Subgroup analysis 
Case, 1993: Analysis of non-cisplatin chemotherapy subgroup: 
Case, D. C., Jr., Bukowski, R. M., Carey, R. W., Fishkin, E. H., Henry, D. H., Jacobson, R. J., . . . et al. 
(1993). Recombinant human erythropoietin therapy for anemic cancer patients on combination 
chemotherapy. J Natl Cancer Inst, 85(10), 801-806. 
Henry, 1995: Analysis of cisplatin chemotherapy subgroup: 
Henry, D. H., B. J. Brooks, Jr., D. C. Case, Jr., E. Fishkin, R. Jacobson, A. M. Keller, J. Kugler, J. Moore, R. 
T. Silver, A. M. Storniolo, R. I. Abels, D. S. Gordon, R. Nelson, K. Larholt, E. Bryant and S. Rudnick (1995). 
"Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy." 
Cancer J Sci Am 1(4): 252-260. Data for plat chemo subgroup 
OTHER 
Generalisability  
Author conclusions r-HuEPO increases haematocrit and corrects anaemia in cancer 
patients whether or not they are receiving chemotherapy, and 
apparently without regard to type of cancer. 
 In a dose of 150 U/kg three times weekly, r-HuEPO appears to 
decrease transfusion requirements after the first month of therapy, but 
not earlier. This therapy also appears to improve functional capacity 
in those anaemic cancer patients who show a significant-increase in 
haematocrit in response to therapy. r-HuEPO also appears to be well-
tolerated in this patient population. 
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Reviewer comments  
 
Endnote Ref ID 
 
2685 Malignancy type Solid (ovarian, lung & stomach) 
Treatment rHuEPO: epoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year  Aravantinos, 2003 N  47 
Objective To evaluate the safety of 
and efficacy of rHuEPO 
for the management of 
anaemia in cancer 
patients receiving 
platinum-based 
chemotherapy 
Inclusion criteria: adults with confirmed 
(histologically proven) malignancies about to start 
or already receiving platinum-based 
chemotherapy. Diagnosis of recent onset 
anaemia due to malignant disease, performance 
status of 0-2 according to the ECOG, and life 
expectancy ≥3 mths. Patients with Hb values 
<10.5 g/dL before initiation or during 
chemotherapy, receiving platinum-based 
combinations on a 3-4 weekly schedule lasting 
for not more than 5 days per cycle. Lab 
requirements WBC >3,500/µl, platelet count 
>100,000/µl, serum creatinine <2 mg/dl, negative 
direct Cooms reaction (to exclude haemolytic 
anaemia) and normal iron levels (to exclude iron 
deficiency anaemia) 
Exclusion criteria: uncontrolled hypertension 
(DBP >100 mg Hb), and suspicion of iron, folic or 
B12 deficiency. Patients who had received 
radiotherapy or had undergone surgery 2 weeks 
prior to study entry, or had received a red blood 
cell transfusion the week before 
# centres 1 
Other references/aliases NA 
Geographical setting Greece 
Duration of treatment Unclear; median 5 cycles 
Length of follow-up (if 
different)  NR 
Country of corresponding 
author Greece 
Language of publication English  
Sources of funding 
Not reported 
RANDOMISATION & 
ALLOCATION 
Randomised, unblinded, single centre 
Stratified: type of malignancy, type of platinum compound (cisplatin or 
carboplatin), & chemo cycle number at study entry (1st vs 2nd vs 3rd) 
TREATMENT ARMS 
ARM Drug name/s rHuEPO Control: No rHuEPO 
N 24 23 
Dose & freq (od, bd etc) 150 IU/kg Q3W NA 
Dose adjustment Y/N 
Y: Hb value >14 g/dL rHuEPO 
administration was interrupted and re-
initiated in a dose reduced by 25% 
when Hb was <12.5 g/dL. No 
escaliation of the rHuEPO dose was 
attempted in case of failure to 
increase Hb >1 g/dL in a month. Dose 
adjustments were made according to 
body weight on the first day of the 
following chemo cycle. 
NA 
Route of administration Subcutaneous NA 
Duration of epo tx NR  NR 
Adj anaemia treatment 200 mg elementary iron daily 200 mg elementary iron daily 
Transfusion trigger Discretion of treating physician but Discretion of treating physician but 
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avoided if Hb was >9 g/dL avoided if Hb was >9 g/dL 
OUTCOMES 
Primary 
outcome 
the reduction 
of transfusion 
requirement: # 
transfusions 
(per grp & per 
patient) 
Other outcomes 
Hb level (chg per cycle); Ht level (chg per 
cycle); RBC (chg per cycle);# patients requiring 
transfusion;  
 
ANALYSIS 
Statistical technique used? 
ANOVA with 2 parameters was used for the 
administration of  EPO, follow-up, RBC transfusions 
and cycle number. Statistical significance was tested 
in relation to EPO administration (with or without 
EPO) and in relation to Cycle number 
 
ANOVA with 1 parameter was used to identify 
statistically significant differences in relation to the 
use of EPO and in relation to Cycle number 
 
Post-hoc comparisons and Scheffe-tests followed in 
order to assess the statistical significance of 
difference between the 2 groups.  
 
Independent Mann-Whitney tests were performed to 
study the differences concerning the number of 
transfusions,and all data were also studied with 
descriptive statistics 
 
P value <0.05 considered significant 
Intention to treat analysis? 
Unclear; likely ITT as no crossover and results 
reported for full data set but not mentioned in the 
study write-up 
Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? Not reported 
Attrition rate (loss to follow-up)? Not reported 
Was attrition rate adequately dealt with? Unclear; attrition rate not reported 
Number (%) followed up from each condition? NA 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) 
Solid – ovarian, lung, 
stomach, other 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Platinum-based(cisplatin 
or carboplatin) 
Adjuvant anaemia treatment 
Iron 200 mg elementary iron daily 
G-CSF Not reported 
Transfusion trigger Discretion of treating physician but avoided if Hb 
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was >9 g/dL 
Hb inclusion criteria level Hb <10.5 g/dL 
 
Arm 1 =  
rHuEPO  
N = 24 
Arm 2 =  
No rHuEPO 
N = 23 
Arm 3 =  
N =  
Sex        
male (%) 2 (8%) 7 (30%)   
female (%) 22  (92%) 16  (70%)   
Age years median (range) 59 (18-76) 64 (23-75)   
Performance status: ECOG 
0 11 (45.8%) 14 (60.9%)   
1 8 (33.3%) 4 (17.4%)   
2 5 (20.9%) 5 (21.7%)   
Type of solid tumour 
Ovarian 16 (67%) 10 (43%)   
Lung 3 (12.5%) 5 (22%)   
Stomach 2 (8%) 2 (9%)   
Other 3 (12.5%) 6 (26%)   
# of chemotherapy cycle at study entry 
1 9 (37.5%) 5 (21.7%)   
2 9 (37.5%) 13 (56.5%)   
3 3 (12.5%) 2 (8.6%)   
4 3 (12.5%) 3 (13.0%)   
Hb baseline (g dl-1) NR NR   
Hb at cycle 1 9.8 0.5 9.32 0.8 
Reported values are 
assumed to be 
means and SD 
Iron baseline (U/l median (range) NR NR   
Epo baseline (mU ml-1) NR NR   
Target Hb NR NR   
Were intervention and control groups comparable? 
No p values reported, authors stated “all 
characteristics were well-balanced between the two 
groups”. 
RESULTS 
 
Arm 1 =  
rHuEPO  
Arm 2 =  
No rHuEPO 
Arm 3 =  
N =  p  
N = 24 N = 23    
Median # of chemo cycles 5 5    
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Mean Hb by cycle (Reported values are assumed to be means and SD) 
Cycle 1 9.8 ± 0.5 9.32 ± 0.8    
Cycle 2 10.36 ± 1.08 10.2 ±1.01    
Cycle 3 10.66 ± 1.3 10.07 ± 1.32    
Cycle 4 
11.47 ± 1.67 
Hb increase 
compared to 
controls: P<0.03 
10.31 ± 1.56 
    
Cycle 5 
12.11 ± 1.39 
Hb increase 
compared to 
controls P<0.03 
10.55 ± 1.83    
P value for all cycles <0.0002 
Mean haematocrit by cycle 
Cycle 1 28.56 ± 4.92 28.74 ± 2.68    
Cycle 2 31.5 ± 0.47 31.09 ± 3.14    
Cycle 3 32 ± 4.06 30.57 ± 4.21    
Cycle 4 
34.9 ± 4.48 
Ht increase 
compared to 
controls P<0.002 
31.58 ± 4.54    
Cycle 5 36.43 ± 4.33 32.2 ± 5.63    
RBC count (x 104/mm3) by cycle 
Cycle 1 3.46 ± 0.42 3.46 ± 0.59    
Cycle 2 3.62 ± 0.50 3.71 ± 0.59    
Cycle 3 3.64 ± 0.57 3.61 ± 0.62    
Cycle 4 3.77 ± 0.55 3.54 ± 0.66    
Cycle 5 4.01 ± 0.4 3.61 ± 0.61    
RBCT        
# patients requiring RBCT 9 (37.5%) 23 (100%)   <0.0001 
# transfusions:        
total 20  73    <0.04 
per patient 2.22  3.17     
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM 
ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients 
number, date of birth, alternate; Unclear = if the method not stated) 
Unclear; stratification 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY 
CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially 
NR 
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numbered coded vials; other methods where the triallist allocating 
treatment could not be aware ; Inadequate = allocation was alternate, 
or based on information known to the triallist) 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? 
Unclear; p values not reported 
authors stated “all characteristics 
were well-balanced between the 
two groups”. 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT 
ALLOCATION?  No 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? No 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? 
Partially 
(variability can be calculated from 
data presented in the paper) 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT 
ANALYSIS OR WERE LESS THAN 10% OF EACH STUDY ARM 
EXCLUDED? 
Yes; results reported for full 
population, no crossover so 
appears to be ITT but not 
mentioned in study description 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP 
IN EACH GROUP STATED? NR 
NOTES: 
Levels of Hb within rHuEPO group increased with cycle number becoming statistically significant in Cycle 5. 
Similarly there was a trend for increase in the no rHuEPO group (<0.06) 
 
There was statistically significant increase of the Ht level in rHuEPO compared to no rHuEPO especially in 
Cycle 4 (p<0.002), with a statistically significant increase of Ht level during cycles, more significant in 
Cycles 4 and 5 
 
A tendency towards higher RBC numbers per cycle was seen in Group A patients 
 
Detailed analysis per group and per cycle of treatment showed that for rHuEPO there was a decrease in 
the transfusion requirements from cycle to cycle (20.1% in Cycle 2 compared to 4.2% in Cycle 5). Similarly 
in no-rHuEPO there was a decrease in transfusion requirements from 65.2% in Cycle 2 to 30.4% in Cycle 
5. Not statistically significant for either group 
 
For the 9 patients in the rHuEPO group requiring transfusion, 56% of them received their first transfusion in 
Cycle 2 of chemotherapy, while only 22.2% in Cycles 3 or 4. There was a significant fluctuation of the % of 
patients requiring transfusion per cycle (21.7% Cycle 1; 47.8% in Cycle 2; 8.7% in Cycle 3; 13% in Cycle 4) 
OTHER 
Generalisability Mixed population – majority women (81%) (majority of women had ovarian cancer); 
other solid tumours included lung and stomach cancer 
Author conclusions Administration of rHuEPO is an effective intervention for the management of 
chemotherapy induced anaemia, significantly reducing RBCT requirements in 
patients receiving platinum-based chemotherapy. Hb and Ht levels proved reliable 
indicators for response to rHuEPO treatment. 
Reviewer comments Trial unblinded 
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Endnote Ref ID 
 
2710 Malignancy type haem & solid 
Treatment Epoetin beta 
STUDY DESIGN PARTICIPANTS 
Author, year Boogaerts, 2003 N  262 
Objective To assess the impact of 
epoetin beta on QoL 
compared with standard 
care in anaemic patients 
with lymphoid or solid 
tumour malignancies 
Inclusion criteria:  
Adult outpatients; Hb ≤11 g/dl associated with 
non-Hodgkin’s lymphoma or chronic lymphocytic 
leukaemia and any solid tumour treated with 
myelosuppressive chemotherapy with at least 3 
cycles remaining; WHO performance status of ≤2 
& a life expectancy of 6 mths 
Exclusion  criteria:  
Anaemia arising for other reasons (iron or 
Vitamin B12 deficiency, acute bleeding, 
haemolytic anaemia), refractory hypertension, 
severe renal insufficiency (serum creatinine of 
>2.5 mg/dl (>220 µmol/l), epilepsy or acute 
infection; pregnant or lactating women and 
women of child bearing age who were practising 
unreliable contraception. Any patient scheduled 
to undergo bone marrow or peripheral stem cell 
transplantation during the study period or 4 wks 
prior to the study. 
# centres Multicentre, conducted 
between October 1996 
and September 1998. 
Other references/aliases Coiffier 1999 (abstract) 
see notes  
Geographical setting 8 countries: Austria, 
Belgium, Franec, 
Germany, Italy, South 
Africa, Sweden, UK) 
Duration of treatment 12 wks (plus run in period 
of up to 2 weeks) 
Length of follow-up (if 
different) 
26 wks? 
Country of corresponding 
author 
Belgium 
Language of publication English 
Sources of funding NR 
RANDOMISATION & 
ALLOCATION 
Patients were randomised 1:1 stratified according to centre to receive either 
epoetin beta or standard care with transfusion support 
TREATMENT ARMS 
ARM Drug name/s Epoetin beta Standard care 
N 133 129 
Dose & freq (od, bd etc) 
150 U/kg/Q3W 
Average dose of epo over the study 
period was174 IU/kg per 
administration. 
– 
Dose adjustment Y/N 
Dose increased to 300 U/kg/Q3W for 
those patients in whom Hb levels 
increased by <0.5 g/dl after 3-4 wks 
or <1 g/dl after 6-8 wks. The dose 
was reduced by 50% if the Hb level 
increased by >2 g/dl per mth, while 
treatment was interrupted if Hb levels 
increased to >14 g/dl.Treatment was 
recommenced at half the previous 
dose once the Hb level had declined 
to <12 g/dl. 
– 
Route of administration Subcut. – 
Duration of epo tx 12 wks NR 
Adj anaemia treatment Oral iron supplementation (200–300 Oral iron supplementation (200–300 
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mg elemental iron per day) as 
indicated (transferrin sat. <15%) 
mg elemental iron per day) was 
indicated (transferrin sat. <15%) 
Transfusion trigger Hb 8.5 g/dl was a guide to initiate transfusion throughout the centres  
Hb 8.5 g/dl was a guide to initiate 
transfusion throughout the centres  
OUTCOMES 
Primary 
outcome 
HRQL (chg 
from BL to Wk 
12 in SF-36, 
FACT-An, 
FACT-F) 
 
Other outcomes 
HaemR (defined as ≥2 g/dl without transf. req. 
after the first 4 wks (lso measured HaemR as 
inc in ≥2 g/dl or increase to ≥12 g/dl); Change in 
Hb BL to Wk 12 (+ changes in Hb& 
corresponding changes in QoL); RBCT; HRQL* 
(chg from BL to Wk 12 VAS;  FACT-An Global); 
AEs** (incl # of hospitalisations) 
NOTES: 
Clinic visits were every 3 or 4 weeks for pts off chemotherapy. Clinical outcomes were collected at each 
psot baseline visit. QoL was assessed at baseline, after 3-4 wekke sand 6-8 weeks and et the end fo the 
study. 
* All QoL assessments were performed immediately prior to the clinic visits so that patients could not eb 
influenced by reference to Hb levels 
** Defined as any undesired, noxious or pathological change in a patient as indicated by signs, symptoms 
and/or laboratory changes that occurred in association with the use of a drug or placebo whether 
considered drug-related or not 
ANALYSIS 
Statistical technique used? 
Psychometric evaluation was performed to evaluate 
how well the QoL scale items satisfied the 
assumptions underlying the Likert method for 
summated rating. The internal consistency reliability 
of each scale score was estimated using Cronbach’s 
a. Cronbach’s a, which ranges from 0 to 1, where ‘1’ 
equals perfect reliability, is based on the average 
inter-item correlation and the number of items. 
Minimum values equal to or greater than 0.70 have 
been recommended for group level comparisons 
(Nunnaly, 1978). 
 
For QoL assessments only patients for whom values 
were available at baseline and at least one follow-up 
visit were included in the analysis. The data are 
presented in its raw form and using the last 
observation carried forward (LOCF) approach, for 
patients with missing values at the final visit. For the 
percentage of clinical responders, Kaplan–Meier 
estimates and corresponding confidence intervals 
(CIs) for time to treatment response were determined, 
and curves were compared using the log-rank test. 
The O/P log serum erythropoietin ratio was derived 
from reference regression at the particular Hct or Hb 
level, and was calculated for responders and 
nonresponders to epoetin b. The relation between 
endogenous erythropoietin level and response to 
treatment was explored using the odds ratio (OR) and 
relative risks (RR) (Cazzola and Beguin, 1992). 
 
Appropriate parametric and nonparametric tests were 
used to analyse between-group differences for 
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continuous and categorical variables, respectively. All 
tests were two sided and P<0.05 was considered 
significant. Assessment of statistical significance was 
not adjusted for multiple comparisons. 
Intention to treat analysis? Yes, ITT=262 
Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? 
Based on expected change in SF-36 PCS score. To 
detect a between-group difference in SF-36 PCS 
score of at least 4 points, assuming an SD of 10 
using a two-sided test with a statistical power of 80% 
and α 2.5%, at least 121 patients/group were required 
to complete the study and be evaluable for efficacy. 
To allow for dropouts approximately 310 patients 
were to be enrolled. However, this was not achieved. 
Attrition rate (loss to follow-up)? 
51 patients were withdrawn in the study (epoetin 
beta, n=30; control (n=21); 20 of them were for AEs 
(epoetin beta, n=15; control, n=5. Other reasons for 
withdrawal included death, loss to follow-up, 
withdrawal of consent and protocol violation 
Was attrition rate adequately dealt with? LOCF for patients with missing values at final visit 
Number (%) followed up from each condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  (e.g.solid / solid head neck, 
lung, ovarian, cervical / haem / MDS / mixed) Haem & solid 
Treatment 
(e.g. chemotherapy platinum / non-platinum 
based; chemo + radio; no specific malignancy 
treatment; not reported) 
Chemo, NR 
Adjuvant anaemia 
treatment 
Iron Oral iron supplementation (200–300 mg elemental iron per day) was indicated (transferrin sat. <15%) 
G-CSF NR 
Transfusion trigger Hb 8.5 g/dl 
Hb inclusion criteria 
level Hb ≤11 g/dl 
Evaluable population 
Arm 1 =  
EPO 
N=133 
Arm 2 =  
Controls 
N=129 
p  
male, n 46 (35) 52 (40) 
 
female, n 87 (65) 77 (60) 
Age years median 
(range) 62 (24–85) 62 (24–85)   
Hb g/dl median (range) 9.0 (5–13) 9.2 (5–12)  
EPO, mU/mL mean 
(SD) (N=25) 54 (7–1,650) 58 (5–4,300)   
Iron, serum, mg/dL 
mean (SD) (N=26) 63.7 (6–472) 78.8 (4–510)   
Iron saturation, % 
mean (SD) (N=26) 20.6 (1–97) 29.0 (2–100)   
Folic acid, mg/mL 
mean (SD) (N=25) NR NR   
B12, pg/mL mean (SD) NR NR   
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(N=24) 
BL QoL score     
SF-36 PCS mean (SD); 
median (range) 
35 (8.4) 
35 (17–60) 
38 (9.5) 
38 (15–60)   
FACT-F mean (SD); 
median (range) 
27 (12) 
28 (1–49) 
31 (11)* 
33 (2–51)  P=0.02 
FACT-AN mean (SD); 
median (range) 
20 (3.8) 
21 (6–27) 
21 (4.4) 
22 (2–28)   
VAS mean (SD); 
median (range) 
56 (17) 
53 (11–96) 
62 (17) 
60 (18–96)   
Were intervention and 
control groups 
comparable? 
Authors report that “Overall, there were no significant differences between groups 
in baseline demographics and clinical characteristics, except for a significantly 
higher proportion of patients in the control group having received prior 
chemotherapy 80 vs 68%; p= 0.025)” With respect to QoL measures, BL scores 
on the FACT-An subscale were comparable between treatment groups, although 
those randomised to epoetin beta therapy had lower Fact-F subscale score 
relative to the control group (p=0.02). 
RESULTS 
 
Arm 1=  
EPO 
n=133 
Arm 2 =  
Controls 
n=129 
  p  
HaemR, n (%) 
Responders increase ≥2 g/dl 63 (47) 17 (13)   <0.001 
Responders increase ≥2 g/dl or 
increase to ≥12 g/dl 65 (49) 19 (15)    
Graph showing response Figure 2 
Hb BL to Wk 12, median increase (range) (n) 
All patients 2.1 (-3 to 8) (n=112) 
0.9 (-3 to 6) 
(n=112)   <0.001 
Patients with solid tumours 2.1 (-1 to 8) (n=45) 
0.9 (-3 to 4) 
(n=51)   No p 
values 
provided 
for 
subgroup 
analyses 
Patients with lymphoid tumours 1.9 (-3 to 8) (n=67) 
0.9 (-3 to 6) 
(n=61)   
With chemotherapy 2.1 (NR) (n=74) 
1.0 (NR) 
(n=88)   
Without chemotherapy 2.0 (NR) (n=38) 
0.2 (NR) 
(n=24)   
Graph showing Hb change Figure 3   add the figure here? 
Transfusions 
Hb level before transfusion, 
median 7.64g/dl 7.8g/dl    
Pts transfused, in last 8 weeks 
of study, % 22% 43%   <0.001 
Pts transfused, overall, % 32% 52%   =0.001 
Units transfused per patient was reduced by 45% during the treatment period with epo beta. 
Health-related QoL 
Cronbach α: Reliabilities for SF-36 subscales varied from 0.83 to 0.90 for the pooled population, apart from 
the General health subscale (0.75). The FACT-F subscale and the FACT-An global scale showed high 
consistency: >0.9, while the FACT-An 7-item subscale reached 0.68 using the pooled population. 
Median change BL to Wk 12 LOCF data  LOCF data    vs control 
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 SF-36 PCS  +3.1 (n=104) 
NR  
(n=109)   P<0.05  
 FACT-F  +3.0 (n=104) 
NR  
(n=109)   P<0.05  
 FACT-AN  +1.0 (n=104) 
NR  
(n=109)   p-0.076 
 VAS  +10.0 (n=111) 
+1.0 
(n=112)   P=0.004 
Median change BL to Wk 12 Data without LOCF  Data without LOCF n=129   Vs control 
 SF-36 PCS  +3.3  (n=77) NR   P=0.01 
 FACT-F  +4.0 (n=90) NR   P=0.001 
 FACT-AN  +1.0 (n=89) NR   P=0.068 
 VAS  +10.0 (n=89) 
+3.0 
(n=98)   P=0.001 
Patients with lymphoproliferative malignancies derived at least as much QoL benefit from epoetin b therapy 
as patients with solid tumours; likewise, patients previously exposed to chemotherapy showed similar QoL 
benefit with epoetin b as chemotherapy-naıve patients (data not shown). However, patients who responded 
to epoetin b therapy (i.e. achieved the target Hb response) experienced a greater improvement in QoL from 
baseline to final visit than patients who were nonresponders (i.e. did not achieve the target Hb response). 
Patients who responded to epoetin b therapy had a mean increase of 3.7 points in their SF-36 score, 7.2 
points in their FACT-F score and 1.2 points in their FACT-An subscale scores; the corresponding 
improvements in the nonresponder group were 3.1, 3.4 and 0.5 points, respectively. Changes in SF-36 
PCS and FACT-F scores were mediated through changes in Hb level (P<0.01) as shown by a path analysis 
where epoetin b treatment, QoL increase and Hb increase were used as 
dependent variables in turn. 
 
Mean change in QoL scores from baseline in the epoetin b and control groups for the without LOCF 
population are reported graphically. 
 
Adverse events in ≥5% of patients in at least one treatment group, n (%) 
Malignancy progression 33 (25) 42 (33)    
Anaemia 18 (14) 33 (26)    
Leucopenia 20 (15) 19 (15)    
Thrombocytopenia 8 (6) 13 (10)    
Bronchitis 7 (5) 8 (6)    
Fever 5 (4) 10 (8)    
Nausea 6 (5) 8 (6)    
Pain 9 (7) 5 (4)    
Pneumonia 9 (7) 5 (4)    
Asthenia 6 (5) 7 (5)    
Diarrhoea 11 (8) 2 (2)    
Infection 8 (6) 4 (3)    
Sepsis 3 (2) 7 (5)    
Vomiting 9 (7) 1 (<1)    
Depression 8 (6) 1 (<1)    
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Headache 7 (5) 2 (2)    
Number of hospitalisations per 
patient, menaq  SD 3.8 (4.5) 4.1 (4.9)   =0.52 
Number of hospital days, mean 
SD 11.7(13.7) 9.4 (10.3)   =0.46 
Admissions related to anaemia, 
mean SD 0.8 (2.2) 1.5 (3.6)   =0.043 
Iron  
Iron supplementation, n 
(mostly oral) 30 28    
Parenteral iron, n 9 2    
Serum iron deficit  
BL to study end 4.5µg/dl 16.8mg/dl   <0.01 
No clinically relevant changes in transferrin saturation were observed for either group between baseline 
and study end (data not shown). 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM 
ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients 
number, date of birth, alternate; Unclear = if the method not stated) 
Unclear: randomised but method not 
specified. 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY 
CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially 
numbered coded vials; other methods where the triallist allocating 
treatment could not be aware ; Inadequate = allocation was 
alternate, or based on information known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? 
NO 
Higher proportion of participants in 
the control group that had received 
prior chemotherapy (80 vs 68%; 
p=0.025); participants randomised to 
epoetin beta had lower FACT-F 
scores relative to the control group 
p=0.02 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Y 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT 
ALLOCATION?  N (open label) 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? N (open label) 
7. WERE THE POINT ESTIMATES AND MEASURE OF 
VARIABILITY PRESENTED FOR THE PRIMARY OUTCOME 
MEASURE? 
Y 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPOTED? N 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT 
ANALYSIS OR WERE LESS THAN 10% OF EACH STUDY ARM 
EXCLUDED? 
Y. 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-
UP IN EACH GROUP STATED? 
Partially; # total per group reported & 
# withdrawing due to AEs reported 
per group. Other reasons stated but # 
not reported 
NOTES: 
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Also presented in abstract: Coiffier, B., et al. (2001). Impact of epoetin beta versus standard care on 
quality of life in patients with malignant disease. 6th Congress of the European Haematological 
Association. Coiffier included in Wilson review 
  
OTHER 
Generalisability  
Author conclusions Compared with transfusion therapy, epoetin beta produces a clinically significant 
improvement in QoL in patients with anaemia associated with malignancy. Epoetin 
beta improved physical function and well-being as a result of diminished anaemia-
related symptoms as measured by the FACT-An and FACT-F questionnaires. These 
improvements in QoL accompany and are mediated through improvements in Hb 
concentration, and can be achieved after a few weeks of epoetin beta therapy.In 
addition, baseline epo serum levels and the O/P ratio might identify those patients 
with lymphoproliferative malignancies who are more likely respond to epoetin beta; 
however, this required further study 
Reviewer comments Included in Wilson HTA as Coiffier, B., M. Boogaerts and C. Kaine (2001). Impact of 
epoetin beta versus standard care on quality of life in patients with malignant 
disease. 6th Congress of the European Haematological Association. We have 
included the full paper (Boogaerts et al, 2003) in this review 
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Endnote Ref ID 2689 
Malignancy type Haem (multiple myeloma) 
Treatment epoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Dammacco, 2001 N  ITT = 145 
Objective To evaluate the efficacy of 
epoetin alfa in correcting 
anaemia in patients with 
multiple myeloma thereby 
decreasing transfusion 
requirements 
Inclusion criteria: Men and women aged 40-80 
years with multiple myeloma, a life expectancy of 
at least 3 months and an ECOG score of 0-3; 
receiving chemotherapy for at least 6 months; 
baseline Hb level <11.0 g/dL 
 
Exclusion  criteria: Patients with uncontrolled 
hypertension or evidence of untreated iron, 
folate, or Vitamin B12 deficiency; those who had 
received a blood transfusion within 7 days of 
study entry; patients with a major infection within 
1 month or an acute illness within 7 days of study 
entry 
# centres 31 
Other references/aliases None 
Geographical setting 12 countries (Italy, 
Poland, Gt Britain, 
Norway, Sweden, Czech 
Republic, Hungary, 
Belgium, Israel, Denmark, 
Spain and Switzerland) 
Duration of treatment 12 weeks double blind 
Length of follow-up (if 
different) 
12 weeks open label 
optional 
Country of corresponding 
author Italy 
Language of publication English 
Sources of funding Supported by a grant from 
the RW Johnson 
Pharmaceutical Research 
Institute, Bassersdorf, 
Switzerland 
RANDOMISATION & 
ALLOCATION 
Stratified according to receipt of blood transfusion within the preceding three 
months. Patients within each transfusion stratum were then randomised to 
treatment or control. 
Patients in both arms who completed the 12 weeks had an option to receive 
epo for up to 12 weeks in the open-label extension of the study. 
TREATMENT ARMS 
ARM Drug name/s epoetin alfa placebo 
N 69 76 
Dose & freq (od, bd etc) 150 IU/kg Q3W (each dose separated by at least 1 day) Matched to epoetin alfa dose 
Dose adjustment Y/N 
Y: if Hb level had not increased by ≥1 
g/dl after 4 wks of tmt the dose was 
doubled to 300IU/kg Q3w for the 
remaining 8 wks of study; if Hb level 
increased to >14 g/dl treatment 
withheld until Hb level was <12 g/dl 
and then reinitiated at does approx.. 
25% lower than start dose; increased 
by ≥2 g/dl within a 4-wk period dose 
Matched to epoetin alfa dose 
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reduced by approx.. 25% to maintain 
an increase of <2 g/dl  
Route of administration Subcutaneous Subcutaneous 
Duration of epo tx 12 weeks (double blind) 12 weeks (double blind) 
Adj anaemia treatment NR NR 
Transfusion trigger <8 g/dl; to be avoided if possible, if Hb >8 g/dl  to be avoided if possible, if Hb >8 g/dl 
OUTCOMES 
Primary 
outcome 
Transfusion 
requirement 
stratified by 
baseline 
transfusion 
status 
Other outcomes 
HRQoL (chg in QoL scores (Nottingham Health 
Profile & CLAS/LASA)); AEs REPORTED: AEs 
– questioning patients at study visits . All AEs 
together with investigators assessment of its 
seriousness, severity and presumed 
relationship to study medication were recorded 
Vital signs, clinical lab tests (eg complete blood and reticulocyte count), serum chemistry and urinalysis 
were competed 7 days prior study, on day 1 and weekly. Serum erythropoietin was evaluated prior study 
entry, at day 1 and weeks 2, 4, 8. Serum iron, transferrin, total iron-binding capacity and ferritin evaluated 
prior study entry, at day 1 and every 4 weeks. 
 
Responders = proportion of patients during d-blind phase with increase of ≥2 g/dl in Hb level 
 
Correctors = achieved an Hb level of ≥12 g/dl without receiving a transfusion within the previous month 
 
NHP = 38 questions combined to form six separate scales: emotional reactions, pain, energy, sleep, scoail 
isolation & physical mobility. Pts respond yes/no. Scale calculated by counting the number of items rated as 
a yes within each scale. Scale is then converted to a scale (0 good to 100 bad. 
 
CLAS = 100 mm scale separately evaluates energy level, ability to do daily activities, and overall QoL 
 
Also measured pre study and at the end were complete physical examination, clinical signs and symptoms 
of multiple myeloma, bone marrow biopsy, skeletal radiography, serum M-component, urine light-chain M-
component, folate , B12, myeloma staging and physician ‘s performance score and global assessment. 
ANALYSIS 
Statistical technique used? 
Proportion of patients transfused stratified by 
prestudy transfusion history was analysed by the 
Cochran-Mantel-Haenszel test. Only data for Month 
2 and 3 were analysed (effects not expected before 
this time [Abels, 1992]) 
 
Between group changes in haematological 
parameters from baseline to last determination were 
compared using t tests; between-group differences 
in the proportions of responders and correctors were 
compared using the Fisher exact test 
 
QoL : Kruskal-Wallis test were performed to ensure 
no bias had been introduced by deleting patients. 
Assessments evaluated by univariate analyses 
using t tests; multivariate analyses were also 
performed 
 
Changes in performance scores between treatment 
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groups, categories of response to chemotherapy, 
and the treatment groups stratified by response to 
chemotherapy were analysed using Kruskal-Wallis 
and Cochran-Mantel_Haenzel tests. Between-group 
differences in the physician’s global assessment 
were analysed using the Kruskal-Wallis test. 
 
All statistical tests were 2-sided 
Intention to treat analysis? 
Results for primary efficacy evaluation of transfusion 
requirements & safety are reported for the ITT 
population. 
 
Results for the secondary efficacy parameters are 
reported for the efficacy population (patients 
randomised to a treatment group who remained in 
the study for at least 2 months (it was believed that 
this duration would allow patients, including those 
who required a dose increase at Wk 4 sufficient time 
to respond). 
 
QoL analyses were performed for the ITT population 
minus patients who died during the double-blind 
phase of the study for whom QoL data were 
incomplete. 
Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? NR 
Attrition rate (loss to follow-up)? 
Yes: 5 Epo patients discontinued (2 AEs [death due 
to septic shock n=1 & disease progression n=1] and 
3 for personal reasons). 15 PBO patients 
discontinued (3 AEs [pneumonia n=1, death due to 
septic shock n=1, death due to acute renal failure 
n=1]; 6 disease progression; 3 personal reasons; 3 
other unspecified reasons  
Was attrition rate adequately dealt with? Partially: ITT population was not used for secondary efficacy parameters and HRQL data 
Number (%) followed up from each condition? NA 
BASELINE CHARACTERISTICS 
Malignancy type    (e.g.solid / solid head neck, lung, ovarian, 
cervical / haem / MDS / mixed) Haem: multiple myeloma 
Treatment (e.g. chemotherapy platinum / non-platinum based; 
chemo + radio; no specific malignancy treatment; not reported) 
Unclear: though most commonly used 
non-plat based chemo  
Adjuvant anaemia treatment 
Iron NR 
G-CSF NR 
Transfusion trigger to be avoided if possible, if Hb >8 g/dl  
Hb inclusion criteria 
level <11.0 g/dL 
 
Arm 1 =  
Epo Alfa 
N=69 
Arm 2 =  
Placebo 
N=76 
Arm 3 =  
N =  
male (%) 34 (49%) 31 (41%)   
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female (%) 35 (51%) 45 (59%)   
Age years median (range) 67.3 (43.0-80.4) 65.0 (38.2-88.9)   
Performance score (0-4; higher score the worse the performance status): ECOG 
Missing 1 0   
0 9 8   
1 51 50   
2 33 34   
3 6 8   
Creatinine µmol/l, mean 106.3 ± 42.29 102.4 ± 35.60   
# chemotherapy cycles within 6 
months prestudy: mean ± SD 
(range) 
N=68 N=75   
3 ± 2.5 (0-15) 4 ± 2.0 (0-8)   
Malignancy staging (Durie & Salmon 1975), % 
 
IA 4 5   
IB 0 1   
IIA 33 34   
IIB 4 0   
IIIA 46 54   
IIIB 12 5   
Hb baseline (g dl-1),  
mean ± SD (median; range) 
9.3 ± 1.27  
(9.6; 5.7-11.5) 
9.6 ± 0.95  
(9.7; 7.4-11.8)   
Hb level g/dl at transfusion (for pts 
receiving transfusions at baseline), 
mean ± SD 
N=25 N=28   
8.1 ± 1.08 8.1 ± 0.93   
Serum Epo level (mU ml-1), 
median (range) 
N=36 N=36   
116 (18-5,220) 93 (10-408)   
Were intervention and control 
groups comparable? 
No p values reported but authors state “baseline demographic and 
clinical characteristics were comparable between treatment groups”. 
Based on the reported values the groups appear comparable. 
RESULTS 
 Arm 1 =  Epo Alfa 
Arm 2 =  
Placebo 
Arm 3 =  
N =  p  
ITT POPULATION Epo alfa N=69 
Placebo 
N=76    
RBCT 
Pts transfused during Month 2 & 
3 (double-blind study), n (%) 19 (27.5%) 36 (47.4%)  =0.017 
Transfused (by transfusion history) 
[either having or not having received 1+ transfusions during the prior 3 months], n (%): 
Transfused prestudy 14 (56.0) 22 (78.6)  =0.006 
PenTAG   CONFIDENTIAL 
481 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Not transfused prestudy 5 (11.4) 14 (29.2)  
Hb level g/dL triggering RBCT, 
mean (range) 
7.66 g/dl (6.1-9.7 
g/dl) 
7.89 g/dl (6.47-
9.45 g/dl    
Adverse effects of tmt (reported in 10% or more of patients in any treatment group) 
Any adverse event, n (%) 50 (72.5) 57 (75.0)    
Fever, n (%) 5 (7.2) 10 (13.2)    
Pain, n (%) 9 (13.0) 3 (3.9)    
Skeletal pain, n (%) 5 (7.2) 2 (2.6)    
Leukopenia, n (%) 9 (13.0) 6 (7.9)    
Granulocytopenia, n (%) 3 (4.3) 4 (5.3)    
Dyspnoea, n (%) 2 (2.9) 3 (3.9)    
Hypertension, n (%) 3 (4.3) 1 (1.3)    
Infection, n (%) 1 (1.4) 4 (5.3)    
Deaths* 1 7    
* No deaths were attributed to the study drug (reasons reported for double-blind and open-label phases not 
reported separately. FYI reasons included disease progression (50% of deaths for both periods); septic 
shock/infection; acute renal failure or cardiogenic shock.  
FYI Disease response comparable between patients receiving epoetin alfa & those receiving placebo (epo 
alfa did not appear to influence effects of chemotherapy, treatment or disease status) – data not reported 
ECOG N=66 N=66    
Change from baseline NR NR   =0.038 
I point improvement  13 (19.7%) 4 (6.1%)    
2 point deterioration 1 (1.5%) 5 (7.6%)    
Response to anaemia treatment rated by physician : excellent, 19.7 vs 0%; very good, 19.7 vs 3%; 
good,13.6 vs 9.1%; fair,18.2 vs 24.2%;  and  poor, 28.8 vs 63.6% for epo and placebo arms respectively (it 
is not clear if results are provided for the double blind phase of the study only):  
EFFICACY POPULATION Epo alfa N=66 
Placebo 
N=66    
Hb 
Chg Hb level g/dl (baseline to 
last value), mean ±  SD 1.8 ± 2.05 g/dl 0.0 ± 1.18 g/dl   <0.001 
Mean Hb level g/dl  Wk 12 11.2 g/dl 9.7 g/dl    
Responders, n (%) 38 (57.6%) 6 (9.1%)   <0.001 
Mean time for responders to 
achieve Hb level ≥2 g/dl above 
baseline 
46 days 35 days*    
Correctors, n (%) 30 (45.5%) 2 (3%)   <0.001 
Mean time for correctors to 
achieve Hb level ≥12 g/dl  50 days 23 days*    
* most likely due to the small numbers of placebo treated responders and correctors 
Health-related QoL 
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QoL POPULATION Epo alfa N=66 
Placebo 
N=72    
Health state utility scale = Nottingham Health Profile; CLAS 
DATA NOT REPORTED 
 
Both treatment groups showed some improvement in QoL but multivariate analysis did not show a 
significant difference between the groups for Wk 12 change scores, although nearly all trends favoured 
patients treated with epoetin alfa (data not reported). 
 
Univariate analyses of within-group meand changes from baseline to Wk 12 indicated significant 
improvement in 4 QoL scales for the epoetin alfa group (NHP scale emotional reaction p<0.001 & social 
isolation p=0.05; & for the CLAS energy level (p=0.01) & ability to do daily activities (p<0.001)) and 1 QoL 
scale for the placebo group (NHP scale sleep p=0.03).  A trend towards improvement was also noted for 
CLAS Overall QoL for the Epoetin alfa treated group whereas for the placebo group scores were virtually 
unchanged since baseline 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Unclear 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the 
triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? 
Unclear; no p values 
reported but groups 
appear comparable 
based on the values 
reported in the table 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  
Yes (though not 
blinded to dose – 
placebo dose matched 
epoetin alfa dose) 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? 
Yes (though not 
blinded to dose – 
placebo dose matched 
epoetin alfa dose) 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? 
Partially 
(variability can be 
calculated from data 
presented in the paper)
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? 
Partially: primary 
endpoint and HRQoL 
only 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? Yes 
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NOTES: 
OTHER 
Generalisability Haem cancer 
Author conclusions Epo alfa is an effective and well tolerated agent for the 
management of myeloma-associated anaemia. Benefits include 
prevention or amelioration of anaemia, reduction in transfusion 
requirements and improvements in QoL 
Reviewer comments  
 
Endnote Ref ID 
 
2700 Malignancy type Solid (breast) 
Treatment EPO (assumed epo alfa) 
STUDY DESIGN PARTICIPANTS 
Author, year Del Mastro, 1997 N  62 
Objective To evaluate the ability of 
EPO in preventing the 
development of clinically 
significant anaemia in 
patients treated with 
chemotherapy 
Inclusion criteria: Stage II breast cancer 
patients receiving accelerated (every 14 days) 
adjuvant chemotherapy after radical mastectomy 
or breast-conserving surgery; Hb≤12 g/dl; normal 
mean corpuscular volume of RBC (within 80 to 
100 fL) 
 
Exclusion  criteria: uncontrolled hypertension; 
inadequate iron reserves as evidenced by serum 
iron level less than normal (37 µg/dL) associated 
with ferritin level <10 ng/mL and/or transferrin 
saturation < 20% 
# centres 1 (February 1993-June 
1995) 
Other references/aliases None 
Geographical setting Italy 
Duration of treatment 12 weeks:  
6 cycles and 2 weeks 
(starting on day 1 of 
chemo, until 2 weeks after 
last chemo cycle); 36 
administrations planned 
per participant 
Length of follow-up (if 
different) 
A blood count was 
performed 6 months after 
the last chemo cycle. 
Country of corresponding 
author Italy 
Language of publication English 
Sources of funding Supported in part by a 
grant from Associazione 
Italiana per la Ricerca sul 
Concro, Milan (ITALY) 
RANDOMISATION & 
ALLOCATION 
Randomisation was performed by a telephone call to a central office. 
Randomisation was balanced with blocks of variable size. No stratification was 
planned 
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Two-arm phase III study. 
TREATMENT ARMS 
ARM Drug name/s Epo Best supportive care 
N 31 31 
Dose & freq (od, bd etc) 150 U/kg Q3W NA 
Dose adjustment Y/N 
Y. Hb increased to 15 g/dl in two 
consecutive weekly assays; EPO 
treatment was stopped until Hb <13 
g/dl (N=4) 
NA 
Route of administration Subcutaneous NA 
Duration of epo tx 
12 weeks: 6 cycles and 2 weeks 
(starting on day 1 of chemo, until 2 
weeks after last chemo cycle); 36 
administrations planned per pts 
12 weeks 
Adj anaemia treatment 
G-CSF 5 µg/kg SC Day 4 to Day 11 
during the first 5 cycles; it was 
withdrawn after the sixth cycle 
Oral iron supplement (ferrous 
sulphate 325 mg/d) was started at the 
occurrence of: serum iron < 37 
mcg/dL; serum ferritin <10 ng/ml; or 
transferrin saturation <20% (N=4) 
G-CSF 5 mcg/kg SC Day 4 to Day 11 
during the first 5 cycles; it was 
withdrawn after the sixth cycle 
Oral iron supplement (ferrous 
sulphate 325 g/d) was started at the 
occurrence of: serum iron < 37 µg/dL; 
serum ferritin <10 ng/ml; or transferrin 
saturation <20% (N=3) 
Transfusion trigger 
Hb <8 g/dl or in presence of anaemia 
related symptoms (dyspnea, 
tachycardia, severe asthenia) 
Hb <8 g/dl or in presence of anaemia 
related symptoms (dyspnea, 
tachycardia, severe asthenia) 
OUTCOMES 
Primary 
outcome  Other outcomes 
RBC (MCV, MCH, MCHC); haematocrit; 
reticulocyte; HRQoL (PDI) 
At day 1 of each cycle: blood cell count, reticulocyte count, serum iron, transferrin, ferritin, total iron binding 
capacity. Assay of EPO serum at baseline and 2 weeks post last chemo cycle only for first 15 pts. in each 
arm 
 
NOTES: 
 
MCV, mean corpuscular volume; MCH, mean corpuscular Hb level; MCHC, mean corpuscular Hb 
concentration 
 
PDI = Psychological Distress Inventory score; 5-point, 13-item self-assessment scale, developed and 
validated in Italy to measure psychological distress in cancer patients. Measured before randomisation, 
after 3rd cycle of chemo. And at the first follow-up visit (approx. 6 mths after randomisation 
 
AEs severity assessed by WHO criteria. Worst toxicity for each patient during all cycles was documented 
 
OTHER measures: Iron metabolism – serum iron, transferrin, ferritin, and total iron binding capacity; serum 
EPO: observed/predicted ratio (predicted was derived from a regression equations for haematocrit ≤38% 
and >38%) 
ANALYSIS 
Statistical technique used? 
Student’s t test for dependent and independent 
samples was used. ANCOVA for repeated 
measures was used to evaluate differences in 
terms of Hb, iron-related parameters & psychologic 
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distress after adjustment for baseline values.  
 
The probability of maintaining Hb levels >10 g/dl 
was calculated using the Kaplan-Meier method. 
The log-rank test was used to assess the difference 
between the curves. Patients who did not develop 
anaemia were censored at the cycle at which they 
were taken off treatment. Patients who received 
RBCT were considered as events 
Intention to treat analysis? Yes (HRQL- PDI available only  in 53 (85.5%) pts. 
Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? 
Yes. Previous study indicated that 50% of patients 
treated with accelerated CEF chemotherapy 
developed clinically significant anaemia defined as 
hb level ≤10 g/dL. Study interested in reducing 
anaemia occurrence to 10% patients, 30 patients 
per arm had to be randomised to ensure a 
significance of .05, 2-sided, and a power of .90 
Attrition rate (loss to follow-up)? 
Partially: 2 patients in the control group and 3 in the 
EPO group did not complete all 6 cycles of 
chemotherapy. 2 patients refused accelerated 
chemotherapy and EPO treatment. They were 
treated with CEF at the same doses but every 3 
weeks, no attrition rate for last measurement (2 
weeks post 6th cycle) and for  HRQoL data 
Was attrition rate adequately dealt with? Unclear as attrition rate not fully reported 
Number (%) followed up from each condition? Yes 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / 
mixed) 
Solid (breast) 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; 
no specific malignancy treatment; not reported) 
Chemo: 6 cycles of CEF 
(cyclophosphamide and epirubicin 
and fluoroacil ), cycles repeated 
every 2 weeks (unless delayed 
until hematologic recovery) 
Adjuvant anaemia treatment 
Iron 
Oral iron supplement (ferrous sulphate 
325 mg/d) was started at the 
occurrence of: serum iron < 37 
mcg/dL; serum ferritin <10 ng/ml; or 
transferrin saturation <20% 
G-CSF 
G-CSF 5 mcg/kg SC Day 4 to Day 11 
during the first 5 cycles; it was 
withdrawn after the sixth cycle 
Transfusion trigger 
Hb <8 g/dl or in presence of anaemia 
related symptoms (dyspnea, 
tachycardia, severe asthenia)
Hb inclusion criteria level Hb≥12 g/dl 
 
Arm 1 =  
EPO 
N=31 
Arm 2 =  
Control 
N=31 
Arm 3 =  
N =  
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Age years median (range) 54 (31-68) 56 (29-68)  
Hb (g dl-1), mean ± SD 13.0 ± 0.7 13.1 ± 0.6  
WBC count (x 109/L), mean ± SD 7.2 ± 2.0 7.1 ± 2.0  
Platelet count (x 109/L) , mean ± 
SD 247 ± 60.7 241 ± 51.3  
RBC count (x 1012/L), mean ± SD 4.4 ± 0.2 4.4 ± 0.3  
Haematocrit (%),mean ± SD 39.8 ± 2.2 40.0 ± 2.0  
Reticulocyte count (%),mean ± SD 8.8 ± 6.8 7.0 ± 5.6  
Mean corpuscular volume (fL) 91.2 ± 3.7 90.7 ± 4.7  
Mean corpuscular Hb (pg) 29.9 ± 1.1 29.8 ± 1.6  
Mean corpuscular Hb 
concentration (g/dL), mean ± SD 32.7 ± 1.1 32.8 ± 1.0  
Serum iron (mmol/L) 77.3 ± 46.2 93.1 ± 37.0  
Transferrin saturation(%), mean ± 
SD 20.7 ± 14.5 27.1 ± 11.4  
Ferritin (ng/mL) 61.2 ± 48.1 45.1 ± 35.1  
Total iron binding capacity 
(mcg/dL), mean ± SD 348 ± 55.6 352 ± 51.3  
Serum EPO (mU/mL) 
, median (range) 21.0 (0-512) 25.5 (0-800) 
Evaluated in 16 pts 
per arm, note that 
methods section 
states 15 pts. 
Observed/Predictive ratio, median 
(range) 1.13 (0.82-1.31) 1.19 (0.87-2.34) 
# received conservative surgery 22 (71%) 26 (84%)  
HRQoL N=27 N=26  
PDI, mean ± SD 27.5 ± 8.6 27.1 ± 7.3  
Were intervention and control groups comparable? 
Unclear. P values not reported but authors state 
“no statistically significant difference in baseline 
haematologic and iron-related parameters” 
RESULTS 
 
Arm 1 =  
EPO 
N=31 
Arm 2 =  
Control 
N=31 
Arm 3 =  p  
RBC-related parameters, mean ± SD at EOTP 
RBC count (x1012/L) 4.1 ± 0.5 3.3 ± 0.4  0.000 
Hb (g/dl) 12.2 ± 1.2 10.0 ± 1.1  0.000 
Hb decrease at the end of 
chemo* 
0.8 ± 1.4  
(CI:0.3-1.4) 
3.05 ± 1 
(CI:2.6-3.5)  <0.001 
Hb (g/dl) at 6 months follow 
up 13.2 ± 0.87 13.2 ± 0.61  >0.05 
Anaemia (Hb level ≤10 g/dl)** 0 (0%) 95% CI 0 to 14 
16 (52%) 
95% CI 33 to 69  =0.00001
RBCT (# patients requiring)  2   
Haematocrit (%) 37.8 ± 3.9 31.0 ± 3.8  0.000 
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Reticulocytes count (%) 10.1 ± 9.8 11.8 ± 8.7  0.6 
MCV (fL) 91.9 ± 6.7 94.7 ± 4.3  0.08 
MCH (pg) 29.6 ± 2.3 30.7 ± 1.8  0.07 
MCHC (g/dL) 32.3 ± 1.3 32.4 ± 1.2  0.8 
Observed/Predictive ratio, 
median (range) 1.32 (0.85-2.19) 1.05 (0.63-2.14) Evaluated in 16 pts per arm, 
note that methods section 
states 15 pts. 
Serum EPO (mU/mL)*, 
median (range) 83 (18-774) 66 (14.5-469) 
<1, % 1 37 
 
* RBC and haematocrit values showed a similar course to Hb data, but data not reported in the paper.  
** In the control group, patients developing anaemia had mean baseline Hb level significantly lower than 
those who did not (12.8 g/dl ± 0.6 g/dl [treatment group] vs 13,4 ± 0.5 [control group]; p=0.005). Probability 
of maintaining Hb level >10 g/dl significantly lower in the control group compared with the EPO group 
(p<0.0001 (no data reported; reported graphically Fig 3) 
 
Reticulocytes increased in both arms from baseline to Wk 2 (treatment arm 8% to 17% and control arm 7% 
to 11%). After this early increase reticulocytes decreased and in both arms final value not significantly 
different from baseline (treatment arm 10% and control arm 12%).  
Iron metabolism 
Throughout 6 cycles of treatment serum iron (p<0.001) and transferrin 
saturation (p=0.0002) significantly decreased, regardless the treatment 
arm. Differences between the two arms for serum iron (p=0.33) and 
transferrin saturation (p=0.79) were not statistically significant.  
 
After the first cycle of chemo. A sharp increase in mean serum ferritin 
was observed in both arms. After that ANCOVA showed that the ferritin 
values did not significantly change (p=0.14) during the treatment, but its 
levels were significantly lower in the EPO group compared with 
thecontrol group (p=0.0015). 
 
Results graphically presented. 
 
 
Total iron binding capacity, 
(mean ± SD) at the end of 
chemo 
356.4 ± 62.0 338.5 ± 58.6    
HRQoL 
Health state utility scale = Psychological Distress Inventory Score 
 N=27 N=26    
During treatment, mean ± SD 30.6 ± 10.4 28.3 ± 8.0    
Follow-up, mean ± SD 27.4 ± 11.2 26.3 ± 9.8    
Psychological distress increased during treatment and decreased at first follow-up visit p=0.03.  
Treatment groups did not differ in terms of psychological distress p=0.4 
Adverse effects of tmt 
 WHO grade      
No Grade IV 
toxicity reported 
Leukopenia I-II -  4 (13%)  No statistically 
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 III 2 (7%) - -  significant 
difference in main 
toxicities observed 
between the 2 
arms 
Thrombocytopenia I 4 (13%) 4 (13%)  
Nausea/vomiting I-II 22 (71%) 23 (74%)  
 III 6 (19%) 3 (10%)  
Alopecia III 31 (100%) 31 (100%)  
Mucositis I-II 16 (52%) 15 (48%)  
 III 3 (10%) 4 (13%)  
Diarrhoea I-II 1 (3%) 3 (10%)  
 III 1 (3%) 1 (3%)  
Bone pain I-II 12 (39%) 10 (32%)  
 III 4 (13%) 4 (13%)  
Fatigue I-II 18 (58%) 19 (61%)  
 III 1 (3%) 1 (3%)  
Fever I-II 5 (16%) 5 (16%)  
 III - - 1 (3%)  
EPO-related toxicities included: facial rash (n=2) after the first administrations. In 1 of these patients, 
dyspnea and headache requiring dose reduction also occurred. Almost all patients experienced mild or 
moderate local burning during EPO administration 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of birth, 
alternate; Unclear = if the method not stated) 
Yes 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded vials; 
other methods where the triallist allocating treatment could not be aware ; Inadequate = 
allocation was alternate, or based on information known to the triallist) 
Unclear; 
Randomisation was 
performed by a telephone 
call to a central office
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? 
Unclear: no p values 
reported but authors 
state “no significant 
differences between 
groups 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  No 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? NR 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY PRESENTED 
FOR THE PRIMARY OUTCOME MEASURE? 
No; no primary 
outcome stated. 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED MORE 
OUTCOME DATA THAN THEY REPOTED? 
Partial; some evidence 
e.g. WBC mentioned 
but data not reported 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR WERE 
LESS THAN 10% OF EACH STUDY ARM EXCLUDED? 
yes, however for 
HRQoL 
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only 87 and 84%  
participants analysed 
in epo and control  
groups respectively 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? partially 
NOTES: 
OTHER 
Generalisability Women only (breast cancer patients) 
Author conclusions EPO prevents anaemia in patients undergoing 
chemotherapy. Further trials are required to identify 
subsets of patients in which the preventive use of 
this drug could be cost-effective 
Reviewer comments  
 
Endnote Ref ID 
 
2701 Malignancy 
type 
advanced head and neck or lung 
carcinoma 
Treatment EPO (assumed epo alfa) 
STUDY DESIGN PARTICIPANTS 
Author, year Dunphy 1999 N 30 
Objective The effects of paclitaxel 
and carboplatin with or 
without concurrent EPO in 
the treatment of patients 
with head and neck 
carcinoma and lung 
carcinoma, on anemia and 
# of transfusions. 
Inclusion criteria:  
 patients with head and neck carcinoma 
and lung carcinoma treated at Saint 
Louis University Health Sciences Center 
on a Phase II trial using paclitaxel and 
carboplatin 
 histologically confirmed advanced head 
and neck carcinoma (clinical Stage III 
and IV) or advanced nonsmall cell lung 
carcinoma (Stage IV) 
 No prior therapy was permitted and all 
patients had measurable or evaluable 
disease 
 serum iron saturation ≥15%;  
 Zubrod performance status of ≤ 2;  
 serum creatinine <, 3 mg/dL;  
 serum bilirubin < 1.5 mg/dL;  
 granulocyte count> 1500/uL; 
 platelet count > 100,000/uL;  
 life expectancy > 4 months. 
 Hb level: NR; see dose adjustment 
# centres 1 
Other references/aliases  
Geographical setting USA 
Duration of treatment Unclear:  while on 
chemotherapy. 
The mean number of 
chemotherapy courses 
administered was three for 
each group (6 weeks?). 
Length of follow-up (if 
different) NR 
Country of corresponding 
author USA 
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Language of publication English  
Exclusion  criteria: NR; see inclusion criteria Sources of funding NR 
RANDOMISATION & 
ALLOCATION 
Patients were randomized in a non-blinded fashion either to receive or not 
receive EPO 
TREATMENT ARMS 
ARM Drug name/s Epo Control 
N 15 15 
Dose & freq (od, bd etc) 150 U/kg, 3 times per week (Mon, Wed and Fri). NA 
Dose adjustment Y/N 
Y: If the Hb fell ≥1 g/dL (Course 1) 
dose was escalated to 300 U/kg 
(Course 2); if the Hb fell ≥1 g/dL, the 
dose was escalated to 450 U/kg 
(Course 3). EPO was not initiated if 
the Hb was ≥16 g/dL. Once EPO was 
initiated the Hb was checked weekly. 
If theHb level rose to 18 g/dL, EPO 
was discontinued until it fell to 16 
g/dL, at which point treatment was re-
initiated 
NA 
Route of administration NR NR 
Duration of epo tx NR NR 
Adj anaemia treatment 
Oral iron and folic acid for the duration 
of chemotherapy (ferrous sulfate, 325 
mg orally, 3 times per day and folic 
acid, 1 mg orally, twice per day 
Oral iron and folic acid for the 
duration of chemotherapy (ferrous 
sulfate, 325 mg orally, 3 times per 
day and folic acid, 1 mg orally, twice 
per day 
Transfusion trigger <8.0 g/dL or cardiovascular symptoms of anemia developed 
<8.0 g/dL or cardiovascular 
symptoms of anemia developed 
OUTCOMES 
Primary 
outcome  Other outcomes HaemR, RBCT 
NOTES 
CBC with differential and platelet counts was obtained at enrolment and every week during chemotherapy 
ANALYSIS 
Statistical technique used? 
Accrual was limited by the number of patients who 
were to be enrolled in local Phase II protocols for 
the treatment of carcinoma of the head and neck 
and lung carcinoma with paclitaxel and carboplatin. 
Therefore the sample size was insufficient to 
ensure adequate power for subset analyses. 
 
Repeated ANOVA was used to compare the 
difference in post-chemotherapy Hb levels between 
the two groups during the first two courses of 
chemotherapy.  
The Fisher exact test was used to compare the 
difference in the rate of transfusion between the 
two groups.  
The Mann–Whitney U test and Fisher exact test 
were used to compare characteristics between the 
PenTAG   CONFIDENTIAL 
491 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
two groups. 
 
An a priori level of significance of 0.05 was used for 
all comparisons. 
Intention to treat analysis? 
Evaluable population used in data analyses 2 pts 
(noncompliance and EPO was initiated on Day 8) in 
EPO group and 1 participant (early death) in control 
group were not evaluable) 
Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? 
Y : A minimum of 20 evaluable patients was 
required to a difference of 2.5 g/dL in post-
chemotherapy Hb levels between EPO and controls 
with a power of 
>90% at a significance level of 0.05. 
Attrition rate (loss to follow-up)? 
Partially: 2 pts (noncompliance and EPO was 
initiated on Day 8) in Epo group and 1 participant 
(early death) in control group were not evaluable. 
Was attrition rate adequately dealt with? NR 
Number (%) followed up from each condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  (e.g.solid / solid head neck, lung, 
ovarian, cervical / haem / MDS / mixed) advanced head and neck or lung carcinoma 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; 
chemo + radio; no specific malignancy treatment; 
not reported) 
paclitaxel and carboplatin, repeated every 21 days:  
Patients with advanced lung carcinoma were 
treated until best response or six courses of 
chemotherapy.  
After 2–3 preoperative chemo courses, patients 
with head and neck carcinoma were treated with 
radiation if they were observed to have a >50% 
response or surgery if a <50% response was 
observed. They then were followed with no further 
treatment until they developed a recurrence 
Adjuvant anaemia 
treatment 
Iron 
oral iron and folic acid for the duration of 
chemotherapy (ferrous sulfate, 325 mg orally, 3 
times per day and folic acid, 1 mg orally, twice per 
day 
G-CSF NR 
Transfusion trigger <8.0 g/dL or cardiovascular symptoms of anemia developed 
Hb inclusion criteria 
level NR 
Evaluable population 
Arm 1 =  
EPO 
N=13 
Arm 2 =  
Controls 
N=14 
p  
male, n 12 (92%) 7 (50%) Gender was not 
Distributed equally 
between the two 
treatment groups (P 
= 0.003). 
female, n 1 (8%) 7 (50%) 
Age years median 
(range) 59 (42–76) 67 (32–82)   
Hb g/dl mean (SD) 14.1 (2.1) 14.1 (1.6) P = 0.68 
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EPO, mU/mL mean 
(SD) (N=25) 8.8 (5.1) 7.3 (4.4)   
Iron, serum, mg/dL 
mean (SD) (N=26) 67.2 (22.9) 75.7 (51.1)   
Iron saturation, % 
mean (SD) (N=26) 26.8 (8.7) 31.9 (24.3)   
Folic acid, mg/mL 
mean (SD) (N=25) 8.3 (4.2) 6.1 (3.1)   
B12, pg/mL mean (SD) 
(N=24) 552 (243) 445 (139)   
Type of solid tumour of randomised pts:  
Head and neck, n (%) 10 11   
Lung, n (%) 5 4   
Were intervention and control groups comparable? No 
RESULTS 
 
Arm 1=  
EPO 
n=13 
Arm 2 =  
Controls 
n=14 
Arm 3 =  
N =  p  
Hb 
Change in Hb; after 2 courses 
of chemotherapy g/dl 1.2 2.8   =0.037 
There was a highly significant decrease inHb over time (2 courses of chemotherapy or 6 weeks) in patients 
who did not receive EPO compared with those who did (p=0.008) (Fig. 1). 
Transfusions  
# transfused pts during  2 
courses of chemo 1 (8%) 2 (14%)   >0.05 
# transfused pts at 4 courses 
of chemo 2 (15%) 5 (36%) 
These differences were not 
compared statistically 
because after the second  
chemo 
fewer patients were treated in 
subsequent courses (Fig. 2) 
Units received per pts at 4 
courses of chemo 3 2.8 
Serum EPO 
N=10 N=10 
3 epo and 4 control 
participants have no follow up 
serum epo data. 
EPO levels increased significantly over time for both groups (P =0.007); 
however, the increase in the group treated with EPO was significantly 
greater than the increase in the control group (P = 0.002) (Fig. 3). 
      
Health-related QoL 
NR 
Adverse effects of tmt 
NR 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Unclear: not 
specified. 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded NR 
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vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the triallist) 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? 
Gender was not 
distributed equally 
between the two 
treatment groups (P 
= 0.003). 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Y 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  N 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? NR 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? 
NA, no primary 
outcome specified 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? N 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? N 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? yes 
NOTES: 
OTHER 
Generalisability Gender was not distributed equally between the two 
treatment groups (P = 0.003). 
Author conclusions There was significantly less anemia and 
transfusions were reduced by 50% in patients 
randomized to receive EPO during chemotherapy 
with paclitaxel and carboplatin. 
Reviewer comments No Hb inclusion criteria; EPO was not initiated if the 
Hb was ≥16 g/dL. 
In addition head and neck pts interrupted treatment 
after 2-3 chemo courses with no further treatment 
until they developed a recurrence. 
 
Endnote Ref ID 
 
362 Malignancy type Small cell lung cancer (SCLC) 
Treatment Epo alfa 
STUDY DESIGN PARTICIPANTS 
Author, year  Grote 2005 N  224 
Objective To evaluate tumour 
response in pts 
receiving etoposide 
and cisplatin after third 
chemo cycle. The 
study hypothesis was 
that epo alfa overall 
tumour response rate 
won’t be ≥15% below 
placebo group. 
Inclusion criteria: age ≥18years; newly diagnosed both 
extensive stage and limited stage SCLC scheduled for at 
least 3 chemo cycles; ECOG=0-2; life expectancy ≥3 
months; Hb≤14.5g/dl 
Exclusion criteria: Previous cytotoxic chemo or 
radiotherapy, or scheduled curative-intent radiotherapy 
during the first three chemo cycles; uncontrolled 
underlying disease not attributable to malignancy; 
uncontrolled hypertension; evidence of untreated iron, 
folate or vitamin B12 deficiency or on-going haemolysis. 
# centres 35 sites 
Other 
references/aliases  N93-004 
Geographical setting  USA 
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Duration of treatment 12 wks = from start of 
treatment until 3 
weeks after 
chemotherapy 
completed (the mean 
number of chemo 
cycles was 4 and 4.1 
in epo and placebo 
groups respectively, 
duration of a cycle=3 
weeks) 
Length of follow-up (if 
different) 
 3 years after 
treatment 
Country of 
corresponding author  USA 
Language of 
publication  ENGLISH 
Sources of funding Johnson & Johnson 
LLC 
RANDOMISATION & 
ALLOCATION 
Randomised double blind, parallel group, placebo controlled trial. 1:1 computer 
generated randomisation, no details provided on allocation concealment.   
TREATMENT ARMS 
ARM Drug name/s Epo alfa Placebo 
N 109 115 
Dose & freq (od, bd 
etc) 150U/kg three times a week 150U/kg three times a week 
Dose adjustment Y/N Y: epo stopped if Hb>16 till Hb<14 and resumed at 75U/kg, no dose escalation   
Route of 
administration 
Subcutaneous Subcutaneously 
Duration of epo tx Approx.  three weeks after final chemo Approx.  three weeks after final chemo 
Adj anaemia 
treatment NR NR 
Transfusion trigger NR NR 
OUTCOMES 
Primary 
outcome  
Other 
outcomes 
HaemR (weekly Hb, after 3 cycles and final cycle); 
RBCT (patients, units, time to first transfusion); tumour 
response (after 3 cycles and final cycle); survival (up to 
3 years); AEs 
NOTES: 
Study early terminated because of slow recruitment and suboptimal enrolment: enrolled 224 from 400 
planned pts. Thus some power issues. 
ANALYSIS 
Statistical technique used? 
Overall tumour response rate (complete response 
(CR) plus partial response (PR)) and 95% 
confidence intervals reported.. 
Kaplan-Meier estimates for survival data. 
Intention to treat analysis? 
Yes for all efficacy data.  
Safety data analysed patients receiving at least one 
dose of study drug with available safety data. 
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Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? 
Yes, (based on 15% one sided decrease in overall 
tumour response rate in epo arm). However trial was 
terminated early, thus power issues. 
Attrition rate (loss to follow-up)? Number of patients and reasons for treatment discontinuation reported for both arms. 
Was attrition rate adequately dealt with? NR except to say ITT was conducted 
Number (%) followed up from each condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) SCLC 
Treatment (e.g. chemotherapy platinum / non-platinum based; chemo + 
radio; no specific malignancy treatment; not reported) etoposide and cisplatin 
Adjuvant anaemia treatment 
Iron NR 
G-CSF NR 
Transfusion trigger NR 
Hb inclusion criteria level Hb≤14.5 
 Arm 1 = Epo N =109 Arm 2 = Placebo N = 115   
male (%) 59 54.1% 64 55.7%   
female (%) 50 45.9% 51 44.3%   
Age years mean (SD)[range] 64.4 (8.7) [37-78] 63.2 (8.9) [37-78]   
Performance status 
ECOG       0 - 1 73 67% 83 72.2%   
2 34 31.2% 32 27.8%   
3 1 0.9% 0 0%   
4 0 0% 0 0%   
missing 1 0.9% 0 0%   
Mean Hb baseline (g dl-1) (SD) 12.8 (1.5)  13 (1.5)    
Iron baseline (U/l median) (range) 75.3  (65.41)  81.6 (66.35)   
Mean Feritin, ng/dL (SD) 471.7 (856.3) 460.3 (632.9)   
Number of Chemo cycles received 4 (2.1) 4 (1-10) 4.1 (2.2) 4 (1-12)   
Radiotherapy received 16  14.7% 14 12.2%   
Extensive stage SCLC 72 66.1% 68 59.1%   
Were intervention and control groups comparable? 
No p-values reported, authors stated that 
“demographics and clinical characteristics were 
generally similar between groups” 
RESULTS 
 Arm 1 = Epo N = 109 
Arm 2 = Palacebo
N = 115 
Diff: Epo-
placebo: 95% CI  
Tumour response 
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Tumour response; CR or PR at 
final cycle 65 59.6% 
64 55.7% 4% -9 to17 % 
Tumour response;  CR at final 
cycle 20 18.3% 
21 18.3%   
Hb 
(Mean Hb at cycle 3) 12.5  10.6  1.9 g/dl 1.4 to 2.4 g/dl 
Mean Hb at final cycle 12.2  10.3  1.9 g/dl  1.4 to 2.4 g/dl 
Change  from baseline to end of 
treatment -0.6  -2.7    
Mean Hb change at 13 weeks-
median drug exposure -0.2  -2.9    
Health-related QoL NR      
         
Overall survival        
Median survival (Kaplan-Meier) 10.5 months 10.4 months    
Transfusions Difference in Kaplan-Meier estimates of time to first transfusion showed 
that probability of transfusion was greater in Placebo group starting at 
month 3. 
Participants 26 24% 42 37% HR=0.597,  
95%CI(0.365 -0.977) 
Mean number of units (SD) 0.5 (3.6)* 0.4 (0.7)    
Safety data$        
Discontinued chemo because of 
AE 23 21% 32  28%    
Deaths (at 3 years follow up) 100 91.7% 101 87.8%    
Cause of death = disease 
progression:  91%  84%    
Nausea 80 73.4% 79 68.7%    
Vomiting 56 51.4% 58 50.4%    
Fatigue 32 29.4% 40 34.8%    
Constipation 34 31.2% 40 34.8%    
Clinically relevant thrombo-
vascular events 
12 11% 11 9.6%    
Thromoboembolic events 1 0.9% 0 0.9%    
Hypertension NR; Patients with uncontrolled hypertension were excluded. 
ECOG At baseline 98 % and 100% patients had ECOG ≤2 in Epo and Placebo 
groups respectively, at the end of treatment 71 % of patients had ECOG 
≤2 in both groups. 
* One patient in EPO arm had abdominal aortic aneurysm requiring 37 units of blood 
$ Data for all 224 participants available 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
yes 
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birth, alternate; Unclear = if the method not stated) 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? 
Unclear; no p-
values reported. 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  yes 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? yes 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? yes 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? no 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? yes 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? 
Yes, during 
treatment period 
only 
NOTES: 
Complete tumour response (CR)=total disappearance of all all known malignant disease. 
 
Partial tumour response (PR)= defined as a ≥ 50% decrease in total tumour area (added products of 
bidimensional measurements of all measurable disease) and as no growth of any measurable lesion by 
more than 25% and no estimated growth of any unmeasurable but assessable lesions by more than 25% 
and as no new lesions. 
 
Patients without a date of death were censored on the date that the patient was last known to be alive. 
 
RESULTS 
Fig 1 page 9382: Kaplan-Meier plot of survival over time. (*) One month = 28 days. 
Fig 2 page 9382: mean Hb values and 95% CI (estimates based on graph reading reported below) 
Hb estimated from Figure 2 Arm 1 = Epo N=64 
Arm 2 = Placebo 
N=58 
Week 13 mean (SD) 12.5 (0.6) 10.24 (0.4) 
OTHER 
Generalisability  
Author conclusions Results suggest that in newly diagnosed patients with SCLC 
epoetin alfa does not affect tumour response to chemotherapy or 
survival. However, the early trial closure makes these conclusions 
preliminary. 
Reviewer comments Divergence in survival curves after 12 months (figure 1). The 
author notes, that there is no information on patients medication 
after the end of the treatment, and the possible differences in the 
proportion of patients with extensive stage SCLC. However the 
paper does not report whether any significant differences were 
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found for outcomes measured at baseline. In addition, although 
unknown the medication could be expected to be similar for all 
patients. 
 
Endnote Ref ID 
 
2703 Malignancy type Lymphoproliferative  
Treatment Darbepoetin alpha 
STUDY DESIGN PARTICIPANTS 
Author, year Hedenus, 2002 N  66 
Objective To assess the safety and 
dose-response 
relationship of darbepoetin 
alpha in patients with 
different types of 
lymphoproliferative 
malignancies receiving 
multicyle chemo 
Inclusion criteria:  
 Pts with a diagnosis of lymphoproliferative 
malignancy (MM, low- and intermediate-
grade NHL, Hodgekin’s disease or CLL) 
 Life expectancy of ≥6 months 
 ECOG performance status of 0-2 
 At least 12 more weeks of chemo 
 Adequate iron stores (transferrin 
saturation ≥15% or ferratin ≥10µg/l) 
 Normal serum vit B12 and folate 
concentrations 
 Adequate liver function (serum bilirubin 
≤1.5 times the upper limit of the normal 
range 
 Adequate renal function (serum creatinine 
≤177µmol/l) 
 Not received two RBC transfusions within 
4 wks of randomisation or any RBC 
transfusion within 2 wks of randomisation 
 Hb level: ≤11.0 g/dl 
Exclusion  criteria:  
 High-grade NHL 
 Myleoablative chemo or radiotherapy for 
transplantation or chemo regimens using 
investigational agents 
 Primary or metastatic malignancy 
involving the CNS 
 Clinical evidence of active infection or 
inflammatory disease  
 Other disorders that could potentially 
interfere with the response of darbe 
 
# centres 15 
Other references/aliases NR 
Geographical setting Europe/Australia 
Duration of treatment 12 weeks 
Length of follow-up (if 
different) 
4 weeks after treatment 
period 
Country of corresponding 
author 
Sweden 
Language of publication English 
Sources of funding Amgen, Inc. 
RANDOMISATION & 
ALLOCATION 
Multicentre, randomized (1:2:2:1 ratio, see notes), double-blind, placebo-
controlled, dose-finding study.  
Randomization was performed using a central computerised system and was 
stratified to balance the treatment groups with respect to malignancy type 
(myeloma vs lymphoma). 
TREATMENT ARMS 
ARM Drug name/s Darbepoetin alpha Placebo 
N 22 11 
Dose & freq (od, bd etc) 2.25 µg/kg once weekly NR 
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Dose adjustment Y/N 
Y; doses reduced by 50% for pts who 
had ≥2g/dl increase in Hb during any 
28 day period in the absence of RBC 
transfusion; withheld for pts with Hb 
concentrations >15.0g/dl (men) or 
>14.0g/dl (women) and reinstated at 
50% of weekly dose once Hb 
concentrations decreased to 
≤13.0g/dl.  
NR 
Route of administration Subcutaneous Sub cut 
Duration of epo tx 12 weeks 12 weeks 
Adj anaemia treatment NR NR 
Transfusion trigger 
RBC transfusions were recommended 
for pts with Hb concentrations 
≤8.0g/dl. 
NR but assumed to match darbe 
group 
OUTCOMES 
Primary 
outcome 
HaemR (haem 
response 
defined as an 
increase in Hb 
of ≥2.0 g/dl from 
baseline in the 
absence of RBC 
transfusion; 
haematopoietic 
response 
defined as Hb 
response or 
increase in Hb 
concentration to 
≥12.0 g/dl in the 
absence of RBC 
transfusion; 
sustained Hb 
response 
defined as Hb 
response 
maintained for 
28 days or until 
the end of 
treatment;  
Hb 
concentrations 
measured 
weekly 
Other outcomes 
RBCT (from Wk 5 until the end of the treatment 
period); AEs (AEs, excess increases in Hb, 
changes in lab variables and vital signs, 
antibody formation resulting from darbe 
administration) 
 
ANALYSIS 
Statistical technique used? 
Rates of Hb and Hb response estimated using the 
Kaplan-Meier method. Logistic regression was used 
to assess treatment effect, dose response 
relationships and the effect of covariates. 
Intention to treat analysis? Described as ITT, defined as all randomised who 
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received at least one dose of study drug, so not 
strict ITT analysis 
Does statistical technique adjust for confounding? 
Covariates included in models were malignancy 
type, sex, baseline Hb (categorical variable), RBC 
transfusions in 4 weeks before randomisation, 
baseline serum endogenous erythropoietin 
concentration (categorical vaiable) 
Power calculation (priori sample calculation)? NR 
Attrition rate (loss to follow-up)? 
N=3 of the 66 recruited to the four study groups (two 
pts in darbe groups withdrawn due to delay in 
chemo; one in placebo group withdrew consent) 
Was attrition rate adequately dealt with? Not clear, although attrition rate low 
Number (%) followed up from each condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) Lymphoproliferative 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Chemo (type NR) 
Adjuvant anaemia treatment 
Iron NR 
G-CSF NR 
Transfusion trigger 
RBC transfusions were 
recommended for pts with 
Hb concentrations ≤8.0g/dl. 
Hb inclusion criteria level ≤11.0 g/dl 
 
Arm 1 =  
Darbe 
N=22 
Arm 2 =  
Placebo 
N=11 
Arm 3 =  
N =  
Sex        
male, n (%) 14 (64) 2 (18)   
female, n (%) 8 (36) 9 (82)   
Age years median (range) 69 (20-84) 63 (25 -80)   
Mean (SD) neutrophil count 
(X109/l) 2.9 (2.2) 7.0 (7.5)   
RBC tfn during 4 wks pre-
randomisation, n (%) 4 (18) 2 (18)   
Haemoglobin g/dl, Mean (SD) 9.4 (1.3) 9.5 (1.0)   
Mean (SD) platelet count (X109/l) 232.4 (157.6) 283.1 (188.6)   
Median (range) Endogenous 
serum erythropoietin (U/l) 69 (12-1362) 45 (12-132)   
Lymphoma, n (%) 
Hodgkin’s disease 4 (18) 3 (27)   
NHL 11 (50) 3 (27)   
CLL 1 (5) 2 (18)   
Multiple myeloma, n (%) 6 (27) 3 (27)   
Median (range) Serum ferritin µg/l 430 (15-1288) 524 (14-2178)   
Median (range) Transferrin 
saturation (%) 25 (6-71) 18 (9-37)   
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Were intervention and control groups comparable? 
 
No; Stated that there was a higher proportion of 
women in placebo group, and that neutrophil and 
platelet counts were higher in placebo group. No 
analyses presented to support these statements. 
RESULTS 
 
Arm 1=  
Darbe n=22 
Arm 2 =  
Placebo n=11 
Arm 3 =  
N =  p  
       
Haematology 
Proportion pts with 
haematologic response 55% 10%   
Analysis 
comparing 
these two 
groups 
NR 
Median time to response 13 weeks (1-13) Not estimated    
% pts with a haematopoietic 
response (95% CI) 60 (39-81) 19 (0-43)    
Mean change (95% CI) in Hb 
from baseline to wk 13 1.64 (1.05-2.24) 1.00 (0.55-1.45)    
Transfusions 
% patients transfused (95% 
CI)) 27 (9-46) 45 (16-75)    
Health-related QoL 
NR 
Adverse effects of tmt 
Note: safety data given for all three darbe groups combined versus placebo. Most AEs are presented 
graphically (bar chart), and it is not possible to extract exact data from the chart. 
 Darbe n=55 Placebo n=11    
At least one AE during study 
period, n (%) 52 (95%) 10 (91%)    
Rapid rise in Hb ≥2g/dl within 28 
day period 22 (40%) 1 (9%)    
Changes in lab measures and vital signs were reported as ‘similar between patients receiving darbepoetin 
alpha and placebo’. 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Yes, computerised 
stratified system 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the triallist) 
Unclear, stated as 
central computer 
but further details 
not provided 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? 
Higher proportion of 
women in placebo 
group (but sex 
included as 
confounder in 
models), neutrophil 
and platelet counts 
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higher in placebo 
group 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  Yes 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? Yes 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? Yes 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? Yes 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? Partially* 
NOTES: 
 Four study groups: darbe 1.0µg/kg (n=11); darbe 2.25 µg/kg (n=22); darbe 4.5µg/kg (n=22); 
placebo (n=11). Only darbe 2.25 µg/kg (n=22) and placebo (n=11) relevant to this review. 
 Withdrawals given for the three darbe groups combined (n=2), although only one of these 
groups is relevant to this review  
OTHER 
Generalisability Small sample sizes. Analyses conducted using combined 
data from the three darbe groups versus placebo, but only 
one of the darbe groups is relevant to this review 
Author conclusions The results of the study indicated that darbepoetin alpha, 
administered once weekly at doses of 1.0, 2.25, and 4.5 
µg/kg, was associated with greater effects on haemoglobin 
than placebo in patients with lymphoproliferative 
malignancies. 
Reviewer comments Difficult to interpret results specifically for the dosage 
relevant to this review 
 
Endnote Ref ID 
 
2704 Malignancy type Lymphoproliferative 
Treatment Darbepoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Hedenus 2003 N   
Objective To evaluate the efficacy 
and safety of darbepoetin 
alfa in anaemic patients 
with lymphoproliferative 
malignancies. The study 
included patients with 
myeloma and lymphoma, 
and was stratified to 
enable a comparison of 
darbepoetin alfa and 
placebo within each 
malignancy type. 
Inclusion criteria 
 Men and women aged 18 or over  
  lymphoproliferative malignancies 
(Hodgkin’s disease, non-Hodgkin’s 
lymphoma, chronic lymphocytic 
leukaemia, or multiple myeloma) 
 Anaemia (Hb ≤11 g/dl), primarily due to 
cancer or chemotherapy (i.e. serum folate 
‡ 4Æ5 nmol/l and vitamin B12 ‡ 148 
pmol/l, no haemolysis, and no 
gastrointestinal bleeding 
 ECOG performance status 0-3. 
 Pts scheduled to receive cytotoxic chemo 
for at least 12 additional weeks 
# centres  
Other references/aliases 49 
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Geographical setting   Pts anaemia was primarily due to cancer 
or chemotherapy  
 Pts had adequate renal and liver function 
(serum creatinine concentration ≤177 
lmol/l, serum bilirubin ≤ 1.5 times the 
central laboratory upper limit of normal) 
 life expectancy of  ≥4 months 
 
Exclusion criteria 
 Burkitt’s or lymphoblastic lymphoma,  
 were scheduled toreceive a stem cell 
 transplant within 16 weeks of 
randomization 
 had received myeloablative 
chemotherapy, 
 radiotherapy for transplantation, or 
chemotherapy regimenscontaining 
investigational agents 
 transferrin saturation <15% and ferritin 
 <10 lg/l 
 significant central nervous system, 
cardiac, or 
 inflammatory diseases; 
 or any known primary haematological 
 disorders that could cause anaemia 
 Patients were not to have received 
epoetin 
 within 8 weeks, >2 RBC transfusion within 
4 weeks, or any RBC transfusion within 2 
weeks before randomization. 
Duration of treatment Secondary analysis in 
Littlewood 2006  (#375) 
Length of follow-up (if 
different) 
Europe, Australia and 
Canada 
Country of corresponding 
author 
12 weeks 
Language of publication Unclear, a median follow-
up period of approximately 
11 months 
Sources of funding Sweden 
RANDOMISATION & 
ALLOCATION 
Central randomization 1:1 to receive DA or placebo. Randomization was 
stratified to balance the treatment groups with respect to malignancy type 
(lymphoma vs myeloma), region (Australia vs Canada vs Western Europe) 
and chemotherapy before randomization (heavily pre-treated vs not heavily 
pretreated; NB * patients were considered heavily pre-treated if they received 
two or more lines of chemotherapy, or one line of chemotherapy and a stem 
cell transplant) 
TREATMENT ARMS 
ARM Drug name/s Darbepoetin alfa Placebo 
N 174 170 
Dose & freq (od, bd etc) 2.25 ug/kg  
Dose adjustment Y/N 
Y: doubled for patients who had ≤ 1 
g/dl Hb increase from baseline after 4 
weeks of treatment. It was withheld if 
a patient’s haemoglobin value 
increased to > 15g/dl for men or > 14 
g/dl for women, and was to be 
reinstated at 50% once Hb ≤13 g/dl. 
 
Route of administration Subcut  
Duration of epo tx 12 weeks  
Adj anaemia treatment Iron therapy were at the discretion of  
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the investigators 
Transfusion trigger 
transfusion policies were left to the 
discretion of the investigators, 
recommended If Hb≤8 g/dl. 
 
OUTCOMES 
Primary 
outcome 
HaemR 
(proportion of 
pts with Hb 
response*) 
Other outcomes 
HaemR (proportion of pts with 
haematopoietic response); RBCT (incidence 
of transfusions from week 5 to the end of the 
treatment (and from Wk 1 to the end of the 
treatment); tumour response (continue to be 
collected during a long-term follow-up period); 
survival (continue to be collected during a long-
term follow-up period); AEs (AE and antibody 
formation); HRQL (FACT-Fatigue (every 4 
weeks on d 1 of each cycle of chemotherapy, 
before any other study procedures) 
NOTES: 
* haemoglobin response, defined as an increase in haemoglobin of ≥2 g/dl from baseline in the absence of 
any RBC transfusions during the previous 28 days 
$ haematopoietic response=haemoglobin response or a haemoglobin concentration ≥12 g/dl in the 
absence of any RBC transfusions during the previous28 days 
£ completers analysis= pts with ≥ 12 weeks of treatment (had a week 13 Hb with no transfusions during the  
preceding 28 days) 
ANALYSIS 
Statistical technique used? 
The Kaplan–Meier method was used to estimate the 
percentages of patients with a Hb response, haematopoietic 
response or RBC transfusion, because of the anticipated 
withdrawal rate and approximate 95% CI were calculated using 
Greenwood’s formula. Statistical comparisons of these 
percentages between treatment groups were based on the chi-
squared test. 
 
Cox proportional hazards modelling was performed as an 
exploratory analysis to evaluate the effect of baseline serum 
erythropoietin (≤100 vs > 100 IU/l) on the time to Hb response. 
 
The mean (±SEM) change in Hb concentration was assessed in 
two ways: first, by subtracting the baseline Hb value from the last 
value during the treatment phase; and, second, by evaluating 
completers analysis£. 
 
Efficacy endpoints were analysed with and without adjusting for 
the stratification factors of malignancy type, region and 
chemotherapy before randomization. Results of these analyses 
were similar; thus, only the results of the unadjusted analyses are 
presented. 
 
Exploratory analyses of changes in the FACT-Fatigue subscale 
were conducted using ANOVA.  The relationship between the 
change in the FACT-Fatigue subscale and the change in Hb was 
investigated using simple linear regression 
 
Intention to treat analysis? Y: ITT population (N=344)  = all patients who received at least 
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one dose of study drug, was used in the analyses of efficacy and 
safety;  
With the exception of transfusion endpoints,valuated during week 
5 to the end of the treatment phase: these endpoints, patients 
who did not complete the first 4 weeks of treatment were 
excluded from the analysis (N=332). 
For Hb and haematopoietic response, patients who withdrew 
from the study early for any reason were censored at the time of 
withdrawal. For the RBC transfusion endpoints, patients who 
withdrew from the study before the completion of the treatment 
period were considered to have been transfused, and patients 
who withdrew because of either  disease progression or death 
were censored at the time of withdrawal. 
Does statistical technique adjust for 
confounding? NR 
Power calculation (priori sample 
calculation)? 
Y: sample size to detect an increase in Hb response rates from 
25% in the placebo group to 50% in the darbepoetin alfa group 
within each malignancy type with 90% power at a two-sided 
significance level of 0.05 (estimated withdrawal rate of 10% 
during the 12 weeks study) 
Attrition rate (loss to follow-up)? Y: until the end of treatment 
Was attrition rate adequately dealt 
with? Yes 
Number (%) followed up from each 
condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type   (e.g.solid / solid head neck, lung, ovarian, 
cervical / haem / MDS / mixed) Lymphoproliferative 
Treatment (e.g. chemotherapy platinum / non-platinum based; 
chemo + radio; no specific malignancy treatment; not reported) 
Chemotherapy – no further 
details given 
Adjuvant anaemia treatment 
Iron Iron therapy were at the discretion of the investigators 
G-CSF None 
Transfusion trigger at the discretion of the investigators, recommended If Hb≤8 g/dl. 
Hb inclusion criteria level ≤11 g/dl 
 Darbe N =174 
Placebo 
N = 170 
Arm 3 =  
N =  
male (%) 87 50% 78 46%   
female (%) 87 50% 92 54%   
Age years, mean (SD) 64.8 13.8 64.6 12.2   
ECOG : 0 54 31% 43 25%   
       1 80 46% 92 54%   
2 32 18% 28 16%   
>2 8 5% 6 4%   
Missing 0 0% 1 1%   
Hb baseline , g dl-1 , mean (SD) 9.59 1.22 9.5 1.21   
Ferritin, µg/l 
Median, range 324.5 5-5352 253.5 15-5027   
Transferrin saturation, %  26.5 5-95 25 4-95   
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Median, range 
Serum Epo baseline (mU ml-1) 
Median, range 68.99 2.3-1522.7 54.49 10.9-3169.1   
Prior chemotherapy, n (%) 
Heavily pretreated** 46 26% 47 28%   
Not Heavily pretreated* 128 74% 123 72%   
Malignancy type, n (%) 
Lymphoma (Hodgkin’s disease, non-
Hodgkin’s lymphoma, chronic 
lymphocytic leukaemia) 
85 49% 86 51%   
Multiple myeloma 89 51% 84 49%   
Were intervention and control groups 
comparable? 
No p values reported, authors stated “baseline 
demographic and clinical characteristics were generally 
well balanced between the treatment groups”. 
RESULTS 
 Darbe N =174 
Placebo 
N = 170  Difference p  
Haemoglobin response * 
% (95% CI) 60% 52-68% 
18% 12-24% 42% (32-52%) P<0.001 
Haematopoietic response$ 65% 57-73 24% 18-31   P<0.001
Mean change in Hb (SEM) ; ITT 1.8 0.17 0.19 0.1   P<0.001
Mean change in Hb (SEM) ; 
completers analysis£ 2.66 0.2 0.69 0.14   P<0.001
Lymphoma subgroup N =85 N = 86   
Haemoglobin response  
% (95% CI) 64%  13%  51% P<0.001
Myeloma subgroup N =89 N = 84   
Haemoglobin response  
% (95% CI) 56%  23%  33% P<0.001
baseline serum erythropoietin 
levels ≤ 100 IU/l, N =89 N = 84    
Haemoglobin response  
% (95% CI) 69% 60-79% 16% 9-22%   
baseline serum erythropoietin 
levels > 100 IU/l, N =89 N = 84    
Haemoglobin response  
% (95% CI) 44% 31-58% 25% 11-39% 19% (0-38%)  
        
 N =167 N = 165    
Transfusions ; from week 5 to 
end of treatment 31% 24-38% 48% 41-56%   P<0.001
When the data were analysed within each malignancy type, darbe was associated with a reduction in 
transfusions compared with placebo both in pts with lymphoma (27% vs 49%,P =0.002) and pts with 
myeloma (35% vs 48%, P =0.042) 
Transfusions ; from week 1 to 
end of treatment     
17% 
(6-27%) P<0.001
This reduction in transfusions with darbe compared with placebo was observed both in pts with lymphoma 
(P =0.011) and pts with myeloma (P=0.018) 
        
Change in FACT Fatigue subscale score from baseline to EOTP: 
(84% of pts completed the FACT-Fatigue subscale at week 13) 
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Improvement in FACT-Fatigue subscale score compared with placebo, regardless of their level of fatigue at 
baseline. Patients with the lowest baseline FACT-Fatigue subscale scores reported the largest 
improvement in FACT-Fatigue subscale score at EOTP. After adjusting for the effect of baseline score, 
increases in FACT-Fatigue subscale scores with darbepoetin alfa treatment were significantly greater than 
those observed with placebo (P=0.032). 
For every 1 g/dl increase in haemoglobin, the estimated mean increase in FACT-Fatigue subscale score 
was 1Æ39 (95% CI 0.83-1.94); p<0.001. 
For FACT change scores in the Lymphoma and Myeloma subgroups, see Littlewood 2006. 
        
Adverse effects         
Deaths(during the study or 
within 30 d after the last dose of 
study drug) 
10 6% 4 2%    
Withdrawal due AE (not 
including death)  3%  4%    
        
No evidence of neutralizing antibodies to darbepoetin alfa  was detected for any patient. 
        
Iron supplementation received; 
oral 
 6%  7%    
Iron supplementation received; 
subcutaneous 
 0%  1%    
        
Survival  
a median follow-up period of approximately 11 months 
PFS 82 47% 76 45%    
        
NOTES: 
One patient was randomized to receive placebo, but received darbepoetin alfa as the result of an error at 
the study centre. Efficacy data for this patient were analysed in the placebo group, and safety data were 
analysed in the darbepoetin alfa group. 
** Prior chemotherapy: Heavily pre-treated = Two or more lines of chemotherapy or one line of 
chemotherapy and a stem cell transplant 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, 
date of birth, alternate; Unclear = if the method not stated) 
Y 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered 
coded vials; other methods where the triallist allocating treatment could not 
be aware ; Inadequate = allocation was alternate, or based on information 
known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? 
No p values reported, 
authors stated “baseline 
demographic and clinical 
characteristics were 
generally well balanced 
between the treatment 
groups”.  
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Y 
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5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  Y 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? Y 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? Y 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPORTED? N 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS 
OR WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? 
Yes, ITT defined as 
all randomised who 
received ≥ 1 dose of 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN 
EACH GROUP STATED? Y: until the end of treatment 
NOTES:  
References: investigates the effects of HB levels on fatique and examines the relationship between 
improvement in fatigue andHRQoL: 
Littlewood, Timothy J.; Kallich, Joel D.; San Miguel, Jesus; Hendricks, Lisa; Hedenus, Michael. (2006). 
Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients 
with lymphoproliferative malignancies. Journal of Pain & Symptom Management, 31, 317-325 
 
OTHER 
Generalisability yes 
Author conclusions The efficacy of darbepoetin alfa was consistent for patients with lymphoma 
or myeloma. Improvements in quality of life were also observed with 
darbepoetin alfa. The overall safety profile of darbepoetin alfa as consistent 
with that expected for this patient population. Darbepoetin alfa significantly 
increased haemoglobin and reduced red blood cell transfusions in patients 
with lymphoproliferative malignancies receiving chemotherapy. 
Darbepoetin alfa demonstrated clinically important improvements in 
response rate relative to placebo, regardless of baseline endogenous 
erythropoietin level. 
Reviewer comments  
 
Endnote Ref ID 
 
2705 Malignancy type Solid – breast, gynae, GI, lung, other 
Treatment Chemo: darbepoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Kotasek, 2003 N  249 
Objective To assess the safety of 
darbepoetin alfa in 
patients with cancer 
receiving chemotherapy & 
to assess the feasibility of 
administering darbepoetin 
alfa Q3W & to 
characterise the dose-
repsonse relationships for 
darbepoetin alfa when 
given Q3W 
Inclusion criteria: Patients ≥18 years of age with 
solid tumours receiving cyclic chemotherapy ; ≥6 
month life expectancy, ECOG performance status 
of 0-2; adequate liver and renal function; 
anaemia (Hb level ≤11.0 g/dl) due to cancer 
and/or chemotherapy 
 
Exclusion  criteria: Patients who: were iron-
deficient (transferrin saturation <15% and ferritin 
10 mcg/l; had received recombinant human 
erythropoietin within 8 weeks before 
randomisation; >2 RBCTs within 4 weeks of 
randomisation; any RBCT within 2 weeks of 
randomisation; known primary haematological 
# centres 26 
Other references/aliases None 
Geographical setting Australia, Canada, Costa 
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Rica, & Europe disorders that could cause anaemia & central 
nervous system, cardiac, or inflammatory 
diseases 
Duration of treatment 12 weeks (double-blind 
treatment. NB: study in 2 
parts (Part B open-label 
treatment period Wk 12 to 
24) 
Length of follow-up (if 
different) 
Unclear: 8-week 
observation period after 
last dose of study drug at 
Wk 12 ( Fig 1 shows Part 
A of study has obs period 
running to Wk 18, thus 6 
weeks), however results 
for the observation period 
are not  reported. 
Country of corresponding 
author Australia 
Language of publication English 
Sources of funding Supported by Amgen Inc, 
USA 
RANDOMISATION & 
ALLOCATION 
Randomised, double-blind, placebo-controlled, dose-finding study of 
darbepoetin alfa  
Randomised 4:1 to receive darbepoetin alfa (4.5, 6.75, 9.0 or 13.5 µg/kg) or 
placebo. Later, after review of data by the safety monitoring committee, dose 
cohorts of 12.0 and 15.0 µg/kg were added, thus a 5-arm study. 
TREATMENT ARMS 
ARM Drug name/s Darbepoetin alfa Placebo 
N 17 51 
Dose & freq (od, bd etc) 
6.75 µg/kg Q3W * 
(2.2 mcg/kg QW) 
The mean administered number of 
darbepoetin alfa doses over the 12-
week treatment phase was 3.6. 
NR 
Dose adjustment Y/N 
Y: No dose increase for inadequate 
response was allowed in the double-
blind part of the study. If Hb level 
increased to >15.0 g/dl for men or 
≥14.0 g/dl for women treatment was 
interrupted & reinstated at a lower 
dose level when Hb level was ≤13.0 
g/dl  
NR 
Route of administration Subcutaneous NR 
Duration of epo tx 12 weeks 12 weeks 
Adj anaemia treatment NR NR 
Transfusion trigger NR NR 
OUTCOMES 
Primary 
outcome 
AEs (incidence of AE by dose 
and treatment group and 
formation of antibodies) 
Other 
outcomes
HaemR (responders; HaemR; Hb 
level (chg from baseline); RBCT ((Wk 
5 to EOTP); HRQL (FACT-General, 
FACT-Fatigue) 
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NOTES: 
Pre-dose  and 48-h post-dose serum samples (darbe concentration) were collected at Weeks 1, 4, 10; QOL 
assessments at Weeks 1, 4, 7, 10 (to assess the feasibility,reliability, validity, sensitivity and timing of QOL, 
rather than to evaluate fatigue 
Responders = increase in Hb of ≥2.0 g/dl during the treatment phase in the absence of any RBCTs in the 
previous 28 days 
Haematopoietic response = haematologica response and/or haemoglobin concentration of ≥12.0 g/dl 
during the treatment phase in the absence of any RBCT in the previous 28 days 
AEs- classified using a modified WHO AE term dictionary 
ANALYSIS 
Statistical technique used? 
Proportion of patients per dose group (haemoglobin 
response, haematopoietic response)  estimated by taking 1 
minus the Kaplan-Meier estimate of the survivor function at 
the time of the last observed endpoint. Approx. 95% CI for 
the Kaplan-Meier estimate of the proportion were calculated 
using Greenwood’s estimate of the variance & assuming a 
normal distribution for the Kaplan-Meier estimate. 
 
Incidence of RBCT a subset was used  (transfusions from 
week 5 to EOTP): all patients who received at least one 
dose of study drug and who ended their treatment phase 
during week 5 or later. Patients who have more than one 
transfusion were counted only once in calculating the 
incidence of transfusions. 
 
Chg in Hb  from baseline 
 If a patient had a RBCT within 28 days of the last 
treatment-phase Hb value, then the last pre-
transfusion Hb value was substituted to discount the 
effect of RBCT on the chg in Hb. All patients had an 
observed or imputed value for this analysis (pts who 
withdrew after one dose were given a chg score of 
zero).  
 Using the set of patients who completed at least 12 
weeks of treatment. 
 
ESTABLISHED POST-HOC tests (not specified in 
protocol): Trend tests were conducted using a distribution-
free test (asymptotic p values were obtained using the 2-
sided Jonckheere-Terpstra test) to investigate the dose 
relationship of darbepoetin alfa:  
 mean chg in Hb at EOTP across dose groups 
 mean change in FACT-F across categorised 
chg in Hb (chg in Hb at last available QoL 
assessment) 
Intention to treat analysis? Analyses conducted on patients randomised to study drug who received at least one dose 
Does statistical technique adjust for 
confounding? NR 
Power calculation (priori sample calculation)?
Statistically based on the secondary objectives to 
determine a clinically effective dose, by means of 
estimating Hb response rates. 4:1 randomisation allowed 
for 36 darbepoetin alfa patients per dose cohort. 
Anticipated premature withdrawal rate of approximately 
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20%, a sample size of 29 allows estimation of the Hb 
response rate within a standard error of 0.09.  
Exact number of patients in each cohort was determined by 
the rate of enrolment & how long it took the data monitoring 
committee to determine safety before allowing dose 
escalation 
Attrition rate (loss to follow-up)? Yes (detailed in patient flow chart in Fig 2 of paper) 
Was attrition rate adequately dealt with? Yes 
Number (%) followed up from each 
condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) 
Solid – breast, gynae, GI, 
lung, other 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Chemo: NR 
Adjuvant anaemia treatment 
Iron NR 
G-CSF NR 
Transfusion trigger NR 
Hb inclusion criteria level ≤11.0 g/dl 
 
Arm 1 =  
Darbepoetin alfa 
N-198 
Arm 2 =  
Placebo 
N=51 
Arm 3 =  
N =  
Baseline demographics and clinical characteristics reported for all darbepoetin alfa patients not 
separated out by dose 
Sex     
Male, n (%) 56 (28%) 16 (31%)   
Female, n (%) 142 (72) 35 (69)   
Age years mean (SD) 58.3 (11.9) 56.2 (12.4)   
Performance status; ECOG 
<2, n (%) 180 (91) 45 (88)   
Type of solid tumour 
Breast  61 (31) 13 (25)   
Gynaecological 46 (23) 9 (18)   
Gastrointestinal 34 (17) 13 (25)   
Lung 33 (17) 10 (20)   
Other 24 (12) 6 (12)   
Hb (g l-1), mean (SD) 99.3 (10.0) 98.7 (11.2)   
Hb (g dl-1), mean (SD) 9.93 (1.00) 9.87 (1.12) PenTAG calculated 
Ferritin(mcg/l) <50, mean 
(SD) 21 (11) 3 (6)   
Endogenous epo baseline 
(pts with ≥100 mU ml-1); n 
(%) 
N=183 N=47   
32 (17) 7 (15)   
Mean (SD) FACT-F Score;  
Darbe and placebo 
combined 
QoL population N=239   
27.2 (12.4)   
Were intervention and No p values reported, authors stated: “In general, baseline demographic 
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control groups comparable? and clinical characteristics of patients were well balanced between the 
darbepoetin alfa and placebo groups. A slightly higher proportion of patients 
in the 12.0-mg/kg group had breast cancer (61%) compared with the other 
groups, which ranged from 15 to 38%. The 12.0-mg/kg group also had a 
slightly higher mean baseline Hb concentration (104 g/l) compared with 
mean concentrations between 97 and 102 g/l for the other groups. No 
clinically meaningful differences in pretreatment chemotherapy were seen 
between the darbepoetin alfa and placebo patients (data not shown)”. 
 
RESULTS: data extraction for 6.75 mcg/kg Q3W and placebo arms only 
 
 
Arm 1 =  
Darbepoetin alfa 
6.75 mcg/kg Q3W 
N=17  
(of total 198) 
Arm 2 =  
Placebo 
N=51 
Arm 3 =  
N =  p  
Hb 
Responders,  
K-M proportion (95% CI) 52 (27-78) 31 (16-45) 
Haemoglobin values within 28 
days of a red blood cell 
transfusion have been 
omitted 
Chg in Hb from baseline 
to EOTP (g/l), mean (SE) 8.6 (3.8) -0.2 (2.0) 
g/dl PenTAG calculated 0.86 (0.38) -0.02 (0.2) 
Chg in Hb from baseline 
after 12 weeks (g/l)*, 
mean (SE) 
n=11 n=37 
10.2 (5.4) 3.1 (2.4) 
g/dl PenTAG calculated 1.02 (0.54) 0.31 (0.24) 
* Chg after 12 weeks, a window was used allowing Wk 12 or 14 to be sued in the absence of an evaluable 
Wk 13 Hb value (Using the set of patients who completed at least 12 weeks of treatment). 
Safety: withdrawal due to: 
Deaths 7 (4%) 3 (6%)   
Tumour progression 6 (3%) 0   
AE 1 (1%) 0   
Adverse events are not reported by dose. 
Authors state: “No relationship between the dose and adverse events was noted.” AND “ AEs reported 
were comparable between the darb alfa and placebo patients and generally consistent with those expected 
for patients being treated with myelosuppressive chemotherapy.” 
 
Results presented graphically  
 
 
Fig. 3. Adverse events that occurred with 515% incidence in patients receiving darbepoetin alfa or placebo. 
Grey bars, darbepoetin alfa (n=198);solid bars, placebo (n=51). 
RBCT (Wk 5 to EOTP) 
N=188 N=50   
Results presented graphically  
Results presented graphically 
 
FOR ALL DOSES FYI: A lower percentage of patients in the darbepoetin alfa group required RBCT Wk 5 
to EOTP compared with patients receiving placebo (46% (95% CI 32-61). No differences between the 
darbepoetin alfa groups could be observed: transfusion rates varied from 19% (95% CI 6-32) to 30% (95% 
CI 16-44). 
 
HRQoL: Chg in QoL FACT-F score baseline to EOTP by change in haemoglobin 
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Results presented graphically 
 
FOR ALL DOSES FYI: Mean chg in FACT-F score appears to increase with increasing Hb concentration, 
from roughly no change in patients who had no improvement in their Hb to an approx.. 5-point improvement 
in patients whose Hb increased by >2.0 g/dl. A trend test of the relationship between FACT-F score and Hb 
concentration was significant at a level of p=0.0023 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM 
ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients 
number, date of birth, alternate; Unclear = if the method not stated) 
Unclear; process not described  
2. WAS THE TREATMENT ALLOCATION ADEQUATELY 
CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially 
numbered coded vials; other methods where the triallist allocating 
treatment could not be aware ; Inadequate = allocation was 
alternate, or based on information known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? 
No;* 
No p values reported, authors state: 
“ In general, … well balanced 
between groups” and “a slightly 
higher proportion of patients in the 
12.0-mg/kg group had breast cancer 
(61%) and  higher mean baseline 
Hb concentration (104 g/l) 
compared with the other groups. 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT 
ALLOCATION?  Yes 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? yes 
7. WERE THE POINT ESTIMATES AND MEASURE OF 
VARIABILITY PRESENTED FOR THE PRIMARY OUTCOME 
MEASURE? 
Partially: presented AEs ≥15% 
incidence in pts for all darb alfa 
doses don’t separate out by dose 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT 
ANALYSIS OR WERE LESS THAN 10% OF EACH STUDY ARM 
EXCLUDED? 
Yes, all randomised  
who received ≥ 1  
dose of study drug  
were analysed (100%  
and 95% participants  
in epo and  
placebo respectively). 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-
UP IN EACH GROUP STATED? 
Partially; only until the end of the 
double blind study. 
NOTES: 
* yes for the placebo and 6.75 µg/kg Q3W (2.2 mcg/kg QW) darbe subgroup 
OTHER 
Generalisability Dose-finding study 
Author 
conclusions 
Administration of darbepoetin alfa Q3W is well-tolerated & effective in the treatment of 
anaemic patients receiving chemotherapy. Need for further research to investigate 
proportion of patients responding to treatment and the time to achieve response in this 
setting. Ability to administer Q3W as well as the possibility of administering darbepoetin 
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alfa to coincide with chemotherapy that is administered Q3W, represents an opportunity 
to simplify the treatment of anaemia and fatigue in cancer patients undergoing 
chemotherapy. 
Reviewer 
comments 
 
 
Endnote Ref ID 
 
2691 Malignancy type Solid 
Treatment rHuEPO assume epoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Kurz, 1997 N   
Objective To evaluate the 
effectiveness of rHuEPO 
with respect to increasing 
Hb levels and decreasing 
RBCT requirements & to 
assess the influence on 
QoL parameters 
Inclusion criteria: Patients between 18 and 75 
years; Hb level <11 g/dl; ferritin serum levels 
>29 ng/ml; stool negative for occult blood; life 
expectancy >3 mths 
 
Exclusion  criteria: clinically significant disease 
or dysfunction of the pulmonary, cardiovascular, 
endocrine, neurological, GI or genitourinary 
system not attributable to the underlying 
malignancy; uncontrolled hypertension (DBP 
>100 mmHb; anaemia attributable to factors 
other than chronic neoplastic disease, such as 
vitamin B12 deficiency, iron deficiency, and ferritin 
serum levels <29 ng/ml, GI bleeding or 
autoimmune haemolysis, acute illness within the 
last 7 days, & creatinine >2.5 mg/dl 
# centres 4 
Other references/aliases None 
Geographical setting Austria 
Duration of treatment 12 weeks 
Length of follow-up (if 
different) NR 
Country of corresponding 
author Austria 
Language of publication English 
Sources of funding Supported in part by 
Janssen-Cilag Austria 
RANDOMISATION & 
ALLOCATION 
Random permuted blocks and a corresponding randomisation list was used in 
the randomisation office at Cilag-Janssen. A 2:1 ratio between rHuEPO and 
placebo was implemented  
Randomisation code broken after documentation of all data 
TREATMENT ARMS 
ARM Drug name/s rHuEPO (Erypo® EPO ALFA) Placebo 
N 23 12 
Dose & freq (od, bd etc) 150 U/kg Q3W 150 U/kg Q3W 
Dose adjustment Y/N 
Y: Hb levels at Wk 4 were <1 g/dl 
above the baseline value each dose 
was increased to 300 U/kg Q3W. If at 
Wk 4 Hb levels were >1 g/dl above 
the baseline value but still within the 
anaemic range, the patient received 
150 U/kg SC Q3W for the next 8 wks 
Y: Hb levels at Wk 4 were <1 g/dl 
above the baseline value each dose 
was increased to 300 U/kg Q3W. If at 
Wk 4 Hb levels were >1 g/dl above 
the baseline value but still within the 
anaemic range, the patient received 
150 U/kg SC Q3W for the next 8 wks 
Route of administration Subcutaneous Subcut. 
Duration of epo tx 12 wks 12 wks 
Adj anaemia treatment 
Iron saccharate substitution following 
each dose of chemotherapy beginning 
with the next cycle 
Iron saccharate substitution following 
each dose of chemotherapy 
beginning with the next cycle 
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Transfusion trigger Hb level <8 g/dl Hb level <8 g/dl 
OUTCOMES 
Primary 
outcome  Other outcomes 
HaemR (Hb levels measured every 4 weeks); 
RBCT (number of transfusions documented); 
HRQoL (VAS, beginning of treatment and then 
every 4 weeks before receiving chemotherapy 
patients completed a standardise questionnaire 
(10-item); VAS (1-5). Self administration; 
collected by a nurse but results not read 
immediately and physician did not comment on 
the results) 
NOTES: 
 
ANALYSIS 
Statistical technique used? 
Significance of the # responders & the # 
transfusions evaluated by Χ2 test. 
 
Differences between the treatment and control 
group shown in Kruskall-Wallis test for variables with 
a non-parametric distribution 
 
QoL described per patient by 10 different scores 
each of which was calculated as the average value 
of Weeks 4, 8 and 12 minus the pretreatment value. 
Described the average of these 10 scores 
separately for each treatment and evaluated the 
significance in an exploratory mode by Student’s t 
test for unpaired samples. A multivariate evaluation 
of all 10 different scores was obtained by Hotelling’s 
T2 test 
 
Effect of achieving response from a state of non-
response is described for each responding patient 
(n=13) by the difference of average QoL score 
values for the items for feeling of wellbeing, level of 
activity, physical ability, and social activities under 
response and non-response 
Intention to treat analysis? 
Assumed ITT: Unclear; results reported for total 
patient population and no reported crossover 
however not reported explicitly in the paper 
Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? Not reported 
Attrition rate (loss to follow-up)? Not reported 
Was attrition rate adequately dealt with? Unclear as attrition rate not reported 
Number (%) followed up from each condition? NA 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) 
Solid – ovarian; cervical; 
uterine 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Plat-based chemother 
(n=28 (17 EPO; 11 PBO)) 
& non-plat based 
chemother (n=7 (6 EPO; 1 
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PBO)) 
Adjuvant anaemia treatment 
Iron 
Iron saccharate substitution 
following each dose of 
chemotherapy beginning 
with the next cycle 
G-CSF NR 
Transfusion trigger Hb level <8 g/dl 
Hb inclusion criteria level Hb level <11 g/dl 
 
Arm 1 =  
rHuEPO EPO ALFA 
N=23 
Arm 2 =  
PLACEBO 
N=12 
P value  
Age years mean ± SD (range) 54.4 ± 9.7 (32-68) 52.7 ± 7.5 (43-63) 0.36* 
Performance status; WHO 
0 - 1 17 9 
0.88** 
1 - 2 6 3 
Type of solid tumour, n 
Ovarian 17 8 
0.64** Uterine sarcoma 3 1 
Cervical carcinoma 3 3 
Hb baseline (g dl-1), mean ± SD 9.88 ± 0.889 9.85 ± 0.60 0.63* 
Haematocrit baseline (ng/ml), 
mean ± SD 29.9 ± 3.1 29.9 ± 1.7 0.95* 
Ferritin baseline (ng/ml), mean ± 
SD 300 ± 255 245 ± 196 0.71* 
* Kruskall-Wallis test; ** Χ2test 
Were intervention and control groups comparable? Yes; no statistically significant differences between the groups were reported 
RESULTS 
 
Arm 1 =  
rHuEPO EPO 
ALFA 
N=23 
Arm 2 =  
PLACEBO 
N=12 
  p  
       
Hb level, mean 
Wk 4 11.3 g/dL No chg    
Wk 8 11.9 g/dL No chg    
Wk 12 13.1 g/dL No chg    
Haem response        
Yes 13 (56.5%) 0 (0%) Χ2 =10.79 0.001 
No 10 (43.5%) 12 (100%) 
Of the 13 responders, 9 responded after 4 weeks of treatment, 2 after 8 weeks of treatment, and after 12 
weeks of treatment in the EPO ALFA arm 
RESPONDER = if HB levels at Wk 4, 8, 12 were >2 g/dl above the baseline value and/or >12 g/dl the 
patient was classified as a responder 
NON-RESPONDERS = pts receiving RBCT (those with Hb level <8 g/dl; erythrocytes <3 x 106/ml; or 
clinical symptoms of anaemia which made transfusion necessary) 
 
Values estimated from figure: 
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Hb  EPO ALFA 
N=23  
PLACEBO 
N=12 
 
4 weeks (mean  and SD) 11.34 1.75 9.82 1.75 
8 weeks (mean  and SD) 11.87 2.25 10.32 2.25 
12 weeks (mean  and 
SD) 
13.14 2.25 10.1 2.25 
 
 
RBCT requirement, n (%) 5 (21.7%) 8 (66.6%) Χ2 = 6.81 0.009 
The 5 patients receiving RBCT in the treatment group, received 33 units for transfusion; whereas 8 of the 
placebo group received 44 blood units 
None of the responding patients had to be transfused during the study period. A 2.5 times increased 
demand of transfusions in the placebo-treated group in comparison to the rHuEPO group 
Health-related QoL – NOT VALIDATED  QUESTIONNAIRE 
Health state utility scale = See notes in Outcomes re questionnaire used 
     p value* 
Feeling of well being 0.004 -0.16   0.77 
Mood -0.21 -0.18   0.94 
Level of activity 0.26 0.58   0.71 
Pain 0.37 -0.26   0.32 
Nausea -0.11 -0.43   0.17 
Appetite -0.32 -0.07   0.61 
Physical ability -0.33 -0.32   0.53 
Social activities -0.04 -0.51   0.89 
Anxiety 1.92 2.45   0.38 
Treatment is helping 1.76 2.34   0.11 
* t test 
Multivariate Hotelling’s T p=0.34 
Adverse effects of tmt 
Well tolerated without any significant side effects (data not reported). No 
local reactions at the injection area nor any dermatitis or eruption could 
be observed 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Yes 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the triallist) 
Unclear, 
Randomisation was 
performed in the 
randomisation 
office, but  details 
on allocation 
concealment were 
not reported 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? Yes 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  Yes 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? Yes 
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7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? 
No; variability 
measure not 
reported, unclear 
what the primary 
endpoint was 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? 
Yes; results report 
response for all 
patients & no 
crossover so 
assume ITT 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? Not reported 
NOTES: 
OTHER 
Generalisability Women only  
Author conclusions rHuEPO significantly increases Hb levels and 
decreases RBCT requirements while maintaining 
QoL in patients with gynaecological malignancies 
who are undergoing polychemotherapy 
Reviewer comments rHuEPO is Epo Alfa (Erypo, Janssen-Cilag) 
 
Endnote Ref ID 
 
2692 Malignancy type solid or non-myeloid haematologic malignancies 
Treatment epoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Littlewood, 2001 N   
Objective To assess the effects of 
epoetin alfa on RBCT 
requirements, 
haematopoetic 
parameters, QoL, and 
safety in patients receiving 
non-platinum based 
chemotherapy 
Inclusion criteria: age ≥18 years; confirmed 
diagnosis of solid or nonmyeloid hematologic 
malignancy and receiving or scheduled to receive 
nonplatinum chemotherapy (with a minimum 
cycle duration of 3 weeks); life expectancy ≥ 6 
months; Hb level: Hb≤10.5  or > 10.5 g/dL but ≤ 
12.0 g/dL with at least 1.5-g/ decrease in Hb 
per cycle/month since beginning 
chemotherapy 
 
Exclusion  criteria: Patients with acute leukemia  
and myeloid malignancies; uncontrolled 
hypertension or untreated iron,folate, or vitamin 
B12 deficiency; previous myeloablative 
chemotherapy ; acute major 
infection or bleeding within 1 month; radiotherapy 
or allogeneic blood transfusion within 14 days;  
severe illness or surgery within 7 days of study 
entry. 
# centres 73 sites 
Other references/aliases Patrick 2005 (#300), 
Aapro 2004 (#755) and 
Bajetta 2004 (#376) and – 
all retrospective analyses 
of this trial 
Geographical setting 15 countries (Germany, 
The Netherlands , United 
Kingdom and Ireland, 
Belgium, Luxembourg, 
Italy , South Africa, 
France, Greece, 
Switzerland, Poland, 
Portugal, Hungary, Czech 
Republic) 
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Duration of treatment Up to 28 weeks 12 to 24 
weeks (3-6 cycles) of 
chemotherapy and a 4-
week period after the last 
dose of chemotherapy 
Length of follow-up (if 
different) 
Survival rates were 
determined 
based on data collected 
during the 12-month 
period after 
the study was completed 
by the last patient 
Country of corresponding 
author UK 
Language of publication English 
Sources of funding Research grant JohRW 
Johnson Research 
Institute and Ortho 
Biotech Europe / Janssen 
Cilag 
RANDOMISATION & 
ALLOCATION 
Stratified by tumor stratum (solid or ematologic) and haemoglobin level (≤10.5 
g/dL, or ≤ 12.0 but  > 10.5 g/dL). 
Double blind trail, but concealed allocation not reported. 
TREATMENT ARMS 
ARM Drug name/s Epo alfa Placebo 
N 251 124 
Dose & freq (od, bd etc) 150 IU/kg three times  a week Matching volume to epo alfa 
Dose adjustment Y/N 
Y : at 4 weeks: Dose was doubled if 
Hb increase <1 and  the  reticulocyte 
count increase <40,000 above BL. 
Dose reduction by 25%  if Hb 
increased ≥2 per month or cycle. 
If at any time Hb >15, medication was 
interrupted till Hb <12, restarted with 
25% dose reduction. 
  
 
Route of administration Subcutaneously Subcutaneously 
Duration of epo tx Up to 28 weeks Up to 28 weeks 
Adj anaemia treatment Oral daily dose of 200 mg of elemental iron daily 
Oral daily dose of 200 mg of 
elemental iron daily 
Transfusion trigger   
OUTCOMES 
Primary 
outcome 
RBCT 
(proportion of 
patients 
transfused 
after first 4 
weeks of 
treatment) 
Other outcomes 
HaemR (chg in Hb level (baseline to last value); 
proportion of responders); Survival; HRQoL 
(chg in QoL score (baseline to last value) on 5 
cancer specific scales [FACT-An, FACT-G 
Total, FACT-An Fatigue, CLAS, LASA]) 
NOTES: 
RESPONDERS = patients with an increase in Hb level ≥2 g/dl unrelated to transfusion; i.e. no transfusion 
within 28 days before measurement 
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ANALYSIS 
Statistical technique used? 
Primary endpoint analysed for ITT and EFF 
populations (see below). Patients on study 28 days 
or less were counted as transfused for the ITT 
analysis. The analyses were performed using a 
logistic regression model that included terms 
correcting for the main effects of treatment group, 
primary tumour stratum (solid or haem), and 
haematologic stratum (≤10.5 g/dl or >10.5 g/dl). 
Since the interaction terms for treatment by tumour 
stratum and treatment by haemoglobin stratum were 
not significant at the 10% level, they were not 
included in the model 
 
Secondary efficacy variables (other than QoL) were 
analysed for the EFF population. Chgs in Hb level 
from baseline to last value were compared by t 
tests, and the proportions of responders were 
compared by the Fisher’s exact test. 
 
Univariate analysis was performed to test within-
group mean QoL change scores for differences from 
0 with a paired t test, and differences in mean 
change scores between the treatment groups were 
examined using independent sample t tests (2-
sided). The p values for the primary QoL measures 
were adjusted for multiple comparisons using a 
sequentially rejective version of the Bonferroni 
procedure. All hypothesis tests were performed on 
the adjusted p values.  
 
In a separate analysis Pearson correlation 
coefficients were calculated to assess the 
relationship between change in Hb level and QoL 
scores for each primary QoL measure 
 
Protocol not designed or powered for survival was 
amended before unblinding and study end to permit 
prospective analysis of survival. Information for this 
analysis was collected 12 months after study end, 
and survival distributions were estimated using 
Kaplan-Meier curves, which were compared by 
means of log-rank tests. In addition to compensate 
for the variable survival times associated with 
different malignancies, Kaplan-Meier estimates of 
survival by tumour strata (haem vs solid) were also 
performed. Further analysis with the Cox regression 
model was performed using a stepwise selection 
procedure to correct for effects of potential 
prognostic factors on patient survival. 8 factors were 
tested for; 4 – tumour stratum, baseline Hb level, 
age and area under the curve for neutrophils were 
found to be significant and included in the model 
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For all analyses p<0.05 was considered significant. 
The study was not powered for subgroups 
Intention to treat analysis? 
Partially. 
 
Three populations were used for the efficacy 
analyses: the intent-to-treat population, which 
included all randomized patients; the efficacy group, 
which included all randomized patients on study >28 
days (EFF); and the QoL population, which was 
defined as all patients who had been randomized, 
received the study drug, and had a baseline and at 
least one follow-up QoL assessment. Safety 
population was same as for ITT population. 
 
Baseline demographics and primary efficacy 
variable analyses for both the ITT and EFF 
population. Secondary variables other than QoL 
domains were analysed for the EFF population 
Does statistical technique adjust for confounding? Not reported 
Power calculation (priori sample calculation)? Not reported 
Attrition rate (loss to follow-up)? 
Yes:16 pts (7 receiving epo alfa and 9 receiving 
PBO) were excluded from the efficacy evaluation; 14 
(6 receiving epo alfa and 8 receiving placebo) 
because they discontinued before completing 
treatment (no reasons reported); and 2 (1 per 
patient group) because the blind on their treatment 
codes was broken permanently. The remaining 359 
patients were assessable for efficacy. #s also 
reported for QoL data set. 
Was attrition rate adequately dealt with? 
Yes: Patients on study 28 days or less were counted 
as transfused for the ITT analysis (although no 
sensitivity analysis) 
Number (%) followed up from each condition? Yes; 2 epo alpha patients and 1 placebo patient lost to follow up for 12 month survival analysis 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) Solid: breast 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Non-platinum 
chemotherapy 
Adjuvant anaemia treatment 
Iron 
An oral daily dose of 200 
mg of iron was 
recommended, if  
transferrin saturation ≤ 
20%, intravenous iron was 
recommended, use of iron 
dextran was not allowed 
G-CSF No 
Transfusion trigger 
At the discretion of the 
physician with 
recommended Hb < 8 g/dL 
unless clinically indicated 
Hb inclusion criteria level Haemoglobin levels ≤ 10.5 
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g/dL, or levels greater than 
10.5 g/dL but ≤ 12.0 g/dL 
after a 1.5-g/dL or greater 
decrease in haemoglobin 
level per cycle or month 
since beginning 
chemotherapy. 
 Arm 1 = Epoetin alfaN =251 
Arm 2 = Placebo 
N = 124 
Arm 3 =  
N =  
male (%) 85 (34) 39 (31)   
female (%) 166 (66) 85 (69)   
Age years mean ± SD 58.3±14.2 59.5±13.9   
Performance status 
WHO / ECOG /  NR 
Hb baseline (g dl-1), mean ±SD 9.9±1.1 9.7±1.1   
Hb stratum        
≤10.5 g/dL 209 (83) 109 (88)   
>10.5 g/dL 42 (17) 15 (12)   
Chemo within 3 mths before study 231 (92) 114 (92)   
Pre-study transfusions (within 3 
mths before study start 71 28 44 36   
Iron baseline (U/l median (range) NR  NR    
Epo baseline (mU ml-1) NR  NR    
Target Hb NR  NR    
Tumour stratum (Littlewood 2001)       
Solid 136 (54) 66 (53)   
Haematologic 115 (46) 58 (47)   
Were intervention and control groups comparable? 
No p values reported, authors stated “Demographic 
and baseline characteristics of the patients in the 
ITT population were generally comparable between 
the epoetin alfa and placebo treatment groups 
…although a further 12% of the placebo arm 
received prestudy transfusions” 
RESULTS  ITT AND EFFICACY POPULATION 
 
Arm 1 =  
Epoetin alfa 
 
Arm 2 =  
Placebo 
 
Arm 3 =  
N =  p  
 N=251 N=124    
Pts transfused (%) (ITT 
population) 
Overall 
62/251 (24.7) 49/124 (39.5)   0.0057 (adjusted) 
Solid tumour 
33/136 24.3 24/66 36.4    
Haematologic 
29/155 (25.2%) 25/58 (43.1)    
 
 N=244 N=115    
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Mean change in Hb after 28 
wks(g/dl) (SD) (efficacy pop) 2.2 (2.18)* 0.5 (1.79)   
*<0.001 – 
chg from BL 
to 28 wks 
Hb levels increased for first 10-14 weeks on epoetin alfa, while the Hb levels in the placebo group did not 
differ significantly from BL over the same period 
 
Responders (increase of Hb 
level by 2 g/dl during the study 
without transfusion 30 days 
prior) (%) (efficacy pop)  
 
 
N=244 N=115    
172 (70.5) 22 (19.1)   
<0.001 
(Fisher exact 
test) 
Solid tumour 
87/131 (66.4) 13/61 (21.3)    
Haematologic 
85/113 (75.2) 9/54 (16.7)    
Hb ≤ 10.5 g/dl 
139/203 (68.5) 22/100 (22.0)    
Hb > 10.5 g/dl 
33/41 (80.5) 0/15 (0.0%)    
127/203 (62.6) 14/100 (14.0)    
Hb > 10.5 g/dl 
38/41 (92.7) 4/15 (26.7)    
 
Survival 
12 months after the last patient enrolled completed the study (median follow-up, 26 months)  
SAFETY POP 
 N = 251 N = 124    
Overall survival at 12-month assessment (median follow-up, 26 months) 
Alive 94 (37%) 41 (33%)    
Dead 155 (62%) 82  (66%)    
Lost to follow-up 2 (1%) 1 (1%)    
Median survival  (ITT 
population) 17 mths* 11 mths    
Overall survival (note study 
insufficiently powered for this 
outcome) Kaplan-Meier 12 
month survival estimates (%)  
(ITT population) 
60% 49%   0.13 
Estimated hazard ratio (placebo 
v epoetin alfa) 1.309   0.052 
HR in favour of epo alfa; during the entire follow-up period the risk of dying was approximately 31% higher 
for placebo-treated patients compared with epo alfa treated patients 
Overall survival at 12-month assessment (median follow-up, 26 months):  
HAEM MALIGNANCIES (n=173) 
SAFETY POP 
 N=115 N=58    
Alive 60 (52%) 28 (48%)    
Dead 54 (47%) 30 (52%)    
Lost to follow-up 1  (1%) 0 (0%)    
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Overall survival at 12-month assessment (median follow-up, 26 months):  
SOLID TUMOURS (n=202) 
SAFETY POP 
 N=136 N=66    
Alive 34 (25%) 13 (20%)    
Dead 101 (74%) 52 (79%)    
Lost to follow-up 1 (1%) 1 (2%)    
Health state utility scale  
Of the 375 ITT patients, 349 were evaluated for changes in QOL parameters 
Presented as change from baseline to last assessment  (unclear when)  
 Results for FACT and CLAS  
 N=200 N=90    
Mean change score  
FACT-An:fatigue 3.0 -2.2   0.004 
Mean change score  
FACT-An:anaemia 4 -2.6   
0.0007 (not 
adjusted for 
multiple 
comparisons
Mean change score FACT-G  
N=194 N=88 
  0.004 
2.5 -3.6 
 N=228 N=108    
CLAS-ENERGY 8.1 -5.8   0.0007 
CLAS-DAILY ACTIVS 7.5 -6.0   0.0018 
CLAS-OVERALL QoL 
N=228 N=107 
  0.0048 
4.8 -6.0 
Adverse effects of tmt SAFETY POPULATION 
 N=251 N=124    
Any AE 216 (86%) 101 (81%)    
Fever 55 (22%) 21 (17%)    
Granulocytopenia 49 (20%) 16 (13%)    
Disease progression 44 (18%) 27 (22%)    
Nausea 46 (18%) 17 (14%)    
Abdominal pain 30 (12%) 13 (10%)    
Constipation 30 (12%) 16 (13%)    
Leukopenia 31 (12%) 13 (10%)    
Diarrhoea 27 (11%) 10 (8%)    
Vomiting 24 (10%) 13 (10%)    
Fatigue 17 (7%) 15 (12%)    
Dyspnoea 15 (6%) 14 (11%)    
AEs were reported in at least 10% of patients in either treatment group 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM 
ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients 
number, date of birth, alternate; Unclear = if the method not stated) 
Unclear: stratified by tumour 
stratum (solid or haematologic) 
and haemoglobin level (≤10.5 
g/dL, or ≤12.0 but  >10.5 g/dL) 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY NR 
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CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially 
numbered coded vials; other methods where the triallist allocating 
treatment could not be aware ; Inadequate = allocation was alternate, 
or based on information known to the triallist) 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? Unclear*  
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT 
ALLOCATION?  Yes 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? Yes 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? Partially no variability 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT 
ANALYSIS OR WERE LESS THAN 10% OF EACH STUDY ARM 
EXCLUDED? 
Yes, apart  from 
HRQoL (only 80% 
and 73% participants  
analysed in epo and  
placebo groups  
respectively)** 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP 
IN EACH GROUP STATED? 
Yes  numbers given but detailed 
reasons not provided 
NOTES: 
*no p values reported; authors report “Demographic and baseline characteristics of patients in ITT pop 
generally comparable between groups” 
 
**secondary endpoints (other than QoL) analyses using Efficacy population (see Stats section above) 
OTHER 
Generalisability Yes – broad population 
Author conclusions Epoetin alfa safely and effectively ameliorates anaemia and 
significantly improves QoL in cancer patients receiving non-
platinum chemotherapy. Encouraging results regarding increased 
survival warrant another trial designed to confirm these findings 
Reviewer comments Caution required with survival results due to being 
underpowered. Also concern with lack of explanation for drop 
out/withdrawal; some explanation reported in Littlewood 2001 but 
reasons for withdrawals not specified in detail 
 
Endnote Ref ID 
 
2680 Malignancy type Breast Cancer 
Treatment Epoetin Alfa 
STUDY DESIGN PARTICIPANTS 
Author, year 
 Moebus 2013 N 
1,284 of which 643 in the IDD-
ETC arm randomised to EPO A 
(n=324) or No EPO (n=319) 
Objective AGO-ETC trial compared 
intense dose-dense 
sequential chemotherapy 
every 2 weeks vs 
conventional scheduled 
Inclusion criteria: women aged 18-65 years, 
histologically confirmed primary breast cancer of 
stages II to IIIa with four or more tumor-infiltrated 
axillary lymph nodes, M0 status, and R0 
resection of the primary tumor and axilla with a 
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therapy in high-risk breast 
cancer patients. The 
objective of this study 
was to evaluate the 
safety and efficacy of 
epoetin alfa in a second 
randomization of the 
intense dose-dense arm 
(IDD arm).  
minimum of 10 axillary lymph nodes removed, 
ECOG performance status of 0 to 1; normal left 
ventricular ejection fraction; neutrophils 
≥1,500/µL; platelets ≥ 100,000/µL; serum  
creatinine, transaminases, and total bilirubin 
<1.25; alkaline phosphatase <3.0 times the 
institutional upper normal limit. 
 
Exclusion criteria: history of severe cardiac 
disease, previous systemic tumor therapy, and 
simultaneous contralateral breast cancer or any 
other cancer except for basal cell skin carcinoma 
# centres 165 (recruitment between 
November 1998 and April 
2003) 
Other references/aliases EPO-GER-10 
AGO-ETC trial 
Moebus 2010  
(in Tonia as abstracts 
Moebus 2005 and 2007) 
Geographical setting Germany 
Duration of treatment Median 18 weeks 
(mean=16.9 weeks) 
Length of follow-up (if 
different) 
Median follow-up duration 
was 62 months, but the 
study is ongoing for 
continued 10-year follow-
up 
Country of corresponding 
author Germany 
Language of publication English 
Sources of funding Bristol-Myers Squibb, 
Amgen, Pharmacia, and 
Johnson& Johnson 
RANDOMISATION & 
ALLOCATION 
Pts stratified by center, menopausal status (pre- vs postmenopausal),and the 
number of affected lymph nodes (4–9 vs≥10) at the central fax randomization. 
Computer-generated lists with permuted blocks of randomly variable size were 
used 
TREATMENT ARMS 
ARM Drug name/s Epo alfa Controls, standard care 
N  324 319 
Dose & freq (od, bd etc) 150 IU/kg three times weekly NA 
Dose adjustment Y/N 
To maintain Hb level of 12.5 to 13.0 
g/dL. Dose doubled if Hb dropped >2 
g/dL within a 4-week period. Epo was 
withdrawn when the Hb >14.0 g/dL 
was restarted when the Hb level 
<13.0 g/dL. 
NA 
Route of administration Subcutaneously NA 
Duration of epo tx 
Started on Day 1 and continued up to 
14 days after the last dose of 
cyclophosphamide. 
NA 
Adj anaemia treatment 200 mg/day oral iron 200 mg/day oral iron. 
Transfusion trigger Pts with an Hb level <9.0 g/dL were Pts with an Hb level < 9.0 g/dL were 
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evaluated for transfusions by the 
physician. The indication for RBC 
transfusion depended on the 
symptoms of the patients and was at 
the discretion of the physician. 
evaluated for transfusions by the 
physician 
OUTCOMES 
Primary 
outcome 
Hb levels BL to 
Cycle 9 Other outcomes 
RBCT (# blood transfusions); Survival (OS, 
recurrence-free survival); HRQoL (European 
Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire, version 
[assessed at before the start of treatment, at 
every second cycle, at the end of  treatment, 
and at each follow-up visit]); AEs 
NOTES: 
Primary outcome (as specified by study authors) is highlighted in bold 
Complete blood counts were obtained at each cycle, and Hb level was measured at least weekly during 
chemotherapy. 
Follow-up visits performed every 3 months for 3 years, every 6 months during years 4 and 5, and annually 
thereafter. 
M0 status: ie, normal findings on chest radiography, liver ultrasonography, and bone scan. 
Radiation of the supraclavicular, infraclavicular, and parasternal lymph nodes, as well as radiation of the 
breast in patients with partial mastectomy or to the chest wall in case of mastectomy, was recommended in 
all patients. 
ANALYSIS 
Statistical technique used? 
All statistical tests were two-sided, except for the 
primary endpoint of transfusions for which a one-
sided hypothesis was prospectively defined.  
 
Comparison of Hb levels evaluated with ANOVA and 
Wilcoxon tests.  
 
Numbers of at least one on-study RBC transfusions 
were compared between the two groups using 
Fisher exact test. On-study defined as the period 
from randomisation to the date of the last cycle of 
chemo plus 14 days or the date of withdrawal, 
whichever occurred first. 
 
Kaplan-Meier estimates of the relapse-free survival 
were compared using a 2-sided log rank test with 
and without the stratification factors for menopausal 
status and number of positive lymph nodes. Cox 
regression models, with and without adjustment for 
the stratification factors, were performed to calculate 
HRs and 95% CI. 
Intention to treat analysis? 
Yes: ITT and per-protocol analyses for primary 
outcomes and relapse-free survival. 
 
The safety population included 627 subjects (309 in 
epo arm 318  in control arm); all epo ptc receiving 
epo and all controls with no epo treatments. 
The per-protocol population included 511 subjects, 
258 ptc in the epoetin alfa group and 253 ptc in the 
control group. Ptc excluded if unknown ECOG/WHO 
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performance status; < four positive lymph nodes at 
baseline; not receiving  the assigned treatment (the 
majority of ptc excluded if they failed to received 9 
cycles of chemotherapy). 
Does statistical technique adjust for confounding? NA 
Power calculation (priori sample calculation)? 
Yes, based on the size needed to detect any 
difference in Hb levels and proportions needing 
transfusion. In addition, the size had approx. 85% 
power to detect a 10% difference in the 5-year 
relapse-free survival rate after a median follow-up of 
5 years using a log-rank test. 
Attrition rate (loss to follow-up)? Yes 
Was attrition rate adequately dealt with? Yes 
Number (%) followed up from each condition? Yes 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, 
cervical / haem / MDS / mixed) 
Solid tumour: breast cancer 
Treatment (e.g. chemotherapy platinum / non-
platinum based; chemo + radio; no specific 
malignancy treatment; not reported) 
9 cycles of: three sequential cycles of epirubicin  (150 
mg/m2), paclitaxel (225 mg/m2), and cyclophosphamide 
(2500 mg/m2),  every 2 weeks (IDD arm A). 
Adjuvant anaemia treatment 
Iron 200 mg/day oral iron 
G-CSF All cycles were administered in 3-week intervals without growth factor support 
Transfusion 
trigger 
Pts with an Hb level < 9.0 g/dL were evaluated for 
transfusions by the physician 
Hb 
inclusion 
criteria 
level 
NR 
 Arm 1 = epo N =324 
Arm 2 = controls 
N = 319 
Arm 3 =  
N =  
Age years median (range) 50 29-65 52 28-67   
ECOG   315 312   
0 254 81% 260 83%   
1 61 19% 52 17%   
Body mass index, kg/m2     
Median (range) 24.5 (17-42) 24.4 (17-48)   
Median Hb baseline (g/dL) 313 303   
median (IQR) 12.4 (11.7-13.3) 12.8 
(12.2-
13.6)   
Tumour stage:        
pT1 81 25% 100 31%   
pT2 190 59% 172 54%   
pT3 50 15% 46 14%   
Were intervention and control groups comparable? 
 
No p-values reported, authors stated “the two 
treatment groups were generally similar with 
respect to the demographic and baseline 
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characteristics”. 
RESULTS 
 Arm 1 = epo N =324 
Arm 2 = controls 
N = 319 
Arm 3 =  
N =  p  
Change in Hb (cycle 9) 0  -2.2*    *<0.001 chg from BL 
Mean Hb values presented graphically 
 
Hb level (g/dL) by cycle (intent-to-treat population). Based on available measurements in the patients 
receiving the respective chemotherapy cycle. Results from similar to those of the per-protocol population 
Analysis of variance and Wilcoxon test: p<0.001 
Transfusions:  Numbers of transfusions: assessed during the period from randomization to the date of the 
last cycle of chemotherapy plus 14 days or the date of withdrawal, whichever occurred first 
Transfusions (ITT) 41 12.8% 86 28.1%   <0.0001 
HR: 0.37 (95% CI = 0.25 to 0.57). Similar results were obtained when the per-protocol population was 
analysed.  
Most transfusions, regardless of treatment group, occurred during Cycles 7 to 9. # of subjects in the control 
group who received transfusions increased steadily from Cycle 1 to Cycle 9; # of subjects in the epoetin 
alfa who received transfusions increased mainly during Cycles 7 to 9 
Health-related QoL        
Results for health-related patient-reported outcome analyses are not presented because of the large 
amount of missing baseline data (in excess of 40% of baseline measurements were missing). 
Survival (ITT) 324 317   
5-yr relapse-free survival 
(95% CI) 71% (66-76%) 72% (67-77%)    
 HR= 1.03 (95% CI = 0.77 to 1.37)   P = 0.86 
5 yr overall survival (95% CI) 81% (76-86%) 83% (78-87%)    
 HR= 0.97 (95% CI = 0.67 to 1.41)   P = 0.89 
Safety 
Incidence is based on the number of pts experiencing at least one AE, not the number of AE 
 309 318    
Total # subjects with AEs 10 (3%) 22 (7%)    
Embolism 1 <1% 0 0%    
Pts with thromboembolic 
vascular event while on 
chemotherapy 
39 13% 22 7%    
Pts with clinically relevant 
thromboembolic vascular events 22 7% 10 3%   P = 0.03 
Vascular disorders 
Thrombosis 21 (7%) 9 (3%)    
Venous thrombosis 2 (1%) 0     
Arterial thrombosis 1 (<1%) 0     
Deep vein thrombosis 1 (<1%) 0     
Embolism 0  1 (<1%)    
Subclavian vein thrombosis 0  1 (<1%)    
Respiratory, thoracic, and mediastinal disorders 
Pulmonary embolism 0  1  (<1%)    
Serious AE 10% 13%    
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QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM 
ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients 
number, date of birth, alternate; Unclear = if the method not stated) 
Yes 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY 
CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially 
numbered coded vials; other methods where the triallist allocating 
treatment could not be aware ; Inadequate = allocation was alternate, 
or based on information known to the triallist) 
Unclear 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? Unclear; no p-values reported. 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT 
ALLOCATION?  No 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? NR 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? Yes 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPOTED? 
Yes; this study was a Latin 
Square design and this paper 
reports second randomisation 
(first randomisation results 
published in an alternative ref 
[2010] excluded as epo vs epo 
not measured 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT 
ANALYSIS OR WERE LESS THAN 10% OF EACH STUDY ARM 
EXCLUDED? 
Yes 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP 
IN EACH GROUP STATED? Yes 
NOTES: 
Moebus 2010 reference: 
Moebus, V., Jackisch, C., Lueck, H. J., du Bois, A., Thomssen, C., Kurbacher, C., . . . Untch, M. (2010). 
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared 
with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO 
phase III study. J Clin Oncol, 28(17), 2874-2880. doi: 10.1200/jco.2009.24.7643 
OTHER 
Generalisability Females only (breast cancer) 
Author conclusions Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions 
without an impact on relapsefree or overall survival. However, epoetin alfa had an 
adverse effect, resulting in increased thrombosis 
Reviewer comments Although epoetin alfa dosing  information had to be reported in the case report 
form as the number of units administered per kilogram of body weight, a fixed 
dose of 10 000 IU was specified for some subjects. In these instances, a per-
kilogram dose was calculated using the subject’s body weight. 
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Endnote Ref ID 
 
2693 Malignancy type Lymphoproliferative malignancies: 
Non-Hodgkin’s lymphoma (NHL) 
Chronic  lymphocytic leukaemia (CLL) 
Multiple myeloma (MM) 
Treatment ESA- epoetin beta 
 
STUDY DESIGN PARTICIPANTS 
Author, year Osterborg 2005 N  349 (ITT=343) 
Objective To investigate the efficacy 
of epoetin beta in 
eliminating severe 
anaemia and transfusion 
dependency and 
concomitant effects on 
QOL, with the FACT scale 
in pts with advanced MM, 
low grade NHL and CLL. 
Inclusion criteria:  
 18 years and over 
 Confirmed diagnosis of NHL, CLL, MM 
 Hb less than 10 g/dl with a transfusion 
requirement of ≥ 2 U RBCs in the 3 
months before the study 
 Pts required to have an inadequately low 
endogenous serum erythropoietin 
concentration ≤100 IU/l (if Hb was >9 to 
<10 g/dl), ≤180 IU/l (if Hb level was >8 to 
≤9 g/dl) or ≤ 300 IU/l (if Hb level was ≤8 
g/dl) 
 Pts must have been scheduled to receive 
antitumour therapy for the next 4 months 
 Life expectancy of more than 4 months 
 WHO performance score of 0 to 3 
 
Exclusion  criteria:  
 Therapy resistant hypertension 
 Relevant acute or chronic bleeding in 3 
months before study commencement 
 Thrombocytopenia or thrombocytosis 
(platelets <20 and >450 x 109/L, 
respectively) 
 Vitamin B12 or folic acid deficiencies 
 Creatinine levels more than 2.5 mg/dl 
 Haemolysis (haptoglobin level <50 mg/dl) 
 Epilepsy 
 Known hypersensitivity to preservatives 
used in study medication injection 
formulation  
 Pts with evidence of functional iron 
deficiency (transferring <25%)
# centres 63, conducted between 
June 1997 and July 1999 
Other references/aliases Osterborg, 2002 (#682) 
Geographical setting 12 countries 
Duration of treatment 16 weeks 
Length of follow-up (if 
different) 
Pts followed up for at least 
one year after EOTP. The 
minimum length of follow 
up was approx 17.5 
months in both treatment 
groups, with only 4 pts in 
each gp having a shorter 
follow up (reported in 
Osterborg 2005) 
Country of corresponding 
author Sweden 
Language of publication English 
Sources of funding 
F.Hoffman-La Roche 
RANDOMISATION & 
ALLOCATION 
Randomised, double-blind, placebo controlled. Stratified according to 
malignancy type and study centre. 
 After a run-in period of approximately 2 weeks, patients suitable for inclusion 
were randomized. 
TREATMENT ARMS 
ARM Drug name/s Epoetin beta Placebo 
N 170 173 
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Dose & freq (od, bd etc) 150 IU/kg three times a week  
Dose adjustment Y/N 
The dose was increased to 300 IU/kg 
if Hb < 8.5g/dl, or if Hb increase from 
baseline < 0.5 g/dl after 4 weeks. 
Dose was decreased by 50% if Hb 
increased > 2 g/dL within this period. 
If Hb >14 g/dL, the study medication 
was suspended until Hb declined to 
≤13 g/dL, when epo was reinstated at 
50% of the previous dose.  
 
Route of administration Subcutaneous Sub cut 
Duration of epo tx 16 weeks  16 wks 
Adj anaemia treatment 
Enrolled pts with a baseline 
transferring saturation of less than 
25% received IV iron substitution 
(100mg Fe) before the start of study 
treatment. Where transferring 
saturation levels decreased to below 
25% during the course of the study, IV 
Fe substitution therapy was 
administered at a dose  of 100 mg Fe 
per week until transferrin saturation 
reached ≥25%. Oral Fe substitution 
therapy (200-300 mg Fe) was 
administered to those in whom IV Fe 
was precluded. 
Enrolled pts with a baseline 
transferring saturation of less than 
25% received IV iron substitution 
(100mg Fe) before the start of study 
treatment. Where transferring 
saturation levels decreased to below 
25% during the course of the study, 
IV Fe substitution therapy was 
administered at a dose  of 100 mg Fe 
per week until transferrin saturation 
reached ≥25%. Oral Fe substitution 
therapy (200-300 mg Fe) was 
administered to those in whom IV Fe 
was precluded. 
Transfusion trigger 
If  Hb was less than 8.5 g/dL or at 
higher levels if medically indicated—
that is, the presence of marked 
anemic symptoms such as angina 
pectoris. 
If  Hb was less than 8.5 g/dL or at 
higher levels if medically indicated—
that is, the presence of marked 
anemic symptoms such as angina 
pectoris. 
OUTCOMES 
Primary 
outcome 
Transfusion-
free survival 
(during weeks 
5 to 16 of 
study. Also 
analysed 
severe 
anaemia free 
survival 
(Hb≥8.5 g/dl) 
during weeks 5 
to 16. Death 
without 
previous event 
was 
considered a 
failure) 
Other outcomes 
HaemR (increase in Hb level of ≥2 g/dl above 
baseline without the need for a blood 
transfusion in the previous 6 weeks. Hb nadir 
(measured at 4-week long intervals); HRQoL 
(subjective QoL was assessed at baseline and 
every 4 weeks during the study via FACT-An. 
Questionnaires were completed before any 
examination or treatment so that pts 
assessment could not be influenced by 
references to current Hb level.; AEs (Adverse 
events, hematologic parameters, concomitant 
medications, blood transfusions, and antitumor 
therapy were documented throughout the 
course of the study) 
NOTES: 
Although the anemia and fatigue subscales were part of the original study plan, the FACT-G questionnaire 
was introduced by an amendment to the study protocol in January 1998. 
ANALYSIS 
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Statistical technique used? 
Subgroup analyses with a one sided Wald chi –squared test (α = 0.05) 
should be performed if the difference in the total study population was 
significant and no significant interaction between study treatment and 
strata were present (P>.1 
 
Hazard ratios were calculated to estimate the relative risk of failure and 
event-free curves were displayed that were based on Kaplan-Meier 
estimates. Multivariate Cox proportional hazard methods were used to 
assess the contribution of other baseline characteristics on event-free 
rates. Cumulative response rates were analysed by the stratified log-
rank test and displayed as Kaplan-Meier curves. Analysis of covariance 
techniques were used to analyse the changes from baseline QoL and 
Hb data, where baseline values were considered as covariates. 
 
Long term Survival data:  Osterborg 2005: 
Survival data were analysed by standard Kaplan-Meier methods and 
differences in survival between groups were assessed using a log-rank 
test. 
 
Median time to patients being censored was 27.8 months in the epoetin 
beta group and 27.5 months in the placebo group. 
Intention to treat analysis? 
Yes – the primary efficacy variable was analysed on an ITT basis via a 
Cox proportional hazard model adjusted for the type of underlying 
malignant disease at a significance level of 5%.  
Although ITT population is defined as all participants receiving study 
treatment N= 343, while 349 pts were randomised. ITT = safety 
population in this study (n=343). 
Does statistical technique adjust 
for confounding? Yes 
Power calculation (priori sample 
calculation)? 
Yes –150 patients with low-grade NHL, CLL, or MM to detect an 
improvement in the primary variable from 25% to 50% with a power of 
85% via a Cox proportional hazard model. In an amendment to the 
study protocol, the sample size was increased: 
Enroll at least 100 pts per stratum (MM, NHL, CLL; 50 pts per 
treatment group) to achieve a power of 80% for the three 
corresponding subgroup analyses. ). A lost-to follow-up  rate of ≤10% 
in Weeks 5 – 16 weeks was assumed. 
Attrition rate (loss to follow-up)? 
Three pts in each treatment group were withdrawn prior to receiving 
study medication due to withdrawal of consent (n=5) and protocol 
violation (n=1). In total, of 349 pts, 281 completed the study. The main 
reasons for withdrawal were death (n=35), withdrawal of consent 
(n=12) and adverse events (n=11). 
Was attrition rate adequately 
dealt with? 
In case or premature withdrawal from study treatment, pts were 
observed and Hb level, blood transfusions and vital status were 
recorded whenever possible until study week 16. 
Number (%) followed up from 
each condition? Yes, until the end of treatment only 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, 
cervical / haem / MDS / mixed) 
Non-Hodgkin’s lymphoma (NHL) 
Chronic  lymphocytic leukaemia (CLL) 
Multiple myeloma (MM) 
Treatment (e.g. chemotherapy platinum / non-
platinum based; chemo + radio; no specific 
malignancy treatment; not reported) 
Non-plat chemo 
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Adjuvant anaemia treatment 
Iron Yes, see treatment description  above for more details 
G-CSF NR 
Transfusion 
trigger 
If  Hb was less than 8.5 g/dL or at higher levels if 
medically indicated—that is, the presence of marked 
anemic symptoms such as angina pectoris. 
Hb inclusion 
criteria level <10 g/dl 
 Epoetin beta N= 170 
Placebo 
N= 173 
Arm 3 =  
N =  
male, n (%) 91 (54.0) 82 (47.0)   
female, n(%) 79 (46.0) 91 (53.0)   
Age years median (range) 63 (32-86) 64 (28-83)   
WHO performance status, n (%)      
0 10 (6.0) 13 (7.5)   
1 57 (33.5) 62 (36.0)   
2 73 (43.0) 68 (39.0)   
3 30 (17.5) 30 (17.5)   
Body weight,  
kg (mean ±SD) 69±12 69±13   
Underlying malignancy     
CLL, n (%) 59 (35.0) 66 (38.0)   
MM, n (%) 58 (34.0) 58 (33.5)   
NHL, n (%) 53 (31.0) 49 (28.5)   
Transfusion requirement (%)     
None 11 (6.5) 6 (3.5)   
1 unit 4 (2.5) 6 (3.5)   
2-5 units 126 (74.0) 131 (76.0)   
≥6 units 29 (17.0) 30 (17.0)   
Haematological     
Hb g/dl, mean ± SD 9.2 ±1.1 9.3 ±1.0   
Haematocrit, %, mean ±SD 28.2±4.7 28.6±4.2   
Neutrophil count, x 109/L, 
mean±SD 2.8±2.5 3.0±3.1   
Platelet count, x 109/L,  
mean (IQR) 149 (100-195) 141 (94-190)   
Serum EPO, IU/L, median (IQR) 38 (20-72) 41 (21-77)   
Serum ferritin, ng/mL,  
median (IQR) 586 (235-1121) 514 (195-1183)   
Transferrin saturation, % 
mean±SD 38±22 39±23   
QoL scores     
FACT-An 115.2±28.0 114.0±28.3   
FACT-G 69.1±14.4 68.5±15.0   
FACT-F 28.8±10.7 29.2±11.0   
FACT-An subscale 17.3±4.6 17.0±5.0   
Were intervention and control groups comparable? Unclear: No p-values reported, author states “There 
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were no major differences in the demographics and 
clinical characteristics of the two treatment groups “. 
RESULTS 
 Epo Beta n=170 
Placebo 
n=173   p  
Haematological 
Hb response (≥ 2 g/dl increase in 
Hb without transfusion) at 16 
weeks 
67% 27%   <0.0001 
Hb response MM patients (n=116) 76% 29%   <0.0001 
Hb response NHL patients (n=102) 62% 24%   <0.0001 
Hb response Cll patients (n=125) 63% 26%   <0.0001 
Fig2 p 2490 represents time to response graphically  
Hb nadir Mean ± SD (g/dl) Epo Beta n=170 
Placebo 
n=173 
Epoetin 
(N) 
Placebo 
(N)  
1-4 weeks 9.1±1.4 8.7±1.2 169 173 0.0003 
5-8 weeks 10.0±1.9 8.8±1.5 161 165 0.0001 
9-12 weeks 10.5±2.0 8.9±1.5 152 153 0.0001 
13-16 weeks 10.8±2.0 9.2±1.6 146 147 0.0001 
The difference in mean Hb nadir was 0.4 g/dl at week 1 to 4, increasing to 1.6 g/dl at wk 13 to 16 (P=0.001 
v placebo). Similar findings were observed for mean Hb levels and haematocrit, which increased 
significantly in epo group from wk 2 onward (both P<0.005 v placebo) during the course of the study. 
 
Prediction of Response  (Cox’s multivariate regression analysis of factors in transfusion free survival during 
weeks 5 to 16): 
Treatment, epopetin beta v 
placebo 
HR 0.555 95%CI (0.369-0.776), p=0.0006 
Platelet count, ≥100 v <100 x 109 
g/L 
HR 0.416 95%CI (0.292-0.592), p=0.0001 
Hb level, ≥ 9 v <9 g/dl HR 0.589 95%CI (0.423-0.821), p=0.0018 
Pretreatment transfusion 
requirement, ≤ 2 v 3 units 
HR 0.645 95%CI (0.458-0.909), p=0.0123 
Underlying malignancy HR 0.803 95%CI (0.565-1.140p=0.2198 
Baseline platelet count ≥ 100 x 109/L, Hb levels ≥ 9 g/dl and a lower prestudy transfusion requirement (≤2 
units) were the factors strongly associated with a low risk of failure. Subgroup analyses also demonstrated 
that risk reduction in epoetin beta pts versus placebo was stronger in pts with a high platelet count (55%) 
and high Hb levels (51%) than in pts with a low platelet count (21%) and low Hb levels (26%).The 
type of underlying malignancy (MM, NHL, CLL), sex, age, baseline neutrophil count, transferrin saturation, 
WHO performance score, or QOL score had no significant effect ineither analysis. 
Severe Anemia and Transfusion  free survival 
 Epo Beta n=170 
Placebo 
n=173   p 
Pts with blood transfusions in first 
4 weeks of study treatment (%) 29.0 27.2   0.707 
Transfusion free survival during 16 
weeks treatment (%) 66.7 47.6 
Risk reduction 
favouring Epo of 
43% 
0.0012 
Severe anaemia and transfusion 
free survival   
Risk reduction 
favouring Epo of 
51% 
0.0001 
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Interaction between underlying 
malignant disease and treatment      >0.1 
Fig1 p 2490 represents severe anaemia free survival graphically: 
The difference in transfusion- and severe  anaemia-free survival was statistically significant across all 
malignancy subtypes and was particularly apparent in pts with MM (P=0.0001) with a risk reduction of 66% 
in those receiving epoetin beta compared with placebo. In those with NHL and CLL, the risk was reduced 
by ~ 40% in both groups (P=0.02 and P=0.03, respectively). 
Survival (long-term follow up Osterborg 2005): 
 Epoetin beta N= 170 
Placebo 
N= 173 p 
number of deaths 
 
110 (65%) 
censored, n =60 
109 (63%) 
censored, n =64  
Kaplan–Meier : Median 
survival (months) 
17.4 
95% CI: 15.0-20.5 
18 
95% CI: 16-22.3  
 HR: 1.04, 95% CI: 0.8-1.36 0.76 
Fig1 p 207 Osterborg 2005 represents graphically OS 
 
 
Health-related QoL 
Baseline and Change From Baseline in Quality-of-Life Questionnaires: 
 
*P<0.5 (After 12 and 16 weeks, the improvement in FACT-An and FACT-G score was greater in epo arm). 
Analysis of the dimensions of the FACT-G scale revealed statistically significant differences after 12 weeks: 
P<0.01 and P<0.05 favouring epo for social and family wellbeing and emotional wellbeing, respectively. 
 
QOL results at baseline and change from baseline in epoetin beta responders and non-responders: 
      
  
Baseline 
 
Week 4 
 
Week 8 
 
Week 12 
 
Week 16 
Variable Mean 
Score ±SD 
No. 
pts 
Mean 
Score 
±SD 
No. 
pts 
Mean 
Score 
±SD 
No. 
pts 
Mean 
Score ±SD 
No. 
pts 
Mean 
Score ±SD
No. 
pts 
 
FACT-An, 49 items, range 0-196 
Epoetin 
beta 
115.2±28.0 128 4.9±21.4 127 7.9±25.7 118 13.1±27.6* 114 14.8±28.0* 105 
Placebo 114.0±28.3 121 5.3±19.5 119 7.4±22.7 110 7.1±26.3 102 8.7±28.9 101 
 
FACT-G, 29 items, range 0-116 
Epoetin 
beta 
69.1±14.4 129 1.7±11.8 128 3.7±13.0 118 5.9±14.5* 114 6.5±13.8* 106 
Placebo 68.5±15.0 122 2.2±10.1 120 2.9±11.5 112 2.6±12.9 104 3.1±14.4 103 
 
FACT-F subscale, 13 items, range 0-52 
Epoetin 
beta 
28.8±10.7 160 2.2±8.7 157 2.8±10.8 148 4.2±11.7 145 5.2±12.2 133 
Placebo 29.2±11.0 157 1.8±8.4 157 1.9±9.8 145 2.5±10.9 135 3.0±12.1 130 
 
FACT-An subscale, 7 items, range 0-28 
Epoetin 
beta 
17.3±4.6 160 0.9±3.3 157 1.2±4.2 148 1.7±4.4 145 2.0±4.3 133 
Placebo 17.0±5.0 157 0.8±3.5 157 1.2±4.1 145 1.2±4.5 135 1.7±5.2 130 
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Baseline Week 4 Week 8 Week 12 Week 16 
Variable Mean 
Score ±SD 
No. 
pts 
Mean 
Score 
±SD 
No. 
pts 
Mean 
Score 
±SD 
No. 
pts 
Mean 
Score ±SD 
No. 
pts 
Mean 
Score ±SD
No. 
pts 
 
FACT-An, 49 items, range 0-196 
Responder 118.9±25.1 92 5.1±21,6 91 9.7±25.2* 87 15.2±26.3* 88 17.4±25.9* 82 
Non-
responder 
105.7±32.9 36 4.3±21.0 36 3.0±27.0 31 5.8±31.0 26 5.8±33.7 23 
 
FACT-G, 29 items, range 0-116 
Responder 70.6±12.9 92 1.5±12.2 91 4.9±12.4* 87 6.9±14.3* 88 7.8±13.4* 83 
Non-
responder 
65.6±17.2 37 2.0±10.8 37 0.5±14.2 31 2.6±14.7 26 1.9±14.5 23 
 
FACT-F subscale, 13 items, range 0-52 
Responder 30.4±10.1 114 2.5±8.3* 112 3.8±10.5* 108 5.3±10.5* 110 6.3±10.5* 102 
Non-
responder 
24.8±11.2 46 1.3±9.5 45 0.2±11.4 40 0.5±14.3 35 1.7±15.0 31 
 
FACT-An subscale, 7 items, range 0-28 
Responder 17.8±4.4 114 1.0±3.2 112 1.3±4.3 108 2.1±3.9* 110 2.2±4.0* 102 
Non-
responder 
16.0±4.7 46 0.7±3.5 45 1.2±4.2 40 0.4±5.4 35 1.3±5.2 31 
*P<0.05 
 
Analysis of the relationship between final Hb in wk 16 and change in total FACT-An score from baseline in 
the epoetin group was undertaken by regression analysis. A statistically significant correlation was found on 
the basis of a log linear relationship regression (r=0.3167, P=0.001), but the variability between pts was 
considerable and a uniform target Hb value associated with an optimal QoL could not be identified. 
Adverse effects  
 Epoetin beta Placebo    
Pts reporting at least on 
adverse event, n (%) 122 (72) 132 (76)    
Hypertension 9% 5%    
Local transient reaction after 
injection 1% 0%    
SAE, n (%) 57 (33) 55 (32)    
Deaths, n (%) 28 (16) 22 (13)    
Death due to PE 1 0    
stable disease or partial 
remission 68% 68% 
Reported in Osterborg 2005 Remission 9 5% 5 3% 
Progressive disease 31 18% 40 23% 
No antibodies to erythropoietin were detected in any patient. 
Iron 
The proportion of patients who developed transferrin saturations of less than 25% during the study period 
was 66% in the epoetin beta group and 63% in the placebo group. The average exposure to intravenous 
iron supplementation was slightly higher in epoetin beta patients (235 mg elemental iron) than in placebo 
patients (195 mg). The number of patients in each treatment group receiving orally administered iron 
supplementation was similar (35% and 33% for epoetin beta– and placebo-treated patients, respectively). 
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QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, 
date of birth, alternate; Unclear = if the method not stated) 
Unclear 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered 
coded vials; other methods where the triallist allocating treatment could not 
be aware ; Inadequate = allocation was alternate, or based on information 
known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? Unclear 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  Yes 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? Yes 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? 
Partially  
(variability can be 
calculated from data 
provided in the paper 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS 
OR WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? Yes 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN 
EACH GROUP STATED? 
Yes, until the end of 
treatment only 
 
NOTES: 
 
References: 
 
Osterborg, Anders; Brandberg, Yvonne; Hedenus, Michael. (2005). Impact of epoetin-beta on survival of 
patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. British 
Journal of Haematology, 129, 206-209.  
OTHER 
Generalisability Reasonably sized, broad sample 
Author conclusions This randomised, placebo-controlled study has demonstrated that epoetin beta 
treatment is effective in relieving anaemia and improving QoL in severely anaemic, 
transfusion dependent pts with advanced phase NHL, CLL and MM. Overall, the 
improvement in QoL was particularly apparent in pts with Hb increases of ≥2 g/dl. 
This suggests that the minimum increase in Hb may be a more important 
determinant of improved QoL than a uniform and close to normal target Hb level. 
 
Osterborg 2005: 
The treatment of severe, transfusion-dependent anaemia with epoetin-beta had no 
significant effect on the risk of progressive disease or long term survival in patients 
with lymphoproliferative malignancies. A limitation of these data is that the 16-week 
treatment period was relatively short compared with the median survival time of 
patients. 
Reviewer comments  
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Endnote Ref ID 
 
1119 Malignancy type solid tumours and  
hematologic cancer 
Treatment Epo alfa 
STUDY DESIGN PARTICIPANTS 
Author, year  Ray-Coquard 2009 N  218 
Objective This randomized phase III 
study aimed to identify the 
effects of epo alfa in 
patients at high risk for 
anemia requiring RBC: 
patients receiving 
chemotherapy with Hb 
level <12, and PS >1, or 
≤Ly £700/ll (score of 4 and  
more according to the 
ELYPSE risk model).  
Inclusion criteria: histologically documented 
cancer necessitating chemotherapy; age≥ 18 
years with solid tumours or hematologic cancer 
requiring CT; Hb<12g/dl (@ Day 1 of chemo), 
and Ly ≤700/ µl, or PS >1; negative HIV test in 
patients with non–Hodgkin’s lymphoma; 
chemotherapy not requiring hematopoietic stem-
cell support, chemotherapy planned for at least 3 
months and inclusion during first or second 
course of chemotherapy (regardless of line of 
treatment). 
 
Exclusion criteria: systematic administration of 
epo 
during chemotherapy; uncontrolled hypertension 
(i.e. diastolic blood pressure >95 mmHg), patient 
refusal; anemia in cancer patients not receiving 
chemotherapy; history of nervous or psychiatric 
disorder that would preclude informed consent or 
compliance; anemia resulting from factors other 
than cancer or its treatment untreated folate or 
vitamin B12 deficiency, pregnancy, history of 
thrombovascular events in the preceding 6 
months, current dose intensification 
chemotherapy for bone marrow, or stem-cell 
transplant in the preceding 8 weeks. 
# centres   
 9 sites; September 200-
January 2005 
Other references/aliases   
Geographical setting  France 
Duration of treatment  12 weeks 
Length of follow-up (if 
different) 
median follow-up of 12 
months (95% CI: 12–12.4) 
Country of corresponding 
author  France 
Language of publication  English 
Sources of funding The Ministry of Health; the 
Ligue contre le cancer 
(Ain, Rhoˆne and Savoie 
RANDOMISATION & 
ALLOCATION 
Randomization was centralized and stratified according to the participating 
centers and the number of prognostic factors for severe anemia, with two 
versus three of the following criteria: Hb level at day 0 <12 g/dl, Ly <700/ll, and 
PS >1. 
TREATMENT ARMS 
ARM Drug name/s Epo alfa No treatment 
N 110 108 
Dose & freq (od, bd etc) 150UI/kg TIW  
Dose adjustment Y/N 
Decrease to 75% if Hb increased >2 
g/dl. If after 4 weeks the Hb was 
<10.5 with <1 g/dl decrese, and is 
retriculocyte count was <40 000 
cells/µl , Epo was increased to 60 
000UI weekly. If Hb increased 
>12g/dl, it was interrupted till it got 
back to 12 g/dl. 
  
Route of administration Subcutaneous injections NA 
Duration of epo tx 12 weeks 
Oral iron supplementation was 
administered to support 
erythropoiesis in patients with iron 
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deficiency since no information on the 
improved efficacy of i.v. iron treatment 
was available at the initiation of the 
trial 
Adj anaemia treatment 
Oral iron supplementation was 
administered to support erythropoiesis 
in patients with iron deficiency since 
no information on the improved 
efficacy of i.v. iron treatment was 
available at the initiation of the trial 
Incidence of severe anemia 
Transfusion trigger Incidence of severe anemia  
OUTCOMES 
Primary 
outcome  Other outcomes 
RBCT (rate of transfusion; number of 
transfusions); survival (OS, time to disease 
progression); HRQoL (EORTC QLQ-C30); AEs 
NOTES: 
Not clear what PS used, assumed ECOG as ECOG reported in results section. 
Ly= lymphocyte count 
PS=performance status 
severe anemia= grade III anemia (Hb <8 g/dl) or grade II anemia (Hb <10 g/dl and ≥8 g/dl) in patients with 
grade III symptomatic cardiopathy, tachycardia (>100 beats/min), symptomatic angina with electric signs 
(modification of ST segment), grade III dyspnea, symptomatic pneumopathy (PaO2, 50–64; diffusion of 
carboxy oxygen, 54%–40%; volume capacity, 54%–40%), and grade III asthenia. 
Elypse model: Score of 4 or more: scoring based on Hb <12g/dl (score of three), and Lymphocyte count 
≤700/ µl or performance status >1 (score of one each). 
reference: Ray-Coquard I, Le Cesne A, Rubio MT et al. Risk model for severe anemia requiring red blood 
cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin  
Oncol 1999; 17: 2840–2846. 
prognostic factors for no RBC: The final model showed that no previous history of RBC transfusion [odds 
ratio (OR): 0.36; 95% CI: 0.135–0.978] and Hb level >10 g/dl at baseline (OR: 0.27; 95% CI: 0.09–0.84) 
were independent risk factors for no RBC. 
ANALYSIS 
Statistical technique used? 
OS was the time interval from randomization to date 
of death or last follow-up. Kaplan–Meier survival 
estimates, and differences were assessed by the 
log-rank test. 
Safety variables were analyzed using the safety 
population (all randomly assigned patients with at 
least one safety assessment). 
QoL scores were compared between the two arms 
for each chemotherapy cycle, and variations from 
baseline were calculated for each patient and 
compared between arms after stratification into 
three levels on the assumption that a 10-point 
disparity represented a clinically pertinent 
differential. 
Intention to treat analysis? Yes 
Does statistical technique adjust for confounding? NA 
Power calculation (priori sample calculation)? 
Yes, to detect a 15% difference in RBC transfusions 
with a power of 80% and a one-sided significance 
level of 5%. 
Attrition rate (loss to follow-up)? NR; numbers of patient and reasons for treatment discontinuation reported (but not by study arm):  
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Was attrition rate adequately dealt with? NR 
Number (%) followed up from each condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) 
solid tumours and  
hematologic cancer 
Treatment(e.g. chemotherapy platinum / non-platinum based; chemo + 
radio; no specific malignancy treatment; not reported) Unspecified chemotherapy 
Adjuvant anaemia treatment 
Iron 
Yes; oral supplementation 
in patients with iron 
deficiency 
G-CSF 
Yes; could be used in 
primary or secondary 
prophylaxis 
Transfusion trigger Incidence of severe anemia
Hb inclusion criteria level Hb<12g/dl 
 Arm 1 = Epo N =110 
Arm 2 = control 
N = 108 
Arm 3 =  
N =  
male (%) 52 47.3% 41 38%   
female (%) 58 52.7% 67 62%   
Age years mean (SD) 62.7 11.6 61.7 11.6   
ECOG /: 0-1 8 7.3% 8 7.4%   
2 87 79.1% 8 76.9%   
3-4 15 13.6% 17 15.7%   
Hb baseline (g dl-1) mean (SD) 10 1.2 10 1.2   
Haematocrit (%) mean (SD) 30.3 3.4 30.4 3.8   
Mean Feritin, µg/dL (SD) 585 697 701 1005   
Stage (%): Local 16 14.5% 12 11.1%   
Metastatic stage  92 83.6% 94 94%   
NA  2 1.8 % 2 1.9%   
2 Strata (prognostic factor) 84 76.4% 79 73.1%   
3 Strata (prognostic factor) 26 23.6% 29 26.9%   
Health state utility scale = EORTC 
QLQ-C30      P=0.048 
Were intervention and control groups comparable? 
No p-values reported aprt from HRQoL data, 
authors stated “Patients distribution was well 
balanced between the two groups of treatments”. 
RESULTS 
 
Arm 1 = Epo A 
N = 110 
Arm 2 = controls 
N = 108 
Arm 3 =  
N =  p  
       
Health-related QoL$ 
Health state utility scale = EORTC QLQ-C30. 
Baseline       P=0.048 
Follow up 
no statisticallydetectable differences were noted during the study period, 
whatever the date of evaluation (at 1, 2, 3, or 4 months or at the end of 
the study, all P > 0.2). Global scores remained stable or slightly 
increased in both arms during the entire study. 
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Survival 
Overall survival* Ly was found to be correlated to OS, with a median OS of 4.2 months 
(95% CI: 3.0–5.5) for patients with £700/ll lymphocytes versus 8.3 
months (95% CI: 6.6–10.4) otherwise. And patients with two prognostic 
factors had a significantly better OS than patients with three factors 
(median 8.3 versus 3.6 months, P < 0.0001; hazard ratio: 2.36, 95% CI: 
1.7–3.3) However, Hb counts <10 versus ≥10 were not. 
Median survival (months ; CI) 7.6 5.3 to 10.4 6 
5.0 to 
8.0   
P = 
0.148 
PFS (months ; CI) 5 4.3–6.6 4.4 3.8–5.2   P=0.17 
Transfusions*        
Participants (%) 39 36.1% 61 58%   P=0.001 
 relative risk: 0.62 [95% confidence interval (CI): 0.46–0.84 
Safety data$ 
At least one AE 59 (53.6%) 50 (46.7%)   P=0.31 
At least one SAE 54 (49.1%) 49 (45.4%)   P=0.58 
Fatal  AE 20 18.2% 20 18.5%   P=0.95 
Deaths  A majority (73%) of patients had died at the time of final analysis 
Cause of death = 
thrombovascular events  1.3%  0.6%    
Cause of death = disease 
progression:  27%  22%    
thrombovascular events  4.5%  3.7%    
hematological toxic effects  18.2%  13%    
serious adverse events were 
considered related to the study 
drug 
 4.6%  2.9%   P=0.72 
incidence of serious adverse 
events, including 
deaths 
 50%  46.7%   P=0.63 
* 213 patients were assessable primary criteria (rate of RBC transfusions) and toxicity; Five patients (2.3%) 
were enrolled but did not receive chemotherapy (four died before the beginning of treatment). 
$ Only 54% of the questionnaires (118) were available for QoL evaluation, 57% in arm 1 (n = 63) and 51% in 
arm 2 (n = 55). 
85% of the patients were metastatic at inclusion in the study; and the majority was in  the stratum for two 
prognostic factors 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, 
date of birth, alternate; Unclear = if the method not stated) 
Unclear – method was 
centralised but not reported  
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered 
coded vials; other methods where the triallist allocating treatment could not 
be aware ; Inadequate = allocation was alternate, or based on information 
known to the triallist) 
Unclear 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? 
Unclear and no for  from 
HRQL scores 9 Significant 
differences in favour of the 
EPO arm were noted for 
QoL scores at inclusion) 
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4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  No (open-label) 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? No (open-label) 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? Yes 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS 
COLLECTED MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS 
OR WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? 
Yes, apart from HRQoL 
(54% and 57% participants 
analysed in epo and control 
groups respectively). 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN 
EACH GROUP STATED? NR, see stats section above 
NOTES: 
OTHER 
Generalisability A very specific population group. 
Author conclusions Patients at high risk for RBC transfusion according 
to Hb<12g/dl, and Ly ≤700/ µl and/or PS >1could be 
given prophylactic Epo. 
with significantly reduced RBC transfusions and no 
significant impact on side-effects, progression-free 
survival, and OS 
Reviewer comments Not very well reported trial, e.g. data in results and 
methods section only partially reported. 
 
Endnote Ref ID 
 
2695 Malignancy type Multiple myeloma 
Treatment Second induction chemo 
rHU-EPO – assume epoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Silvestris, 1995 N 54 
Objective Not stated – paper reports 
the results of a long term 
trial using rHuEPO in MM 
pts undergoing second-
induction chemo 
Inclusion criteria:  
 MM stages I-IIIA, resistant to conventional 
melphalan-prednisone 
 Chronic anaemia Hb level ≤8.0 g/dl with 
or without transfusional supplementation 
 Commencement of second induction 
chemotherapy 
 Preserved kidney function 
 Karnofsky performance status lower than 
50 
 
Exclusion criteria: NR 
# centres NR 
Other references/aliases None 
Geographical setting NR 
Duration of treatment NR – according to graph 
24 wks 
Length of follow-up (if 
different) NR 
Country of corresponding 
author Italy 
Language of publication English 
Sources of funding This work was supported 
in part by the Finalised 
Project ‘Clinical 
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Application of Oncology 
Research’ of the Italian 
National Research 
Council. No further details 
provided 
RANDOMISATION & 
ALLOCATION 
Randomisation was obtained directly by the biostatistical department of the 
pharmaceutical company providing the recombinant hormone (Cilag AG, 
Schaffhausen, Switzerland). 
TREATMENT ARMS 
ARM Drug name/s rHU-EPO Control (assumed as this arm is not mentioned) 
N 30 24 
Dose & freq (od, bd etc) 
150 IU/kg, three times a week, started 
within first month of conventional 
cytotoxic protocol 
 
Dose adjustment Y/N This dose was increased to 300 IU/kg by the 6th week of treatment.  
Route of administration Sub cut  
Duration of epo tx   
Adj anaemia treatment Regular iron supplementation was provided throughout the study  
Transfusion trigger 9.5 g/dl  
OUTCOMES 
Primary 
outcome  Other outcomes 
HaemR (An increase of 2 g/dl or more of the 
original Hb level, or no further red cell 
supplementation in TD pts was taken as 
response to the treatment) 
NOTES: 
No outcomes clearly identified in Methods. 
Weekly controls included a thorough physical examination (including monthly assessment of performance 
status), a complete blood count, Hb and haematocrit levels, iron, transferring and ferritin concentrations, 
electrolytes and kidney function tests. 
ANALYSIS 
Statistical technique used? 
Since the majority of laboratory parameters studies 
are not normally distributed, ANOVA was performed 
by evaluating the median of each parameter and its 
range between minimum and maximum. The 
Wilcoxin test was adopted as a nonparametric 
method to compare different groups 
Intention to treat analysis? NR 
Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? NR 
Attrition rate (loss to follow-up)? 4 pts withdrawn, although the results table suggests 5 
Was attrition rate adequately dealt with? Yes 
Number (%) followed up from each condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) Multiple myeloma 
Treatment Second induction chemo 
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(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Adjuvant anaemia treatment 
Iron Regular iron was provided 
G-CSF NR 
Transfusion trigger NR 
Hb inclusion criteria level ≤8.0 g/dl 
 
Arm 1 =  
rHuEPO 
30 
Arm 2 =  
control 
24 
Arm 3 =  
N =  
Sex        
male, n NR    
female, n NR    
Age years median (range) NR    
Median neutrophil count, cell/µL     
Patients transfused, n (%)     
# RBC units transfused per patient 
over 3 mths prior to study, mean 
(range) 
    
Mean haematocrit, n (%)     
Endogenous EPO level, mU/mL, 
mean (median) [range]     
Type of solid tumour:  
Haematologic, n (%)     
Breast, n (%)     
Gynaecologic, n (%)     
Gastrointestinal, n (%)     
Lung (SCLC & NSCLC), n (%)     
Prostate, n (%)     
Head & neck, n (%)     
Other, n (%)     
Unknown primary, n (%)     
Were intervention and control groups comparable?  NR – no baseline characteristics reported 
RESULTS 
 
Arm 1=  
rHuEPO 
n=30 (27 evaluable) 
 Arm 2 =  
Control 
n=24 
(22evalauble) 
p  
Hb response (≥2g/dl) 
21 (77.7%) after a 
median period of 8 
weeks 
    
Chemotherapy groups NTD (n) 
Responders 
evaluable 
pts 
TD 
(n) 
Responders 
evaluable 
pts 
NTD 
(n) 
TD 
(n)  
     VMCP 11 9/10 9 5/8 12a 5b  
     VMCP + α-IFN 5 5/5 - - 3 -  
     VED 1  3 2/3 1 2  
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     CTX -  1 -/1 - 1  
aEleven pts were evaluable at the end of the study, bFour pts were evaluable at the end of the study 
NTD – non transfusion dependant 
TD – transfusion dependant 
VMCP – vincristine+melphalan+cyclophosphamide+prednisone 
IFN – interferon 
VED – vincristine+epirubicin+dexamethasone 
CTX – high dose cyclophosphamide 
 
 
Median Hb (g%) (Approximate interpretation from graphs by PenTAG) 
 Wk 0 Wk 4 Wk 8 Wk 12 Wk 16 Wk 20 Wk 24 
NTD - 
VMCP+EPO 
(9pts) 
7.6 8.2 9.5 10.5 10.4 10.4 10.2 
NTD- 
VCMP-EPO 
(11pts) 
7.8 7.6 7.5 7.6 7.6 7.6 7.6 
TD - 
VMCP+EPO 
(5pts) 
7.4 9.0 9.5 9.4 9.4 9.2 9.4 
TD- VCMP-
EPO (4pts) 
7.8 8.4 8.1 8.6 9.0 8.9 9.0 
 
 
In NTD pts, rHu-EPO promoted a significant (p<0.05) and stable increase in Hb levels by the 12th week as 
compared with initial values. 
Health-related QoL 
NR 
Adverse effects  
Mild hypertension recorded in 4 cases. 
The first of four withdrawals suffered a cerebral vascular stroke during the 5th week. One pt was lost to 
follow up at the 7th week and the remaining two pts were excluded at the 3rd and 11th week because of 
severe pneumonia and multiple bone fractures, respectively. No evident Hb increase was observed in the 
three EPO drop out pts during their inclusion in the trial. 
      
Diarrhoea, n (%)      
Diaphoresis, n (%)      
Hypertension, n (%)*      
Seizure, n (%)**      
Thromboembolic events, n 
(%)   
   
 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Unclear 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
NR 
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Inadequate = allocation was alternate, or based on information known to the triallist) 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? NR 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  Unclear 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? Unclear 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? No 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? 
No, ≥10% dropout 
in 
epo group. 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? Yes 
NOTES: 
OTHER 
Generalisability Unable to assess 
Author conclusions Our data suggest that α-IFN plus rHu-EPO 
treatment in MM pts is effective in restoring normal 
B cell function. These results may reflect in vivo the 
modulation of normal human B cells and 
lymphoblasts by rHu-EPO observed in vitro 
Reviewer comments Small sample size, no baseline characteristics, 
poorly reported outcomes. 
 
Endnote Ref ID 
 
341 Malignancy type Cervical cancer 
Treatment Epoetin beta 
STUDY DESIGN PARTICIPANTS 
Author, year Strauss, 2008 N 74 
Objective To investigate whether in 
patients with cervical 
cancer the effectiveness 
and outcome of 
radiotherapy plus cisplatin 
could be positively 
influenced by treatment 
with epoetin beta. The 
design of the second 
stage was to be adapted 
or rejected depending on 
the outcome of the first 
stage of the trial. 
 
The primary objective of 
the first stage was to 
investigate if there was a 
correlation between 
anaemia correction with 
Inclusion criteria:  
 18yrs or over 
 A histologically confirmed diagnosis of 
cervical cancer 
 FIGO stage IIB-IVA (except  chorion 
carcinoma and neuroendocrine small cell 
carcinoma) 
 Hb levels between 9 and 13 g/dl at 
screening 
 WHO performance status of 0-2 
 A life expectancy of at least 3 months 
 Adequate bone marrow function (platelets 
>100 x109/L and leukocytes>3.0 x 109/L) 
 Adequate liver function (transaminases 
and/or alkaline phosphatises no greater 
than 2.5.x upper normal limit; bilirubin no 
greater than 1.5 x normal limit) 
 Adequate renal function (calculated 
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epoetin beta and 
treatment failure in women 
with cervical cancer 
receiving RCT. 
 
After the first stage had 
been analyzed the study 
protocol outlined a 
continuation of the study 
where a further 450 pts 
were to be enrolled to 
investigate the potential 
impact of anaemia 
correction with epoetin on 
survival. 
creatinine clearance >60 ml/min) 
 No previous systemic antineoplastic 
therapy or RT for cervical cancer, except 
previous single brachytherapy fraction of 
the protocol prescribed RT course as 
clinically indicated 
 
Exclusion criteria: 
 Pts with distant metastasis (M1 disease) 
 Positive para-aortic lymph nodes 
 Chronic heart failure (NYHA ≥2) 
 Uncontrolled arterial hypertension 
(systolic ≥170 mm Hb, diastolic ≥100 mm 
Hb) 
 Known history of DVT 
 Thrombocytosis 
 Known haemoglobin opathies 
 Vitamin B12 and/or folic acid deficiencies 
 Haemolytic anaemia 
 Bleeding requiring transfusion within 3 
months before planned start of treatment 
 Acute infection 
 Transferrin saturation less than 20% 
 Known presence of other neoplasias 
within the last five yrs 
 Pregnancy or lactation 
 Exposure to epoetins within 3 months 
 Contraindications against cisplatin therapy
# centres 20 
Other references/aliases Full paper 
Geographical setting Europe, Turkey and 
Thailand 
Duration of treatment Unclear -  pts scheduled 
to receive RT over 6 wks 
(to a maximum of 50 
days), plus concomitant 
cisplatin 
Length of follow-up (if 
different) 
447 – 513 days (unclear if 
this starts after EOTP) 
Country of corresponding 
author 
Germany 
Language of publication English  
Sources of funding F-Hoffman-La Roche Ltd 
RANDOMISATION & 
ALLOCATION 
Open, randomised, two arm, parallel group, two-stage, adaptive study. 
Patients were centrally randomised to epoetin arm or control arm. Open label. 
No details given on randomization procedure. 
TREATMENT ARMS 
ARM Drug name/s Epoetin beta Control (standard care) 
N 34 40 
Dose & freq (od, bd etc) 450 IU/kg in three divided doses   
Dose adjustment Y/N 
Y.  
If insufficient Hb response (inc in Hb 
of <0.5 g/dl after 4 weeks of 
treatment, or requirement of RBCTin 
the fourth week of epoetin beta 
treatment) the dose could be doubled 
to 900 IU/kg 
 
If Hb >15 g/dl epo stopped and 
resumed at 50% of previous dose 
until Hb≤14 g/dl 
 
If Hb increased by > 2 g/dl in 4 weeks 
dose reductions of 50% were applied. 
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Route of administration Subcutaneous  
Duration of epo tx 
The median duration of epoetin beta 
treatment was 63 days ( range: 3-98 
days) 
 
Adj anaemia treatment 
If transferrin saturation <20% IV iron 
supplementation with a dose of 100 
mg Fe3+. was recommended. If 
contraindicated or not available, daily 
oral iron supplementation at a dose of 
200-300 mg Fe3+ could be used 
 
Fe was received by 27 pts (79%) in 
epoetin group. Of these 15 received 
IV and 12 oral. In the control group, 
Fe was received by 22 pts (55%), 12 
pts received IV and 10 pts received 
oral. 
 
Transfusion trigger 
At physicians’ discretion if Hb levels 
were <8.5 g/dl and were to be 
avoided in pts with an Hb >8.5 g/dl 
 
NOTES:  
2-week pre-treatment period to ensure anaemic patients had acceptable Hb level at the start of the study 
OUTCOMES 
Primary 
outcome 
Treatment 
failures in 
correlation with 
Hb change from 
baseline to 
study end 
(defined as pts 
with no 
complete 
response or 
relapsing within 
6 months after 
initiation of 
RCT) 
Other outcomes 
Tumour response; progression / relapse-free 
survival; overall survival; overall response rate; 
AEs 
ANALYSIS 
Statistical technique used? 
The effect of Hb change from baseline on treatment 
failure (defined as pt with no complete response or 
relapsing within 6 months after initiation of RCT) was 
analysed using a logistical regression analysis (two-
sided test at α = 5% with change from baseline in Hb as 
main factor in the model). 
 
A proof of concept for the first stage of the study was to 
be accepted if a positive correlation between change in 
Hb levels from baseline to the end of the treatment 
period and treatment failure could be established and no 
important safety concerns were raised in an initial group 
of approximately 80 pts.  
 
PFS and OS were analysed by log-rank testing and Cox 
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regression analysis. Multivariate analysis was performed 
using a stepwise Cox regression procedure. The overall 
response was analysed using the Chi –squared test with 
Schouten correction and 95% Clopper-Pearson 
confidence intervals. Change from baseline in Hb at the 
end of the treatment period was tested in an analysis of 
covariance model, with Hb at baseline as covariate. Hb 
change from baseline was assessed at week 4 and at 
the end of the treatment period. 
Intention to treat analysis? 
Yes – all randomised patients were included in the ITT 
population and all efficacy results are provided for this 
population. The safety population comprised of all 
patients who received at least one dose of the trial 
medication with RCT and/or epoetin in the epoetin beta 
group and at least one dose of RCT in the control group. 
Does statistical technique adjust for 
confounding? 
NR (only baseline Hb values mentioned as covariate in 
ANCOVA) 
Power calculation (priori sample calculation)? NR 
Attrition rate (loss to follow-up)? See below 
Was attrition rate adequately dealt with? 
Three pts were excluded from safety analysis (one from 
treatment arm and two from control arm), as they did not 
receive study treatment. 
 
A total of 12 pts (16%) were withdrawn prematurely from 
the study, 8 in the epoetin arm and 4 in control arm.  
 
There were no withdrawals due to adverse events in 
either group. Reasons for withdrawal were death (not 
related to study medication), refusal of further treatment, 
failure to return for treatment, inclusion criteria not being 
met or exclusion criteria being fulfilled.  
 
 
Number (%) followed up from each condition? 
Median follow-up for survival was 482 (IQR 447-617) 
days in the epoetin beta group and 466 (IQR 446-513) 
days in the control group. 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / 
mixed) 
Cervical 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; 
radio; no specific malignancy treatment; not reported) 
Chemo+radio 
Adjuvant anaemia treatment 
Iron 
Enrolled pts with a transferrin 
saturation of less than 20% were 
recommended to receive IV iron 
supplementation with a dose of 
100 mg Fe3+.. If contraindicated 
or not available, daily oral iron 
supplementation at a dose of 
200-300 mg Fe3+ could be used. 
 
G-CSF No 
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Transfusion trigger 
 Blood transfusions were given 
according to physicians’ decision 
if Hb levels were less than 8.5 
g/dl and were to be avoided in pts 
with an Hb greater than 8.5 g/dl 
Hb inclusion criteria level 
Hb levels between 9 and 13 g/dl 
at screening 
 
 
Arm 1 = Epoetin 
beta 
N =34 
Arm 2 = Control 
N = 40 P-value  
Sex        
male (%) N/A  N/A    
female (%) 34 (100) 40 (100) 0.957 
Age years mean (SD) 48.8 (10.2) 49.2 (12.8)   
Performance status 
WHO , n (%)       
0 21 (61.8) 27  (67.5) 0.689 
1 13 (38.2) 12 (30.0) 0.529 
2 0  1 (2.5) - 
3       
4       
Hb baseline (g dl-1) median (IQR) 11.4 (10.8-12.0) 11.6 
(10.9-
12.4) 0.371 
Hb before RCT (g dl-1) (IQR) 11.8 (10.6-13.1) 11.7 
(10.9-
12.4) 0.633 
Epo baseline (mU ml-1)       
Were intervention and control groups comparable? Yes.   
RESULTS 
 
Arm 1 = Epoetin 
beta 
N = 34 
Arm 2 = Control 
N = 40 
Arm 3 =  
N =  p  
Haematological outcomes and transfusions  
Median change in Hb (baseline 
to last value) 1.3  -0.7     
Transfusion free pts (%) 25 (73.5) 28 (70)    
RBC units rec’d, median (range) 3.3 (0.9-6.4) 12 
(0.9-
6.0)   
Not 
significant 
Survival 
Overall survival, deaths (%) 8 (23.5) 5 (12.5)   0.22 
Treatment failures (%) 11 (32.4) 12 (30.0)   0.32 
Complete response (%) 18 (52.9) 23 (57.5)   0.86 
Partial response (%) 4 (11.8) 6 (15)   0.83 
Stable disease (%) 0  3 (7.5)   - 
Progressive disease (%) 7 (20.6) 3 (7.5)   0.12 
PFS (%) 10 (29.4) 13 (32.5)   0.96 
Tumour response N=29 N=35    
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Complete response 18  23     
        
Health-related QoL 
Health state utility scale =  Not collected 
Adverse effects  
Total (%) 19 (58) 26 (68)   0.409 
Deaths 8 (23.5) 5 (12.5)   0.22 
Thromoboembolic events        
Hypertension        
Haemorrhage/thrombocytopenia 1 (3) 4 (11)   0.313 
Rash/irritation/pruritus 1 (3) 0 (0)    
Seizures        
Notes: By week 4 after initiation of RCT, median Hb increased by 1.1 g/dl from baseline in the epoetin 
group, but decreased by 0.6 g/dl in the control group. An analysis of covariance showing a difference in 
least square means (adjusting for baseline Hb) indicated that the change in Hb from baseline was highly 
significant between groups (P<0.0001). More pts in the treatment group achieved target Hb levels of 13 g/dl 
than those in the control group (71% vs 25%). 
 
Overall survival – RR 2.0, 95% CI 0.65-6.15, P=0.22 
 
Seven pts reported SAE (epoetin arm: 5 pts (15%); control arm (2 pts (5%)). Only one SAE was considered 
by the investigator to be related to study treatment: a DVT in a pt receiving epoetin beta.  This pt had 
several other risk factors including hypertension, diabetes mellitus and obesity.  
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Unclear 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the triallist) 
Unclear: although 
described as 
‘centrally 
randomized’, further 
details were not 
provided  
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? Yes 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  No 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? No 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? 
Partially 
(variability can be 
calculated from data 
presented in the 
paper) 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? Yes 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? Yes 
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NOTES: 
OTHER 
Generalisability  
Author conclusions This study shows that epoetin beta rapidly, effectively and safely 
increases Hb levels in pts with cervical cancer receiving RCT. 
Because no positive correlation of Hb increase and improvement in 
clinical outcomes, such as a reduction in treatment failure could be 
demonstrated in stage 1 of this study, this study was not expanded 
to its second stage, which was designed to investigate the potential 
benefits of anaemia correction on survival. Therefore, this study 
does not allow any definite conclusions to be drawn with respect to 
the positive or negative effects of epoetin therapy on survival or 
disease progression in patients with cervical cancer receiving RT. 
Reviewer comments Unsure how run-up to trial with Epo will affect results 
 
Endnote Ref ID 
 
2696 Malignancy type Ovarian carcinoma 
Treatment Epoetin beta (assumed) 
STUDY DESIGN PARTICIPANTS 
Author, year Ten Bokkel Huinink 1998 N 122 
Objective To investigate the 
influence of rhEPO on 
anaemia and transfusion 
requirement in pts with 
ovarian carcinoma treated 
with platinum based 
therapy 
Inclusion criteria:  
 18 yrs or over 
 Ovarian cancer  IIb-IV (according to the 
International Federation of Gynaecology 
and Obstetrician’s classification) 
 Performance status 0-2 (WHO) 
 Hb <13 g/dl prior to treatment 
 Overall life expectancy > 2 months 
 Previously treated pts who had achieved 
a complete remission (CR) and had not 
received treatment for at least 1 yr could 
be enrolled into the study. 
 Pts receiving cisplatin ≥ 75 mg/m2, or 
carboplatin ≥350 mg/m2, because lower 
doses induce anaemia in only a small 
proportion of pts. 
 
Exclusion criteria: 
 Prior chemotherapy or radiotherapy for 
ovarian cancer if they did not meet the 
requirements for previously treated pts as 
detailed in incl criteria 
 White blood cell count ≤3.5 x 109/l 
 Platelet counts ≤ 100 x 109/l 
 Hypertension [SBP > 160mmHb or DBP 
>95 mmHb) 
 Impaired liver function (bilirubin >25 
mmol/l) 
 Impaired renal function (creatinine >120 
µmol/l) 
 Thrombocytosis (≥500 x 109/l) 
# centres NR 
Other references/aliases None 
Geographical setting NR 
Duration of treatment Treatment with EPO and 
chemo began 2 days after 
randomisation in most pts. 
EPO continued throughout 
the course of 
chemotherapy and for a 
further 3-24 weeks after 
the last cycle of treatment, 
depending on the duration 
of chemo. 
 
Median duration of 
observation (between 
randomisation  and last 
examination) was 170 
days in the control group 
and 167 days in group I. 
Length of follow-up (if 
different)  
Country of corresponding 
author The Netherlands 
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Language of publication English  Other reasons for anaemia 
 Severely impaired coagulation 
 Iron deficiency 
 Epilepsy 
 Blood transfusion less than 1 week prior 
to protocol treatment 
 Haemoglobinopathies 
 Acute infections 
 Second primary tumours 
 Administration of an investigational drug 
within 30 days preceding the first dose of 
the study drug 
Sources of funding 
NR 
RANDOMISATION & 
ALLOCATION 
Pts were randomly allocated to three study groups. Randomisation was 
performed centrally using permuted blocks stratified by institute and previous 
treatment (previously untreated, first line or recurrent disease). 
TREATMENT ARMS 
ARM Drug name/s Not given – assume epoetin alfa  
N 46  
Dose & freq (od, bd etc) 150 µg/kg three times a week  
Dose adjustment Y/N 
The dose of EPO was reduced by 
50% if Hb increased by more than 2 
g/dl during chemo. If Hb exceeded 15 
g/dl at any time, EPO administration 
was stopped until it returned to <14 
g/dl and was then resuned at half the 
previous dose. EPO was withheld 
while platelet counts were <20 x 109 
g/l. If chemo was delayed due to 
thrombocytopaenia, but platelet count 
was > 20 x109 g/l, EPO was 
continued. 
 
Route of administration Sub cut  
Duration of epo tx 
Treatment with EPO and chemo 
began 2 days after randomisation in 
most pts. EPO continued throughout 
the course of chemotherapy and for a 
further 3-24 weeks after the last cycle 
of treatment, depending on the 
duration of chemo. 
 
Adj anaemia treatment NR  
Transfusion trigger <9.7 g/dl  
OUTCOMES 
Primary 
outcome 
Time from randomisation to 
first erythrocyte transfusion; 
RBCT (# patients study 
period) 
Other 
outcomes 
# and vol of RBCT per patient and 
per chemo cycle; course of Hb per 
chemo cycle; response to chemo; 
number of deaths; AEs 
NOTES: 
SAE:  fatal or life-threatening event; hospitalisation; pt permanently disabled; new cancer diagnosed; 
congenital abnormality detected 
All other AEs defined as non-serious 
ANALYSIS 
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Statistical technique used? 
The time to first erythrocyte transfusion was 
analysed using failure-time methods (Kaplan-Meier 
estimates), by log-rank tests based on months from 
randomisation and on number of cycles of chemo. 
Univariate and multiple failure-time analyses (Cox 
proportional hazard method, maximum likelihood 
methods) were also performed. 
 
Laboratory parameters were analysed by means of 
parametric and non-parametric statistics. 
Intention to treat analysis? Described as ITT but two pts excluded from analysis due to insufficient data 
Does statistical technique adjust for confounding? NR 
Power calculation (priori sample calculation)? NR 
Attrition rate (loss to follow-up)? 
Numbers unclear – author states 84 pts completed 
protocol. 
 
From 120 pts, one pt in Gp 1 and one in Gp2 
dropped out of study before start of treatment. 
Twenty nine plus seven withdrew (through death, 
non-compliance etc) to give 82 pts. 
Was attrition rate adequately dealt with? Safety was assessed according to ITT, but unclear how missing data was handled 
Number (%) followed up from each condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) Ovarian cancer 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Platinum-based chemo 
Adjuvant anaemia treatment 
Iron NR 
G-CSF N/A 
Transfusion trigger <9.7 g/dl 
Hb inclusion criteria level <13 g/dl 
 
Arm 2 = rhEPO 
n=45 
 
Arm 1 = Control 
N=33 
 
Arm 3 =  
N =  
Sex  All female All female   
male (%)       
female (%)       
Age years mean (range) 58.81 58.83   
WHO performance status (%);  
0 24 (53.3) 20 (60.6)   
1 19 (42.2) 13 (39.4)   
2 2 (4.4) 0    
Previous chemo (%)       
Carboplatin ≤350 mg/m2 17 (37) 15 (45)   
Carboplatin >350 mg/m2 9 (20) 8 (24)   
Cisplatin, <75 mg/m2 0  1 (3)   
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Cisplatin, 75-<100 mg/m2 16 (35) 7 (21)   
Cisplatin, ≥100 mg/m2 3 (6) 2 (6)   
Haematological parameters 
[median (range])       
Hb (g/dl) 12.0 (10.3-12.6) 11.8 
(10.6-
12.5) 
There appear to be 
a“typo” in the results 
(Table 1 p 177) for Bl 
Hb epo values: 12.0
 (1.3-12.6) 
assumed to be 12.0
 (10.3-12.6). 
Haematocrit (%) 37.0 (34.2-38.5) 37.0 
(33.0-
38.0)   
Erythrocytes (x 109/l) 4.0 (3.7-4.3) 4.0 (3.8-4.3)   
Reticulocytes (%) 10.5 (7.6-14.0) 12.8 (15.7-16.9)   
Platelet count (x 109/l) 383 (304-433) 395 (302-505)   
Neutrophil count (x 109/l) 4.3 (3.3-5.7) 5.1 (3.4-6.2)   
       
       
Iron baseline (U/l median (range) NR      
Epo baseline (mU ml-1) NR      
Target Hb NR      
Were intervention and control groups comparable? 
No p values reported, authors stated “The three 
groups were comparable with respects to age, stage 
of disease, WHO performance status, primary and 
recurrent disease, previous chemotherapy and 
baseline haematological parameters”. 
RESULTS 
 
Arm 2 = Epo 
N=44a 
 
 
Arm 1 = Control 
N=33 
 
 
Arm 3 =  
N =  p  
Response to chemo N=40 N=30   
# Progression 6  2     
# Complete remission 23  19     
# Deaths 1   2     
Transfusion 
Time to first transfusion (mnts) Longer in Epo group than control 0.0002 
No pts receiving at least one 
transfusion (%) 2 (4.4) 13 (39.4)    
No units  15 units in 6 transfusion events 
41 units in 19 
transfusion events    
Haematological outcomes 
Pts with Hb <10g/dl (%)        
Cycle 1 2 (4.5) 8 (24.2)    
Cycle 2 1 (2.4) 10 (32.3)    
Cycle 3 1 (2.5) 15 (50)    
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Cycle 4 3 (8.1) 15 (53.7)    
Cycle 5 6 (16.7) 13 (50)    
Cycle 6 6 (17.6) 12 (50)    
No. pts evaluable 31  19     
Median (range) 9 (9-584) 8 (2-29)    
No. pts evaluable 28  18     
O/P ratio b ≥0.8 16  7     
O/P ratio b <0.8 12  11     
Health-related QoL NR       
Adverse effects (%)        
Thromoboembolic events 1       
Hypertension 1/43 (2.3 1/28 (3.6)    
No. pts suffering at least one 
adverse event (%) 
39/45 (86.7) 28/33 (84.8)    
No. pts suffering more than one 
adverse event (%) 
 (20.0)  (15.2)    
Superficial thrombophlebitis 1       
Due to adverse events 25 pts in control group and 34 pts in group 1 completed the planned protocol. Seven 
pts (15.6% in group I and four (12.1%) in the control group were withdrawn due to adverse events. 
Notes: a One pt withdrew before start of treatment with Epo; b the ratio between observed serum EPO level 
and the level predicted from the degree of anaemia (O/P) was selected as a possible predictor of 
transfusion requirement because a relative EPO deficiency (O/P <0.8) is considered to indicate an 
inadequate eondogenous EPO concentration. 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Unclear 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? Yes 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  No 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? No 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? No 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? Yes 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? 
Partially; 
Number unclear 
NOTES: 
OTHER 
Generalisability Small sample size – all female population 
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Author conclusions The use of rhEPO should be considered in pts with 
ovarian cancer receiving platinum based chemo, 
particularly if they have an endogenous EPO 
deficiency, to delay the onset of anaemia and 
reduce the need for blood transfusion. 
Reviewer comments Some of the results for the two dosing arms (one of 
which is not applicable to this review) have been 
combined and therefore not extracted 
 
Endnote Ref ID 
 
2697 Malignancy type Small cell lung cancer 
Treatment Epoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Thatcher, 1999 N 130 
Objective To determine the efficacy 
and safety of epoetin alfa 
in preventing the decline 
in Hb level in patients 
undergoing cyclic 
chemotherapy for SCLC 
and to evaluate whether a 
reduction in RBC 
transfusion requirements 
could also be achieved. 
The impact of epoetin alfa 
therapy on pts quality of 
life was also assessed 
Inclusion criteria:  
 Male or female pts aged 18-75 yrs 
 Planned for treatment with 4-6 cycles of 
combination chemo, primarily Pt based 
 Small cell lung cancer 
 All pts required to be ambulatory and 
capable of self care (WHO  performance 
score ≤2) 
 Hb ≤10.5 g/dl 
 Neutrophil count >3000 mm-3 
 Platelet count >100,000 mm-3 
 No clinically relevant abnormalities of 
renal or hepatic function 
 Serum calcium <10.6 mg/dl  
 Stool samples negative for occult blood 
 
Exclusion criteria: 
 Pregnant or of childbearing potential and 
not taking adequate contraceptive 
measures 
 Any clinically significant disease 
 History of primary haematological disease 
 History of seizures or acute illness within 
7 days of study entry 
 Pts who had received androgen therapy 
within 2 months of study entry and those 
who had received any experimental 
treatment, immunosuppressive drugs or 
other agents known to affect haematocrit 
within 1 month prior to study entry 
 Pts receiving haematopoietic growth 
factors (including epoetin alfa)  
 Pts participating in another trial
# centres NR 
Other references/aliases None 
Geographical setting Unclear 
Duration of treatment Maximum study duration 
was 26 weeks 
Length of follow-up (if 
different) NR 
Country of corresponding 
author UK 
Language of publication English 
Sources of funding 
NR 
RANDOMISATION & 
ALLOCATION 
Pts randomised to one of three groups – epoetin alfa 150 IU/kg, epoetin alfa 
300 IU/kg (outside licence therefore N/A and control 
TREATMENT ARMS 
ARM Drug name/s Epoetin alfa Control (standard care) 
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N 42 44 
Dose & freq (od, bd etc) 
150 IU/kg three times a week. 
Treatment started 1 day after 
administration of each cycle of 
chemotherapy and continued until 3 
days prior to the following cycle; 
treatment continued for 1 month after 
the final cycle. 
 
Dose adjustment Y/N 
If Hb level exceeded 15g/dl, epoetin 
alfa was discontinued until the value 
had fallen to <13 g/dl, at which point 
treatment was reinstated at half the 
initial dose. 
 
Route of administration Subcutaneous  
Duration of epo tx Maximum study duration was 26 weeks  
Adj anaemia treatment 
Transfusions were allowed as 
necessary. No pt received iron 
supplementation 
 
Transfusion trigger NR  
OUTCOMES 
Primary 
outcome 
HaemR (prevention of 
anaemia defined as 
maintenance of a Hb ≥10 
g/dl) 
Other 
outcomes 
HRQoL (Pt well-being in the week 
prior to each cycle of chemo was 
assessed by QoL questionnaire 
where pt response  to three levels 
(energy level, daily activity and 
overall QoL) were scored on a 
100mm VAS, and WHO performance 
score); AEs (Safety assessments 
included pt discontinuation 
information, vital signs (recorded in 
the treated groups only) and the 
incidence and severity of adverse 
events, laboratory parameters at the 
start of each cycle and epoetin alfa 
antibody titre at study end compeared 
to baseline) 
ANALYSIS 
Statistical technique used? 
Comparability of the three groups with regard to demographic 
and clinical characteristics at baseline was tested by means of 
analysis of variance, Kruskal-Wallis or chi-squared tests, as 
appropriate. Differences between treatment groups for mid-
cycle Hb and haematocrit through cycles 1-6 were tested using 
ANOVA. Within group differences from baseline for efficacy 
parameters were tested using a paired Student’s t-test. The 
proportion of pts transfused was compared between treatment 
groups using a Cochran-Mantel-Haenszel analysis. For pairwise 
comparison of treatment groups, the sequentially rejective 
Bonferroni-Holm procedure was applied to adjust for three 
multiple comparisons. The time to become anaemic or require 
transfusion was analysed by survival analysis using Kaplan-
Meier estimates and the log-rank test. All tests were conducted 
at the two-sided, 0.05 significance level. 
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Intention to treat analysis? Yes 
Does statistical technique adjust for 
confounding? NR 
Power calculation (priori sample 
calculation)? NR 
Attrition rate (loss to follow-up)? 
Reasons for premature study discontinuation 
Parameter Control (n=42) 
Adverse events 2 
Death 3 
Intercurrent illness 1 
Othera 8 
Total 14 
aIncluding personal reasons, loss to follow-up, non-responder to 
chemotherapy, disease progression or remission, 
discontinuation of chemotherapy, toxicity of chemotherapy, 
elevated Hb, deterioration of general condition and physician 
decision 
Was attrition rate adequately dealt with? NR 
Number (%) followed up from each 
condition? NR 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) Small Cell Lung Cancer 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Pt - based chemo 
Adjuvant anaemia treatment 
Iron None 
G-CSF None 
Transfusion trigger NR 
Hb inclusion criteria level Hb ≥10.5 g/dl  
 
Arm 2 =  
Epoetin alfa 
N=42 
Arm 1 =  
Control 
N=44 
Arm 3 =  
N =  
Sex      
male, n 26 27   
female, n 16 17   
Age years median (range) 59.0 (43-72) 60 (39-74)   
Median Hb, g/dl (range) 13.7 (10.7-16.1) 13.4 (10.9-16.4)   
Median Haematocrit, % (range) 41.0 (32.6-50.3) 39.4 (32.3 – 46.8)   
Median reticulocyte count, x 109 /l 
(range) 40.1 (1.0-76.2) 39.3 (0.1-109.1)   
Median neutrophil count, x 109 /l 6.0 (1.7-11.3) 5.9 (2.9-16.4)   
Median WHO performance score, 
0-4 (range) 1.0 (0-3) 1.0 (0-2)   
Median QoL scores, 0-100 mm 
(range)     
     Energy level 47.0 (11-100) 51.0 (0-94)   
     Daily activity 46.0 (5-100) 32.0 (0-97)   
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     Overall QoL 44.0 (1-100) 49.0 (0-98)   
Chemotherapy regimen (n)     
     Carboplatin based 34 38   
     Cisplatin based 2 2   
     Other 6 4   
     
Were intervention and control groups comparable? 
No p values reported, authors stated “no statistically 
significant between-group differences”. 
 
RESULTS 
 
Arm 2 =  
Epoetin alfa 
N=42 
Arm 1 =  
Control 
N=44 
Arm 3 =  
N =  p  
Haematological  and transfusion outcomes 
Pts experiencing Hb < 10g/dl, % 48 66   <0.05 
Pt requiring of transfusion (%) 19/42 (20) 26/44 (59)   <0.05 
Total number of transfusions 41 73    
Mean cumulative transfusion 
rate for 6 cycles of chemo (±sd) 3.84±5.58 6.13±7.13   <0.01 
Median time to become 
anaemic/ require first 
transfusion, days 
116/98 59/48    
Health-related QoL notes: 
Parameters assessed by the QoL questionnaire did not show any marked  changes from baseline at the 
end of the study in any group, with the exception of significant improvement in overall QoL in the epoetin 
alfa 150 IU/kg group (P<0.05). There were no significant between group differences which may be related 
to the fact that all groups had similar Hb values at study end. Evaluation of WHO performance scores 
revealed similar findings, with no significant between- or within-group differences. 
Change in QoL parameter from 
baseline, 0-100mm (sd) n=33 n=27    
     Energy level  -2.3 ± 31.9 1.6 ± 23.9    
     Daily activity   3.0 ± 31.7 10.8 ± 35.6    
     Overall QoL 11.7 ± 30.6a 7.5 ± 29.1    
Notes: aP<0.05 vs baseline 
Adverse effects reported by ≥5% of pts in any treatment group 
Anaemia 19 (43%) 14 (33%)    
Thrombocytopenia 9 (20%) 11 (26%)    
Bacterial infection 10 (23%) 8 (19%)    
Nausea 6 (14%) 3 (7%)    
Neutropenia 8 (18%) 5 (12%)    
Pyrexia 7 (16%) 7 (17%)    
Dyspnoea 1 (2%) 1 (2%)    
Vomiting 5 (11%) 5 (12%)    
Dizziness 1 (2%) 3 (7%)    
Cough 0 0    
Headache 1 (2%) 2 (5%)    
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Constipation 1 (2%) 2 (5%)    
Malaise 0 2 (5%)    
UTI 0 0    
Alopecia 3 (7%) 1 (2%)    
Oedema 0 4 (10%)    
Diarrhoea 2 (5%) 5 (12%)    
Rash 4 (9%) 5 (12%)    
Decreased WBC count 3 (7%) 1 (2%)    
Lethargy 3 (7%) 1 (2%)    
There was no evidence of a sustained increase in hypertension in the epoetin alfa arm. One patient had 
several recordings of a diastolic BP around 105 mmHg, while another patient with a history of hypertension 
experienced an elevation of BP to 180/120 after the second dose. Overall, there was significant reduction in 
mean systolic BP over time in the epoetin alfa treatment group. 
 
Notes:  
Low serum iron and transferring saturation values were seen in pts in the treatment group. 
 
No statistically significant differences in neutropenia suggesting no differences in chemotherapy intensity. 
 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Unclear 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? Yes 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  No 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? NR 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? 
Partially 
(variability can be 
calculated from data 
presented in the 
paper) 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? 
Yes (except for 
QoL) 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? Yes 
NOTES:  
 
OTHER 
Generalisability Relatively small sample size. 
Author conclusions This study has demonstrated that epoetin alfa is 
effective and well tolerated in maintaining Hb level 
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≥10 g/dl and reducing transfusion requirements in 
pts with SCLC undergoing pt-based cyclic 
combination chemo. 
Reviewer comments QoL of limited used due to unvalidated scale. 
Although WHO performance scores were measured.
 
Endnote Ref ID 
 
435 Malignancy type solid tumours 
Treatment epo theta & beta & placebo 
STUDY DESIGN PARTICIPANTS 
Author, year  Tjulandin 2010 N  223 
Objective To assess effects of 
epoetin theta compared 
to placebo for efficacy and 
to compare the efficacy 
and safety profile of 
epoetin theta with epoetin 
beta 
Inclusion criteria: secondary anaemia (Hb 
≤11g/dl) related to platinum-containing 
chemotherapy; age ≥ 18 years; histologically or 
cytologically proven diagnosis of a solid tumour; 
at least 1 platinum-based chemotherapy cycle as 
treatment of the current malignancy during the 
last 4 weeks (Hb concentration of ≤11 g/dL after 
the last chemotherapy); ECOG≥3 
 
Exclusion criteria: patients with head and neck 
tumours, uncontrolled severe hypertension and 
patients receiving concomitant radiotherapy 
# centres  54 sites; Between 
October 2005 and July 
2007 
Other references/aliases Trial reg # 
ISRCTN09530309 
XM01-21 
Geographical setting International, 10 countries 
(Argentina, Belarus, 
Brazil, 
Bulgaria, Croatia, India, 
Moldova, Romania, 
Russia, Ukraine) 
Duration of treatment 12 weeks 
The mean treatment 
duration ±SD was 
comparable in all 3 groups 
(75.0 ± 16.9 days Epoetin 
theta vs. 71.0 ± 19.7 days 
Epoetin beta vs. 70.5 ± 
23.7 days placebo) 
Length of follow-up (if 
different) NR 
Country of corresponding 
author Germany 
Language of publication English 
Sources of funding Sponsored by BioGeneriX 
AG a company of the 
ratiopharm Group S. A.  
RANDOMISATION & 
ALLOCATION 
Randomised using a computer generated allocation schedule in a 1:1:1 ratio 
stratified by country to double-blind treatment for 12 weeks with either epoetin 
theta, epoetin beta, or placebo.  
Randomisation list generated by the Department of Biostatistics, Merckle 
GmbH.  
Only the person administering study medication was unblinded (due to the 
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difference in dosing schemes).  
An unblinded data monitoring committee closely monitored the safety  
TREATMENT ARMS 
ARM Drug name/s epoetin theta epoetin beta placebo 
N 76 73 74 
Dose & freq (od, bd etc) 20 000 IU once per week$ 
450 IU/kg three times 
per week* NR*$ 
Dose adjustment Y/N 
Y: after 4 weeks 
increase to 40 000 IU if 
Hb increase <1 g/dL, 
with further increase to 
60 000IUif after next 4 
weeks still insufficient 
response. Reduction by 
50% if Hb increase >2 
g/dL at 4 weeks. If Hb > 
13 g/dl, dose 
interruption or 50 % 
dose reduction. 
Y: after 4 weeks dose 
doubled if if Hb increase 
<1 g/dL. Reductions 
same as for Epo Theta. 
three times per week* 
Route of administration Subcutaneously   
Duration of epo tx 12 weeks subcutaneously 12 weeks 
Adj anaemia treatment Iron substitution was allowed during the study 12 weeks NR** 
Transfusion trigger 
At the discretion of the 
investigator, but should 
have been avoided if Hb 
≥8.5 g/dL, 
Iron substitution was 
allowed during the study 
At the discretion of the 
investigator, but should 
have been avoided if Hb 
≥8.5 g/dL, 
OUTCOMES  
Primary 
outcome 
HaemR (inc in Hb of ≥2 g/dL from 
BL without the benefit of a 
transfusion within previous 4 
weeks) 
Other 
outcomes 
HaemR (partial Hb response 
≥1 g /dL from BL; # patients 
having complete Hb 
response with initial dose; 
time course of Hb, 
haematocrit and 
reticulocytes; dose of epo 
theta or epo beta at the time 
of complete/partial Hb 
response); RBCT (# patients 
requiring blood transfusion; # 
of blood units transfused); 
HRQoL (FACT-An (incl 
FACT-G and FACT-F)); AEs 
(Safety lab, vital signs, 
incidence of AEs, adverse 
drug reactions, overall 
tolerability & screening for 
anti-drug antibodies to 
epoetin theta & epoetin beta 
at the beginning and end of 
study & 60 days after the 
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end of the individual 
treatment period) 
NOTES: 
 
ANALYSIS 
Statistical technique used? 
Logistic regression analysis with treatment and BL Hb level as 
explanatory variables was performed to estimate the difference in 
the proportion of complete Hb responders for epo theta vs 
placebo, epo beta vs placebo, & epo theta vs epo beta in the 
confirmatory analysis of the primary endpoint. For other binary 
secondary efficacy endpoints same logistic regression model as 
for the primary endpoint. Changes of QoL (FACT score) from BL 
to EOTP were compared pairwise among treatment groups with 
the Wilcoxon-Mann-Whitney test, treatment groups for other 
secondary endpoints only compared descriptively 
Intention to treat analysis? Yes. Full analysis set  used for efficacy endpoints,  no crossover and endpoints reported for full patient numbers 
Does statistical technique adjust for 
confounding? 
NR, however logistic regression analysis was adjusted for 
baseline Hb to estimate the effects of treatment on Hb response. 
Power calculation (priori sample 
calculation)? 
Partial: sample size calculation given for statistical superiority test 
comparing epoetin theta and placebo but not overall (two-sided α 
= 5%, assuming the actual Hb response rates for Epoetin theta 
and placebo were 50% and 20% respectively) 
Attrition rate (loss to follow-up)? 
Y: Placebo n=21 withdrawals (4 due to AE, 12 patient request,2 
loss to follow-up, 3 other); epo beta n=9 withdrawals (1 due to 
AE, 7 patient request, 1 other; epo theta n=12 withdrawals (2 due 
to AE, 2 patient request, 1 due to incl/excl criteria, 3 loss to 
follow-up, 4 other)  
Was attrition rate adequately dealt 
with? Unclear 
Number (%) followed up from each 
condition? NA: No follow-up reported 
BASELINE CHARACTERISTICS 
Malignancy type (e.g.solid / solid head neck, lung, ovarian, cervical / 
haem / MDS / mixed) Solid tumours 
Treatment (e.g. chemotherapy platinum / non-platinum based; chemo 
+ radio; no specific malignancy treatment; not reported) Platinum containing chemotherapy
Adjuvant anaemia treatment 
Iron 
Iron 
substitution was allowed during 
the study 
G-CSF  
Transfusion trigger ≤8.5 g/dL 
Hb inclusion criteria level ≤11.0 g/dL 
 Arm 1 = Epo theta N = 76 
Arm 2 = Epo beta 
N = 73 
Arm 3 = Placebo 
N = 74 
male (%) 30 (39.5%) 22 (30.1%) 19  (25.7%) 
female (%) 46 (60.5%) 51 (69.9%) 55 (74.3%) 
Age years mean±SD 
median (range) 
53.7±10.3 
53.5 (19.0 to 76.0) 
57.3±10.5 
57.0 (28.0 to 83.0) 
57.3±11.5 
59.5 (26.0 to 76.0) 
Performance status  ECOG  
0 6  (7.9%) 9 (12.3%) 5 (6.8%) 
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1 55 (72.4%) 40 (54.8%) 48  (64.9%) 
2 15 (19.7%) 24 (32.9%) 20  (27.0%) 
3 0  0  1 (1.4%) 
Mean Hb baseline (g dl-1) (SD) 9.6±1.1 9.5±0.8 9.4±1.2 
Iron baseline (U/l median (range) NR NR NR NR NR NR 
Epo baseline (mU ml-1) NR NR NR NR NR NR 
Target Hb NR NR NR NR NR NR 
Most common tumour types       
ovarian epithelial cancer 14 (18.4%) 21 (28.8%) 20 (27.0%) 
gastric cancer 6 (7.9%) 5  (6.8%) 7 (9.5%) 
lung squamous cell carcinoma 4 (5.3%) 5  (6.8%) 7 (9.5%) 
breast cancer 6 (7.9%) 3 (4.1%) 6 (8.1%) 
ovarian epithelial cancer 
metastatic 6 (7.9%) 6  (8.2%) 3 (4.1%) 
Most common on-study treatment       
Cisplatin 55 (72.4%) 48 (65.8%) 42  (56.8%) 
Carboplatin 22 (28.9%) 29 (39.7%) 24 (32.4%) 
Cyclophosphamide 18  (23.7%) 17 (23.3%) 15 (20.3%) 
Etoposide 20 (26.3%) 11 (15.1%) 14 (18.9%) 
Were intervention and control groups 
comparable? 
No p-values reported, authors stated that “no relevant 
differences between treatment groups with regard to 
medical history, prior or concomitant medications, ECOG 
performance status, blood transfusions prior to study 
entry, concomitant diseases, tumour types and on-study 
chemotherapies” were found. 
RESULTS 
 
Arm 1 =  
Epo theta 
N = 76 
Arm 2 =  
Epo beta 
N = 73 
Arm 3 =  
Placebo 
N = 74 
p  
Hb 
Hb at the end of study, (g dl-1), mean 
(SD) 11.2 2 11.4 2 9.6 1.2  
Change in Hb levels, g dl-1), mean 
(SD) 1.6  1.9  0.2   
Notes: 
Results for Hb change from baseline presented graphically;  Fig 3 p 50 in paper 
The changes of haematocrit values were very similar to the changes of Hb values over time. Absolute 
reticulocyte values showed a high degree of variability in all 3 treatment groups and at all timepoints. 
Complete Hb response without 
blood transfusion  (increase of 
≥2 g/dl from baseline);n, % 
50  (65.8%) 52 (71.2%) 15 (20.3%)  
Epoetin beta vs placebo   OR 10.25 (95% CI: 4.86, 22.83) <0.0001 
Epoetin theta vs placebo   OR 8.06 (95% CI: 3.89, 17.63) <0.0001 
Epoetin theta vs beta   OR 0.79 (95% CI: 0.39, 1.58) 0.5004 
Complete Hb response without 
blood transfusion & dose 
adjustment, n, % 
26  (34.2%) 29 (39.7%) 8 (10.8%)  
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Epoetin beta vs placebo   OR 5.40 (95% CI: 2.35, 13.68) 0.0001 
Epoetin theta vs placebo   OR 4.24 (95% CI: 1.84, 10.76) 0.0012 
Epoetin theta vs beta   OR 0.79, 95% CI: 0.40, 1.53) 0.4765 
Partial Hb response without blood 
transfusion  (increase of 
≥1 g/dl from baseline);n, % 
69 (90.8%) 66 (90.4%) 37 (50%)  
Epoetin beta vs placebo   OR 9.39 (95% CI: 4.01, 24.93) <0.0001 
Epoetin theta vs placebo   OR 9.8 (95% CI: 4.19, 26.00) <0.0001 
Epoetin theta vs beta   OR 1.04, 95% CI: 0.34, 3.20 0.9394 
Notes: 
The mean ± SD average weekly dose was higher in the Epoetin beta group compared to the Epoetin theta 
group (36,973±13,967 vs. 26,425± 9,157 IU). This was to be expected as the weekly starting dose were 
different. 
Baseline Hb levels had no statistically significant effects on the response rates. 
Transfusions 
Patients received blood 
transfusions,n ,% 8  (10.5%) 9 (12.3%) 18 (24.3%)  
Epoetin beta vs placebo   NR 0.1042 
Epoetin theta vs placebo   OR 0.38 (0.14, 0.95) 0.0433 
Epoetin theta vs beta   OR 1.04, 95% CI: 0.34, 3.20 0.9394 
Number of Blood Units Transfused, 
mean (SD) 3.3 2.2 1.8 0.7 2.8 2.9  
Baseline Hb levels had a statistically significant effect on the rate of blood transfusion (P = 0.0005) with an 
odds ratio of 0.53 (95% CI: 0.37, 0.75) per g/dL baseline Hb comparing Epoetin theta with placebo 
Health-related QoL 
Health state utility scale = FACT-An incl FACT-F and FACT-G MEASURED NOT REPORTED 
        
Adverse effects of tmt 
Any TEAE 58 (76.3%) 63 (86.3%) 63 (85.1%)  
Related TEAE = TEADR 14 (18.4%) 16 (21.9%) 13 (17.6%)  
Serious TEAE 9 (11.8%) 9 (12.3%) 15 (20.3%)  
Serious TEADR 1 (1.3%) 1 (1.4%) 0 –  
Death* 5 (6.6%) 4 (5.5%) 12 (16.2%)  
Discontinuation 4  3  6   
* Most frequent reason for death was disease progression (1 epoetin beta, 6 placebo, 3 epoetin theta) 
 
Tolerability – assessed by the patients was very good or good in 89.3%, 76.4% and 90.3% of patients in 
the epoetin theta, placebo, and epoetin beta; assessed by the investigator was very good or good in 93.3%, 
88.9% and 93.1% of patients, respectively 
 
No patients in the study developed neutralising anti-epoetin antibodies to epoetin beta or epoetin theta 
(assessed at the beginning and end of the study and 60 days after the end of the treatment period) 
 
Overall – frequencies of AEs exceeded 10% for nausea (33.2%), neutropenia (22.9%), asthenia (22.4%), 
vomiting (18.4%), thrombocytopenia (16.6%), and leukopenia (16.1%). Incidence of skin reactions possibly 
caused by SC administration was low and comparable across groups (epoetin theta 1, epoetin beta 3, 
placebo 1. Hypertension 2.6% in epoetin theta and 2.7% in epoetin beta and placebo groups 
PenTAG   CONFIDENTIAL 
568 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Yes 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the 
triallist) 
Unclear* 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF 
PROGNOSTIC FACTORS; E.G. SEVERITY OF DISEASE? 
Unclear, No p-values 
reported; similar ECOG 
scores between groups; 
other characteristics 
similar 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  Yes$ 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT 
ALLOCATION? Yes 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? 
Partially 
(variability can be 
calculated from data 
presented in the paper) 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? 
Yes; quality of life data 
not reported 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? Yes 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? 
Yes; however 4 and 3 
pts withdrew for 
unspecified “other” 
reasons in epo and 
placebo groups 
respectively 
NOTES: 
$ e.g. Patients randomised to Epoetin theta received a starting dose of 20,000 IU Epoetin theta 
subcutaneously (s.c.) once weekly (e.g., on Mondays) and in addition the same volume of placebo twice 
weekly (e.g., on Wednesdays and Fridays) for blinding purposes 
*”only the person administering study medication was unblinded” which might imply that the person 
allocating treatment was unaware of the next allocation, but there is nothing explicitly stated so remains 
unclear 
OTHER 
Generalisability Yes 
Author conclusions No conclusions re epoetin beta 
Epoetin theta with a weekly starting dose of 20,000 IU is superior to 
placebo in terms of complete Hb response without blood transfusion. Epo 
theta is a safe and effective treatment for the treatment of anaemia due to 
platinum based chemotherapy in patients with solid tumours 
Reviewer comments The differences between Epoetin beta and placebo and between Epoetin 
beta and Epoetin theta were estimated with the same statistical  model. 
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Endnote Ref ID 
 
436 
 
Malignancy type solid tumour or non-myeloid 
haematological tumour 
Treatment Epo theta  
STUDY DESIGN PARTICIPANTS 
Author, year  Tjulandin 2011 N  186 
Objective The objective of this study was 
to demonstrate superiority of 
Epoetin theta compared to 
placebo for efficacy during the 
treatment period of 12 weeks 
in patients with solid tumours 
or nonmyeloid haematological 
malignancies receiving 
nonplatinum chemotherapy. 
Inclusion criteria: 
 patients ≥18 years of age with 
histologically or cytologically 
proven diagnosis of a solid tumour 
or non-myeloid haematological 
tumour  
 anaemia caused by nonplatinum-
based chemotherapy defined by a 
documented Hb concentration of 
≤11 g/dl after the last 
chemotherapy prior to inclusion 
 at least 1 previous nonplatinum-
based chemotherapy cycle as 
treatment of the current 
malignancy during the last 4 
weeks 
 ECOG= 0, 1, 2 or 3 
 
Exclusion criteria: 
 any other primary haematologic 
disorder that would cause 
anaemia 
 headand neck tumours 
 uncontrolled severe hypertension  
 concomitant radiotherapy 
# centres  72 sites; Between November 
2005 and May 2007 
Other references/aliases Trial reg # ISRCTN08063129 
XM01-22 
Geographical setting International, 10 countries 
(Argentina, Belarus, Brazil, 
Bulgaria, Croatia, India, 
Moldova, Romania, 
Russia, Ukraine) 
Duration of treatment 12 weeks 
The mean treatment duration ± 
SD was comparable in both 
groups (71.9 ± 16.9 days 
placebo vs.72.1 ± 15.7 days 
Epoetin theta. 
Length of follow-up (if 
different) NA 
Country of corresponding 
author Germany 
Language of publication English 
Sources of funding Sponsored by BioGeneriX AG 
a company of the ratiopharm 
Group S. A.  
RANDOMISATION & 
ALLOCATION 
A total of 186 patients were randomised using a 
computer-generated allocation schedule in a 1:1 ratio stratified by country to 
double blind treatment for 12 weeks with either Epoetin theta (N = 95) or 
placebo (N = 91). All persons involved in the conduct of the study were blinded 
with respect to the study medication. The investigator and all other study 
personnel were kept blinded and performed all assessments of the patient 
without knowledge of treatment. An unblinded independent Data Safety 
Monitoring Committee closely monitored the safety in order to ensure that 
patients were not exposed to an unjustifiable risk. 
TREATMENT ARMS 
ARM Drug name/s Epo theta Placebo 
N 95 91 
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Dose & freq (od, bd etc) 
 20 000 IU once per week 
The mean ±SD average weekly dose 
was 25,905 ±10,956 IU in the Epoetin 
theta group 
 
Dose adjustment Y/N 
Y: after 4 weeks increase to 40 000 IU 
if Hb increase <1 g/dl, with further 
increase to 60 000IU if after next 4 
weeks still insufficient response. 
Reduction by 50% if Hb increase >2 
g/dl at 4 weeks. If Hb > 13 g/dl , dose 
interruption or  50 % dose reduction. 
Y: according to the same schedule as 
for epoetin theta for blinding purposes 
Route of administration Subcutaneously Subcutaneously 
Duration of epo tx 12 weeks 12 weeks 
Adj anaemia treatment Iron substitution was allowed during the study. 
Iron substitution was allowed during 
the study. 
Transfusion trigger 
At the discretion of the investigator, 
but should have been avoided if Hb ≥ 
8.5 g/dl 
At the discretion of the investigator, 
but should have been avoided if Hb ≥ 
8.5 g/dl 
OUTCOMES  
Primary 
outcome 
HaemR (inc in Hb of ≥2 g/dL 
from BL without the benefit 
of a transfusion within 
previous 4 weeks) 
Other 
outcomes 
HaemR (partial Hb response ≥1 g /dL 
from BL; # patients having complete 
Hb and partial response with initial 
dose; the time course of 
Hb,haematocrit and reticulocytes; 
dose of epo theta at the time of Hb 
response); RBCT (# patients 
requiring blood transfusion; # of blood 
units transfused); HRQoL (FACT-An; 
FACT-G; FACT-F); AEs 
(immunogenicity was assessed by a 
predefined cascade of antibody 
assays. This cascade was structured 
into a sequential scheme comprising 
screening, confirmation and 
characterisation of clinical specimens. 
Confirmed positive samples were 
investigated for neutralising 
antibodies in a cellular assay using 
an erythropoietin dependent UT-7 cell 
line) 
ANALYSIS 
Statistical technique used? 
A logistic regression analysis with treatment and type of cancer 
as explanatory and baseline haemoglobin value as continuous 
variables was performed to estimate the difference in the 
proportion of complete haemoglobin responders between 
Epoetin theta and placebo in the confirmatory analysis of the 
primary efficacy endpoint. For the primary efficacy endpoint a 
subgroup analysis with type of malignancy (solid, non-myeloid 
haematological) was performed. 
 
For the other binary secondary efficacy endpoints the same 
logistic regression model as for the primary endpoint was 
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estimated. 
 
Changes of QoL from baseline to end of study were compared 
pairwise with the Wilcoxon-Mann- 
Whitney test. 
 
Other secondary efficacy endpoints were only compared 
descriptively. Descriptive P-values were calculated with 
appropriate statistical tests but were regarded as supportive 
only. 
Intention to treat analysis? Yes. Full analysis set  used for efficacy endpoints,  no crossover and endpoints reported for full patient numbers 
Does statistical technique adjust for 
confounding? 
NR, however logistic regression analysis was adjusted for 
baseline Hb to estimate the effects of treatment on Hb 
response. 
Power calculation (priori sample 
calculation)? 
Partial: sample size calculation given for statistical superiority 
test comparing epoetin theta and placebo but not overall : n= 80 
patients per treatment group to achieve a power of 90% for the 
statistical superiority test comparing Epoetin theta and placebo 
assuming a response rate of 45% for Epoetin theta and 20% for 
placebo. 
Attrition rate (loss to follow-up)? 
Y: n=25 prematurely discontinued: n=15 in placebo group 
(AE=6 pts, patients request=4, lack of efficacy=2, lost to follow 
up=1 and other=2) and n=10 in epo theta group: (AE=4 pts, 
patients request=5, lack of efficacy=0, lost to follow up=1 and 
other=0). 
Was attrition rate adequately dealt with? Unclear. Full analysis set used for efficacy endpoints. 
Number (%) followed up from each 
condition? NA: No follow-up reported 
BASELINE CHARACTERISTICS 
Malignancy type (e.g.solid / solid head neck, lung, ovarian, cervical / 
haem / MDS / mixed) 
solid tumour or non-myeloid 
haematological tumour 
Treatment (e.g. chemotherapy platinum / non-platinum based; chemo 
+ radio; no specific malignancy treatment; not reported) 
Nonplatinum-Based 
Chemotherapy 
Adjuvant anaemia treatment 
Iron 
Iron 
substitution was allowed during 
the study 
G-CSF NR 
Transfusion trigger ≤8.5 g/dL at the discretion of the investigator 
Hb inclusion criteria level ≤11.0 g/dL 
 Arm 1 = Epo theta N = 95 
Arm 3 = Placebo 
N = 91  
male (%) 30 (31.6%) 34 (37.4%)   
female (%) 65 (68.4%) 57 (62.6%)   
Age years mean±SD 
median (range) 
56.9±14.7 
60 (18.0 to 83.0) 
55.8±14.3 
57.0 (18.0 to 82.0)  
Performance status ECOG  
0 14  (14.7%) 9 (9.9%)   
1 53 (55.8%) 60 (65.9%)   
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2 28 (29.5%) 21 (23.1%)   
3 0  1 (1.1%)   
Mean Hb baseline (g dl-1) (SD) 9.2±1.3 9.1±1.3  
Iron baseline (U/l median (range) NR NR NR NR   
Epo baseline (mU ml-1) NR NR NR NR   
Target Hb NR NR NR NR   
Most common malignancies       
Multiple myeloma 19 (20%) 17  (18.7%)   
Breast cancer 16 (16.8%) 17  (18.7%)   
Chronic lymphocytic leukaemia 5 (5.3%) 7  (7.7%)   
Gastric cancer 6 (6.3%) 3 (3.3%)   
Most common on-study chemo       
Cyclophosphamide 50 (52.6%) 47 (51.6%)   
Doxorubicin 32 (33.7%) 29 (31.9%)   
Vincristine 26  (27.4%) 28 (30.8%)   
Dexamethasone 22 (23.2%) 21 (23.1%)   
Prednisolone 14 (14.7%) 26 (28.6%)   
Were intervention and control 
groups comparable? 
No p-values reported, authors stated that “There were no relevant 
differences between treatment groups with regard to medical history, 
prior or concomitant medications, ECOG performance status, 
previous chemotherapy, concomitant diseases, and primary 
malignant disease (Table 1).There were no clinically noteworthy 
differences between the treatment groups with regard to on-study 
chemotherapies”. 
RESULTS 
 Arm 1 = Epo thetaN = 95 
Arm 3 = 
Placebo 
N = 91 
 p  
Hb 
Hb at the end of study, (g dl-1), mean 
(SD) 11.3 2 <10     
Change in Hb levels, g dl-1), mean 
(SD) 2.1      <0.0001 
Results for Hb change from baseline presented graphically; Fig 3 p 38  
 
Hb  
estimated from above 
figure 
Arm 1 = Epo theta 
N = 95 
Arm 3 = Placebo 
N = 91 
at the end of study 
 (g dl-1), 
mean SEM SD mean SEM SD 
11.31 0.22 2.14 9.89 0.22 2.10 
 
The changes of haematocrit values were very similar to the changes of Hb values over time. Absolute 
reticulocyte values showed a high degree of variability in both treatment groups and at all timepoints 
(results not reported).  
Complete Hb response without 
blood transfusion  (increase of 
≥2 g/dl from baseline);n, % 
69 72.6% 23 25.3%    
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Epoetin beta vs placebo: Hb adjusted odds ratio: OR 7.944 (4.182, 15.632), p <0.0001 
Complete Hb response without 
blood transfusion  &  dose 
adjustment, n, % 
43 45.3% 9 9.9%    
Epoetin beta vs placebo OR 7.728(3.59, 18.285), p <0.0001 
Partial Hb response without blood 
transfusion  (increase of 
≥1 g/dl from baseline);n, % 
78 82.1% 56 61.5%    
Epoetin beta vs placebo OR 2.841 (1.462, 5.694), p =0.0025 
Partial Hb response without blood 
transfusion & dose adjustment, n, % 56 58.9% 24 26.4%    
Epoetin beta vs placebo OR 4.028 (2.179, 7.632), p <0.0001 
Type of cancer and baseline haemoglobin levels had no statistically significant effects on any measure of 
the response rate and blood transfusion. 
 
The mean ± SD weekly dose of Epoetin theta at the time of complete Hb response without blood 
transfusion was 27,681.2 ±14,260.7 IU (median 20,000 IU), and at the time of partial Hb response it was 
24,871.8±10,659.3 IU (median 20,000 IU). The mean dose of Epoetin theta at the time of complete and 
partial Hb response was similar for solid tumours and haematological malignancies. A dose of up to 20,000 
IU/week was sufficient for complete Hb response in 66.7% of patients with complete response in the 
Epoetin theta group. In a further 23.2% of patients with complete response, response was achieved with a 
dose of 40,000 IU/week. 
Transfusions 
Patients received blood 
transfusions, n, % 13 13.7% 23 25.3%    
Epoetin beta vs placebo OR 0.352 (0.133, 0.868), p =0.0277 
Number of Blood Units Transfused, 
mean (SD) 3.5 3.5 4.1 2.8    
Health-related QoL 
FACT-Anaemia Total, mean (SD) 6.3 21.7 0.6 22   0.243 
FACT-Anaemia Trial outcome index, 
mean (SD) 5.6 17.1 1.2 18.8   0.222 
FACT-Fatigue, mean (SD) 2.9 7.9 0.6 8.8   0.142 
FACT-General scale, mean (SD) 3.0 12.7 -0.2 12.4   0.224 
The completion rate of valid FACT-An questionnaires was high in both treatment groups: 89.5-97.9% in epo 
and 85.7 to 96.7% in the placebo group with only small decreases in completion rates observed over the 
course of the study in both groups. 
AE 
Any EAE 76 80.0 % 71 78.0 %    
Related EAE = EADR 27 28.4 % 18 19.8 %    
Serious EAE 11 11.6 % 14 15.4 %    
Serious EADR 0 0 % 1 1.1 %    
Death* 6 6.3 % 5 5.5 %    
Discontinuation$ 4 4.2% 6 6.6%    
Hypertension 8 8.4 1 1.1%   <0.05 
* Most frequent reason for death was disease progression (3 placebo, 2 epoetin theta) 
$ 1 patient in the placebo group discontinued due to a thrombophlebitis 
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Adverse drug reactions (ADRs) with a causal relationship to the study medication as assessed by the 
investigator were reported in 27 (28.4%) patients in the Epoetin theta group and 18 (19.8%) patients in the 
placebo group (Table 4). The most common ADRs were asthenia (7.5%), nausea (5.4%), headache 
(3.2%), pyrexia (2.7%) and vomiting (2.2%). All of these events commonly occur in cancer patients 
receiving chemotherapy. 
 
Results for safety lab variables, vital signs, body weight, 12-lead ECG, physical examination, tolerability, 
skin irritation, and results of current chemotherapy did not give rise to any safety concerns. 
 
Tolerability as assessed by the patients was very good or good in 89.5% and 89.0% of patients in the 
Epoetin theta and placebo group, respectively. The investigators assessed tolerability as very good 
or good in 98.9% (Epoetin theta) and 96.7% (placebo) of the patients. 
 
Overall – frequencies of AEs exceeded 10% for asthenia (20.4%), neutropenia (18.8%), nausea (17.2%), 
leukopenia (15.6%) and pyrexia (12.9%).  
 
Skin reactions that might have been caused by the subcutaneous administration of study medication were 
reported in 20 patients (13 Epoetin theta, 13.7% and 7 placebo, 7.7%). None of the skin reactions was 
severe or serious. 
 
The incidence of anti-drug antibodies to Epoetin theta was assessed at the beginning and end of the study. 
Only 1 patient treated with placebo developed a single positive result at baseline. A cellular assay to detect 
neutralisation was negative and a blood sample taken from this placebo-treated patient at the end of the 
study was also negative. None of the patients enclosed in the study developed neutralising anti-epoetin 
antibodies to Epoetin theta. 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE 
RANDOM ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = 
for patients number, date of birth, alternate; Unclear 
= if the method not stated) 
Yes 
2. WAS THE TREATMENT ALLOCATION 
ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; 
sequentially numbered coded vials; other methods 
where the triallist allocating treatment could not be 
aware ; Inadequate = allocation was alternate, or 
based on information known to the triallist) 
NR 
3. WERE THE GROUPS SIMILAR AT BASELINE IN 
TERMS OF PROGNOSTIC FACTORS; E.G. 
SEVERITY OF DISEASE? 
Unclear,  
No p-values reported, authors stated that “There 
were no relevant differences between treatment 
groups with regard to medical history, prior or 
concomitant medications, ECOG performance 
status, previous chemotherapy, concomitant 
diseases, and primary malignant disease (Table 
1).There were no clinically noteworthy differences 
between the treatment groups with regard to on-
study chemotherapies”. 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO 
TREATMENT ALLOCATION?  Yes 
6. WERE THE OUTCOME ASSESSORS BLIND TO 
TREATMENT ALLOCATION? 
Yes.  
An unblinded independent Data Safety Monitoring 
Committee closely monitored the safety in order to 
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ensure that patients were not exposed to an 
unjustifiable risk. 
7. WERE THE POINT ESTIMATES AND MEASURE 
OF VARIABILITY PRESENTED FOR THE 
PRIMARY OUTCOME MEASURE? 
Partially 
(variability can be calculated from data presented in 
the paper) 
7. IS THERE EVIDENCE TO SUGGEST THAT THE 
AUTHORS COLLECTED MORE OUTCOME DATA 
THAN THEY REPOTED? 
No 
8. DID THE ANALYSES INCLUDE AN INTENTION-
TO-TREAT ANALYSIS OR WERE LESS THAN 10% 
OF EACH STUDY ARM EXCLUDED? 
Yes, apart from HRQoL (89.5-97.9 and 85.7 to 
96.7% participants  analysed in epo and placebo 
groups respectively). 
9. WERE WITHDRAWALS DROPOUTS AND LOSS 
TO FOLLOW-UP IN EACH GROUP STATED? Yes 
NOTES: 
 
 
OTHER 
Generalisability Yes 
Author conclusions Epoetin theta showed a superior efficacy to placebo in terms of 
complete Hb response without blood transfusion within the 
previous 4 weeks. Treatment with Epoetin theta resulted in a 
statistically significant increase in mean haemoglobin levels 
compared to placebo. The overall frequencies of adverse events 
were similar in both treatment groups 
Reviewer comments  
 
Endnote Ref ID 
 
961 Malignancy type Breast cancer 
Treatment Darbepoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Untch 2011 N 736 enrolled, with 733 randomly allocated 
Objective Latin square design : In a 
second randomization, the 
short- and long-term effects of 
primary use of darbepoetin alfa 
independent from Hb levels on 
tumor response and safety 
were investigated. The 
toxicity and response data 
are described here (#961) 
and the effect on DFS and 
OS is reported in #962 
Inclusion criteria: age 18-65 years with 
histologically confirmed primary breast 
cancer by core biopsy; the primary tumour 
had to be 2 cm based on either clinical or 
ultrasound measurement; inflammatory 
breast cancer was also included; no 
systemic metastasis according to chest X-
ray, sonography, or computed tomography 
scan of upper abdomen and bone scan; 
ECOG <2; adequate organ function: 
aspartate aminotransferase and bilirubin = 
1.5 x upper limit, white blood cells = 3000/µl, 
neutrophils = 1000/µl, platelets = 100 000/µl, 
and serum creatinine  <2.0 mg/dl, and 
normal left ventricular ejection fraction. 
 
Exclusion criteria: NR (but see inclusion 
criteria above) 
# centres 78 
Other references/aliases PREPARE trial 
Untch 2011(#962) 
NCT00544232 
Geographical setting Germany 
Duration of treatment 26 weeks: There were 24 
weeks of chemo. Darbe was 
administered with the first dose 
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of epirubicin (day 1) until 14 
days after the last dose of 
paclitaxel. 
Length of follow-up (if 
different) 
Median follow-up of 43.5 
months 
Country of corresponding 
author Germany 
Language of publication English 
Sources of funding Amgen; Bristol Myers Squibb. 
RANDOMISATION & 
ALLOCATION 
Latin square design: Patients were randomized in a 1:1 allocation to receive 
standard-dose or dose intensified preoperative chemotherapy. Patients within 
each treatment arm were further randomized in a 1:1 allocation to receive DA 
or no DA therapy. 
TREATMENT ARMS 
ARM Drug name/s Darbepoetin alfa Controls (standard care) 
N 356 377 
Dose & freq (od, bd etc) 4.5 µg/kg Q2W NA 
Dose adjustment Y/N 
To achieve the target Hb level 12.5 - 
13 g/dl, the dose was doubled if the 
increase was <1 g/dl during the first 4 
weeks, or discontinued if Hb >14 g/dl. 
Treatment was re-induced with 50% 
of the dose, if Hb≤13.0 g/dl 
 NA 
Route of administration NR  
Duration of epo tx 
starting with the first dose of 
epirubicin (day 1) until 14 days after 
the last dose of paclitaxel 
NA 
Adj anaemia treatment 200 mg oral iron daily NA 
Transfusion trigger NR None 
NOTES: 
Of 318 patients receiving DA, 165 (51.9%) had dose modifications with any dose withheld (25%), missing 
doses (3%), a dose decrease (17%), a dose increase (8%), or extra doses >14 days after chemotherapy 
(3%) 
 
OUTCOMES 
Primary 
outcome  
Other 
outcomes 
RBCT; tumour response (pCR at 
surgery (defined as regression 
Grades 4–5 according to the modified 
regression grading system); survival 
(DFS, OS); AEs (haematological and 
non-haematological, cardiovascular 
and thromboembolic) 
NOTES: 
Other efficacy end points included lymph node status, clinical response at surgery, surgical outcome as 
well as effects of DA on DFS, OS, pCR, and anemia 
ANALYSIS 
Statistical technique used? 
Comparisons between intensified or standard chemotherapy and 
between treatments with and without DA used the chi- square tests. 
All secondary end point tests were two sided, and 95% CI were 
provided for relevant estimates. 
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The change in Hb level difference between the treatments with and 
without DA used ANCOVA with baseline Hb level as covariate. 
 
Binary logistic regression analysis was employed in order to adjust for 
major predictive factors. 
 
Kaplan–Meier curves were used to estimate DFS and OS 
probabilities. DFS was defined as the time from informed consent to 
first documentation of relapse or death due to any cause. OS was the 
time from the date of informed consent to the date of death due to any 
cause. Local DFS was defined as time in weeks between thedate of 
signing informed consent and date of local recurrence. Patients with 
no local recurrence reported were censored at the date of the last 
contact. 
Intention to treat analysis? 
Yes. The change in Hb level was analysed on the full analysis set (all 
patients who met all eligibility criteria and were randomly allocated to 
the chemotherapy treatment) using the last observation carried 
forward approach.  
Patients who did not meet eligibility criteria but received at least one 
dose of study treatment were only included in the safety (toxicity) 
evaluation. 
Does statistical technique adjust 
for confounding? 
Yes; OS and DFS were analysed adjusted for baseline factors 
 
Binary logistic regression analysis was employed in order to adjust for 
major predictive factors. 
 
For multivariable analysis, Cox proportional hazards models for 
adjusting survival end points were used; adjustments were made for 
age, hormone receptor status, clinical tumor size& nodal status,grade, 
chemotherapy arm, darbepoetin alfa application, and pCR. 
Power calculation (priori sample 
calculation)? 
Yes: 720 patients needed to detect an improvement of 10% in PFS 
with the dose-dense regimen with an expected proportion of relapses 
of 30% after 5 years in the standard treatment arm. This equals an 
HR of 1.4 with a type I error of α 5% using a one-sided test 
Attrition rate (loss to follow-up)? 
Partially: Until the point of surgery (as reported in supplemental online 
materials). 
 
733 participants were randomly allocated, 19 did not receive any 
study treatment: 318 of 356 patients randomly allocated to DA 
actually received the treatment. 
 
Most of the patients had surgery after chemotherapy: n=326 darbe 
and n=343 controls remained at that point. 
Was attrition rate adequately dealt 
with? 
Partially: The change in Hb level was analysed on the ‘full analysis 
set’ using the last observation carried forward approach, but patient 
flow and numbers used in analysis were difficult to follow and remain 
unclear. 
Number (%) followed up from each 
condition? 
NR 
BASELINE CHARACTERISTICS 
Malignancy type  Breast cancer 
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(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS 
/ mixed) 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + 
radio; no specific malignancy treatment; not reported) 
Preoperative chemotherapy epirubicin, 
cyclophosphamide and paclitaxel each 
3-weekly (N=370) for four cycles, or 
epirubicin, paclitaxel with pegfilgrastim, 
followed by CMF each 2-weekly and for 
three cycles (N=363).There were 8 and 
9 planned cycles in the standard and 
intensified regimen respectively. 
Adjuvant anaemia 
treatment 
Iron 200 mg oral iron in darbe arm 
G-CSF Yes in intensified regimen chemo only(5µg/kg/d) 
Transfusion trigger NR 
Hb inclusion criteria level NR 
 Arm 1 = darbe N =356 
Arm 2 = controls 
N = 377 
Arm 3 =  
N =  
Sex        
Age years median (range) 
NR, median age reported for the separately for the intensified and standard 
chemotherapy arms only; the median age at randomization was 48 years 
(range 23–65years) 
<50 years 183 51.4% 213 56.4%   
≥50 years 173 43.6% 164 43.6%   
ECOG        
0 306 86.0% 323 85.7%   
1 20 5.6% 29 7.7%   
2/3 2 0.6% 4 1.1%   
missing 28 7.9% 21 5.6%   
Mean Hb baseline (g dl-1) 
(SD) 
n = 333 
13.64 (1.17) 
n=360 
13.61 (1.16) 
as reported in 
supplemental online 
materials 
Clinical tumour stage       
T1-T3 315 88.5% 334 88.6%   
T4 27 7.6% 31 8.2%   
missing 14 3.9% 12 3.2%   
Tumour grade       
1-2 118 33.1% 120 31.8%   
3 97 27.3% 117 31%   
missing 141 39.6% 140 37.2%   
Were intervention and 
control groups comparable? 
No p-values are reported, just stated that ‘baseline characteristics were 
similar in the treatment arms’. It is assumed that this refers to the chemo 
arms, and it is not clear whether it also refers to the epo vs no epo arms. 
RESULTS 
 Arm 1 = darbe N =356 
Arm 2 = controls 
N = 377 
Arm 3 
=  
N =  
p  
Hb 
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Mean  Hb at the end of 
chemotherapy (g dl-1) (SD) 
n=342 
13.59 (1.7) 
n=368 
12.61 (1.38) 
as reported in 
supplemental online 
materials: 
Mean change in Hb (g dl-1) (SD)  n=330 -0.07 (0.11) 
n=359 
-0.98 (0.07) 
The Hb levels in the 
control group 
decreased 
significantly, whereas 
the levels in the Darbe 
group did not change 
significantly. It is not 
clear why the numbers 
analysed differ from 
the numbers 
randomised if LOCF 
was used.  Hb at 
baseline n=360 darbe, 
n=333 control; Hb at 
end of chemo n=368 
darbe, n=342 control;  
change in Hb data 
from n=359 darbe, 
n=330 control). Could 
not find full analysis of 
the Hb data.  
(95% CI) -0.28; 0.14 -1.12; -0.84 
Tumour response 
Pathological CR 57 16% 60 15.9% P=0.972  (pCR vs no pCR) 
CR(by most appropriate method) 46 12.9% 54 14.3% P=0.580  
No difference for clinical response, or nodal response 
Toxicity (safety analysis set) Darbe n=318, controls n=396    
Cardiovascular and 
thromboembolic  events 20 6.3% 17 4.3%   P=0.232 
Thromboembolic events: 
Embolism/thrombosis/ 
 
18 5.7% 12 3%   P=0.055 
Nausea grade 1-4 251 78.9% 315 79.5%    
Nausea grade 3-4 19 6.0% 19 4.8%    
Anaemia grade 1-4 31 9.7% 35 8.8%    
Anaemia grade 3-4 1 0.3% 1 0.3%    
Transfusions 1  0     
        
        
        
Survival  At a median follow-up of 43.5 months; as reported in Untch 2011b 
DFS Arm 1 = darbe 
N =345 
Arm 2 = controls 
N = 369 
 
DFS: estimated at 3 years  74.3%  78% HR=1.31; 95% CI 
(0.99-1.74), P=0.061 
DFS: events, n 106   90   
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DFS: events adjusted for BL  104  30% 88  24% as reported in 
supplemental online 
materials 
DFS: events adjusted for BL : HR=1.23; 95% CI (0.83-1.83), p=0.296 in 
multivariate analyses adjusted for chemo, age, initial tumour size, grading, 
ER/PgR status. 
DFS Subgroup analyses:  
no pCR vs pCR (better outcome observed for patients who achieved a pCR): 
With darbe: HR=2.38; 95% CI (1.2-4.71), p=0.013 
Without darbe: HR=2.13; 95% CI (1.03-4.41), p=0.041 
as reported in 
supplemental online 
materials 
OS      
OS: estimated at 3 years  88%  91.8% HR=1.33; 95% CI 
(0.91-1.95), P=0.139 
OS: events, n % 59  48  HR=1.33; 95% CI 
(0.91-1.95), P=0.139 
in univariate analysis.  
OS: events adjusted for BL 59 17% 48 13% as reported in 
supplemental online 
materials 
OS: events adjusted for BL HR=1.24; 95% CI (0.71-2.19), p=0.4502 multivariate 
analyses adjusted for chemo, age, initial tumour size, grading, ER/PgR status. 
OS Subgroup analyses:  
no pCR vs pCR (better outcome observed for patients who achieved a pCR): 
With darbe: HR=4.02; 95% CI (1.26-12.85), p=0.019 
Without darbe: HR=3.08; 95% CI (0.95-9.92), p=0.060 
as reported in 
supplemental online 
materials 
A trend (without showing a relevant effect on the clinical and pathohistological response) toward s a worse 
DFS in the darbepoetin alfa arm compared with the darbepoetin free arm was found. The absolute DFS 
difference in the dose-dense arm between patients treated with and without darbepoetin alfa is larger than 
the difference between the two chemotherapy regimens. An unplanned subgroup analysis the study 
revealed poor prognostic factors to be associated with significantly decreased DFS and OS in patients who 
received darbepoetin 
 
In an unplanned subgroup analysis, the impact of darbe on DFS and OS was investigated. Patients with 
either grade 3  tumor or a tumor size ≥4 cm had significantly worse DFS when treated with darbepoetin 
alfa. This effect on OS was only significant for grade 3 tumors: 
NOTES: 
pCR: Regression Grade 5 means no microscopic evidence of residual viable tumor cells (invasive or 
noninvasive) in all breast specimens and lymph nodes; Grade 4, no residual tumor in breast specimens but 
involved lymph nodes; Grade 3, only residual noninvasive (in situ) tumor in breast tissue irrespective of 
lymph node status; Grade 2, extensive tumor sclerosis with focal or multifocal evidence only of minimally 
invasive residual tumor (<0.5 cm), frequently extensive ductal carcinoma in situ; Grade 1, increased 
tumor sclerosis with focal resorptive inflammation and/or marked cytopathic effects; and Grade 0, no effect. 
 
pCR was defined as no residual tumor in the breast regardless of lymph node status. 
 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM 
ALLOCATIONS ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for 
patients number, date of birth, alternate; Unclear = if the 
method not stated) 
Unclear 
 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY 
CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially 
numbered coded vials; other methods where the triallist 
allocating treatment could not be aware ; Inadequate = 
allocation was alternate, or based on information known to the 
NR 
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triallist) 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS 
OF PROGNOSTIC FACTORS; E.G. SEVERITY OF 
DISEASE? 
NR 
p-values for baseline comparisons are not 
reported, authors stated that ‘baseline 
characteristics were similar in the 
treatment arms’. It is assumed that this 
refers to the chemo arms, and it is not 
clear whether it also refers to the epo vs 
no epo arms . 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Yes 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT 
ALLOCATION?  No (open label) 
6. WERE THE OUTCOME ASSESSORS BLIND TO 
TREATMENT ALLOCATION? No (open label) 
7. WERE THE POINT ESTIMATES AND MEASURE OF 
VARIABILITY PRESENTED FOR THE PRIMARY OUTCOME 
MEASURE? 
Yes 
7. IS THERE EVIDENCE TO SUGGEST THAT THE 
AUTHORS COLLECTED MORE OUTCOME DATA THAN 
THEY REPOTED? 
No 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-
TREAT ANALYSIS OR WERE LESS THAN 10% OF EACH 
STUDY ARM EXCLUDED? 
Yes  
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO 
FOLLOW-UP IN EACH GROUP STATED? 
Partially: only until the point of surgery; 
n=326 darbe and n=343 controls. 
 
Untch 2011 ref( #962) reports DFS and OS follow up data. 
Untch, M., von Minckwitz, G., Konecny, G. E., Conrad, U., Fett, W., Kurzeder, C., . . . Fasching, P. A. 
(2011). PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified 
chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide 
followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. Ann 
Oncol, 22(9), 1999-2006. doi: 10.1093/annonc/mdq713 
 
OTHER 
Generalisability  
Author conclusions Primary use of darbepoetin did not affect pCR, while darbepoetin might have 
detrimental effects on DFS. Patients should not be treated with ESA in the 
neoadjuvant setting under the assumption of better tumor oxygenation because a 
negative influence of darbepoetin alfa on DFS cannot completely be ruled out. 
The dose-intensified regimen was found to be superior to conventional 
chemotherapy in terms of pCR, but no difference in DFS or OS was found. 
Reviewer comments Patient flow and numbers used in analysis were difficult to follow and remain 
unclear. 
 
Endnote Ref ID 
 
2698 (HTA) Malignancy type lung cancer 
Treatment darbepoetin alfa 
STUDY DESIGN PARTICIPANTS 
Author, year Vansteenkiste 2002 N  314 
Objective The safety and efficacy of 
darbepoetin 
Inclusion criteria:  
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alfa compared with 
placebo in patients with 
lung cancer receiving 
chemotherapy. 
 lungcancer  
 expected to receive at least 12 additional 
weeksof platinum-containing 
chemotherapy 
 age≥18years 
 had a life expectancy of at least 6 months 
 ECOG= 0 -2 
 Anemia (i.e., Hb level of ≤11.0 g/dL) 
primarily because of their cancer or 
chemotherapy 
 have adequate serum folate, vitamin B12, 
ferritin, and saturated transferrin levels  
 have adequate renal and hepatic 
functions 
 
Exclusion criteria:  
 iron deficient pts 
 primary or metastatic malignancy of the 
central nervous system 
 pts with more than two red blood cell 
transfusions within 4 weeks of 
randomization or had received any red 
blood cell transfusion within 2 weeks of 
randomization 
 pts with rHuEPO therapy within 8 weeks 
of randomization or any previous 
treatment with darbepoetin alfa 
 pregnant, breastfeeding, or not using 
adequate birth control measures 
 history of seizure disorders, active cardiac 
disease, uncontrolled hypertension, active 
infection or inflammation, or a primary 
hematologic disorder as the cause of their 
present anemia 
# centres 70 
  
Other references/aliases NESP 980297 
Tchekmedyian 2003 
Secondary analysis in 
Vantenkeenste 2004 
(#240) 
Geographical setting Australia, Canada, 
Western Europe, and 
Central and Eastern 
Europe 
Duration of treatment 12 weeks 
Length of follow-up (if 
different) 
4-week follow-up period 
after the last dose of study 
drug, and a long-term 
follow-up to determine 
tumor status and surviva ( 
in this paper 6 months 
after the last patient 
completed the study; 
planned for at least 1 
year) 
Country of corresponding 
author 
Belgium 
Language of publication English 
Sources of funding R. Pirker has received 
research and travel grants 
and consulting fees from 
Amgen Inc. D. Tomita 
holds stock in Amgen Inc., 
the maker of darbepoetin 
alfa and erythropoietin 
alfa. 
RANDOMISATION & 
ALLOCATION 
A double-blind, placebo-controlled, randomized phase III study; patients were 
randomly assigned, by a central randomization service for all sites, in a 1 : 1 
ratio. Randomization was stratified by tumour type (small-cell lung cancer or 
non-small-cell lung cancer) and geographic region (Australia, Canada, 
Western Europe, or Central and Eastern Europe). 
TREATMENT ARMS 
ARM Drug name/s Darbepoetin alfa Placebo 
N 156 158 
Dose & freq (od, bd etc) 2.25 µg/kg/week Volume equivalent to darbe treatment 
Dose adjustment Y/N 
Y: At Week 6: if baseline HB ≤ 1.0 
g/dL over  baseline Hb, the dose of 
the study drug was doubled to 4.5 
µg/kg/week, or the volume equivalent, 
beginning at week 7(and continuing 
for the remainder of the study). 
Y: same as darbepoetin (see above) 
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Treatment withheld if Hb>15.0 g/dL 
(for men) or >14.0 g/dL (for women). 
After the patient’s Hb decreased 
≤13.0 g/dL, dose was reinstated at 
50%. 
Route of administration Subcutaneous Subcutaneous 
Duration of epo tx 12 weeks  
Adj anaemia treatment   
Transfusion trigger 
Recommended when  Hb≤8.0 g/dL 
and based on clinical judgment 
(transfusion policies can vary widely 
from country to country) 
As darbepoetin alfa 
OUTCOMES 
Primary 
outcome 
RBCT (proportion of pts who 
received a red blood cell 
transfusion during a specific 
time period—from week 5 
until the end-of-treatment *) 
Other 
outcomes 
HaemR (hematopoietic response$; 
Hb collected weekly); RBCT (the 
incidence of RBCT from Week 1 
until the end-of-treatment, the 
incidence of transfusion or Hb 
concentrations ≤8.0 g/dL, and the 
number of units of blood 
transfused.); tumour response 
(tumour status and survival 
information are being collected 
during an open-label, long-term 
follow-up period); survival (disease 
progression and survival were also 
assessed quarterly for a minimum 
of 1 year, if applicable); HRQL 
(FACT–Fatigue, collected every 3–
4 weeks on the first day of each 
cycle of chemotherapy, before any 
other study procedures); AEs 
(adverse event profile; 
incidence and duration of 
hospitalization) 
NOTES:  
Antibody formation to darbepoetin alfa was assessed 
 
*the effects on RBCT requirements are not apparent until the second month of treatment, therefore, the 
proportion of patients receiving a transfusion from Week 5 until the end-of-treatment phase was selected as 
the primary endpoint 
 
$ hematopoietic response was defined as an increase in Hb concentration of greater than or equal to 2.0 
g/dL or a Hb concentration of greater than or equal to 12.0 g/dL in the absence of a red blood cell 
transfusion within the previous 28 days. 
ANALYSIS 
Statistical technique used? 
Kaplan–Meier estimates were used for proportion of 
patients who received at least one transfusion during week 
5 until the end of the treatment and for secondary 
transfusion-related endpoints and OS and PFS. The SE of 
the Kaplan–Meier proportion was calculated using 
Greenwood’s formula; 95% CI were also reported. 
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Efficacy endpoints were analysed with and without 
adjusting for the two factors used to stratify the 
randomization: tumour type and geographic region. Results 
of both types of analyses were consistent, so only results of 
the unstratified analyses are presented. Cox proportional 
hazards and logistic regression were used to compare 
treatment groups after adjusting for tumour type, 
geographic region, and other potentially prognostic factors 
after determining that data complied with assumption for 
this method. No adjustments were made for multiple 
significance tests. 
 
The percentage of change from baseline for the FACT–
Fatigue score was analysed as two dichotomous variables 
(any improvement and at least a 25% improvement) in 
patients who had the baseline and at least one post-
treatment score using   
uncorrected chi-square test. 
 
Safety was evaluated in all patients who received at least 
one dose of study drug. 
Intention to treat analysis? 
NR 
All patients randomly assigned into the study who received 
at least one dose of study drug were included in the 
analyses. 314 pts received study drug and were included in 
the analysis for all 
Endpoints,(including OS and PFS). However this does not 
seem to apply to analyses of FACT. 
 
However, in the analysis of transfusions during week 5 until 
the end-of-treatment phase, patients who withdrew (n = 17) 
before study day 29 were excluded. 297 pts  (93%) 
completed the first 28 days of the study and were included 
in the analysis of the primary endpoint. 
Does statistical technique adjust for 
confounding? NR 
Power calculation (priori sample calculation)?
Y: 90% power to detect a 50% reduction (from 40% to 20%) 
in the proportion of pts with at least one transfusion during 
week 5 until the end-of-treatment (anticipated that 30% of 
patients would withdraw) 
Attrition rate (loss to follow-up)? 
Yes;  
n=14 and n=11 for epo and placebo respectively  
withdrew consent, administrative decision, and loss to 
follow-up 
Was attrition rate adequately dealt with? NR 
Number (%) followed up from each 
condition? Partially 
BASELINE CHARACTERISTICS 
Malignancy type  
(e.g.solid / solid head neck, lung, ovarian, cervical / haem / MDS / mixed) 
Lung cancer 
Treatment 
(e.g. chemotherapy platinum / non-platinum based; chemo + radio; no 
specific malignancy treatment; not reported) 
Pt based chemo 
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Adjuvant anaemia treatment 
Iron NR 
G-CSF NR 
Transfusion trigger 
Recommended when  
Hb≤8.0 g/dL and based on 
clinical judgment 
Hb inclusion criteria level <11 g/dl 
 Arm 1 = darbe N =156 
Arm 2 = placebo 
N = 158   
male (%) 111 71% 116 73%   
female (%) 45 29% 42 27%   
Age years, mean (SD); 
median [range] 61.6 (9.2) 62.5 [39-80] 61.3 (8.8) 61 [36-79]   
Performance status 
WHO / ECOG /        
0 22 14% 23 15%   
1 109 70% 98 62%   
2 24 15% 37 23%   
>2 1 1% 0 0%   
Hb baseline (g dl-1) mean (SD); 
median [range] 10.28 (1.08) 10.4 [7.4-13.6] 9.93 (1.01) 
10.15 [6.6-
12.3]   
Iron baseline (U/l median 
(range)       
Epo baseline (mU ml-1)       
Target Hb       
Feritin µg/l, mean (SD); 
median [range] 
552.22 
(453.45) 431 [36-3046] 534.5 (528.1) 402 [14-4895]   
Transferrin saturation, %  
mean (SD); 
median [range] 
20.98 (13.25) 18 [5-90] 18.95 (12.26) 16 [6-73]   
Data from secondary analyses Vansteenkiste 2004: 
BL Hb, mean (SD) Arm 1 = darbe N =51 
Arm 2 = placebo 
N = 69   
Hb <10 9.1 (0.7) 9 (0.7)   
 Arm 1 = darbe N =105 
Arm 2 = placebo 
N = 89   
Hb≥10 10.9 (0.7) 10.7 (0.5)   
Were intervention and control groups comparable? No p-values are reported, stated “Baseline 
demographics and clinical characteristics were 
similar between the two treatment groups”. 
RESULTS 
 Arm 1 = darbe N =156 
Arm 2 = placebo 
N = 158 
Arm 3 =  
N =  p  
Haematological & transfusions 
Transfusions N=148 and N=149 for darbe and placebo respectively. 
Pts with RBC transfusions 
 % (95%CI), from wk 5 to 
EOTP 
27% 20-35% 52% 44-66%
The difference 
was 25% (CI 14 -
36%), p<.001. 
P<0.001 
First RBC transfusion or 32% 24-39% 62% 54-71%  P<0.001 
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HB≤8g/dl 
Mean RBC units transfused 
(SD) 0.67 1.7 1.92 3.27 
The difference 
was 1.25 (CI 
0.65-0.84), 
p<.001. 
P<0.001 
hematopoietic response$;  
% (95%CI) 
66% 58-74% 24% 16-31%
The difference 
was 42% (CI 31-
53%) , p<.001. 
P<0.001 
103pts calculated 38pts calculated 
As reported in  
 Vansteenkiste 2004: 
Pts with RBC transfusions 
 % (95%CI), from wk 1 to 
EOTP 
28% 21-35% 57% 49-65%
Time to disease progression or 
death, weeks, median (95% 
CI) 
23 19-31 20 17-23 
Data from secondary analyses Vansteenkiste 2004: 
 Arm 1 = darbe N =51 
Arm 2 = placebo 
N = 69   
Hb <10 65% 50-80% 31% 17-45%  P<0.002 
 33pts calculated 21pts calculated   
 Arm 1 = darbe N =105 
Arm 2 = placebo 
N = 89   
Hb≥10 67% 57-77% 20% 11-29%  P<0.001 
 70pts calculated 17pts calculated   
The difference between epo and placebo change from BL was, the mean Hb change was 1.3 (p<0.001) 
and 1.4 (p<0.001) for the two Hb <10 and Hb≥10 groups respectively. 
Health-related QoL 
N=127 and N=128 for darbe and placebo respectively completed the 
scale through study week 4, also completed  baseline and at least one 
time from week 5 until the end-of-treatment phase. 
Improvement in  
FACT–Fatigue scale, % (CI) 56% 47-65% 44% 35-52%   P=0.052 
patients with at least a 25% 
improvement from baseline in  
FACT–Fatigue scale,  % (CI) 
32% 23-40% 19% 12-26%
The difference 
was 13% (CI 2- 
23%), p=0 .019. 
P=0.019 
Adverse effects of tmt        
Deaths 22 14% 19 12%    
Deaths due to disease 
progression  61%  58%    
Thromobotic events 7 5% 5 3%    
Hypertension 9 6% 6 4%    
Hospitalizations for overnight 
stays: mean days (SD) 
10.3 13.7 13 17.7   P=0.13 
An analysis of the proportion of pts hospitalized was also done considering all hospitalizations (i.e., with or 
without an overnight stay), with similar results. 
an average of 1 year follow-up after pts first dose of study drug: 
(N=156 and N=158 for darbe and placebo respectively.) 
Median OS  weeks,  (95% CI) 46 39-53 34 29-39    
Deaths 92 59% 109 69%    
Median PFS weeks,  (95% CI) 22 18-31 20 17-23    
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Disease progression or died  129 83% 141 89%    
Changes in laboratory test variables and patient vital signs from baseline, and the minimum absolute 
neutrophil count values on study in both treatment groups were similar. 
No anti-darbe antibodies were detected in 1054 serum samples (darbe N =531 and placebo N= 523). 
And no clinical sequelae indicative of antibody formation have been observed during the follow-up period. 
QUALITY APPRAISAL 
1. WAS THE METHOD USED TO GENERATE RANDOM ALLOCATIONS 
ADEQUATE? 
(Yes – random numbers; coin toss; shuffle etc; No = for patients number, date of 
birth, alternate; Unclear = if the method not stated) 
Unclear; no 
randomisation 
details given. 
2. WAS THE TREATMENT ALLOCATION ADEQUATELY CONCEALED? 
(Yes = central allocation at trials office/pharmacy; sequentially numbered coded 
vials; other methods where the triallist allocating treatment could not be aware ; 
Inadequate = allocation was alternate, or based on information known to the triallist) 
Unclear; 
Randomisation was 
performed using a 
centralised system, 
but no details on 
allocation 
concealment were 
not reported 
3. WERE THE GROUPS SIMILAR AT BASELINE IN TERMS OF PROGNOSTIC 
FACTORS; E.G. SEVERITY OF DISEASE? 
Unclear; no p-
values are reported, 
stated “Baseline 
demographics and 
clinical 
characteristics were 
similar between the 
two treatment 
groups”. 
4. WERE THE ELIGIBILITY CRITERIA SPECIFIED? Y 
5. WERE THE PARTICIPANTS BLIND TO TREATMENT ALLOCATION?  Y 
6. WERE THE OUTCOME ASSESSORS BLIND TO TREATMENT ALLOCATION? Y 
7. WERE THE POINT ESTIMATES AND MEASURE OF VARIABILITY 
PRESENTED FOR THE PRIMARY OUTCOME MEASURE? Y 
7. IS THERE EVIDENCE TO SUGGEST THAT THE AUTHORS COLLECTED 
MORE OUTCOME DATA THAN THEY REPOTED? N 
8. DID THE ANALYSES INCLUDE AN INTENTION-TO-TREAT ANALYSIS OR 
WERE LESS THAN 10% OF EACH STUDY ARM EXCLUDED? 
Yes*, not for 
HRQoL; only 81% 
of patients analysed 
in both treatment 
groups 
9. WERE WITHDRAWALS DROPOUTS AND LOSS TO FOLLOW-UP IN EACH 
GROUP STATED? Partially 
NOTES: 
* less than 10% dropout, but ITT defined as all randomised participants who received ≥ 1 dose of study 
drug 
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Krzakowski, M. (2008). "Epoetin Delta: Efficacy in the 
Treatment of Anaemia in Cancer Patients Receiving 
Chemotherapy." Clinical oncology 20: 705-713. 
Intervention 
Comparator 
Auerbach MB, Harold: Trout, J. Richard: McIlwain, Marilyn: 
Ackerman, Alan: Bahrain, Huzefa: Balan, Stefan: Barker, 
Lance: Rana, Jeevindra. (2004). Intravenous iron optimizes the 
response to recombinant human erythropoietin in cancer 
patients with chemotherapy-related anemia: a multicenter, 
open-label, randomized trial. Journal of Clinical 
Oncology.22:1301-7. 
Comparator 
PenTAG   CONFIDENTIAL 
619 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Balleari ER, Edoardo: Clavio, Marino: Congiu, Angela: Gobbi, 
Marco: Grosso, Marco: Secondo, Vincenzo: Spriano, Mauro: 
Timitilli, Silvana: Ghio, Riccardo. (2006). Erythropoietin plus 
granulocyte colony-stimulating factor is better than 
erythropoietin alone to treat anemia in low-risk myelodysplastic 
syndromes: results from a randomized single-centre study. 
Annals of Hematology. 85:174-80. 
Comparator 
Bastit LV, A.: Altintas, S.: Gaede, B.: Pinter, T.: Suto, T. S.: 
Mossman, T. W.: Smith, K. E.: Vansteenkiste, J. F. (2008). 
Randomized, multicenter, controlled trial comparing the 
efficacy and safety of darbepoetin alfa administered every 3 
weeks with or without intravenous iron in patients with 
chemotherapy-induced anemia. Journal of Clinical Oncology. 
26:1611-1618. 
Comparator 
Canon JLV, J.: Bodoky, G.: Mateos, M. V.: Bastit, L.: Ferreira, 
J.: Rossi, G.: Amado, R. G. (2006). Randomized, double-blind, 
active-controlled trial of every-3-week darbepoetin alfa for the 
treatment of chemotherapy-induced anemia. Journal of the 
National Cancer Institute. 98:273-284. 
Comparator 
Courneya KSJ, Lee W.: Peddle, Carolyn J.: Sellar, Christopher 
M.: Reiman, Tony: Joy, Anil A.: Chua, Neil: Tkachuk, Linda: 
Mackey, John R. (2008). Effects of aerobic exercise training in 
anemic cancer patients receiving darbepoetin alfa: a 
randomized controlled trial. Oncologist. 13:1012-20. 
Comparator 
Crawford JR, Francisco: Perry, Michael C.: Belani, Chandra: 
Williams, Denise. (2007). Anemia Prevention in, Nsclc Group. 
A randomized trial comparing immediate versus delayed 
treatment of anemia with once-weekly epoetin alfa in patients 
with non-small cell lung cancer scheduled to receive first-line 
chemotherapy. Journal of Thoracic Oncology: Official 
Publication of the International Association for the Study of 
Lung Cancer. 2:210-20. 
Comparator 
Glaspy JH, D.: Patel, R.: Tchekmedyian, D.: Applebaum, S.: 
Berdeaux, D.: Lloyd, R.: Berg, R.: Austin, M.: Rossi, G. (2005). 
Effects of chemotherapy on endogenous erythropoietin levels 
and the pharmacokinetics and erythropoietic response of 
darbepoetin alfa: A randomised clinical trial of synchronous 
versus asynchronous dosing of darbepoetin alfa. European 
Journal of Cancer. 41:1140-1149. 
Comparator 
Gupta SS, P. K.: Bhatt, M. L.: Pant, M. C.: Sundar, S.: Verma, 
J.: Paul, S.: Kumar, D.: Shah, A.: Gupta, R.: Negi, M. P. 
(2010). Clinical benefits of two different dosing schedules of 
recombinant human erythropoietin in anemic patients with 
advanced head and neck cancer. Bioscience trends. 4:267-
272. 
Comparator 
Justice GK, J. F.: Jadeja, J.: Campos, L.: Weick, J.: Chen, C. 
F.: Heatherington, A. C.: Amado, R. G. (2005). A randomized, 
multicenter study of subcutaneous and intravenous 
darbepoetin alfa for the treatment of chemotherapy-induced 
anemia. Annals of Oncology. 16:1192-1198. 
Comparator 
Larsson AML, G.: Pahlman, S.: Albertsson, M. (2004). 
Erythropoietin enhances response to treatment in patients with 
Comparator 
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advanced breast cancer [2]. Acta Oncologica. 43:594-597. 
Steensma DPS, J. A.: Dakhil, S. R.: Dalton, R.: Kahanic, S. P.: 
Prager, D. J.: Stella, P. J.: Rowland,, Jr.: K.M,: Novotny, P. J.: 
Loprinzi, C. L. (2011). Phase III, randomized study of the 
effects of parenteral iron, oral iron, or no iron supplementation 
on the erythropoietic response to darbepoetin alfa for patients 
with chemotherapy-associated anemia. Journal of Clinical 
Oncology. 29:97-105. 
Comparator 
Outcome 
Bell DG, D.: Gurney, H.: Dalley, D.: Blackwell, T.: Fox, R.: 
Jeffery, M. (2008). Outcomes and predicting response in 
anaemic chemotherapy patients treated with epoetin alfa. A 
multicentre, 4-month, open-label study in Australia and New 
Zealand. Internal Medicine Journal. 38:751-7. 
Outcome 
Bennett CLS, S. M.: Djulbegovic, B.: Samaras, A. T.: Blau, C. 
A.: Gleason, K. J.: Barnato, S. E.: Elverman, K. M.: Courtney, 
D. M.: McKoy, J. M.: Edwards, B. J.: Tigue, C. C.: Raisch, D. 
W.: Yarnold, P. R.: Dorr, D. A.: Kuzel, T. M.: Tallman, M. S.: 
Trifilio, S. M.: West, D. P.: Lai, S. Y.: Henke, M.(2008). Venous 
thromboembolism and mortality associated with recombinant 
erythropoietin and darbepoetin administration for the treatment 
of cancer-associated anemia. Jama-Journal of the American 
Medical Association. 299:914-924. 
Outcome 
Bohlius JT, S.: Weingart, O.: Schwarzer, G.: Brillant, C.: 
Clarke, M. J.: Djulbegovic, B.: Piper, M.: Rades, D.: Seidenfeld, 
J.: Somerfield, M.: Steensma, D.: Schumacher, M.: Engert, A.: 
Egger, M. (2008). Erythropoietin or Darbepoetin for patients 
with cancer - Meta-analysis based on individual patient data. 
Cochrane Database of Systematic Reviews. 
Outcome 
Bohlius JW, J.: Seidenfeld, J.: Piper, M.: Schwarzer, G.: 
Sandercock, J.: Trelle, S.: Weingart, O.: Bayliss, S.: 
Djulbegovic, B.: Bennett, C. L.: Langensiepen, S.: Hyde, C.: 
Engert, A. (2006). Recombinant human erythropoietins and 
cancer patients: Updated meta-analysis of 57 studies including 
9353 patients. Journal of the National Cancer Institute. 98:708-
714. 
Outcome 
Bohlius JL, S.: Schwarzer, G.: Seidenfeld, J.: Piper, M.: 
Bennett, C.: Engert, A. (2005). Recombinant human 
erythropoietin and overall survival in cancer patients: Results 
of a comprehensive meta-analysis. Journal of the National 
Cancer Institute. 97:489-498. 
Outcome 
Bohlius JS, Kurt: Brillant, Corinne: Schwarzer, Guido: Trelle, 
Sven: Seidenfeld, Jerome: Zwahlen, Marcel: Clarke, Michael: 
Weingart, Olaf: Kluge, Sabine: Piper, Margaret: Rades, Dirk: 
Steensma, David P.: Djulbegovic, Benjamin: Fey, Martin F.: 
Ray-Coquard, Isabelle: Machtay, Mitchell: Moebus, Volker: 
Thomas, Gillian: Untch, Michael: Schumacher, Martin: Egger, 
Matthias: Engert, Andreas. (2009). Recombinant human 
erythropoiesis-stimulating agents and mortality in patients with 
cancer: a meta-analysis of randomised trials.[Erratum appears 
in Lancet. 373:1532-42. 
Outcome 
Bohlius JS, K.: Brillant, C.: Schwarzer, G.: Trelle, S.: Outcome 
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Seidenfeld, J.: Zwahlen, M.: Clarke, M. J.: Weingart, O.: Kluge, 
S.: Piper, M.: Napoli, M.: Rades, D.: Steensma, D.: 
Djulbegovic, B.: Fey, M. F.: Ray-Coquard, I.: Moebus, V.: 
Thomas, G.: Untch, M.: Schumacher, M.: Egger, M.: Engert, A. 
(2009). Erythropoietin or Darbepoetin for patients with cancer - 
Meta-analysis based on individual patient data. Cochrane 
Database of Systematic Reviews. 
Devon KMM, Robin S. Pre and peri-operative erythropoietin for 
reducing allogeneic blood transfusions in colorectal cancer 
surgery. Cochrane Database of Systematic Reviews 
2009:CD007148. 
Outcome 
Duh MSW, J. R.: White, L. A.: Lefebvre, P.: Dreenberg, P. E. 
(2008). Management of anaemia - A critical and systematic 
review of the cost effectiveness of erythropoiesis-stimulating 
agents. Pharmacoeconomics. 26:99-120. 
Outcome 
Henry DHD, N. V.: Auerbach, M.: Tchekmedyian, S.: Laufman, 
L. R. (2007). Intravenous ferric gluconate significantly improves 
response to epoetin alfa versus oral iron or no iron in anemic 
patients with cancer receiving chemotherapy. Oncologist. 
12:231-242. 
Outcome 
Henry DHG, L. N.: Charu, V.: Wilhelm, F. E.: Williams, D.: Xie, 
J.: Woodman, R. C. (2006). Randomized, open-label 
comparison of epoetin alfa extended dosing (80000U Q2W) vs 
weekly dosing (40000U QW) in patients with chemotherapy-
induced anemia. Current Medical Research and Opinion. 
22:1403-1413. 
Outcome 
Machtay MP, T. F.: Suntharalingam, M.: Shenouda, G.: 
Hershock, D.: Stripp, D. C.: Cmelak, A. J.: Schulsinger, A.: Fu, 
K. K. (2007). Radiotherapy with or without erythropoietin for 
anemic patients with head and neck cancer: A randomized trial 
of the radiation therapy oncology group (RTOG 99-03). 
International Journal of Radiation Oncology Biology Physics . 
69:1008-1017. 
Outcome 
Moyo VL, P.: Duh, M. S.: Yektashenas, B.: Mundle, S. (2008). 
Erythropoiesis-stimulating agents in the treatment of anemia in 
myelodysplastic syndromes: a meta-analysis. Annals of 
Hematology. 87:527-536. 
Outcome 
Reed SDR, J. I.: Daniel, D. B.: Fastenau, J. M.: Williams, D.: 
Schulman, K. A. (2005). Early hemoglobin response and 
alternative metrics of efficacy with erythropoietic agents for 
chemotherapy-related anemia. Current Medical Research and 
Opinion. 21:1527-1533. 
Outcome 
Reed SDR, J. I.: Daniel, D. B.: Mody, S. H.: Forlenza, J. B.: 
McKenzie, R. S.: Schulman, K. A. (2006). Economic evaluation 
of weekly epoetin alfa versus biweekly darbepoetin alfa for 
chemotherapy-induced anaemia - Evidence from a 16-week 
randomised trial. Pharmacoeconomics. 24:479-494. 
Outcome 
Rosenzweig MQB, Catherine M.: Lucke, Joseph P.: Yasko, 
Joyce M.: Brufsky, Adam M. (2004). The decision to 
prematurely terminate a trial of R-HuEPO due to 
thromboembolic events. Journal of Pain & Symptom 
Management. 27:185-90. 
Outcome 
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Schwartzberg LSY, L. K.: Senecal, F. M.: Charu, V.: Tomita, 
D.: Wallace, J.: Rossi, G. (2004). Symptom management and 
supportive care. A randomized comparison of every-2-week 
darbepoetin alfa and weekly epoetin alfa for the treatment of 
chemotherapy-induced anemia in patients with breast, lung, or 
gynecologic cancer. Oncologist . 9:696-707. 
Outcome 
Schwartzberg LY, L.: Charu, V.: Tomita, D.: Rossi, G.: 
Senecal, F. Comparable efficacy and safety of darbepoetin alfa 
200 mug every 2 weeks and epoetin alfa 40,000 U weekly in 
patients with breast cancer: Results of a randomized 
comparison. (2005) Journal of Supportive Oncology.3:30-31. 
Outcome 
Schwartzberg LSY, L. K.: Senecal, F. M.: Charu, V.: Tomita, 
D.: Wallace, J.: Rossi, G. (2004). Symptom management and 
supportive care. A randomized comparison of every-2-week 
darbepoetin alfa and weekly epoetin alfa for the treatment of 
chemotherapy-induced anemia in patients with breast, lung, or 
gynecologic cancer. Oncologist. 9:696-707. 
Outcome 
Senecal FMY, L.: Gabrail, N.: Charu, V.: Tomita, D.: Rossi, G.: 
Schwartzberg, L. (2005) Treatment of chemotherapy-induced 
anemia in breast cancer: results of a randomized controlled 
trial of darbepoetin alfa 200 microg every 2 weeks versus 
epoetin alfa 40,000 U weekly. Clinical Breast Cancer. 6:446-
454. 
Outcome 
Strauss HGH, G.: Dunst, J.: Hayward, C. R. W.: Burger, H. U.: 
Scherhag, A.: Koelbl, H. Effects of anemia correction with 
epoetin beta in patients receiving radiochemotherapy for 
advanced cervical cancer. International Journal of 
Gynecological Cancer 2008;18:515-524. 
Outcomes 
Tonia TB, J. (2011). Ten Years of Meta-analyses on 
Erythropoiesis-Stimulating Agents in Cancer Patients. 
Hematopoietic Growth Factors in Oncology. Volume 157,217-
238. 
Outcomes 
Study design 
Aapro, M. C., B.; Dunst, J.; Osterborg, A.; Burger, H. U. (2006). 
"Effect of treatment with epoetin beta on short-term tumour 
progression and survival in anaemic patients with cancer: A 
meta-analysis." British Journal of Cancer 95: 1467-1473. 
Study design 
Aapro MSD, David C.: Blasi, Michael: Sarokhan, Brenda: 
Ahmed, Fawzia: Woodman, Richard C. (2006). Epoetin alfa 
increases hemoglobin levels and improves quality of life in 
anemic geriatric cancer patients receiving chemotherapy. 
Supportive Care in Cancer. 14:1184-94. 
Study design 
Aapro MS, A.: Burger, H. U. (2008). Effect of treatment with 
epoetin-beta on survival, tumour progression and 
thromboembolic events in patients with cancer: an updated 
meta-analysis of 12 randomised controlled studies including 
2301 patients. British Journal of Cancer. 99:14-22. 
Study design 
Aapro, M. O., B.; Scherhag, A.; Burger, H. U. (2009). "Epoetin-
beta treatment in patients with cancer chemotherapy-induced 
anaemia: the impact of initial haemoglobin and target 
haemoglobin levels on survival, tumour progression and 
thromboembolic events." British Journal of Cancer 101: 1961-
Study design 
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1971. 
Ariganello OM, Andrea: Di Molfetta, Michele: Diana, 
Francesco: Beccaglia, Patrizia: Cortesi, Enrico: De Marinis, 
Filippo. (2004). A new induction schedule of epoetin alfa 
40.000 IU in anemic patients with advanced lung cancer. Lung 
Cancer. 46:119-24. 
Study design 
Azzara AC, G.: Galimberti, S.: Barate, C.: Fazzi, R.: Cervetti, 
G.: Petrini, M. (2011). High-dose (40,000 IU twice/week) alpha 
recombinant human erythropoietin as single agent in 
low/intermediate risk myelodysplastic syndromes: a 
retrospective investigation on 133 patients treated in a single 
institution. American Journal of Hematology. 86:762-767. 
Study design 
Badzek SC, Zvonimir: Krajina, Zdenko: Plestina, Stjepko: 
Golubic-Cepulic, Branka: Radman, Ivo. (2008). Treatment of 
cancer-related anemia. Collegium Antropologicum. 32:615-22. 
Study design 
Beer TMB, Misty: Birt, Karlee: Higano, Celestia S. (2007). 
Darbepoetin alfa administered every 4 weeks for anemia in 
patients with advanced prostate cancer. Clinical Genitourinary 
Cancer. 5:329-33. 
Study design 
Boccia RL, Tom: Tomita, Dianne: Balducci, Lodovico. (2007). 
The effectiveness of darbepoetin alfa administered every 3 
weeks on hematologic outcomes and quality of life in older 
patients with chemotherapy-induced anemia. Oncologist. 
12:584-93. 
Study design 
Bogdanos JK, D.: Milathianakis, K.: Repousis, P.: Chloraki-
Bobota, A.: Majed, H.: Pagalou-Thoua, E.: Tsintavis, A.: 
Koutsilieris, M. (2004). Epoetin beta (NeoRecormon (R)) 
corrects anaemia in patients with hormone-refractory prostate 
cancer and bone metastases. Anticancer Research . 24:1957-
1961. 
Study design 
Boogaerts, M. O., C.; Ten Bokkel Huinink, W.; Nowrousian, M. 
R.; Hayward, C. R. W.; Burger, H. U. (2006). "Epoetin beta 
(NeoRecormon) therapy in patients with solid tumours 
receiving platinum and non-platinum chemotherapy: a meta-
analysis." Anticancer Research 26: 479-484. 
Study design 
Bohlius, J. W., Jayne; Seidenfeld, Jerome; Piper, Margaret; 
Schwarzer, Guido; Sandercock, Josie; Trelle, Sven; Weingart, 
Olaf; Bayliss, Sue; Djulbegovic, Benjamin; Bennett, Charles L.; 
Langensiepen, Simon; Hyde, Chris; Engert, Andreas (2006). 
"Recombinant human erythropoietins and cancer patients: 
updated meta-analysis of 57 studies including 9353 patients." 
Journal of the National Cancer Institute 98: 708-714. 
Study design 
Boulaamane L, Goncalves, A., Boutayeb, S., Viens, P., 
M'Rabti, H., Bertucci, F., Errihani, H. (2013). Prognostic impact 
of the combination of erythropoiesis-stimulating agents to 
cancer treatment: Literature review. Supportive Care in 
Cancer. 21, 2359-2369. 
Study design 
Burstein HJP, L. M.: Keshaviah, A.: Doherty, J.: Partridge, A. 
H.: Schapira, L.: Ryan, P. D.: Younger, J.: Harris, L. N.: Moy, 
B.: Come, S. E.: Schumer, S. T.: Bunnell, C. A.: Haldoupis, M.: 
Gelman, R.: Winer, E. P. (2005). Efficacy of pegfilgrastim and 
darbepoetin alfa as hematopoietic support for dose-dense 
Study design 
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every-2-week adjuvant breast cancer chemotherapy. Journal of 
Clinical Oncology. 23:8340-8347. 
Cacic DLH, Tor: Seghatchian, Jerard. Anemia treatment of 
lymphoproliferative malignancies with erypoiesis: An overview 
of state of the art. (2013). Transfusion & Apheresis Science . 
48:277-81. 
Study design 
Caocci GLN, G.: Efficace, F. (2009). Health-related quality of 
life and symptom assessment in patients with myelodysplastic 
syndromes. Expert Review of Hematology. 2:69-80. 
Study design 
Cella DV, Hema N.: Hays, Ron D.: Mendoza, Tito R.: Stein, 
Kevin D.: Pasta, David J.: Foreman, Aimee J.: Vadhan-Raj, 
Saroj: Kallich, Joel D. (2008). Development of a fatigue and 
functional impact scale in anemic cancer patients receiving 
chemotherapy. Cancer. 113:1480-8. 
Study design 
Cella DK, J.: McDermott, A.: Xu, X. (2004). The longitudinal of 
hemoglobin, fatigue and quality of life in anemic cancer 
patients: Results from five randomised clinical trials. Annals of 
Oncology. 15:979-986. 
Study design 
Eton DTC, D. (2011). Do erythropoietic-stimulating agents 
relieve fatigue? A review of reviews. Hematopoietic Growth 
Factors in Oncology.Cancer Treatment and Research. 
157:181-194. 
Study design 
Cersosimo, R. J. J., Daniel R. (2006). "Epoetin alfa versus 
darbepoetin alfa in chemotherapy-related anemia." Annals of 
Pharmacotherapy 40: 58-65; quiz 169-170. 
Study design 
Chu EE, Lawrence H.: Lefebvre, Patrick. (2006). Clinical 
benefits of once-weekly epoetin alfa in anemic patients with 
colorectal cancer receiving chemotherapy. The Journal of 
Supportive Oncology. 4:243-50. 
Study design 
Corapcioglu FA, Gorkem: Basar, Evic Z.: Demirel, Atalay: 
Oncel, Selim: Mutlu, Ajda. (2008). Recombinant human 
erythropoietin beta therapy: an effective strategy to reduce 
transfusion requirement in children receiving anticancer 
treatment. Pediatric Hematology & Oncology . 25:509-21. 
Study design 
Cornes, P. C., B.; Zambrowski, J. J. (2007). "Erythropoietic 
therapy for the treatment of anemia in patients with cancer: a 
valuable clinical and economic option." Current Medical 
Research and Opinion 23: 357-368. 
Study design 
Couture, F. T., A. R.; Melosky, B.; Xiu, L.; Plante, R. K.; Lau, C. 
Y.; Quirt, I. (2005). "Prior red blood cell transfusions in cancer 
patients increase the risk of subsequent transfusions with or 
without recombinant human erythropoietin management." 
Oncologist 10: 63-71. 
Study design 
Durmaz OD, Metin: Sevinir, Betul. Recombinant human 
erythropoietin : the effect of weekly dosing on anemia, quality 
of life, and long-term outcomes in pediatric cancer patients. 
Pediatric Hematology & Oncology 2011;28:461-8. 
Study design 
Esquerdo GL, Cristina: Cervera, Jose Manuel: Orts, David: 
Juarez, Asuncion: Carrato, Alfredo. (2011). Effectiveness of 
darbepoetin alfa in a cohort of oncology patients with 
chemotherapy-induced anaemia. Relationship between 
variation in three fatigue-specific quality of life questionnaire 
Study design 
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scores and change in haemoglobin level. Clinical & 
Translational Oncology: Official Publication of the Federation of 
Spanish Oncology Societes & of the National Cancer Institute 
of Mexico. 13:341-7. 
Fagnoni PL, S.: Chaigneau, L.: Briaud, S.: Schmitt, B.: 
Merrouche, Y.: Pivot, X.: Woronoff-Lemsi, M. C. (2006). 
Clinical and economic impact of epoetin in adjuvant-
chemotherapy for breast cancer. Supportive Care in Cancer . 
14:1030-1037. 
Study design 
Folloder, J. (2005). "Effects of darbepoetin alfa administered 
every two weeks on hemoglobin and quality of life of patients 
receiving chemotherapy." Oncology Nursing Forum 32: 81-89. 
Study design 
Gascon, P. (2005). "Evaluating erythropoietic agents for the 
treatment of anaemia in the oncology setting." European 
Journal of Cancer 41: 2601-2612. 
Study design 
Gaston KEK, E.: Moore, D. T.: Pruthi, R. S. (2006) The use of 
erythropoietin in patients undergoing radical prostatectomy: 
Effects on hematocrit, transfusion rates and quality of life. 
Urologia Internationalis. 77:211-215.  
Study design 
Glaspy, J. A. (2011). "Randomized controlled trials of the 
erythroid-stimulating agents in cancer patients." Hematopoietic 
Growth Factors in Oncology.Cancer Treatment and Research 
157: 195-215. 
Study design 
Glaspy, J. C., J.; Vansteenkiste, J.; Henry, D.; Rao, S.; 
Bowers, P.; Berlin, J. A.; Tomita, D.; Bridges, K.; Ludwig, H. 
(2010). "Erythropoiesis-stimulating agents in oncology: a study-
level meta-analysis of survival and other safety outcomes." 
British Journal of Cancer 102: 301-315. 
Study design 
Gregory SA. Efficacy of Darbepoetin Alfa in the Treatment of 
Chemotherapy-Induced Anemia in Non-Hodgkin's Lymphoma. 
(2006). Supportive Cancer Therapy.3:232-9. 
Study design 
Jones, M. S., Brad; Just, Julie; Fallowfield, Lesley (2004). 
"Epoetin alfa improves quality of life in patients with cancer: 
results of metaanalysis.[Erratum appears in Cancer. 2005 May 
1;103(9):1984]." Cancer 101: 1720-1732. 
Study design 
Kallich JM, A.: Xu, X.: Fayers, P.: Cella, D. (2006). The 
relationship between patient knowledge of hemoglobin levels 
and health-related quality of life. Quality of Life Research. 
15:57-68. 
Study design 
Kimel, M. L., Nancy K.; Mannix, Sally; Dixon, Julia (2008). 
"Does epoetin alfa improve health-related quality of life in 
chronically ill patients with anemia? Summary of trials of 
cancer, HIV/AIDS, and chronic kidney disease." Value in 
Health 11: 57-75. 
Study design 
Larsson GJ, E. T. (2008). Anemia in patients with midgut 
carcinoid, treated with alpha interferon: effects by 
erythropoietin treatment on the perceived quality of life. 
European Journal of Cancer Care.17:200-4. 
Study design 
Latagliata RO, E. N.: Volpicelli, P.: Carmosino, I.: Breccia, M.: 
Vincelli, I.: Alati, C.: Napoleone, L.: Vozella, F.: Nobile, F.: 
Alimena, G. (2008). Twice-weekly high-dose rHuEpo for the 
treatment of anemia in patients with low-risk myelodysplastic 
Study design 
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syndromes. Acta Haematologica. 120:104-107. 
Ludwig, H. C., Jeffrey; Osterborg, Anders; Vansteenkiste, 
Johan; Henry, David H.; Fleishman, Alex; Bridges, Ken; 
Glaspy, John A. (2009). "Pooled analysis of individual patient-
level data from all randomized, double-blind, placebo-
controlled trials of darbepoetin alfa in the treatment of patients 
with chemotherapy-induced anemia." Journal of Clinic 
Study design 
Lyman, G. H. G., J. (2006). "Are there clinical benefits with 
early erythropoietic intervention for chemotherapy-induced 
anemia? A systematic review." Cancer 106: 223-233. 
Study design 
Maisnar VC, K. (2004). Treatment of associated anemia in 
different hematological disorders with epoetin alpha. 
Neoplasma. 51:379-84. 
 
Michallet MG, K.: Sobh, M.: Morisset, S.: Chelghoum, Y.: 
Thomas, X.: Barraco, F.: Ducastelle, S.: Labussiere, H.: 
Renzullo, C.: Paillet, C.: Pivot, C.: Badol-Van Straaten, P.: 
Denis, A.: Termoz, A.: Detrait, M.: Nicolini, F. E.: Jaisson-Hot, 
I. (2013). Prospective study of erythropoietin use on quality of 
life and cost effectiveness in acute myeloid leukemia and 
allogeneic hematopoietic stem cell transplantation patients. 
Cancer . 119:107-114. 
Study design 
Moul JWD, N. (2012). Quality of life associated with treatment 
of castration-resistant prostate cancer: A review of the 
literature. Cancer investigation. 30:1-12. 
Study design 
Newland AMB, C. D. Tumor progression associated with 
erythropoiesis-stimulating agents.(2008).  Annals of 
Pharmacotherapy 42:1865-1870. 
Study design 
Ohashi, Y. U., Yukari; Fujisaka, Yasuhito; Sugiyama, Toru; 
Ohmatsu, Hironobu; Katsumata, Noriyuki; Okamoto, Rumiko; 
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Huddart, R. A., Welch, R. S., Chan, S et al (2002). "A 
prospective randomised comparative group evaluation of 
epoetin alfa for the treatment of anaemia in UK cancer patients 
receivin platinum-based chemotherapy." Ann Oncol 13: 177. 
Abstract only (no 
paper identified) 
Thomas, H., McAdam, K. F., Thomas, R. J. et al (2002 ). "Early 
intervention with Epoetin alfa for treatment of anaemia and 
improvement of quality of life in cancer patients undergoing 
myelotoxic chemotherapy." Ann Oncol 13: 177. 
Abstract only (no 
paper identified) 
Quirt, I., S. Micucci, L. A. Moran, J. Pater and J. Browman 
(1996). "The roel of recombinant human erythropoietin (EPO) 
ni reducing red blood cell transfusions and maintaining quality 
of life (QoL) in patients with lymphoma and solid tumours 
receiving cytotoxic chemotherapy. Results of a randomized, 
double-blind, placebo-controlled clinical trial." Blood 88: 347a. 
Abstract only (no 
paper identified) 
Carabantes, F. J., M. Benavides, R. Trujillo, M. Cobo, M. L. 
Herbrero and S. Garcia (1999). Epoetin alfa in the prevention 
of anaemia in cancer patients undergoing platinum-based 
chemotherapy (CT). A prospective randomised study [abstract 
2303]. ASCO. 
Abstract only (no 
paper identified) 
Duplicate  
Casadevall, N. D., Dubois, S., Hemery, F et al. (2004). "Health, 
economic, and quality-of-life effects of erythropoietin and 
granulocyte colony-stimulating factor for the treatment of 
myelodysplastic syndromes: A randomized, controlled trial." 
Blood 104: 321-327. 
Duplicate; study 
also identified 
and accounted 
for in update 
searches 
Rosenzweig, M. Q. B., Catherine M.; Lucke, Joseph P.; Yasko, 
Joyce M.; Brufsky, Adam M. (2004). "The decision to 
prematurely terminate a trial of R-HuEPO due to 
thromboembolic events." Journal of Pain & Symptom 
Management 27: 185-190. 
Duplicate; study 
also identified 
and accounted 
for in update 
searches 
Unlicensed dose  
Bamias, A., G. Aravantinos, C. Kalofonos, N. Timotheadou, V. 
Siafaka, I. Vlahou, D. Janinis, D. Pectasides, N. Pavlidis, G. 
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"Prevention of anemia in patients with solid tumors receiving 
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Erythropoietin (rHuEpo): a prospective, open label, randomized 
trial by the Hellenic Cooperative Oncology Group." Oncology 
64(2): 102-110. 
Cascinu, S., A. Fedeli, E. Del Ferro, S. Luzi Fedeli and G. 
Catalano (1994). "Recombinant human erythropoietin 
treatment in cisplatin-associated anemia: a randomized, 
double-blind trial with placebo." J Clin Oncol 12: 1058-1062. 
Unlicensed dose 
Cazzola, M., D. Messinger, V. Battistel, D. Bron, R. Cimino, L. 
Enller-Ziegler, U. Essers, R. Greil, A. Grossi, G. Jager, A. 
LeMevel, A. Najman, V. Silingardi, M. Spriano, A. van Hoof and 
B. Ehmer (1995). "Recombinant human erythropoietin in the 
anemia associated with multiple myeloma or non-Hodgkin's 
lymphoma: dose finding and identification of predictors of 
response." Blood 86(12): 4446-4453. 
Unlicensed dose 
Hedenus, M., S. Hansen, K. Taylor, C. Arthur, B. Emmerich, C. 
Dewey, D. Watson, G. Rossi, A. Osterborg and G. Darbepoetin 
alfa 990114 Study (2002). "Randomized, dose-finding study of 
darbepoetin alfa in anaemic patients with lymphoproliferative 
malignancies." Br J Haematol 119(1): 79-86. 
Dose-response 
study; licensed 
dose included in 
PenTAG but 
unlicensed 
doses excluded 
Iconomou, G., A. Koutras, A. Rigopoulos, A. G. Vagenakis and 
H. P. Kalofonos (2003). "Effect of recombinant human 
erythropoietin on quality of life in cancer patients receiving 
chemotherapy: results of a randomized, controlled trial." J Pain 
Symptom Manage 25(6): 512-518. 
Unlicensed dose 
Kotasek, D., G. Steger, W. Faught, C. Underhill, E. Poulsen, A. 
B. Colowick, G. Rossi, J. Mackey and G. Aranesp 980291 
Study (2003). "Darbepoetin alfa administered every 3 weeks 
alleviates anaemia in patients with solid tumours receiving 
chemotherapy; results of a double-blind, placebo-controlled, 
randomised study." Eur J Cancer 39(14): 2026-2034. 
Dose-response 
study; licensed 
dose included in 
PenTAG but 
unlicensed 
doses excluded 
Kunikane, H., K. Watanabe, M. Fukuoka, N. Saijo, K. Furuse, 
H. Ikegami, Y. Ariyoshi and S. Kishimoto (2001). "Double-blind 
randomized control trial of the effect of recombinant human 
erythropoietin on chemotherapy-induced anemia in patients 
with non-small cell lung cancer." Int J Clin Oncol 6(6): 296-301. 
Unlicensed dose 
Leyland-Jones, B., B. Investigators and G. Study (2003). 
"Breast cancer trial with erythropoietin terminated 
unexpectedly." Lancet Oncol 4(8): 459-460. 
Unlicensed dose 
Oberhoff, C., B. Neri, D. Amadori, K. U. Petry, T. Gamucci, U. 
Rebmann, M. R. Nowrousian, R. Voigtmann, S. Monfardini, J. 
P. Armand, R. Herrmann, J. Netter-Pinon, N. Tubiana-Mathieu 
and H. Zwierzina (1998). "Recombinant human erythropoietin 
in the treatment of chemotherapy-induced anemia and 
prevention of transfusion requirement associated with solid 
tumors: a randomized, controlled study." Ann Oncol 9(3): 255-
260. 
Unlicensed dose 
Osterborg, A., M. A. Boogaerts, R. Cimino, U. Essers, J. 
Holowiecki, G. Juliusson, G. Jager, A. Najman and D. Peest 
(1996). "Recombinant human erythropoietin in transfusion-
dependent anemic patients with multiple myeloma and non-
Hodgkin's lymphoma--a randomized multicenter study. The 
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European Study Group of Erythropoietin (Epoetin Beta) 
Treatment in Multiple Myeloma and Non-Hodgkin's 
Lymphoma." Blood 87(7): 2675-2682. 
Rosen, F. R., D. J. Haraf, M. S. Kies, K. Stenson, L. Portugal, 
M. A. List, B. E. Brockstein, B. B. Mittal, A. W. Rademaker, M. 
E. Witt, H. Pelzer, R. R. Weichselbaum and E. E. Vokes 
(2003). "Multicenter randomized Phase II study of paclitaxel (1-
hour infusion), fluorouracil, hydroxyurea, and concomitant twice 
daily radiation with or without erythropoietin for advanced head 
and neck cancer." Clin Cancer Res 9(5): 1689-1697. 
Unlicensed dose 
Ten Bokkel Huinink, W. W., C. A. de Swart, D. W. van Toorn, 
G. Morack, W. P. Breed and H. F. Hillen (1998). "Controlled 
multicentre study of the influence of subcutaneous recombinant 
human erythropoietin on anaemia and transfusion dependency 
in patients with ovarian carcinoma treated with platinum-based 
chemotherapy." Med Oncol 15: 174-182. 
Multi dose 
comparison 
study; licensed 
dose included 
but unlicensed 
doses excluded 
Thatcher, N., E. S. De Campos, D. R. Bell, W. P. Steward, G. 
Varghese, R. Morant, J. F. Vansteenkiste, R. Rosso, S. B. 
Ewers, E. Sundal, E. Schatzmann and H. Stocker (1999). 
"Epoetin alpha prevents anaemia and reduces transfusion 
requirements in patients undergoing primarily platinum-based 
chemotherapy for small cell lung cancer." Br J Cancer 80: 396-
402. 
Multi dose 
comparison 
study; licensed 
dose included 
but unlicensed 
doses excluded 
Throuvalas, N., D. Antonadu, M. Boufi, R. S. Lavey and N. 
Malamos (2000). Erythropoietin decreases transfusion 
requirements during radiochemotherapy [abstract 1558]. 
American Society of Clinical Oncology Annual Meeting, New 
Orleans (USA). 
Unlicensed dose 
Welch, R. S., R. D. James, P. M. Wilkinson, F. Belli and R. A. 
Cowan (1995). "Recombinant human erythropoietin and 
platinum-based chemotherapy in advanced ovarian cancer." 
Cancer J Sci Am 1: 261-266. 
Unlicensed dose 
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 Appendix F: Study & baseline characteristics excluded unlicensed 
Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
WILSON AND COLLEAGUES, 2007 
Bamias,  
2003200 
ROL 
n = 72 
Age, yrs: 60 (18–77) 
n (%) Male: 35 (49) 
Hb BL (g/dl): 11.5 (11.1–
11.9) 
Epo mU/ml BL: 24.8 (16.6–
37) 
n = 72 
Age, yrs: 62 (19–80) 
n (%) Male: 39 (54) 
Hb BL (g/dl): 11.5 (11.2–11.8) 
Epo mU/ml BL: 12.5 (8.7–18) 
Brand: epoetin alfa 
Dose: 30,000 IU QW 
Dose adjustment: Y,  
Duration of epo tx: 21–24 
wks (duration of chemo 
Duration of trial: duration 
of chemo + 3 wks 
Follow-up:  
SC Iron: NR 
G-CSF: NR 
RBCT trigger: prn 
(Hb incl. criteria 
level: <13 g/dl) 
Disease: solid 
Treatment: chemo, plat 
Hb, patients' 
RBCT 
 
HRQoL measured 
in a subset 
Y 
Cascinu, 
1994201 
RCT 
n = 50 
Age, yrs: 58 (44–72)* 
n (%) Male: 24 (48) 
Hb BL (g/dl): 8.63 ± 0.62 
Epo mU/ml L: 67.9 ± 66.6 
n = 50 
Age, yrs: 57 (45–68)* 
n (%) Male: 29 (58) 
Hb BL (g/dl): 8.73 ± 0.52 
Epo mU/L BL: 49.3 ± 39.9 
Brand: epoetin alfa 
Dose: 300 IU/kg QW 
Dose adjustment: Y  
Duration of epo tx: 9 wks 
Duration of trial: 9 wks 
Follow-up: NR 
PBO Iron: Y, oral (as 
indicated by serum 
iron, serum ferritin, 
transferrin sat.) 
G-CSF: NR 
RBCT trigger: <8 
g/dl 
(Hb incl. criteria 
level: <9 g/dl) 
Disease: solid 
Treatment: chemo, plat 
Hb, RBCT,AE Y 
Cazzola, 
1995202 
ROL 
EPO BETA 5,000 IU/kg 
n = 31 (analysed 31) 
Age, yrs: NR 
n (%) Male: NR 
Hb BL (g/dl): ≤10 g/dl 
Epo mU/ml BL: NR 
 
EPO BETA 10,000 IU/kg 
n = 26 (analysed 326) 
Age, yrs: NR 
n (%) Male: NR 
Hb BL (g/dl): ≤10 g/dl 
Epo mU/ml BL: NR 
n = 55 (analysed 55) 
Age, yrs: NR 
n (%) Male: NR 
Hb BL (g/dl): ≤10 g/dl 
Epo mU/ml BL: NR 
Brand: epoetin beta 
Dose: 5,000 IU/day or 
10,000 IU/day 
Dose adjustment: NR 
Duration of epo tx: 8 wks 
Duration of trial: NR 
Follow-up: 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: NR) 
Disease: haem 
Treatment: chemo, non-
plat 
HaemR, Hb, 
RBCT, AE 
Y 
Hedenus,  
200249a 
RCT 
 
Dose-response 
study, only 
licensed dose 
included in 
current review 
DARBEPOETIN ALFA 1.0 
µg/kg/QWa 
n = 11 
Age, yrs: 64 (26–80) 
n (%) Male: 7 (64) 
Hb BL (g/dl): 9.7 (0.8) 
Epo mU/ml BL: 46 (12–208) 
DARBEPOETIN ALFA 4.5 
µg/kg/QWa 
n = 11 
Age, yrs: 63 (25–80) 
n (%) Male: 2 (18) 
Hb BL (g/dl): 9.5 (1.0) 
Epo mU/ml BL: 45 (12–132 
Brand: darbepoetin alfa 
Dose: 1.0 & 4.5 µg/kg QWa
Dose adjustment: Y 
Duration of epo tx: 12 wks
Duration of trial: 16 wks 
Follow-up: Unclear 
PBO Iron: NR 
G-CSF:  
RBCT trigger: Hb ≤8 
g/dl 
(Hb incl. criteria 
level: ≤11.0 g/dl) 
Disease: haem 
Treatment: chemo, NR 
HaemR, Hb, 
RBCT, AE 
Y 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
n = 22 
Age, yrs: 70 (52–84) 
n (%) Male: 14 (64) 
Hb BL (g/dl): 9.7 (0.9) 
Epo mU/ml BL: 57 (12–227) 
Iconomou, 
2003203 
ROL 
n = 57 
Age, yrs: 60.6 (33–85) 
n (%) Male: 22 (39) 
Hb BL (g/dl): 10.1 ± 0.6 
Epo mU/ml BL: NR 
n = 55 
Age, yrs: 62.6 (34–80) 
n (%) Male: 24 (44) 
Hb BL (g/dl): 10.1 ± 0.6 
Epo mU/ml BL: NR 
Brand: rHuEPO 
Dose: 30,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 12 wks
Duration of trial: 12 wks 
Follow-up: 
SC Iron: Y 
G-CSF: NR  
RBCT trigger: Hb 
7.5 g/dl or prn 
(Hb incl. criteria 
level: ≤11 g/dl) 
Disease: solid 
Treatment: chemo, 
mixed 
HaemR, HRQoL Y 
Kotasek, 
200346a 
RCT 
 
Dose-response 
study, only 
licensed dose 
included in 
current review 
DARB ALFA 1.5 µg/kg/QW 
n = 32 
n (%) Male: 9 (28) 
DARB ALFA 3.0 µg/kg/QW 
n = 46 
n (%) Male: 13 (28) 
DARB ALFA  4.0 µg/kg/QW 
n = 28 
n (%) Male: 8 (28) 
DARB ALFA 4.5µg/kg/QW 
n = 35 
n (%) Male: 10 (28) 
DARB ALFA 5.0 µg/kg/QW 
n = 40 
n (%) Male: 11 (28) 
 
 
Age, yrs: 58.3 (11.9)c 
Hb BL (g/dl): 9.93 (1.0)c 
Epo BL: 17% patients ≥100 
mU/mLc 
n = 51 
Age, yrs: 56.2 (12.4)  
n (%) Male: 16 (31) 
Hb BL (g/dl): 9.87 (1.12) 
Epo mU/ml BL: NR 
Brand: darbepoetin alfa 
Dose: 1.0, 3.0, 4.0, 4.5, 
5.0 g/kg QW 
Dose adjustment: Yes, 
Duration of epo tx: 12 wks 
Duration of trial: 12 wks 
Follow-up: Unclear 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: ≤11.0 g/dl) 
Disease: solid (breast, 
gynae., GI, lung) 
Treatment: chemo, NR 
HaemR, Hb, 
RBCT, HRQoLc, 
AEc 
Y 
Kunikane, 
2001204 
RCT 
EPOETIN BETA 
300U/kg/QW 
n = 16 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): >12 g/dl 
Epo mU/ml BL:  
EPOETIN BETA 
600U/kg/QW 
n = 18 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): >12 g/dl 
n = 38 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): >12 
Epo mU/ml BL:  
Brand: epoetin beta 
Dose: 300 IU/kg QW & 
600 IU/kg QW 
Dose adjustment: NR 
Duration of epo tx: 6 wks 
Duration of trial: NR 
Follow-up: 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: NR) 
Disease: solid (NSCLC) 
Treatment: chemo, plat 
Hb, patients' 
RBCT 
Y 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
Epo mU/ml BL:  
Leyland-Jones,  
200313 
n = NR (total for trial 939) 
Age, yrs: NR 
n (%) Male: NR 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n = NR (total for trial 939) 
Age, yrs: NR 
n (%) Male: NR 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: NR 
Dose adjustment: NR 
Duration of epo tx: NR 
Duration of trial: 12–19 
mths 
Follow-up: 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: 13 g/dl (aim of 
study to keep Hb 
>12 <14 g/dl) 
Disease: solid 
(metastatic breast) 
Treatment: NR 
Survival Y 
Oberhoff, 
1998205 
ROL 
n = 114 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): ≤10 
Epo mU/ml BL:  
n = 104 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): ≤10 
Epo mU/ml BL:  
Brand: epoetin beta 
Dose: 5,000 IU/day 
Dose adjustment: 12 wks 
Duration of epo tx:  
Duration of trial:  
Follow-up: 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: ) 
Disease: solid 
Treatment: chemo, plat 
HaemR, Hb, 
RBCT, AE 
Y 
Osterborg, 
1996206 
ROL 
EPOETIN BETA 10,000 
U/OD 
n = 47 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): ≤10 
Epo mU/ml BL:  
EPOETIN BETA 2,000 
U/OD 
n = 48 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): ≤10 
Epo mU/ml BL:  
n = 49 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): ≤10 
Epo mU/ml BL:  
Brand: epoetin beta 
Dose: 2,000 IU/day & 
10,000 IU/day 
Dose adjustment:  
Duration of epo tx: 24 wks
Duration of trial:  
Follow-up: 
SC Iron:  
G-CSF:  
RBCT trigger: NR 
(Hb incl. criteria 
level: ) 
Disease: haem 
Treatment: chemo, non-
plat 
HaemR, Hb, 
RBCT, AE 
Y 
Rosen,  
2003207 
ROL 
n = 47 
Age, yrs: 56 (35–80) 
n (%) Male: 33 (71) 
Hb BL (g/dl): <10 g/dl 
Epo mU/ml BL: NR 
n = 43 
Age, yrs: 56 (35–80) 
n (%) Male: 31 (71) 
Hb BL (g/dl): <10E 
po mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: NR 
Duration of epo tx: 14 wks 
+ 4 wks continuation 
Duration of trial: 48 mths 
Follow-up: 
SC Iron: Y (tx arm only) 
G-CSF: NR 
RBCT trigger: Hb 
<10 g/dl  
Hb incl. criteria 
level: ≤16 g/dl) 
Disease: solid 
(head/neck) 
Treatment: chemo + 
radio 
Hb, patients' 
RBCT 
Y 
Ten Bokkel, 
199847a 
ROL 
 
3-arm study, 
only comparison 
with licensed 
dose included in 
current review 
n = 42 (analysed 42)a 
Age, yrs: 60.97 
n (%) Male: all female 
Hb BL (g/dl): 12.0 (1.3–
12.6)* 
Epo mU/ml BL: NR 
n = 34 (analysed 33) 
Age, yrs: 58.83 
n (%) Male: all female 
Hb BL (g/dl): 11.8 (10.6–12.5)*
Epo mU/ml BL: NR 
Brand: epoetin beta 
Dose: 300 IU/kg TIWa 
Dose adjustment: Y 
Duration of epo tx: 24 wks
Duration of trial: 24 wks 
Follow-up: NR 
SC Iron: NR 
G-CSF: No 
RBCT trigger: Hb 
<9.7 g/dl  
(Hb incl. criteria 
level: <13 g/dl) 
Disease: solid (ovary) 
Treatment: chemo, plat 
Patients' RBCT, 
AE 
Y 
PenTAG   CONFIDENTIAL 
640 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
Thatcher, 
199948a 
ROL 
 
3-arm study, 
only comparison 
with licensed 
dose included in 
current review 
n = 44a 
Age, yrs: 58.5 (30–72)* 
n (%) Male: 29 (66)  
Hb BL (g/dl): 13.6 (10.9–
17.0)* 
Epo mU/ml BL: NR 
n = 44 
Age, yrs: 60 (39–74)*  
n (%) Male: 27 (61.3) 
Hb BL (g/dl): 13.4 (10.9–16.4)*
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 300 IU/kg TIWa 
Dose adjustment: Y 
Duration of epo tx: 26 wks
Duration of trial: 26 wks 
Follow-up: NR 
SC Iron: No 
G-CSF: No 
RBCT trigger: prn 
(Hb incl. criteria 
level: ≥10.5 g/dl) 
Disease: solid (SCLC) 
Treatment: chemo, 
mixedd 
Hb. Patients' 
RBCT, HRQoL, 
AE 
Y 
Throuvalas, 
2000208 
ROL 
n = 28 (analysed 28) 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): >10 ≤12 
Epo mU/ml BL:  
n = 27 (analysed 26) 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl): >10 ≤12 
Epo mU/ml BL:  
Brand: rHuEPO 
Dose: 50,000 IU QW 
Dose adjustment:  
Duration of epo tx:  
Duration of trial: 6 wks 
Follow-up: 
SC Iron:  
G-CSF:  
RBCT trigger: Hb  
(Hb incl. criteria 
level: ) 
Disease: solid (cervix, 
bladder) 
Treatment: chemo (plat) 
+ radio 
RBCT   Y 
Welch, 
1995209 
ROL 
n = 15 
Age, yrs: NR 
n (%) Male: NR 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n = 15 
Age, yrs: NR 
n (%) Male: NR 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 300 IU/kg TIW 
Dose adjustment:  
Duration of epo tx:  
Duration of trial: 24 wks 
Follow-up: NR 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: NR) 
Disease: solid (ovary) 
Treatment: chemo, plat 
Hb, RBCT, 
HRQoL, AE    
Y 
PENTAG REVIEW: 2004 to CURRENT 
Aapro  
2008210 
ROL 
 
BRAVE 
 
Suppl refs: 
Aapro, 2009 
n = 231 
Age, yrs: 56 (27–78)* 
n (%) Male: all female 
Hb BL g/dl: 11.2 ± 1.2 
Epo mU/ml BL: NR 
n = 232 
Age, yrs: 57.5 (29–83)* 
n (%) Male: all female 
Hb BL g/dl: 11.5 ± 1.1 
Epo mU/ml BL: NR 
Brand: Epoetin beta 
Dose: 450 IU/kg QW 
Dose adj.: Y 
Dur. of epo tx: 24 wks 
Dur. of trial: 24 wks 
Follow-up: 18 mths 
SC Iron: Y, oral or i.v. 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: <12.9 g/dl) 
Disease: solid (breast) 
Treatment: chemo: non-
plat 
HaemR, Hb, 
RBCT, HRQoL, 
AE, TR, survival 
Y 
Aapro  
2009211 
 
Subgroup 
analysis of 
Aapro, 2008 
n = 231 
Age, yrs: 56 (27–78)* 
n (%) Male: all female 
Hb BL g/dl: 11.2 ± 1.2 
Epo mU/ml BL: NR 
n = 232 
Age, yrs: 57.5 (29–83)* 
n (%) Male: all female 
Hb BL g/dl: 11.5 ± 1.1 
Epo mU/ml BL: NR 
Brand: Epoetin beta 
Dose: 450 IU/kg QW 
Dose adj.: Y 
Dur. of epo tx: 24 wks 
Dur. of trial: 24 wks 
Follow-up: 18 mths 
SC Iron: Y, oral or i.v. 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: <12.9 g/dl) 
Disease: solid (breast) 
Treatment: chemo: non-
plat 
AE (subgroup 
analysis, TVEs 
among patients 
receiving and not 
receiving 
antithromboemboli
c therapy; 
hypothesis 
generating) 
N 
Berndt, 
2005212 
ROL 
 
Subgroup 
n = 300k,l 
Age, yrs: 60.8 (12.3) (20–91) 
n (%) Male: 91 (30.3) 
Hb BL (g/dl): 9.9 (0.9) (6.2–12.2) 
Epo mU/ml BL: NR 
Brand: darbepoetin alfa 
Dose: 0.5, 1.0, 1.5, 2.25, 
4.5, 6.0 & 8.0 µg QW and 
3.0, 5.0, 7.0 & 9.0 µg Q2W
Dose adjustment: Y,  
Head-to-
head 
Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: ≤11 g/dl) 
Disease: solid 
Treatment: chemo, 
mixed 
Analysis explores 
the impact of 
fatigue on 
productivity & 
caregiver burden 
N 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
analysis of 
Glaspy 2002 
(not included in 
previous HTA) 
Duration of epo tx: 12 wks
Duration of trial: 12 wks 
Follow-up: 
 
Brand: epoetin alfa 
Dose: 150 IU/kg TIW & 
40,000 IU/QW 
Dose adjustment: Ym 
Duration of epo tx: 12 wks
Duration of trial: 12 wks 
Follow-up: NR 
(although includes 
licensed doses of 
intervention under 
review; results 
reported are 
based on pooled 
data) 
Blohmer, 
2011213 
ROL 
 
NOGGO-AGO 
n = 127 
Age, yrs: 41 (24–73)* 
n (%) Male: all female 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n = 129 
Age, yrs: 42 (25–66)* 
n (%) Male: all female 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: rHuEPO 
Dose: 10,000 IU TIW 
Dose adjustment: Y 
Duration of epo tx: Unclear
Duration of trial: Unclear 
Follow-up: 3 yrs 
No epo Iron: Y, oral 
G-CSF: NR 
RBCT trigger: Hb <9 
g/dl 
(Hb incl. criteria 
level: NR) 
Disease: solid (cervix) 
Treatment: chemo + 
radio 
Hb, RBCT, 
HRQoL (ECOG), 
AE, survival 
Y 
Cabanillas, 
2012214 
ROL 
n = 55 
Age, yrs: 41 ± 16.7 
n (%) Male: 33 (58) 
Hb BL (g/dl): 9 ± 1.5 
Epo g/dl BL: 473 ± 570 
n = 54 
Age, yrs: 42 ± 17.3 
n (%) Male: 24 (42) 
Hb BL (g/dl): 8.9 ± 1.5 
Epo mU/ml BL: 326 ± 514 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: Unclear
Duration of trial: Unclear 
Follow-up: 3 yrs 
No epo Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: >10 g/dl) 
Disease: haem 
Treatment: chemo, non-
plat 
RBCT, HRQoL, 
AE, TR, survival 
N 
Excluded trials 
if >80% of 
participants 
were 
diagnosied 
with an acute 
leukaemia 
Chang, 
200531 
ROL 
n = 175 
Age, yrs: 50.4 (11.1) (27–78) 
n (%) Male: all female 
Hb BL (g/dl): 11.2 (0.9) 
(8.15–12.6)e 
Epo mU/ml BL: NR 
n = 175 
Age, yrs: 50.1 (10.0) (31–85) 
n (%) Male: all female 
Hb BL (g/dl): 11.3 (0.8) (7.8–
13.4)e 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 16 weeks 
Follow-up: NR 
SC Iron: Y, oral, daily 
(as indicated by 
transferrin sat.) 
G-CSF: NR 
RBCT trigger: Hb <8 
g/dl, prn 
(Hb incl. criteria 
level: ≤15 g/dl  at 
screening; ≤12 g/dl 
randomised) 
Disease: solid (breast) 
Treatment: chemo, NR 
HaemRf, Hb, 
RBCT, HRQoL, 
AE 
Y 
Chang, 
2004215 
ROL 
 
Subgroup 
analysis of 
Chang 2005 
(published 
online ahead of 
print 2004) 
n = 176 
Age, yrs: 50.4 (11.1) (27–78) 
n (%) Male: all female 
Hb BL (g/dl): 11.2 (0.9) 
(8.15–12.6)* 
Epo mU/ml BL: NR 
n = 178 
Age, yrs: 50.1 (10.0) (31–85) 
n (%) Male: all female 
Hb BL (g/dl): 11.3 (0.8) (7.8–
13.4)* 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 16 weeks 
Follow-up: NR 
SC Iron: Y, oral, daily 
(as indicated by 
transferrin sat.) 
G-CSF: NR 
RBCT trigger: Hb <8 
g/dl, prn 
(Hb incl. criteria 
level: ≤15 g/dl  at 
screening; ≤12 g/dl 
randomised) 
Disease: solid (breast) 
Treatment: chemo, NR 
Analysis of the 
effect of epoetin 
alfa on changes in 
QoL & utility 
scales at 12 wks 
Y 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
Charu, 
2007216 
ROL 
n = 226 
Age, yrs: 71.7 (10.4) 
n (%) Male: 95 (42) 
Hb BL (g/dl): 10.1 (0.9) (for 
n=220) 
Epo mU/ml BL: NR 
n = 59 
Age, yrs: 67.2 (12.5) 
n (%) Male: 23 (39) 
Hb BL (g/dl): 10.3 (0.9) (for 
n=55) 
Epo mU/ml BL: NR 
Brand: darbepoetin alfa 
Dose: 3 µg/kg Q2W 
Dose adjustment: Y 
Duration of epo tx: 12 wks
Duration of trial: 12 wksg 
Follow-up: NR 
No epo Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: ≤11 g/dl) 
Disease: Mixed 
Treatment: chemo, NR 
HaemR, Hb, 
RBCT, HRQoL, 
AE, # 
hospitalisations 
Y 
Christodoulou,
2009217 
ROL 
n = 167 
Age, yrs: 61 (22–82)* 
n (%) Male: 88 (53) 
Hb BL (g/dl): 10.15 ± 0.69 
Epo mU/ml BL: NR 
n = 170 
Age, yrs: 63 (30–89)* 
n (%) Male: 81 (48) 
Hb BL (g/dl): 10.30 ± 0.58) 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 10,000 IU TIW 
Dose adjustment: 
YDuration of epo tx: 
Duration of trial: Follow-up: 
NR 
No epo Iron: Y, oral G-CSF: 
NRRBCT trigger: Hb 
<8.5 g/dl prn(Hb incl. 
criteria level: ≤12 
g/dl) 
Disease: solid 
Treatment: chemo, 
mixed 
Hb, RBCT, 
HRQoL, TR, 
survival 
Y 
Engert, 
2010218 
RCT 
 
GHSG -HD15-
EPO 
n = 648 
Age, yrs: 34 (18–60)* 
n (%) Male: 402 (62) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n = 685 
Age, yrs: 34 (18–60)* 
n (%) Male: 406 (62) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: Unclear
Duration of trial: Unclear 
Follow-up: Unclear 
PBO Iron: Y, oral (as 
indicated by BL 
transferrin sat. or 
serum ferritin level) 
G-CSF: NR 
RBCT trigger: Hb <8 
g/dl 
(Hb incl. criteria 
level: NR) 
Disease: haem 
Treatment: chemo, non-
plat 
Hb, RBCT, 
HRQoL, AE, 
survival 
Y 
Fujisaka, 
2011219 
RCT 
n = 89 
Age, yrs: 67 (40–79)* 
n (%) Male: 47 (53) 
Hb BL (g/dl): 9.4 (8.1–11.4)* 
Epo mU/ml BL: 43 (7.78–
577)* 
n = 92 
Age, yrs: 63.5 (44–79)* 
n (%) Male: 40 (43) 
Hb BL (g/dl): 9.3 (7.2–11.4)* 
Epo mU/ml BL: 43.6 (10.5–
320)* 
Brand: epoetin beta 
Dose: 36,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 12 wks
Duration of trial: 12 wks 
Follow-up: 12 mths 
PBO Iron: Y, oral daily (as 
indicated by 
transferrin sat). 
G-CSF: NR  
RBCT trigger: prn 
(Hb incl. criteria 
level: ≤8 / ≤10 g/dl ) 
Disease: solid (lung or 
gynae.) 
Treatment: chemo, plat 
Hb, RBCT, 
HRQoL, AE, 
survival 
Y 
Glaspy,  
2006220 
ROL 
active control 
DARBEPOETIN ALFA 
n = 606 
Age, yrs: 63.2 (12.4) 
n (%) Male: 191 (32) 
Hb BL (g/dl): 10.2 (0.9) 
Epo mU/ml BL: NR 
EPOETIN ALFA 
n = 603 
Age, yrs: 63.7 (11.6) 
n (%) Male: 222 (37) 
Hb BL (g/dl): 10.2 (0.9) 
Epo mU/ml BL: NR 
DARBEPOETIN ALFA 
Brand: darbepoetin alfa 
Dose: 200 µg Q2W 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 16 wks 
Follow-up: NR 
 
EPOETIN ALFA 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 16 wks 
Follow-up: NR 
NA (active 
control 
see left) 
Iron: NR 
G-CSF: NR 
RBCT trigger: Hb >8 
g/dl prn 
(Hb incl. criteria 
level: ≤11 g/dl) 
Disease: solid 
Treatment: chemo, NR 
Hb, RBCT, 
HRQoL, AE 
 
HaemR measured 
but defined as 
achievement of 
target Hb range 
11-13 g/dl) 
N 
Excluded as 
ESAs were 
given in 
context with 
surgery, stem 
cell 
transplantation 
Gupta. 
2009221 
n = 60 (analysed 58) 
Age, yrs: 48.27 (18–70) 
n = 60 (analysed 57) 
Age, yrs: 48.18 (20–65) 
Brand: epoetin beta 
Dose: 10,000 IU TIW 
PBO Iron: Y, oral 10–15 
days before 
Disease: solid (cervix) 
Treatment: chemo (plat) 
Hb, RBCT, 
HRQoL, AE, TR, 
Y 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
RCT n (%) Male: NR 
Hb BL (g/dl): 10.45 (9.5–
11.0) 
Epo mU/ml BL: NR 
n (%) Male: NR 
Hb BL (g/dl): 10.70 (10.0–
12.5) 
Epo mU/ml BL:  
Dose adjustment: NR 
Duration of epo tx: Unclear
Duration of trial: Unclear  
Follow-up: 24 mths 
chemo+radio 
(unclear whether 
given in control arm)
G-CSF: NR 
RBCT trigger: Hb 
≤10 g/dl 
(Hb incl. criteria 
level: 9.5–12.5 g/dl) 
+ radio survival 
Hernandez, 
2009222 
RCT 
n = 193 
Age, yrs: 64.5 (12.1) 
n (%) Male: 76 (39) 
Hb BL (g/dl): 10.1 (0.9) 
Epo mU/ml BL: 90.3 (96.1) 
(n=186) 
n = 193 
Age, yrs: 63.6 (12.3) 
n (%) Male: 76 (39) 
Hb BL (g/dl): 10.0 (0.9) 
Epo mU/ml BL: 109.9 (186.4) 
(n=184) 
Brand: darbepoetin alfa 
Dose: 300 g/Q3W 
Dose adjustment: Y 
Duration of epo tx: 13 wks
Duration of trial: 16 wks 
Follow-up: 29 wks 
PBO Iron: Y, not 
specified, though 
based on serum 
iron, serum ferritin, 
or transferrin 
saturation 
G-CSF: NR 
RBCT trigger: Hb ≤8 
g/dl, or if >8 g/dl & 
signs of anaemia 
present 
(Hb incl. criteria 
level: <11 g/dl) 
Disease: solid & haem? 
Treatment: chemo, 
mixed  
Hb, RBCT, 
HRQoL, AE, TR, 
survival 
Y 
Leyland-Jones, 
2005223 
RCT (BEST) 
n = 469 
Age, yrs: 55.8 (11.1; 24–83)  
n (%) Male: all female 
Hb BL (g/dl): 12.5 (1.8) 
Epo mU/ml BL: NR 
n = 470 
Age, yrs: 55.1 (10.5; 30–84) 
n (%) Male: all female 
Hb BL (g/dl): 12.5 (1.7) 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 12 mths
Duration of trial: 12 mthsg 
Follow-up: NR 
PBO Iron: Y, oral (as 
indicated by 
transferrin sat.) 
G-CSF: NR 
RBCT trigger: prn 
(Hb incl. criteria 
level: ) 
Disease: solid (breast) 
Treatment: chemo, NR 
Hb, RBCT, 
HRQoL, AE, TR, 
survival 
Y 
Milroy,  
2011224 
ROL 
n = 214 (analysed 189) 
Age, yrs: 61.6 ± 8.7 (41–82) 
n (%) Male: 142 (75.1) 
Hb BL (g/dl): 12.8 ± 1.4 
Epo mU/ml BL: NR 
n = 191 (analysed 191) 
Age, yrs: 60.1 ± 9.3 (34–83) 
n (%) Male: 148 (77.5) 
Hb BL (g/dl): 12.6 ± 1.6 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 10,000 IU TIW 
Dose adjustment: Y 
Duration of epo tx: 22–28 
weeks 
Duration of trial: 22–28 
weeks 
Follow-up: 6 & 12 mths 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: NR  
(Hb incl. criteria 
level: ≤15 g/dl 
[males]; ≤14 g/dl 
[females]) 
Disease: solid (NSCLC) 
Treatment: Chemo, plat 
HaemR, Hb, 
RBCT, HRQoL, 
AE, TR, survival  
Y 
Nagel,  
2011225 
ROL 
n = 37 
Age, yrs: 61 (41–88) 
n (%) Male: 29 (77.8) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n = 37 
Age, yrs: 59 (37–80) 
n (%) Male: 24 (63.9) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: darbepoetin alfa 
Dose: 300 µg Q2W 
Dose adjustment: Y 
Duration of epo tx: up to 
28 wks 
Duration of trial: up to 28 
wks 
Follow-up: 24 mths 
SC Iron: Y, oral 
G-CSF: Y, 
pegfilgastrim D4 
each C 
RBCT trigger: prn 
(Hb incl. criteria 
level: <12 g/dl; 
treatment initiated at 
this point in the 
Disease: solid (SCLC) 
Treatment: Chemo, plat 
HRQoL, AE, TR, 
survival  
N 
Excluded as 
too many 
patients in 
experimental 
arm did not 
receive ESAs 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
intervention group) 
O'Shaugnessy, 
2005226 
RCT 
n = 47 
Age, yrs: 53.3 ± 9.7 
n (%) Male: all female 
Hb BL (g/dl): 12.8 ± 1.0 
Epo mU/ml BL: NR 
n = 47 
Age, yrs: 54.3 ± 12.0 
n (%) Male: all female 
Hb BL (g/dl): 13.0 ± 1.0 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 12 wks 
Duration of trial: 16 wks 
Follow-up: 6 mths 
PBO Iron: Y, not specified 
but prnG-CSF: 
NRRBCT trigger: Hb 
<8 g/dl(Hb incl. 
criteria level: 9–14 
g/dl) 
Disease: solid 
(breast)Treatment: 
chemo, plat 
Hb, cognitive 
function & mood 
(EXIT25, CLOX 1 
& 2, POMS), 
HRQoL, AE 
Y 
Pirker, 
2008227 
RCT 
n = 298 
Age, yrs:  
n (%) Male:  
Hb BL (g/dl):  
Epo mU/ml BL:  
n = 298  
Age, yrs:  
n (%) Male:  
Hb BL (g/dl):  
Epo mU/ml BL:  
Brand: darbepoetin alfa 
Dose: 300 µg/QW for 4 
wks then every 3 wks up to 
6 cycles chemo 
Dose adjustment: Y 
Duration of epo tx: 13 
wks? 
Duration of trial: 24 wks  
Follow-up: 12 mths 
PBO Iron:  
G-CSF: NR 
RBCT trigger: Hb  
(Hb incl. criteria 
level: ≥9 and ≤13 
g/dl) 
Disease: solid (SCLC) 
Treatment: chemo, plat 
Hb, RBCT, 
HRQoL, AE, 
survival, disease 
progression 
Y 
Pronzato, 
2010228 
ROL 
 
EPO-INT-47 
n = 107 
Age, yrs: 58.3 ± 10.3 (29–
76) 
n (%) Male: all female 
Hb BL (g/dl): 10.6 
Epo mU/ml BL: NR 
n = 109 
Age, yrs: 54.3 ± 11.6 (27–77) 
n (%) Male: all female 
Hb BL (g/dl): 10.8 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 10,000 IU TIW 
(5,000 IU/QW if <45 kg) 
Dose adjustment: Y 
Duration of epo tx: up to 
28 wks 
Duration of trial: up to 28 
wks 
Follow-up: 6 & 12 mths 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: ≤12 g/dl) 
Disease: solid  
Treatment: chemo, plat 
HaemR, Hb, 
HRQoL, AE, TR, 
survival  
Y 
Razzouk, 
2006229h 
RCT 
n = 111 
Age, yrs: 12.4 (3.6) 
n (%) Male: 63 (56.8) 
Hb BL (g/dl): 9.8 (1.3) 
Epo mU/ml BL: NR 
n = 111 
Age, yrs: 10.8 (4.0) 
n (%) Male: 58 (52.3) 
Hb BL (g/dl): 9.5 (1.0) 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 600 IU/kg QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 16 wks 
Follow-up:  
PBO Iron: Y, oral (as 
indicated by 
transferrin sat. or 
ferritin level) 
G-CSF: NR 
RBCT trigger: Hb ≤7 
g/dl 
(Hb incl. criteria 
level: (<10.5; <11.0, 
or <12.0 g/dl 
dependent on age) 
Disease: haem 
Treatment: chemo, NR 
Hb, RBCT, 
HRQoL, AE 
Y 
Reed, 
2005230 
ROL 
active control 
 
Subgroup 
analysis of 
Waltzman 2005 
n = 274* 
Age, yrs: 62.4 (11.7) 
n (%) Male: 93 (34) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
EPOETIN ALFA 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 16 wks 
Follow-up: NR 
 
Head-to-
head 
Iron: Y, oral, daily or 
i.v. if contraindicated 
G-CSF: NR 
RBCT trigger: Hb  
(Hb incl. criteria 
level: ≤11 g/dl) 
Disease: solid 
Treatment: chemo, 
mixed 
Analysis of the 
patients with a 
baseline Hb value 
& at least one 
post-
randomisation Hb 
value or 
documentation of 
N 
Compared 
different ESA 
products 
(epoetin vs 
darbepoetin) 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
DARBEPOETIN ALFA 
Brand: darbepoetin alfa 
Dose: 200 µg Q2W 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 16 wks 
Follow-up: NR 
RBCT. Patients 
were dichotomised 
based on whether 
they experienced 
early Hb 
response, 
regardless of 
treatment 
assignment 
Rosenzweig, 
2004231n 
 
Retrospective 
analysis, original 
trial unknown 
n = 14 
Age, yrs: 55.9 ± 11.7 
n (%) Male: all female 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n = 13 
Age, yrs: 53.9 ± 14.20 
n (%) Male: all female 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: rHuEPO 
Dose: 40,000 IU QW 
Dose adjustment: NR 
Duration of epo tx: NR 
Duration of trial: NRn 
Follow-up: NA 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: <12 g/dl) 
Disease: solid (breast) 
Treatment: chemo, NR 
Analysis to 
determine the 
efficacy of 
rHuEPO in 
reducing cancer-
related fatigue & 
improving QoL & 
fatigue in patients 
with metastatic 
breast cancer 
experiencing mild 
anaemia 
(retrospective 
review over an 18-
mth period) 
Y 
Savonije, 
2006a232 
RCT 
 
Subgroup 
analysis of 
Savonije 2005 
n = 211 
Age, yrs: 57 ± 11 (20–80) 
n (%) Male: 117 (55) 
Hb BL (g/dl): 10.7 ± 1.0 
(7.6–13.8) 
Epo mU/ml BL: NR 
n = 104 
Age, yrs: 58 ± 10 (27–78) 
n (%) Male: 61 (59) 
Hb BL (g/dl): 10.8 ± 10 (8.5–
12.7) 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 10,000 IU TIW 
Dose adjustment: Y 
Duration of epo tx:  
Duration of trial: 13.9 wks 
vs 14.5 wks (mean int. vs 
control) 
Follow-up: 12 mths 
SC Iron: Y, oral (as 
indicated by BL 
transferrin sat. +/- 
serum ferritin level) 
G-CSF: NR 
RBCT trigger: Hb 
≥9.7 g/dl prn 
(Hb incl. criteria 
level: ≤12.1 g/dl) 
Disease: solid 
Treatment: Chemo, plat 
HRQoL in patients 
with solid tumours 
& mild-to-
moderate anaemia 
receiving plat. 
chemo. relative to 
population norms 
Y 
Savonije, 
2006b233 
RCT 
 
Subgroup 
analysis of 
Savonije 2005 
n = 211 
Age, yrs: 57 ± 11 (20–80) 
n (%) Male: 117 (55) 
Hb BL (g/dl): 10.7 ± 1.0 
(7.6–13.8) 
Epo mU/ml BL: NR 
n = 104 
Age, yrs: 58 ± 10 (27–78) 
n (%) Male: 61 (59) 
Hb BL (g/dl): 10.8 ± 10 (8.5–
12.7) 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 10,000 IU TIW 
Dose adjustment: Y 
Duration of epo tx:  
Duration of trial: 13.9 wks 
vs 14.5 wks (mean int. vs 
control) 
Follow-up: 12 mths 
SC Iron: Y, oral (as 
indicated by BL 
transferrin sat. +/- 
serum ferritin level) 
G-CSF: NR 
RBCT trigger: Hb 
≥9.7 g/dl prn 
(Hb incl. criteria 
level: ≤12.1 g/dl) 
Disease: solid 
Treatment: Chemo, plat 
Analyse the effect 
of BL Hb level on 
HaemR, Hb, 
RBCT, & HRQoL 
N 
Savonije, 
2005234 
n = 211 
Age, yrs: 57 ± 11 (20–80) 
n (%) Male: 117 (55) 
n = 104 
Age, yrs: 58 ± 10 (27–78) 
n (%) Male: 61 (59) 
Brand: epoetin alfa 
Dose: 10,000 IU TIW 
Dose adjustment: Y 
SC Iron: Y, oral (as 
indicated by BL 
transferrin sat. +/- 
Disease: solid 
Treatment: Chemo, plat 
HaemR, Hb, 
RBCT, HRQoL, 
AE, survival (6 & 
Y 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
RCT 
 
NCT00283465 
Hb BL (g/dl): 10.7 ± 1.0 
(7.6–13.8) 
Epo mU/ml BL: NR 
Hb BL (g/dl): 10.8 ± 10 (8.5–
12.7) 
Epo mU/ml BL: NR 
Duration of epo tx:  
Duration of trial: 13.9 wks 
vs 14.5 wks (mean int. vs 
control) 
Follow-up: 12 mths 
serum ferritin level) 
G-CSF: NR 
RBCT trigger: Hb 
≥9.7 g/dl prn 
(Hb incl. criteria 
level: ≤12.1 g/dl) 
12 mths) 
Schwartzberg, 
2004235 
ROL 
active control 
 
Integrated 
analysis of 3 
RCTs incl 
Senecal, 2005 
DARBEPOETIN ALFA 
n = 157 
Age, yrs: 58.7 (11.5)  
n (%) Male: 23 (15) 
Hb BL (g/dl): 10.4 (0.8) 
Epo mU/ml BL: NR 
EPOETIN ALFA 
n = 155 
Age, yrs: 61.7 (12.1) 
n (%) Male: 26 (17) 
Hb BL (g/dl): 10.4 (0.8) 
Epo mU/ml BL: NR 
DARBEPOETIN ALFA 
Brand: darbepoetin alfa 
Dose: 200 µg Q2W 
Dose adjustment: Y 
Duration of epo tx: 16 wks 
Duration of trial: 19/20 wks 
Follow-up: NR 
 
EPOETIN ALFA 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks 
Duration of trial: 19/20 wks 
Follow-up: NR 
Head-to-
head 
Iron: NRG-CSF: 
NRRBCT trigger: Hb 
(Hb incl. criteria 
level: ≤11 g/dl) 
Disease: solid (breast, 
lung, gynae.)Treatment: 
chemo, mixed 
Hb, RBCT, 
HRQoL, PSQ, AE 
Subgroup analysis 
by BL Hb category 
<10 g/dl and ≥10 
g/dl) 
N 
Excluded as 
compared 
ESAs 
darbepoetin vs 
epoetin 
Senecal, 
2005236 
active control 
 
Also reported in 
Schwartzberg, 
2004 
DARBEPOETIN ALFA 
n = 72 
Age, yrs: 53.6 ± 11.4 (35–
81) 
n (%) Male: all female 
Hb BL (g/dl): 10.5 ± 0.8 
Epo mU/ml BL: NR 
EPOETIN ALFA 
n = 69 
Age, yrs: 58.4 ± 12.5 (34–81) 
n (%) Male: all female 
Hb BL (g/dl): 10.6 ± 0.7 
Epo mU/ml BL: NR 
DARBEPOETIN ALFA 
Brand: darbepoetin alfa 
Dose: 200 µg Q2W 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 19/20 wks
Follow-up: NR 
 
EPOETIN ALFA 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 19/20 wks
Follow-up: NR 
Head-to-
head 
Iron: Y, not 
specified, per 
institution standards
G-CSF: NR 
RBCT trigger: Hb <8 
g/dl 
(Hb incl. criteria 
level: ≤11 g/dl) 
Disease: solid (breast) 
Treatment: chemo, 
mixed 
HaemR, Hb, 
RBCT, PSQ, AE  
 
Subgroup analysis 
by BL Hb category 
<10 g/dl and ≥10 
g/dl) 
N 
Excluded as 
ESAs were 
given in 
context with 
surgery, stem 
cell 
transplantation 
Thomas,  
2008237 
ROL 
 
GOG-0191; 
NCT00017004; 
CAN-NCIC-CX4 
n = 57 
Age, yrs: 46 (25–77)* 
n (%) Male: all female 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n = 52 
Age, yrs: 50 (32–78)* 
n (%) Male: all female 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: rHuEPO 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: Unclear
Duration of trial: Unclear 
Follow-up: 37 mths (9.8–
50.4 mths)* 
SC Iron:  
G-CSF: NR 
RBCT trigger: Hb 
<12 g/dl (as a result 
of vaginal bleeding, 
intervention arm) 
(Hb incl. criteria 
level: <12 g/dl for 
Disease: solid (cervix) 
Treatment: chemo (plat) 
+ radio 
Hb, RBCT, AE 
(TVEs), survival 
 
Trial terminated 
early with <25% of 
planned accrual 
due to concerns 
with TVEs with 
Y 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
randomisation; <14 
g/dl at study entry) 
rHuEPO 
Tsuboi, 
2009238 
RCT 
n = 61 
Age, yrs: 61.8 ± 11.9 
n (%) Male: 34 (56) 
Hb BL (g/dl): 10.0 ± 1.0 
Epo mU/ml BL: 67.3 ± 72.0 
n = 56 
Age, yrs: 62.1 ± 9.6 
n (%) Male: 33 (59) 
Hb BL (g/dl): 10.4 ± 1.0 
Epo mU/ml BL: 49.1 ± 33.4 
Brand: epoetin beta 
Dose: 36,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 8 wks 
Duration of trial: 8 wks 
Follow-up: median follow-
up 670 days* 
PBO Iron: Y, oral, if 
indicated by serum 
iron sat. or MCV) 
G-CSF: NR 
RBCT trigger: prn 
(Hb incl. criteria 
level: ≤8.0 and ≤11 
g/dl) 
Disease: solid (lung) & 
haem 
Treatment: chemo, 
mixed 
HaemR, Hb, 
RBCT, HRQoL, 
AE, survivali 
Y 
Wagner, 
200461 
ROLh 
n = 18 
Age, yrs: 3.2 (1.2–19.4)* 
n (%) Male: NR 
Hb BL (g/dl): 8.85 (6.10–
11.20)* 
Epo mU/ml BL: NR 
n = 20 
Age, yrs: 3.2 (1.1–7.3)* 
n (%) Male: NR 
Hb BL (g/dl): 9.35 (7.00–15.3)*
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 200 IU/kg/day 
Dose adjustment: Y 
Duration of epo tx: D6, C1 
to 48 hrs before start C2 in 
subseq cycles given 24 hrs 
after completion of chemo 
Duration of trial: Unclear 
Follow-up: NR 
SC Iron: Y, oral, daily 
(as indicated by 
transferrin sat.) 
G-CSF: 10 
µg/kg/OD both tx 
arms 
RBCT trigger: Hb ≤8 
g/dl 
(Hb incl. criteria 
level: NR) 
Disease: haem 
Treatment: chemo, 
mixed 
Hb, RBCT, 
survival 
N 
Excluded as 
no usable data 
for any 
outcome 
Waltzman, 
2005239 
ROL 
 
active control 
EPOETIN ALFA 
n = 178 
Age, yrs: 62.1 ± 11.8 
n (%) Male: 69 (38.8) 
Hb BL (g/dl): 10.16 ± 0.749 
Epo mU/ml BL: NR 
DARBEPOETIN ALFA 
n = 180 
Age, yrs: 63.4 ± 11.8 
n (%) Male: 61 (33.9) 
Hb BL (g/dl): 10.07 ± 0.787 
Epo mU/ml BL: NR 
EPOETIN ALFA 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks 
Duration of trial: 16 wks 
Follow-up: 
 
DARBEPOETIN ALFA 
Brand: darbepoetin alfa 
Dose: 200 µg/Q2W 
Dose adjustment: Y 
Duration of epo tx: 16 wks 
Duration of trial: 16 wks 
Follow-up 
Head-to-
head 
Iron: Y, oral, daily or 
i.v. if contraindicated 
G-CSF: NR 
RBCT trigger: Hb 
(Hb incl. criteria 
level: ≤11 g/dl) 
Disease: solid 
Treatment: chemo, 
mixed 
HaemR, Hb, 
RBCT, HRQoL, 
AE 
N 
Excluded as 
ESAs were 
given in 
context with 
surgery, stem 
cell 
transplantation 
Wilkinson, 
2006240 
ROL 
n = 114 
Age, yrs: 59.1 ± 10.6 (35–
87)  
n (%) Male: all female 
Hb BL (g/dl): 10.75 ± 0.94 
Epo mU/ml BL: NR 
n = 59 
Age, yrs: 60.3 ± 11.2 (30–79) 
n (%) Male: all female 
Hb BL (g/dl): 10.66 ± 0.83 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 10,000 IU TIW 
Dose adjustment: Y 
Duration of epo tx: up to 
28 wks 
Duration of trial: up to 28 
wks 
Follow-up: NR 
SC Iron: Y, oral (as 
indicated by 
transferrin sat.) 
G-CSF: Y, not 
specified 
RBCT trigger: Hb <9 
g/dl prn 
(Hb incl. criteria 
level: ≤12 g/dl) 
Disease: solid (ovary) 
Treatment: chemo, plat 
HaemR, Hb, 
RBCT, HRQoL, 
AE, TR   
Y 
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Study, year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia 
treatment 
Malignancy type  
and treatment 
Outcomes 
sought 
Incl in 
Cochrane 
2012, Y/N 
Winquist, 
2008241 
RCT 
n = 26 
Age, yrs: 71 (53–87)* 
n (%) Male: all male 
Hb BL (g/dl): 104 (73–120)* 
Epo mU/ml BL: NR 
n = 30 
Age, yrs: 71 (50–83)* 
n (%) Male: all male 
Hb BL (g/dl): 104 (81–120)* 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU TIW 
Dose adjustment: Y 
Duration of epo tx: 16 
weeksj 
Duration of trial: 16 weeksj
Follow-up: NAj 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria 
level: ≤12 g/dl) 
Disease: solid (prostate)
Treatment: Unclear, NR 
Hb, RBCT, 
HRQoL, AE, 
survival 
Y 
Witzig, 
2005242 
RCT 
 
NCT00003600; 
CDR000006667
3; NCCTG-
979253; NCI-
P98-0133 
n = 174 
Age, yrs: 63.6 (11.89) 
n (%) Male: 75 (45) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n = 170 
Age, yrs: 63.7 (13.0) 
n (%) Male: 71 (43) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 16 wks
Duration of trial: 16 wks 
Follow-up: 12 mths 
PBO Iron: Y, oral, daily 
G-CSF: NR 
RBCT trigger: Hb 
prn 
(Hb incl. criteria 
level: <11.5 g/dl 
[men]; <10.5 g/dl 
[women]) 
Disease: solid & haem 
Treatment: chemo, 
mixed 
HaemR, Hb, 
RBCT, HRQoL, 
AE, TR, survival 
Y 
Wright, 
200718 
RCT 
n = 33 
Age, yrs: 68 (47–86)* 
n (%) Male: 17 (52) 
Hb BL (g/dl): 103 (72–118) 
Epo mU/ml BL: NR 
n = 37 
Age, yrs: 70 (39–87)* 
n (%) Male: 20 (54) 
Hb BL (g/dl): 103 (76–120) 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 40,000 IU QW 
Dose adjustment: Y 
Duration of epo tx: 12 wks
Duration of trial: 12 wks  
Follow-up: 26 wks + 
PBO Iron: Y, not 
specified, prn 
G-CSF: NR 
RBCT trigger: Hb  
(Hb incl. criteria 
level: ) 
Disease: solid (NSCLC) 
Treatment: chemo non-
platm 
Hb, RBCT, 
HRQoL, AE, 
survival 
Y 
Key: ~, approximately; decrease only; AE, adverse event; BL, baseline; C, cycles; chemo, chemotherapy; D, days; G-CSF, granulocyte colony stimulating factor; GI, gastrointestinal; gynae, gynaecological; HaemR, haematopoietic 
response; Hb, haemoglobin; HRQoL, health-related quality of life; inc., increase; incl., includ(e/ing); mcv, mean corpuscular volume; mths., months; NR, not reported; OD, once-daily; OS, overall survival; PBO, placebo; plat, platinum-
based chemotherapy; prn, pro re nata; as needed; QoL, quality of life; QW, weekly; Q2W, every two weeks; RBCT, red blood cell transfusion; RCT, randomised controlled trial; rHuEPO, recombinant human erythropoietin; ROL, 
randomised open label; sat., saturation; SC, standard care; SCLC, small-cell lung cancer; TIW, thrice weekly; TR, tumour response; TVEs, thrombovascular events; tx, treatment; wks., weeks; yrs., years 
Notes: * indicates median (range) (a) Study includes other doses of intervention under review (either dose-response study Hedenus,2002, 2003; Kotasek, 2003; or three-arm trial Ten-Bokkel, 1998; Thatcher, 1999; for licensed dose 
details see Appendix G); (b) Baseline characteristics not reported for epoetin or no epoetin arms of study – Henry 1994; (c) BL characteristics and some efficacy outcomes reported for all participants randomised (i.e. for all doses of 
Darbepoetin alfa [Kotasek 2003]; (d) Randomised comparative phase followed by optional open-label treatment phase (12 wks); (e) Majority of participants received platinum-based chemotherapy; (f) Haematology values were protocol 
entry deviations; g Definition changed retrospectively to allow comparison with other studies (from maintenance of Hb ≥12 g/dl to 2 g/dl increase without transfusion in the previous 4 wks); (h) Intervention evaluated in a paediatric 
population; (i) A retrospective analysis was performed for survival; (j) Trial terminated early due to low accrual (contributors emergent widespread availability of epoetin alfa therapy through provincial drug plans and third-party payers, 
and the early closure of a concurrent trial of epoetin alfa in patients with NSCLC. Both trials underwent underplanned safety analysis because of increase thromboembolism reported in other trials; (k) A total of 389 patients in the 
original RCT. Patients were included in this retrospective analysis if they were randomised, received at least four weeks of study treatment & reported outcomes at BL & at least once after 4 wks of treatment (n=300). 89 patients did not 
report outcomes at baseline or at least once after 4 wks of treatment; (l) Because dose increases were allowed with epoetin alfa the ability to directly compare the dose of darbepoetin alfa with epoetin alfa is confounded, although 
descriptive comparisons were made; (m) Eligibility criteria relaxed to exclude only plat-based chemo; (n) Trial was halted early by the DSMB due to 28.5% participants developing thromboembolic events
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 Appendix G: Study & baseline characteristics licensed studies 
Study year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia  
treatment 
Malignancy type  
and treatment 
Outcomes sought Incl. in 
Cochrane 
2012, Y/N 
WILSON AND COLLEAGUES, 2007: PRIMARY STUDIES  
Abels 
199354 
RCT 
 
Multiple pubs.: 
Abels 1996, 
Henry, 1995; 
Henry, 1994; 
Case, 1993 
n = 153/213 (analysed 
143/206)a 
Age, yrs: 61.2 ± 13.0 
n (%) Male: 102 (47.8) 
Hb BL g/dl: NR 
Epo mU/ml BL: 146 ± 260 
n = 200 (analysed 135/190) 
Age, yrs: 62.5 ± 12.3 
n (%) Male: 95 (47.5) 
Hb BL g/dl: NR 
Epo mU/ml BL: 149 ± 217 
Brand: rHuEPOb 
Dose: 150 IU/kg TIW 
Dose adj.: NR 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wksc 
Follow-up: NR 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: ≤10.5 
g/dl) 
Disease: haem & 
solid  
Treatment: chemo, 
mixed 
HaemR, Hct, RBCT, 
HRQoLa, AEa 
Y 
Aravantinos 
200363 
ROL 
n = 24 
Age, yrs: 59 (18–76)* 
n (%) Male: 2 (8) 
Hb BL g/dl: 9.8 ± 0.5 
Epo mU/ml BL: NR 
n = 23 
Age, yrs: 64 (23–75)* 
n (%) Male: 7 (30%) 
Hb BL g/dl: 9.3 ± 0.8 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Y, prn 
Dur. of epo tx: Unclear, 
med. 5 C 
Dur. of trial: NR 
Follow-up: NR 
SC Iron: Y, oral, fixed  
G-CSF: NR 
RBCT trigger: Hb <9 g/dl 
(Hb incl. criteria level: <10.5 
g/dl) 
Disease: solid (incl 
ovarian) 
Treatment: chemo, 
plat 
Hb, Hct, patients' 
RBCT 
Y 
Boogaerts, 
200352 
ROL 
(Abstract – 
Coiffier, 2001 
included in 
Wilson and 
colleagues 
review) 
n = 133 
Age, yrs: 62 (24–85)* 
n (%) Male: 46 (35) 
Hb BL g/dl: 9.0 (5–13)* 
Epo mU/ml BL: 54 (7–
1,650)* 
n = 129 
Age, yrs: 62 (24–85)* 
n (%) Male: 52 (40) 
Hb BL g/dl: 9.2 (5–12)* 
Epo mU/ml BL: 58 (5–4,300)* 
Brand: Epoetin beta 
Dose: 150 IU/kg TIW 
Dose adj.: Y  
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: NR 
SC Iron: Y, oral (as indicated by 
transferrin sat. level) 
G-CSF: NR 
RBCT trigger: Hb <8.5 g/dl 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: haem & 
solid 
Treatment: chemo, 
NR 
HaemR, Hb, RBCT, 
HRQoL, AE 
Y 
Dammacco  
200164 
RCT 
 
NCT00270101; 
CR005911 
n = 69 
Age, yrs: 67 (43–80)* 
n (%) Male: 34 (49) 
Hb BL g/dl: 9.3 ± 1.27 
Epo mU/ml BL: 116 (18–
5,220)* 
n = 76 
Age, yrs: 65 (38–89)* 
n (%) Male: 31 (41) 
Hb BL g/dl: 9.6 ± 0.95 
Epo mU/ml BL: 93 (10–408)* 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Dur. of epo tx: 12 
Dur. of trial: 12 wksc 
Follow-up: 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: Hb <8 g/dl 
(Hb incl. criteria level: <11.0 
g/dl) 
Disease: haem 
Treatment: chemo, 
mixedd 
HaemR, Hb, RBCT, 
HRQoL, AE 
Y 
Del Mastro  
199765 
ROL 
n = 31 
Age, yrs: 54 (31–68)* 
n (%) Male: NR 
Hb BL g/dl: 13.0 ± 0.7 
Epo mU/ml BL: 21.0 (0–
512)* 
n = 31 
Age, yrs: 56 (29–68)* 
n (%) Male: NR 
Hb BL g/dl: 13.1 ± 0.6 
Epo mU/ml BL: 25.5 (0–800)* 
Brand:rHuEPOb 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Dur. of epo tx: 14 wks 
Dur. of trial: 14 wks 
Follow-up: 6 mths 
SC Iron: Y, oral iron (as indicated 
by serum iron, ferritin, & 
transferrin sat. levels) 
G-CSF: Y, 5 mcg/kg SC D4-
11; C1-5 
RBCT trigger: Hb <8 g/dl 
(Hb incl. criteria level: ≥12.0 
g/dl) 
Disease: solid 
(breast) 
Treatment: chemo, 
non-plat 
Hb, RBCT, HRQoL, 
AE 
Y 
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Study year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia  
treatment 
Malignancy type  
and treatment 
Outcomes sought Incl. in 
Cochrane 
2012, Y/N 
Dunphy  
199966 
ROL 
n = 15 (analysed 13) 
Age, yrs: 59 (42–76)* 
n (%) Male: 12 (92) 
Hb BL g/dl: 14.1 ± 2.1 
Epo mU/ml BL: 8.8 (5.1) 
n = 15 (analysed 14) 
Age, yrs: 67 (32–82)* 
n (%) Male: 7 (50) 
Hb BL g/dl: 14.1 ± 1.6 
Epo mU/ml BL:7.3 (4.4) 
Brand: rHuEPOb 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Dur. of epo tx: Unclear, 
~6 wks 
Dur. of trial: Unclear 
Follow-up: NR 
SC Iron: Y, oral, dailly 
G-CSF: NR 
RBCT trigger: Hb <8 g/dl 
(Hb incl. criteria level: NR) 
Disease: solid (incl 
head & neck, lung) 
Treatment: chemo, 
mixed 
Hb, RBCT Y 
Hedenus  
200249 
RCT 
 
Dose response 
study, 2 
unlicensed 
doses excluded 
n = 22e 
Age, yrs: 69 (20–84) 
n (%) Male: 14 (64) 
Hb BL g/dl: 9.4 (1.3) 
Epo IU/L BL: 69 (12–1,362)* 
n = 11 
Age, yrs: 63 (25–80) 
n (%) Male: 2 (18) 
Hb BL g/dl: 9.5 (1.0) 
Epo IU/L BL: 45 (12–132)* 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg QWe 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 16 wks 
Follow-up: Unclear 
PBO Iron: prn 
G-CSF: NR 
RBCT trigger: Hb ≤8 g/dl prn 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: haem 
Treatment: chemo, 
NR 
HaemR, Hb, RBCT, 
AE 
Y 
Hedenus  
200316 
RCT 
 
Multiple pubs.: 
Littlewood, 2006 
n = 176 (analysed 174)e 
Age, yrs: 64.8 (13.8) 
n (%) Male: 87 (50) 
Hb BL g/dl: 9.59 (1.22) 
Epo mU/ml BL: 68.99 (2.3–
1,522.7)* 
n = 173 (analysed 170) 
Age, yrs: 64.6 (12.2) 
n (%) Male:78 (46) 
Hb BL g/dl: 9.5 (1.21) 
Epo mU/ml BL: 54.49 (10.9–
3,169.1)* 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg QWe 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 16 wks 
Follow-up: median ~11 
mths 
PBO Iron: prn 
G-CSF: NR 
RBCT trigger: Hb ≤8 g/dl prn 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: haem 
Treatment: chemo, 
NR 
HaemR, RBCT, 
HRQoL, AE 
Y 
Kotasek  
200346 
RCT 
 
Dose response 
study, 5 
unlicensed 
doses excluded 
n = 17/198a,e 
Age, yrs: 58.3 (11.9)a 
n (%) Male: 56 (28)a 
Hb BL g/dl: 9.93 (1.00)a 
Epo mU/ml BL: NR 
n = 51 
Age, yrs: 56.2 (12.4) 
n (%) Male:16 (31) 
Hb BL g/dl: 9.87 (1.12) 
Epo mU/ml BL: NR 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg QWe 
Dose adj.: Y, 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wksc 
Follow-up: Unclear 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: solid 
(breast, gynae, GI, 
lung) 
Treatment: chemo, 
NR 
HaemR, Hb, RBCT, 
HRQoLa, AEa 
Y 
Kurz  
199767 
RCT 
n = 23 
Age, yrs: 54.4 ± 9.7 
n (%) Male: NR 
Hb BL g/dl: 9.88 ± 0.8 
Epo mU/ml BL: NR 
n = 12 
Age, yrs: 52.7 ± 7.5 
n (%) Male: NR 
Hb BL g/dl: 9.85 ± 0.60 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Y,  
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: NR 
PBO Iron: Y, i.v. iron 
G-CSF: NR 
RBCT trigger: Hb <8 g/dl 
(Hb incl. criteria level: <11.0 
g/dl) 
Disease: solid 
(overy, cervix, 
uterus) 
Treatment: chemo, 
mixedh 
HaemR, RBCT, 
HRQoL, AE   
Y 
Littlewood  
200168 
RCT 
 
EPO-INT-1 
 
Multiple pubs.: 
Aapro, 2004; 
Bajetta, 2004; 
n = 251 (analysed 244) 
Age, yrs: 58.3 ± 14.2 
n (%) Male: 85 (34) 
Hb BL g/dl: 9.9 ± 1.1 
Epo mU/ml BL: NR 
n = 124 (analysed 115) 
Age, yrs: 59.5 ± 13.9 
n (%) Male: 39 (31) 
Hb BL g/dl: 9.7 ± 1.1 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW
Dose adj.: Y 
Dur. of epo tx: up to 28 
wks 
Dur. of trial: up to 28 
wks 
Follow-up: 12-mthf 
PBO Iron: Y, oral (or i.v. as 
indicated by transferrin sat. 
level) 
G-CSF: No 
RBCT trigger: Hb <8 g/dl prn 
(Hb incl. criteria level: ≤10.5 
g/dL or >10.5 but ≤12.0 g/dl 
after a ≥1.5 g/dl decrease in 
Hb) 
Disease: solid + 
haem
Treatment: chemo, 
non-plat 
HaemR, Hb, RBCT, 
HRQoL, AE, survival 
(at 12-mths follow-up) 
Y 
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Study year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia  
treatment 
Malignancy type  
and treatment 
Outcomes sought Incl. in 
Cochrane 
2012, Y/N 
Patrick, 2003 
Osterborg  
2002 
2005, follow-
up69,70 
RCT 
n = 173 (analysed 170) 
Age, yrs: 63 (32–86)* 
n (%) Male: 91 (54) 
Hb BL g/dl: 9.2 ± 1.1 
Epo IU/L BL: 38 (20–72)* 
n = 176 (analysed 173) 
Age, yrs: 64 (28–83)* 
n (%) Male: 82 (47) 
Hb BL g/dl: 9.3 ± 1.0 
Epo IU/L BL: 41 (21–77)* 
Brand: Epoetin beta 
Dose: 150 IU/kg TIW  
Dose adj.: Y  
Dur. of epo tx: 16 wks 
Dur. of trial: up to 16 
wks 
Follow-up: min 17.5 
mths both tx grps 
PBO Iron: Y, i.v. (or oral if i.v. 
precluded) 
G-CSF: NR 
RBCT trigger: Hb <8.5 g/dl or 
inc.in Hb <0.5 g/dl vs BL 
(Hb incl. criteria level: <10 
g/dlg) 
Disease: haem 
Treatment: chemo, 
non-plat 
HaemR, Hb, RBCT, 
HRQoL, AE, survival; 
long-term survival 
Y 
Silvestris  
199571 
ROL 
n = 30 (analysed 27) 
Age, yrs: NR 
n (%) Male: NR 
Hb BL g/dl: NR 
Epo mU/ml BL: NR 
n = 24 (analysed 22) 
Age, yrs: NR 
n (%) Male: NR 
Hb BL g/dl: NR 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Y,  
Dur. of epo tx: to 24 wks
Dur. of trial:  to 24 wks 
Follow-up: NR 
SC Iron: Y, not specified 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: ≤8 g/dl) 
Disease: haem  
Treatment: chemo, 
NR 
HaemR, HbAE Y 
Ten Bokkel  
199847 
ROL 
 
Multiple 
treatment arms, 
1 unlicensed 
dose excluded 
n = 46 (analysed 45)e 
Age, yrs: 58.81 
n (%) Male: all female 
Hb BL g/dl: 12.0 (1.3–12.6) 
Epo mU/ml BL: NR 
n = 34 (analysed 33) 
Age, yrs: 58.83 
n (%) Male: all female 
Hb BL g/dl: 11.8 (10.6–12.5) 
Epo mU/ml BL: NR 
Brand: Epoetin beta 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Dur. of epo tx: 24 wks 
Dur. of trial: 24 wks 
Follow-up: NR 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: Hb <9.7 g/dl 
(Hb incl. criteria level:<13 g/dl) 
Disease: solid 
(ovary) 
Treatment: chemo: 
plat 
Patients' RBCT. AE Y 
Thatcher  
1999 
ROL 
 
Multiple 
treatment arms, 
1 unlicensed 
dose excluded 
n = 42 e 
Age, yrs: 59 (43–72)* 
n (%) Male: 26 (61.9) 
Hb BL g/dl: 13.7 (10.7–16.1) 
Epo mU/ml BL: NR 
n = 44 
Age, yrs: 60 (39–74)* 
n (%) Male: 27 (61.3) 
Hb BL g/dl: 13.4 (10.9–16.4) 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Dur. of epo tx: 26 wks  
Dur. of trial: 26 wks 
Follow-up: NR 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: prn 
(Hb incl. criteria level: ≥10.5 
g/dl) 
Disease: solid 
(SCLC) 
Treatment: chemo: 
mixedh 
Hb, Patients' RBCT, 
HRQoL, AE 
Y 
Vansteenkiste 
200272 
RCT 
 
Multiple pubs.: 
Vansteenkiste, 
2004 
n = 156 
Age, yrs: 61.6 (9.2) 
n (%) Male: 111 (71) 
Hb BL g/dl: 10.28 (1.08) 
Epo mU/ml BL: 53.17 
(58.87)i 
n = 158 
Age, yrs: 61.3 (8.8) 
n (%) Male: 116 (73) 
Hb BL g/dl: 9.93 (1.01) 
Epo mU/ml BL: 51.10 (71.72) i 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg QW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: 12 mths 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: Hb ≤8 g/dl  
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: solid (lung)
Treatment: chemo: 
plat 
HaemR, Hb, RBCT 
(from Wk 5 and Wk 1), 
HRQoL, AE, disease 
progression, survival 
Y 
WILSON AND COLLEAGUES, 2007: MULTIPLE PUBLICATIONS  
Abels,  
199658 
 
Double-blind 
n = 153/213 (analysed 
143/206)a 
Age, yrs: 61.2 ± 13.0 
n (%) Male: 102 (47.8) 
n = 200 (analysed 135/190) 
Age, yrs: 62.5 ± 12.3 
n (%) Male: 95 (47.5) 
Hb BL g/dl: NR 
Brand: rHuEPOb 
Dose: 150 IU/kg TIW 
Dose adj.: NR 
Dur. of epo tx: 12 wks 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: ≤10.5 
Disease: haem & 
solid  
Treatment: chemo, 
mixed 
HaemR, Hct, RBCT, 
HRQoLa, AEa 
Y 
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Study year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia  
treatment 
Malignancy type  
and treatment 
Outcomes sought Incl. in 
Cochrane 
2012, Y/N 
data + unified 
analysis  
 
Identified: 
citation checking 
 
Primary study: 
Abels 1993 
Hb BL g/dl: NR 
Epo mU/ml BL: 146 ± 260 
Epo mU/ml BL: 149 ± 217 Dur. of trial: 12 wksc 
Follow-up: NR 
g/dl) 
Case  
199355 
RCT 
 
Primary study: 
Abels 1993 
n = 81 (analysed 79) 
Age, yrs: 64 (27–92)* 
n (%) Male: 33 (40.7) 
Hb BL (g/dl): NR 
Epo mU/ml BL: 95.0 (16–
1,262)* 
n = 76 (analysed 79) 
Age, yrs: 64 (30–88)* 
n (%) Male: 29 (38.1) 
Hb BL (g/dl): NR 
Epo mU/ml BL: 93.5 (16–
1,734)* 
Brand: epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Yes, prn 
Dur. of epo tx: NR 
Dur. of trial: NR 
Follow-up: NR 
SC Iron: Y, oral iron fixed 
G-CSF: no 
RBCT trigger: Hb <9 g/dl 
(Hb incl. criteria level: <10.5 
g/dl) 
Disease: solid (incl 
ovarian) 
Treatment: chemo, 
plat 
Hb, Hct, patients' 
RBCT 
Y 
Henry, 
199557 
ROL 
 
Primary study: 
Abels 1993 
n=69 (analysed 64) 
Age, yrs: 58  
n (%) Male: 30 (45) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
n=61 (analysed 65) 
Age, yrs: 59 
n (%) Male: 32 (49) 
Hb BL (g/dl): NR 
Epo mU/ml BL: NR 
Brand: epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Yes, prn 
Dur. of epo tx: 12 wks or 
until haematocrit =38%− 
40% 
Dur. of trial: 12 weeks 
Follow-up: NR 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: NR) 
Disease: haem & 
solid  
Treatment: chemo, 
plat 
Hct, RBCT, AE Y 
Henry, 
199456 
ROL 
 
Double-blind &  
open-label 
extension data  
 
Identified: 
citation checking 
 
Primary study: 
Abels 1993 
n = 67 (analysed 64) 
Age, yrs: NRb 
n (%) Male: NRb 
Hb BL (g/dl): NRb 
Epo mU/ml BL: NRb 
n = 65 (analysed 61) 
Age, yrs: NRb 
n (%) Male: NRb 
Hb BL (g/dl): NRb 
Epo mU/ml BL: NRb 
Brand: epoetin alfa 
Dose: 450 IU/kg QW 
Dose adjustment: NR 
Duration of epo tx: 12 
wks 
Duration of trial: NR 
Follow-up: 
SC Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: NR) 
Disease: solid & 
haem 
Treatment: chemo, 
plat 
HaemR, RBCT, 
HRQoL, AE 
Y 
PENTAG REVIEW: STUDY CHARACTERISTICS: PRIMARY STUDIES 2004 to CURRENT  
Grote 
200573 
ROL 
 
N93-004 
n = 109 
Age, yrs: 64.4 (8.7) 
n (%) Male: 59 (54.1) 
Hb BL g/dl: 12.8 (1.5) 
Epo mU/ml BL: NR 
n = 115 
Age, yrs: 63.2 (8.9) 
n (%) Male: 64 (55.7) 
Hb BL g/dl: 13 (1.5) 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Dur. of epo tx: Unclear 
Dur. of trial: Unclear 
Follow-up: 3 yrs 
PBO Iron: NR 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: <14.5 
g/dl) 
Disease: solid 
(SCLC) 
Treatment: chemo: 
plat 
Hb, RBCT, AE, TR, 
survival 
Y 
Moebus  
201362 
n = 324 
Age, yrs: 50 (29–65)* 
n = 319 
Age, yrs: 52 (28–67) 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW 
SC Iron: Y, oral  
G-CSF: NR 
Disease: solid 
(breast) 
Hb, RBCT, HRQoL, 
AE, survival 
N 
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Study year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia  
treatment 
Malignancy type  
and treatment 
Outcomes sought Incl. in 
Cochrane 
2012, Y/N 
ROL 
 
AGO ETC trial 
n (%) Male: all female 
Hb BL g/dl: 12.4 (9–16)* 
Epo mU/ml BL: NR 
n (%) Male: all female 
Hb BL g/dl: 12.8 (9–16) 
Epo mU/ml BL: NR 
Dose adj.: Y 
Dur. of epo tx: 18 wks* 
Dur. of trial: 18 wks* 
Follow-up: 10 yr 
(ongoing) 
RBCT trigger: Hb <9 g/dl & 
investigator discretion 
(Hb incl. criteria level: NR) 
Treatment: chemo: 
non-plat 
However, 
Moebus 
2004, 
2007 
included 
Ray-Coquard  
200974 
ROL 
 
ELYPSE study 
n = 110 
Age, yrs: 62.7 (11.6) 
n (%) Male: 52 (47.3) 
Hb BL g/dl: 10 (1.2) 
Epo mU/ml BL: NR 
n = 108 
Age, yrs: 61.7 (11.6) 
n (%) Male: 41 (38) 
Hb BL g/dl: 10 (1.2) 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: 12 mths 
(95% CI 12–12.4)* 
SC Iron: Y, oral  
G-CSF: Y 
RBCT trigger: NR 
(Hb incl. criteria level: ≤12.0 
g/dl) 
Disease: solid & 
haem 
Treatment: chemo: 
NR 
RBCT, OS, HRQoL, 
AE 
Y 
Strauss 
200875 
RCT 
 
NCT00046969; 
Roche 
MO16375; 
Strauss 2005 
n = 34 
Age, yrs: 48.8 ± 10.2 
n (%) Male: all female 
Hb BL g/dl: 11.4 (10.8–
12.0)* 
Epo mU/ml BL: NR 
n = 40 
Age, yrs: 49.2 ± 12.8) 
n (%) Male: all female 
Hb BL g/dl: 11.6 (10.9–12.4)* 
Epo mU/ml BL: NR 
Brand: Epoetin beta 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: 6 mths 
PBO Iron: Y, oral or i.v. 
G-CSF: NR 
RBCT trigger: ≤8.5 g/dl prn 
(Hb incl. criteria level: 9–13 
g/dl) 
Disease: solid 
(cervix) 
Treatment: chemo + 
radio 
Hb, RBCT TR, 
survival, AE 
Y 
Tjulandin 
201045 
RCT 
 
ISRCTN095303
09 
EPOETIN THETA 
n = 76 
Age, yrs: 53.7 ± 10.3 
n (%) Male: 30 (39.5) 
Hb BL g/dl: 9.6 ± 1.1 
Epo mU/ml BL: NR 
EPOETIN BETA 
n = 73 
Age, yrs: 57.3 ± 10.5 
n (%) Male: 22 (30.1) 
Hb BL g/dl: 9.5 ± 0.8 
Epo mU/ml BL: NR 
n = 74 
Age, yrs: 57.3 ± 11.5 
n (%) Male: 19 (25.7) 
Hb BL g/dl: 9.4 ± 1.2 
Epo mU/ml BL: NR 
Brand: Epoetin beta 
Dose: 150 IU/kg TIW 
Dose adj.: Y 
Brand: Epoetin theta 
Dose: 20,000 IU/QW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: NR 
PBO Iron: Y, not specified 
G-CSF: NR 
RBCT trigger: ≤8.5 g/dL prn 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: solid  
Treatment: chemo: 
plat 
HaemR, Hb, patients' 
RBCT, units RBCT, 
HRQoL, AE 
Y 
Tjulandin  
201176 
RCT 
n = 95 
Age, yrs: 56.9 ± 14.7 
n (%) Male: 30 (31.6) 
Hb BL g/dl: 9.2 ± 1.3 
Epo mU/ml BL: NR 
n = 91 
Age, yrs: 55.8 ± 14.3 
n (%) Male: 34 (37.4) 
Hb BL g/dl: 9.1 ± 1.3 
Epo mU/ml BL: NR 
Brand: Epoetin theta 
Dose: 20,000 IU QW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: NR 
PBO Iron: Y, not specified 
G-CSF: NR 
RBCT trigger: ≤8.5 g/dL 
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: solid & 
haem 
Treatment: chemo: 
non-plat 
HaemR, Hb, patients' 
RBCT, units RBCT, 
HRQoL, AE 
Y 
Untch 
2011a, b77,78 
RCT 
n = 356 
Age, yrs: 48 (23–65)*a 
n (%) Male: NR 
Hb BL g/dl: 13.64 ± 1.17 
Epo mU/ml BL: NR 
n = 377 
Age, yrs: 48 (23–65)*a 
n (%) Male: NR 
Hb BL g/dl: 13.61 ± 1.16 
Epo mU/ml BL: NR 
Brand: Darbepoetin alfa 
Dose: 4.5 mg/kg Q2Wk 
Dose adj.: Y 
Dur. of epo tx: NR 
Dur. of trial: NR 
Follow-up:median 43.5 
mths 
SC Iron: Y, oral 
G-CSF: NR 
RBCT trigger: NR 
(Hb incl. criteria level: NR 
Disease: solid 
(breast) 
Treatment: chemo: 
non-plat 
Hb, pathological 
response, disease 
progression, survival, 
AE 
Y 
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Study year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia  
treatment 
Malignancy type  
and treatment 
Outcomes sought Incl. in 
Cochrane 
2012, Y/N 
MULTIPLE PUBLICATIONS: PENTAG REVIEW  
Aapro  
200480 
 
Primary study: 
Littlewood, 2001 
n = 251 (analysed 244) 
Age, yrs: 58.3 ± 14.2 
n (%) Male: 85 (34) 
Hb BL g/dl: 9.9 ± 1.1 
Epo mU/ml BL: NR 
n = 124 (analysed 115) 
Age, yrs: 59.5 ± 13.9 
n (%) Male: 39 (31) 
Hb BL g/dl: 9.7 ± 1.1 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW
Dose adj.: Y 
Dur. of epo tx: up to 28 
wks 
Dur. of trial: up to 28 
wks 
Follow-up: 12-mthf 
PBO Iron: Y, oral or i.v.  
G-CSF: No 
RBCT trigger: Hb <8 g/dl prn 
(Hb incl. criteria level: ≤10.5 
g/dL or >10.5 but ≤12.0 g/dl 
after a ≥1.5 g/dl decrease in 
Hb) 
Disease: solid + 
haem
Treatment: chemo, 
non-plat 
HaemR, Hb, RBCT, 
HRQoL, AE, survival 
(at 12-mths follow-up)  
N 
Bajetta 
200479 
 
Primary study: 
Littlewood, 2001 
SUBGROUP: BREAST POP 
n = 78 (analysed 75) 
Age, yrs: 54.6 
n (%) Male: 1 (1) 
Hb BL g/dl: 10.0 ± 1.6 
Epo mU/ml BL: NR 
SUBGROUP: BREAST POP 
n = 36 (analysed 35) 
Age, yrs: 52.9 
n (%) Male: all female 
Hb BL g/dl: 9.9 ± 1.01 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW
Dose adj.: Y 
Dur. of epo tx: up to 28 
wks 
Dur. of trial: up to 28 
wks 
Follow-up: 12-mthf 
PBO Iron: Y, oral (or i.v. as 
indicated by transferrin sat. 
level) 
G-CSF: No 
RBCT trigger: Hb <8 g/dl prn 
(Hb incl. criteria level: ≤10.5 
g/dL or >10.5 but ≤12.0 g/dl 
after a ≥1.5 g/dl decrease in 
Hb) 
Disease: solid + 
haem
Treatment: chemo, 
non-plat 
HaemR, Hb, RBCT, 
HRQoL, AE 
(retrospective analysis 
of breast cancer 
cohort; trial 
[Littlewood, 2001]) 
N 
Littlewood  
200682 
 
Primary study: 
Hedenus, 2003 
SUBGROUP: HRQoL SAMPLE 
n = 303l 
Age, yrs: 64.8 (12.8) 
n (%) Male: 146 (48.2) 
Hb BL g/dl: 9.6 (1.2) 
Epo mU/ml BL: NR 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg QW 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: median ~11 
mths 
PBO Iron: prn 
G-CSF: NR 
RBCT trigger: Hb ≤8 g/dl  
(Hb incl. criteria level: ≤11.0 
g/dl) 
Disease: haem 
Treatment: chemo, 
NR 
HRQoL (alleviating 
fatigue & effect of 
fatigue on QoL) 
N 
Osterborg  
2005, follow-up 
of Osterborg 
200270 
RCT 
 
Primary study: 
Osterborg, 2002 
n = 173 (analysed 170) 
Age, yrs: 63 (32–86)* 
n (%) Male: 91 (54) 
Hb BL g/dl: 9.2 ± 1.1 
Epo IU/L BL: 38 (20–72)* 
n = 176 (analysed 173) 
Age, yrs: 64 (28–83)* 
n (%) Male: 82 (47) 
Hb BL g/dl: 9.3 ± 1.0 
Epo IU/L BL: 41 (21–77)* 
Brand: Epoetin beta 
Dose: 150 IU/kg TIW 
Dose adj.: Y  
Dur. of epo tx: 16 wks 
Dur. of trial: up to 16 
wks 
Follow-up: min 17.5 
mths both tx grps 
PBO Iron: Y, oral iron, or i.v. iron if 
transferrin saturation ≤20% 
G-CSF: No 
RBCT trigger: Hb <8.5 g/dl or 
inc.in Hb <0.5 g/dl vs BL 
(Hb incl. criteria level: <10 
g/dlg) 
Disease: haem 
Treatment: chemo, 
non-plat 
long-term survival  Y 
Patrick 
200360 
 
Primary study: 
Littlewood, 2001 
n = 251 (analysed 244) 
Age, yrs: 58.3 ± 14.2 
n (%) Male: 85 (34) 
Hb BL g/dl: 9.9 ± 1.1 
Epo mU/ml BL: NR 
n = 124 (analysed 115) 
Age, yrs: 59.5 ± 13.9 
n (%) Male: 39 (31) 
Hb BL g/dl: 9.7 ± 1.1 
Epo mU/ml BL: NR 
Brand: Epoetin alfa 
Dose: 150 IU/kg TIW
Dose adj.: Y 
Dur. of epo tx: up to 28 
wks 
Dur. of trial: up to 28 
wks 
Follow-up: 12-mthf 
PBO Iron: Y, oral (or i.v. as 
indicated by transferrin sat. 
level) 
G-CSF: No 
RBCT trigger: Hb <8 g/dl prn 
(Hb incl. criteria level: ≤10.5 
g/dL or >10.5 but ≤12.0 g/dl 
after a ≥1.5 g/dl decrease in 
Hb) 
Disease: solid + 
haem
Treatment: chemo, 
non-plat 
HRQoL (minimally 
important difference in 
HRQoL) 
N 
Vansteenkiste 
200481 
SUBGROUP <10 g/dl 
n = 51 
SUBGROUP <10 g/dl 
n = 69 
Brand: Darbepoetin alfa 
Dose: 2.25 µg/kg QW 
PBO Iron: No 
G-CSF: No 
Disease: solid (lung)
Treatment: chemo: 
HaemR, Hb, RBCT 
(from Wk 5 and Wk 1), 
Y 
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Study year Intervention group 
characteristics 
Control group  
characteristics 
Study intervention Control Adjuvant anaemia  
treatment 
Malignancy type  
and treatment 
Outcomes sought Incl. in 
Cochrane 
2012, Y/N 
 
Primary study: 
Vansteenkiste, 
2002 
Age, yrs: 63 (47–76) 
n (%) Male: 42 (82) 
Hb BL g/dl: 9.2 (7.4–9.9) 
Epo mU/ml BL: 50.3 (13.3–
739.8) 
SUBGROUP ≥10 g/dl 
n = 105 
Age, yrs: 62 (39–80) 
n (%) Male: 69 (66) 
Hb BL g/dl: 10.8 (10.0–13.6) 
Epo mU/ml BL: 28.8 (12.0–
106.1) 
Age, yrs: 60 (42–78) 
n (%) Male: 52 (75) 
Hb BL g/dl: 9.2 (6.6–9.9) 
Epo mU/ml BL: 52.2 (14.3–
1,998.6) 
SUBGROUP ≥10 g/dl 
n = 89 
Age, yrs: 62 (36–76) 
n (%) Male: 64 (72) 
Hb BL g/dl: 10.6 (10.0–12.3) 
Epo mU/ml BL: 30.2 (12.0–
109.8) 
Dose adj.: Y 
Dur. of epo tx: 12 wks 
Dur. of trial: 12 wks 
Follow-up: 12 mths 
RBCT trigger: Hb ≤8 g/dl & prn
(Hb incl. criteria level: ≤11.0 
g/dl) 
plat HRQoL, AE, disease 
progression, survival 
Key: ~, approximately; , decrease only; AE, adverse event; BL, baseline; C, cycles; chemo, chemotherapy; D, days; G-CSF, granulocyte colony stimulating factor; GI, gastrointestinal; grps., groups; gynae, gynaecological; HaemR, 
haematopoietic response; Hb, haemoglobin; HRQoL, health-related quality of life; inc., increase; incl., includ(e/ing); med., median; min., minimum; mths., months; NR, not reported; OS, overall survival; PBO, placebo; plat, platinum-based 
chemotherapy; prn, pro re nata (as needed); QoL, quality of life; QW, weekly; Q2W, every 2 weeks; RBCT, red blood cell transfusion; rHuEPO, recombinant human erythropoietin; SC, standard care; SCLC, small-cell lung cancer; TIW, 
thrice weekly; TR, tumour response; TVEs, thrombovascular events; tx, treatment; wks., weeks; yrs., years 
Notes: * indicates median (range) a BL characteristics /and some efficacy outcomes reported for all participants randomised (i.e. includes participants not receiving chemotherapy [Abels, 1993]); for all doses of Darbepoetin alfa [Kotasek 
2003]); for intervention and control combined at randomisation [Untch 2011a,b]); b Assumed to be either Epoetin alfa or Epoetin beta based on date of trial and dose administered in the trial; c Double-blind phase only; participants given 
the option to enter 12-week open-label treatment period; d Majority of participants received non-platinum chemotherapy; e Study includes other doses of intervention under review (either dose-response study Hedenus,2002, 2003; 
Kotasek, 2003; or three-arm trial Ten-Bokkel, 1998; Thatcher, 1999); f Survival based on data collected during 12-mth after study completed by last participant; Reported based on proportion of patients randomised (only available for a 
proportion of patients randomised; 151 and 145 intervention and control groups respectively); g Inclusion criteria for Hb further stratified by serum epo level; h Majority of participants received platinum-based chemotherapy; i Serum 
endogenous epo (mU/mL not available for all participants randomised; n= 145 and n= 151 in intervention and control group respectively; j Study conducted in paediatric population; k Dose administered in study equates to 2.25 
µg/kg/QW; l Patients evaluated for HRQoL from trial sample (Hedenus 2003), not separated by intervention and control for HRQoL sample 
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 Appendix H: Multiple publications in 
clinical-effectiveness review 
Primary study 
Hedenus, M., Adriansson, M., San Miguel, 
J. et al (2003). "Efficacy and safety of 
darbepoetin alfa in anaemic patients with 
lymphoproliferative malignancies: a 
randomized, double-blind, placebo-
controlled study." Br J Haematol 122(3): 
394-403. 
Multiple publications 
Littlewood, T. J. K., Joel D.; San Miguel, J. 
et al (2006). "Efficacy of darbepoetin alfa 
in alleviating fatigue and the effect of 
fatigue on quality of life in anemic patients 
with lymphoproliferative malignancies." 
Journal of Pain & Symptom Management 
31: 317-325. 
Primary study 
Osterborg, A., Brandberg, Y., Molostova, 
V. et al (2002). "Randomized, double-
blind, placebo-controlled trial of 
recombinant human erythropoietin, 
epoetin Beta, in hematologic 
malignancies." J Clin Oncol 20: 2486-
2494. 
Multiple publications 
Osterborg, A. B., Hedenus, Michael 
(2005). "Impact of epoetin-beta on survival 
of patients with lymphoproliferative 
malignancies: long-term follow up of a 
large randomized study." British Journal of 
Haematology 129: 206-209. 
Primary study 
Vansteenkiste, J., Pirker, R., Massuti, B. 
et al (2002). "Double-blind, placebo-
controlled, randomized phase III trial of 
darbepoetin alfa in lung cancer patients  
receiving chemotherapy." J Natl Cancer 
Inst 94: 1211-1220. 
Multiple publications 
Vansteenkiste, J. T., Rossi, G.; Pirker, R. 
(2004). "Darbepoetin alfa in lung cancer 
patients on chemotherapy: a retrospective 
comparison of outcomes in patients with 
mild versus moderate-to-severe anaemia 
at baseline." Supportive Care in Cancer 
12: 253-262.. 
Primary study 
Littlewood, T. J., Bajetta, E. Nortier, J.W. 
et al (2001). "Effects of epoetin alfa on 
hematologic parameters and quality of life 
in cancer patients receiving nonplatinum 
chemotherapy: results of a randomized, 
double-blind, placebo-controlled trial." J 
Clin Oncol 19: 2865-2874. 
Multiple publications 
Bajetta, E. V., E.; Reinhardt, IU.; 
Janmohamed, R.; Costa, R. M.; Matulonis, 
IU. (2004) "Efficacy of epoetin alfa in a 
retrospective non-stratified subgroup 
analysis of a breast cancer cohort 
receiving non-platinum chemotherapy." 
Tumori, 449-457. 
Aapro, M. B., E., Freund, M., Littlewood, 
T. J. et al (2004). "Is there a possible 
survival benefit to increasing hemoglobin 
levels with epoetin alfa during 
chemotherapy?" European Journal of 
Cancer, Supplement 2: 20-28. 
Patrick, D. L., Gagnon, D. D., Zagari, M. J. 
et al (2003). "Assessing the clinical 
significance of health-related quality of life 
(HrQOL) improvements in anaemic cancer 
patients receiving epoetin alfa." Eur J 
Cancer 39(3): 335-345. 
Primary study 
Abels, R. (1993). "Erythropoietin for 
anaemia in cancer patients." Eur J Cancer 
29A Suppl 2: S2-8. 
Multiple publications 
Case, D. C., Jr., Bukowski, R. M., Carey, 
R.W. et al. (1993). "Recombinant human 
erythropoietin therapy for anemic cancer 
patients on combination chemotherapy." J 
Natl Cancer Inst 85: 801-806. 
Henry, D. H. and R. I. Abels (1994). 
"Recombinant human erythropoietin in the 
treatment of cancer and chemotherapy-
induced anemia: results of double-blind 
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and open-label follow-up studies." Semin 
Oncol 21: 21-28. 
Henry, D. H., Brooks, B. J. Jr., Case, D. C. 
Jr. et al (1995). "Recombinant human 
erythropoietin therapy for anemic cancer 
patients receiving cisplatin 
chemotherapy." Cancer J Sci Am 1(4): 
252-260. 
Abels, R. I., Larholt, K. M., Krantz, K.D. et 
al (1996). "Recombinant Human 
Erythropoietin (rHuEPO) for the Treatment 
of the Anemia of Cancer." Oncologist 1(3): 
140-150. 
 
Primary study 
Untch, M., P., Fasching, A., Konecny, 
G.E. et al (2011). "PREPARE trial: A 
randomized phase III trial comparing 
preoperative, dose-dense, dose-
intensified chemotherapy with epirubicin, 
paclitaxel and CMF versus a standard-
dosed epirubicin/cyclophosphamide 
followed by paclitaxel +/- darbepoetin alfa 
in primary breast cancer-results at the 
time of surgery." Annals of Oncology 22: 
1988-1998. 
Multiple publications 
Untch, M., P., Fasching, A., Konecny, 
G.E. et al (2011). "PREPARE trial: a 
randomized phase III trial comparing 
preoperative, dose-dense, dose-
intensified chemotherapy with epirubicin, 
paclitaxel, and CMF versus a standard-
dosed epirubicin-cyclophosphamide 
followed by paclitaxel with or without 
darbepoetin alfa in primary breast cancer--
outcome on prognosis." Annals of 
Oncology, 1999-2006 
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 Appendix I: Systematic reviews 
Table 104. Systematic reviews: study characteristics 
Author    
Year  
Title 
(No. of included studies) 
Participants Intervention Comparator Outcomes Design Results Comment 
Lawrence, 
2004106 
Evidence Report on the 
Occurrence, Assessment, 
and Treatment of Fatigue in 
Cancer Patients 
 
(27 studies included) 
All cancer 
patients (or 
cancer 
survivors) with, 
or assessed for, 
fatigue 
Various. 1 
study incl on 
epo alfa 
Various. PBO 
used in 
single epo 
alfa study 
Fatigue as 
determined by 
HaemR and QoL 
measures 
Variety. 
Only 
RCTs 
included 
for 
treatment 
of CRF 
For the epo alfa vs PBO study, there was a 
strong statistically significant correlation 
between Hb levels and QoL. The mean 
increase in Hb level from baseline to last value 
was significantly greater in the epo alfa group 
than the PBO group (2.2 g/dL vs 0.5 g/dL, P< 
0.001). Significant differences observed for 
epo for all 5 cancer and anaemia-specific 
primary QoL measures (P≤ 0.0048) 
Only 1 relevant study 
involving epo was included in 
this SR 
Bokemeyer, 
2007a,107 
EORTC guidelines for the 
use of erythropoietic 
proteins in anaemic patients 
with cancer: 2006 update  
 
(43 studies included in 
updated search plus 
additional 78 relevant 
abstracts) 
All anaemic 
adults  with 
cancer or 
lymphoproliferati
ve malignancies 
ESAs Various (few 
individual 
study details 
given) 
HaemR, 
transfusion 
requirement, QoL, 
OS, QoL 
Variety.19 
studies 
were level 
1 
standard 
(meta-
analysis 
of good 
quality 
controlled 
studies or 
RCTs) 
Level 1 evidence exists for a positive impact of 
erythropoietin proteins on Hb levels when 
administered to patients with chemotherapy-
induced anaemia or anaemia of chronic 
disease, when used to prevent cancer 
anaemia, and in patients undergoing cancer 
surgery. 
  
Ross,  
2007108 
Efficacy and Safety of 
Erythropoiesis-Stimulating 
Proteins in MDS: A 
Systematic Review and 
Meta-Analysis  
 
(59 studies included) 
Anaemic adults 
with MDS 
ESAs SC, PBO HaemR, QoL Uncontroll
ed case 
studies 
and 
controlled 
trials 
including 
RCTs (4 
RCTs 
included 
for epo vs 
control) 
Significant increase in HaemR (OR, 5.2; CI 
2.5-10.8) found for patients receiving epo  
compared to control. Patients receiving 
erythropoiesis-stimulating proteins attained a 
pre-post change (measured using FACT-F) 
that exceeded minimum clinically important 
differences. 
Only 4 relevant studies ( 
RCTs of epo vs control) were 
included in this SR 
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Author    
Year  
Title 
(No. of included studies) 
Participants Intervention Comparator Outcomes Design Results Comment 
Wilson, 
2007b1 
A systematic review and 
economic evaluation of epo 
alfa, epo beta and darbepo 
alfa in anaemia associated 
with cancer, especially that 
attributable to cancer 
treatment 
 
(46 studies included) 
Anaemic adults 
with cancer  
ESAs plus 
supportive 
care for 
anaemia (incl. 
RBCT) 
SC for 
anaemia 
(incl. RBCT) 
alone 
HaemR, RBCT, 
Hb change, 
HRQoL, tumour 
response, OS, 
AEs 
RCTs Epo improves HaemR (defined as an 
improvement by 2 g dl-1)(RR of 3.4 CI 3-3.8; 
response rate for epo of 53%). Hb change 
showed a weighted mean difference of 1.63 g 
dl -1 (CI 1.46-1.8) in favour of epo. The 
number of CIA patients receiving RBCT 
reduced by an estimated 18%. A positive 
effect was was observed in favour of an 
improved HRQoL for patients receiving epo 
The incidence of side-effects 
and effects on survival 
remains highly uncertain. 
Authors suggest that if there 
is no impact on survival, it 
seems highly unlikely that epo 
would be considered a cost-
effective use of healthcare 
resources 
Shehata, 
2008109 
The use of erythropoiesis-
stimulating agents in 
patients with non-myeloid 
hematological malignancies: 
a systematic review 
 
(22 studies included [17 
published reports and 5 
abstracts]) 
Adults with non-
myeloid 
hematological 
malignancies 
ESAs PBO RBCT, HRQoL, 
OS 
RCT's Statistically significant decrease in transfusion 
requirements. No evidence that the use of 
ESAs improved survival. Impact on QoL was 
difficult to assess due to limitations in available 
studies. 
Authors stare that more data 
is required to confirm 
improvements in QoL and 
inferior survival associated 
with ESA use. 
Kvam,  
2009110 
Health-related quality of life 
assessment in randomised 
controlled trials in multiple 
myeloma: a critical review of 
methodology and impact on 
treatment recommendations 
 
(15 studies included ) 
Adults with MM 
receiving 
chemotherapy 
(total n=2,200; 
Epo n= 1,207) 
Epo alfa, beta; 
Darb alfa 
PBO (in 
relevant 
studies) 
RBCT, Hb 
change, 
transfusion-free 
survival, HRQOL 
outcomes and 
HRQOL influence 
on clinical 
decision making 
(author's 
statement) 
RCTs Statistically significant decrease in RBCT and 
rise in Hb levels in patients receiving ESAs. 
Improvement in HRQOL for  Epo beta (1 
study); improvement in HRQOL for Darb alfa 
(1 study); improvement of cancer and 
anaemic-specific HRQOL domains for epo alfa 
(1 study) 
Only 4 relevant studies were 
included in this SR. Epo alfa 
was recommended based on 
better clinical outcomes and 
improvement in HRQOL (2 
studies). Epo beta was 
recommended based on 
improved HRQOL and better 
clinical outcomes (1 study). 
Darb alfa was recommended 
based on better clinical 
outcomes and less fatigue  (1 
study). However, average 
HRQOL benefit of ESA's in 
these trals appears to be of 
limited subjective importance, 
despite HRQOL data being 
used widely for marketing  of 
ESA's. 
Tonelli, 
2009112 
Benefits and harms of 
erythropoiesis-stimulating 
Anaemic adults 
with cancer 
Epo alfa, beta; 
Darb alfa 
No treatment; 
PBO 
Mortality, CV 
events, HTN, 
RCTs Pooled all-cause mortality during treatment 
was significantly higher in the group receiving 
Use of ESA's resulted in 
increased risk of 
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Author    
Year  
Title 
(No. of included studies) 
Participants Intervention Comparator Outcomes Design Results Comment 
agents for anemia related to 
cancer: a meta-analysis 
 
(52 trials included) 
HRQoL, RBCT, 
tumour response  
erythropoiesis-stimulating therapy compared to 
control (RR 1.15. 95% CI 1.03-1.29). 
Compared with no treatment, use of ESAs led 
to clinically detectable improvements in 
disease-specific measures of quality of life. It 
also reduced the use of blood transfusions 
(RR 0.64, 95% CI 0.56-0.73) 
thromboembolic events (RR 
1.69, 95% CI 1.27 to 2.24) 
and serious AEs (RR 1.16, 
95% CI 1.08 to 1.25) 
Bohlius 
2010 
(results also 
reported in 
Bohlius 
2009)c 
Recombinant human 
erythropoiesis-stimulating 
agents and mortality in 
patients with cancer: a meta-
analysis of randomised trials 
 
(53 studies included) 
Paediatric and 
adult cancer 
patients 
Epo alfa, epo 
beta, or darb 
alfa plus 
RBCT(as 
necessary) 
RBCT alone 
(as 
necessary) 
Mortality during 
the active study 
period, overall 
survival 
RCTs 1,530 patients died during the active study 
period and 4,993 overall (out of a total of 
13,933 cancer patients).ESAs increased 
mortality during the active study period (cHR 
1.17, 95% CI 1.06, 1.30) and worsened OS 
(1.06, 1, 1.12), with little heterogeneity 
between trials. The cHR for mortality during 
the active period for patients on chemotherapy 
was 1.10 (0.98-1.24), and 1.04 (0.97, 1.11) for 
OS. There was little evidence for a difference 
betwen trials of patients given different 
anticancer treatments. 
Authors conclude that 
treatment with ESAs in 
patients with cancer increased 
mortality during active study 
periods and worsened OS. 
They recommend that the 
increased risk of death 
associated with treatment with 
these drugs should be 
balanced against their 
benefits. 
Minton, 
2010d113 
Drug therapy for the 
management of cancer-
related fatigue (CRF)  
 
(50 studies included ) 
Adult cancer  
patients with 
CRF 
Drug therapy 
for CRF 
(haemopoietic 
growth factors 
e.g. ESAs) 
PBO, usual 
care or a 
non-
pharmacologi
cal 
intervention 
for CRF  
Hb concentration 
and subsequent 
change in fatigue 
scores 
RCTs  
(11 
relevant 
studies 
for epo; 4 
relevant 
studies 
for darb 
alfa 
A meta-analysis of studies for ESAs showed 
an effect of ESAs over standard care or PBO 
for the treatment of CRF. A meta-analysis of 
studies for darbopoetin studies showed a sma 
ll but statistically significant difference between 
darbopoetin and PBO for the treatment of CRF 
Authors note increased safety 
concerns raised regarding 
ESAs and recommend that it 
is not used in practice. There 
was a very high degree of 
statistical and clinical 
heterogeneity in the trials. 
Grant, 
201359 
Epoetin and darbepoetin for 
managing anemia in patients 
undergoing cancer 
treatment: comparative 
effectiveness update  
 
(54 studies included) 
Anaemic adults 
undergoing 
chemotherapy 
and/or radiation 
for malignancy 
ESAs Control 
(various) 
OS (on-study and 
longest available 
follow-up), PFS, 
QoL, HaemR, 
RBCT, tumour 
response, 
thromboembolic 
complications, 
AEs 
RCTs, 
Obs 
In 38 trials, ESA's decreased the risk of 
transfusion (pooled RR 0.58, CI 0.53, 0.64). In 
37 trials, thromboembolic event rates were 
higher in ESA-treated patients (pooled RR 
1.51; CI 1.3, 1.74). In 14 trials reporting quality 
of life (FACT-fatigue subscale), scores 
decreased by -0.6 in control arms (CI -6.4, 5.2) 
and increased by 2.1 in ESA arms (CI -3.9, 
8.1). In 37 trials, mortality was increased 
during the on-study period (pooled HR 1.17; 
95% CI, 1.04,  1.31).  
Authors conclude that ESAs 
reduce the need for RBCT 
and increased the risk of 
thromboembolism. FACT-F 
scores were better with ESA 
use but the magnitude was 
less than the minimal clinically 
important difference. An 
increase in mortality 
accompanied the use of 
ESAs.  
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Author    
Year  
Title 
(No. of included studies) 
Participants Intervention Comparator Outcomes Design Results Comment 
Tonia, 
2012e10 
Erythropoietin or 
darbepoetin for patients with 
cancer  
 
(91 studies included) 
Paediatric and 
adult cancer 
patients with 
anaemia 
with/without 
chemotherapy, 
radiotherapy or 
combination 
therapy 
ESAs +/- 
RBCT 
PBO, no 
treatment, 
RBCT+/- 
PBO  
HaemR, RBCT, 
changes in QoL, 
tumour response, 
on-study mortality, 
OS, AEs 
RCTs Use of ESAs significantly reduces the relative 
risk of red blood cell transfusion (RR 0.65; CI 
0.62, 0.68) Haematological respons was 
observed more often in participants receiving 
ESAs (RR 3.93; CI 3.10, 3.71). There was 
suggestive evidence that ESA's may improve 
QoL. There was strong evidence that ESAs 
increase mortality during active study period 
(HR 1.17. CI 1.06 to 1.29) and some evidence 
that ESA's decrease OS (HR 1.05; CI 1 to 
1.11) Risk of AEs for thromboembolic 
complications was increased for patients 
receiving ESA's compared to controls, while 
HTN and thrombocytopenia/haemorrhage may 
be increased in patients receiving ESAs 
compared to controls. 
Authors conclude that ESAs 
reduce the need for RBCT but 
increase the risk for 
thromboembolic events and 
deaths. Authors recommend 
that the increased risk of 
death and thromboembolic 
events should be balanced 
againstthe potential balance 
benefits of ESA treatment 
Key: AE, adverse event; chemo, chemotherapy; cHR, combined hazard ratio; CI, confidence interval; CIA, cancer induced anaemia; CRF, cancer related fatigue; CV, cardiovascular; darb, darbepoietin; epo, erythropoietin; ESAs, 
erythropoietin stimulating agents; FACT-F, Functional Assessment of Cancer Therapy – Fatigue;  HaemR, haematological response; Hb, haemoglobin; HRQoL, health-related quality of life; HTN, hypertension; incl., includ(e/ing); 
MM< multiple myeloma; NR, not reported; Obs, observational; OS, overall survival; PFS, progression-free survival; PBO, placebo; QoL, quality of life; RBCT, red blood cell transfusion; RCT, randomised controlled trial; RR, risk ratio; 
SC, standard care; TR, tumour response 
Notes: a This study is an update of the 2004 guidelines by the same author published as Bokemeyer, C.;Aapro, A.; Courdi, J.; et al (2004). "EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer." 
European journal of cancer 40: 2201-2216243; b Previous HTA report (TA142)34 (Wilson and colleagues, 2007); c The results of this Cochrane Review are also published in Bohlius, J. S., Kurt; Brillant, C., et al (2009). "Recombinant 
human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.[Erratum appears in Lancet. 2009 Jul 4-2009 Jul 10;374(9683):28]." Lancet 373: 1532-15426; d This study is an 
update of 2008 Cochrane Review: Minton, O.; Richardson, A.; Sharpe, M.; et al. (2008). "Drug therapy for the management of cancer related fatigue." Cochrane Database of Systematic Reviews: CD006704.111 Also published in 
Minton, O; Richardson, A; Sharpe, M. et al (2008). "A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue." Journal of the National Cancer Institute 100: 1155-1166244; e This study is an 
update of 2006 Cochrane Review: Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2006, Issue 3245. Also published in Bohlius J, 
Langensiepen S, Schwarzer G et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. Journal of the National Cancer Institute 2005;97(7):489–98246; Bohlius J, 
Wilson J, Seidenfeld et al.Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9,353 patients. Journal of the National Cancer Institute 2006; 98:708–14247; and, Bohlius, J. F.; 
Langensiepen, S.; Engert, A; et al. (2005). "Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review." Bailliere's Best Practice in Clinical Haematology 18: 
449-454248  
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Table 105. Systematic reviews: PRISMA quality assessment 
 Studies  
Section/ 
topic 
Item Checklist item A B C D E F G H I J K 
Title 
Title 1 Identify the report as a systematic review, meta-analysis or both N N Y Y Y N Y Y N N N 
Abstract 
Structured 
summary 
2 Provide a structured summary including, as applicable, background, objectives, data 
sources, study eligibility criteria, participants, interventions, study appraisal and synthesis 
methods, results, limitations, conclusions and  implications of key findings, systematic review 
registration number 
N N P j P p N P y P ad P al P ap P av P ba 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Y Y Y Y Y Y Y Y Y Y Y 
Objectives 4 Provide an explicit statement of questions being addressed  with reference to participants, 
interventions, comparisons, outcomes and study design  
P f N P k Y q P t P z Y ae P am P aq P aw Y 
Methods 
Protocol & 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed and if available, provide 
registration information including registration number 
N N N Y N N N N N N Y 
Eligibility 
criteria 
6 Specify study characteristics and report characteristics used as criteria for eligibility, giving 
rationale 
Y g Y Y Y Y Y Y Y Y Y Y 
Information 
sources 
7 Describe all information sources in the search and date last searched P h Y Y Y Y Y Y Y P ar Y Y 
Search 8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated 
N N Y Y Y Y Y af Y an Y as Y ax Y bb 
Study 
selection 
9 State the process for selecting studies N N N Y r Y Y Y Y Y Y Y 
Data 
collection 
process 
10 Describe method of data extraction from reports and any processes for obtaining and 
confirming data from investigators 
N N P l Y P u N P ag Y ao P at Y ay P bc 
Data items 11 List and define all variables for which data are sort and any assumptions and simplifications 
made 
Y N N Y Y N N Y P au Y Y 
Risk of bias 12 Describe methods used for assessing risk of bias of individual studies and how this N N Y Y Y P aa Y ah Y Y Y Y 
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 Studies  
Section/ 
topic 
Item Checklist item A B C D E F G H I J K 
in individual 
studies 
information is to be used in any data synthesis 
Summary 
measures 
13 State the principal summary measures N/A N/A Y N N/A Y Y Y Y Y Y 
Synthesis of 
results 
14 Describe the methods of handling data and combining results of studies, if done, including 
measure of consistency for each meta-analysis 
N/A N/A Y Y N/A N/A Y Y Y Y Y 
Risk of bias 
across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence N/A N/A N Y N/A Y N Y N Y Y 
Additional 
analyses 
16 Describe methods of additional analyses, if done, indicating which were pre-specified N N Y Y P v N Y Y N Y Y 
Results 
Study 
selection 
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally from a flow diagram 
N N N Y N P ab Y Y Y Y Y 
Study 
characteristi
cs 
18 For each study, present characteristics for which data were extracted and provide the 
citations 
Y N N Y Y Y Y ai Y Y Y Y 
Risk of bias 
within 
studies 
19 Present data on risk of bias of each study  and, if available, any outcome-level assessments Y P i N Y Y P ac Y aj Y Y Y Y 
Results of 
individual 
studies 
20 For all outcomes considered, present for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
N N P m Y N N Y Y Y Y Y 
Synthesis of 
results 
21 Present results of each meta-analysis done, including confidence intervals and measure of 
consistency 
N N P n Y N N Y Y Y Y Y 
Risk of bias 
across 
studies 
22 Present results of any assessment of risk of bias across studies N N N Y N Y N Y N Y N 
Additional 
analysis 
23 Give results of additional analyses, if done N/A N/A Y Y Y w N/A Y Y N/A Y Y 
Discussion 
Summary of 
evidence 
24 Summarise the main findings including the strength of evidence for each main outcome: 
consider their relevance for key groups 
N Y P 0 Y Y Y P ak Y Y Y P bd 
Limitations 25 Discuss limitation at study and outcome level and at review level N N N P s Y Y Y N Y P az N 
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 Studies  
Section/ 
topic 
Item Checklist item A B C D E F G H I J K 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and 
implication for future research 
Y Y Y Y Y x Y Y Y Y Y Y 
Funding 
Funding 27 Describe sources of funding for the systematic review and  other support and role of funders 
for the systematic review 
N Y Y Y Y Y Y Y Y Y Y 
Studies: A Lawrence 2004106; B, Bokemeyer, 2007 a 107 C, Ross, 2007108; D, Wilson, 2007b1; E, Shehata, 2008109; F, Kvam, 2009110; G, Tonelli, 2009112; H, Bohlius, 2010c; I, Minton, 2010d113; J, Tonia, 2012e10; K, Grant, 
201359 
Key: Y, present; N, absent; P, partially reported; ?, unclear 
Notes: a This study is an update of the 2004 guidelines by the same author published as Bokemeyer, C.;Aapro, A.; Courdi, J.; et al (2004). "EORTC guidelines for the use of erythropoietic proteins in anaemic patients 
with cancer." European journal of cancer 40: 2201-2216243; b Previous HTA report (TA142)34 (Wilson and colleagues, 2007); c The results of this Cochrane Review are also published in Bohlius, J. S., Kurt; Brillant, C., 
et al (2009). "Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.[Erratum appears in Lancet. 2009 Jul 4-2009 Jul 10;374(9683):28]." Lancet 
373: 1532-15426; d This study is an update of 2008 Cochrane Review: Minton, O.; Richardson, A.; Sharpe, M.; et al. (2008). "Drug therapy for the management of cancer related fatigue." Cochrane Database of 
Systematic Reviews: CD006704.111 Also published in Minton, O; Richardson, A; Sharpe, M. et al (2008). "A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue." Journal of 
the National Cancer Institute 100: 1155-1166244; e This study is an update of 2006 Cochrane Review: Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database of 
Systematic Reviews 2006, Issue 3245. Also published in Bohlius J, Langensiepen S, Schwarzer G et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-
analysis. Journal of the National Cancer Institute 2005;97(7):489–98246; Bohlius J, Wilson J, Seidenfeld et al.Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9,353 
patients. Journal of the National Cancer Institute 2006; 98:708–14247; and, Bohlius, J. F.; Langensiepen, S.; Engert, A; et al. (2005). "Effectiveness of erythropoietin in the treatment of patients with malignancies: 
methods and preliminary results of a Cochrane review." Bailliere's Best Practice in Clinical Haematology 18: 449-454248 f Research questions defined in methods section; full PICOS criteria not applicable g Full PICOS 
criteria not applicable h No search start date specified i Risk of bias assessed using ASCO levels of evidence and grades of recommendation j No background, databases, incl/excl criteria, pareticipants, quality 
appraisal, review implications/limitations or review registration number mentioned in abstract k Comparators, main outcome, study design not mentioned in introduction l No mention of piloting or processes for 
obtaining/confirming data m Event rates given as percentages rather than frequencies, and only odds ratios provided n I2 values not given in results section o Relevance for key groups not addressed p No details of 
quality assessment, study appraisal and synthesis in abstract, with full detaisl presented in methods section q PICOS contained in executive summary r PRISMA flow diagram in appendix s Limitations at review level 
mentioned t Population, intervention and outcome described in abstract, study design in methods section; comparator not defined in either abstract, introduction or methods u No mention of piloting or processes for 
obtaining/confirming data v Intention to treat analysis conducted w Summary of numbers needed to treat x Implications for future research not mentioned y Background detailed in introduction. Ojectives specified in 
abstract but PICOS not appropriate. Data extraction detailed in methods section. Limitations detailed in discussion section. No systematic review registration number z Patients, outcomes, and study design detailed in 
objectives (intervention and comparator not applicable) aa Methodological quality was assessed according to a checklist developed for evaluating HRQoL outcomes in clinical trials ab Minimum detail provided ac 
Summary of checklist given but no detailed breakdown of criteria ad Details online. No systematic review registration number ae PICOS covered in abstract and introduction, despite being no defined "objectives" section 
af Details in online appendix ag No mention of piloting or processes for obtaining / confirming data ah Online (Appendix 4) ai Details online aj Details online ak No assessment/ranking of evidence robustness al Data 
extraction detailed in methods section. No limitations mentioned in abstract, but stated in discussion section. No systematic review registration number am Population, intervention and outcome covered in objectives; 
comparator and study detailed in methods section an Online (Appendix A) ao No mention of piloting ap Objectives in abstract lacking in detail. Elements of PICOS detailed in methods section. Synthesis methods not 
described. Limitations not described in abstract, but described in methods. Limitations of study detailed in discussion. No systematic review  registration number aq Population, intervention and comparator covered in 
objectives. Outcome and study details in methods section ar No search start date specified as Online appendix at No mention of piloting or processes for obtaining / confirming data au Broad categories described rather 
than individual data items av Objectives lacking in detail with respect to comparators and studt design ; details described in methods section . Data synthesis not detailed in abstract  but described in methods. 
Limitations of study described in discussion. No systematic review registration number. aw Population, intervention and outcome covered in objectives. Comparator and study detailed in methods section. ax Details in 
appendix ay No mention of piloting or processes for obtaining/confirming data az Limitations at review level ba Data sources listed in methods section together with details of  study selection criteria, data extraction, 
synthesis methods, outcomes of interest. Outcomes detailed in executive summary. No systematic review registration number provided bb Appendix bc No mention of processes for obtaining/confirming data bd No 
consideration of applicability of review's findings 
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 Appendix J: Comparison of search 
results with the manufacturer submissions 
Table 106. Sandoz UK Ltd submission 
Haag-Weber, M., K. IU. Eckardt, W. H. Horl, S. D. Roger, A. 
Vetter and K. Roth (2012). "Safety, immunogenicity and 
efficacy of subcutaneous biosimilar epoetin-alpha (HX575) in 
non-dialysis patients with renal anemia: A multi-center, 
randomized, double-blind study." Clinical nephrology 77: 8-17. 
Comparator (alfa 
vs alfa); no 
control 
Weigang-Kohler, K. V., Andrea; Thyroff-Friesinger, Ursula 
(2009). "HX575, recombinant human epoetin alfa, for the 
treatment of chemotherapy-associated symptomatic anaemia 
in patients with solid tumours." Onkologie 32: 168-174. 
Comparator (alfa 
vs alfa); no 
control 
Desrame J et al. Haemoglobin outcomes with biosimilar 
epoetin alfa in the management of chemotherapy-induced 
anaemia in cancer patients: first results from the French 
OncoBOS observational study. Poster presented at the 
European Cancer Congress, Amsterdam, The Netherlands, 27 
Sept – 1 Oct 2013. 
Abstract only; 
observational 
study 
Kerkhofs L et al. Use of biosimilar epoetin to increase 
haemoglobin levels in patients with chemotherapy-induced 
anemia: real-life clinical experience. Future Oncol 2012; 8: 
751–756 
Abstract only; 
retrospective 
analysis 
Lorenz A et al. First comparison of biosimilar epoetin alfa and 
darbepoetin alfa for the treatment of chemotherapy-induced 
anaemia. Poster presented at the European Cancer Congress, 
Amsterdam, The Netherlands, 27 Sept – 1 Oct 2013 
Abstract only; 
retrospective, 
matched-cohort 
analysis 
Rodriguez Garzotto A et al. Use of erythropoiesis-stimulating 
agents and comparison of different products for the treatment 
of chemotherapy-induced anaemia. Poster presented at the 
European Cancer Congress, Amsterdam, The Netherlands, 27 
Sept – 1 Oct 2013 
Abstract only; 
study design 
single centre 
audit 
 
Table 107. Amgen Ltd submission 
Delarue R. Delarue, R. (2012). "Survival impact of prophylactic 
administration of darbepoetin alfa in patients with diffuse large 
B-cell lymphoma treated with immunochemotherapy: The 
LNH03-6B study." Educational Cancer Convention Lugano of 
the European School of Oncology, ECCLU 2012 Lugano 
Switzerland 82: S12-S13 
Abstract only; 
included in 
ongoing studies 
table 
Hartmann, J. T. M., B.; Binder, C.; Mergenthaler, H. G.; Rick, 
O.; Sayer, H. G.; Mayer, F.; Beyer, J.; Lorch, A.; Berdel, W. E.; 
Abstract only; 
included in 
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Frickhofen, N.; Bokemeyer, C.; Schleicher, J.; Gauler, T. C. 
(2012). "Addition of darbepoetin alfa to sequential high-dose 
VIP chemotherapy for patients with advanced metastatic germ 
cell cancer." 2012 Annual Meeting of the American Society of 
Clinical Oncology, ASCO Chicago, IL United States 30 (15 
SUPPL. 1.) 
ongoing studies 
table 
Katsumata, N., Y. Fujiwara, N. Katakami, Y. Nishiwaki, M. 
Tsuboi, K. Takeda, T. Nakanishi, Y. Ichinose, Y. Kawahara, T. 
Hotta and N. Saijo (2009). "Randomized, double blind, 
placebo-controlled phase III study of weekly administration of 
darbepoetin alfa in anemic patients with lung or gynecologic 
cancer receiving platinum-containing chemotherapy." 20th 
Regional Congress of the International Society of Blood 
Transfusion, Asia Nagoya Japan 97: 58. 
Abstract only; 
included in 
ongoing studies 
table 
Nitz IU, Oberhoff C, Reimer T, Schumacher C, Hackmann J, 
Warm M. Adjuvant chemotherapy with or without darbepoetin 
in node-positive breast cancer: a safety analysis from the 
phase III ARA plus trial. Paper presented at 31st Annual San 
Antonio Breast Cancer Symposium; 10-14 Dec 2008; San 
Antonio, USA. Cancer Res 2009;69. 
Abstract only; 
included in 
ongoing studies 
table 
Suzuki Y, Tokuda Y, Okamoto R, Nakagawa K, Ando K, Iwata 
H. Randomized, placebo-controlled phase II study of 
darbepoetin alfa (DA) administered every three weeks (Q3W) 
in patients with chemotherapy induced anemia (CIA). Paper 
presented at 34th Congress of the European Society for 
Medical Oncology (ESMO); 12-16 Sep 2008; Stockholm, 
Sweden. Annals of oncology : official journal of the European 
Society for Medical Oncology / ESMO 2008;19:viii277. 
Abstract only; 
included in 
ongoing studies 
table 
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 Appendix K: Ongoing studies 
Register/ identifier 
number (if not 
available Study ID 
cited) 
Sponsor/Collaborators Trial name Investigator Country 
Established/ 
anticipated 
sample size 
Phase  Status 
Incl in PenTAG 
Review 
ACTIVE  NOT RECRUITING  
NCT00482716 / 
CDR0000549549 / 
BARTS-06/Q0605/93 / 
ISRCTN11830961 / EU-
20731 
St. Bartholomew's 
Hospital, London 
Epoetin alfa or epoetin beta with or without 
iron infusion in treating anemia in patients 
with cancer 
Samir G Agrawal (St. 
Bartholomew's Hospital, 
London) 
UK 80 Phase 3 Active, not 
recruiting 
NA 
NCT01444456 / 
20101123 
Amgen Assessment of Quality of Life in Patients 
With Symptomatic Chemotherapy-induced 
Anaemia 
MD, Amgen Austria, Belgium, 
France, Germany, 
Greece, Italy, 
Netherlands, Poland, 
Romania 
1,264 ? Ongoing, not 
recruiting 
NA 
RECRUITING  
NCT00875004 / 
CDR0000633325 / 
CLCC-PLATON / 
CLCC-VA-2007/21 / 
CLCC-AFSSAPS-
A70755-52 / INCA-
RECF0639 / 
EUDRACT-2007-
003615-31 / ROCHE-
CLCC-PLATON 
Centre Val d'Aurelle - 
Paul Lamarque 
Epoetin Beta in Patients Undergoing 
Chemotherapy for Solid Tumors 
Damien Pouessel and Paul 
Lamarque (Centre Val 
d'Aurelle) 
France 300 ? Recruiting NA 
NCT00338286 / 
CR005143 / 
EPOANE3010 / 
CR005143 / 2005-
001817-17 
Janssen Research & 
Development LLC 
A Study of Epoetin Alfa Plus Standard 
Supportive Care Versus Standard 
Supportive Care Only in Anemic Patients 
With Metastatic Breast Cancer Receiving 
Standard Chemotherapy 
Janssen Research & 
Development LLC 
USA, Argentina, 
Australia, Brazil, 
Bulgaria, Chile, 
Colombia, Ecuador, 
Georgia, Hong Kong, 
India, Indonesia, 
Macedonia, Malaysia, 
Mexico, Philippines, 
Poland, Romania, 
Russian Federation, 
South Africa, Taiwan, 
Ukraine 
2,100 Phase 3 Recruiting NA 
NCT00858364 / 
20070782 
Amgen Anemia Treatment for Advanced Non-Small 
Cell Lung Cancer (NSCLC) Patients 
Receiving Chemotherapy 
MD, Amgen USA, Austria, Belgium, 
Brazil, Bulgaria, 
Canada, Chile, China, 
Croatia, Czech 
Republic, Germany, 
Greece, Hong Kong, 
3,000 Phase 3 Recruiting NA 
PenTAG   CONFIDENTIAL 
668 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
Register/ identifier 
number (if not 
available Study ID 
cited) 
Sponsor/Collaborators Trial name Investigator Country 
Established/ 
anticipated 
sample size 
Phase  Status 
Incl in PenTAG 
Review 
India, Ireland, Israel, 
Italy, Korea, 
Luxembourg, 
Malaysia, Mexico, 
Netherlands, 
Philippines, Poland, 
Puerto Rico, Romania, 
Russian Federation, 
Serbia, Slovenia, 
South Africa, Spain, 
Switzerland, Taiwan, 
Ukraine, UK 
NCT01374373 / BIOS-
012010 
Bio Sidus SA Epoetin Alfa (Hemax®) Phase IV Study in 
Chemotherapy Induced Anemia 
Roberto Diez MD (Bio Sidus 
SA) 
Argentina 30 Phase 4 Recruiting NA 
NCT01795690 / iOM 
TAn 
iOMEDICO AG Clinical Registry on Anemia-Therapy (TAn-
Registry) 
? Germany 1,000 ? Recruiting NA 
STATUS UNKNOWN  
NCT00381836 / 2005-
005658-37 / LM: 2612-
3148 / Ethical: 
20060074 / Data 
Protection: 2005-41-
6015 
University of Aarhus 
and Amgen 
Effect of darbepoetin alfa (Aranesp®) on 
anemia in patients with advanced hormone 
independent prostate cancer 
Michael Borre (Department of 
Urology, Aarhus University 
Hospital) 
Denmark 140 Phase 3 
(anaemia)
Unknown NA 
NCT00400686 / CASE-
CCF-5497 / 
P30CA043703 / CASE-
CCF-5497 / ORTHO-
CASE-CCF-5497 
The Cleveland Clinic Epoetin alfa in treating anemia in patients 
undergoing chemotherapy for multiple 
myeloma 
Ronald M. Sobecks (Case 
Comprehensive Cancer 
Center) 
USA 50 ? Unknown NA 
NCT00144755 Lymphoma Study 
Association 
R-CHOP-14 Versus R-CHOP-21 and 
Darbepoetin Alpha in Patients Aged 60-80 
Years With Diffuse Large B-cell Lymphoma 
Richard Delarue (Lymphoma 
Study Association) 
Belgium, France, 
Switzerland 
600 Phase 3 Unknown NA 
NCT00039884 / 
01/155A 
Mirhashemi, Ramin, 
M.D. 
Will Radiation/Chemotherapy Treatment of 
Cervical Cancer Work Better With 
Medication That May Improve Anemia? 
Mirhashemi, Ramin USA 64 Phase 2 Unknown NA 
NCT00309920 / 
CDR0000458037 / 
WGSG-ARA-PLUS / 
AVENTIS-WGSG-ARA-
PLUS / SANOFI-WGSF-
ARA-PLUS / EU-
205108 
Heinrich-Heine 
University, Dusseldorf 
Combination Chemotherapy With or Without 
Darbepoetin Alfa in Treating Women With 
Stage III Breast Cancer 
Ulrike Nitz (Heinrich-Heine 
University, Dusseldorf) 
Germany 1,234 ? Unknown NA 
NCT00281892 /  German CLL Study 
Group 
Fludarabine and Darbepoetin Alfa in 
Treating Older Patients With Chronic 
Lymphocytic Leukemia  
Michael Hallek MD 
(Medizinische 
Universitaetsklinik I, University 
Germany 348 Phase 3 Unknown - 
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Register/ identifier 
number (if not 
available Study ID 
cited) 
Sponsor/Collaborators Trial name Investigator Country 
Established/ 
anticipated 
sample size 
Phase  Status 
Incl in PenTAG 
Review 
of Cologne) 
TERMINATED  
NCT00386152 / 
CR012985 / 
EPOANE2007 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
A Study Comparing Two Different PROCRIT 
Doses to a Dose of ARANESP in Anemic 
Cancer Patients Receiving Chemotherapy 
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
USA 235 Phase 2 Terminated, 
has results 
- 
NCT01736215 / 
CR016558 / 
EPOCAN4028 
Janssen-Cilag 
Ltd.,Thailand 
An Observational Study to Predict the 
Response of Erythropoietin Treatment in 
Participants With Cancer Related Anemia 
Receiving Chemotherapy 
Janssen-Cilag Ltd.,Thailand Thailand 33 Phase 4 Terminated, 
has results 
- 
NCT00258440 / 
CDR0000445450 / 
OHSU-ONC-03017-LP / 
OHSU-1616 / OHSU-
7754 / ORTHO-ONC-
03017-L 
OHSU Knight Cancer 
Institute 
Epoetin Alfa in Treating Patients With 
Anemia Who Are Undergoing Chemotherapy 
for Cancer 
Joseph Bubalo (OHSU Knight 
Cancer Institute) 
USA 7 ? Terminated, 
has results 
- 
NCT00989092 / 
20000219 
Amgen Darbepoetin Alfa and Anemia of Cancer Amgen ? 287 Phase 2 Terminated 
(slow 
enrollment 
and change in 
product 
development 
strategy) 
- 
NCT00254436 / ID00-
264 
M.D. Anderson Cancer 
Center 
A Double-Blind, Randomized, Placebo-
Controlled Study of the Efficacy and Safety 
of Weekly Procrit Given to Gastric or Rectal 
Patients 
Saroj Vadhan-Raj MD (M.D. 
Anderson Cancer Center) 
USA 50 Phase 3 Terminated - 
NCT00246597 / 
CR002305 
Ortho Biotech Products, 
L.P. 
A Phase III Clinical Trial of PROCRIT 
(Epoetin Alfa) Versus Placebo in Women 
Undergoing Adjuvant Chemotherapy for 
Stage I, II or III Breast Cancer 
Ortho Biotech Products, L.P. ? 37 Phase 3 Terminated - 
NCT00189371 / AGO-
OVAR 2.7 
Christian Jackisch MD 
(AGO Study Group) 
Reinduction Chemotherapy Containing 
Carboplatin and Paclitaxel With or Without 
Epoetin Alpha in Recurrent Platinum 
Sensitive Ovarian Cancer, Cancer of the 
Fallopian Tube or Peritoneum 
AGO Study Group Germany 300 Phase 3 Terminated - 
NCT00306267 / 
CR10540 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
A Study of PROCRIT (Epoetin Alfa) 80,000 
Units (U) Once Every Four Weeks (Q4W) 
vs. 40,000 U Once Every Two Weeks (Q2W) 
in Cancer Patients Not Receiving 
Chemotherapy  
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 61 Phase 2 Terminated - unlicensed / 
fixed dose or 
both* 
NCT00310232 / CTA-
Control-076080 / HC 
File 9427-J0921-22C 
Ontario Clinical 
Oncology Group 
(OCOG) 
Epoetin Alfa in Advanced Non-Small Cell 
Lung Cancer (EPO-CAN-20) 
Ontario Clinical Oncology 
Group (OCOG) 
Canada 70 Phase 3 Terminated - 
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Register/ identifier 
number (if not 
available Study ID 
cited) 
Sponsor/Collaborators Trial name Investigator Country 
Established/ 
anticipated 
sample size 
Phase  Status 
Incl in PenTAG 
Review 
NCT00495378 / 
CR005128 
Ortho Biotech Products, 
L.P. 
RAPID-2. A Study to Evaluate the 
Effectiveness of Alternate Dosing of 
PROCRIT (Epoetin Alfa) in Maintaining 
Hemoglobin Levels in Patients With 
Chemotherapy Related Anemia  
Ortho Biotech Products, L.P. ? 25 Phase 4 Terminated 
(25 out of 200 
patients 
enrolled) 
- non-
randomised 
study* 
COMPLETED  
NCT00117039 / 
20030206 
Amgen A Study to Evaluate the Effectiveness of 
Aranesp® for Cancer Patients with Anaemia 
MD Amgen ? 1,500 Phase 4 Completed 
(results 
published 
Boccia 2006 
and Boccia 
2007) 
Identified but 
excluded as 
studies non-
randomised 
NCT00272662 / AFX01-
05, 2005-003354-10 
Affymax Study of Subcutaneously Administered 
Peginesatide in Anemic Cancer Patients 
Receiving Chemotherapy  
Study Director Affymax Inc Czech Republic, 
Poland, UK 
60 Phase 2 Completed - non-
randomised; 
dose finding; 
new ESA* 
NCT 00210600 / 
CR003196 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
Early and Standard Intervention With 
120,000 Units of PROCRIT (Epoetin Alfa) 
Every Three Weeks in Patients Receiving 
Chemotherapy  
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 186 Phase 2 Completed 
(results 
published, 
Glaspy 2006) 
- unlicensed / 
fixed dose or 
both* 
NCT00117117 / 
20020132 
Amgen A Study to Assess Symptom Burden in 
Subjects With Nonmyeloid Malignancies 
Receiving Chemotherapy and Aranesp® 
MD Amgen ? 2,423 Phase 4 Completed 
(results 
published 
Gregory 2006 
and Gabrilove 
2007) 
Identified 
Gabrilove 2007 
but not Gregory 
2006. However, 
both non-
randomised, 
single-arm 
studies 
NCT00072059 / 
ROCHE-NA17101 / 
UCLA-0303085 / 
CDR0000335429 
Jonsson 
Comprehensive Cancer 
Center 
Ro 50-3821[Mircera® epoetin beta] in 
Treating Anemia in Patients Receiving 
Antineoplastic Therapy for Stage IIIB or 
Stage IV Non-Small Cell Lung Cancer 
John Glaspy MD (Jonsson 
Comprehensive Cancer 
Center) 
USA 210 Phase 2 Completed -  
NCT00212862 / 
CR004561 / ABT-OP-
03-02 
Ortho Biotech Products, 
L.P. 
Dosing and Outcomes Study of 
Erythropoietic Stimulating Therapies in 
Patients With Chemotherapy Induced 
Anemia (DOSE)  
Ortho Biotech Products, L.P. ? 2,130 Phase 4 Completed 
(results 
published 
Larholt 2008) 
Not identified as 
beyond scope 
of review; an 
observational 
cohort study 
NCT00270101 / 
CR005911 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
The Effect of Epoetin Alfa on the Anemia of 
Patients With Multiple Myeloma 
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 156 Phase 3 Completed 
(results 
published 
Dammacco 
1997) 
Not identified as 
pre-2004 
(PenTAG 
searches 2004-
2013) 
NCT00158379 / 
3002000 
North Eastern Germany 
Society of Gynaecologic 
Taxol Carboplatin and Erythropoetin  Jalid Sehouli, Charité Campus 
Virchow Klinikum 
? 105 Phase 2 Completed - non-
randomised 
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Register/ identifier 
number (if not 
available Study ID 
cited) 
Sponsor/Collaborators Trial name Investigator Country 
Established/ 
anticipated 
sample size 
Phase  Status 
Incl in PenTAG 
Review 
Oncology study* 
NCT00315484 / 
CR004609 
Ortho Biotech Products, 
L.P. 
Hematologic Response of Epoetin Alfa 
(PROCRIT) Versus Darbepoetin Alfa 
(ARANESP) in Chemotherapy Induced 
Anemia  
Ortho Biotech Products, L.P. ? 358 Phase 4 Completed 
(results 
published 
Waltzman 
2005) 
Identified; 
excluded as 
unlicensed/fixed 
dose or both 
NCT00540384 / 980291 Amgen Dose-finding Study of Novel Erythropoiesis 
Stimulating Protein (NESP) for the 
Treatment of Anaemia in Subjects With Solid 
Tumours Receiving Multicycle 
Chemotherapy 
MD Amgen ? 405 Phase 2 Completed 
(results 
published 
Kotasek 
2003) 
Identified; 
included 
treatment arm 
evaluating at 
licensed 
dosage 
NCT00344409 / 
KRN321-SC/05-A54 
Kyowa Hakko Kirin 
Company, Limited 
A Double-blind Study of KRN321 for the 
Treatment of Anemia in Cancer Patients 
Nagahiro Saijo MD (National 
Cancer Center Hospital East) 
Japan 200 Phase 3 Completed - 
NCT00144482 / 
EPO307JP 
Chugai Pharmaceutical A Study of Recombinant Human 
Erythropoietin in Anemic Cancer Patients 
Undergoing Chemotherapy  
Yoshiharu Ishikura (Chugai 
Pharmaceutical) 
? 122 Phase 3 Completed - unlicensed / 
fixed dose or 
both* 
NCT00628043 / 
EPO316JP 
Chugai Pharmaceutical Clinical Study of Epoetin Beta to 
Chemotherapy-Induced Anemia (CIA) 
Patients  
Yoshito Suzuki (Chugai 
Pharmaceutical) 
Japan 160 Phase 3 Completed - unlicensed / 
fixed dose or 
both* 
NCT00338299 / 
CR005098 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
Alternate Dosing of PROCRIT (Epoetin Alfa) 
in Patients With Cancer and Chemotherapy 
Induced Anemia  
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 51 Phase 3 Completed 
(results 
published 
Reddy 2006) 
Not identified; 
study was a 
non-
randomised, 
single arm 
study 
NCT00144495 / 
EPO308JP 
Chugai Pharmaceutical A Study of Recombinant Human 
Erythropoietin in Anemic Cancer Patients 
Undergoing Chemotherapy  
Yoshiharu Ishikura (Chugai 
Pharmaceutical) 
? 104 Phase 3 Completed - non-
randomised; 
unlicensed / 
fixed dose or 
both* 
NCT00776425 / 
ML20197 
Hoffmann-La Roche A Study of the Quality of Life and Treatment 
Response to Once Weekly NeoRecormon 
(Epoetin Beta) Treatment in Anemic Patients 
With Solid and Lymphoid Malignancies 
Clinical Trials, Hoffman-La 
Roche 
Russian Federation 125 Phase 4 Completed - non-
randomised, 
single arm; 
unlicensed / 
fixed dose* 
NCT00035607 / 
20010199 
Amgen Chemotherapy Related Anemia  MD Amgen ? 120 Phase 3 Completed 
(results 
published 
Justice 2005) 
Identified; 
excluded as 
comparison DA 
vs DA beyond 
scope 
NCT00711958 / 2003-
31-INJ-11 
Novartis Study to Assess the Efficacy and Safety of 
HX575 in the Treatment of Chemotherapy 
Associated Anemia in Cancer Patients  
Andrea Vetter MD (Hexal AG) Germany, Romania 105 Phase 3 Completed  - unlicensed/ 
fixed dose or 
both; 
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bioequivalence 
study* 
NCT00117624 / 
20020118 
Amgen A Study of Darbepoetin Alfa for the 
Treatment of Anemia in Subjects With a 
Non-Myeloid Malignancy  
MD Amgen ? ? Phase 3 Completed 
(results 
published 
Kotasek 
2007) 
Identified; 
excluded as 
comparison DA 
vs DA beyond 
scope 
NCT00046969 / 
AGOSG-OVAR-
MO16375-MARCH /  
CDR0000257189, EU-
20217 / ROCHE-
MO16375  ROCHE-
RO2053859 
AGO Study Group Epoetin Beta in Treating Anemia in Patients 
With Cervical Cancer 
Heinz Koelbl MD (Martin-
Luther-Universität Halle-
Wittenberg) 
Germany 450 Phase 4 Completed - 
NCT00261313 / 
20040137 
Amgen ACCELERATE: Doxorubicin and 
Cyclophosphamide Followed by Paclitaxel 
With Pegfilgrastim and Darbepoetin Alfa 
Support for the Treatment of Women With 
Breast Cancer  
MD Amgen ? 80 Phase 2 Completed - appears G-
CSF not given 
in both 
treatment arms* 
NCT00148421 / 
20030125 
Amgen  Study for the Treatment of Anemia in 
Patients With Non-myeloid Malignancies 
Receiving Multicycle Chemotherapy 
MD Amgen ? ? Phase 3 Completed 
(results 
published 
Glaspy 2006) 
Identified; 
excluded as 
unlicensed/fixed 
dose or both 
NCT00401544 / 
20060103 
Amgen Darbepoetin Alfa With or Without IV Iron  MD Amgen ? ? Phase 3 Completed - 
NCT00338416 / 
CR004612 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
An Efficacy and Safety Study of PROCRIT 
(Epoetin Alfa) in Cancer Patients Receiving 
Chemotherapy Every Three Weeks  
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 115 Phase 2 Completed 
(results 
published 
Montoya 
2007) 
Not identified; 
study non-
randomised, 
single arm 
NCT00269984 / 
CR005833 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
A Study to Determine the Safety and 
Effectiveness of Epoetin Alfa Versus 
Placebo in Patients With Persistent Anemia 
Caused by Advanced Cancer  
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 56 Phase 2 Completed - non-
randomised; 
unlicensed / 
fixed dose or 
both* 
NCT00559195 / 
CDR0000574173 / 
CHUL-NEOPALIA / 
RECF0359 
Centre Hospital 
Regional Universitaire 
de Limoges 
Epoetin Beta in Treating Fatigue and 
Anemia in Patients Receiving Palliative Care 
for Malignant Solid Tumors  
Jean-Luc Labourey (Centre 
Hospital Regional Universitaire 
de Limoges) 
France 40 Phase 2 Completed  - non-
randomised 
study* 
NCT00120705 / 
20020167 
Amgen Treatment for Anemic Subjects With Non-
Myeloid Malignancies Receiving 
Chemotherapy 
MD Amgen ? 204 Phase 2 Completed 
(results 
published 
Charu 2007) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00364455 (info Janssen-Ortho Inc., Impact of Erythropoietin Treatment Versus ? ? 56 Phase 3 Completed  - 
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taken from Source 
Solution website as 
record not available on 
NCT website) 
Canada and Ontario 
Clinical Oncology Group 
Placebo on Quality-of-Life in Patients With 
Advanced Prostate Cancer. 
NCT00135317 /  Amgen AIM 3: Anemia and Iron Management With 
Every 3 Week Dosing in Anemic Subjects 
With Nonmyeloid Malignancies  
MD Amgen ? ? Phase 3 Completed 
(results 
published 
Bastit 2008)  
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00269997 / 
CR005839 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
A Study to Evaluate the Safety and 
Effectiveness of Epoetin Alfa Versus 
Placebo in Patients With Persistent Anemia 
as a Result of Cancer Treatment With 
Cisplatin, a Platinum-containing 
Chemotherapy Drug  
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 72 Phase 2 Completed - 
NCT00266617 / 
CR005845 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
A Study to Evaluate the Safety and 
Effectiveness of Epoetin Alfa in Patients 
With Anemia as a Result of Advanced 
Cancer and Treatment With Aggressive 
Chemotherapy 
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 86 Phase 2 Completed - 
NCT00110955 / 
20030232 
Amgen Treatment of Anemia in Subjects With Non-
Myeloid Malignancy Receiving Multicycle 
Chemotherapy 
MD Amgen ? 391 Phase 3 Completed 
(results 
published 
Hernandez 
2009) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00337948 / 
CR004615 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
An Efficacy and Safety Study of PROCRIT 
(Epoetin Alfa) in Cancer Patients Receiving 
Chemotherapy Every Week or Every Four 
Weeks  
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 129 Phase 2 Completed 
(results 
published 
Gregory 
2003) 
Not identified; 
non-
randomised, 
single arm 
study 
NCT00255749 / 
CDR0000449950 / 
UCLA-0504038 / 
ORTHO-PR04-27-018 
Jonsson 
Comprehensive Cancer 
Centre 
Epoetin Alfa in Treating Patients With 
Anemia Who Are Undergoing Chemotherapy 
for Cancer  
John A. Glaspy MD (Jonsson 
Comprehensive Cancer 
Center) 
USA 89 Phase 2 Completed 
(results 
published 
Glaspy 2009) 
Identified; 
excluded – 
includes 
randomized and 
non-
randomised; 
unlicensed/fixed 
dose used 
NCT00058331 / 
CDR0000288821 / 
NCCTG-N02C2 
North Central Cancer 
Treatment Group 
Epoetin Alfa in Treating Anemia in Patients 
With Solid Tumors 
David P Steensma MD (Mayo 
Clinic) 
USA ? Phase 3  Completed 
(results 
published 
Steensma 
2005 abstr 
and 2006) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00003600 / North Central Cancer Epoetin Alfa in Treating Anemia in Patients Thomas E Witzig MD (Mayo USA ? Phase 3 Completed  - 
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CDR0000066673, 
NCCTG-979253, NCI-
P98-0133 
Treatment Group Who Are Receiving Chemotherapy Clinic) 
NCT00524407 / 
CR005125 
Ortho Biotech Products, 
L.P. 
Effect of Epoetin Alfa on Hemoglobin, 
Symptom Distress, and Quality of Life in 
Patients Receiving Chemotherapy 
Ortho Biotech Products, L.P. ? 273 Phase 4 Completed 
(result 
published 
Straus 2006) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00261677 / 
CR002296 
Ortho Biotech Products, 
L.P. 
A Study to Evaluate the Effect of Weekly 
PROCRIT (Epoetin Alfa) or Placebo on 
Anemia and Quality of Life in Children With 
Cancer Undergoing Chemotherapy  
Ortho Biotech Products, L.P. ? 224 Phase 3 Completed 
(results 
published 
Razzouk 
2006) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
(FYI paediatric 
population) 
NCT00036023 / 
NCT00039247[obsolete] 
/ 20010162 
Amgen Chemotherapy Related Anemia in Patients 
With Non-Myeloid Malignancies 
MD Amgen ? ? Phase 2 Completed 
(results 
published 
Glaspy 2005) 
 
NCT00145652 (info 
taken from Source 
Solution website as 
record not available on 
NCT website) 
Sundsvall Hospital Adjuvant I.V. Iron Therapy During 
Erythropoetin Treatment of Anemic Patients 
With Lymphoproliferative Disorders 
? ? 66 ? Completed - 
NCT00270166 / 
CR005923 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
The Effect of Epoetin Alfa on the Anemia of 
Patients With Selected Cancers Receiving 
Chemotherapy 
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 201 Phase 3 Completed - 
NCT01626547 / 
ORHEO 
Hospira Inc Biosimilar RetacritTM (Epoetin Zeta) in the 
Treatment of Chemotherapy-Induced 
Symptomatic Anaemia in Haematology and 
Oncology  
? Germany 240 ? Completed - non-
randomised 
study* 
NCT00121030 / 
20020166 
Amgen Treatment for Patients With Gynecological 
Malignancies Who Suffer From Anemia Due 
to Chemotherapy  
MD Amgen ? ? Phase 2 Completed 
(results 
published 
Schwartzberg 
2004) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00038064 / 
NCT00046982 
[obsolete], 20010101 
Amgen Anemia in Patients With a Non-Myeloid 
Malignancy  
MD Amgen ? 707 Phase 3 Completed - unlicensed / 
fixed dose or 
both* 
NCT00120679 / 
20020165 
Amgen Treatment for Patients With Non-Small Cell 
Lung Cancer Who Developed Anemia Due 
to Chemotherapy 
MD Amgen ? ? Phase 2 Completed 
(results 
published 
Schwartzberg 
2004) 
 
NCT00264108 / Janssen-Cilag BV Cost-effectiveness Study of Epoetin Alfa and Clinical Trials Janssen-Cilag ? 492 Phase 4 Completed - non-
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CR002455 / 
EPOCAN4015 
Darbepoetin Alfa in Adult Patients With 
Cancer Who Have Anemia  
BV randomised; 
unlicensed/fixed 
dose or both* 
NCT00239239 / 
20040232 
Amgen Fractionated Dosing Study: Study to 
Evaluate Darbepoetin Alfa for the Treatment 
of Anemia in Subjects With Non-Myeloid 
Malignancies  
MD Amgen ? 44 Phase 3 Completed  - non-
randomised; PK 
study* 
NCT00146562 / 03-154 Harold J. Burstein, MD, 
PhD and Dana-Farber 
Cancer Institute ; 
Massachusetts General 
Hospital; Beth Israel 
Deaconess Medical 
Center; Lowell General 
Hospital; Brigham and 
Women's Hospital; 
North Shore Medical 
Center 
Pegfilgrastim and Darbepoetin Alfa in 
Support of Adjuvant Chemotherapy for 
Breast Cancer  
Harold Burstein, MD, PhD 
(Dana-Farber Cancer Institute)
USA 109 Phase 2 Completed - non-
randomised* 
NCT00120692 / 
20020152 
Amgen Treatment for Patients Suffering From 
Anemia Due to Chemotherapy 
MD Amgen ? ? Phase 2 Completed 
(results 
published 
Senecal 
2005) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00119613 / 
20010145 
Amgen A Study of Subjects With Previously 
Untreated Extensive-Stage Small-Cell Lung 
Cancer (SCLC) Treated With Platinum Plus 
Etoposide Chemotherapy With or Without 
Darbepoetin Alfa  
MD Amgen ? 600 Phase 3 Completed 
(results 
published 
Pirker 2008) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00028938 / 
CDR0000069148 / 
CCWFU-62299 / 
CCCWFU-BG01-193 / 
NCI-P01-0200 
Wake Forest Baptist 
Health / National 
Cancer Institute 
Chemotherapy and Radiation Therapy With 
or Without Epoetin Alfa in Treating Patients 
With Stage IIIA or Stage IIIB Non-Small Cell 
Lung Cancer 
Arthur William Blackstock MD 
(Comprehensive Cancer 
Center of Wake Forest 
University) 
USA 202-232 Phase 3 Completed - 
NCT00111137 / 
20020139 
Amgen Treatment for Patients With Non-Myeloid 
Malignancies Receiving Chemotherapy  
MD Amgen ? 718 Phase 3  Completed  - unlicensed / 
fixed dose or 
both* 
NCT00022386 / 
ORTHO-PR-00-27-012 / 
UCLA-0011004 / 
CDR0000068811 / 
ORTHO-PR-01-27-003, 
NCI-G01-2002 
Jonsson 
Comprehensive Cancer 
Center and National 
Cancer Institute 
Epoetin Alfa in Treating Chemotherapy-
Related Anemia in Women With Stage I, 
Stage II, or Stage III Breast Cancer  
John A. Glaspy MD (Jonsson 
Comprehensive Cancer 
Center) 
? 2,500 Phase 4 Completed - non-
randomised 
study* 
NCT00017004 / 
CDR0000068641 / 
Gynecologic Oncology 
Group / National Cancer 
Radiation Therapy and Cisplatin With or 
Without Epoetin Alfa in Treating Patients 
Gillian M. Thomas (Odette 
Cancer Centre at 
USA, Canada, 
Norway, UK 
460 Phase 3 Completed - 
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available Study ID 
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sample size 
Phase  Status 
Incl in PenTAG 
Review 
GOG-0191 / CAN-
NCIC-CX4 
Institute & NCIC Clinical 
Trials Group 
With Cervical Cancer and Anemia Sunnybrook); and, Peter S. 
Craighead (Tom Baker Cancer 
Centre – Calgary) 
NCT00270127 / 
CR005917 / EPO-C111-
457/EPO-INT-10 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
Epoetin Alfa for Anemia in Patients With 
Cancer Receiving Non-platinum 
Chemotherapy 
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 375 Phase 3 Completed - 
NCT00211133 / 
CR004414 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C 
A Study to Evaluate the Impact of 
Maintaining Hemoglobin Levels Using 
Epoetin Alfa in Patients With Metastatic 
Breast Cancer Receiving Chemotherapy 
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C 
? 939 Phase 3 Completed 
(results 
published 
Leyland-
Jones 2005) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00284365 / 
CR002047 
Janssen Cilag BV A Study of the Effectiveness and Safety of 
Treatment With Epoetin Alfa on Hemoglobin 
Levels, Red Blood Cell Transfusions, and 
Quality of Life in Patients With Cancer 
Receiving Platinum-containing 
Chemotherapy 
Clinical Trials Janssen Cilag 
BV 
? 316 Phase 4 Completed 
(results 
published 
Savonije 
2005) 
Identified; 
excluded 
unlicensed/fixed 
dose or both 
NCT00095277 / 
20030204 
Amgen Darbepoetin Alfa Administered Once Every 
4 Weeks in the Treatment of Subjects With 
Anemia of Cancer 
MD Amgen ? 220 Phase 2 Completed 
(results 
published 
Gordon 2008) 
Identified; 
excluded as 
patients not 
receiving 
chemotherapy  
NCT00118638 / 
20030231 
Amgen A Study of Darbepoetin Alfa for the 
Treatment of Anemia in Subjects With Non-
Myeloid Malignancy Receiving Multicycle 
Chemotherapy 
MD Amgen ? 705 Phase 3 Completed 
(results 
published 
Canon 2012; 
Canon 2006; 
Vansteenkiste 
2009) 
All identified; 
excluded 
Canon 2006 as 
comparison DA 
vs DA beyond 
scope; and, 
excluded 
Canon 2012 & 
Vansteenkiste 
2009 as 
retrospective 
analyses 
NCT00144131 / 
20040262 
Amgen Flexibility: A Study to Assess the Impact of 
Darbepoetin Alfa in Subjects with Non-
Myeloid Malignancies With Anemia Due to 
Chemotherapy 
 
MD Amgen ? 750 Phase 2 Completed 
(results 
published 
Schwartzberg 
2010) 
Identified; 
excluded as 
comparison DA 
vs DA beyond 
scope 
NCT00091858 / 
NCT00098696 
[obsolete] /  
Amgen Study of Darbepoetin Alfa for the Treatment 
of Anemia of Cancer 
MD Amgen ? 1,000 Phase 3 Completed 
(results 
published 
Identified; 
excluded as 
patients not 
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20010103 Smith 2008) receiving 
chemotherapy 
NCT00216541 / 
CR003541 
Janssen Cilag BV A Study of the Safety and Effectiveness of 
Epoetin Alfa on Hemoglobin Levels and 
Blood Transfusions in Cancer Patients 
Receiving Chemotherapy 
Clinical Trials Janssen Cilag 
BV 
? 110 Phase 4 Completed 
(results 
published 
Schouwink 
2008) 
Identified; 
excluded as 
comparison EA 
vs EA beyond 
scope; & 
unlicensed/fixed 
dose or both 
NCT00245895 / 03-
6503-A 
University of 
Washington / Amgen 
Study of Aranesp to Treat Anemia in 
Prostate Cancer Patients  
Celestia S Higano MD 
(University of Washington); 
and, Tomasz M Beer MD 
(Oregon Health and Science 
University) 
USA 20 Phase 2 Completed - non-
randomised 
study* 
NCT00039247 / 
20010162 
Amgen Chemotherapy related anemia in patients 
with non-myeloid malignancies 
MD, Amgen ?  Phase 2 Completed 
(results 
published 
Glaspy 2005) 
Identified; 
excluded as 
comparison DA 
vs DA 
NCT01099202 M.D. Anderson Cancer 
Center 
Procrit Versus No Procrit in Acute 
Lymphocytic Leukemia, Lymphoblastic 
Lymphoma, or Burkitt's Undergoing 
Induction/Consolidation Chemotherapy 
Jorge Cortes (UT MD 
Anderson Cancer Center) 
USA 109 Completed - 
NCT00661999 Darbepoetin Alfa With or Without Iron in 
Treating Anemia Caused By Chemotherapy 
in Patients With Cancer 
Charles L Loprinzi (Mayo 
Clinic) 
USA 502 Phase 3 Completed - 
NCT01394991 / 
CR010543 / 
EPOANE4008 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C. 
A Safety Study of Epoetin Alfa in Patients 
With Cancer Who Have Chemotherapy-
Related Anemia 
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C. 
? 504 Phase 4 Completed - 
NCT00236951 Luitpold 
Pharmaceuticals 
Intravenous (IV) Iron vs. No Iron as the 
Treatment of Anemia in Cancer Patients 
Undergoing Chemotherapy and 
Erythropoietin Therapy 
Marc Tokars (Senior Director 
of Clinical Operations, Luitpold 
Pharmaceuticals, Inc.) 
? 224 Phase 3 Completed - 
NCT00270049 / 
CR005905 
Johnson & Johnson 
Pharmaceutical 
Research & 
Development, L.L.C. 
Epoetin Alfa for the Treatment of Anemia 
Resulting From Chronic Lymphocytic 
Leukemia 
Johnson & Johnson 
Pharmaceutical Research & 
Development, L.L.C. 
? 195 Phase 2 Completed - 
NCT00003341 / 97-125 
/ MSKCC-97125 / 
ORTHO-PR-96-27-031 / 
RPCI-DS-97-38 / NCI-
G98-1436 
Memorial Sloan-
Kettering Cancer Center 
Epoetin Alfa in Treating Anemia in Patients 
With Lymphoma, Chronic Lymphocytic 
Leukemia, or Multiple Myeloma and Anemia 
Caused By Chemotherapy 
David J. Straus (Memorial 
Sloan-Kettering Cancer 
Center) 
USA 275 Phase 3 Completed - 
NCT00070382 / 
CDR0000333213 / 
Jonsson 
Comprehensive Cancer 
Darbepoetin Alfa Compared With Epoetin 
Alfa in Treating Anemia in Patients 
John A. Glaspy (MPH Jonsson 
Comprehensive Cancer 
? 14 Phase 3 Completed 
(published 
Identified; 
excluded 
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P30CA016042 / UCLA-
0306021 / AMGEN-
20030125 
Center and National 
Cancer Institute (NCI) 
Receiving Chemotherapy for Cancer Center) Glaspy 2006) unlicensed/fixed 
dose or both. 
Possibly 
duplicate of 
NCT00148421. 
NCT00416624 / 
CDR0000522677 / 
P30CA015083 / 
RC05CB / 06-002991 / 
EPOANE3015 
Mayo Clinic Epoetin alfa or darbepoetin alfa in treating 
patients with anemia caused by 
chemotherapy 
Charles L. Loprinzi (Mayo 
Clinic) 
USA 320 ? Completed - 
Key & notes: ?, not reported / unclear; - unable to match to a publication text; * indicates possible reasons for exclusion based on the information provided in the ClinicalTrials or Controlled Trials databases; DA, 
darbepoetin alfa; EA, epoetin alfa;  
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 Appendix L: Supplementary analyses 
23.1. Anaemia-related outcomes 
23.1.1. Hb change 
23.1.1.1.  Publication bias 
Figure 77. Hb change: publication bias, funnel plot 
 
Key: se(WMD): standard error of weighted mean difference; WMD, weighted mean difference 
 
Table 108. Hb change: Egger’s test for small study effects 
Number of studies 18 Root MSE 1.952
Std_Eff Coef SE t p>|t| 95% CI 
slope 1.002 0.33 3.06 <0.01 0.31, 1.70 
bias 2.020 1.28 -1.16 0.13 -0.69, 4.73 
Test of H0 no small-study effects p=0.133 
Key: CI, confidence interval; coef, coefficient; SE, standard error 
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Figure 78. Hb change: Publication bias; meta-regression plot, year of publication as a 
covariate 
 
Key: se(WMD): standard error of weighted mean difference; WMD, weighted mean difference 
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23.1.1.2.  Fixed effects 
Figure 79. Hb change: Forest plot (fixed effects) 
 
Key: CI, confidence intervals; ID, identification; N, number of participants; SD, standard deviation; WMD, 
weighted mean difference 
Notes: Fixed effects, Mantel-Haenszel; Studiesl with multiple experimental arm split into subsets in the analysis: 
Tjulandin 2010 a, b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 1993 reported 
data for participants on platinum-based chemotherapy and non-platinum based chemotherapy 
23.1.1.3.  Metagression  
Table 109. Hb change: Results of meta-regression analysis (g/dl)  
Variable Mean difference Standard error P-value 
Intercept (other chemotherapy and 
erythropoietin) 
1.576 0.115 <0.001 
Darbepoetin -0.491 0.212 0.035 
Mixed chemotherapy  0.879 0.006 0.018 
Key: NR, not reported 
 
 
Overall  (I-squared = 75.9%, p = 0.000)
Untch (2011a,b)
Tjulandin_Beta (2010a)
Littlewood (2001)
Tjulandin_Theta (2010b)
Osterborg (2002, 2005)
Hedenus (2003)
Ten Bokkel (1998)
Boogaerts (2003)
Tjulandin (2011)
Dammacco (2001)
Study
Abels_NonCisplatin (1993)
Kotasek (2003)
Kurz (1997)
ID
Del Mastro (1999)
Grote   (2005)
Aravantinos (2003)
Abels_Cisplatin (1993)
Hedenus (2002)
1.49 (1.37, 1.60)
0.91 (0.65, 1.17)
1.70 (1.01, 2.39)
1.70 (1.27, 2.13)
1.40 (0.75, 2.05)
1.66 (1.29, 2.03)
1.61 (1.22, 2.00)
1.23 (0.48, 1.98)
1.20 (0.80, 1.60)
1.45 (0.97, 1.93)
2.00 (1.42, 2.58)
1.98 (1.42, 2.54)
0.88 (0.04, 1.72)
3.01 (1.77, 4.25)
WMD (95% CI)
2.25 (1.60, 2.90)
2.70 (2.18, 3.22)
1.08 (0.27, 1.89)
1.60 (0.87, 2.33)
0.64 (-0.10, 1.38)
1681
330, -.07 (2)
73, 1.9 (1.74)
244, 2.2 (2.18)
76, 1.6 (1.42)
138, 2.48 (1.74)
174, 1.8 (2.24)
34, .66 (1.76)
133, 2.1 (1.83)
95, 2.1 (1.3)
69, 1.8 (2.11)
N, mean
79, 2.35 (2.04)
17, .86 (1.57)
23, 3.26 (1.98)
(SD); Treatment
28, -.8 (1.4)
64, -.2 (1.38)
24, 2.31 (1.22)
63, 2.04 (2.38)
17, 1.64 (1.25)
1489
359, -.98 (1.33)
37, .2 (1.74)
115, .5 (1.79)
37, .2 (1.74)
142, .82 (1.4)
170, .19 (1.3)
24, -.57 (1.16)
129, .9 (1.5)
91, .65 (1.94)
76, -.2 (1.31)
N, mean
74, .37 (1.46)
51, -.02 (1.43)
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23.1.2. Haematological response 
23.1.2.1.  Publication bias 
Figure 80. HaemR: Publication bias, funnel plot   
 
Key: CI, confidence interval; sqrt: square root; Z, efficient score; V, Z score variance 
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Figure 81. HaemR: Publication bias, meta-regression plot, year of publication as a 
covariate 
 
Key: RR, risk ratio 
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23.1.2.2.  Fixed effects 
Figure 82. HaemR: Forest plot (fixed effects) 
 
Key: CI, confidence intervals; events, treatment, number of events/ number of participants in treatment group; 
events, control, number of events/ number of participants in control group; ID, identification; RR, risk ratio 
Notes: Fixed effects, Mantel-Haenszel; Studiesl with multiple experimental arm split into subsets in the analysis: 
Tjulandin 2010 a, b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 1993 reported 
data for participants on platinum-based chemotherapy and non-platinum based chemotherapy 
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23.1.2.3.  Addit ional analyses 
Figure 83. HaemR (including Kurz and colleagues, 1997 and Vansteenkiste and 
colleagues, 2002): Forest plot (random effects) 
 
Key: CI, confidence intervals; events, treatment, number of events/ number of participants in treatment group; 
events, control, number of events/ number of participants in control group; ID, identification; RR, risk ratio 
Notes: Random effects, Der-Simonian-Laird; Studiesl with multiple experimental arm split into subsets in the 
analysis: Tjulandin 2010 a, b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 1993 
reported data for participants on platinum-based chemotherapy and non-platinum based chemotherapy 
 
NOTE: Weights are from random effects analysis
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Figure 84. HaemR: Random effects meta-analysis using Hb subgroups (Littlewood 
and colleagues, 2001), forest plot (random effects) 
 
Key: CI, confidence intervals; events, treatment, number of events/ number of participants in treatment group; 
events, control, number of events/ number of participants in control group; ID, identification; RR, risk ratio 
Notes: Random effects, Der-Simonian-Laird; Studiesl with multiple experimental arm split into subsets in the 
analysis: Tjulandin 2010 a, b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 1993 
reported data for participants on platinum-based chemotherapy and non-platinum based chemotherapy; 
Littlewood and colleagues, 2001 reports data by baseline Hb ≤10.5 g/dl and >10.5 g/dl 
 
NOTE: Weights are from random effects analysis
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Figure 85. HaemR: Random effects meta-analysis using malignancy subgroups 
(Littlewood and colleagues, 2001), forest plot (random effects) 
 
Key: CI, confidence intervals; events, treatment, number of events/ number of participants in treatment group; 
events, control, number of events/ number of participants in control group; ID, identification; RR, risk ratio 
Notes: Random effects, Der-Simonian-Laird; Studiesl with multiple experimental arm split into subsets in the 
analysis: Tjulandin 2010 a, b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 1993 
reported data for participants on platinum-based chemotherapy and non-platinum based chemotherapy; 
Littlewood and colleagues, 2001 reports data by malignancy type (solid and haematological tumours) 
 
NOTE: Weights are from random effects analysis
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23.1.2.4.  Meta-regression 
Table 110. HaemR: Results of meta-regression analysis with iron subgroup as a 
covariate 
Variable RR Standard error P-value 
Intercept (NR) 5.163 0.497 <0.001 
Iron -2.163 0.626 0.006 
Key: NR, not reported; RR, risk ratio 
 
Table 111. HaemR: Results of meta-regression analysis with Hb baseline levels as a 
covariate (using Hb subgroup data [Littlewood and colleagues, 2001) 
Variable RR Standard error P-value 
Intercept ( Hb <12 g/dl) 25.524 2.108 <0.001 
Hb <11 g/dl -21.480 2.642 <0.001 
Hb <10 g/dl -21.215 2.163 <0.001 
Key: NR, not reported; RR, risk ratio 
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23.1.3. RBCT 
23.1.3.1.  Publication bias 
Figure 86. RBCT: Publication bias, publication bias, funnel plot 
 
 
Table 112. RBCT: Harbord’s modified test for small study effects 
Number of studies 24 Root MSE – 1.108
Z/sqrt(V) Coef SE t p>|t| 95% CI 
sqrt(V) -0.60 0.17 -3.44 0.002 -0.96, -0.24 
bias -0.62 0.51 -1.22 0.234 -1.68, 0.43 
Test of H0 no small-study effects p=0.234 
Key: CI, confidence interval; coef, coefficient; SE, standard error 
Notes: Regress Z/sqrt(V) on sqrt(V) where Z is efficient score and V is score variance 
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Figure 87. RBCT: Publication bias, analysis of year of publication 
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23.1.3.2.  Fixed effects 
Figure 88. RBCT: Fixed effects meta-analysis 
 
Key: CI, confidence interval; ID, identification; N, number of participants; RR, risk ratio
Notes:  (a) Mantel-Haenzel pooled RR; (b) Trial with multiple experimental arm split into subsets in the analysis: 
Tjulandin 2010a,b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 1993 reported 
data for participants on platinum-based chemotherapy and non-platinum based chemotherapy 
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23.1.3.3.  Addit ional analyses 
Figure 89. RBCT: Random effects meta-analysis using Hb subgroups (Vanteenkiste 
and colleagues, 2002 and Littlewood and colleagues, 2001), forest plot (random 
effects) 
 
Key: CI, confidence interval; ID, identification; N, number of participants; RR, risk ratio
Notes:  (a) Random effects, Der Simonian pooled RR; (b) Trial with multiple experimental arm split into subsets 
in the analysis: Tjulandin 2010a,b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 
1993 reported data for participants on platinum-based chemotherapy and non-platinum based chemotherapy 
 
NOTE: Weights are from random effects analysis
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Figure 90 RBCT: Random effects meta-analysis using malignancy subgroups 
(Littlewood and colleagues, 2001), forest plot (random effects) 
 
Key: CI, confidence interval; ID, identification; N, number of participants; RR, risk ratio
Notes:  (a) Random effects, Der Simonian pooled RR; (b) Trial with multiple experimental arm split into subsets 
in the analysis: Tjulandin 2010a,b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 
1993 reported data for participants on platinum-based chemotherapy and non-platinum based chemotherapy 
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23.1.4. RBC units transfused 
23.1.4.1.  Publication bias 
Figure 91. RBC units transfused: Publication bias, Egger’s test  
  
Key: se, standard error; WMD, weighted mean difference 
 
Table 113. RBC units transfused: Egger’s test for small study effects 
Number of studies 11 Root MSE – 1.455
Std_Eff Coef SE t p>|t| 95% CI 
slope -0.4604 0.16 -2.96 0.02 -0.81, -0.11 
bias -1.986 0.60 -1.63 0.14 -2.35, 0.38 
Test of H0 no small-study effects p=0.137 
Key: CI, confidence interval; coef, coefficient; SE, standard error 
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23.1.4.2.  Addit ional analyses 
Figure 92. RBC units transfused: Random effects meta-analysis using Hb subgroups 
(Vanteenkiste and colleagues, 2002), forest plot (random effects) 
 
Key: CI, confidence interval; ID, identification; N, number of events/participants intervention and control; WMD, 
weighted mean difference 
Notes:  (a) Random effects (Dersimonian Laird pooled RR); (b) Trial with multiple experimental arm split into 
subsets in the analysis: Abels 1993 reported data for participants on platinum-based chemotherapy and non-
platinum based chemotherapy 
 
NOTE: Weights are from random effects analysis
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23.1.4.3.  Fixed effects 
Figure 93. RBC units transfused: Fixed effects 
 
Key: CI, confidence interval; ID, identification; N, number of events/participants intervention and control; WMD, 
weighted mean difference 
Notes:  (a) Fixed effects (Mantel-Haenzel pooled RR); (b) Trial with multiple experimental arm split into subsets 
in the analysis: Abels 1993 reported data for participants on platinum-based chemotherapy and non-platinum 
based chemotherapy 
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23.2. Malignancy-related outcomes 
23.2.1. Tumour response 
23.2.1.1.  Fixed effects 
Figure 94. Tumour response: Forest plot (fixed effects) 
 
Key: CI, confidence intervals; events, treatment, number of events/ number of participants in treatment group; 
events, control, number of events/ number of participants in control group; ID, identification; RR, risk ratio 
Notes: Fixed effects, Mantel-Haenszel; Studiesl with multiple experimental arm split into subsets in the analysis: 
Tjulandin 2010 a, b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels 1993 reported 
data for participants on platinum-based chemotherapy and non-platinum based chemotherapy 
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23.2.2. Overall survival 
23.2.2.1.  Publication bias 
Figure 95. Funnel plot: Overall survival 
 
Key: hr, hazard ratio; se, standard error 
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Figure 96. Funnel plot: Overall survival; excluding Dunphy and colleagues, 1999 trial 
 
Key: hr, hazard ratio; se, standard error 
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Figure 97. Overall survival: Publication bias, meta-analysis using year of publication 
as covariate 
 
Key: hr, hazard ratio; pub year, publication year
 
 
 
 
 
-2
-1
0
1
ln
_h
r
1995 2000 2005 2010 2015
pubyear
PenTAG   CONFIDENTIAL 
701 
Commercial in confidence information is redacted 
Academic in confidence information is redacted 
 
 
23.2.2.2.  Fixed effects 
 
Figure 98. Overall survival: Fixed effects 
 
Key: CI, confidence interval; ES effect size; ID, identification
Notes: (a) Fixed effects; (b) Trial with multiple experimental arm split into subsets in the analysis: Tjulandin and 
colleagues, 2010a, b reports data for epoetin theta (2010a) and epoetin beta (2010b) and Abels and 
colleagues 1993 reported data for participants on platinum-based chemotherapy and non-platinum based 
chemotherapy; (c) Effect sizes reported are hazard ratios; (d)  IPD data as reported in Tonia and colleagues, 
2012 (Cochrane review): Abels and colleagues, 1993; Boogaerts and colleagues, 2003; Dammacco and 
colleagues, 2001; Grote and colleagues, 2005; Hedenus and colleagues, 2003; Littlewood and colleagues, 2001; 
Osterborg and colleagues, 2002; Ray-Coquard and colleagues, 2009; Strauss and colleagues, 2008; 
Vansteenkiste and colleagues, 2002. HRs reported for other trials calculated using other accepted methods. 
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23.2.3. On-study mortality 
23.2.3.1.  Publication bias 
Figure 99. Funnel plot: Mortality 
 
 
Key: HR, hazard ratio; se, standard error 
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Figure 100. Funnel plot: Mortality; excluding Dunphy and colleagues, 1999 trial 
 
Key: HR, hazard ratio; se, standard error 
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Figure 101. Meta-regression plot: Mortality 
 
Key: HR, hazard ratio. 
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23.2.3.2.  Fixed effects 
Figure 102. Forest plot: Mortality (fixed effects) 
 
Key: CI, confidence interval; ID, identification; HR, Hazard ratio
Notes:  (a) Der-Simonian Laird pooled HR; (b) Trial with multiple experimental arm split into subsets in the 
analysis: Tjulandin and colleagues, 2010a,b reports data for epoetin theta (2010a) and epoetin beta (2010b) 
and Abels and colleagues 1993 reported data for participants on platinum-based chemotherapy and non-
platinum based chemotherapy; (c) IPD data as reported in Tonia and colleagues, 2012 (Cochrane review): Abels 
and colleagues, 1993; Boogaerts and colleagues, 2003; Dammacco and colleagues, 2001; Grote and 
colleagues, 2005; Hedenus and colleagues, 2003; Littlewood and colleagues, 2001; Osterborg and colleagues, 
2002; Ray-Coquard and colleagues, 2009; Vansteenkiste and colleagues, 2002. HRs reported for other trials 
calculated using other accepted methods. 
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23.3. Safety-related outcomes 
23.3.1. Thromboembolic events 
23.3.1.1.  Publication bias 
Figure 103. Thromboembolic events: Publication bias, funnel plot 
 
Key: se, standard error; RR, risk ratio 
 
Table 114. Thromboembolic events: Harbord’s modified test for small study effects 
Number of studies 14 Root MSE 0.9755
Z/sqrt(V) Coef SE t p>|t| 95% CI 
sqrt(V) 0.30 0.33 0.91 0.38 -0.42, 1.03 
bias 0.28 0.56 0.63 0.63 -0.94, 1.50 
Test of H0 no small-study effects p=0.627 
Key: CI, confidence interval; coef, coefficient; SE, standard error 
Notes: Regress Z/sqrt(V) on sqrt(V) where Z is efficient score and V is score variance 
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Figure 104. Thromboembolic events: Publication bias (meta-regression plot, year of 
publication as a covariate) 
 
Key: RR, risk ratio 
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23.3.1.2.  Fixed effects 
Figure 105. Thromboembolic events: Overall, Forest plot (fixed effects) 
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: Fixed effects (Mantel-Haenzel); Trial with multiple experimental arm split into subsets in the analysis: 
Abels and colleagues 1993 reported data for participants on platinum-based chemotherapy and non-platinum 
based chemotherapy 
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23.3.2. Hypertension 
23.3.2.1.  Publication bias 
Figure 106. Hypertension: Forest plot (fixed effects) 
 
Key: se, standard error; RR, risk ratio 
 
Table 115. HTN: Harbord’s modified test for small study effects 
Number of studies 12 Root MSE 0.8809
Z/sqrt(V) Coef SE t p>|t| 95% CI 
sqrt(V) 0.49 0.51 0.95 0.364 -0.66, 1.63 
bias 0.28 0.68 0.41 0.689 -1.22, 1.79 
Test of H0 no small-study effects p=0.689 
Key: CI, confidence interval; coef, coefficient; SE, standard error 
Notes: Regress Z/sqrt(V) on sqrt(V) where Z is efficient score and V is score variance 
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Figure 107. Hypertension: Publication bias (meta-regression plot, year of publication 
as a covariate) 
 
Key: se, standard error; RR, risk ratio 
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23.3.2.2.  Fixed effects 
Figure 108. Hypertension: Overall, Forest plot (fixed effects) 
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: Fixed effects (Mantel-Haenszel); Trial with multiple experimental arm split into subsets in the analysis: 
Abels and colleagues 1993 reported data for participants on platinum-based chemotherapy and non-platinum 
based chemotherapy 
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23.3.3. Thrombocytopenia/haemorrhage 
23.3.3.1.  Fixed effects 
Figure 109. Thrombocytopenia/haemorrhage: Overall, Forest plot (fixed effects) 
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: (a) Fixed effects (Mantel-Haenzel) 
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23.3.4. Seizure 
23.3.4.1.  Fixed effects 
Figure 110. Seizure: Overall, Forest plot (fixed effects)  
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: Fixed effects (Mantel-Haenzel); Trial with multiple experimental arm split into subsets in the analysis: 
Abels and colleagues 1993 reported data for participants on platinum-based chemotherapy and non-platinum 
based chemotherapy 
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23.3.5. Pruritus 
23.3.5.1.  Fixed effects 
Figure 111.Pruritus: overall (fixed effects) 
 
Key: CI, confidence interval; events, treatment, control, number of events/participants in the treatment and 
control groups; ID, identification; RR, risk ratio 
Notes: (a) Fixed effects (Mantel-Haenzel) 
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23.4. Sensitivity ‘close to licence’ analyses 
Figure 112. ‘Close to licence’ subgroup analyses using Hb subgroups results from 
Littlewood and colleagues, 2001 and Vansteenkiste and colleagues, 2002 
Licence Outcome   Trials ES (95% CI) I2 
St
ar
tin
g 
do
se
 c
rit
er
ia
 m
et
 
Hb changed,e 18 WMD 1.59 (1.33 − 1.84) 75.9%; p<0.01 
HaemR a,d,e 13 RR 3.29 (2.81 − 3.85) 13.4%; p=0.31 
RBCTb,d,e 26 RR 0.61 (0.55−0.68) 22.4%; p=0.15 
Unitsc,d 12 WMD -0.87 (-1.24 − -
0.50) 
55.6%; p=0.01 
Tumour response 7 RR 1.10 (0.86 – 1.41) 37.5%; p=0.14 
Overall survivald,e 18 HR 0.97 (0.83 − 1.13) 42.4%; p=0.03 
On study mortalityd,e 14 HR 0.86 (0.67 − 1.11) 16.4%; p=0.27 
Thromboembolic eventsd 14 RR 1.46 (1.07 − 1.99) 0%; p=0.73 
Hypertensiond,e 12 RR 1.80 (1.14 − 2.85) 0%; p=0.79 
Thrombocytopenia/ 
haemorrhage 
7 RR 0.93 (0.65 – 1.34) 0%; p=0.81 
Seizuresd 2 RR 1.19 (0.33 – 4.38) 0%; p=0.74 
Pruritus 6 RR 2.04 (1.11 – 3.75) 0%; p=0.87 
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d,e 13 WMD 1.52 (1.30 − 1.75) 48.1%; p=0.03 
HaemR a,d,e 12 RR 3.20 (2.78 − 3.68) 2.0%; p=0.43 
RBCTb,d,e 16 RR 0.64 (0.57 − 0.71) 7.3%; p=0.37 
Unitsc,d 9 WMD -0.99 (-1.41 − -
0.56) 
56.2%; p=0.02 
Tumour response 2 RR 1.60 (0.88 – 2.90) 0%; p=0.70 
Overall survivald,e 10 HR 0.91 (0.70 − 1.20) 51.7%; p=0.03 
On study mortalityd,e 10 HR 0.89 (0.61 − 1.30) 37.7%; p=0.11 
Thromboembolic eventsd 7 RR 1.29 (0.66 – 2.54) 12.2%; p=0.34 
Hypertensiond,e 9 RR 1.68 (1.03 – 2.74) 0%; p=0.64 
Thrombocytopenia/ 
haemorrhage 
2 RR 0.73 (0.37 – 1.46) 0%; p=0.41 
Seizuresd 2 RR 1.19 (0.33 – 4.38) 0%; p=0.74 
Pruritus 3 RR 2.20 (1.05 – 4.58) 0%; p=0.66 
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Hb changee 4 WMD 1.29 (0.90 − 1.67) 61.9%; p=0.05 
HaemR e 3 RR 3.06 (2.28 – 4.09) 0%; p=0.79 
RBCTe 4 RR 0.52 (0.34 − 0.80) 48.4%; p=0.14 
Unitsc 1 WMD -0.56 (-0.74 − 
0.39) 
NA 
Tumour response 1 RR 0.90 (0.63 – 1.3) NA 
Overall survivale 4 HR 0.73 (0.32 − 1.64) 61.8%; p=0.05 
On study mortalitye 3 HR 0.50 (0.20 − 1.23) 29.7%; p=0.24 
Thromboembolic events 2 RR 1.38 (0.75 – 2.57) 0%; p=0.36 
Hypertensione 3 RR 2.19 (0.53 – 9.12) 16.8%; p=0.30 
Thrombocytopenia/ 
haemorrhage 
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Hb changee 3 WMD 1.50 (1.16 − 1.83) 0%; p=0.80 
HaemR e 3 RR 3.06 (2.28 – 4.09) 0%; p=0.79 
RBCTe 3 RR 0.50 (0.33 − 0.77) 0%; p=0.92 
Unitsc 1 WMD -0.56 (-0.74 − 0.39) NA 
Tumour response 0 NA NA 
Overall survivale 3 HR 0.50 (0.20 − 1.23) 29.7%; p=0.24 
On study mortalitye 3 HR 0.50 (0.20 − 1.23) 29.7%; p=0.24 
Thromboembolic events 1 RR 0.32 (0.01 – 7.74) NA 
Hypertensione 3 RR 2.19 (0.53 – 9.12) 16.8%; p=0.30 
Thrombocytopenia/ 
haemorrhage 
0 NA NA 
Seizures 0 NA NA 
Pruritus 1 RR 1.78 (0.74 – 4.26) NA 
Key: HaemR, haematological response; Hb, haemoglobin; NA, not applicable; RBCT, red blood cell transfusion; 
Units, units transfused per participant; RR, risk ratio; HR, hazard ratio; WMD, weighted mean difference. 
Notes : (a) Using Littlewood and colleagues, 2001 Hb subgroups; (b) Using Littlewood and colleagues, 2001 and 
Vansteenkinste and colleagues, 2002 Hb subgroups; (c) using Vansteenkinste and colleagues, 2002 Hb 
subgroups; (d) Abels and colleagues, 1993 reported data for participants on plat-based et non-plat based 
chemotherapy which we combined; (e) Tjulandin and colleagues, 2010 reported data for erythropoietin beta et 
theta  which were combined. 
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 Appendix M: Supplementary material: 
HRQoL review 
24.1. FACT scales 
All scales reproduced in this section reproduced from: 
http://www.facit.org/FACITOrg/Questionnaires (copyright © 2010 FACIT.org). 
24.1.1. FACT-G Version 4 
Below is a list of statements that other people with your illness have said are important. 
Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 
 PHYSICAL WELL-BEING Not at 
all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very 
much 
GP1 I have a lack of energy 0 1 2 3 4 
GP2 I have nausea 0 1 2 3 4 
GP3 Because of my physical condition, I 
have trouble meeting the needs of 
my family 
0 1 2 3 4 
GP4 I have pain 0 1 2 3 4 
GP5 I am bothered by side effects of 
treatment 
0 1 2 3 4 
GP6 I feel ill 0 1 2 3 4 
GP7 I am forced to spend time in bed 0 1 2 3 4 
 SOCIAL/FAMILY WELL-BEING Not at 
all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very 
much 
GS1 I feel close to my friends 0 1 2 3 4 
GS2 I get emotional support from my 
family 
0 1 2 3 4 
GS3 I get support from my friends 0 1 2 3 4 
GS4 My family has accepted my illness 0 1 2 3 4 
GS5 I am satisfied with family 
communication about my illness 
0 1 2 3 4 
GS6 I feel close to my partner (or the 
person who is my main support) 
0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 EMOTIONAL WELL-BEING Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
GE1 I feel sad 0 1 2 3 4 
GE2 I am satisfied with how I am coping 
with my illness 
0 1 2 3 4 
GE3 I am losing hope in the fight against 
my illness 
0 1 2 3 4 
GE4 I feel nervous 0 1 2 3 4 
GE5 I worry about dying 0 1 2 3 4 
GE6 I worry that my condition will get 
worse 
0 1 2 3 4 
 
 FUNCTIONAL WELL-BEING Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
GF1 I am able to work (include work at 
home) 
0 1 2 3 4 
GF2 My work (include work at home) is 
fulfilling 
0 1 2 3 4 
GF3 I am able to enjoy life 0 1 2 3 4 
GF4 I have accepted my illness 0 1 2 3 4 
GF5 I am sleeping well 0 1 2 3 4 
GF6 I am enjoying the things I usually do 
for fun 
0 1 2 3 4 
GF7 I am content with the quality of my 
life right now 
0 1 2 3 4 
 
Q1 Regardless of your current level of sexual activity, please answer the following question. If 
you prefer not to answer it, please mark this box           and go to the next section. 
GS7 I am satisfied with my sex life 0 1 2 3 4 
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24.1.2. FACT-An (version 4) 
Below is a list of statements that other people with your illness have said are important. 
Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 
   
 PHYSICAL WELL-BEING Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
GP1 I have a lack of energy 0 1 2 3 4 
GP2 I have nausea 0 1 2 3 4 
GP3 Because of my physical condition, I 
have trouble meeting the needs of 
my family 
0 1 2 3 4 
GP4 I have pain 0 1 2 3 4 
GP5 I am bothered by side effects of 
treatment 
0 1 2 3 4 
GP6 I feel ill 0 1 2 3 4 
GP7 I am forced to spend time in bed 0 1 2 3 4 
 
 SOCIAL/FAMILY WELL-BEING Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
GS1 I feel close to my friends 0 1 2 3 4 
GS2 I get emotional support from my 
family 
0 1 2 3 4 
GS3 I get support from my friends 0 1 2 3 4 
GS4 My family has accepted my illness 0 1 2 3 4 
GS5 I am satisfied with family 
communication about my illness 
0 1 2 3 4 
GS6 I feel close to my partner (or the 
person who is my main support) 
0 1 2 3 4 
Q1 Regardless of your current level of sexual activity, please answer the following question. If 
you prefer not to answer it, please mark this box           and go to the next section. 
GS7 I am satisfied with my sex life  0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 EMOTIONAL WELL-BEING Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
GE1 I feel sad 0 1 2 3 4 
GE2 I am satisfied with how I am coping 
with my illness 
0 1 2 3 4 
GE3 I am losing hope in the fight against 
my illness 
0 1 2 3 4 
GE4 I feel nervous 0 1 2 3 4 
GE5 I worry about dying 0 1 2 3 4 
GE6 I worry that my condition will get 
worse 
0 1 2 3 4 
 
 FUNCTIONAL WELL-BEING Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
GF1 I am able to work (include work at 
home) 
0 1 2 3 4 
GF2 My work (include work at home) is 
fulfilling 
0 1 2 3 4 
GF3 I am able to enjoy life 0 1 2 3 4 
GF4 I have accepted my illness 0 1 2 3 4 
GF5 I am sleeping well 0 1 2 3 4 
GF6 I am enjoying the things I usually do 
for fun 
0 1 2 3 4 
GF7 I am content with the quality of my 
life right  now 
0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 ADDITIONAL CONCERNS Not at 
all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
HI7 I feel fatigued 0 1 2 3 4 
HI12 I feel weak all over 0 1 2 3 4 
An1 I feel listless (“washed out”) 0 1 2 3 4 
An2 I feel tired 0 1 2 3 4 
An3 I have trouble starting things because 
I am tired 
0 1 2 3 4 
An4 I have trouble finishing things 
because I am tired 
0 1 2 3 4 
An5 I have energy 0 1 2 3 4 
An6 I have trouble walking 0 1 2 3 4 
An7 I am able to do my usual activities 0 1 2 3 4 
An8 I need to sleep during the day 0 1 2 3 4 
An9 I feel lightheaded (dizzy) 0 1 2 3 4 
An10 I get headaches 0 1 2 3 4 
B1 I have been short of breath 0 1 2 3 4 
An11 I have pain in my chest 0 1 2 3 4 
An12 I am too tired to eat 0 1 2 3 4 
BL4 I am interested in sex 0 1 2 3 4 
An13 I am motivated to do my usual 
activities 
0 1 2 3 4 
An14 I need help doing my usual activities 0 1 2 3 4 
An15 I am frustrated by being too tired to 
do the things I want to do 
0 1 2 3 4 
An16 I have to limit my social activity 
because I am tired 
0 1 2 3 4 
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24.1.3. FACT-F (Version 4) 
Below is a list of statements that other people with your illness have said are important. 
Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
  Not at 
all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
HI7 I feel fatigued 0 1 2 3 4 
HI12 I feel weak all over 0 1 2 3 4 
An1 I feel listless (“washed out”) 0 1 2 3 4 
An2 I feel tired 0 1 2 3 4 
An3 I have trouble starting things 
because I am tired 
0 1 2 3 4 
An4 I have trouble finishing things 
because I am tired 
0 1 2 3 4 
An5 I have energy 0 1 2 3 4 
An7 I am able to do my usual activities 0 1 2 3 4 
An8 I need to sleep during the day 0 1 2 3 4 
An12 I am too tired to eat 0 1 2 3 4 
An14 I need help doing my usual activities 0 1 2 3 4 
An15 I am frustrated by being too tired to 
do the things I want to do 
 
0 
 
1 
 
2 
 
3 
 
4 
An16 I have to limit my social activity 
because I am tired 
0 1 2 3 4 
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24.2. Meta-analysis: HRQoL  
24.2.1. FACT-F: Fixed effects 
Figure 113. HRQoL, Change in FACT-F Score: overall (fixed effects) 
 
Overall  (I-squared = 14.9%, p = 0.316)
Osterborg (2002, 2005)
Tjulandin (2011)
ID
Vansteenkiste (2002)
Hedenus (2003)
Littlewood (2001)
Kotasek (2003)
Boogaerts (2003)
Study
2.49 (1.48, 3.51)
2.20 (-0.74, 5.14)
2.30 (-0.20, 4.80)
WMD (95% CI)
1.40 (-0.89, 3.69)
1.88 (-0.22, 3.98)
5.20 (2.01, 8.39)
1.10 (-2.58, 4.78)
5.06 (1.86, 8.26)
1022
133, 5.2 (12.2)
88, 2.9 (7.9)
(SD); Treatment
156, .8 (10)
152, 2.68 (8.88)
200, 3 (13.5)
189, 3.4 (12.6)
104, 5.47 (14.5)
N, mean
772
130, 3 (12.1)
84, .6 (8.8)
(SD); Control
158, -.6 (10.7)
151, .8 (9.71)
90, -2.2 (12.5)
50, 2.3 (11.6)
109, .41 (8.47)
N, mean
100.00
12.03
16.57
Weight
19.79
23.64
10.21
7.65
10.12
%
Favours control Favours treatment 
0-8.39 8.39
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24.2.2. FACT-F: Subgroup analyses 
Figure 114. HRQoL: Change in FACT-F by chemotherapy type (random effects) 
 
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
Notes: a Mantel-Haenzel pooled RR; 
NOTE: Weights are from random effects analysis
.
.
.
Overall  (I-squared = 14.9%, p = 0.316)
Platinum based
Not reported
Vansteenkiste (2002)
Subtotal  (I-squared = .%, p = .)
Osterborg (2002, 2005)
Tjulandin (2011)
Subtotal  (I-squared = 17.1%, p = 0.299)
Littlewood (2001)
ID
Kotasek (2003)
Boogaerts (2003)
Hedenus (2003)
Subtotal  (I-squared = 40.2%, p = 0.188)
Non-platinum based
Study
2.54 (1.42, 3.65)
1.40 (-0.89, 3.69)
1.40 (-0.89, 3.69)
2.20 (-0.74, 5.14)
2.30 (-0.20, 4.80)
3.07 (1.26, 4.87)
5.20 (2.01, 8.39)
WMD (95% CI)
1.10 (-2.58, 4.78)
5.06 (1.86, 8.26)
1.88 (-0.22, 3.98)
2.62 (0.45, 4.80)
1022
156, .8 (10)
156
133, 5.2 (12.2)
88, 2.9 (7.9)
421
200, 3 (13.5)
(SD); Treatment
189, 3.4 (12.6)
104, 5.47 (14.5)
152, 2.68 (8.88)
445
N, mean
772
158, -.6 (10.7)
158
130, 3 (12.1)
84, .6 (8.8)
304
90, -2.2 (12.5)
(SD); Control
50, 2.3 (11.6)
109, .41 (8.47)
151, .8 (9.71)
310
N, mean
100.00
19.04
19.04
12.56
16.47
39.90
10.87
Weight
8.39
10.78
21.90
41.06
%
Favours control Favours treatment 
0-8.39 8.39
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Figure 115. HRQoL: Change in FACT-F by malignancy (random effects) 
 
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
NOTE: Weights are from random effects analysis
.
.
.
Overall  (I-squared = 14.9%, p = 0.316)
Subtotal  (I-squared = 0.0%, p = 0.862)
Vansteenkiste (2002)
Hedenus (2003)
Boogaerts (2003)
ID
Kotasek (2003)
Osterborg (2002, 2005)
Solid
Subtotal  (I-squared = 0.0%, p = 0.892)
Study
Subtotal  (I-squared = 26.2%, p = 0.258)
Mixed
Tjulandin (2011)
Haem
Littlewood (2001)
2.54 (1.42, 3.65)
1.99 (0.28, 3.69)
1.40 (-0.89, 3.69)
1.88 (-0.22, 3.98)
5.06 (1.86, 8.26)
WMD (95% CI)
1.10 (-2.58, 4.78)
2.20 (-0.74, 5.14)
1.32 (-0.63, 3.26)
3.95 (1.98, 5.93)
2.30 (-0.20, 4.80)
5.20 (2.01, 8.39)
1022
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156, .8 (10)
152, 2.68 (8.88)
104, 5.47 (14.5)
(SD); Treatment
189, 3.4 (12.6)
133, 5.2 (12.2)
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N, mean
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88, 2.9 (7.9)
200, 3 (13.5)
772
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158, -.6 (10.7)
151, .8 (9.71)
109, .41 (8.47)
(SD); Control
50, 2.3 (11.6)
130, 3 (12.1)
208
N, mean
283
84, .6 (8.8)
90, -2.2 (12.5)
100.00
34.46
19.04
21.90
10.78
Weight
8.39
12.56
27.42
%
38.12
16.47
10.87
Favours control Favours treatment 
0-8.39 8.39
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Notes: a Random effects (Der-Simonian–Laird pooled RR) 
 
Figure 116. HRQoL: Change in FACT-F by intervention (random effects) 
 
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
Notes: a Random effects (Der-Simonian–Laird pooled RR) 
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 14.9%, p = 0.316)
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Subtotal  (I-squared = 0.0%, p = 0.920)
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Hedenus (2003)
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Study
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Figure 117. HRQoL: Change in FACT-F by study duration (random effects)  
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
Notes: a Random effects (Der-Simonian–Laird pooled RR) 
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 14.9%, p = 0.316)
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152, 2.68 (8.88)
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Figure 118. Change in FACT-F with Boogaerts and colleagues (2003) removed 
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
Notes: a Random effects (Der-Simonian–Laird pooled RR) 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.506)
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88, 2.9 (7.9)
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200, 3 (13.5)
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N, mean
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24.2.3. FACT-G 
Figure 119. HRQoL: Change in FACT-G: overall (random effects) 
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
Notes: a Random effects (Der-Simonian–Laird pooled WMD) 
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Figure 120. HRQoL: Change in FACT-G: overall (fixed effects) 
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
Notes: a Mantel-Haenzel pooled WMD 
Overall  (I-squared = 70.7%, p = 0.033)
Study
ID
Tjulandin (2011)
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Osterborg (2002, 2005)
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24.2.4. FACT-An 
Figure 121. HRQoL: Change in FACT-An overall (fixed effects) 
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
Notes: a Mantel-Haenzel pooled WMD 
Overall  (I-squared = 70.7%, p = 0.033)
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ID
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Figure 122. HRQoL: Change in FACT-An overall (fixed effects) 
 
Key: CI, confidence interval; ID, identification; N, number of participants; SD, standard deviation; WMD, weighted mean difference 
Notes: a Mantel-Haenzel pooled WMD 
Overall  (I-squared = 97.5%, p = 0.000)
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1.00 (0.88, 1.12)
437
(SD); Treatment
133, 2 (4.3)
200, 4 (4.3)
104, .9 (.5)
N, mean
329
(SD); Control
130, 1.7 (5.2)
90, -2.6 (5.2)
109, -.1 (.4)
N, mean
100.00
Weight
1.09
0.97
97.94
%
Favours control Favours treatment 
0-7.83 7.83
PenTAG   CONFIDENTIAL 
733 
 
 Appendix N: Excluded studies (cost-
effectiveness review) 
Study Reason 
for 
exclusion 
Notes 
Could not be obtained 
Sheffield R, Sullivan S, Saltiel E, Nishimura L. Cost 
comparison of recombinant human erythropoietin and 
blood transfusion in cancer chemotherapy-induced 
anemia. Annals of Pharmacotherapy (The). 1997;31:15-
22. 
Could not 
be 
obtained 
Published pre-2004
Roungrong J, Teerawattananon Y, Chaikledkaew IU. 
Cost utility analysis of recombinant human erythropoietin 
in anemic cancer patients induced by chemotherapy in 
Thailand. Journal of the Medical Association of Thailand. 
2008;91(Suppl 2):S119-S125. 
Could not 
be 
obtained 
 
Griggs JJ, Sorbero MES. Cost-utility of erythropoietin in 
the treatment of cancer-related anemia. Medical 
Decision Making. 1997;17(4):529. 
Could not 
be 
obtained 
Published pre-2004
Griggs JJ, Blumberg N. Recombinant erythropoietin and 
blood transfusions in cancer chemotherapy-induced 
anemia. Anti-Cancer Drugs. 1998;9:925-932. 
Could not 
be 
obtained 
Published pre-2004
Malonne H, editor Cost evaluation of erythropoiesis 
stimulating agents in the treatment of platinum 
chemotherapyinduced anaemia. 20th Annual meeting of 
the Belgian Hematology Society; 2005. 
Could not 
be 
obtained 
 
Study design 
Reeder CE. Anemia in cancer and critical care patients: 
pharmacoeconomic considerations. American Journal of 
Health-System Pharmacy. 2007 Feb 1;64:S22-7. 
Study 
design 
Non-systematic 
review 
Dale DC. The benefits of haematopoietic growth factors 
in the management of gynaecological oncology. 
European journal of gynaecological oncology. 
2004;25:133-44. 
Study 
design 
Expert commentary
Marchetti M, Barosi G. Clinical and economic impact of 
epoetins in cancer care. Pharmacoeconomics. 
2004;22:1029-45. 
Study 
design 
Non-systematic 
review 
Scarpace SL, Miller K, Elefante A, Czuczman MS, 
McCarthy P, Chanan-Khan A. Cost-utility of darbepoetin 
alfa (DARBE) on an every-2 week (QOW) schedule in 
anemic non-myeloid hematologic malignancies: A 
positive overall impact on the healthcare system (HCS). 
Journal of Clinical Oncology. 2004 Jul;22:797S-S. 
Study 
design 
Cost study, not UK 
Steensma DP, Loprinzi CL. Epoetin alfa and darbepoetin 
alfa go head to head. Journal of Clinical Oncology. 
2006;24:2232-6. 
Study 
design 
Review/commentar
y 
Cornes P, Coiffier B, Zambrowski J-J. Erythropoietic 
therapy for the treatment of anemia in patients with 
cancer: a valuable clinical and economic option. Curr 
Med Res Opin. 2007 Feb;23:357-68. 
Study 
design 
Non-systematic 
review 
Herrmann R. Erythropoietin therapy in cancer-related Study Non-systematic 
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anaemia, yes or no? Internal Medicine Journal. 
2008;38:749-50. 
design review 
Repetto L, Moeremans K, Annemans L. European 
guidelines for the management of chemotherapy-
induced anaemia and health economic aspects of 
treatment. Cancer Treat Rev. 2006;32:S5-S9. 
Study 
design 
Non-systematic 
review 
Stasi R, Amadori S, Littlewood TJ, Terzoli E, Newland 
AC, Provan D. Management of cancer-related anemia 
with erythropoietic agents: doubts, certainties, and 
concerns. Oncologist. 2005 Aug;10:539-54. 
Study 
design 
Non-systematic 
review 
Reichardt B. Evidence-based, novel comparison 
between epoetin alfa, epoetin beta, and darbepoetin alfa 
based on drug use, efficacy and treatment costs in daily 
oncological clinical practice. Hematol J. 2004;5(Suppl 
2):S177. 
Study 
design 
Cost study, not UK 
Population 
Wadelin FR, Myers B. Darbepoetin is more cost-effective 
than regular transfusion: A review of the use of 
erythropoietin in haematology patients. 49th Annual 
Scientific Meeting of the British Society for Haematology 
Brighton United Kingdom. 2009;145:58. 
Population Results not 
presented 
separately for 
malignancy 
subgroup 
Intervention 
Glaspy J, Tchekmedyian N, Gupta S. PCN17 comparing 
the cost-effectiveness of 3 mcg/kg Q2W darbepoetin alfa 
with standard dose epoetin alfa for anemia management 
in chemotherapy-treated cancer patients in united states. 
Value in Health. 2002;5(6):543. 
Interventio
n 
Abstract; uses 
unlicensed Q2W 
dosing for 
darbepoetin alfa; 
published pre-2004 
Outcome 
Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, 
McKenzie S, Fastenau J, et al. Cost-effectiveness of 
once weekly epoetin alfa and darbepoetin alfa in treating 
chemotherapy-induced anemia. Value in Health. 2005 
May-Jun;8:238. 
Outcome Abstract; cannot 
calculate ICERs 
from reported data 
Gozzo M, Lucioni C, Mazzi S. Economics evaluation of 
erythropoiesis-stimulating agents for the treatment of 
chemotherapy-induced anaemia in Italy. 2012 European 
Association of Hospital Pharmacists, EAHP Congress 
Milan Italy. 2012;19:202. 
Outcome Abstract; cannot 
calculate ICERs 
from reported data 
No usable data 
Coiffier B, Schlag R, Velasco A, Yao B, Schupp M, 
Demarteau N, et al. Cost and effectiveness of 
darbepoetin ALFA administered every 3 weeks (Q3W 
DA) compared with weekly epoetin ALFA (QW EA) or 
epoetin beta (QW EB) in patients (PTS) with 
chemotherapy-induced anemia (CIA): A retrospective 
study. Annals of Oncology. 2006;17:293. 
No usable 
data 
Abstract 
Grocott R, Metcalfe S, Moodie P. PHARMAC and 
erythropoietin for cancer patients. N Z Med J. 
2006;119:U2039. 
No usable 
data 
Study not complete 
at time of 
publication 
Published pre-2004 
Cremieux P-Y, Finkelstein SN, Berndt ER, Crawford J, 
Slavin MB. Cost effectiveness, quality-adjusted life-years 
Published 
pre-2004 
Included in Wilson 
and colleagues 
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and supportive care: recombinant human erythropoietin 
as a treatment of cancer-associated anaemia. 
PharmacoEconomics. 1999;16(5 Pt 1):459-472. 
(2007) 
Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of 
recombinant human erythropoietin in the prevention of 
chemotherapy-induced anaemia. British Journal of 
Cancer. 1998;78(6):781-787. 
Published 
pre-2004 
Included in Wilson 
and colleagues 
(2007) 
Language (not English) 
Borget I, Chouaid C, Demarteau N, Annemans L, Pujol 
JL. Cost-effectiveness of darbepoetin a in an every-3-
weeks schedule. Bulletin Du Cancer. 2008 Apr;95:465-
73. 
Language French language 
Danish Centre for Evaluation and Health Technology 
Assessment (DACEHTA). Epoetin (EPO) for anaemic 
cancer patients (Structured abstract). Health Technology 
Assessment Database [Internet]. 2004; (2):[45 p.]. 
Available from: 
http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HT
A-32005000197/frame.html. 
Language Danish language 
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 Appendix O: Multiple publications in 
cost-effectiveness review 
Primary study 
I. Borget, P. Tilleul, M. Baud, A. C. Joly, A. 
Daguenel, and C. Chouaid. Routine once-
weekly darbepoetin alfa administration is 
cost-effective in lung cancer patients with 
chemotherapy-induced anemia: a Markov 
analysis. Lung Cancer:369-376, 2006. 
Multiple publications 
C. Chouaid, I. Borget, M. Baud, A. C. Joly, 
A. Daguenel, and P. Tilleul. Routine once-
weekly darbepoetin alfa administration is 
cost-effective in lung cancer patients with 
chemotherapy-induced anemia: A Markov 
analysis. Lung Cancer 49:S23, 2005. 
I. Borget, P. Tilleul, A. C. Joly, and C. 
Chouaid. Incremental cost-effectiveness 
ratio of darbepoetin alfa (Aranesp (R)) in 
the treatment of chemotherapy-induced 
anemia in lung cancer patients. Value 
Health 9:A278-A279, 2006. 
I. Borget, P. Tilleul, M. Baud, A. C. Joly, 
and C. Chouaid. Routine once-weekly 
darbepoetin alfa administration is cost-
effective in lung cancer patients with 
chemotherapy-induced anemia: a Markov 
analysis. Pharm World Sci 29:454, 2007. 
Primary study 
J. Finek, L. Holubec, A. Wiesnerova, Z. 
Pav, and L. Dusek. Darbepoetin alfa 
versus epoetin alfa for treatment of 
chemotherapy-induced Anemia: A health 
economic evaluation. Value Health 13 
(7):A465, 2010. 
Multiple publications 
J. Finek, L. Holubec, A. Wiesnerova, Z. 
Pav, and V. Dusek. Darbepoetin alfa 
versus epoetin alfa for treatment of 
chemotherapy-induced anemia: A health 
economic evaluation. Ann Oncol 21 (suppl 
8):344, 2010. 
Primary study 
Tonelli M, Lloyd A, Weibe N, Hemmelgarn 
B, Reiman T, Manns B et al. 
Erythropoiesis-stimulating agents for 
anemia of cancer or of chemotherapy: 
systematic review and economic 
evaluation. Technology report number 
119. 2009. Ottawa, Canadian Agency for 
Drugs and Technologies in Health. 
Multiple publications 
Klarenbach S, Manns B, Reiman T, 
Reaume MN, Lee H, Lloyd A et al. 
Economic Evaluation of Erythropoiesis-
Stimulating Agents for Anemia Related to 
Cancer. Cancer 2010; 116:3224-3232.
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 Appendix P: Study characteristics, key parameters and results 
of conference abstracts identified in the cost-effectiveness 
review 
  Szucs, 2001141 Cremieux, 2003142 Mark, 2003144 van Hout, 2004145 
Evaluation type Cost-effectiveness analysis Cost-effectiveness analysis Cost-consequences analysis Cost-effectiveness analysis 
Modelling used No No No Yes 
Nature of modelling N/A N/A N/A “Bayesian simulation model” 
Perspective Societal Societal Drug cost only Healthcarea 
Country (setting) Multiple (France, Germany, 
Italy, Sweden and UK) 
Not stated (probably USA) Not stated (probably USA) UKa 
Intervention/comparato
r 
Epo-b TIW: 150 IU/kg 
Standard care 
Epo-a QW: 40,000 IU 
Darb-a QW: 2.25 µg/kg 
Epo-a 
Darb-a 
Epo-a QW: 150 IU/kgb 
Darb-a QW: 2.25 µg/kgc 
Population Patients with solid or 
lymphoid tumours 
Patients with lung cancer 
receiving chemotherapy 
Non-myeloid cancer patients 
with chemotherapy-related 
anaemia 
Anaemic cancer patients 
receiving chemotherapy 
Outcomes considered SF-36 PCS 
FACT-F 
FACT-An 
Cumulative change in Hb 
(AUC) 
Change in FACT-F 
Proportion of patients 
requiring transfusion 
Change in Hb from baseline 
Hb AUC 
Hb response (≥2 g/dL change 
or Hb ≥12 g/dL, unrelated to 
transfusion) 
Dose-escalation 
Avoidance of transfusion 
Time-frame 12 weeks 12 weeks 12 weeks 12 weeks 
Discounting Not stated Not stated Not stated Not stated 
Funding Not stated Ortho Biotec (manufacturers 
of Epo-a) 
Ortho Biotec (manufacturers 
of Epo-a) 
Johnson & Johnson 
(manufacturers of Epo-a) 
Key: AUC, area under the curve; Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; FACT-F/An, Functional Assessment of Cancer Therapy - 
Fatigue/Anemia; Hb, haemoglobin; IU, International Units; QW, once weekly; SF-36 PCS, Short form questionnaire physical component summary; TIW, three times weekly 
Notes: (a) Separate analyses were conducted for UK (healthcare), France (healthcare) and US (private health insurance); only UK results abstracted; (b) Dose doubled if Hb 
not increased by >1 g/dL by Week 4; (c) Dose doubled if Hb not increased by >1 g/dL by Week 6 
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  Ben-Hamadi, 2005146 Van Bellinghen, 2006147 } Esposito, 2007148 Van Bellinghen, 2007149 
Evaluation type Cost-effectiveness Cost-consequences analysis Cost-consequences analysis Cost-consequences analysis 
Modelling used Minimal Yes Yes Yes 
Nature of modelling Integration of costs with Hb 
levels from separate placebo-
controlled RCTs 
Decision tree Decision tree Decision tree 
Perspective Societal Societal Healthcare Societal 
Country (setting) Not stated (probably USA) France Italy Germany 
Intervention/comparato
r 
Epo-a QW: 40,000 IU 
Darb-a QW: 2.25 µg/kg 
Darb-a Q3W: 500 µg 
Epo-a QW: European label 
dose 
Epo-b QW: European label 
dose 
Darb-a Q3W: 500 µg 
Epo-a QW: European label 
dose 
Epo-b QW: European label 
dose 
Darb-a Q3W: 500 µg 
Epo-a QW: European label 
dose 
Epo-b QW: European label 
dose 
Population Patients with chemotherapy-
induced anaemia 
Patients with chemotherapy-
induced anaemia 
Patients with chemotherapy-
induced anaemia 
Patients with chemotherapy-
induced anaemia 
Outcomes considered Area under the Hb change 
curve over 12 weeks 
Hb levels Hb levels Hb levels 
Time-frame 12 weeks 16 weeks (assumed based on 
trial length) 
16 weeks (assumed based on 
trial length) 
16 weeks (assumed based on 
trial length) 
Discounting Not stated Not stated Not stated Not stated 
Funding Ortho Biotec (manufacturers 
of Epo-a) 
Amgen (manufacturers of 
Darb-a) 
Amgen (manufacturers of 
Darb-a) 
Amgen (manufacturers of 
Darb-a) 
Key: Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; Hb, haemoglobin; IU, International Units; QW, once weekly; Q3W, once every three weeks 
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  Finek, 2010150 Liwing, 2010151 Walter, 2010152 Fragoulakis, 2011143 
Evaluation type Cost-effectiveness analysis Cost-effectiveness analysis Cost-effectiveness analysis Cost-effectiveness analysisa 
Modelling used Minimal Yes Yes Yes 
Nature of modelling Integration of drug acquisition 
costs with retrospective, 
single centre analysis 
Simulation model Decision tree Decision tree 
Perspective Not stated Not stated (probably 
healthcare) 
Healthcare Healthcare (plus patient 
transportation) 
Country (setting) Czech Republic (not explicitly 
stated) 
Sweden Austria Greece 
Intervention/comparato
r 
Epo-a QW: 40,000 IU 
Darb-a Q3W: 500 µg 
Epo-a 
Darb-a 
Darb-a Q3W: 500 µg 
Darb-a QW: 150 µg 
Epo-a QW: 40,000 IU 
Epo-b QW: 30,000 IU 
Epo-b TIW: 30,000 IU (per 
week) 
Darb-a Q3W: 500 µg 
Darb-a QW: 150 µg 
Epo-a QW: 40,000 IU 
Epo-b QW: 30,000 IU 
Epo-b TIW: 30,000 IU (per 
week) 
Population Patients with chemotherapy-
induced anaemia 
Patients with chemotherapy-
related anaemia 
Patients with chemotherapy 
induced anaemia 
Patients with chemotherapy-
induced anaemia 
Outcomes considered Clinical response (Hb ≥ 11 
g/dL) 
Haematopoietic response 
rates 
Dose escalation rates 
Mean number of RBC 
transfusions required 
Hb response rate Hb response (≥ 2 g/dL) 
Time-frame Not stated 12 weeks 12 weeks Not stated 
Discounting Not stated Not stated Not stated Not stated 
Funding None Johnson & Johnson 
Pharmaceutical Service 
(parent company of Janssen-
Cilag, manufacturers of Epo-
a) 
Amgen (manufacturers of 
Darb-a) 
Genesis Pharma (distributor 
of Darb-a) 
Key: Darb-a, darbepoetin alfa; Epo-a, epoetin alfa; Epo-b, epoetin beta; Hb, haemoglobin; QW, once weekly; Q3W, once every three weeks; TIW, three times weekly; RBC, 
red blood cell(s) 
Notes: (a) Although study is described as cost-minimisation analysis, with similar efficacy for all treatments, in fact treatment responses when calculated are different 
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 Appendix Q: Update of cost-
effectiveness review 
All searches were updated on 2 December 2013 and date-limited from 1 January 2013 to 2 
December 2013.Seventy-three records were obtained from main database searches, 
resulting in 51 records following deduplication.  Two additional records were obtained from 
DARE, such that 53 records were identified for title/abstract screening. 
Independent, blinded screening was performed by two reviewers (TS and LC) and both 
reviewers included exactly one (and the same) study.  The full-text of this study was 
retrieved and assessed for eligibility by two reviewers (TS and NH) who both judged it 
eligible. 
Data extraction was conducted by TS. 
The included study by Michallet and colleagues (2013)249 describes itself as including a 
cost-effectiveness analysis, although on inspection it is a combined assessment of various 
effectiveness outcomes as well as a cost analysis.  As such it would normally be considered 
a cost-consequences analysis. 
Michallet and colleagues (2013) is a historically controlled study matching patients 
receiving ESA therapy with those in the past known not to receive ESA therapy.  Not all 
outcomes were recorded for the control group so only transfusion requirement and survival 
(overall and event-free) are evaluated comparatively. 
The study found that patients receiving ESA therapy experienced an improvement in health-
related quality of life compared to baseline, but this was not compared with patients not 
receiving ESA therapy.  The study found that patients receiving ESA therapy had lower 
transfusion need and no statistically significant difference was found in overall or event-free 
survival between patients receiving ESA therapy and controls.  RBCT costs were lower for 
patients receiving ESA therapy but these did not sufficiently offset the increased cost due to 
ESA acquisition/administration. 
The tables below show the characteristics, key parameters and results of the study. 
  Michallet, 2013 
Evaluation type Cost-consequences analysis 
Modelling used No 
Nature of modelling n/a 
Perspective Healthcare 
Country (setting) France 
Intervention/comparator DA 150 µg QW 
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No tx 
Population Patients with anaemia following consolidation chemotherapy for AML 
Outcomes considered HRQoL (FACT-General, FACT-Fatigue, FACT-Anemia) 
Hb response (CR = Hb >= 12 g/dL; PR = Hb increase >= 2 g/dL) 
Adverse events 
Costs 
Hb levels 
Transfusion need 
Survival (overall and event-free) 
Time-frame n/a 
Discounting Not stated 
Funding Not disclosed 
Key: AML, acute myeloid leukaemia; CR, complete response; DA, darbepoetin alfa; FACT, Functional 
Assessment of Cancer Therapy; Hb, haemoglobin; HRQoL, health-related quality of life; PR, partial response; 
QW, once weekly; tx, treatment 
Notes: All data presented for Group 1 (patients with AML treated with chemotherapy); Group 2 (patients having 
received allogeneic hematopoietic stem cell transplant for any haematological disease) excluded 
 
  Michallet, 2013 
Effectiveness (source): 
transfusion, response rate, 
survival, QALYs 
Historically controlled study (this study) 
Effectiveness (data): transfusion, 
response rate 
Transfusion requirement 
Median reduction RBC units, 3.9 (P = 0.0002) 
Median reduction platelet units, 1.7 (P = 0.029) 
Effectiveness (data): survival Not statistically significant (overall survival, P = 0.77; event-
free survival, P = 0.57) 
Effectiveness (data): QALYs n/a 
QoL/utility (source) This study 
QoL/utility (data) n/a (Not evaluated for control group) 
Costs (source) This study 
Cost year Not stated 
Key: Hb, haemoglobin; HRQoL, health-related quality of life; RBC, red blood cell 
Notes: Following outcomes were not evaluated for control group and hence are not shown here: Hb response 
rate, Hb level, adverse events, HRQoL 
 
  Michallet, 2013 
Measure Costs; transfusion requirement; survival 
Cost year; currency NR; euros (EUR; €) 
Base case ESA cost: DA, €3,904; No tx, €0 
RBCT cost: DA, €2,568; No tx, €4,280 
Total cost: DA, €6,472; No tx, €4,280 
Probabilistic results n/a 
Sensitivity analyses n/a 
Key: DA, darbepoetin alfa; ESA, erythropoiesis stimulating agent; NR, not reported; RBCT, red blood cell 
transfusion; tx, treatment 
Notes: Costs presented are median costs. Consequences as shown in Key Parameters table 
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 Appendix R: Summary of parameters used 
in PenTAG cost-effectiveness model 
Parameter Base case (SE) Subgroup 
inclusion Hb 
level ≤ 11.0 
g/dL (SE) 
Location in 
report 
Wilson value 
Overall survival ESA vs. control 
(HR, SE in log scale) 
0.967 (0.079) 0.914 (0.137) §4.2.6.3.2, p101 1 
Overall survival (control arm) 2.670 (1.335) 1.447 (0.723) §7.1.2.1.8, p277 1.54 
Change in Hb from baseline to 
end of ESA treatment: difference 
between ESA and control arms 
1.59 (0.130) 1.52 (0.115) §4.2.6.2.1, p75 1.63 (clinical 
effectiveness 
review) 
Mean number of units transfused 
in control arm 
2.09 2.30 §7.1.2.1.1, p266 2 
Mean difference # units RBCs 
transfused ESA vs. control arm 
−0.87 (0.21) −0.99 (0.22) §4.2.6.2.4, p91 −1.05 
Relative risk of adverse event rates in ESA vs. control arm (reported on natural log scale) 
Thrombotic events ln(1.46) = 0.378 
(0.158) 
ln(1.29) = 0.255 
(0.344) 
§4.2.6.4.1, p110  
Hypertension  ln(1.80) = 0.588 
(0.234) 
ln(1.68) = 0.519 
(0.250) 
§4.2.6.4.2, p113  
Thrombocytopenia ln(0.93) = 
−0.073 (0.185) 
ln(0.73) = 
−0.315 (0.350) 
§4.2.6.4.3, p116  
Probability of adverse event in 
control arm 
   0, but 5% SAE 
on EPO 
Thrombotic events 3.3% (0.4%) 3.7% (0.8%) §7.1.2.3.6, p304  
Hypertension  2.9% (0.5%) 1.8% (1.0%) §7.1.2.3.6, p304  
Thrombocytopenia 6.4% (0.8%) 2.5% (0.8%) §7.1.2.3.6, p304  
Baseline Hb level (g/dL) 10.38 (1.59) 9.40 (0.22) §7.1.2.1.4, p269 9.9 (calculated 
using reported 
figures at 
baseline) 
Change in Hb (no ESA) g/dL −0.155 (1.25) 0.469 (0.41) §7.1.2.1.5, p271  
Mean diff Hb over time / mean 
final diff Hb 
80.6% (55.0%) 55.5% (12.0%) §7.1.2.1.6, p273  
Mean age (years) 59.1 (5.3) 60.8 (4.2) §7.1.2.4.2, p307 Not used 
Mean weight (kg) 66.6 (3.3) 66.1 (3.6) §7.1.2.4.2, p307 Not used 
Probability patient is male 0.46 §7.1.2.4.2, 
p307 
 
Mean OS (No ESA) (years) 2.670 (1.335) 1.447 (0.724) §7.1.2.1.8, p277 1.54 
Mean weekly ESA dose 
Epoetin alfa (IU) 24,721 (4,944) 24,947 (4,989) §7.1.2.1.2, p266  
Epoetin beta (IU) 31,138 (6,228) 30,997 (6,199) §7.1.2.1.2, p266  
Epoetin theta (IU) 22,859 (4,572) 22,810 (4,562) §7.1.2.1.2, p266  
Epoetin zeta (IU) 24,721 (4,944) 24,947 (4,989) §7.1.2.1.2, p266  
PenTAG   CONFIDENTIAL 
743 
 
Parameter Base case (SE) Subgroup 
inclusion Hb 
level ≤ 11.0 
g/dL (SE) 
Location in 
report 
Wilson value 
Darbepoetin alfa (µg) 141.1 (28.2) 141.2 (28.2) §7.1.2.1.2, p266  
Number of RBC units per 
transfusion 
2.7 (0.54)  §7.1.2.1.1, p266  
Duration of ESA treatment 
(weeks) 
12    
Normal Hb level (g/dL) 12a (0.51)  §7.1.2.1.7, p275 24  
Normalisation rate (g/dL per 
week) 
0.2 (0.051)  §7.1.2.1.7, p275 13 
Utility increase per Hb level 
increase (1g/dL) 
0.028 (0.006)  §7.1.2.2.5, p296 0.2 (approx) 
Long term utility 0.763 (0.183) 0.756 (0.151) §7.1.2.2.6, p297 0.06 
ESA acquisition cost    £276.70 week 
(inc SAEs) 
per 1,000 IU 
Epoetin alfa Eprex® £5.53 §7.1.2.3.2, p299 §7.1.2.3.2, p299  
Binocrit® £5.09 §7.1.2.3.2, p299 §7.1.2.3.2, p299  
Epoetin beta NeoRecormon® £7.01 §7.1.2.3.2, p299 §7.1.2.3.2, p299  
Epoetin 
theta 
Eporatio® £5.99 §7.1.2.3.2, p299 §7.1.2.3.2, p299  
Epoetin zeta Retacrit® £5.66 §7.1.2.3.2, p299 §7.1.2.3.2, p299  
per µg 
Darbepoetin 
alfa 
Aranesp® £1.47  §7.1.2.3.2, p299  
Dosing schedule of ESA Once weekly  §7.1.2.3.4, p302 3 times per week
Average cost per ESA 
administration 
£9.13  §7.1.2.3.4, p302 £8.01 
Additional blood tests for ESA 4  §7.1.2.3.5, p303  
Cost of blood test £15.14  §7.1.2.3.5, p303  
Cost of adverse event    £101 
Thrombotic events £1,243 (£249)  §7.1.2.3.6, p304  
Hypertension £826 (£165)  §7.1.2.3.6, p304  
Thrombocytopenia £744 (£149)  §7.1.2.3.6, p304  
Unit cost of RBCs £127 (£25)  §7.1.2.3.7, p305  
Cost of transfusion appointment £688  §7.1.2.3.8, p305  
Time frame Lifetime    
Cycle length NA    
HaemR RR (ESA vs. control) NA  §7.1.2.1, p258  
Key: §, Section; ESA, erythropoiesis stimulating agent; HaemR, haematological response; Hb, haemoglobin; HR, hazard 
ratio; IU, international units; NA, not applicable; OS, overall survival; RBC(T), red blood cell (transfusion); RR, relative risk; 
SE, standard error; SR, systematic review 
Notes: a Normalised Hb level equals 12 g/dL or the final Hb level in the ESA arm, whichever is higher 
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 Appendix S: Mean difference in Hb level 
as a proportion of final difference in Hb 
level 
The PenTAG economic model uses a parameter corresponding to the mean difference in Hb level 
as a proportion of the final difference in Hb level.  The final difference in Hb level is a commonly 
reported outcome, but cumulative differences (which incorporate information about Hb levels over 
time between measurement of baseline and final Hb levels) are not generally reported succinctly.  In 
some studies figures are presented showing the trajectory of Hb levels. 
In the case where the parameter is set to 100% this means the average difference in Hb level 
between the intervention and control arm over time is the same as the final difference in Hb level 
(adjusting for any differences at baseline). 
Two calculation methods were applied to estimate this parameter, with the easiest to apply method 
being used for each figure. 
30.1. Method 1 
Measuring tools of Adobe Acrobat X Pro (Adobe Systems, Inc., California, USA) were used to 
estimate: 
 The area bounded above by the intervention arm Hb level curve and below by the control 
arm Hb level curve (denoted A); 
 The (vertical) distance between the intervention arm Hb level curve and control arm Hb level 
curve at baseline (denoted L0; positive if baseline Hb higher in intervention arm); 
 The (vertical) distance between the intervention arm Hb level curve and control arm Hb level 
curve at final Hb level measurement (denoted L1; positive if final Hb higher in intervention 
arm); 
 The (horizontal) distance between times of baseline and final Hb level measurement 
(denoted W). 
The required parameter is then calculated as (A – L0 × W) / [W × (L1 – L0)]. 
PenTAG   CONFIDENTIAL 
745 
 
30.2. Method 2 
An appropriate tool was used to estimate the mean Hb level at each measurement for both 
intervention and control arms. 
The area under each Hb level curve was calculated by summing the areas of trapezoids (denoted 
AUCIntervention and AUCControl).  These were adjusted to become area under Hb change curves by 
subtracting the hypothetical area under the curve if the Hb level did not change (denoted 
ΔAUCIntervention and ΔAUCControl). 
The hypothetical area under the curve if Hb level instantaneously jumped to the final Hb level 
difference was calculated (denoted ΔAUCInstantaneous). 
The required parameter is then calculated as (ΔAUCIntervention – ΔAUCControl) / ΔAUCInstantaneous. 
30.3. Results 
Study Calculation steps Result 
Method 1 A L0 L1 W  
Littlewood, 2011 1.00 0.05 0.38 2.42 110% 
Grote, 2005 2.39 −0.09 0.24 3.53 232% 
Tjulandin, 2010 ET, 1.66 
EB, 1.79 
ET, 0.00
EB, 0.00
ET, 0.69
EB, 0.78
ET, 3.85 
EB, 3.85 
ET, 62% 
EB, 60% 
Tjulandin, 2011 2.11 0.11 1.10 3.47 50% 
Moebus, 2013 0.69 0.00 0.39 2.29 77% 
Method 2 ΔAUCIntervention ΔAUCControl ΔAUCInstantaneous   
Silvestris, 1995 46.15 3.04 51.08  84% 
Del Mastro, 1997 0.70 −9.35 13.80  73% 
Kurz, 1997 20.32 2.26 36.12  50% 
Dunphy, 1999 −5.35 −13.00 9.92  77% 
Thatcher, 1999 −6.37 −11.03 5.04  92% 
Dammacco, 2001 12.37 −0.04 22.15  56% 
Hedenus, 2002 9.43 4.11 9.04  59% 
Aravantinos, 2003 4.245 3.235 4.32  23% 
Boogaerts, 2003 15.98 7.02 13.12  68% 
Strauss, 2008 11.80 −6.40 24.00  76% 
Key: EB, epoetin beta; ET, epoetin theta 
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 Appendix T: Use of MathMap to 
construct cumulative hazard and 
Weibull plots 
MathMap [freely available from http://www.complang.tuwien.ac.at/schani/mathmap/] is a 
flexible tool and programming language for constructing and manipulating raster graphics 
with support for general mathematical transformations. 
To construct cumulative hazard and Weibull plots we made use of functionality where the 
result image, B, can be based on the input image, A, using an arbitrary mathematical 
backward mapping, i.e., expressions of the form B(x, y) = A(f(x, y), g(x, y)). 
The cumulative hazard graph plots ln(−S(t)) versus t and therefore the backward mapping 
functions are f(x, y) = x and g(x, y) = exp(−y). 
The Weibull graph plots ln(−n(−S(t))) versus ln(t) and therefore the backward mapping 
functions are f(x, y) = exp(x) and g(x, y) = exp(−exp(y)). 
The code for performing these mappings additionally must account for the dimensions of B 
and the location of the survival graph in A. 
We show example code for transforming the survival plot from Littlewood and colleagues 
(2001).  Note that ‘#’ is used to create a comment (non-functioning line) and has been used 
to ‘comment out’ a number of statements which would otherwise create different plots.  The 
code as presented constructs the Weibull plot (time plotted from 1 to 40 and cumulative 
hazard plotted from 0.1 to 1.2). 
filter littlewood (image in) 
  plotOrigin=[-0.75, -0.37]; 
  plotTopRight=[0.86, 0.953]; 
 
  # CHECK PLOT BOUNDS 
  #if x < plotOrigin[0] || x > plotTopRight[0] || y < plotOrigin[1] || y > 
plotTopRight[1] then 
  #  rgbColor(0,0,0); 
  #else 
  #  in(xy); 
  #end 
 
  # CUMULATIVE HAZARD 
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  #in(xy:[(x+1)/2*(plotTopRight[0]-plotOrigin[0])+plotOrigin[0], 
  #     exp(-(y+1))*(plotTopRight[1]-plotOrigin[1]) + plotOrigin[1]]) 
 
  # WEIBULL PLOT 
  A = 0.5*(log(40)-log(1)); 
  B = 0.5*(log(40)+log(1)); 
  C = 0.5*(log(1.2)-log(0.1)); 
  D = 0.5*(log(1.2)+log(0.1)); 
  in(xy:[exp(A*x + B)*(plotTopRight[0]-plotOrigin[0])/40 + plotOrigin[0], 
       exp(-exp(C*y + D))*(plotTopRight[1]-plotOrigin[1]) + plotOrigin[1]]) 
end 
 
